



Safety of Vaccines Used for Routine Immunization in the United States



Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Evidence-Based
Practice

Evidence Report/Technology Assessment

Number 215

Safety of Vaccines Used for Routine Immunization in the United States

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-2007-10062-I

Prepared by:

Southern California Evidence-based Practice Center
Santa Monica, CA

Investigators:

Margaret A. Maglione, M.P.P.
Courtney Gidengil, M.D., M.P.H.
Lopamudra Das, M.P.H.
Laura Raaen, M.P.H.
Alexandria Smith, M.P.H.
Ramya Chari, Ph.D.
Sydne Newberry, Ph.D.
Susanne Hempel, Ph.D.
Roberta Shanman, M.L.S.
Tanja Perry, B.H.M.
Matthew Bidwell Goetz, M.D.

Addendum

This evidence report summarizes scientific data on the safety of vaccines currently recommended in the United States. High strength of evidence was found for an association of measles-mumps-rubella (MMR) vaccine with febrile seizures in children under age 5 (Key Question 2c). On May 19, 2014 (while this evidence report was in press), an important study investigating the timing of MMR and MMRV (measles-mumps-rubella-varicella) vaccine and risk of febrile seizures¹ was published. We felt this information warranted inclusion in this review of the evidence.

Researchers conducted a self-controlled case series analysis using records from over 300,000 U.S. children from the Vaccine Safety Datalink (VSD). They found timing was unrelated to risk of post-vaccination seizure in infants, but found that delaying measles containing vaccines past 15 months results in a higher risk of seizures.

According to the study's authors, these adverse events are very rare, and occurred at the rate of about 1 per 100,000 person-days at seven months of age, compared to a high of five per 100,000 person-days at 17 months of age.

Reference

1. Hambidge S J, Newcomer SR, Narwaney KJ, et al. Timely versus delayed early childhood vaccination and seizures. *Pediatrics*. 2014 Jun;133(6):e1492-e1499. PMID: 24843064.

This report is based on research conducted by the Southern California Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10062-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This report may periodically be assessed for the urgency to update. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at: www.effectivehealthcare.ahrq.gov. Search on the title of the report.

This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated.

Persons using assistive technology may not be able to fully access information in this report. For assistance, contact EffectiveHealthCare@ahrq.hhs.gov.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

Suggested citation: Maglione MA, Gidengil C, Das L, Raaen L, Smith A, Chari R, Newberry S, Hempel S, Shanman R, Perry T, Goetz MB. Safety of Vaccines Used for Routine Immunization in the United States. Evidence Report/Technology Assessment No. 215. (Prepared by the Southern California Evidence-based Practice Center under Contract No. 290-2007-10062-I.) AHRQ Publication No. 14-E002-EF. Rockville, MD: Agency for Healthcare Research and Quality; July 2014. www.effectivehealthcare.ahrq.gov/reports/final.cfm.

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. The Office of the Assistant Secretary for Health, National Vaccine Program, requested and provided funding for this report.

The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions and new health care technologies and strategies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments.

To bring the broadest range of experts into the development of evidence reports and health technology assessments, AHRQ encourages the EPCs to form partnerships and enter into collaborations with other medical and research organizations. The EPCs work with these partner organizations to ensure that the evidence reports and technology assessments they produce will become building blocks for health care quality improvement projects throughout the Nation. The reports undergo peer review and public comment prior to their release as a final report.

AHRQ expects that the EPC evidence reports and technology assessments will inform individual health plans, providers, and purchasers as well as the health care system as a whole by providing important information to help improve health care quality.

We welcome comments on this evidence report. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.hhs.gov.

Richard G. Kronick, Ph.D.
Director
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director, EPC Program
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Yen-pin Chiang, Ph.D.
Acting Director, Center for Outcomes
and Evidence
Agency for Healthcare Research and Quality

Kim Marie Wittenberg, M.A.
Task Order Officer
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Acknowledgments

The authors would like to thank Aneesa Motala, B.A., for her excellent assistance on the project after the peer review period. We would like to thank Paul Shekelle, M.D., Ph.D., for his advice and review of the draft and final versions of the report.

Technical Expert Panel

In designing the study questions and methodology at the outset of this report, the EPC consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicted opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts.

Technical Experts must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential conflicts of interest identified.

The list of Technical Experts who participated in developing this report follows:

Meghan Baker, M.D., Sc.D.
Harvard Pilgrim Health Care
Institute/Harvard Medical School
Boston, MA

Richard Beigi, M.D., M.Sc.
Magee-Women's Hospital
University of Pittsburgh Medical Center
Pittsburgh, PA

Kathryn Edwards, M.D.
Vanderbilt University Vaccine Research
Program
Nashville, TN

Kristen Feemster, M.D., M.P.H., M.S.P.H.
Children's Hospital of Philadelphia
University of Pennsylvania Perelman School
of Medicine
Philadelphia, PA

Bruce Fireman, M.A.
Kaiser Permanente Northern California
Oakland, CA

David Martin, M.D.
Deputy Director
U.S. Food and Drug Administration
Rockville, MD

Claudia Vellozzi, M.D., M.P.H.
Deputy Director
Immunization Safety Office
Centers for Disease Control and Prevention
Atlanta, GA

Peer Reviewers

Prior to publication of the final evidence report, EPCs sought input from independent Peer Reviewers without financial conflicts of interest. However, the conclusions and synthesis of the scientific literature presented in this report do not necessarily represent the views of individual reviewers.

Peer Reviewers must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential nonfinancial conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified.

The list of Peer Reviewers follows:

Janet D. Cragan, M.D., M.P.H.
National Center on Birth Defects and
Developmental Disabilities
Centers for Disease Control and Prevention
Atlanta, GA

Francesca Cunningham, Pharm.D.
Director
Center for Medication Safety
(VAMedSAFE)
Department of Veterans Affairs
Hines, IL

Frank Destefano, M.D., M.P.H
Director
Immunization Safety Office
Division of Healthcare Quality Promotion
National Center for Emerging and Zoonotic
Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA

Laura Elizabeth Riley, M.D.
Massachusetts General Hospital
Boston, MA

Safety of Vaccines Used for Routine Immunization in the United States

Structured Abstract

Objectives. To conduct a systematic review of the literature on the safety of vaccines recommended for routine immunization of children, adolescents, and adults in the United States as of 2011.

Data sources. We included placebo-controlled clinical trials and cohort studies comparing vaccinated and unvaccinated patients. We also included the following types of post-licensure analyses: case-control studies, self-controlled case series, and multivariate risk factor analyses. We conducted an electronic search of PubMed® from inception through August 2013, and reviewed Advisory Committee for Immunization Practices statements, vaccine package inserts, and previously published reviews to identify studies. Scientific Information Packets were requested from vaccine manufacturers.

Review methods. We reviewed the methodology of the 2011 Institute of Medicine (IOM) consensus report “Adverse Effects of Vaccines: Evidence and Causality” and accepted their findings. We augmented their work with new studies and additional vaccines. For studies not included in the IOM report, we abstracted data on the presence or absence of adverse health outcomes, characteristics of patients, study design, and vaccine description, including brand, potency, dosage, timing, and formulation, where available. We excluded formulations not used in the United States. The McHarm instrument was used to evaluate the quality of adverse events collection and reporting in each study. We were unable to pool results; we rated the overall strength of evidence (SOE) as high, moderate, low, or insufficient by using guidance suggested by the Agency for Healthcare Research and Quality for its Effective Health Care Program.

Results. A total of 20,478 titles were identified; after title, abstract, and full-text review, 166 studies were accepted for abstraction. The vast majority of studies either did not investigate or could not identify risk factors for adverse events (AEs) associated with vaccination. Similarly, the severity of AEs was inconsistently reported, as was information that would make independent severity determination possible.

SOE was high for the following associations in nonpregnant adults: seasonal influenza vaccine and arthralgia, myalgia, malaise, fever, pain at injection site; 2009 monovalent H1N1 vaccine and Guillain-Barré syndrome (GBS); and a lack of association between influenza and pneumococcal vaccines and cardiovascular events in the elderly. Risk of GBS was estimated at 1.6 excess cases per million persons vaccinated. SOE was high for the following associations in children and adolescents: measles, mumps, rubella (MMR) vaccine and febrile seizures in children under age 5; lack of association between MMR vaccine and autism spectrum disorders; and varicella vaccine and disseminated Oka strain varicella zoster virus with associated complications (i.e., meningitis, encephalitis) in individuals with demonstrated immunodeficiencies. There is moderate SOE that vaccines against rotavirus are associated with intussusception in children; risk was estimated as 1 to 5 cases per 100,000 vaccine doses, depending on brand. Moderate-strength evidence exists regarding human papillomavirus vaccine

and a lack of association with onset of juvenile rheumatoid arthritis, type 1 diabetes, and GBS. Moderate-strength evidence shows no association between inactivated influenza vaccine and serious AEs in pregnant women.

Evidence was insufficient to make conclusions regarding whether several routinely recommended vaccines are associated with serious conditions such as multiple sclerosis, transverse myelitis, and acute disseminated encephalomyelitis.

Conclusions. There is evidence that some vaccines are associated with serious adverse events; however, these events are extremely rare and must be weighed against the protective benefits that vaccines provide. Careful consideration should be given to the investigation of research gaps, including patient risk factors that may be associated with AEs; however, important factors must be taken into account when determining whether studies are warranted, including the severity and frequency of the AE being studied and the challenges of conducting sufficiently powered studies when investigating rare events.

Contents

Executive Summary	ES-1
Introduction.....	1
Background	1
Methods.....	5
Original Proposed Key Questions (KQs).....	5
Technical Expert Panel	6
Analytic Framework	7
Literature Search	7
Article Review	8
Study Inclusion	8
Data Abstraction and Synthesis of Results	9
Assessment of Methodological Quality	10
Grading the Evidence for Each Key Question.....	10
Peer Review and Public Commentary	13
Results	14
Key Question (KQ) 1: What is the evidence that vaccines included in the 2011 immunization schedule recommended for U.S. adults are safe in the short term (within 30–42 days following immunization) or long term (>42 days after immunization)?	16
Influenza Vaccines.....	20
Pneumococcal Vaccines.....	42
Zoster	47
Varicella.....	58
HPV.....	60
Diphtheria Toxoid, Tetanus Toxoid, and Acellular Pertussis.....	62
Miscellaneous Other Vaccines.....	64
Key Question (KQ) 2: What is the evidence that vaccines included in the immunization schedules recommended for U.S. children and adolescents in 2011 are safe in the short term (within 30–42 days following immunization) or long term (>42 days after immunization)?	67
Influenza Vaccines.....	71
<i>Haemophilus Influenza</i> Type B (Hib) Vaccine.....	86
Measles-Mumps-Rubella (MMR).....	89
Rotavirus Vaccines: RotaTeq and Rotarix.....	95
Hepatitis B Vaccine	114
HPV.....	116
Varicella	131
Diphtheria Toxoid, Tetanus Toxoid, and Acellular Pertussis-Containing Vaccines	133
Meningococcal Vaccine.....	133
Studies of Multiple Vaccines	135
Key Question (KQ) 3: What is the evidence that vaccines recommended for pregnant women are safe both for the woman and for her fetus/infant?	150
Influenza Vaccines.....	152
Summary and Discussion	159
Limitations	159

Conclusions.....	160
Research Gaps.....	171
Adults	171
Children and Adolescents	171
Pregnant Women.....	172
General Methodological Observations	172
References.....	174
Abbreviations/Acronyms.....	190

Tables

Table A. Vaccines routinely recommended for children and adolescents, 2011	ES-1
Table B. Vaccines routinely recommended for nonpregnant adults, 2011	ES-2
Table C. Vaccines routinely recommended for pregnant women, 2011.....	ES-2
Table D. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children	ES-10
Table 1. Vaccines routinely recommended for children and adolescents, 2011.....	2
Table 2. Vaccines routinely recommended for nonpregnant adults, 2011	2
Table 3. Vaccines routinely recommended for pregnant women, 2011	2
Table 4. Grading the strength of a body of evidence: required domains and their definitions	11
Table 5. Adverse events collected or reported in trials of adults.....	16
Table 6. Adverse events investigated in postmarketing studies of adults.....	18
Table 7. Vaccinated versus unvaccinated adults: influenza vaccines	23
Table 8. Postmarketing studies of influenza vaccines in adults.....	31
Table 9. Postmarketing studies of pneumococcal vaccines in adults	43
Table 10. Vaccinated versus unvaccinated adults: zoster vaccine.....	48
Table 11. Postmarketing studies of zoster vaccine	53
Table 12. Vaccinated versus unvaccinated adults: varicella vaccine	59
Table 13. Vaccinated versus unvaccinated adults: HPV vaccine	61
Table 14. Vaccinated versus unvaccinated adults: Td (tetanus/diphtheria) vaccine	63
Table 15. Postmarketing studies of multiple vaccines in adults	66
Table 16. Adverse events collected or reported in trials in children and adolescents	68
Table 17. Adverse events investigated in postmarketing studies of children and adolescents	70
Table 18. Vaccinated versus unvaccinated children or adolescents: influenza vaccines	73
Table 19. Postmarketing studies of influenza vaccines in children and adolescents.....	79
Table 20. Vaccinated versus unvaccinated children or adolescents: Hib vaccine	87
Table 21. Postmarketing studies of measles-mumps-rubella (MMR) vaccine in children and adolescents	91
Table 22. Vaccinated versus unvaccinated children: rotavirus vaccines	96
Table 23. Postmarketing studies of rotavirus vaccines in children.....	112
Table 24. Postmarketing study of Hepatitis B vaccine in children and adolescents.....	115
Table 25. Vaccinated versus unvaccinated adolescents: HPV vaccine	118
Table 26. Postmarketing studies of HPV vaccine in children and adolescents	127
Table 27. Vaccinated versus unvaccinated children and adolescents: varicella vaccine.....	132

Table 28. Vaccinated versus unvaccinated studies of meningococcal vaccines in children and adolescents	134
Table 29. Postmarketing studies of multiple vaccines in children and adolescents	138
Table 30. Adverse events collected or reported in studies of pregnant women	150
Table 31. Cohort comparison studies of influenza vaccines in pregnant women.....	154
Table 32. Postmarketing studies of influenza vaccines in pregnant women	156
Table 33. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children	161

Figures

Figure A. Study/literature flow diagram.....	ES-8
Figure 1. Analytic framework.....	7
Figure 2. Study/literature flow diagram.....	15

Appendices

Appendix A. Literature Search Strategy
Appendix B. Data Abstraction Tools
Appendix C. Evidence Tables
Appendix D. Excluded Studies and Background Papers

Executive Summary

Background

Vaccines are considered one of the greatest public health achievements of the last century for their role in eradicating smallpox and controlling polio, measles, rubella, and other infectious diseases in the United States.¹ Despite their effectiveness in preventing and eradicating disease, substantial gaps in vaccine uptake persist. Vaccination rates for young children are high;² however, vaccination rates remain well below established Healthy People 2020 targets for many vaccines recommended for adolescents,³ adults,⁴ and pregnant women.⁵

In the United States, vaccine guidelines are set by the Centers for Disease Control and Prevention's Advisory Committee for Immunization Practices (ACIP). The number of routine immunizations recommended for children and adolescents, adults, and pregnant women has expanded considerably over the past 10 years. For example, since 2005, the routine adolescent vaccination schedule has grown to include the following vaccines at ages 11 or 12 years: meningococcal conjugate vaccine; tetanus, diphtheria, and acellular pertussis (Tdap); human papillomavirus (HPV); and influenza (one dose annually). Tables A–C display ACIP recommendations as of October 2011. These recommendations were in effect when this review began.

Table A. Vaccines routinely recommended for children and adolescents, 2011

Vaccine	Age
DTaP (diphtheria, tetanus, and acellular pertussis)	2 months–6 years
Hepatitis A	12 months and older
Hepatitis B	Birth and older
Hib (<i>Haemophilus influenzae</i> type b)	6 weeks–59 months
HPV (human papillomavirus)	9 years–21 years (male) 9 years–26 years (female)
Influenza (inactivated)	6 months and older
Influenza (live attenuated)	2 years and older
IPV (inactivated polio vaccine)	6 weeks and older
MCV (meningococcal conjugate vaccine)	2 years and older
MMR (measles, mumps, and rubella)	12 months and older
MPSV (meningococcal polysaccharide vaccine)	2 years and older in specific circumstances
PCV13 (pneumococcal conjugate vaccine)	6 weeks–18 years
Pneumococcal polysaccharide vaccine	2 years and older in specific circumstances
Rotavirus	6 weeks–8 months
Tdap (tetanus, diphtheria, and acellular pertussis)	7 years and older
Varicella	12 months and older

Table B. Vaccines routinely recommended for nonpregnant adults, 2011

Vaccine	Recommendation
Hepatitis A	All adults at increased risk for hepatitis A infection
Hepatitis B	All unvaccinated adults at risk for or requesting protection from hepatitis B infection
HPV (human papillomavirus)	Adults 26 years and younger
Influenza (inactivated)	All adults
Influenza (live attenuated)	All adults 49 years and younger
Meningococcal conjugate vaccine (MCV4) and meningococcal polysaccharide vaccine (MPSV)	Adults at risk of meningococcal disease (MCV4 or MPSV if younger than 55 years; MPSV if 55 years and older)
MMR (measles, mumps, and rubella)	All adults
Pneumococcal polysaccharide vaccine	Adults 64 years and younger with certain conditions and all adults 65 years and older
Td (tetanus, diphtheria)	All adults who are not immune through prior infection
Tdap (tetanus, diphtheria, and acellular pertussis)	All adults 19–64 years old; some adults 65 years and older
Varicella	All adults without evidence of varicella immunity
Zoster	All adults 60 years and older

Table C. Vaccines routinely recommended for pregnant women, 2011

Vaccine	Recommendation
Hepatitis B	Recommended in some circumstances
Influenza (inactivated)	All pregnant women
Td (tetanus, diphtheria)	If indicated
Tdap (tetanus, diphtheria, and acellular pertussis)	All pregnant women at the first trimester if indicated ^a

^aIn 2013, pregnant women were advised to receive Tdap during every pregnancy to protect their newborns from pertussis.

As the number of recommended immunizations has expanded across the population, so too have concerns about the safety of vaccines. Perhaps the most highly publicized safety concern of the last two decades was the proposed link between autism and the measles, mumps, and rubella (MMR) vaccine, first reported in 1998 in *The Lancet* by Dr. Andrew Wakefield.⁶ In 2010, *The Lancet* fully retracted the 1998 report,⁷ noting that elements of the research had been deliberately falsified. Although multiple large studies have confirmed the lack of association between MMR and autism, parental worries about the safety of vaccines persist. Other parental concerns about childhood vaccines include potential links to multiple sclerosis, sudden infant death syndrome, asthma, and diabetes.⁸ Thus, vaccine safety is high on the Nation's public health agenda.

Objectives

The Agency for Healthcare Research and Quality (AHRQ) requested an evidence report on the safety of vaccines recommended for routine immunization of adults (including pregnant women), children, and adolescents as of October 2011. This report, which represents the results of a comprehensive and systematic review of scientific evidence, describes potential associations between vaccines and adverse events (AEs) and will be used by the Office of the Assistant Secretary for Health (OASH) to identify the gaps in evidence. The report was guided by the following Key Questions (KQs):

- **KQ 1.** What is the evidence that vaccines included in the 2011 immunization schedule recommended for U.S. **adults**⁹ are safe in the short term (within 30 to 42 days following immunization) or long term (>42 days after immunization)?
 - a. What adverse events are collected in clinical studies (Phases I–IV) and in observational studies containing a control/comparison group?
 - b. What AEs are reported in clinical studies (Phases I–IV) and in observational studies containing a control/comparison group?
 - c. What AEs are associated with these vaccines?
 - 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 - 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 - 3. For each AE associated with a particular vaccine, what are the risk factors for the AE (including age, sex, race/ethnicity, genotype, underlying medical condition, whether a vaccine is administered individually or in a combination vaccine product, schedule of vaccine administration, adjuvants, and medications administered concomitantly)?
- **KQ 2.** What is the evidence that vaccines included in the immunization schedules recommended for U.S. **children and adolescents** in 2011¹⁰ are safe in the short term (within 30 to 42 days following immunization) or long term (>42 days after immunization)?
 - a. What AEs are collected in clinical studies (Phases I–IV) and in observational studies containing a control/comparison group?
 - b. What AEs are reported in clinical studies (Phases I–IV) and in observational studies containing a control/comparison group?
 - c. What AEs are associated with these vaccines?
 - 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 - 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 - 3. For each AE associated with a particular vaccine, what are the risk factors for the AE (including age, sex, race/ethnicity, genotype, underlying medical condition, whether a vaccine is administered individually or in a combination vaccine product, schedule of vaccine administration, adjuvants, and medications administered concomitantly)?
- **KQ 3.** What is the evidence that vaccines recommended for **pregnant women**¹¹ are safe both for the woman and for her fetus/infant?
 - a. What AEs are collected in clinical studies (Phases I–IV) and in observational studies containing a control/comparison group?
 - b. What AEs are reported in clinical studies (Phases I–IV) and in observational studies containing a control/comparison group?

^a Level of certainty was operationalized as the 95-percent confidence interval surrounding the risk or odds estimate—i.e., the statistical significance.

- c. What AEs are associated with these vaccines in women?
 - 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 - 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 - 3. For each AE associated with a particular vaccine, what are the risk factors for the AE (including age, sex, race/ethnicity, genotype, underlying medical condition, whether the vaccine is administered individually or in a combination vaccine product, the schedule of vaccine administration, adjuvants, and medications administered concomitantly)?
- d. What AEs are associated with these vaccines in the fetus/infant?
 - 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 - 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 - 3. For each AE associated with a particular vaccine, what are the risk factors for the AE (including age, sex, race/ethnicity, genotype, underlying medical condition, whether the vaccine is administered individually or in a combination vaccine product, the schedule of vaccine administration, adjuvants, and medications administered concomitantly)?

Methods

In 2011, the Institute of Medicine (IOM) published a consensus report titled “Adverse Effects of Vaccines: Evidence and Causality.”¹² That report evaluated the scientific evidence for event-vaccine relationships and covered the following vaccines on the 2011 recommended immunization schedules: varicella, influenza, hepatitis A, hepatitis B, HPV, MMR, meningococcal, tetanus, diphtheria, and pertussis. We report the IOM findings and update them by identifying and evaluating studies published after the IOM searches. We also searched for studies of pneumococcal, rotavirus, *Haemophilus influenzae* type b, inactivated poliovirus, and zoster vaccines; these were not included in the IOM report.

We searched electronic databases such as Medline[®] for relevant studies; complete search terms are provided in Appendix A of the full report. Databases were searched from inception through August 2013 for the vaccines not covered by the IOM report; for the other vaccines, the searches dated from a year before the IOM search. We also reviewed ACIP statements, package inserts, and Scientific Information Packets requested from vaccine manufacturers by an AHRQ-funded Scientific Resource Center. Finally, we scanned review articles for relevant references.

The following study designs were included:

- **Controlled clinical trial.** Human subjects are assigned prospectively, usually through randomization, to receive an intervention (in this case, a vaccine) or an alternative intervention (another vaccine) or placebo. Clinical trials are used to determine safety and efficacy.¹³

^a Level of certainty was operationalized as the 95-percent confidence interval surrounding the risk or odds estimate—i.e., the statistical significance.

- **Cohort study.** Cohort studies follow two or more similar groups that differ with respect to whether they received a vaccine (the “exposure”) to determine how/whether the vaccination affects rates of one or more AEs (the “outcome”).^{13,14}
- **Case-control study.** Case-control studies compare people who have a disease or adverse event (“cases”) with people who do not have the disease or event (“controls”) and look back retrospectively to compare exposure to vaccine in each group to determine the relationship between the vaccine and the disease/event.^{13,14}
- **Self-controlled case series (SCCS).** Only cases (individuals who experienced the AE) are included in the analysis. Each individual serves as his or her own control. The analysis inherently controls for covariates that remain stable within a person during the study period—for example, race and sex. SCCSs compare outcome event rates during times when a person is exposed (postvaccination) with those during times when the same person is unexposed (prevaccination) to calculate the relative incidence of AEs.^{13,15}
- **Other designs.** We included all active surveillance studies that used regression to control for confounders and test multiple relationships simultaneously. We refer to these as multivariate risk factor analyses. Data sources may include medical records, health insurance claims, and government registries.¹³

Studies that use passive surveillance, such as the U.S. Vaccine Adverse Event Reporting System,¹⁶ are crucial in identifying signals regarding AEs postlicensure. However, because by definition they do not consider the rate of such events in nonvaccinated populations, they are not designed to assess a statistical association between a vaccine and an adverse event, so such studies were excluded from this project. We also excluded studies of vaccine formulations never used or no longer available in the United States. Examples include whole-cell pertussis vaccine, oral polio vaccine, and PCV7 pneumococcal vaccine. The recent IOM report “The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies”¹⁷ makes recommendations for future research on childhood vaccination schedules and cumulative effect, so this report focuses on assessing the association between AEs and specific vaccines rather than the cumulative effect of vaccines.

Two researchers independently reviewed the titles and abstracts identified. The union of their selections was retrieved. Two researchers also independently reviewed the full text of study reports and met to reach consensus regarding exclusion/inclusion. Disputes were settled by the lead investigators and team physician experts. Patient and study characteristics were abstracted by single researchers and confirmed by the principal investigator.

If a study reported severity or if adequate information was provided for our investigators to categorize severity, we used the Common Terminology Criteria for Adverse Events classification system¹⁸ to characterize AEs. The definition of “serious” differs by AE type; each category of AE (e.g., fever, headache) is rated on a scale of 1 to 5, with 1 being very mild and 5 being death due to the event.

The McHarm instrument¹⁹ was used to evaluate the quality of the studies with regard to assessment of adverse events. Studies that reported timing and severity and that defined AEs using standard precise definitions were rated higher than those that did not. (Many studies provided data on a list of AEs but did not address severity.) Epidemiological studies that used medical records to ascertain vaccination and health outcomes were rated higher than those that relied on patient or parent report.

We assessed the overall strength of evidence using guidance suggested by AHRQ for its Effective Health Care Program.²⁰ This method is based on one developed by the GRADE

(Grading of Recommendations Assessment, Development and Evaluation) Working Group²¹ and classifies the evidence according to the following criteria:

- **High.** High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
- **Moderate.** Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
- **Low.** Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of effect and is likely to change the estimate.
- **Insufficient.** Evidence either is unavailable or does not permit a conclusion.

The evidence grade is based on four primary (required) domains and four optional domains. The required domains are risk of bias, consistency, directness, and precision, as described in the Methods section of the full report. The additional domains are dose response, plausible confounders that would decrease the observed effect, strength of association, and publication bias.

It is important to note that the 2011 IOM report used different terminology; evidence was classified as either “convincingly supports,” “favors acceptance,” “inadequate to accept or reject,” or “favors rejection” of a causal association. The IOM included mechanistic studies and individual case reports to assess the biological plausibility of AEs and considered this information in addition to any statistical association. For each vaccine discussed in the IOM report, we started with the IOM findings and modified them, if needed, based on any additional evidence identified. If the IOM found that evidence “convincingly supports” an association, we rated the strength of evidence as “high” unless additional evidence was identified. Similarly, if the IOM found evidence “favors acceptance” we started with by rating as “moderate” strength of evidence and evidence rated as “inadequate to accept or reject” was considered “insufficient” in our grading system. If new evidence was identified for vaccines evaluated by the IOM, ratings could be adjusted up or down according to our assessment of the new studies. If the IOM found that evidence “favors rejection” of a causal relationship we choose between moderate and high based on our review of the IOM evidence plus any studies published after their search.

Results


As presented in Figure A, a total of 20,478 titles were identified through electronic literature searches; review of product inserts; review of Food and Drug Administration, ACIP, and other Web sites; reference mining; and requests for Scientific Information Packets from drug manufacturers. Of those, 17,270 were excluded upon review of abstract or title, mostly due to lack of data on safety of vaccines. Other reasons for exclusion included use of vaccines not within the scope of this project (e.g., not formulations available in the United States, recommended only for travel), publication in languages other than English, and study not conducted on humans. Five reports could not be obtained; based on their titles, we do not think this affected the project.

Based on abstract screening, 3,210 articles were selected for full-text review. Of those, 392 were identified as relevant background/theoretical materials and set aside as potential references. A total of 2,650 other articles were excluded. The most common reason for exclusion was lack of suitable study design (1,549): individual case reports, nonsystematic reviews, and studies using passive surveillance were excluded. Many publications (458) discussed vaccines on the recommended schedule but did not report or assess AEs.

Studies using formulations never available or discontinued in the United States were excluded at full-text review (e.g., H5N1 vaccine, vaccines with the squalene adjuvant ASO3, and BCG vaccine against tuberculosis). Determining whether the potency or formulation was the one approved for clinical use in the United States was often difficult; the process involved comparing the potency, dosage, and ingredients listed on product materials and in Food and Drug Administration filings with the information reported in the study.

Based on full-text screening, 166 studies were accepted for abstraction. These include 86 controlled trials or cohort studies directly comparing a group that received a vaccine with an unvaccinated group. (Five of the 86 studies also reported a multivariate analysis.) We also abstracted 80 case-control studies, SCCSs, or multivariate risk factor analyses that met our inclusion criteria. These studies are in addition to those included in the 2011 IOM consensus report “Adverse Effects of Vaccines: Evidence and Causality,” which were not abstracted.

Figure A. Study/literature flow diagram



IOM = Institute of Medicine

^aFive studies also contributed multivariate risk factor analyses.

Table D displays a summary of our results. The second column displays the strength of evidence regarding statistical association of vaccines with AEs. Where we identified no additional studies on a vaccine, our conclusions are based entirely upon the 2011 IOM report. It is important to recognize that the strength of evidence refers to the chances the vaccine is truly associated with a particular AE, rather than the **rate** of that AE or **severity**. Strength of evidence may be high for an AE that is extremely rare, very mild, or without long-term consequences. Further details on the scientific evidence behind the findings are available in the full report and its appendices.

Importantly, the vast majority of studies did not report potential risk factors for AEs that were statistically associated with vaccination. Similarly, the severity of AEs was inconsistently reported, as was information that would make independent severity determination possible.

Table D. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Adults			
Diphtheria Toxoid, Tetanus Toxoid, and Acellular Pertussis Vaccines (Td, Tdap)	High: Anaphylaxis	Evidence “convincingly supports” a causal relationship between the tetanus toxoid vaccine and anaphylaxis.	We identified 2 additional trials in adults. No AEs were associated with vaccine.
Hepatitis A Vaccine	Insufficient: Acute disseminated encephalomyelitis, transverse myelitis, MS, GBS, chronic inflammatory demyelinating polyneuropathy, Bells' palsy, anaphylaxis, and autoimmune hepatitis	Evidence is “inadequate to accept or reject” any causal relationships with AEs the committee was tasked with investigating: acute disseminated encephalomyelitis, transverse myelitis, MS, GBS, chronic inflammatory demyelinating polyneuropathy, Bells' palsy, anaphylaxis, and autoimmune hepatitis.	We identified 1 additional postlicensure study; there was no association of the vaccine with any AEs or onset of medical conditions.
Hepatitis B Vaccine	Insufficient: Optic neuritis, first demyelinating event, GBS, SLE, onset or exacerbation of vasculitis, polyarteritis nodosa, and onset or exacerbation of rheumatoid arthritis Moderate: No association with MS onset or exacerbation Moderate: Anaphylaxis in patients allergic to yeast	Although no epidemiological studies were identified on anaphylaxis, mechanistic evidence “ favors acceptance ” of a causal relationship between the vaccine and anaphylaxis in yeast-sensitive individuals. Epidemiological studies of the following AEs in adults had evidence “ inadequate to accept or reject ” a causal relationship: optic neuritis, first demyelinating event, GBS, SLE, onset or exacerbation of vasculitis, polyarteritis nodosa, and onset or exacerbation of rheumatoid arthritis. A 2002 IOM review on Hep B vaccine and demyelinating neurological disorders concluded that the evidence “ favors rejection ” of a causal relationship with incident MS or MS relapse.	No additional studies met our inclusion criteria.

Table D. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Hepatitis B Vaccine (continued)		No epidemiological studies of the following AEs in adults were found and evidence is also “ inadequate to accept or reject ” a causal relationship: encephalitis, encephalopathy, ADEM, transverse myelitis, neuromyelitis optica, chronic inflammatory demyelinating polyneuropathy, brachial neuritis, erythema nodosum, onset or exacerbation of psoriatic arthritis, onset or exacerbation of reactive arthritis, and fibromyalgia.	
Influenza Vaccines	<p>High: Arthralgia, myalgia, malaise, fever, pain at injection site. Anaphylaxis in allergic persons.</p> <p>High: 2009 monovalent H1N1 vaccine with GBS</p> <p>High: No association with cardiovascular events in the elderly</p> <p>Insufficient: MS onset and exacerbation</p>	<p>Two forms of influenza vaccine were studied: live attenuated form, administered intranasally (LAIV), and inactivated form (TIV), administered intramuscularly.</p> <p>Evidence “convincingly supports” a causal relationship between influenza vaccines and anaphylaxis in people allergic to egg or gelatin. However, in recent years, manufacturers have reduced the egg protein content.</p>	<p>Many clinical trials reported that influenza vaccines are associated with arthralgia, myalgia, malaise, fever, and pain in the short term in adults. These AEs were not considered serious; severity was graded mild to moderate. Odds of experiencing these events were 1.5 to 2 times higher in vaccinated patients than in unvaccinated people. Risk factors were not discussed in the trials.</p> <p>A high-quality meta-analysis found an association between 2009 monovalent H1N1 vaccine and GBS in the 42 days postvaccination; results translate to about 1.6 excess cases per million vaccinated.</p> <p>Postlicensure studies have found inconsistent evidence associating influenza vaccines with onset or exacerbation of MS in adults.</p> <p>Postlicensure studies have found influenza vaccines are NOT associated with increased risk of cardiovascular or cerebrovascular events in the elderly.</p> <p>Postlicensure studies have shown that influenza vaccines are NOT associated with increased risk of serious AEs in renal patients.</p>

Table D. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
MMR Vaccine	Moderate: No association with Type 1 diabetes Moderate: Transient arthralgia in women Insufficient: MS onset, GBS, chronic arthralgia in women, and chronic arthritis and arthropathy in men	Evidence “ favors acceptance ” of a causal relationship with transient arthralgia in women. Evidence is “ inadequate to accept or reject ” a causal relationship with MS onset, GBS, chronic arthralgia in women, and chronic arthritis and arthropathy in men.	MMR was NOT associated with onset of type 1 diabetes in adults in 1 large high-quality epidemiological study: RR=0.71 (95% CI, 0.61 to 0.83).
Pneumococcal Polysaccharide Vaccine	High: No association with cardiovascular or cerebrovascular events in the elderly	Not covered.	We found no placebo-controlled trials of the current formulation that reported AE data. (We found trials of the current formulation that reported pneumonia or mortality; these were considered efficacy outcomes.) Postlicensure studies of pneumococcal polysaccharide vaccine found vaccination was not associated with increased risk of cardiovascular events in older adults.
Zoster Vaccine	Moderate: Injection site reactions, allergic reactions, cellulitis possibly related to allergy	Recommended for U.S. adults 60 years and older; AEs specific to this age group were not covered.	In some reports of clinical trials, AEs were reported only in categories such as “injection-related adverse events,” “systematic adverse events,” or “serious adverse events.” Vaccination was associated with injection site reactions. In postlicensure studies, vaccination was associated with cellulitis possibly related to allergy and allergic reactions such as redness and swelling 1 to 7 days postvaccination. These mild AEs occurred in less than 1% of patients and were more likely in the younger (aged 50-59) vaccinees.

Table D. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
<i>Children and Adolescents</i>			
Diphtheria Toxoid, Tetanus Toxoid, and Acellular Pertussis-Containing Vaccines (DTap, Td, Tdap)	Moderate: No association with type 1 diabetes Insufficient: Infantile spasms, seizures, cerebellar ataxia, autism, ADEM, transverse myelitis, MS relapse, serum sickness, immune thrombocytopenic purpura, and SIDS	<p>Evidence “favors rejection” of a causal relationship between vaccines containing diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens and type 1 diabetes.</p> <p>Evidence is “inadequate to accept or reject” causal relationships between vaccination and the following: infantile spasms, seizures, cerebellar ataxia, autism, ADEM, transverse myelitis, MS relapse in children, serum sickness, immune thrombocytopenic purpura, and SIDS.</p>	We found no additional studies that met our inclusion criteria.
Hepatitis B Vaccine	Insufficient: Food allergy Moderate: No association with MS	<p>Although no epidemiological studies were identified by the IOM, mechanistic evidence “favored acceptance” of a causal relationship between the vaccine and anaphylaxis in yeast-sensitive individuals. The IOM found evidence “inadequate to accept or reject” a causal relationship with any other AEs.</p> <p>A 2002 IOM report “favors rejection” of a causal relationship with MS onset or exacerbation.</p>	Hep B vaccine in the first 6 months of life was associated with elevated total IgE in a postlicensure study of children with a family history of food allergy, but not with clinical allergy.
Hib Vaccine	Moderate: No association with serious AEs in short term	Not covered.	No serious AEs were associated in 3 high-quality clinical trials.

Table D. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
HPV Vaccine	<p>Moderate: No association with juvenile rheumatoid arthritis, type 1 diabetes, appendicitis, GBS, seizures, stroke, syncope, venous thromboembolism</p> <p>Moderate: Anaphylaxis in persons with allergies, fever, headache, mild gastrointestinal AEs, skin infection</p> <p>High: Pain at injection site</p> <p>Insufficient: ADEM, transverse myelitis, neuromyelitis optica, MS, onset of Hashimoto's disease, chronic inflammatory demyelinating polyneuropathy, brachial neuritis, amyotrophic lateral sclerosis, transient arthralgia, pancreatitis, thromboembolic events, and hypercoagulable states</p>	<p>Evidence “favors acceptance” of a causal relationship between the HPV vaccine and anaphylaxis.</p> <p>Evidence is “inadequate to accept or reject” causal relationships between HPV vaccines and the following: ADEM, transverse myelitis, neuromyelitis optica, MS, GBS, chronic inflammatory demyelinating polyneuropathy, brachial neuritis, amyotrophic lateral sclerosis, transient arthralgia, pancreatitis, thromboembolic events, and hypercoagulable states.</p>	<p>A large postlicensure study found HPV vaccine was not associated with onset of juvenile rheumatoid arthritis or type 1 diabetes. This study reported an IRR of 1.29 (95% CI, 1.08 to 1.56) of onset of Hashimoto's disease. However, investigation of a temporal relationship and biological plausibility revealed no consistent evidence of a safety signal.</p> <p>A large postlicensure study found HPV vaccine was NOT associated with GBS, seizures, stroke, syncope, or venous thromboembolism.</p> <p>Several clinical trials found HPV vaccination associated with short-term severe pain at injection site. Trials also found vaccine associated with fever, headache, nausea, and stomach ache.</p> <p>A secondary analysis including only Black women who became pregnant within 3 to 4 years of receiving HPV vaccine in 2 trials reported a higher rate of spontaneous abortion in vaccinated subjects.</p>
Inactivated Polio Vaccine	Insufficient: Food allergy	Not covered.	One postlicensure study reported association between polio vaccine in newborns and sensitivity to food allergens.

Table D. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Influenza Vaccines	<p>Moderate: Mild gastrointestinal disorders, febrile seizures</p> <p>Low: No association with any serious AEs in the short term in children with cancer or who have received organ transplants</p> <p>Low: Influenza-like symptoms</p> <p>Insufficient: Asthma exacerbation (with live vaccine), ADEM, transverse myelitis</p>	<p>The IOM committee studied seasonal influenza vaccines. The influenza vaccine is administered in 2 forms: a live attenuated form, administered intranasally, and an inactivated form, administered intramuscularly.</p> <p>Evidence was “inadequate to accept or reject” a causal relationship in the pediatric population between seasonal influenza vaccines and the following: seizures, ADEM, and transverse myelitis.</p> <p>Evidence was “inadequate to accept or reject” a causal relationship between LAIV and asthma exacerbation or reactive airway disease episodes.</p>	<p>In postlicensure studies, seasonal influenza vaccines were NOT associated with any serious adverse events in the short term in children with malignancy, inflammatory bowel disease, or urea cycle disorders, or children who had received organ transplants.</p> <p>Both seasonal influenza vaccines and monovalent H1N1 vaccine were associated with mild gastrointestinal disorders, such as vomiting and diarrhea, in children in the short term in several large postlicensure studies. One large study found that younger vaccinated children (aged 5 to 8 years) were more likely to experience these symptoms than older vaccinated children (aged 9 to 17 years). (Children under 5 years of age were not included in that study).</p> <p>Both live and inactivated seasonal influenza vaccines were associated with influenza-like symptoms in children in the short term in multiple studies, while not associated in others. A large U.S. postlicensure study of children under age 5 years found TIV associated with febrile seizures. Risk was increased if PCV13 was administered concomitantly.</p>

Table D. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
MMR Vaccine	High: No association with autism spectrum disorders High: Anaphylaxis in children with allergies, febrile seizures Moderate: Transient arthralgia Moderate: Thrombocytopenic purpura Insufficient: Encephalitis, encephalopathy, afebrile seizures, meningitis, cerebellar ataxia, acute disseminated encephalomyelitis, transverse myelitis, optic neuritis, neuromyelitis optica, MS onset, and chronic arthropathy	Evidence “ convincingly supports ” causal relationships with febrile seizures and anaphylaxis. Evidence “ convincingly supports ” a causal relationship with measles inclusion body encephalitis in immunocompromised patients. Evidence “ favors acceptance ” of a causal relationship between MMR and transient arthralgia Evidence “ favors rejection ” of a causal relationship between MMR and autism. Evidence is “ inadequate to accept or reject ” a causal relationship with encephalitis, encephalopathy, afebrile seizures, cerebellar ataxia, acute disseminated encephalomyelitis, transverse myelitis, optic neuritis, neuromyelitis optica, MS onset, and chronic arthropathy.	Four additional postmarketing studies were identified. Vaccination was associated with thrombocytopenic purpura in the short term. MMR vaccination was associated with increased emergency department visits within 2 weeks; this is indirect support of the IOM’s findings that MMR vaccine is associated with febrile seizures.
Meningococcal Vaccines (MCV4, MPSV)	Moderate: Anaphylaxis in children with allergies Insufficient: Encephalitis, encephalopathy, ADEM, transverse myelitis, MS, GBS, CIDP, chronic headache	Evidence “ convincingly supports ” a causal relationship with anaphylaxis in children who may be allergic to ingredients. Evidence is “ inadequate to accept or reject ” causal relationships between meningococcal vaccine (unspecified) and the following: encephalitis, encephalopathy, ADEM, transverse myelitis, MS, GBS, CIDP, and chronic headache.	Two new trials of quadrivalent meningococcal conjugate vaccines found no association with any AEs assessed.

Table D. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Miscellaneous and Combination Vaccines	<p>Moderate: DTaP-IPV-Hib vaccination with febrile seizures</p> <p>High: No association of childhood leukemia with MMR, DTaP, Td, Hib, Hep B, and polio vaccines</p> <p>Moderate: Hepatitis A, MMR, and varicella vaccine with purpura</p>	Not covered.	<p>Association of DTaP-IPV-Hib vaccination with febrile seizures in children was found in a very large high-quality postlicensure study. Rate for first dose was estimated as 5.5 cases per 100,000 person/days. Rate for second dose was estimated as 5.7 cases per 100,000 person/days.</p> <p>Multiple large epidemiological studies have assessed MMR, DTaP, Td, Hib, Hep B, and polio vaccine and have found no association with childhood leukemia.</p> <p>In a large postlicensure study of over 1.8 million vaccine recipients, purpura was associated with vaccination against hepatitis A in children aged 7 to 17 years, vaccination against varicella in children aged 11 to 17, and MMR in children from 12 to 19 months of age. These results were based on 1 or 2 cases per vaccine type/age group. According to the authors most cases were mild and acute.</p>
Pneumococcal Conjugate (PCV13)	Moderate: Febrile seizures	Not covered.	A recent study using the U.S. Vaccine Safety Datalink (VSD) found an association with febrile seizures. Estimated rate for 16-month-old patients is 13.7 cases per 100,000 doses for PCV13 without concomitant TIV and 44.9 per 100,000 doses for concomitant TIV and PCV13.

Table D. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Rotavirus Vaccines: RotaTeq and Rotarix	Moderate: Intussusception	Not covered.	In clinical trials, there was no association between either of the 2 currently available vaccines (RotaTeq and Rotarix) and any serious AEs, including intussusception, in the long or short term. A high-quality epidemiological study in Australia found RotaTeq was associated with intussusception 1 to 21 days following the first of 3 required doses in infants 1 to 3 months of age. Two case-control studies conducted in Latin America found an association of Rotarix with intussusception in children following the first of 2 required doses. Although 1 U.S. epidemiological study found no association, a recent analysis of the U.S. Post-Licensure Rapid Immunization Safety Monitoring (PRISM) program found both RotaTeq and Rotarix associated with intussusception in the short term. Estimated rate was 1.1 to 1.5 cases per 100,000 doses of RotaTeq and 5.1 cases per 100,000 doses of Rotarix.
Varicella Vaccine	High: Anaphylaxis; disseminated Oka VZV without other organ involvement; disseminated Oka VZV with subsequent infection resulting in pneumonia, meningitis, or hepatitis in individuals with demonstrated immunodeficiencies; vaccine strain viral reactivation without other organ involvement; vaccine strain viral reactivation with subsequent infection resulting in meningitis or encephalitis	Evidence “ convincingly supports ” causal relationships between varicella virus vaccine and the following: disseminated Oka VZV without other organ involvement; disseminated Oka VZV with subsequent infection resulting in pneumonia, meningitis, or hepatitis in individuals with demonstrated immunodeficiencies; vaccine strain viral reactivation without other organ involvement; vaccine strain viral reactivation with subsequent infection resulting in meningitis or encephalitis; and anaphylaxis. The evidence is “ inadequate to accept or reject ” a causal relationship between the vaccine and seizures, ADEM, transverse myelitis, GBS, small fiber neuropathy, onset or exacerbation of arthropathy, and thrombocytopenia.	We identified 1 small trial in children with SLE; the trial reported no association with AEs.

Table D. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Varicella Vaccine (continued)	Insufficient: Seizures, ADEM, transverse myelitis, GBS, small fiber neuropathy, onset or exacerbation of arthropathy, thrombocytopenia		
<i>Pregnant Women</i>			
Influenza Vaccines	Moderate: No association with serious adverse events	Results not specific to pregnant women.	Both monovalent H1N1 vaccine and seasonal influenza vaccine (inactivated) containing H1N1 strains were not associated with serious adverse events in pregnant women or their offspring in multiple trials and postlicensure studies. Studies report an association with lower risk of adverse pregnancy outcomes.

ADEM = acute disseminated encephalomyelitis; AE = adverse event; CI = confidence interval; CIDP = chronic inflammatory demyelinating polyneuropathy; DTaP = diphtheria, tetanus, and pertussis vaccine; EPC = Evidence-based Practice Center; GBS = Guillain-Barré syndrome; Hep B = hepatitis B; Hib = *Haemophilus influenzae* type B; HPV = human papillomavirus; IgE = immunoglobulin E; IOM = Institute of Medicine; LAIV = live attenuated influenza vaccine; MMR = measles, mumps, rubella vaccine; MS = multiple sclerosis; SIDS = sudden infant death syndrome; SLE = systemic lupus erythematosus; Td = tetanus-diphtheria; TIV = trivalent influenza vaccine; IPV = inactivated polio vaccine; IRR = incidence rate ratio; MCV = meningococcal conjugate vaccine; MPSV = meningococcal polysaccharide vaccine; PCV = pneumococcal conjugate vaccine; RR = relative risk; Tdap = tetanus, diphtheria, and acellular pertussis vaccine; VZV = varicella-zoster virus

Discussion

In 2011, the IOM released “Adverse Effects of Vaccines: Evidence and Causality.” At the request of AHRQ and OASH, we assessed the additional evidence on the safety of vaccines recommended for routine use among adults, children, and pregnant women as of 2011. We conducted an extensive literature search for clinical trials and observational studies with strong study designs and analysis methods: cohort studies comparing vaccinated and unvaccinated groups, case-control studies, self-controlled case series, and designs using multivariate risk factor analyses. Our results support most findings of the IOM report, add conclusions on some adverse events for which new evidence was identified, and include findings on additional vaccines.

Our findings may allay some patient, caregiver, and health care provider concerns. Strength of evidence is high that vaccines against pneumonia and influenza are not associated with cardiovascular or cerebrovascular events in the elderly; many studies reported a decreased risk for vaccinated patients. Strength of evidence is high that MMR vaccine is not associated with the onset of autism in children; this conclusion supports findings of all previous reviews on the topic. There is moderate-strength evidence that HPV vaccine is not associated with appendicitis, stroke, seizures, syncope, venous thromboembolism, onset of juvenile arthritis, or onset of type 1 diabetes and high-strength evidence that MMR, DTaP (diphtheria, tetanus, and pertussis), Td (tetanus-diphtheria), Hib (*Haemophilus influenzae* type B), and hepatitis B vaccines are not associated with childhood leukemia.

Evidence of association with vaccines was found for several serious AEs; however, these events were extremely rare. Absolute risk is extremely rare. Strength of evidence is high that 2009 monovalent H1N1 influenza vaccine was associated with Guillain-Barré syndrome (GBS), but results translate to about 1.6 additional cases per million persons vaccinated. Since 2010, U.S. seasonal influenza vaccines have contained an H1N1 strain. No association with GBS has been found for inactivated seasonal vaccine (TIV). Strength of evidence is moderate for association of vaccines against rotavirus with intussusception. Although one U.S. epidemiological study found no association, a recent analysis of the U.S. Post-Licensure Rapid Immunization Safety Monitoring (PRISM) program²² found both RotaTeq and Rotarix associated with intussusception in the short term. Estimated rate was 1.1 to 1.5 cases per 100,000 doses of RotaTeq and 5.1 cases per 100,000 doses of Rotarix.

Evidence is insufficient to make conclusions regarding whether several routinely recommended vaccines are associated with serious conditions such as multiple sclerosis (MS), transverse myelitis, and acute disseminated encephalomyelitis (ADEM). This leaves an important research gap.

We identified a recent secondary analysis of data on Black women who participated in two placebo-controlled trials of quadrivalent HPV vaccine (Gardasil) conducted in several countries. In women who became pregnant in the 4 years following the trial, there was a significantly higher rate of spontaneous abortion for women who were vaccinated.²³ The authors state that the rate of “fetal loss” was statistically similar for vaccinees and nonvaccinees; however, “fetal loss” included planned abortion. In the vaccine group, 19 of 307 pregnancies resulted in spontaneous abortion, compared with 7 of 393 pregnancies in the control group. Databases such as the Vaccine Safety Datalink (VSD) could be used to further investigate this signal in a much larger population.

Conclusions must be viewed in light of the important caveats below.

Literature search procedures were extensive; however, some unpublished trial results may not have been identified. An independent Scientific Resource Center under contract with AHRQ requested Scientific Information Packets from vaccine manufacturers. (The research team was prohibited from contacting manufacturers directly.) Only two companies responded.

We included trials of the formulations currently on the market in the United States. We tried to exclude Phase II studies that used dosages that were never licensed and/or formulations available only in foreign countries. Some studies reported the potency or formulation of the vaccines in a different manner or unit than reported in the product materials. Large epidemiological studies sometimes included any available formulation of vaccines against a particular disease and did not stratify results by dosage or formulation. For example, the relationship between the “seasonal influenza vaccine” and an AE could be studied over several years of data without addressing the changes in formulation over the seasons.

Our findings are based on only the most rigorous study designs to assess potential statistical associations; however, these designs have limitations that must be considered. Controlled trials often have insufficient sample size to identify very rare AEs and do not have extended followup to identify long-term sequelae. In addition, trials may purposely exclude subjects such as the elderly, pregnant women, and people with medical conditions who could be more susceptible to AEs. For this reason, any comprehensive review of vaccine safety also includes postlicensure studies, but these are not without limitations. People who avoid vaccinations (whether purposely or not) may differ from those who receive vaccinations in terms of race, sex, age, socioeconomic status, and preexisting medical conditions, and these differences may be associated with health outcomes. Observational studies attempt to control for such potential confounders by using matched cohorts or multivariate regression analysis; still, some factors such as environmental exposures may be unmeasured or challenging to adequately control for. The self-controlled case series was developed specifically to assess the safety of vaccines; this method eliminates confounding by all time-independent variables by using cases as their own controls and predefined “time windows” before and after vaccination. This design has been used to study purpura, febrile seizures, intussusception, and autism in children. The SCCS assumption of no temporal shifts is difficult to justify in very young children, as any patient characteristics that change with time will not be adequately controlled for.

There may be important AE signals not identified in this report that warrant future research. Passive surveillance systems such as the U.S. Vaccine Adverse Event Reporting System¹⁶ are crucial in identifying signals regarding AEs postlicensure, but they are not designed to assess a statistical association so were excluded from this project. The research gaps below are based on the study designs that met our inclusion criteria.

Research Gaps

Adults

There was insufficient evidence to determine whether influenza vaccines are associated with onset or exacerbation of MS.

The unknown association regarding MS and GBS and vaccines for MMR and hepatitis A also presents a research gap; the IOM found evidence inadequate to accept or reject a causal relationship. As these medical conditions are extremely rare, “insufficient” evidence determination may be unavoidable despite additional research.

A recent meta-analysis on 2009 monovalent H1N1 vaccine provided high-strength evidence of association with GBS in adults. As the vaccine is associated with only 1.6 excess cases per million vaccinated, it will be very difficult to assess risk factors.

Some published vaccine trials were not specific in reporting AEs. Broad categories such as “injection-related adverse events,” “systemic adverse events,” “one or more adverse events,” or “serious adverse events” were reported rather than specific AEs. In addition, many studies reported on a list of predefined AEs but did not rate the severity or provide enough information for our investigators to determine severity. Future studies of vaccines should report results with more granularity.

Children and Adolescents

There is insufficient evidence to determine any potential association between trivalent inactivated vaccine and asthma exacerbation, acute disseminated encephalomyelitis, and transverse myelitis.

Febrile seizures were associated with MMR, influenza, and pneumococcal conjugate vaccines. Younger age was associated with increased risk in several studies. Large-scale epidemiological studies could determine other patient risk factors.

A large U.S. postlicensure study found associations between both Rotarix and RotaTeq and intussusception in the short term following vaccination; patient risk factors were not reported.

Strong evidence for a lack of association of HPV vaccines with several serious medical conditions (juvenile rheumatoid arthritis, type 1 diabetes, GBS) has been found in large postlicensure studies. However, there is insufficient evidence regarding other serious conditions such as MS, chronic inflammatory demyelinating polyneuropathy, amyotrophic lateral sclerosis, and pancreatitis. Importantly, a recent analysis of long-term followup data from Black women enrolled in two trials of Gardasil showed a possible increased risk of miscarriage of pregnancies within 4 years of vaccination. Large datasets from U.S. managed care organizations include medical records on both immunization and pregnancy, so they could be used to investigate any potential association.

There is insufficient evidence to determine the possible association, if any, between vaccines such as DTaP, meningococcal vaccine, and varicella vaccine and the onset of nervous system conditions such as ADEM, transverse myelitis, MS, and GBS. Large-scale epidemiological studies could provide additional data; however, as these medical conditions are extremely rare, it may not be possible to reach a level of evidence beyond “insufficient.”

Pregnant Women

There is moderate strength of evidence that inactivated influenza vaccine is not associated with serious adverse events in pregnant women or their offspring. Given the 2013 recommendation to administer the Tdap vaccine during every pregnancy, passive surveillance systems should be monitored regularly for AEs in this population.

A reliable system of tracking when in pregnancy the vaccine was given is extremely important. In addition, in any study of vaccines and pregnancy, followup of newborns should be sufficiently long, as not all adverse effects may be apparent immediately after birth. The need for large numbers of pregnant exposures is particularly important given the relatively low frequency of some birth defects and the need to define which are associated with vaccine. In addition, little is known about the patient factors that may influence the effect of the vaccine. Another unknown is how vaccination in pregnancy may affect the newborn's immune system/reaction to newborn

vaccinations. The Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) has components to monitor safety of maternally administered vaccines and their effect on recipients and their offspring. VAMPSS is a collaboration of the American Academy of Allergy, Asthma & Immunology; the Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego; and the Slone Epidemiology Center (SEC) at Boston University. The U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority contracted VAMPSS to perform safety monitoring of H1N1 influenza vaccine administered during the 2009 pandemic. As this report was being finalized, a VAMPSS study on the safety of H1N1 was released;^{24,25} the authors found no meaningful evidence of increased risk of major birth defects, miscarriage, or low birth weight for gestational age. Existing Federal systems such as the VSD and/or PRISM could potentially be used as well.

General Methodological Observations

Advanced health information technology systems that contain both vaccination and health outcome records can be used to conduct high-quality epidemiological studies. In the United States, the VSD contains data obtained through such systems at nine very large managed care organizations. The FDA's Mini-Sentinel program PRISM system also conducts active surveillance using electronic health care databases from managed care organizations. Nations with single-payer health care systems often have electronic registries that allow very large epidemiological studies of entire populations. Studies using these databases have greater validity than studies that rely on surveys that use patient/parent recall for ascertainment of vaccination or health outcome. Not only are such surveys subject to recall bias, but there may be no way of determining the formulation or brand of vaccination.

Observational studies should be powered adequately to determine risk factors such as demographic and health characteristics of patients. Analysis should be stratified by formulation and brand of vaccine, if possible. This is especially true for influenza vaccine, which differs from season to season.

Independent abstraction and systematic reassessment of the studies included in the IOM consensus report "Adverse Effects of Vaccines: Evidence and Causality" may be a useful future endeavor. Odds ratios could be calculated for each event reported in each trial and postlicensure study and, where appropriate, meta-analysis conducted to calculate overall odds ratios for each AE and each vaccine type. If the additional studies were abstracted, the totality of data abstracted could be statistically analyzed to explore additional hypotheses and issues beyond the scope of the current report.

References

1. Ten great public health achievements--United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999 Apr 2;48(12):241-3. PMID: 10220250.
2. National, state, and local area vaccination coverage among children aged 19-35 months - United States, 2011. MMWR Morb Mortal Wkly Rep. 2012 Sep 7;61:689-96. PMID: 22951450.
3. National and state vaccination coverage among adolescents aged 13-17 years - United States, 2011. MMWR Morb Mortal Wkly Rep. 2012 Aug 31;61:671-7. PMID: 22932301.
4. Adult vaccination coverage--United States, 2010. MMWR Morb Mortal Wkly Rep. 2012 Feb 3;61(4):66-72. PMID: 22298302.
5. Influenza vaccination coverage among pregnant women--United States, 2010-11 influenza season. MMWR Morb Mortal Wkly Rep. 2011 Aug 19;60(32):1078-82. PMID: 21849964.
6. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998 Feb 28;351(9103):637-41. PMID: 9500320.
7. Retraction--Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 2010 Feb 6;375(9713):445. PMID: 20137807.
8. Freed GL, Clark SJ, Hibbs BF, et al. Parental vaccine safety concerns. The experiences of pediatricians and family physicians. Am J Prev Med. 2004 Jan;26(1):11-4. PMID: 14700706.
9. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2011. Ann Intern Med. 2011;154(154):168-73.
10. Centers for Disease Control and Prevention. ACIP Recommendations Advisory Committee for Immunization Practices (ACIP). www.cdc.gov/vaccines/pubs/acip-list.htm. Accessed April 2012.
11. Centers for Disease Control and Prevention. Guidelines for Vaccinating Pregnant Women. www.cdc.gov/vaccines/pubs/preg-guide.htm. Accessed April 2012.
12. Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: The National Academy Press; 2011.
13. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. www.cochrane-handbook.org.
14. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003 Jan;20(1):54-60. PMID: 12533370.
15. Whitaker HJ, Farrington CP, Spiessens B, et al. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006 May 30;25(10):1768-97. PMID: 16220518.
16. Haber P, Iskander J, Walton K, et al. Internet-based reporting to the Vaccine Adverse Event Reporting System: a more timely and complete way for providers to support vaccine safety. Pediatrics. 2011 May;127(Suppl 1):S39-S44. PMID: 21502243.
17. Institute of Medicine. The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies. Washington, DC: The National Academies Press; 2013.
18. National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. May 28, 2009.

19. Santaguida PL, Raina P. The Development of the McHarm Quality Assessment Scale for Adverse Events: Delphi Consensus on Important Criteria for Evaluating Harms. 2008. <http://hiru.mcmaster.ca/epc/mcharm.pdf>. Downloaded December 2008.
20. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--Agency for Healthcare Research and Quality and the effective health-care program. *J Clin Epidemiol*. 2010 May;63(5):513-23. PMID: 19595577.
21. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol*. 2011 Apr;64(4):401-6. PMID: 21208779.
22. Yih K, Lieu T, Kulldorff M, et al. Intussusception Risk After Rotavirus Vaccination in U.S. Infants. Mini-Sentinel Coordinating Center; June 2013. www.minisentinel.org/work_products/PRISM/Mini-Sentinel_PRISM_Rotavirus-and-intussusception-Report.pdf. Accessed June 2013.
23. Clark LR, Myers ER, Huh W, et al. Clinical trial experience with prophylactic human papillomavirus 6/11/18 vaccine in young black women. *J Adolesc Health*. 2013 Mar;52(3):322-9. PMID: 23299013.
24. Louik C, Ahrens K, Kerr S, et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: exposure prevalence, preterm delivery, and specific birth defects. *Vaccine*. 2013 Oct 17;31(44):5033-40. PMID: 24016804.
25. Chambers CD, Johnson D, Xu R, et al. Risks and safety of pandemic h1n1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. *Vaccine*. 2013 Oct 17;31(44):5026-32. PMID: 24016809.

Introduction

Background

Vaccines are considered one of the greatest public health achievements of the last century for their role in eradicating smallpox and controlling polio, measles, rubella, and other infectious diseases in the United States.¹ Despite their effectiveness in preventing and eradicating disease, substantial gaps in vaccine uptake exist. Vaccination rates for young children are high,² however, vaccination rates remain well below established Healthy People 2020 targets for many vaccines recommended for adolescents,³ adults,⁴ and pregnant women.⁵

Increasing vaccination rates remains critically important, as vaccine-preventable diseases such as influenza, pertussis, and human papillomavirus (HPV)-associated cervical cancer continue to take a heavy toll despite the widespread availability of effective vaccines. The health and productivity costs of influenza infection alone in adults have been estimated to be as high as \$87 billion per year.⁶ The recent pertussis outbreaks in California, Washington, Minnesota, and Wisconsin highlight the importance of protecting vulnerable infants by vaccinating their pregnant mothers, caregivers, and other contacts. HPV is the most common sexually transmitted infection. HPV-16 and HPV-18—two strains included in the HPV vaccine—are thought to be responsible for approximately 70 percent of incident cervical cancer. Nationally, in 2005, there were nearly 12,000 new cases of cervical cancer reported, with 4,000 cervical cancer-related deaths.⁷ Despite the availability of an HPV vaccine that could prevent a substantial proportion of these cases of cervical cancer, completion of the three-dose series was only 34.8 percent among adolescent females in 2011.³

The shortfall in vaccination coverage rates occurs in the context of a rapidly changing immunization schedule. Routine immunizations recommended as of October, 2011 for children (Table 1), adolescents (Table 1), adults (Table 2), and pregnant women (Table 3) are presented below. Since 2005, the routine adolescent vaccination schedule has grown to include these vaccines at ages 11 or 12 years: meningococcal conjugate vaccine; tetanus, diphtheria, and acellular pertussis (Tdap); HPV; and influenza (one dose annually). In 2013, pregnant women were advised to receive Tdap during every pregnancy to protect their newborns from pertussis regardless of prior history of receiving Tdap.⁸

Table 1. Vaccines routinely recommended for children and adolescents, 2011

Vaccine	Age
DTaP (diphtheria, tetanus, and acellular pertussis)	2 months–6 years
Hepatitis A	12 months and older
Hepatitis B	Birth and older
Hib (<i>Haemophilus influenzae</i> type b)	6 weeks–59 months
HPV (human papillomavirus)	9 years–21 years (male) 9 years–26 years (female)
Influenza (inactivated)	6 months and older
Influenza (live attenuated)	2 years and older
IPV (inactivated polio vaccine)	6 weeks and older
MCV (meningococcal conjugate vaccine)	2 years and older
MMR (measles, mumps, and rubella)	12 months and older
MPSV (meningococcal polysaccharide vaccine)	2 years and older, in specific circumstances
PCV13 (pneumococcal conjugate vaccine)	6 weeks–18 years
Pneumococcal polysaccharide vaccine	2 years and older, in specific circumstances
Rotavirus	6 weeks–8 months
Tdap (tetanus, diphtheria, and acellular pertussis)	7 years and older
Varicella	12 months and older

Table 2. Vaccines routinely recommended for nonpregnant adults, 2011

Vaccine	Recommendation
Hepatitis A	All adults at increased risk for hepatitis A infection
Hepatitis B	All unvaccinated adults at risk for or requesting protection from Hepatitis B infection
HPV (human papillomavirus)	Adults 26 years and younger
Influenza (inactivated)	All adults
Influenza (live attenuated)	All adults 49 years and younger
Meningococcal conjugate vaccine (MCV4) and meningococcal polysaccharide vaccine (MPSV)	Adults at risk of meningococcal disease (MCV4 or MPSV if younger than 55 years; MPSV if older than 55 years)
MMR (measles, mumps, and rubella)	All adults who are not immune through prior infection
Pneumococcal polysaccharide vaccine	Adults 64 years and younger with certain conditions, and all adults 65 years and older
Td (tetanus, diphtheria)	All adults
Tdap (tetanus, diphtheria, and acellular pertussis)	All adults 19–64 years old; some adults 65 years and older
Varicella	All adults without evidence of varicella immunity
Zoster	All adults 60 years and older

Table 3. Vaccines routinely recommended for pregnant women, 2011

Vaccine	Recommendation
Hepatitis B	Recommended in some circumstances
Influenza (inactivated)	All pregnant women
Td (tetanus, diphtheria)	Should be used if indicated
Tdap (tetanus, diphtheria, and acellular pertussis)	All pregnant women after first trimester if indicated*

*In 2013, pregnant women were advised to receive Tdap during pregnancy to protect their newborns from pertussis.

As the number of recommended immunizations has expanded across the population, so too have concerns about the safety of vaccines, despite the rigorous processes new vaccines must undergo before receiving approval from the U.S. Food and Drug Administration (FDA). Vaccine development and commercialization are complex processes, and the regulatory review process is overseen by the Center for Biologics Evaluation and Research of the FDA.⁹ Vaccines are unique when compared with many other medications because they are administered to a large population of mostly young healthy people to prevent rather than treat disease. Vaccines must meet stringent criteria for safety, efficacy, and potency. Preclinical studies are conducted in the early stages of vaccine development and are meant to be sufficient to rule out overt toxicity and identify potential toxic effects that might occur during the clinical trial. Once a vaccine is ready for clinical evaluation, an Investigational New Drug application must be submitted so the FDA can monitor the safety of clinical trial subjects and ensure that the study design is appropriate to assess the vaccine's effectiveness and safety.

The clinical evaluation of a vaccine typically consists of three phases.⁹ Phase I studies—which typically enroll 20 to 80 subjects—are designed to evaluate vaccine safety and tolerability and to generate preliminary immunogenicity data. Phase II studies evaluate the immunogenicity of the vaccine and provide preliminary estimates on the rates of common adverse events, typically enrolling several hundred subjects. Phase III trials provide the information on a vaccine's safety and efficacy that is required to support licensure. After a vaccine is licensed and in use, multiple systems are in place to ensure ongoing assessments of safety,¹⁰ including post licensure safety surveillance conducted by sponsors as postmarketing commitments or requirements to the FDA,¹¹ the FDA's Post-Licensure Rapid Immunization Monitoring (PRISM) system,¹²⁻¹⁴ FDA surveillance using databases of Federal Partners such as the Centers for Medicare and Medicaid Services (CMS),¹⁵ the Vaccine Adverse Event Reporting System (VAERS) co-administered by the FDA and the Centers for Disease Control and Prevention (CDC),¹⁶ CDC's Vaccine Safety Datalink,¹⁷ and CDC's Clinical Immunization Safety Assessment project.¹⁸

Despite the stringent regulation and evaluation of vaccines, public concerns about vaccine safety continue to persist. Perhaps the most highly publicized safety concern of the last two decades has been the alleged link between autism and the MMR vaccine, first reported in *The Lancet* by Dr. Andrew Wakefield.¹⁹ Vaccination rates for measles, mumps, and rubella plummeted in the United Kingdom leading to measles outbreaks²⁰ and concern about vaccines and autism spread globally. In 2010, *The Lancet* fully retracted the 1998 publication,²¹ noting that elements of the manuscript had been deliberately falsified. Subsequently, Dr. Wakefield was barred from practicing medicine in the United Kingdom. Although multiple large studies have confirmed the lack of association between MMR and autism, parental worries about the safety of the vaccine persist. In addition to autism, other parental concerns about childhood vaccines include possible links to multiple sclerosis, sudden infant death syndrome, asthma, and diabetes.²² Though no systematic data exist on the safety concerns of pregnant women, this is likely to be an active focus given the relatively recent introduction of the recommendation to administer the Tdap vaccine during pregnancy.

The Agency for Healthcare Research and Quality (AHRQ) requested an evidence report on the safety of vaccines used for routine immunization of adults (including pregnant women), children, and adolescents that will, based on a comprehensive and systematic review of the scientific literature, describe associations between vaccines and adverse events (AEs) and help to outline the gaps in evidence. This report focuses on the adverse events (AEs) potentially

associated with vaccines as opposed to the benefits, as all of these vaccines are already recommended.

Our work expands upon the consensus report “Adverse Effects of Vaccines: Evidence and Causality,” published by the Institute of Medicine (IOM) in late 2011. That report evaluated the scientific evidence for event-vaccine relationships and covered many vaccines included in the 2011 U.S. recommended immunization schedules (varicella, influenza, Hepatitis A, Hepatitis B, HPV, MMR, meningococcal, tetanus, diphtheria, and pertussis). Our work builds upon the IOM report in a number of important ways. In addition to vaccines covered by the IOM report, our systematic review covers pneumococcal, rotavirus, *Haemophilus influenzae* type b, inactivated poliovirus, and zoster vaccines. We report the 2011 IOM conclusions, update the literature with more recent studies, and conduct original searches for the recommended vaccines that were not included; we provide an assessment of AEs reported.

Methods

Original Proposed Key Questions

AHRQ provided following original Key Questions (KQs). Not all questions were answerable through a systematic review of the published research; we discuss important research gaps later in this report.

- **KQ 1.** What is the evidence that vaccines included in the 2011 immunization schedule recommended for U.S. **adults**²³ are safe in the short term (within 30–42 days following immunization) or long term (>42 days after immunization)?
 - a. What adverse events (AEs) are collected in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?
 - b. What AEs are reported in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?
 - c. What AEs are associated with these vaccines?
 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 3. For each AE associated with a particular vaccine, what are the risk factors for the AE (including age, sex, race/ethnicity, genotype, underlying medical condition, whether a vaccine is administered individually or in a combination vaccine product, schedule of vaccine administration, adjuvants, and medications administered concomitantly)?
- **KQ 2.** What is the evidence that vaccines included in the immunization schedules recommended for U.S. **children and adolescents** in 2011²⁴ are safe in the short term (within 30–42 days following immunization) or long term (>42 days after immunization)?
 - a. What AEs are collected in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?
 - b. What AEs are reported in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?
 - c. What AEs are associated with these vaccines?
 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 3. For each AE associated with a particular vaccine, what are the risk factors for the AE (including age, sex, race/ethnicity, genotype, underlying medical condition, whether a vaccine is administered individually or in a combination vaccine product, schedule of vaccine administration, adjuvants, and medications administered concomitantly)?

^a Level of certainty was operationalized as the 95-percent confidence interval surrounding the risk or odds estimate—i.e., the statistical significance.

- **KQ 3.** What is the evidence that vaccines recommended for **pregnant women**²⁵ are safe both for the woman and for her fetus/infant?
 - a. What AEs are collected in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?
 - b. What AEs are reported in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?
 - c. What AEs are associated with these vaccines in women?
 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 3. For each AE associated with a particular vaccine, what are the risk factors for the AE (including age, sex, race/ethnicity, genotype, underlying medical condition, whether the vaccine is administered individually or in a combination vaccine product, the schedule of vaccine administration, adjuvants, and medications administered concomitantly)?
 - d. What AEs are associated with these vaccines in the fetus/infant?
 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 3. For each AE associated with a particular vaccine, what are risk factors for the AE (including age, gender, race/ethnicity, genotype, underlying medical condition, whether vaccine administered individually or in a combination vaccine product, vaccine schedule of administration, adjuvants, medications administered concomitantly)?

Technical Expert Panel

For each Agency for Healthcare Research and Quality (AHRQ) systematic review, a Technical Expert Panel (TEP) is assembled to provide clinical expertise and context. A distinguished group of scientists and clinicians were invited to participate in the TEP for this report. Potential members submitted conflict of interest disclosure forms; any current or prior relationship with a vaccine manufacturer was grounds for disqualification per AHRQ. A list of members is included in the front matter.

TEP conference calls were held on June 18, June 19, and July 19, 2012; they were attended by project staff and Task Order Officers (TOO) from AHRQ and the Office of the Assistant Secretary for Health (OASH). The TEP informed staff of recent developments in the field, gave input on which AEs and issues were most important, and emphasized we should only include studies which use the same dosage and formulation as currently used in the U.S. Vaccines with adjuvants not currently used in the U.S. (for example, ASO3) or strengths that were never licensed in the U.S. (for example, those used in Phase II studies that did not advance to Phase III)

^a Level of certainty was operationalized as the 95-percent confidence interval surrounding the risk or odds estimate—i.e., the statistical significance.


should be excluded. They also advised that, given resource limitations, minor AEs such as crying and injection site redness need not be discussed in the report.

Panel members were invited to review the draft version of this report and provide feedback.

Analytic Framework

The analytic framework for the project is displayed in Figure 1. Vaccinations recommended by the Centers for Disease Control and Prevention (CDC) are listed in the large oval. Various subsets are administered annually to children, adolescents, and adults, including pregnant women (next circle), according to a schedule developed by the Advisory Committee on Immunization Practices (ACIP). Both patient factors (i.e., age, pre-existing conditions) and vaccine factors (i.e., formulation, dosage, and timing) may be risk factors for potential AEs.

Figure 1. Analytic framework



Hep A = hepatitis A; Hep B = hepatitis B; HPV = human papillomavirus; MMR = measles, mumps, rubella

Literature Search

The following databases were searched to identify relevant studies: DARE, the Cochrane Database of Systematic Reviews, CENTRAL, PubMed®, EMBASE®, CINAHL®, TOXLINE®, and TOXFILE®. The Institute of Medicine (IOM) report, ACIP statements, and vaccine package inserts were reviewed. Review articles were mined for references.

Our search strategy built upon the recent IOM report for the eight vaccines contained therein. Using the IOM keyword search strategy, we updated their searches on varicella, influenza, Hepatitis A, Hepatitis B, HPV, MMR, meningococcal, diphtheria, pertussis, and tetanus vaccines to identify more recently published studies. The following structure was used in the IOM keyword search strategy: “vaccine term” AND “health term,” where vaccine terms include the technical vaccine name, general descriptions of the vaccine of interest (e.g., rotavirus AND

vaccine), or manufacturer names; health terms include a list of AEs potentially associated with the vaccine. We also added more general AE keywords to the list of health terms such as “safe” or “safety,” “side effect” or “harm.” We searched from a year before the publication of the IOM report through August, 2013.

Using this approach, we developed new search strategies for the vaccines not originally included in the IOM report: pneumococcal, rotavirus, *H. influenzae* type b, inactivated poliovirus, and zoster. We searched each of the databases mentioned above from their inception to August, 2013.

Searches were based on AEs reported in systems such as the Vaccine Injury Compensation Program (VICP), Vaccine Adverse Event Reporting System (VAERS) and the FDA’s Mini-Sentinel Program. The Technical Expert Panel (TEP) reviewed the draft list of AEs and suggested additional AEs of interest. Appendix A contains the detailed search strategy and a list of AEs included in the searches.

Article Review

Two researchers independently reviewed the titles and abstracts identified. The union of their selections was retrieved. Two researchers also independently reviewed the full text of study reports, entered data into an electronic form, and met to reach consensus on any conflicts regarding exclusion/inclusion. Disputes were settled by the lead investigators and team physician experts.

Data were entered directly by researchers into DistillerSR software (Evidence Partners Inc., Ottawa, Ontario, Canada),²⁶ which is designed specifically for systematic reviews and meta-analyses, and exported to SAS (SAS Institute Inc., Cary, NC) for analysis.

Study Inclusion

We included the following study designs:

- **Controlled clinical trial**—A study where human subjects are assigned prospectively, usually through randomization, to receive an intervention (in this case a vaccine) or an alternate intervention (another vaccine) or placebo. Clinical trials are used to determine safety and efficacy.²⁷
- **Cohort study**—Follows two or more groups who differ with respect to whether they received a vaccine (the “exposure”), over time to determine how/whether the vaccination affects rates of one or more adverse events (the “outcome”).^{27,28}
- **Case-control study**—A study that compares persons who have a disease or adverse event (AE) (cases) with persons who do not have the disease or AE (the “outcome”), and looks back retrospectively to compare exposure to vaccine in each group to determine the relationship between the vaccine and the disease / AE.^{27,28}
- **Self-controlled case series (SCCS)**—Only cases (individuals who experienced the AEs) are included in the analysis. With SCCS, each individual serves as their own control. The analysis inherently controls for covariates that remain stable within a person during the study period; for example, race and gender. SCCS compares outcome event rates during times when a person is exposed (post-vaccination) with those during times when the same person is unexposed (pre-vaccination) to calculate the relative incidence of AEs.^{27,29}
- **Other designs**—We included all active surveillance studies that used regression to control for confounders and test multiple relationships simultaneously. We refer to these

as multivariate risk factor analyses. Data sources may include medical records, health insurance claims, and government registries.²⁷

Studies using passive surveillance such as the U.S. Vaccine Adverse Event Reporting System (VAERS)¹⁶ are crucial in identifying signals regarding adverse events post-licensure. However, because by definition they do not consider the rate of such events in non-vaccinated populations, they are not designed to assess a statistical association between a vaccine and an adverse event, so they were excluded from this project. We also excluded studies of vaccines not on the current U.S. recommended schedules. These include brands and formulations never available in the United States and or no longer used. Examples include whole cell pertussis vaccine, oral polio vaccine, and PCV7 pneumococcal vaccine.

The following publication types/studies were **excluded**:

- Letters
- Editorials
- Individual case reports
- Animal studies
- Mechanistic/in vitro studies
- Conference abstracts
- Vaccine efficacy studies that did not report the presence or absence of AEs
- Observational studies which use passive surveillance for AEs
- Non-English-language studies. (Given the focus of this review and the corresponding literature base, we concluded the risk of language bias to be low and that it was thereby acceptable to limit the inclusion criteria to English studies only.)
- Studies of vaccines not on the U.S.-recommended schedules, including brands/formulations never available in the United States, or no longer used.

Data Abstraction and Synthesis of Results

Based on our experience conducting systematic reviews of the evidence on other health care interventions, we developed a structured approach to assessing AEs instead of relying on a random post hoc grouping. We used a tested and standardized form to extract AEs. If a study reported severity, or if adequate information was provided for our investigators to categorize severity, we used the Common Terminology Criteria for Adverse Events (CTCAE) classification system³⁰ to characterize AEs. Serious adverse events (SAE) were defined and coded. The definition of “serious” differs by AE type; each category of AE (i.e. fever, headache) is rated on a scale of 1 to 5, with 1 being very mild and 5 being death due to the event.

Clinical trials and cohort comparisons were abstracted using an electronic form which contained items for sample size, population description (age, gender, race/ethnicity, country, any co-morbidities), items on study quality (described below), vaccine description (name, manufacturer, dosage, formulation, adjuvants, preservatives, timing, mode of administration), and AEs (exact description, severity, timing, number) for each group. Odds ratios of AEs for vaccination and comparison arms were computed for each study, along with the 95% confidence interval. Studies were included for analysis if the total number of people in each group and the number of people with events in each group were reported. Occasionally, this information was missing, or the number of AEs and number of doses (rather than number of persons) was provided. Since AEs are generally rare, conditional pooling using exact methods provided a fixed effects estimate of the odds ratio. Analyses were conducted with StatXact® Procs for

SAS.³¹ Subgroup analyses are narrative in order to be able to make comparisons between study designs and other variables in the heterogeneous dataset.

The case-control, self-controlled case series, and multivariate risk factor analyses were abstracted onto a different electronic form containing similar items; however, the statistical findings were abstracted directly. These types of studies generally do not include enough information for researchers to re-calculate the statistics independently, as they are not simple comparisons of a vaccinated group with an unvaccinated group. To assess the reliability and validity of the findings, we abstracted how vaccination status and health outcomes were ascertained (self-report, national registry, parent interview, medical record, etc.); potential sources of bias due to selection, participation, attrition, and non-response of subjects; amount of missing data; funding source; and how potential confounders were handled. The abstraction forms are presented in Appendix B.

We created detailed evidence tables displaying critical data for each included study. Multiple publications of the same study are noted and counted (extracted, assessed for quality, and analyzed) as one study to ensure that the same participants do not enter the analyses multiple times. Multiple publications were defined by the investigated patients.

Assessment of Methodological Quality

For controlled trials and cohort comparisons, we used a quality-rating instrument Santaguida and colleagues (2008)³² developed for evaluating studies reporting adverse events. Called McHarm, the tool was developed from quality rating items generated by a review of the literature on harms and from previous quality assessment instruments. Scores range from 0 to 15; a copy of the instrument and scoring instructions are included in Appendix B. McHarm was tested for reliability and face, construct, and criterion validity and includes important factors such as:

- Were AEs predefined using standard, precise definitions?
- Was the mode of harms collection active (participants are asked about the occurrence of specific AEs) or passive (participants are not specifically asked about or tested for the occurrence of AEs; patient reports of AEs are made on their own initiative)?
- Did the study specify who collected the AE data?
- Did the study specify the timing of AEs?
- Was the number of participants who withdrew or were lost to follow up reported?

Grading the Evidence for Each Key Question

We assess the overall strength of evidence by using guidance suggested by AHRQ for its Effective Health Care Program.³³ This method is based on one developed by the GRADE Working Group³⁴ and classifies the grade of evidence according to the following criteria:

- **High.** High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
- **Moderate.** Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
- **Low.** Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of effect and is likely to change the estimate.
- **Insufficient.** Evidence either is unavailable or does not permit a conclusion.

The evidence grade is based on four primary (required) domains and four optional domains. The required domains are risk of bias, consistency, directness, and precision, as described in Table 4 below. The additional domains are dose-response, plausible confounders that would decrease the observed effect, strength of association, and publication bias.

It is important to note that the 2011 IOM report used different terminology; evidence was classified as either “convincingly supports,” “favors acceptance,” “inadequate to accept or reject” or “favors rejection” of a causal association. They included mechanistic studies and individual case reports to assess the biological plausibility of AE and considered this in addition to any statistical association. For each vaccine discussed in the IOM report, we started with the IOM findings and modified them, if needed, based on any additional evidence identified. For example, if the IOM found that evidence “convincingly supports” an association, we rated the strength of evidence as “high” unless additional evidence was identified. Similarly, if the IOM found evidence “favors acceptance” we started with by rating as “moderate” strength of evidence and evidence rated as “inadequate to accept or reject” was considered “insufficient” in our grading system. If new evidence was identified for vaccines evaluated by the IOM, ratings could be adjusted up or down according to our assessment of the new studies. If the IOM found that evidence “favors rejection” of a causal relationship we choose between moderate and high based on our review of the IOM evidence plus any studies published after their search.

Table 4. Grading the strength of a body of evidence: required domains and their definitions

Domain	Definition and Elements	Score and Application
Risk of Bias	<p>Risk of bias is the degree to which the included studies for a given outcome or comparison have a high likelihood of adequate protection against bias (i.e., good internal validity), assessed through two main elements:</p> <ul style="list-style-type: none"> • Study design (e.g., RCTs or observational studies) • Aggregate quality of the studies under consideration <p>Information for this determination comes from the rating of quality (good/fair/poor) done for individual studies.</p>	<p>Use one of three levels of aggregate risk of bias:</p> <ul style="list-style-type: none"> • Low risk of bias • Medium risk of bias • High risk of bias

Table 4. Grading the strength of a body of evidence: required domains and their definitions (continued)

Domain	Definition and Elements	Score and Application
Consistency	<p>The principal definition of consistency is the degree to which reported effect sizes from included studies appear to have the same direction of effect. This can be assessed through two main elements:</p> <ul style="list-style-type: none"> • Effect sizes have the same sign (that is, are on the same side of “no effect”). • The range of effect sizes is narrow. 	<p>Use one of three levels of consistency:</p> <ul style="list-style-type: none"> • Consistent (i.e., no inconsistency) • Inconsistent • Unknown or not applicable (e.g., single study) <p>As noted in the text, single-study evidence bases (even mega-trials) cannot be judged with respect to consistency. In that instance, use “Consistency unknown (single study).”</p>
Directness	<p>The rating of directness relates to whether the evidence links the interventions directly to health outcomes. For a comparison of two treatments, directness implies that head-to-head trials measure the most important health or ultimate outcomes.</p> <p>Two types of directness, which can coexist, may be of concern:</p> <p>Evidence is indirect if:</p> <ul style="list-style-type: none"> • It uses intermediate or surrogate outcomes instead of health outcomes. In this case, one body of evidence links the intervention to intermediate outcomes and another body of evidence links the intermediate to most important (health or ultimate) outcomes. • It uses two or more bodies of evidence to compare interventions A and B—e.g., studies of A vs. placebo and B vs. placebo, or studies of A vs. C and B vs. C but not A vs. B. <p>Indirectness always implies that more than one body of evidence is required to link interventions to the most important health outcomes.</p> <p>Directness may be contingent on the outcomes of interest. EPC authors are expected to make clear the outcomes involved when assessing this domain.</p>	<p>Score dichotomously as one of two levels directness</p> <ul style="list-style-type: none"> • Direct • Indirect <p>If indirect, specify which of the two types of indirectness account for the rating (or both, if that is the case)—namely, use of intermediate/surrogate outcomes rather than health outcomes, and use of indirect comparisons. Comment on the potential weaknesses caused by, or inherent in, the indirect analysis. The EPC should note if both direct and indirect evidence was available, particularly when indirect evidence supports a small body of direct evidence.</p>
Precision	<p>Precision is the degree of certainty surrounding an effect estimate with respect to a given outcome (i.e., for each outcome separately).</p> <p>If a meta-analysis was performed, this will be the confidence interval around the summary effect size.</p>	<p>Score dichotomously as one of two levels of precision:</p> <ul style="list-style-type: none"> • Precise • Imprecise <p>A precise estimate is an estimate that would allow a clinically useful conclusion. An imprecise estimate is one for which the confidence interval is wide enough to include clinically distinct conclusions. For example, results may be statistically compatible with both clinically important superiority and inferiority (i.e., the direction of effect is unknown), a circumstance that will preclude a valid conclusion.</p>

Peer Review and Public Commentary

A draft of this report was submitted in May, 2013. The AHRQ Effective Healthcare Program Scientific Resource Center (SRC) located at Portland VA Research Foundation coordinated peer review by experts and stakeholders. The report was posted on AHRQ's web site for a month for public comment. Resulting comments were considered by the authors in preparation of the final report. **Synthesis of the scientific literature presented here does not necessarily represent the views of individual reviewers, and service as a peer reviewer or member of the Technical Expert Panel cannot be construed as endorsement of the report's findings.**

Results


A total of 20,478 titles were identified through electronic literature searches; suggestions from TEP members; review of product inserts; review of FDA, ACIP, and other web sites; reference mining; and finally, Scientific Information Packets (SIPs) requested from vaccine manufacturers by the AHRQ-funded Scientific Resource Center (SRC). Of those, 17,270 were excluded upon review of abstract (where available) or title, mostly due to lack of data on safety of vaccines (see Figure 2). Other reasons for exclusion included use of vaccines not within the scope of this project (i.e. not routinely recommended in the United States, recommended only for travel, no longer used in the United States), publication in languages other than English, and study not conducted on humans. Five could not be obtained; based on their titles, we do not think this affected the project. A list of excluded studies and corresponding reasons for exclusion is provided as Appendix D.

Based on title/abstract screenings, 3,210 articles were selected for full text review. Of those, 392 were identified as relevant background/theoretical materials and set aside as potential references. A total of 2,650 other articles were excluded. The most common reason for exclusion was lack of suitable study design (1,549): Individual case reports, non-systematic reviews, and studies using passive surveillance (for example, reports from VAERS) were not included. Many publications (458) discussed vaccines on the recommended schedule, but did not assess adverse events.

One hundred and ninety-three studies using formulations not currently or routinely recommended in the United States were excluded at full text review. For example, studies of H5N1 vaccine, BCG vaccine, and vaccines using the adjuvant ASO3, or BCG vaccine were excluded. Identifying strength / formulation was often difficult; this process involved comparing product materials and/or FDA filings with formulations reported in the studies.

Based on full text screening, 166 studies were accepted for abstraction, including 86 controlled trials or cohort studies directly comparing a group who received a vaccine with an unvaccinated group. Five of these 86 studies also conducted a multivariate analysis. We also included 80 case-control studies, self-controlled case series, or multivariate risk factor analyses that met our inclusion criteria. These studies are in addition to the studies included in the 2011 IOM consensus report “Adverse Effects of Vaccines: Evidence and Causality”; we summarize their conclusions for each population and vaccine, we did not abstract those studies. The results are presented by population: adults, children and adolescents, and pregnant women.

Figure 2. Study/literature flow diagram



IOM = Institute of Medicine

^aFive studies also contributed multivariate risk factor analyses.

Key Question 1: What is the evidence that vaccines included in the 2011 immunization schedule recommended for U.S. **adults**²³ are safe in the short term (within 30–42 days following immunization) or long term (>42 days after immunization)?

- a. What adverse events (AEs) are collected in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?
- b. What AEs are reported in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?

Table 5 lists all AEs collected or reported in placebo-controlled trials and vaccinated/unvaccinated cohort comparisons of adults, abstracted verbatim. We interpreted “collected” to mean those specified a priori by investigators, while “reported” were any AEs reported by participants. The list does not imply an association with vaccination; it displays reported AEs regardless of whether they were reported in vaccinated or unvaccinated study participants, and whether or not the number reported was zero. (In the latter case, a study could “collect” data on a specific serious AE, but “report” zero cases.) Later in this report, we describe the studies and assess association.

Table 5. Adverse events collected or reported in trials of adults

Vaccine	Adverse Event
HPV*	<ul style="list-style-type: none">• Acute appendicitis• Arthralgia• Fatigue• Fever• GI symptoms• Headache• Lymph node tuberculosis• Myalgia• Pain (Grade 3)• Rash• Redness (>50 mm)• Swelling (>50 mm)• Urticaria

Table 5. Adverse events collected or reported in trials of adults (continued)

Vaccine	Adverse Event
Influenza inactivated	<ul style="list-style-type: none"> • Arthralgia • Bruising • Burning/stinging nose (Grade 2/3) • Burning/stinging throat (Grade 2/3) • Chills • Conjunctival hemorrhage • Cough • Death • Fatigue • Fever • Fits (seizures) • Gingival bleeding • Headache • Hyperhidrosis • Itching nose/throat/eyes (Grade 2/3) • Joint pain • Lightheadedness/Dizziness (Grade 2/3) • Lump formation • Malaise • Muscle pain • Myalgia • Nausea • Nosebleeds • Oropharyngeal pain • Pain • Posttraumatic elbow hematoma • Pyrexia • Redness • Rigors (muscle cramp) • Seizures • Shivering or chills • Shortness of breath (Grade 2/3) • Sweating (mild-moderate) • Swelling • Withdrawal after AE
Influenza—monovalent H1N1	<ul style="list-style-type: none"> • Any systemic AE • Chills • Fever • Headache • Malaise • Myalgia • Nausea • Vomiting
Td	<ul style="list-style-type: none"> • Hypoesthesia • “Serious adverse events”

Table 5. Adverse events collected or reported in trials of adults (continued)

Vaccine	Adverse Event
Varicella/Zoster	<ul style="list-style-type: none"> • Adenopathy • Anaphylaxis • Blood/Lymphatic disorders • Cardiac disorders • Chest pain • Death • Discontinued due to a vaccine-related AE • Fever • GI disorders • Hospitalization related to herpes zoster • Influenza-like illness • Injection-site reaction • Liver enzyme elevation • Neoplasms • Nervous system • Nose bleed • Oka VZV with or without other organ involvement • “Overall - Vaccine related AEs” • Pruritus • Psychiatric • Rash • Respiratory/Thoracic • “Serious adverse events” • “Systemic adverse events” • Systemic rash (non-zosteriform) • “Vaccine-related systemic adverse events”

AE = adverse events; GI = gastrointestinal; HPV = human papillomavirus; VZV = varicella-zoster virus

*For HPV, Table 5 includes trials in adults age 18 to 35; adverse events in trials of younger patients appear in the children & adolescents section.

Table 6 lists all AEs and medical conditions assessed in the post-licensure studies of adults. The majority of these studies were designed to assess the association of a specific AE with vaccination. Again, appearance on the list does not imply an association.

Table 6. Adverse events investigated in postmarketing studies of adults

Vaccine	Adverse Event
Influenza vaccines: H1N1	<ul style="list-style-type: none"> • Allograft loss in kidney patients • Chronic obstructive pulmonary disease – exacerbation • Guillain–Barré Syndrome (GBS) • Hematologic diseases • Immune thrombocytopenia • Mortality • Multiple Sclerosis • Myocardial infarction • Sickle cell disease – exacerbation • Spasmodic dysphonia • Stroke
Influenza vaccines: LAIV or TIV	<ul style="list-style-type: none"> • Anaphylaxis • Asthma exacerbation • Death • Hospitalization • Oculorespiratory syndrome

Table 6. Adverse events investigated in postmarketing studies of adults (continued)

Vaccine	Adverse Event
Influenza with 23-valent pneumococcal vaccine	<ul style="list-style-type: none"> • Cardiac failure • COPD • Hospitalization for influenza • Hospitalization for pneumococcal diseases • Mortality due to pneumonia • Myocardial infarction • Stroke
Hepatitis B	<ul style="list-style-type: none"> • Anaphylaxis • Demyelinating Event, First • Guillain-Barré Syndrome • Multiple Sclerosis – Onset • Multiple Sclerosis – Relapse • Optic Neuritis • Rheumatoid Arthritis • Systemic Lupus Erythematosus • Vasculitis
MMR	<ul style="list-style-type: none"> • Arthropathy in men • Autism • Multiple sclerosis • Transient Arthralgia • Type 1 diabetes
Meningococcal Vaccines	<ul style="list-style-type: none"> • Encephalitis • Encephalopathy • Guillain-Barré Syndrome
Pneumococcal vaccines	<ul style="list-style-type: none"> • Acute coronary syndrome • Death • Major vascular events • Myocardial infarction • Stroke
Studies of multiple vaccines, including Hepatitis A, Hepatitis B, MMR, IPV	<ul style="list-style-type: none"> • Graves' disease • Hashimoto's thyroiditis • Psoriatic arthritis • Type 1 diabetes
Zoster	<ul style="list-style-type: none"> • Acute myocardial infarction • Acute myocarditis • Acute pericarditis • Allergic reactions • Bell's palsy • Cardiomyopathy • Cellulitis • Encephalopathy • Hospitalization for meningitis or encephalitis • Inflammatory bowel disease • Meningitis encephalitis • Pain • Psoriasis • Psoriatic arthritis • Ramsay-Hunt syndrome • Rheumatoid arthritis

COPD = chronic obstructive pulmonary disease; GBS = Guillain–Barré syndrome; IPV = polio vaccine; LAIV = live attenuated influenza vaccine; MMR = measles, mumps, rubella; TIV = trivalent inactivated vaccine

Key Question 1 – Adults (continued):

- c. What AEs are associated with these vaccines?
 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 3. For each AE associated with a particular vaccine, what are the risk factors for the AE (including age, sex, race/ethnicity, genotype, underlying medical condition, whether a vaccine is administered individually or in a combination vaccine product, schedule of vaccine administration, adjuvants, and medications administered concomitantly)?

Our primary focus is the statistical association of AEs with vaccination. The severity of AEs was inconsistently reported. Where reported, or where possible for our researchers to categorize, severity is displayed in the summary tables in this section. Some clinical trials reported severity; most simply provided a list of AEs along with the number of patients in each group reporting them. Postmarketing studies tended to combine all cases of a particular AE, as severity details were often unavailable or inadequate.

Results are organized by vaccine type. For each vaccine, we first describe the findings of the 2011 Institute of Medicine (IOM) report “Adverse Events of Vaccine: Evidence and Causality,” where available. (Not all recommended vaccines are covered in that report.) We then describe the findings from studies published after the IOM report that met our inclusion criteria: clinical trials and cohort studies that included an unvaccinated group, followed by the results of postmarketing studies. The results for all reported AEs, including those not statistically associated with vaccination, are displayed in the right-hand column of tables in this section. The 95% confidence intervals reflect the level of certainty.

We summarize and critique the evidence, taking into consideration the number and size of studies, study methodology and quality, and applicability.

Influenza Vaccines

The seasonal influenza vaccine is administered in two forms: a live attenuated form, administered intranasally (LAIV), and an inactivated form (TIV), administered intramuscularly. Monovalent H1N1 or “swine flu” vaccine was administered widely during the winter of 2009–2010; we were encouraged by our expert panel to include it, as seasonal vaccines developed after 2009 include an H1N1 strain.

^a Level of certainty was operationalized as the 95-percent confidence interval surrounding the risk or odds estimate—i.e., the statistical significance.

The IOM committee studied the two forms of seasonal influenza vaccines. They found that evidence³⁵ “convincingly supports” a causal relationship between influenza vaccine and anaphylaxis. The committee found that evidence³⁶⁻³⁹ “favors acceptance” of a causal relationship between two particular influenza vaccines used in Canada and oculorespiratory syndrome. The IOM committee found the evidence⁴⁰⁻⁴⁵ “favors rejection” of a causal relationship between TIV and asthma exacerbation or reactive airway disease episodes in adults. Finally, despite finding some studies of influenza vaccine and the following AEs, the IOM found evidence was “inadequate to accept or reject” a causal relationship: encephalitis, encephalopathy, optic neuritis, multiple sclerosis (MS) onset or relapse, Guillain-Barré Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy, Bell’s Palsy, onset of exacerbation of systemic lupus erythematosus (SLE), onset or exacerbation of vasculitis, polyarteritis nodosa, onset or exacerbation of arthropathy, ischemic stroke, myocardial infarction, and all-cause mortality.

One comparative cohort study and eight trials of influenza vaccine in adults were published after the IOM search dates. All trials administered inactivated vaccine. One trial studied monovalent H1N1 vaccine; all other trials studied seasonal vaccine. All but one study of seasonal vaccine included an H1N1 strain. The results are summarized in Table 7.

A trial in Canada⁴⁶ included 1,348 adults (54.2% female) who received inactivated trivalent influenza vaccine at study start and 14 days later. Odds ratios were not calculated because the study reported AEs per dose rather than per patient.

A controlled clinical trial in the United States⁴⁷ included 7,250 adults aged 18 to 49 who received one dose of inactivated influenza vaccine. Compared to the control group, vaccinated individuals were more likely to experience arthralgia (OR 2.10, 95% CI 1.67-2.66), chills (OR 2.24, 95% CI 1.77-2.84), fatigue (OR 1.58, 95% CI 1.38-1.80), headache (OR 1.40, 95% CI 1.23-1.59), hyperhidrosis (OR 1.68, 95% CI 1.31-2.16), malaise (OR 2.02, 95% CI 1.74-2.36), myalgia (OR 3.28, 95% CI 2.80-3.85), oropharyngeal pain (OR 1.63, 95% CI 1.06-2.50), and pyrexia (OR 2.27, 95% CI 1.54-3.36).

A controlled clinical trial in the United States, Finland, and Poland⁴⁸ included 11,404 adults (55% female) separated into two vaccine groups that receive one dose inactivated influenza vaccine and one placebo group. Group 1 received Agrippal and Group 2 received Optaflu. Compared to the control group, Group 1 was more likely to experience mild to moderate fever (OR 2.01, 95% CI 1.16-3.49), mild to moderate malaise (OR 1.27, 95% CI 1.06-1.52), and mild to moderate myalgia (OR 1.31, 95% CI 1.11-1.55). A trial in Italy⁴⁹ included 104 adults (45.1% female) who received inactivated influenza vaccine (Fluad) at study start and 42 days later. No statistically significant differences in AEs between vaccinated and unvaccinated groups were reported. A trial in the United States⁵⁰ included 7,611 adults (60% female, 0.7% pregnant) who received one dose of inactivated influenza vaccine (Flulaval). Compared to the unvaccinated group, vaccinated individuals were more likely to experience fever (OR 1.79, 95% CI 1.28-2.50) and myalgia/arthralgia (OR 1.98, 95% CI 1.73-2.26).

A controlled clinical trial in the United States⁵¹ included 4,648 adults (59% female, 0.8% pregnant) who received one dose of inactivated trivalent influenza vaccine (Flublok). Compared to the unvaccinated group, vaccinated individuals were more likely to experience any pain (OR 6.69, 95% CI 5.62-7.95) and muscle pain (OR 1.59, 95% CI 1.28-1.96).

Regarding monovalent H1N1, a trial in the United States⁵² included 1,313 adults (57.1% female) who were divided into two groups receiving different doses (7.5 mg [Group 1] or 15 mg [Group 2]) of at study baseline and 21 days later. The only statistically significant finding was fewer systemic AEs in Group 2 (OR 0.56, 95% CI 0.32-0.99).

A controlled clinical trial in South Africa⁵³ included 189 HIV+ adults (84% female) who received inactivated influenza vaccine (Mutagrip). No statistically significant differences in AEs between vaccinated and unvaccinated groups were reported. This vaccine did not include an H1N1 strain.

The cohort study⁵⁴ compared vaccinated vs. unvaccinated patients with End Stage Renal Disease (ESRD) who were undergoing dialysis. The study was conducted in Taiwan; vaccine was inactivated. Vaccinees were older and more likely to have conditions such as cardiac disease and COPD. The elderly in the vaccine cohort had a lower hospitalization rate (adjusted HR 0.73, 95% CI 0.64-0.82). The time-dependent Cox model revealed an overall adjusted Hazard Ratio for mortality of 0.30 (95% CI 0.26–0.35) after counting vaccination for multi-years.

Table 7. Vaccinated versus unvaccinated adults: influenza vaccines

Author-Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Barrett P. N. et al.,2011 ⁴⁷ U.S.	Controlled Clinical Trial	4	Sample size : 7,250, Mean age: NR, Age range: 18 - 49	Influenza (inactivated), Baxter, Austria, contain 15 µg of hemagglutinin antigen from each of the three virus strains - A/Brisbane/59/2007 (A/H1N1), A/Uruguay/716/2007(A/Brisbane/10/2007-like) (A/H3N2), and B/Florida/4/2006 (B). The three virus strains were egg-derived wild-type strains provided by the National Institute for Biological Standards and Control (Potters Bar, UK)., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days	Arthralgia: OR 2.103 (1.666-2.655)** Chills: OR 2.239 (1.766-2.838) ** Cough: OR 1.427 (0.862-2.361) ** Fatigue: OR 1.577 (1.382-1.8) ** Headache: OR 1.396 (1.229-1.587) ** Hyperhidrosis: OR 1.678 (1.306-2.155) ** Malaise: OR 2.024 (1.736-2.36) ** Myalgia: OR 3.281 (2.799-3.846) ** Oropharyngeal pain: OR 1.626 (1.058-2.5) ** Pyrexia: OR 2.271 (1.537-3.355) **
Frey S. et al.,2010 ⁴⁸ U.S., Finland, Poland	Controlled Clinical Trial	4	Sample size : 11,404, Mean age: 33, Age range: 18 - 49, Percent female: 55%	Influenza (inactivated), Agrippal, Novartis, 15 mg of hemagglutinin per 0.5-mL dose of each virus strain recommended for the 2007–2008 Northern Hemisphere influenza season: A/Solomon Islands/3/2006 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days	Headache (mild-moderate): OR 1 (0.881-1.134) Arthralgia (mild-moderate): OR 0.961 (0.722-1.279) Chills (mild-moderate): OR 1 (0.813-1.23) Death: OR 1.061 (0.066-16.969) Fatigue (mild-moderate): OR 1.112 (0.96-1.289) Fever (mild-moderate): OR 2.01 (1.159-3.487) ** Malaise (mild-moderate): OR 1.27 (1.061-1.521) ** Myalgia (mild-moderate): OR 1.314 (1.112-1.553) ** Sweating (mild-moderate): OR 1 (0.749-1.335) Withdrawal after AE: OR 1.061 (0.066-16.969)
Iorio A. et al.,2010 ⁴⁹ Italy	Controlled Clinical Trial	4	Sample size : 104, Mean age: 71, Age range: 18 - NR, Percent female: 45.1%	Influenza (inactivated), Fluad, Novartis, Fujian/411/02 (influenza A[H3N2]), New Caledonia/20/99 (influenza A[H1N1]), and Shanghai/361/02 (influenza B), Adjuvant: Other adjuvant, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 42 Days	Nosebleeds: OR 0.743 (0.162-3.403)

Table 7. Vaccinated versus unvaccinated adults: influenza vaccines (continued)

Author-Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Jackson L. A. et al., 2010 ⁵⁰ U.S.	Controlled Clinical Trial	7	Sample size : 7,611, Mean age: 32.7, Age range: 18 - 49, Percent female: 60%, Percent Pregnant: 0.7%	Influenza (inactivated), Flulaval, ID Biomedical Corporation of Quebec (trademarked, 15 µg of hemagglutinin (HA) antigen of each recommended influenza strain). Antigens for Season 1 (2005-2006) were A/New Caledonia/20/1999 (H1N1), A/New York/55/2004 (H3N2, A/California/7/2004-like), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like). Antigens for Season 2 (2006-2007) were A/New Caledonia/20/1999 (H1N1) virus, A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 0 Days	Chest tightness or difficulty breathing: OR 1.218 (0.938-1.581) Cough: OR 1.17 (0.982-1.396) Fever: OR 1.786 (1.278-2.496)** Myalgia/arthritis: OR 1.979 (1.732-2.262)** Sore throat, hoarseness, or pain swallowing: OR 0.949 (0.809-1.112) Swelling of the face: OR 1.4 (0.915-2.143)
Langley J. M. et al., 2011 ⁴⁶ Canada	Controlled Clinical Trial	4	Sample size : 1,348, Mean age: 37.1, Age range: 18 - 64, Percent female: 54.2%	Influenza (inactivated), NR, Contains equal parts of three monovalent egg-grown, formalin-inactivated influenza antigens formulated with OMPs of N. meningitidis serogroup B strain 8047 at an initial ratio of OMP to hemagglutinin (HA) of 4:1. After filtration to remove detergents necessary to keep the OMPs in stable solution in the absence of antigen, the overall total protein to HA ratio in the final vaccine product is 2.5 to 5:1. The trivalent vaccine stock contained HA from each of A/New Caledonia/20/99 [H1N1], A/Panama/2007/99 [H3N2] and B/Shandong/7/97 [H1N1], Adjuvant: Not Reported, Preservative: Thimerosal, Delivery: Intranasal	Dose1: 0 Days Dose2: 14 Days	Not calculable

Table 7. Vaccinated versus unvaccinated adults: influenza vaccines (continued)

Author-Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Talaat K. R. et al., 2010 ⁵² United States	Controlled Clinical Trial	5	Sample size : 1,313, Mean age: 56.5, Age range: 18 – 93, Percent female: 57.1%	Influenza – monovalent H1N1, CSL Limited, The 7.5-mg doses were supplied in prefilled syringes that contained 7.5 mg of HA in 0.25 mL of thimerosal-free diluent., Adjuvant: Adjuvant Free, Preservative: Other, Delivery: Intramuscular	Dose1: 0 Days Dose2: 21 Days	Any systemic AE (Dose 1): OR 1.176 (0.701-1.974) Any systemic AE (Dose 2): OR 0.562 (0.32-0.987) Chills(Dose 1): OR 1 (0.208-4.801) Fever (Dose 1): OR 0.99 (0.11-8.922) Headache (Dose 1): OR 1.428 (0.719-2.835) Headache (Dose 2): OR 1 (0.464-2.154) Malaise (Dose 1): OR 1 (0.445-2.247) Malaise (Dose 2): OR 0.704 (0.341-1.452) Myalgia (Dose 1): OR 2.136 (0.885-5.159) Myalgia (Dose 2): OR 0.645 (0.29-1.437) Nausea (Dose 1): OR 1 (0.326-3.067) Nausea(Dose 2): OR 3.062 (0.39-24.025) Vomiting(Dose 1): OR 0.495 (0.089-2.744) Vomiting(Dose 2): OR 0.497 (0.045-5.549)
Treanor J. et al., 2011 ⁵¹ USA	Controlled Clinical Trial	3	Sample size : 4,648, Mean age: 32.5, Age range: 18 – 55, Percent female: 59%, Percent Pregnant: 0.8%	Influenza (inactivated), Flublok, NR, The trivalent vaccine contained 45 mcg of each purified rHA0 derived from the A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 influenza viruses recommended for the 2007–2008 influenza season formulated with 0.005% Tween®-20 in 10mM sodium phosphate buffer pH 7.0 ± 0.4 without a preservative, Adjuvant: Not Reported, Preservative: Preservative Free, Delivery: Intramuscular	Dose1: 0 Days	Bruising: OR 1.258 (0.89-1.778) Fatigue or lack of energy: OR 1.004 (0.853-1.182) Fever (=100.4): OR 1.395 (0.665-2.928) Headache: OR 0.964 (0.821-1.131) Joint pain: OR 1.056 (0.779-1.432) Muscle pain: OR 1.585 (1.283-1.958) ** Nausea: OR 1.173 (0.903-1.524) Pain: OR 6.686 (5.62-7.953) ** Shivering or chills: OR 0.968 (0.692-1.354)
Madhi S. A. et al., 2011 ⁵³ South Africa	Controlled Clinical Trial	3	Sample size : 189, Mean age: 36.3, Percent female: 84%, Condition: HIV	Influenza (inactivated), Mutagrip, Sanofi, 15ugm each (per 0.5 ml) A/Solomon Islands/3/2006 (IVR-145), A/Brisbane/10/2007(IVR-147),B/Florida/4/2006, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: NR Dose2: NR Dose3: NR	Arthralgia: OR 0.694 (0.151-3.19) Fatigue: OR 0.179 (0.021-1.564) Headache: OR 0.936 (0.184-4.762) Itching: OR 2.872 (0.293-28.127) Lump formation: OR 0.464 (0.041-5.201) Myalgia: OR 1.42 (0.232-8.7) Pain: OR 1.955 (0.568-6.73) Redness: OR 1.895 (0.169-21.26)

Table 7. Vaccinated versus unvaccinated adults: influenza vaccines (continued)

Author-Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Wang, I.K. et al. 2013 ⁵⁴ Taiwan	Cohort	5	Sample size : 4018, Mean age: 70/59 (vaccinated/unvaccinated, Age range: 18 – 80+ Percent female: 51%, Conditions: End Stage Renal Disease (ESRD)	Influenza (inactivated) , Not specified , NR , Not reported , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Not reported	Dose1: 0 Days	Intensive care unit admission-hospitalization: OR 0.341 (0.206-0.564)** Respiratory Failure-hospitalization: OR 0.963 (0.727-1.276) Septicemia, bacteremia, and viremia-hospitalization: OR 1.158 (0.916-1.464) Total hospitalization: OR 1.096 (0.94-1.277)

AE = adverse event; CI = confidence interval; HA = hemagglutinin; NR = not reported; OMPs = outer membrane proteins; OR = odds ratio

ADDITIONAL STUDY DETAILS PRESENTED IN APPENDIX C EVIDENCE TABLES

We identified 19 postmarketing studies of influenza vaccines in adults published after the IOM report; they are displayed in Table 8. The vast majority assessed the relationship between vaccination and one adverse event or medical condition of particular interest. A few assessed whether the vaccine was associated with fewer cardiovascular events in the elderly. Finally, some studied the effect of vaccine in adults with pre-existing conditions such as MS, renal disease or COPD.

Guillain–Barré Syndrome (GBS) and Other Autoimmune Disorders

Several studies evaluated whether H1N1 vaccine was associated with an increased risk of developing Guillain–Barré Syndrome. Baxter⁵⁵ studied 415 cases of GBS among managed care enrollees in California. Odds of TIV vaccination in both 6 and 10 week intervals before GBS onset were not significant. (Inactivated polio vaccine, PPV, Tdap, Td, and vaccinations against hepatitis A and B were not associated statistically with GBS onset.) Greene et al. 2012⁵⁶ performed separate self-controlled risk interval and case-centered analyses among members of eight managed care organizations (MCOs) in the United States who received 1.48 million doses of monovalent inactivated pandemic H1N1 vaccine (MIV) and 1.72 million doses of TIV. Altogether thirteen confirmed cases of Guillain–Barré Syndrome were identified after receipt of MIV and 16 after receipt of TIV. Statistically significant increases in GBS risk following receipt of MIV were suggested by the self-controlled risk interval analysis ($RR = 4.4$ 95% CI: 1.3, 14.2 risk difference = 5.0 per million MIV doses (95% CI: 0.5 per million, 9.5 per million). The case-centered analysis found that the OR for having illness onset inside of the 42-day risk period versus outside of that period was 2.0 (95% CI: 0.5, 8.1), but this was not statistically significant. The risk difference was 3.4 per million MIV doses (95% CI: -6.4 per million, 7.6 per million). No increased risk for developing GBS was associated with receipt of seasonal trivalent inactivated influenza vaccine ($RR = 1.3$, 95% CI: 0.5, 3.8), so case-centered analysis was not conducted. A meta-analysis of data from six U.S. surveillance systems established or enhanced during the 2009 H1N1 pandemic⁵⁷ found an association with GBS (IRR 2.35, 95% CI 1.42-4.01), equivalent to about 1.6 excess cases per million monovalent H1N1 vaccines administered.

In contrast, in a prospective case-control study of 1,225 subjects in France, Grimaldi-Bensouda et al. 2011⁵⁸ were unable to demonstrate any statistically significant association between receipt of monovalent H1N1 and/or seasonal influenza vaccine and the development of GBS in eight separate analyses (see Table 8 for statistics). As formulation and brand of vaccines were not reported, it is possible that AS03 adjuvant (not used in the United States) was contained in some vaccines. In Australia, Crawford⁵⁹ conducted a self-controlled case series to assess the potential relationship between monovalent H1N1 vaccine (Panvax) and GBS. No statistically significant association was found, after multiple sensitivity analyses for time period and use of season influenza vaccine. Lee⁶⁰ conducted a study of over 4.5 million doses of monovalent H1N1, TIV, and LAIV administered to enrollees in 8 U.S. MCOs. In a self-controlled case series analysis, a statistical association for monovalent H1N1 vaccine and Bell's palsy was found. However, a subsequent case-centered logistic regression controlling for seasonality found the association not statistically significant (OR 1.26, 95% CI 0.97-1.63). No significant associations were noted during sequential analyses for Guillain–Barré syndrome, most other neurological outcomes, and allergic and cardiac events.

In Europe, Isai and colleagues⁶¹ compared the rate of autoimmune disorders reported to the EUdraVigilance database after vaccination with adjuvanted vs. unadjuvanted H1N1 vaccine. They used MedDRA classifications; autoimmune disorders included GBS, rheumatoid arthritis, type 1 diabetes, onset and exacerbation of MS, and over a dozen other conditions. The rate difference

between adjuvanted and non-adjuvanted H1N1 vaccines was not statistically significant. Using the estimated number of vaccinees as the denominator, they calculated the reporting rate as 9.98 (6.81-13.16) cases per million vaccinees for non-adjuvanted vaccines and 6.87 (6.06-7.68) cases per million vaccinees for adjuvanted vaccines.

Neurological sequelae following MIV vaccination were evaluated in two other studies. Using a self-controlled case series method, Farez et al. 2012⁶² assessed whether receipt of MIV was associated with relapses of MS. No significant relationship was found in this study of 137 patients (98% of whom were receiving interferon-beta and 25% glatiramer acetate) with previously diagnosed MS (for 30-day risk period, OR 0.86, 95% CI: 0.20, 3.62). Tanner et al. 2012⁶³ performed a case-control study of 150 patients with spasmodic dysphonia (cases) and 136 patients with other structural, neurological, and functional voice disorders (controls). There was no difference in post-vaccine incidence of spasmodic dysphonia among persons who did or did not self-report receipt of swine influenza vaccine (OR 2.1, 95% CI 0.9, 5.0), whereas persons who did not know whether they had received swine influenza vaccine were more likely to have spasmodic dysphonia than were persons who reported not receiving the vaccine.

Cardiovascular

The relationship between receipt of influenza vaccination and cardiovascular and cerebrovascular complications was assessed in three studies. In a matched case-control study of 16,012 persons with myocardial infarction and 62,964 controls, Siriwardena et al. 2010⁶⁴ found that receipt of influenza vaccine within the previous year was significantly associated with lower odds of acute myocardial infarction (OR 0.83, 95% CI 0.80, 0.88). A multi-center study including 40 countries⁶⁵ following 31,546 subjects, aged 55 and above, with a history of vascular disease or diabetes with documented end-organ damage between 2004 and 2007 concluded that although initial analyses suggested that influenza vaccination was associated with reduced risk of major adverse vascular events during influenza seasons when the influenza vaccine matched the circulating virus, sensitivity analyses revealed that risk of bias remained. The primary outcomes were a composite of death resulting from cardiovascular causes, and a composite of death from other causes during these four influenza seasons. Data were modeled using logistic regression and adjusted using propensity scores for influenza vaccination (demographics, body mass index, vitamin use, smoking history, alcohol use, history of pneumococcal vaccination, and use of a variety of medications).

Hedlund et al. 2003⁶⁶ compared one-year outcomes among 100,242 persons vaccinated with influenza and/or 23-valent pneumococcal vaccine versus 159,385 unvaccinated individuals; all subjects were aged 65 years or older. Among the vaccinated subjects, 76,177 had both vaccines, 23,224 received only the influenza vaccine, and 841 received only the pneumococcal vaccine. The incidence of hospital admissions for influenza, pneumonia, and invasive pneumococcal disease during one year after vaccination was significantly lower in the vaccinated than in the unvaccinated cohort. The vaccinated cohort had significantly lower rates of in-hospital mortality for pneumonia, COPD, and cardiac failure. The benefits of vaccination were greater during influenza season (December - May) than at other times of the year (June - November). No harms from vaccination were noted among the reported outcomes. Finally, in a self-controlled case series analysis, Gwini et al. 2011⁶⁷ found that the incidence of post vaccination myocardial infarction was reduced at time intervals extending up to 59 days after receipt of vaccine.

Hematological

Two studies addressed the relationship between receipt of influenza vaccine and the development of hematologic diseases. In a self-controlled case series conducted by Garbe et al. 2012,⁶⁸ two different statistical models revealed a significant association between prior influenza vaccination and new onset immune thrombocytopenia (OR 4.0, 95% CI 1.5, 9.6) in a model adjusted for age, sex, and multiple medications). In a self-controlled case series, Hambidge et al. 2011⁶⁹ found no relationship between receipt of influenza vaccine by adults with sickle cell disease and subsequent hospitalization for complications of sickle cell disease (OR 0.92, 95% CI 0.66, 1.28).

Regarding vaccination of dialysis patients, Gilbertson et al. (2011)⁷⁰ studied 118,533 adult U.S. Medicare patients who initiated hemodialysis before August 1, 2003 and were alive through October 31, 2005. Subjects were followed between 2005 and 2006 for data on health outcomes. The analysis adjusted for patient demographics, primary cause of end stage renal disease, duration of dialysis, existing comorbidities, and influenza vaccination. Results indicate that vaccination with influenza (RR 0.77, 95% CI 0.73, 0.81) or pneumococcal (RR 0.94, 95% CI 0.90, 0.98) vaccines was associated with lower mortality. In a retrospective cohort analysis of 51,730 adult Medicare patients with renal transplants, Hurst et al. 2011⁷¹ found that influenza vaccination in the first year after transplant was associated with lower risk of both subsequent allograft loss (adjusted hazard ratio, 0.77, 95% CI 0.69, 0.85) and death (adjusted hazard ratio, 0.82, 95% CI 0.76, 0.89).

Other

In a single retrospective matched cohort study of patients with chronic obstructive pulmonary diseases (COPD), Ting; 2011⁷² found no change in the frequency of COPD exacerbations during the 14 days following vaccination.

General

One study of the safety of live attenuated influenza vaccine (LAIV) was identified (Baxter et al. 2012).⁷³ In this retrospective cohort study of 21,340, 18,316, and 21,340 adults aged 18 to 49 years who received LAIV, TIV, or no vaccine, respectively, the rate of hospitalization or death due to any condition within 180 days of vaccination with LAIV was significantly lower than with TIV or no vaccine. The incidence rate for any serious adverse event within 21 days and 42 days of vaccination with LAIV was lower than for no vaccination. The pattern of medically attended events did not suggest any safety signal associated with LAIV.

Summary

Based on the entire body of available evidence, including the IOM report, clinical trials, and post-licensure studies that met our inclusion criteria, we make the following conclusions regarding key adverse events.

There is high strength of evidence that influenza vaccines currently used in the United States are associated with arthralgia, myalgia, malaise, fever, and pain in the short-term in adults; these associations were consistently reported in randomized, placebo-controlled clinical trials conducted in the U.S. and abroad. These AEs are not considered serious; thus, they are rarely investigated in post-marketing epidemiological studies. Risk factors are not discussed in the trials. Clinical trials have found no association between influenza vaccines currently used in the United States and serious adverse events (SAEs).

There is high strength evidence of an association between 2009 monovalent H1N1 and Guillain-Barré Syndrome (GBS). This conclusion is based on a meta-analysis of data from six large U.S.

surveillance systems established or enhanced during the 2009 H1N1 pandemic⁵⁷. However, this adverse event is extremely rare; the authors estimate about 1.6 excess cases per million doses of monovalent H1N1 vaccine administered.

Based on our review of the IOM report and its conclusion that evidence “convincingly supports” a causal relationship between influenza vaccines and anaphylaxis in persons who may be allergic to egg, we rated the strength of evidence high for this AE. Anaphylactic reactions can be severe if not treated immediately. Manufacturers have decreased the amount of egg protein significantly in recent years.

The IOM conclusion favoring acceptance of a causal relationship between influenza vaccines and oculorespiratory syndrome was based on a specific vaccine used in Canada from 2001 to 2003; there is no basis for current concern in the United States

Post-licensure studies with strong study designs have found inconsistent evidence associating influenza vaccines with onset or exacerbation of MS in adults. Strength of evidence is insufficient to determine an association.

Strength of evidence is high that influenza vaccines do not lead to cardiovascular and cerebrovascular events in the elderly; several high quality post-licensure studies have shown a decreased risk among vaccinees.

Two large post-licensure studies with strong study designs have shown that influenza vaccines are not associated with increased risk of SAEs in renal patients. Strength of evidence is moderate.

Table 8. Postmarketing studies of influenza vaccines in adults

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Greene et al. 2012 ⁵⁶ Self-controlled risk interval and case-centered analysis	N=1.48 million doses Monovalent inactivated H1N1 and 1.72 million doses TIV; 8 U.S. MCOs	Monovalent inactivated influenza vaccine (MIV) and seasonal trivalent inactivated influenza vaccine (TIV) during the 2009-2010 season	Case-centered analyses by stratum of onset date, age, sex, site	Relative Risk (self-controlled risk analysis) of Guillain-Barré Syndrome (GBS), RR, 95% CI MIV Confirmed GBS 4.4 (1.3, 14.2) TIV Confirmed GBS: 1.3 (0.5, 3.8)	Not reported
Grimaldi-Bensouda et al. 2011 ⁵⁸ Prospective case-control	N=1,225; Location=France; Age=Cases/Controls, Mean (SD): 48.6 (18.0)/50.7 (18.1); Setting=Guillain-Barré cases drawn from all university and major regional hospital centers in metropolitan France known to have a large neurology clinic and centers treating neurological disease in children; Controls from registry of general practice patients across France	Influenza vaccines (seasonal and A/H1N1), brand and formulations unclear	Cases/controls matched by age, gender, index date (calendar month), and region Receipt of other vaccines during the same time window, receipt of influenza vaccine in the past (before the time window considered), family history of autoimmune diseases, number of physician consultations in the previous year (0–2, 3–6, 7–12, or >=13), antibiotic or antiviral treatment in the previous 2 months, use of antipyretic agents in the previous 2 months.	OR, Guillain-Barré Syndrome All influenza vaccines (A/H1N1 + seasonal) First 6 weeks: 1.22 (0.45-3.32) 7 weeks to 3 months: 0.66 (0.27-1.65) 4 months to 6 months: 0.80 (0.34-1.88) Seasonal influenza vaccine only First 6 weeks: 1.30 (0.41-4.12) 7 weeks to 3 months: 0.60 (0.23-1.60) 4 months to 6 months: 0.69 (0.29-1.66) Influenza A/H1N1 vaccine only First 6 weeks: 0.92 (0.11-7.55) 7 weeks to 3 months: 1.08 (0.09-13.15)	Not reported

Table 8. Postmarketing studies of influenza vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Farez et al. 2012 ⁶² Self-controlled case series	N=137 Multiple Sclerosis patients; Location=Argentina; Age=37 +/- 8 years (mean)	Monovalent H1N1 or trivalent vaccine containing both H1N1 and seasonal influenza strains	None reported	OR for MS relapse 30-day risk period: 0.86 (95% CI 0.20–3.62) 60-day risk period: 0.61 (95% CI 0.18–2.02) 90-day risk period: 0.51 (95% CI 0.18–1.47)	Not reported
Tanner et al. 2012 ⁶³ Case-control	N=286; Location=Utah; Age=20.4 to 92.5; Setting=The University of Utah Voice Disorders Center	Swine flu of any type from any year	Age, sex, race/ethnicity	OR (95%) CI for Spasmodic Dysphonia Vaccinated v. Non-vaccinated: 2.1 (0.9-5.0) Don't Know v. Non-vaccinated: 2.3 (1.3-4.1)	Not reported
Johnston e et al. 2012 ⁶⁵ Prospective cohort	N=31,546; Location=40 countries; Setting=Participants in the ONTARGET TRANSCEND trials: at least 55 years old and a history of vascular disease or diabetes with document end-organ damage	Seasonal Influenza, 2003-2004, 2004-2005, 2006-2007 pneumococcal	Adjusted by propensity score for influenza vaccination (body mass index, age, sex, ethnicity, education, vitamin use, smoking history, alcohol use, history of pneumococcal vaccination), history of coronary artery disease, diabetes mellitus, hypertension, stroke, admission to a nursing home, or use of aspirin, beta-blocker, lipid-lowering drug, angiotensin-converting enzyme inhibitor, or angiotensin II inhibitor	Association Between Influenza Vaccination and Risk of Major Adverse Vascular Events During the Influenza Season Cohort OR, (95% CI) 2003-2004: 0.96 (0.73–1.27) 2004-2005: 0.62 (0.50–0.77) 2005-2006: 0.69 (0.53–0.91) 2006-2007: 0.52 (0.42–0.65) Association Between Influenza Vaccination and Risk of the Major Adverse Vascular Events During the Non-influenza Season Cohort 2003-2004: 0.81 (0.61–1.09) 2004-2005: 0.64 (0.50–0.83) 2005-2006: 0.74 (0.56–0.98) 2006-2007: 0.50 (0.38–0.67) Association Between Influenza Vaccination and Risk of Non-cardiovascular Death During the	Not reported

Table 8. Postmarketing studies of influenza vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				<p>Influenza Season Cohort 2004-2005 Non-cardiovascular deaths: 0.26 (0.16–0.40) Cancer deaths: 0.20 (0.10–0.39) Deaths resulting from other causes: 0.33 (0.18–0.60)</p> <p>2005–2006 Non-cardiovascular deaths: 0.21 (0.10–0.46) Cancer deaths: 0.27 (0.10–0.69) Deaths resulting from other causes: 0.14 (0.03–0.58)</p> <p>2006-2007 Non-cardiovascular deaths: 0.27 (0.18–0.41) Cancer deaths: 0.17 (0.10–0.31) Deaths resulting from other causes: 0.47 (0.25–0.86)</p>	
Siriwardena et al. 2010 ⁶⁴ Matched case-control	N=78,706 (16,012 cases of myocardial infarction (MI), 62,964 controls); Location=UK; Age=40 to >=65; Setting=United Kingdom General Practice Research Database (GPRD), an extensively validated computerized database, representative of and comprising 5% of the population of England and Wales.	Influenza; pneumococcal (unspecified; did not stratify by formulation or year)	Model 1 adjusted for asthma or chronic obstructive pulmonary disease, chronic heart disease, stroke or transient ischemic attack, diabetes, splenectomy, chronic liver disease, chronic renal failure, immunosuppression and HIV, hyperlipidemia, family history of acute myocardial infarction, peripheral vascular disease, hypertension, smoking status, treatment with acetylsalicylic acid, treatment with statins, treatment with	<p>OR (95% CI) of acute MI Influenza vaccination within previous year: Model 1: 0.81 (0.77–0.85) Model 2: 0.83 (0.80–0.88)</p>	<p>Influenza Vaccination in preceding yr: < 65 yr: Model 1: 0.81 (0.73–0.90) Model 2: 0.83 (0.75–0.92) ≥ 65 yr: Model 1: 0.79 (0.75–0.83) Model 2: 0.82 (0.78–0.86)</p> <p>Time since last vaccination at index date, months: 0–3 months: Model 1: 0.80 (0.74–0.86) Model 2: 0.84 (0.80–0.94) 3–6 months: Model 1: 0.82 (0.76–0.89) Model 2: 0.86 (0.85–0.99)</p>

Table 8. Postmarketing studies of influenza vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
			antihypertensives, and general practice consultations. Each type of vaccination was adjusted for the other type. Second set of models (Model 2) adjusted for all of the above		6–12 months: Model 1: 0.87 (0.81–0.94) Model 2: 0.91 (1.06–1.24) 12–60 months: Model 1: 1.12 (1.03–1.21) Model 2: 1.15 (0.88–1.20) ≥ 60 months: Model 1: 0.96 (0.82–1.13) Model 2: 1.03 Within-season vaccination Yes: Model 1: 0.80 (0.76–0.84) Model 2: 0.83 (0.79–0.87) Early within-season (Sept. to mid-Nov.): Model 1: 0.79 (0.75–0.83) Model 2: 0.82 (0.78–0.86) Late within-season (mid-Nov. to Feb.): Model 1: 0.88 (0.79–0.97) Model 2: 0.90 (0.82–1.00) Vaccination in previous yr, by month of index date: Sept. to Nov.: Model 1: 0.75 (0.68–0.83) Model 2: 0.77 (0.70–0.85) Dec. to Mar.: Model 1: 0.86 (0.79–0.93) Model 2: 0.88 (0.82–0.95) Apr. to Aug.: Model 1: 0.80 (0.73–0.86) Model 2: 0.84 (0.77–0.90)

Table 8. Postmarketing studies of influenza vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Gwini et al. 2011 ⁶⁷ Self-controlled case series	N=8,180 cases of first acute myocardial infarction; Location=UK; Age=>=40 years;	Seasonal influenza, unspecified, 2002-2008	Seasonality	Incidence Rate Ratio, Acute MI Post-vaccination intervals 1-14 days: 0.68 (0.6–0.78) 15-28 days: 0.75 (0.66–0.86) 29-59 days: 0.82 (0.75–0.90) 60-90 days: 0.96 (0.87–1.07) 91-120 days: 0.98 (0.89–1.09) 121-180 days: 1.02 (0.95–1.10)	Not reported
Garbe et al. 2012 ⁶⁸ Case-control	N=1,200 (outpatient + inpatient). Influenza results presented just for outpatients, N=861; Location=Berlin, Germany; Age=18-92; Setting=Berlin hospitals, hematological practices, and laboratories	Influenza vaccine, unspecified (Pneumococcal and poliomyelitis vaccine also assessed as causing 1 case each but ORs were not reported.)	Model 1: age and sex ("single drug assessment") Model 2: age, sex and all drugs that were significant in the single drug assessment ("joint drug assessment")	OR (95% CI) idiopathic thrombocytopenic purpura (ITP) Influenza, outpatient cases and controls: Model 1: 3.8 (1.5–9.1) Model 2: 4.0 (1.5–9.6)	Not reported
Hambidge et al. 2011 ⁶⁹ Case-control and Self-controlled case series	N=348 adults with sickle cell disease in 8 MCOs in the U.S. (Vaccine Safety Datalink (VSD) cohort)	TIV, 1999-2006	Stratification by sex and age, adjustment for month within season	Incidence rate ratios for sickle cell hospitalization All: 0.92 (0.66, 1.28)	Males: 1.00 (0.59, 1.72) Females 0.87 (0.57, 1.31) 18-49 yrs.: 0.84 (0.57, 1.22) 50-64 yrs.: 1.51 (0.72, 3.18) ≥65 yrs.: 0.94 (0.10, 8.55)
Gilbertson et al. (2011) ⁷⁰ Cohort: Multivariate analysis	N=118,533 Medicare patients who initiated hemodialysis before August 1, 2003 and were alive through October 31, 2005; Location= U.S. Age=>=18 years;	Influenza, unspecified 2003-2004, 2004-2005	Patient demographics, doesn't specify but variables assessed include age, sex, race, primary cause of end-stage renal disease, dialysis duration, comorbid conditions.	Relative risk of mortality Influenza vaccine (both seasons): 0.77 (0.73–0.81)	Vaccine associated with lower mortality. Higher risk of mortality if older, longer on dialysis, or comorbid conditions.

Table 8. Postmarketing studies of influenza vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Hurst et al. 2011 ⁷¹ Cohort: Multivariate analysis	N=51,730 adult Medicare patients with renal transplant; Location=U.S.; Age=>=65 years; 9,678 had claims for influenza vaccine in the first year post transplant	Influenza, unspecified, January 2000 – September 2006	Factors known to be independently associated with allograft loss (recipient age, black race, PRA 20%, dialysis vintage, diabetes mellitus, congestive heart failure, ischemic heart disease, tobacco use, HLA matching, donor age of 50 years, donor black race, deceased-donor transplant, expanded criteria donor, delayed graft function, cold ischemic time of 24 hours, year of transplant, and induction/discharge immunosuppression). Others not specified for the relevant model but could include: older age, diabetes, later year of transplant, and tacrolimus or mycophenolate at discharge	Vaccination in the first year after transplant was associated with lower risk of subsequent allograft loss and death Adjusted hazard ratio Allograft loss: 0.77 (0.69-0.85) Death: 0.82 (0.76-0.89) Acute rejection in the first year was not associated with vaccination in the first 6 or 12 months after transplant Adjusted odds ratio Rejection in first 6 mo: 1.00 (0.88-1.14), Rejection in first 12 mo: 0.97 (0.89-1.07)	Not reported
Ting et al. 2011 ⁷² Matched cohort	586 patients with moderate to severe COPD identified in COPD Registers of 6 general practices in North Derbyshire UK. Age range 37-89 (median 68)	Influenza, unspecified, Fall 2005	Environmental factors (weather, prevalence of respiratory viral pathogens)	In the 14 days following vaccination, the control group had 21 COPD exacerbations cf. 11 in the vaccinated group OR 0.52 (95% CI 0.29, 1.14)	Not reported

Table 8. Postmarketing studies of influenza vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Baxter et al. 2012 ⁷³	Sample size: 60,996; Location: U.S.; Age: 18-49; Setting: Kaiser Permanente Managed Care Health Plans	Ann Arbor Strain LAIV	Adjusted for: Matching factors, seasonal changes in background rates	The rate of hospitalization or death due to any condition within 180 days of vaccination with LAIV was lower than with TIV (1.46 vs. 9.10) or no vaccine (1.46 vs. 3.36). The incidence rate for any serious adverse event (SAE) within 21 days and 42 days of vaccination with LAIV was lower compared to no vaccination.	Not reported
Isai et al., 2012 ⁶¹ , cohort	N=50,221 adverse events; Location=European Union; Age=Unknown; Setting=EudraVigilance database	Monovalent H1N1 vaccines: Cantgrip, Celtura, Celvapan, Fluvial, Focetria, Pandemrix, Panenza	None	<p>Analysis 1 included all autoimmune disorder cases as reported. Analysis 2 used cases assessed as certain, probable or possible according to WHO Causality assessment and available Brighton Collaboration definitions</p> <p>Using analysis 1, the reporting ratio calculated as the percentage of autoimmune ADRs amongst all reported ADRs shows comparable results for non adjuvanted (0.94% [0.64–1.24]) and adjuvanted (0.60% [0.53–0.67]) vaccines.</p> <p>The calculation using analysis 2 (restricted analysis) included 15 cases of autoimmune disorders for non adjuvanted vaccines and 121 cases for adjuvanted ones. The reporting ratio was 0.37% (0.18–0.56) and 0.26% (0.22–0.31), respectively.</p> <p>For the calculation of reporting rates using the estimated number of vaccinees as the denominator, analysis 1 resulted in a reporting rate of 9.98 (6.81–13.16) per million for non adjuvanted vaccines and of 6.87 (6.06–</p>	None

Table 8. Postmarketing studies of influenza vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				<p>7.68) per million for adjuvanted vaccines.</p> <p>Using analysis 2, the reporting rates were respectively 3.94 (1.95–5.94) and 3.01 (2.47–3.55) per million.</p>	
Crawford, et al., 2012 ⁵⁹ , Self-controlled case series	N=44 Location=Victoria, Australia Age=48 (median); 7–95 years (range) Setting=An active surveillance system for GBS was established in 10 hospitals in Victoria	Monovalent H1N1 vaccine (Panvax, CSL Limited) TIV (Fluvax, CSL Limited; Vaxigrip, Sanofi Pasteur; Influvac, Abbott)	None, self-controlled design	<p>Pandemic (H1N1) 2009 influenza A immunisation and Guillain-Barré syndrome: relative incidence (RI) estimates from the self-controlled case series with a 42-day postvaccination risk window</p> <p>Base: 3.41 (0.78–14.97)</p> <p>No seasonal trivalent influenza vaccine: 3.39 (0.77–14.91)</p> <p>No period adjustment: 2.92 (0.75–11.31)</p> <p>Three 2-week periods 0–13 days: 3.74 (0.41–34.05) 14–27 days: 3.35 (0.38–29.64) 28–41 days: 3.19 (0.35–28.67)</p> <p>Only Brighton level 1–2 cases: 3.99 (0.82–19.55)</p> <p>Include unconfirmed cases: 2.71 (0.62–11.85)</p> <p>Include incomplete vaccine history: 3.25 (0.75–14.21)</p> <p>Include incomplete vaccine history and second episode: 3.34 (0.76–14.59)</p> <p>Include all: 2.25 (0.54–9.37)</p>	None

Table 8. Postmarketing studies of influenza vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Baxter, et al. 2013, ⁵⁵ Case-centered and cohort	N=415 cases; Location=California; Age=48.5 years (mean), 5-87 years (range); Setting=Kaiser Permanente Northern California (KPNC)	Influenza (TIV), 23-valent pneumococcal polysaccharide, IPV, Tdap, I-typoid, Hepatitis A, Hepatitis B, Td	Case-centered: Age and sex matching for expected odds Cohort: age	Odds Ratio of Vaccination in a 6- or 10-Week Risk Interval Before Onset of Guillain-Barre Syndrome, Using a Case-Centered Analysis Design OR, 95% CI 6-week Risk Interval IPV: 7.19 (0.18-281.03) Tdap: None (0.16 to NE) PPV-23: 0.72 (0.11-2.87) Hep A: 2.22 (0.30-10.63) Hep B: 0.43 (0.02-2.56) Td: 1.43 (0.33-4.56) TIV: 1.11 (0.39-3.08) 10-week Risk Interval IPV: 4.15 (0.11-163.38) Tdap: None (.09 to NE) PPV-23: 0.44 (0.07-1.72) Hep A: 2.00 (0.39-8.74) Hep B: 0.24 (0.01-1.46) Td: 1.14 (0.32-3.29) TIV: 0.99 (0.33-2.70)	None

Table 8. Postmarketing studies of influenza vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Hedlund et al. 2003 ⁶⁶ Prospective cohort	N=100,242 vaccinated with influenza or pneumococcal vaccines, 159,385 unvaccinated controls, in Stockholm County, Sweden; Age=>=65 years;	TIV and 23-valent pneumococcal vaccine (PV), December 1998-November 1999	Age and gender	Hospital admissions/100,000 individuals between 1 December 1998 and 30 November 1999 Influenza 0.68 (0.53-0.88) Pneumonia 0.78 (0.71-0.86) IPD: 0.46 (0.25-0.87) COPD: 1.04 (0.92-1.17) Cardiac failure: 0.95 (0.87-1.05) In-hospital mortality due to investigated diagnoses/100 000 individuals between 1 December 1998 and 30 November 1999 Influenza 1.20 (0.39-3.70) Pneumonia 0.55 (0.43-0.71) IPD: 0.53 (0.06-5.10) COPD: 0.53 (0.29-0.98) Cardiac failure: 0.72 (0.59-0.87) Hospital admissions/100 000 individuals per year between 1 December 1998 and 31 May 1999 Influenza: 0.66 (0.52-0.82) Pneumonia: 0.72 (0.65-0.79) IPD: 0.47 (0.24-0.93) COPD: 1.07 (0.94-1.23) Cardiac failure: 0.90 (0.80-1.01) Hospital admissions/100 000 individuals per year between 1 June and 30 November 1999 Influenza: 1.36 (0.58-3.17) Pneumonia: 0.88 (0.77-1.00) IPD: 0.45 (0.15-1.32) COPD: 1.00 (0.87-1.15) Cardiac failure: 1.02 (0.93-1.11)	Not reported

Table 8. Postmarketing studies of influenza vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Lee et al. 2011, Self-controlled case series and multivariate logistic regression ⁶⁰	N=4,512,366 flu doses in eight U.S. managed care organizations; Age=6 mos to >=65 years;	H1N1 monovalent inactivated (MIV trivalent inactivated (TIV), and live, attenuated (LAIV) influenza vaccines	Case-centered logistic regression: case date, age group, gender, and site.	No significant associations were noted during sequential analyses for Guillain-Barré syndrome, most other neurologic outcomes, and allergic and cardiac events. For MIV, a statistical signal was observed for Bell's palsy for adults aged >=25 years on March 31, 2010, using the self-controlled approach. Subsequent analyses revealed no significant temporal cluster. Case-centered logistic regression adjusting for seasonality demonstrated an OR for Bell's palsy of 1.26 (95% CI=0.97, 1.63).	None

AE = adverse event; CI = confidence interval; COPD = chronic obstructive pulmonary disease; GBS = Guillain-Barré syndrome; GPRD = general practice research database; HLA = human leukocyte antigens; ITP = thrombocytopenic purpura; LAIV = live attenuated influenza vaccine; MCOs = managed care organizations; MI = myocardial infarction; MIV = monovalent inactivated influenza vaccine; MMR = measles, mumps, rubella vaccine; Mo = month; MS = multiple sclerosis; OR = odds ratio; PRA = plasma renin activity; SAE = serious adverse events; SD = standard deviation; TIV = trivalent inactivated influenza vaccine; VAESCO = vaccine adverse events surveillance and communication; VSD = vaccine safety datalink; Yr(s) = year(s)

Note: Additional study details presented in Appendix C evidence tables.

Pneumococcal Vaccines

Pneumococcal vaccines were not covered by the IOM report. We found no placebo-controlled trials of the currently available pneumococcal polysaccharide vaccine (PVC23) that reported adverse events data. (If a study did not explicitly state that no adverse events took place, it was excluded.) We found several trials of PPV23 that reported community-acquired pneumonia and associated mortality; however, these were considered efficacy outcomes. We also found trials of PVC 23 versus old versions (i.e. PCV13, PCV7); however those studies were excluded because they had no unvaccinated comparison group.

Five postmarketing studies in adults were identified; all studied the relationship between pneumococcal polysaccharide vaccine and occurrence of cardiovascular or cerebrovascular disease. Results are displayed in Table 9. No other case-control study, self-controlled case series, or multivariate analysis focused on pneumococcal vaccine alone.

Cardiovascular and Cerebrovascular

In a prospective cohort study of 84,170 men aged 45 to 69 years, Tseng et al. 2010⁷⁴ found that administration of pneumococcal vaccine (unspecified) was not associated with reduced risk adjusted for propensity score of stroke (OR 1.14, 95% CI 1.00, 1.31) and of myocardial infarction (OR 1.09, 95% CI 0.98, 1.21). In contrast, in a prospective cohort of 6,171 subjects, Eurich et al. 2012⁷⁵ showed that administration of pneumococcal polysaccharide vaccine was associated with a decreased rate of acute coronary syndrome-related hospitalization. Other studies did not show a lower risk of myocardial infarction (Siriwardena et al. 2010; Vila-Corcoles et al. 2012;^{64,76,77} Hedlund et al. 2003⁶⁶ compared one-year outcomes among 100,242 persons vaccinated with influenza and/or 23-valent pneumococcal vaccine versus 159,385 unvaccinated individuals; all subjects were aged 65 years or older.(Study details are displayed in Table 8 in the influenza section.) Among the vaccinated subjects, 76,177 had both vaccines, 23,224 received only the influenza vaccine, and 841 received only the pneumococcal vaccine. No harms from vaccination were noted among the reported outcomes. Administration polysaccharide pneumococcal vaccination was not associated with any subsequent change in the age-adjusted rates of first and recurrent myocardial infarction or stroke.

Summary

Pneumococcal vaccines were not covered by the IOM report. We found no placebo-controlled trials of PCV23 which assessed adverse events. Post-licensure studies focused on association of pneumococcal polysaccharide vaccines with cardiovascular and cerebrovascular events in older adults. As results of four high quality post-licensure studies conducted in the US, UK, Canada, and Spain consistently found vaccination was not associated with increased risk of these events in persons age 65 and older, the strength of evidence is rated as high. The studies have low risk of bias, as the analyses adjusted for subject characteristics that would make them more at risk for these adverse events, such as pre-existing medical conditions, demographics, and behavioral risks. The US and UK studies had high statistical power, with about 80,000 subjects each. Results were inconsistent as to whether these vaccines decrease risk of these events.

Table 9. Postmarketing studies of pneumococcal vaccines in adults

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Tseng et al. 2010 ⁷⁴ Prospective cohort	N=84,170; Location=CA; Age=45-69 years; Setting=Kaiser Permanente Northern and Southern California health plans (California Men's Health Study)	Pneumococcal, any	Propensity score was created: age, race/ethnicity, region (northern vs. southern California Kaiser Permanente), household income, education, BMI, cigarette smoking, physical activity level, sedentary for more than 6.5 hours per day outside of work, alcohol consumption, number of influenza vaccines received, calorie intake, fat intake, fruit and vegetable consumption, history of diabetes, history of high blood pressure, history of high cholesterol, history of peripheral artery disease, history of other heart diseases, history of stroke, history of acute MI, and the log scale transformed number of outpatient visits in last 5 years	Adjusted hazard ratio, Pneumococcal Vaccination and Incidence of MI and Stroke Acute MI All men: 1.09 (0.98-1.21) Stroke All men: 1.14 (1.00-1.31)	Association of Pneumococcal Vaccination and Incidence of MI and Stroke Age, years <65: 1.23 (1.08-1.40) ≥65: 0.89 (0.80-1.01) High-risk groups Current smokers: 1.11 (0.83-1.47) Diabetes: 1.04 (0.87-1.24) Hypertension: 1.10 (0.97-1.25) Low-risk group: 0.98 (0.35-2.73) Influenza vaccine 0: 1.10 (0.70-1.72) 1-10: 1.10 (0.97-1.26) >10: 1.00 (0.83-1.21)
Eurich et al. 2012 ⁷⁵ Prospective cohort	N=6,171; Location=Edmonton (Alberta, Canada); Age=mean 59 years; Setting=Population-based cohort of adults presenting with community-acquired pneumonia (CAP) in Edmonton	Pneumococcal polysaccharide vaccination (PPV)	Pneumonia severity based on the PSI; comorbidities including chronic obstructive pulmonary disease, diabetes, ischemic heart disease (IHD); functional status, smoking status and cardiovascular and other medications Authors also completed a propensity (to receive PPV) score analysis	Adjusted HRs for fatal and non-fatal ACS events within 90 days according to pneumococcal vaccination status Primary analysis Death or ACS-related hospitalization: 0.42 (0.27 to 0.66) Death: 0.92 (0.32 to 2.63) Hospitalization due to ACS: 0.35 (0.21 to 0.57) Propensity score analysis Death or ACS-related Hospitalization: 0.46 (0.28 to 0.73) Death: 1.51 (0.42 to 5.34) Hospitalization due to ACS: 0.36 (0.21 to 0.61)	Not reported

Table 9. Postmarketing studies of pneumococcal vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Siriwardena et al. 2010 ⁶⁴ Matched case-control	N=78,706 (16,012 cases of myocardial infarction (MI), 62,964 controls); Location=UK; Age=40 to >=65; Setting=United Kingdom General Practice Research Database (GPRD), an extensively validated computerized database, representative of and comprising 5% of the population of England and Wales.	Influenza; pneumococcal, any	Model 1 adjusted for asthma or chronic obstructive pulmonary disease, chronic heart disease, stroke or transient ischemic attack, diabetes, splenectomy, chronic liver disease, chronic renal failure, immunosuppression and HIV, hyperlipidemia, family history of acute myocardial infarction, peripheral vascular disease, hypertension, smoking status, treatment with acetylsalicylic acid, treatment with statins, treatment with antihypertensives, and general practice consultations. Each type of vaccination was adjusted for the other type. Second set of models (Model 2) adjusted for all of the above	Pneumococcal vaccination within previous year, OR for MI Model 1: 0.96 (0.91–1.02) Model 2: 0.98 (0.93–1.04)	Not reported, but subgroup results shows for the following categories: Pneumococcal Age < 65: Model 1: 0.83 (0.73–0.95) Model 2: 0.91 (0.79–1.05) Age ≥ 65: Model 1: 0.88 (0.83–0.93) Model 2: 0.97 (0.91–1.03)

Table 9. Postmarketing studies of pneumococcal vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Vila-Corcoles et al. 2012 ⁷⁶ Prospective cohort	N=27,204 (8,981 vaccinated, 18,223 unvaccinated); Location=Spain; Age=71.7 (mean at study start); Setting=nine primary care centers in the Health Region of Tarragona (a mixed residential-industrial urban area in the Mediterranean coast of Catalonia, Spain)	Pneumococcal (PPV23)	The following variables were considered in all the initial models: age, sex, number of outpatient visits to family physician in 12-months before study start, influenza vaccination in prior autumn, history of coronary artery disease, history of stroke, history of chronic heart disease, chronic pulmonary disease, hypertension, hypercholesterolemia, obesity, diabetes mellitus, smoking status, alcoholism, chronic severe liver disease, chronic severe nephropathy, cancer, dementia and nursing-home residence. Age, sex and influenza vaccine status were judged epidemiologically relevant variables, being included in all the final models. Final Models: Community Acquired Pneumonia (CAP): Adjusted for age, sex, number of outpatient visits in prior year, influenza vaccination in prior year, chronic pulmonary disease, chronic heart disease, smoking and nursing-home resident Acute Myocardial Infarction (AMI): Adjusted for age, sex, number of outpatient visits in prior year, influenza vaccination in prior year, history of coronary artery disease, chronic heart disease, diabetes mellitus, hypercholesterolemia, smoking (confounder) and nursing-home resident Ischemic Heart Disease: Adjusted for age, sex, number of outpatient visits in prior year, influenza vaccination in	Multivariate hazard ratio (95% CI) CAP: 0.85 (0.62-1.15) AMI: 0.83 (0.56-1.22) Ischemic Stroke: 0.65 (0.42-0.99) Death from any cause: 0.88 (0.75-1.03)	Not reported

Table 9. Postmarketing studies of pneumococcal vaccines in adults (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
			prior year, history of coronary artery disease, history of stroke, smoking (confounder) and nursing-home resident Death from any cause: Adjusted for age, sex, number of outpatient visits in prior year, influenza vaccination in prior year, chronic pulmonary disease, chronic heart disease, diabetes mellitus, cancer, chronic nephropathy, dementia, hypertension, hypercholesterolemia, obesity, smoking, and nursing home-resident		

ACS = acute coronary syndrome; AMI = acute myocardial infarction; CAP = community-acquired pneumonia; CI = confidence interval; GPRD = general practice research database; IHD = ischemic heart disease; OR = odd ratio; MI = myocardial infarction; PPV = pneumococcal polysaccharide vaccination; PSI = pneumonia severity index

**Statistically significant association.

Note: Additional study details presented in Appendix C evidence tables.

Zoster

We identified six trials of Zostavax; results are summarized in Table 10.

One trial conducted in Brazil, Costa Rica, Colombia, Mexico, Peru, Venezuela, and the Philippines⁷⁸ studied the vaccine in varicella-zoster virus sero-negative or low sero-positive adults. This trial included only 21 persons: 18 received the vaccine, while three received placebo. There were no AEs reported in the placebo group; thus, odds ratios could not be calculated. There were no serious AEs in the vaccine group.

Some publications reported only broad categories of AEs. A controlled clinical trial in North America and Europe⁷⁹ included 22,439 adults (62% female) who received one dose of the zoster (Zostavax) vaccine at baseline. Compared to the control group, vaccinated individuals were more likely to experience one or more injection-site AEs (OR 10.38, 95% CI 9.72-11.08), vaccine-related AEs (OR 8.39, 95% CI 7.88-8.92), and one or more systemic adverse events (OR 1.09, 95% CI 1.03-1.15).

A smaller trial in the United States and Netherlands⁸⁰ included 210 older adults (63% female) who received two doses of Zostavax, one at baseline (Dose 1) and another 42 days later (Dose 2). Compared to the control group, vaccinated individuals were more likely to experience one or more adverse events post dose 1 (OR 3.06, 95% CI 1.73-5.41), systemic adverse events post dose 1 (OR 14.70, 95% CI 1.89-114.53), vaccine-related adverse events post dose 1 (OR 8.53, 95% CI 4.18-17.39), one or more adverse events post dose 2 (OR 4.06, 95% CI 2.28-7.24), and vaccine-related adverse events post dose 2 (OR 11.17, 95% CI 5.46-22.87). A crossover trial in the United States⁸¹ randomized 101 adults (59% female) to Zostavax or placebo at study start. The groups were switched at 28 days; those who received placebo on Day 1 were given Zostavax and vice-versa. The study reported overall results and also results according to different subgroups. The only AE associated with vaccination in the overall study population was injection-site AE (OR 19.84, 95% CI 6.77-58.12). The vaccine was associated with “one or more adverse event” in patients over 60 years old (OR 5.37, 95% CI 2.61-11.05).

A controlled clinical trial in the United States included 38,546 older adults (41% female) who received one dose of zoster vaccine. No statistically significant differences in serious adverse events between vaccinated and unvaccinated groups were reported. An Adverse Events Monitoring Substudy of this trial⁸² reported on over 6,600 of the subjects. Compared to the control group, vaccinated individuals were more likely to experience one or more adverse events at the injection site (OR 4.67, 95% CI 4.16-5.24) and one or more vaccine-related systemic adverse events (OR 1.30, 95% CI 1.05-1.60). There were no significant differences in cardiovascular, endocrine, digestive, metabolic, musculoskeletal, or nervous system AEs.

Lastly, a controlled clinical trial conducted in the United States, Canada, Spain, Germany, and the UK⁸³ included almost 12,000 older adults (59% female) who received one dose of Zostavax. This study reported on cardiac, GI, psychiatric, and other categories of serious adverse events. No statistically significant differences in adverse events between vaccinated and unvaccinated groups were reported.

Table 10. Vaccinated versus unvaccinated adults: zoster vaccine

Author- Year- Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Macaladad N. et al., 2007 ⁷⁸ also Brazil, Costa Rica, Colombia, Mexico, Peru and Venezuela and the Philippines	Controlled Clinical Trial	2	Sample size : 21, Mean age: 38.1, Age range: 27 – 69, Percent female: 66.7%	Zoster, NR, 50,000 PFU/0.5 mL, Adjuvant: Not Reported, Preservative: Not reported, Delivery: injected	Dose1: 0 Days	Not calculated
Mills R. et al., 2010 ⁸¹ U.S.	Controlled Clinical Trial – Crossover on Day 28	5	Sample size : 101, Mean age: 67.8 (approx.), Age range: 50 - 93, Percent female: 59.4%	Zoster, Zostavax, Merck, Lyophilized zoster vaccine (~89,000 plaque-forming units[PFU]/dose at release), Adjuvant: Not Reported, Preservative: Not reported, Delivery: Subcutaneous	Dose1: 0 Days	50-59y: Systemic AE: OR 0.245 (0.027-2.231) 50-59y: 1 or more AE: OR 1.899 (0.613-5.88) >=60y: Systemic AE: OR 1.664 (0.685-4.042) >=60y: 1 or more AE: OR 5.371 (2.609-11.054) ** Overall - Injection site AEs: OR 19.841 (6.773-58.123) **
Murray A. V. et al., 2011 ⁸³ U.S., Canada, Spain, Germany, UK	Controlled Clinical Trial	4	Sample size : 11,999, Mean age: 70.4, Age range: 60 - 99, Percent female: 58.6%	Zoster, Zostavax, Merck, Lyophilized ZV, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Subcutaneous	Dose1: 0 Days	Blood/Lymphatic disorders(1-182d): OR 1.253 (0.336-4.669) Cardiac disorders (1-182d): OR 1.016 (0.733-1.41) Cardiac disorders(1-42d): OR 1.002 (0.53-1.895) Death (1-182d): OR 1.417 (0.76-2.64) Death (1-42d): OR 1.203 (0.367-3.944) GI disorders (1-182d): OR 1.281 (0.787-2.085) GI disorders(1-42d): OR 1.337 (0.464-3.855) Neoplasms (1-182d): OR 1.317 (0.934-1.858) Neoplasms(1-42d): OR 1.672 (0.731-3.824) Nervous system(1-182d): OR 0.808 (0.476-1.369) Nervous system (1-42d): OR 0.716 (0.227-2.256) Psychiatric (1-182d): OR 60.2 (0.116-31171.904) Psychiatric (1-42d): OR 1.002 (0.141-7.118) Respiratory/Thoracic (1-182d): OR 1.123 (0.654-1.928) Respiratory/Thoracic (1-42d): OR 1.504 (0.424-5.333)

Table 10. Vaccinated versus unvaccinated adults: zoster vaccine (continued)

Author- Year- Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Simberkoff M. S. et al.,2010 ⁸² U.S.	Controlled Clinical Trial	7	Sample size : 38,546,, Adverse events substudy N = 6,660 Median age: 69 years; Age range: 60 - > 80	Zoster, Merck, Median potency, 24600 plaque-forming units per dose, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Subcutaneous	Dose1: 0 Days	# of SAE (60-69y): OR 1.081 (0.847-1.38) # of SAE (70-80y): OR 0.909 (0.728-1.135) # of SAE (>=70y): OR 0.969 (0.793-1.185) # of SAE (>=80y): OR 1.301 (0.808-2.095) COSTART - Cardiovascular: OR 1.117 (0.835-1.496) COSTART - Digestive: OR 0.719 (0.481-1.075) COSTART - Endocrine: OR 0.25 (0.028-2.237) COSTART - Genitourinary: OR 0.941 (0.476-1.864) COSTART - Hemic/Lymphatic: OR 2.501 (0.485-12.894) COSTART - Metabolic/Nutritional: OR 1.667 (0.398-6.978) COSTART - Musculoskeletal: OR 1 (0.489-2.047) COSTART - Nervous Sys: OR 1.03 (0.642-1.652) COSTART - Skin: OR 0.903 (0.542-1.506) Diagnostic group - Cancer: OR 1.131 (0.76-1.683) Diagnostic group - Vascular (functional): OR 1.155 (0.752-1.774)
Schmader K. E. et al.,2012 ⁷⁹ North America and Europe	Controlled Clinical Trial	4	Sample size : 22,439, Mean age: 54.8, Age range: 50 - 59, Percent female: 61.9%	Zoster, Zostavax, Merck, lyophilized ZV with stabilizers, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Subcutaneous	Dose1: 0 Days	1 or more Injection-site AEs: OR 10.379 (9.722-11.081) ** SAE with death: OR 0.334 (0.035-3.209) Vaccine-related AEs: OR 8.385 (7.882-8.922) ** Vaccine relate systemic AEs: OR 0.43 (0.393-0.471) With vaccine related SAE: OR 0.002 (0-0.013) 1 or more Systemic AEs: OR 1.089 (1.031-1.151) **

Table 10. Vaccinated versus unvaccinated adults: zoster vaccine (continued)

Author-Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Vermeulen J. N. et al., 2012 ⁸⁰ U.S. and Netherlands	Controlled Clinical Trial	5	Sample size : 210, Mean age: 68.7 (Tx); 70.7 (Placebo), Age range: 58–90, Percent female: 62.85% Conditions: Arthritis, hyperlipidemia, hypertension	Zoster, Zostavax, Merck, lyophilized ZV (~23,000 plaque forming unit [PFU]/0.5 mL), Adjuvant: Not Reported, Preservative: Not reported, Delivery: Subcutaneous	Dose1: 0 Days Dose2: 42 Days	1 or more AEs (Post Dose 1): OR 3.062 (1.732-5.412) ** # of patients with any AE Dose 2: OR 4.203 (2.348- 7.522) ** Rash: OR 2.019 (0.18-22.617) Systemic AEs (Post Dose 2): OR 0.825 (0.244-2.791) Systemic AEs (Post Dose 1): OR 14.696 (1.886- 114.525) ** Vaccine-related AEs (Post Dose 1): OR 8.525 (4.179- 17.389) ** Systemic AEs: OR 14.857 (1.906-115.797) ** Systemic AEs Dose 2: OR 0.833 (0.246-2.82) Vaccine-related AEs: OR 8.699 (4.26-17.763) ** Vaccine-related AEs Dose 2: OR 11.44 (5.582-23.446) **

AEs = adverse events; D = day; GI = gastrointestinal; NR = not reported; OR = odds ratio; PD = post dose; PFU = plaque forming units; SAE = serious adverse events; Y = year;

ZV = zoster vaccine

** Statistically significant.

Note: Additional study details presented in Appendix C evidence tables.

Three post-licensure studies evaluated adverse events following administration of adult herpes zoster vaccine. They are displayed in Table 11. Zhang et al. 2012⁸⁴ evaluated the efficacy and safety of zoster vaccine among Medicare beneficiaries 60 years and older who had inflammatory bowel disease, psoriatic arthritis, psoriasis or rheumatoid arthritis. Receipt of zoster vaccine was not associated with increased cases of varicella or herpes zoster within 42 days in the cohort as a whole and specifically in individuals who were receiving biologic immunodulatory agents (principally agents targeted against Tumor Necrosis Factor). The authors also evaluated the relationship between vaccination and hospitalization for meningitis or encephalitis; no such cases were identified. With a median follow-up of two years, receipt of the zoster vaccine was associated with a decreased rate of incident cases of zoster. Lower rates were associated with vaccination in all patient subgroups

Using both a case-centered approach and a self-controlled case series analysis, Tseng et al 2012,⁸⁵ examined the relationship between receipt of zoster vaccine and various adverse events among a cohort of adults age 50 and above receiving care from eight U.S. managed-care organizations. Five specific groupings of events were examined: cerebrovascular events (Group 1); acute myocardial infarction, acute pericarditis, acute myocarditis, cardiomyopathy, heart failure (Group 2); meningitis encephalitis and encephalopathy (Group 3); Ramsay-Hunt syndrome and Bell's palsy (Group 4); and medically attended events, including cellulitis, pain and allergic reactions (Group 5). No increased risk was found for Groups 1 – 4 as a whole or for the any of the individual entities within these groups. An increased rate of cellulitis on days 1 – 7 was found using only the case-centered method (RR 1.30, 95% CI 1.18, 1.44) and an increase in allergic reactions was found by both the case centered analysis (RR 2.13, 95% CI 1.87, 2.40) and the self-controlled case series method (RR 2.32 95% CI 1.85, 2.91). No cases of anaphylaxis occurred with vaccine administration. The authors state the increased rate of cellulitis may be due to patient allergy or inflammatory reactions.

Baxter⁸⁶ compared rates of medical events resulting in emergency room visits or hospitalization in a 42-day time period following vaccination with rates in the same cohort in a subsequent comparison time period. Of the 386 comparisons performed, four conditions (systemic lupus erythematosus, angioplasty, coronary atherosclerosis, and other heart disease) had a statistically significant increased relative risk. However, after medical records review, the timing of these conditions was found to often be prior to vaccination, and no clear increase in health events was observed in the risk period following vaccination compared to later.

Summary

Zostavax is recommended for U.S. adults over age 60; adverse events specific to this population were not covered by the IOM report. In the clinical trials we identified, potency varied from 18,700 to 89,000 PFU (plaque-forming units) per dose. (Two of the six trials did not report potency.) The formulation currently licensed in the United States contains a minimum of 19,400 PFU per 0.65 ml dose.

Adverse events were sometimes reported using broad categories such as “injection-related adverse events,” “systemic adverse events,” or “one or more adverse events;” the quality of adverse events reporting in these trials was thus considered poor. Two trials reported events using more specific categories such as “psychiatric” or “respiratory/thoracic;” in these two trials, the vaccine was not associated with any adverse events other than injection site reaction.

Strength of evidence is moderate for this non-serious adverse event based on high quality of these trials. We found three post-licensure studies; the only adverse events associated with Zoster

vaccine were allergic reactions and cellulitis possibly due to inflammatory or allergic reactions. No cases of anaphylaxis were reported; the events are non-serious. The strength of evidence is moderate; studies used appropriate designs, had low risk of bias, and high statistical power due to sample size.

Table 11. Postmarketing studies of zoster vaccine

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Zhang et al. 2012 ⁸⁴ Retrospective cohort	N=463,541(4,026 with ankylosing spondylitis, 66,751 with inflammatory bowel disease, 11,030 with psoriatic arthritis, 89,565 with psoriasis, and 292,169 with RA); Location=U.S.; Age=74 years (mean at study start); Setting=U.S. Medicare beneficiaries	Zostavax	Sex, race, immune-mediated disease, time varying concurrent medications, and time-varying health care utilization (hospitalization and physician visits)	HR (95% CI) for Herpes Zoster Incidence Using ICD-9-CM diagnosis code+pharmacy claim definition for HZ case (Definition 1) HZ vaccination: 0.61 (0.52-0.71) Using ICD-9-CM diagnosis code only for HZ case (Definition 2) HZ vaccination: 0.67 (0.59-0.75)	Sex Men [Reference] Women Definition 1: 1.22 (1.17-1.28) Definition 2: 1.21 (1.17-1.26) Race White [Reference] Black Definition 1: 0.67 (0.62-0.73) Definition 2: 0.69 (0.64-0.74) Other Definition 1: 0.89 (0.81-0.97) Definition 2: 0.89 (0.83-0.95) Immune-mediated disease Rheumatoid arthritis [Reference] Ankylosing spondylitis Definition 1: 0.98 (0.77-1.25) Definition 2: 0.94 (0.77-1.13) Inflammatory bowel diseases Definition 1: 1.03 (0.97-1.10) Definition 2: 1.02 (0.97-1.07) Psoriatic arthritis Definition 1: 0.92 (0.80-1.05) Definition 2: 0.92 (0.83-1.02) Psoriasis Definition 1: 0.99 (0.93-1.05) Definition 2: 0.97 (0.93-1.02) Hospitalized in the previous 6 mo No [Reference] Yes

Table 11. Postmarketing studies of zoster vaccine (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
					Definition 1: 1.00 (0.95-1.05) Definition 2: 1.25 (1.20-1.29) No. of physician visits in the previous 6 mo Definition 1: 1.04 (1.04-1.04) Definition 2: 1.04 (1.04-1.04)

Table 11. Postmarketing studies of zoster vaccine (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Tseng et al. 2010 ⁸⁵ Case-centered and Self-controlled case series	N=193,083 recipients of zoster vaccine in 8 U.S. MCOs; Age≥50;	Zostavax	No additional confounders controlled for in models	<p>Relative risk (RR) and 95% confidence interval (CI) of pre-specified adverse events within predefined risk windows following vaccination with a zoster vaccine</p> <p><u>Case-centered Day 1-14</u> Stroke: 1.03 (0.83–1.28) Acute myocardial infarction: 1.17 (0.92–1.48) Cardiomyopathy: 0.73 (0.51–1.03) Heart failure: 0.76 (0.46–1.24) Meningitis, encephalitis and encephalopathy: 0.54 (0.19–1.52) Ramsey-Hunt syndromes and Bell's palsy: 0.63 (0.29–1.38)</p> <p><u>Day 15-28</u> Stroke: 0.92 (0.73–1.16) Acute myocardial infarction: 1.04 (0.81–1.34) Cardiomyopathy: 1.11 (0.83–1.48) Heart failure: 1.08 (0.70–1.65) Meningitis, encephalitis and encephalopathy: 0.90 (0.40–2.05)</p> <p><u>Day 29-42</u> Stroke: 1.06 (0.85–1.31) Acute myocardial infarction: 0.97 (0.75–1.26) Acute pericarditis: 1.04 (0.13–8.05) Cardiomyopathy: 1.00 (0.74–1.36) Heart failure: 0.95 (0.60–1.49) Meningitis, encephalitis and encephalopathy: 0.62 (0.23–1.69)</p> <p><u>Day 1-42</u> Stroke: 1.00 (0.87–1.15) Acute myocardial infarction: 1.07 (0.92–1.26) Acute pericarditis: 0.27 (0.03–2.22) Cardiomyopathy: 0.94 (0.77–1.14) Heart failure: 0.91 (0.68–1.21)</p>	Not reported

			<p>Meningitis, encephalitis, and encephalopathy: 0.66 (0.37–1.16) Mortality: 0.31 (0.23–0.40)</p> <p><u>Day 1-7</u> Cellulitis and infection: 1.30 (1.18–1.44) Allergic Reaction: 2.13 (1.87–2.40)</p> <p>Self-controlled case series</p> <p><u>Day 1-14</u> Cerebrovascular diseases: 0.94 (0.70–1.28) Acute myocardial infarction: 1.22 (0.87–1.73) Cardiomyopathy: 0.70 (0.45–1.10) Heart failure: 0.77 (0.41–1.46)</p> <p>Meningitis, encephalitis, and encephalopathy: 0.80 (0.21–2.98) Ramsey-Hunt syndromes and Bell's palsy: 0.78 (0.29–2.09)</p> <p><u>Day 15-28</u> Cerebrovascular diseases: 1.03 (0.74–1.42) Acute myocardial infarction: 1.24 (0.85–1.79) Cardiomyopathy: 1.05 (0.69–1.59) Heart failure: 0.92 (0.51–1.63)</p> <p>Meningitis, encephalitis, and encephalopathy: 0.86 (0.29–2.55)</p> <p><u>Day 29-42</u> Cerebrovascular diseases: 0.97 (0.71–1.30) Acute myocardial infarction: 0.97 (0.67–1.39) Acute pericarditis: 1.00 (0.06–15.99) Cardiomyopathy: 0.86 (0.57–1.29) Heart failure: 0.64 (0.36–1.16)</p> <p>Meningitis, encephalitis, and encephalopathy: 0.80 (0.21–2.98)</p> <p><u>Day 1-42</u> Cerebrovascular diseases: 0.99 (0.83–1.19) Acute myocardial infarction: 1.05 (0.86–1.29) Acute pericarditis: 0.50 (0.05–5.51) Cardiomyopathy: 0.94 (0.73–1.20) Heart failure: 0.88 (0.61–1.25)</p> <p>Meningitis, encephalitis, and encephalopathy: 0.78 (0.39–1.56)</p> <p><u>Day 1-7</u> Cellulitis and infection: 1.10 (0.95–1.26) Allergic Reaction: 2.32 (1.85–2.91)</p>	
--	--	--	--	--

Table 11. Postmarketing studies of zoster vaccine (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Baxter, et al. 2012, ⁸⁶ Retrospective cohort	N=29,000; Location=California Age=60+ years; Setting=Kaiser Permanente Northern California (KPNC), a U.S. managed care organization	Zostavax	Self-controlled	Health outcomes with elevated RR and statistically significant unadjusted p-value ($p<0.05$)(N=29,010). After medical records review. The timing of these conditions was found to be prior to vaccination. Coronary atherosclerosis and other heart disease 1.86 (1.09–3.15) Coronary atherosclerosis (ATS) 1.97 (1.11–3.49) Percutaneous transluminal coronary angioplasty (PTCA) 2.26 (1.19–4.27) Systemic lupus, erythematosus and connective tissue disorders 8.57 (1.08–212.11)	None

CI = confidence interval; CM = clinical modification; HR = hazard ratio; HZ = herpes zoster; ICD = International Classification of Diseases; MCOs = managed care organizations; Mo = month; RA = rheumatoid arthritis; RR = relative risk

Note: Additional study details presented in Appendix C evidence tables.

Varicella

We identified only one study comparing varicella-vaccinated and unvaccinated adults, published after the IOM search. A U.S. trial⁸⁷ randomized 67 HIV positive adults to either varicella vaccine (Varivax) or placebo at baseline and 12 weeks. No statistically significant differences in AEs between vaccinated and unvaccinated groups were reported. Data are presented in Table 12.

Table 12. Vaccinated versus unvaccinated adults: varicella vaccine

Author-Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Weinberg, A., et al. 2010 ⁸⁷ U.S. (No direct mentions)	Cohort	1	Sample size : 82, Mean age: NR, Age range: 18 - 65, Percent female: 35.3%, Conditions: HIV	Varicella, Varivax, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 0 Days Dose2: 12 Weeks	Dose 1: Influenza-like illness: OR 1.55 (0.242-9.94) Dose 1: Pruritus: OR 0.484 (0.042-5.618) Dose1: Systemic rash (non-zosteriform): OR 0.484 (0.042-5.618) Dose2: Liver enzyme elevation: OR 2.065 (0.178-23.943) Dose 2: Systemic rash (non-zosteriform): OR 1 (0.06-16.69)

CI = confidence interval; HIV = human immunodeficiency virus; NR = not reported; OR = odds ratio

Note: Additional study details presented in Appendix C evidence tables.

HPV

The IOM committee found the evidence “favors acceptance” of a causal relationship with anaphylaxis and “convincingly supports” no other causal relationships with AEs. The IOM committee found the evidence is “inadequate to accept or reject” a causal relationship between HPV vaccine and the following AEs: ADEM, transverse myelitis, neuromyelitis optica, MS, Guillain-Barré Syndrome, chronic inflammatory demyelinating d polyneuropathy, brachial neuritis, amyotrophic lateral sclerosis, transient arthralgia, pancreatitis, thromboembolic events, and hypercoagulable states. In the United States, HPV vaccine is generally administered to patients between the ages of 9 and 26. Thus, the post-licensure studies are discussed in the section on children and adolescents.

We identified two double blind randomized trials of HPV vaccine in women aged 18 to 35. Both were administered Cervarix at baseline, one month, and six months. The results are summarized in Table 13. A controlled trial in Hong Kong⁸⁸ included 300 women; compared to the control group, women who were vaccinated were more likely to experience the non-serious AEs, fatigue (OR 1.69, 95% CI 1.05 -2.72) and myalgia (OR 1.71, 95% CI 1.03-2.82). A controlled trial in India⁸⁹ included 337 adult women; compared to the placebo group, women who were vaccinated were more likely to experience Grade 3 (severe) pain (OR 6.19, 95% CI 2.63-14.54). Grade 3 pain was defined as that which limited typical daily activity; 20.5% of the HPV group and 4.0% of the placebo group reported this level of pain. We do not consider this a SAE.

We summarize the totality of the evidence on HPV in the section on children and adolescents.

Table 13. Vaccinated versus unvaccinated adults: HPV vaccine

Author-Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Bhatla N. et al., 2010 ⁸⁹ India	Controlled Clinical Trial	7	Sample size : 337, Mean age: 28.4, Age range: 18 – 35, Percent female: 100%	Human papillomavirus (HPV), HPV-16/18 L1 virus-like particle (VLP) cervical ca, GlaxoSmithKline, HPV-16/18 L1 virus-like particle (VLP) cervical cancer vaccine containing the proprietary ASO4 (3-O-desacyl-4(1)-monophosphoryl lipid [MPL] [0 mcg MPL] adsorbed on aluminum [Al] hydroxide [500 mcg AL(+3)]) adjuvant system, Adjuvant: ASO 4-Aluminum, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 Month Dose3: 6 Month	Pain (Grade 3): OR 6.189 (2.634-14.54) ** Redness (>50 mm): OR 1 (0.063-15.882)
Ngan H. Y. S. et al., 2010 ⁸⁸ Hong Kong	Controlled Clinical Trial	7	Sample size : 300, Age range: 18 – 35, Percent female: 100%	Human papillomavirus (HPV), Cevarix, GlaxoSmithKline, Each dose (0.5 mL) of the HPV-16/18 vaccine contained 20 µg each of HPV-16 and -18 L1 (structural protein of HPV) virus-like particle (VLP) and adjuvanted with a proprietary ASO4 (3-O-desacyl-4'-monophosphoryllipid [50 µg] adsorbed on aluminum hydroxide [Al(OH)3, 500 µg]), Adjuvant: ASO 4, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 Month Dose3: 6 Month	Arthralgia: OR 1.362 (0.556-3.336) Fatigue: OR 1.69 (1.049-2.721)** Fever: OR 0.734 (0.3-1.797) GI symptoms: OR 1.714 (0.86-3.415) Headache: OR 1.439 (0.822-2.519) Myalgia: OR 1.705 (1.031-2.82) ** Rash: OR 3.062 (0.476-19.708) Urticaria: OR 1 (0.199-5.036)

CI = confidence interval; GI = gastrointestinal; HPV = human papillomavirus; MPL = monophosphoryl lipid; OR = odds ratio; VLP = virus-like particle

**Statistically significant.

Note: Additional study details presented in Appendix C evidence tables.

Diphtheria Toxoid, Tetanus Toxoid, and Acellular Pertussis

The IOM studied diphtheria toxoid, tetanus toxoid, and acellular pertussis-containing vaccines alone and in combination; they are administered to both children and adults. Except where noted below, studies did not report specific AEs by age. The IOM committee found the evidence “convincingly supports” a causal relationship in the adult population between the tetanus toxoid vaccine and anaphylaxis.

We identified only one trial of adults published after the IOM search dates. A trial in Korea⁹⁰ included only 20 individuals, all male, who received one dose of SK Td vaccine. No statistically significant differences in AEs between vaccinated and unvaccinated groups were reported. Data are displayed in Table 14.

We identified no post-license studies of vaccines against diphtheria, tetanus, or pertussis in adults published after the IOM searches. Thus, we rate the strength of evidence as high for association of tetanus toxoid with anaphylaxis among persons allergic to ingredients, per the IOM findings.

Table 14. Vaccinated versus unvaccinated adults: Td (tetanus/diphtheria) vaccine

Author- Year- Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Lee S. et al., 2011 ⁹⁰ Korea	Controlled Clinical Trial	5	Sample size : 20, Mean age: 28.1, Age range: NR, Percent female: 0%	Td, SK Td Vaccine Inj, SK Chemicals, Seongnam, Korea, >= 2 IU of diphtheria toxoid and >=20 IU of tetanus toxoid, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days	Hypoesthesia: OR 3.857 (0.326-45.572)

CI = confidence interval; IU = international unit; OR = odds ratio; NR = not reported; Td = tetanus/diphtheria

Note: Additional study details presented in Appendix C evidence tables.

Miscellaneous Other Vaccines

Postmarketing Studies of Multiple Vaccines

We found three postmarketing studies of multiple vaccines in adults not included in the IOM report, as presented in Table 15.

In a case-control study of 159 cases of psoriatic arthritis and 159 persons with psoriasis alone, Eder et al. 2011⁹¹ found vaccination against any of the following diseases was not associated with onset of psoriatic arthritis: Hepatitis A, Hepatitis B, influenza, and pneumonia.

In a multivariate analysis of records from the Defense Medical Surveillance System, Duderstadt and colleagues⁹² found that military personnel vaccinated for MMR were less likely to have new onset of Type 1 diabetes (RR 0.71, 95% CI 0.61, 0.83) than those who were not vaccinated. The same was true for military personnel who had received Hep B vaccine (RR. 0.83, 95% CI 0.72, 0.83).

In a case control study of 355 Graves' disease cases, 418 Hashimoto's thyroiditis cases, and 1,102 controls, Yu et al. 2007⁹³ found that vaccination against Hepatitis B, influenza, MMR, Hepatitis A, or polio was not associated with an increase rate of Graves' disease or Hashimoto's thyroiditis.

The IOM report made the following conclusions regarding other vaccines in adults.

MMR Vaccine

The evidence⁹⁴⁻⁹⁷ “favors acceptance” of a causal relationship with transient arthralgia in women. The IOM committee found the evidence “inadequate to accept or reject” a causal relationship in the adult population between MMR vaccine and MS onset, Guillain-Barré Syndrome, chronic arthralgia in women, and chronic arthritis and arthropathy in men.

Hepatitis A

No epidemiological studies of the following AEs in adults were found: acute disseminated encephalomyelitis, transverse myelitis, MS, Guillain-Barré Syndrome, chronic inflammatory demyelinating polyneuropathy, Bells' Palsy, anaphylaxis, and autoimmune hepatitis. The IOM thus states that the evidence is “inadequate to accept or reject” a causal relationship with these AEs. We found no additional trials of MMR, vaccine in adults published after the IOM searches. We concur with the IOM findings and rate the strength of evidence as insufficient for association of vaccination against Hepatitis A with these potential sequelae.

Hepatitis B

Although no epidemiological studies were identified, mechanistic evidence “favored acceptance” of a causal relationship between the vaccine and anaphylaxis in yeast-sensitive individuals. Epidemiological studies of the following AEs in adults had evidence “inadequate to accept or reject” a causal relationship: optic neuritis, first demyelinating event, Guillain-Barré Syndrome, SLE, onset or exacerbation of vasculitis, polyarteritis nodosa, and onset or exacerbation of rheumatoid arthritis. A 2002 IOM review on Hep B vaccine and demyelinating neurological disorders concluded that the evidence “favors rejection” of a causal relationship with incident MS or MS relapse.⁹⁸ No epidemiological studies of the following AEs in adults were found: encephalitis, encephalopathy, ADEM, transverse myelitis, neuromyelitis optica, chronic inflammatory demyelinating polyneuropathy, brachial neuritis, erythema nodosum, onset

or exacerbation of psoriatic arthritis, onset or exacerbation of reactive arthritis, and fibromyalgia. The IOM thus states that the evidence is “inadequate to accept or reject” a causal relationship with these AEs. We found no controlled trials of Hepatitis B vaccine in adults published after the IOM searches. The only post-licensure study that met our inclusion criteria investigated several vaccines and is described above.

Summary

MMR. Upon our review of the IOM report, we concur and rate the strength of evidence as moderate for association of MMR and transient arthralgia in women, and insufficient for association with the other investigated adverse events. Strength of evidence is moderate that MMR is not associated with onset of type 1 diabetes in adults, per results of a very large recent high quality epidemiological study.

Hepatitis A. There is insufficient evidence regarding association of this vaccine with any adverse events or onset of medical conditions, per evidence presented in the IOM report and recent post-licensure studies.

Hepatitis B. Per evidence presented in the IOM report and recent post-licensure studies, there is insufficient evidence regarding association of this vaccine with any short-term adverse events other than anaphylaxis in yeast-sensitive individuals. This event is considered serious. Hepatitis B vaccine is not associated with onset of type 1 diabetes in adults; strength of evidence is moderate, per results of a very large recent high quality epidemiological study. There is insufficient evidence regarding the association of Hepatitis B vaccine and onset of any other medical conditions.

Table 15. Postmarketing studies of multiple vaccines in adults

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Duders tadt et al. 2012 ⁹² Retros pective cohort	N=2,385,102 active military personnel, including 1,074 cases of type 1 diabetes; Location=U.S.; Age=17-35 years;	Hepatitis B, MMR, smallpox, typhoid, yellow fever	Receipt of multiple vaccines, age, race, sex, service branch, military grade, occupation, deployment, and calendar year	Risk Ratios for Diabetes Type 1 Hepatitis B: 0.83 (0.72, 0.95) MMR: 0.71 (0.61, 0.83)	Not reported
Yu et al. 2007 ⁹³ Case-control	N=1,875 (355 Graves' disease cases, 418 Hashimoto's thyroiditis cases, 1,102 controls); Vaccine Safety Datalink Project: Age=18–69 years; Setting=Three health maintenance organizations (HMOs) In U.S.	Hepatitis B vaccine, influenza, MMR, Hepatitis A, polio	Controls were frequency-matched to cases by birth year, sex, and study site (HMO) All models adjusted for frequency-matching variables (age groups, sex, site, and index year), personal and family history of autoimmune disease, smoking status, race, and education	OR (95% CI) for Graves' disease Main analysis Hepatitis B: 0.90 (0.62–1.32) Influenza: 1.07 (0.80–1.42) MMR: 0.59 (0.29–1.20) Hepatitis A: 0.70 (0.43–1.13) Polio: 1.29 (0.76–2.17) OR (95% CI) for Hashimoto's thyroiditis Main analysis Hepatitis B: 1.23 (0.87–1.73) Influenza: 1.15 (0.89–1.48) MMR: 1.50 (0.79–2.86) Hepatitis A: 0.97 (0.64–1.46) Polio: 1.17 (0.73–1.86)	Not reported

ASD = autism spectrum disorders; CI = confidence interval; COPD = chronic obstructive pulmonary disease; DPT = diphtheria–pertussis–tetanus vaccine; HMO = health maintenance organization; IPD = invasive pneumococcal disease; MMR = measles, mumps, rubella; PV = pneumococcal vaccine; YPDC = Yokohama Psycho-Developmental Clinic

**Statistically significant association.

Note: Additional study details presented in Appendix C evidence tables.

Key Question 2: What is the evidence that vaccines included in the immunization schedules recommended for U.S. children and adolescents in 2011²⁴ are safe in the short term (within 30–42 days following immunization) or long term (>42 days after immunization)?

- a. What AEs are collected in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?
- b. What AEs are reported in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?

Table 16 lists all AEs collected or reported in trials of vaccines on the U.S. routine recommended schedule for children and adolescents. We interpreted “collected” to mean those specified a priori by investigators, while “reported” were any AEs reported by participants. The list does not imply an association with vaccination, as it contains AEs regardless of whether they were reported in vaccinated or unvaccinated study participants. Also, a study could “collect” data on a specific serious AE, but “report” zero cases. Later in this report, we describe the studies further and assess association.

Table 16. Adverse events collected or reported in trials in children and adolescents

Vaccine	Adverse Event
<i>Haemophilus influenzae type b (Hib) protein conjugate</i>	<ul style="list-style-type: none">• Areas of swelling measuring less than 2.54 cm in diameter• Areas of redness measuring less than 2.54 cm in diameter• Conjunctivitis• Fever greater than or equal to 38 C• Hospitalizations 30 days after vaccination• Serious adverse reactions• Viral infections
Human papillomavirus (HPV)	<ul style="list-style-type: none">• Injection site reactions• Ear and eye and respiratory system• "Laboratory abnormality"• Pruritus, severe• Serious AE (any)• Serious AE (vaccine-related)• Systemic AE (any)• Systemic AE (vaccine-related)
Influenza (inactive)	<ul style="list-style-type: none">• Abnormal crying• Allograft rejection, acute• Appetite decrease• Death• Drowsiness• Emesis• Febrile illness, acute• Fever >=38C• Flu virus infection• Irritability
Influenza (live)	<ul style="list-style-type: none">• Chills• Cough• Febrile neutropenia• Fever >=100F• Headache• Irritability• Muscle ache• Rash• Runny nose• Sore throat• Tiredness• Vomiting
Pneumococcal conjugate	<ul style="list-style-type: none">• Febrile seizure• Fever• Kawasaki Disease• Local AE• Otitis media

**Table 16. Adverse events collected or reported in trials in children and adolescents
(continued)**

Vaccine	Adverse Event
Rotavirus	<ul style="list-style-type: none"> • Accidental drowning • Anal fissure • Anemia • “Any AE” • Abdominal pain • Apneic attack (extreme preemie) • Asthma • Bronchiolitis • Bronchopneumonia • Constipation • Convulsions • Cough/runny nose • Death • Death due to SIDS • Death (Outside of 42 day safety window and not associated with vaccine) • Decreased appetite • Dehydration • Diarrhea • Eczema • Femur fracture • Fever • Gastroenteritis • Gastrointestinal disorders • General Body • General disorders and administration site conditions • GERD • Head injury • Hematochezia • Hospitalization • Hypovolemia/dehydration • Infections • Influenza • Intussusception • Intussusception related Death • Irritability • Kawasaki disease • Kidney cyst • Leukocytosis • Meningitis • Meningitis, pneumococcal • Mesenteric adenitis • Nasal congestion • Nasopharyngitis • Nervous system disorders • Oral candidiasis - Grade 3 • Otitis media, acute • Partial seizures • Pertussis • Pneumonia • Pyelonephritis • Pyrexia • Reproductive system and breast disorders • Respiratory • SAE (extreme preemie) • Sepsis

Table 16. Adverse events collected or reported in trials in children and adolescents (continued)

Vaccine	Adverse Event
	<ul style="list-style-type: none"> • SIDS • Serious Adverse Event • Umbilical infection • “Unsolicited symptoms” • Upper respiratory infection • Urinary Tract Infection • Vaccine-related serious adverse event • Viral infections • Vomiting • Wheezing <p>Withdrawal due to AE</p>
Studies of multiple vaccines	<ul style="list-style-type: none"> • Apnea/collapse/cyanosis/pallor • Convulsion/fit/seizure • Crying • Diarrhea • Feeding Problem • Fever • “Vaccine reaction” • Vomiting

AE = adverse events; GERD = gastroesophageal reflux disease; Hib = *Haemophilus influenzae* type B; HPV = human papillomavirus; SAE = severe adverse event; SIDS = sudden infant death syndrome; Tdap = tetanus, diphtheria, and acellular pertussis vaccine

Table 17 lists all AEs and medical conditions investigated in the case-control, self-controlled case series, and multivariate risk factor analyses in children and adolescents. The majority of these studies were designed to assess the association of a specific AE with vaccination. Again, the list does not imply an association.

Table 17. Adverse events investigated in postmarketing studies of children and adolescents

Vaccine	Adverse Event
Influenza vaccines: H1N1	<ul style="list-style-type: none"> • Convulsion • Flu-like symptoms • Hospitalization or ER visit
HPV	<ul style="list-style-type: none"> • Guillain-Barré Syndrome • Hashimoto’s Disease • Rheumatoid Arthritis • Seizures • Stroke • Syncope • Type 1 diabetes • Venous thromboembolism
Hepatitis B	<ul style="list-style-type: none"> • Anaphylaxis (in yeast sensitive children) • Demyelinating Event, First • Multiple Sclerosis – Onset • Multiple Sclerosis – Relapse • Seizures
MMR	<ul style="list-style-type: none"> • Anaphylaxis • Autism • Febrile seizures • Hospitalization or ER visit • Measles Inclusion Body Encephalitis • Purpura • Transient Arthralgia

Table 17. Adverse events investigated in postmarketing studies of children and adolescents (continued)

Vaccine	Adverse Event
Rotavirus vaccines	<ul style="list-style-type: none"> • Intussusception
TIV	<ul style="list-style-type: none"> • GI event, acute • Respiratory infection, acute • Sickle cell disease, exacerbation • Urea cycle disorders

ER = emergency room; GI = gastrointestinal; HPV = human papillomavirus; MMR = measles, mumps, rubella; TIV = trivalent influenza vaccine

Key Question 2 – Children and Adolescents (continued):

- c. What AEs are associated with these vaccines?
 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 3. For each AE associated with a particular vaccine, what are the risk factors for the AE (including age, sex, race/ethnicity, genotype, underlying medical condition, whether a vaccine is administered individually or in a combination vaccine product, schedule of vaccine administration, adjuvants, and medications administered concomitantly)?

Influenza Vaccines

The IOM committee studied seasonal influenza vaccines in children and adolescents. Such vaccines are administered in two forms: a live attenuated form, administered intranasally, and an inactivated form, administered intramuscularly. The IOM committee did not find evidence that “convincingly supports” causal relationships in the pediatric population for any conditions. They found the evidence is “inadequate to accept or reject” a causal relationship between influenza vaccine and the following: seizures, acute disseminated encephalomyelitis (ADEM), and transverse myelitis. The IOM committee also found evidence is “inadequate to accept or reject” a causal relationship between live attenuated influenza vaccine (LAIV) and asthma exacerbation or reactive airway disease (RAD) episodes in children younger than 5 years of age and 5 years of age or older.⁹⁹⁻¹⁰⁴

We identified five trials¹⁰⁵⁻¹⁰⁹ of children published after the IOM search and one cohort study.¹¹⁰ These are displayed in Table 18. Four studies looked at special populations: children with cancer,¹⁰⁶ transplant patients,¹¹⁰ children with HIV¹⁰⁸ and children with egg allergy.¹⁰⁹ The studies were set in the United States, South Africa and Japan. In four trials and the cohort study,

^a Level of certainty was operationalized as the 95-percent confidence interval surrounding the risk or odds estimate—i.e., the statistical significance.

participants received 1-2 doses of either live¹⁰⁶ or inactivated^{105,108-110} seasonal influenza vaccines which included an H1N1 strain. The fifth trial studied monovalent H1N1 vaccine.

In the studies of healthy patients, both inactivated seasonal influenza vaccine (including a strain of H1N1)¹⁰⁵ and 2009 monovalent H1N1¹⁰⁷ were associated with no AEs. Similarly, in the studies of children with cancer¹⁰⁶ and transplant patients,¹¹⁰ inactivated seasonal influenza vaccine (including a strain of H1N1) was associated with no AEs. The study of HIV positive children reported no serious adverse events.¹⁰⁸ Finally, Fluzone¹⁰⁹ was not associated with urticaria, angioedema, wheezing, throat itch or swelling in children with egg allergy.

Table 18. Vaccinated versus unvaccinated children or adolescents: influenza vaccines

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Englund J. A. et al.,2010 ¹⁰⁵ U.S.	Controlled Clinical Trial	6	Sample size : 1,375, Mean age: 9.1, Age range: 2 - 7	Influenza (inactivated), Fluzone, Sanofi, 0.25 mL dose contained 7.5 g hemagglutinin (HA) of A/New Caledonia/20/99(H1N1); A/New York/55/2004 (H3N2), and B/Jiangsu/10/2003, Adjuvant: Not Reported, Preservative: Preservative Free, Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 Month	Abnormal crying (Dose 1): OR 1 (0.794-1.26) Abnormal crying (Dose 2): OR 1.042 (0.83-1.31) Any drowsiness (Dose 1): OR 1.093 (0.863-1.384) Any emesis (Dose 1): OR 1.294 (0.926-1.808) Any emesis (Dose 2): OR 0.193 (0.146-0.256)** Any irritability (Dose 1): OR 1.128 (0.858-1.483) Any irritability (Dose 2): OR 0.922 (0.736-1.156) Decreased appetite (Dose 1): OR 0.883 (0.703-1.109) Decreased appetite (Dose 2): OR 0.944 (0.723-1.234) Fever >=38C (Dose 1): OR 0.952 (0.67-1.352) Fever >=38C (Dose 2): OR 0.596 (0.313-1.135)
Gotoh K. et al.,2011 ¹¹⁰ Japan	Cohort	1	Sample size : 101, Mean age: 9.8, Percent female: 51.5%, Conditions: Transplant	Influenza (inactivated), NR, 15 Ig hemagglutinin per 0.5 mL of each of the following influenza strains: A/New Caledonia/20/99 (H1N1), A/Hiroshima/52/2005 (H3N2), and B/Malaysia/2506/2004 in the 2006–2007 season; A/Solomon Islands/3/2006 (H1N1), A/Hiroshima/52/2005 (H3N2), and B/Malaysia/2506/2004 in the 2007–2008 season; and A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2), and B/Florida/4/2006 in the 2008–2009 season. These inactivated vaccines did not contain adjuvant., Adjuvant: Adjuvant Free, Preservative: Not reported, Delivery: Not reported	Dose1: 0 Days	Acute febrile illness: OR 0.421 (0.16-1.11) Flu virus infection: OR 0.819 (0.143-4.703)

Table 18. Vaccinated versus unvaccinated children or adolescents: influenza vaccines (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Halasa N. et al., 2011 ¹⁰⁶ U.S.	Controlled Clinical Trial	2	Sample size : 20, Mean age: 12.2, Age range: 5 - 17, Percent female: 45%, Conditions: Cancer	Influenza (live), MedImmune, 2005-2005 prep: 106.5-7.5 TCID 50 per dose for each of the following strains: A/New Caledonia/20/99 (A/NC/20/99; A/H1N1), A/Wyoming/3/2003(A/Fujian/411/02 -like, A/Fuj/411/02; A/H3N2), and B/Jilin/20/2003(B/Shanghai/361/20 02-like, Yam88 lineage; B/Yam/166/98; B2005-2006: contained an identical A/H1N1 strain, but the A/H3N2 isolate was updated to A/California/7/2004(A/Cal/7/04) and the B strain was replaced with B/Jiangsu/10/2003(B/Shanghai/361 /2002-like, Yam88 lineage; B/Yam/166/98; B, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intranasal	Dose1: 0 Days	Chills: OR 0.259 (0.022-3.063) Cough: OR 0.259 (0.022-3.063) Fever >=100C (0-42 days): OR 0.375 (0.051-2.772) Headache: OR 0.286 (0.045-1.821) Runny nose: OR 1.556 (0.244-9.913) Sore throat: OR 0.25 (0.034-1.819) Tiredness: OR 0.444 (0.074-2.66) Vomiting: OR 1.556 (0.244-9.913)
Mallory R. M. et al., 2010 ¹⁰⁷ U.S.	Controlled Clinical Trial	3	Mean age: 9, Age range: 2 - 17, Percent female: 51%	Influenza - monovalent H1N1, not reported, MedImmune, derived by genetic reassortment of the hemagglutinin and neuraminidase genes from the wild-type A/California/7/2009 virus and the remaining 6 gene segments from an attenuated master donor virus (in sucrose phosphate buffer and egg allantoic fluid, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intranasal	Dose1: 0 Days Dose2: 29 Days	# with any AE Dose 1: OR 1.103 (0.537-2.267) # with any AE Dose 2: OR 0.985 (0.448-2.167) Ear and labyrinth Dose 2: OR 0.251 (0.015-4.066) GI Dose 1: OR 1.017 (0.367-2.818) GI Dose 2: OR 0.882 (0.281-2.774) Infections and infestations Dose 2: OR 1.821 (0.404-8.219) Injury, poisoning, procedural complications Dose 2: OR 0.759 (0.078-7.414)
Madhi, S.A. et al. 2013 ¹⁰⁸ South Africa	Controlled Clinical Trial	4	Sample size : 410, Mean age: 23.8, Age range: 6 – 59 months, Percent female: 59% Condition: HIV	Influenza (inactivated) , VAXIGRIP, Sano-Aventis, Adjuvant: Adjuvant Free, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 month	Incalkulable – No serious adverse events

Table 18. Vaccinated versus unvaccinated children or adolescents: influenza vaccines (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Greenhawt, M.J. et al. 2012 ¹⁰⁹ U.S.	Controlled Clinical Trial	1	Sample size : 143, Mean age: NR, Age range: 14 - 17, Percent female: 36.7%, Conditions: Egg allergy	Influenza (inactivated) , Fluzone , Sanofi , Formulation had ovo-albumin content of 0.1 microgram per 0.5 ml dose , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Not reported	Dose1: 0 Days Dose2: 30 mins NR	Dyspnea: OR 0.117 (0.02-0.693)** Hypotension: OR 0.577 (0.047-7.119) Localized urticaria: OR 1.019 (0.232-4.466) Oro-facial angioedema: OR 1.8 (0.407-7.957) Stridor: OR 0.577 (0.047-7.119) Systemic urticaria: OR 0.494 (0.116-2.105) Throat itching: OR 1.273 (0.214-7.582) Throat swelling: OR 2.667 (0.216-32.961) Wheezing: OR 2.667 (0.216-32.961)

CI = confidence interval; GI = gastrointestinal; HA = hemagglutinin; OR = odds ratio; TCID = tissue culture infective dose

**Statistically significant.

Note: Additional study details presented in Appendix C evidence tables.

We found eight post marketing studies of influenza vaccines in children or adolescents; they are displayed in Table 19.

Convulsions

Stowe et al. (2011)¹¹¹ studied 2,366 cases of convulsions in children (age <10 years) between May 2000 and April 2010 using the UK's General Practice Research Database (GPRD). The monovalent H1N1 vaccine (MIV) was studied during the 2009/10 influenza season and the TIV vaccine was studied during other seasons. Both vaccination status and health outcomes were ascertained by a review of medical records. The children were followed up for an average of 5.1 years each (range 0.3–10.0 years). The analysis adjusted for age, period, and season. For both the monovalent H1N1 and TIV vaccines, the onset of a convulsion episode was not significantly associated with vaccine at any time point. In contrast, Tse¹¹² analyzed data on over 200,000 U.S. children under age 5 who received TIV in autumn of 2010 and found a signal for febrile seizures was found. In a self-controlled case series including febrile seizures confirmed through medical record, incidence rate ratio was significant for first dose (IRR 4.0; 95% CI 2.1 – 6.2). Vaccine against pneumonia (PCV13) was also associated with febrile seizures; importantly, administration of both vaccines at the same visit was associated with increased risk. For example, for 16 month old children, estimated rate was 12.5 per 100,000 doses for TIV without concomitant PCV13, 13.7 per 100,000 doses for PCV13 without concomitant TIV, and 44.9 per 100,000 doses for concomitant TIV and PCV13. Risk difference estimates varied by age due to the varying baseline risk for seizures in young children.

Influenza-Like Illness

A case-control analysis studied 683 children and adolescents (age 1 month - 18 years) who were hospitalized through the emergency departments of eight hospitals in Italy between November 2009 and August 2010.¹¹³ Vaccination for H1N1 was ascertained via parental report, and health outcomes were collected through active surveillance of both clinically defined and laboratory confirmed hospitalizations for Influenza-Like Illness (ILI) events. AEs were confirmed using parental reports. Data were modeled using logistic regression that adjusted for age, chronic conditions, and other seasonal influenza vaccines. Results indicate that children vaccinated with any influenza vaccine (OR 2.7, 95% CI 1.6, 4.7) or seasonal vaccine (OR 2.1, 95% CI 1.1, 4.1) were significantly more likely to show symptoms of ILI, while those vaccinated for H1N1 were not (OR 1.3, 95% CI 0.6, 3.1).

Gastrointestinal

Baxter et al. (2012)¹¹⁴ examined 43,702 LAIV recipients, 43,702 TIV recipients, and 53,366 matched unvaccinated controls, 5-17 years of age between October 2003 and March 2008. Immunization status and health outcomes were confirmed by a review of Kaiser Permanente's electronic medical records. Data were analyzed using Cox proportional hazards model, and relative risks (RR) were calculated as the ratio of the incidence rates without adjustment for any covariate. Hazard ratios (HR) were also calculated adjusting for matching factors and seasonal changes in background rates. Results were significant in children aged 5 to 8 years vaccinated with LAIV — for acute GI event within 21 days (HR 1.36, 95% CI 1.05, 1.76) and 42 days (HR 1.30, 95% CI 1.08, 1.78) and for acute respiratory tract event in 21 days (HR 1.12, 95% CI 1.00, 1.25) and 42 days (HR 1.15, 95% CI 1.06, 1.24) compared to the unvaccinated same age cohort. The incidence

rates of SAEs overall and by specific diagnosis were not significantly higher or lower in the LAIV recipients relative to control groups in any comparison.

In another self-controlled case series, Glanz et al. (2011)¹¹⁵ studied 66,283 children aged 24-59 months who received TIV vaccine between 2002 and 2006 in the United States. Immunization status and health outcomes were ascertained by a review of medical records. Data were modeled using conditional Poisson regression adjusted for calendar month (indicating influenza season) and age. The results showed that influenza vaccination was significantly associated with medically confirmed GI tract disorders (RR 7.70, 95% CI 1.11, 53.52), fever (RR 1.71, 95% CI 1.64, 1.80), and GI tract symptoms like vomiting and diarrhea (RR 1.18, 95% CI 1.10, 1.25) in the risk windows of 0-2, 1-14, and 1-42 days after vaccination.

Benchim et al¹¹⁶ analyzed data from an Ontario, Canada, registry of over 25,000 pediatric patients with Inflammatory Bowel Disease (IBD). Data were collected from 1999 to 2010. Patients with IBD were matched with controls according to gender, region, and age. The researchers studied receipt of any seasonal influenza vaccine; results were not stratified by type or season. Receipt of influenza vaccination was not associated with health services utilization (hospitalizations, ED visits, outpatient visits). A self-controlled case series analysis of patients with IBD-related health services utilization also found no association with influenza vaccination at any time period within six of months of receipt.

Urea Cycle Disorders

In a self-controlled case series, Morgan et al. (2011)¹¹⁷ studied whether hyperammonemic episodes (HAE) were associated with vaccination in 169 U.S. children with urea cycle disorders.. The study included numerous vaccines but reported only results for the influenza vaccines. Vaccination status and health outcomes were ascertained from clinical records. Data were analyzed used conditional Poisson regression that was adjusted for age. Results indicate that the influenza vaccination was not associated with HAE at any post vaccination risk period.

Sickle Cell Disease

In a matched case-control study, Hambidge et al. (2011)⁶⁹ studied 1,294 (269 cases, 1,025 controls) children and adolescents (age 6 months to 17 years) in the United States using data from the 1999-2006 Vaccine Safety Datalink program. This study also included a self-controlled case series analysis. Cases were identified as children who had received the TIV and had been hospitalized due to sickle cell crisis. Medical records were reviewed to confirm vaccination and hospitalization. Data were modeled using a conditional logistic regression and cases and controls were matched on age, gender, location, and influenza season. Results from both the case-control study and the self-controlled case series indicated that TIV is not associated with hospitalizations due to sickle cell crises. The authors noted that children classified as not receiving vaccine may have received vaccine from an outside provider.

Summary

Seasonal influenza vaccines were not associated with SAEs in the short term in children with cancer or who have received organ transplants. Due to small number and size of trials, the strength of evidence is low.

Seasonal influenza vaccines were not associated with events requiring medical attention in IBD patients; strength of evidence is moderate due to a high quality epidemiological study including all children with IBD in a Canadian province.

In clinical trials of healthy children, seasonal influenza vaccines were not associated with SAEs in the short term. However, a recent study using the U.S. Vaccine Safety Datalink (VSD) found an association with febrile seizures, which increases with concomitant administration of PCV13. In the highest risk age group (16 months) estimated rate was 12.5 per 100,000 doses for TIV without concomitant PCV13, 13.7 per 100,000 doses for PCV13 without concomitant TIV, and 44.9 per 100,000 doses for concomitant TIV and PCV13. Strength of evidence is moderate for this AE, given the large number of subjects / statistical power of the study and the low risk of bias given that all vaccination and AE data was obtained through medical records.

Our review of the IOM findings that evidence is “inadequate to accept or reject” an association between influenza vaccines and ADEM, transverse myelitis, asthma exacerbation, or RAD in children, due to the dearth of studies on these issues, leads us to rate the evidence as insufficient to determine an association between influenza vaccines and these potential sequelae.

In large, high quality post-licensure studies, both LAIV and TIV were associated with mild gastrointestinal disorders, such as vomiting and diarrhea in children in the short-term. Strength of evidence is moderate for these AEs. One large study found that younger vaccinated children (aged 5 to 8 years) were more likely to experience these symptoms than older vaccinated children (aged 9 to 17 years). (Children under 5 years of age were not included in that study).

Seasonal influenza vaccines were associated with influenza-like symptoms in children in the short term, but strength of evidence is low, given the inconsistency of results.

Table 19. Postmarketing studies of influenza vaccines in children and adolescents

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Stowe et al., 2011 ¹¹¹ Self-controlled case series	N=2,366 cases of convulsions; Location=UK; Age=Under 10 years; Used General Practice Research Database (GPRD)	Monovalent H1N1 influenza vaccine during the 2009/10 influenza season or seasonal TIV	Age, period and season	<p>Incidence rate ratio (IRR) estimates for the onset of a convulsion episode in relation to the timing of influenza vaccination and type of vaccine administered</p> <p>Vaccine, Period, IRR</p> <p>TIV</p> <p>2 Weeks pre-vaccine: 1.00 (0.70–1.42) Day of vaccination: 1.23 (0.39–3.83) 1–3 Day post vaccine: 0.98 (0.47–2.07) 4–7 Days post vaccine: 0.96 (0.50–1.86) 0–7 Days post vaccine: 1.00 (0.64–1.59)</p> <p>Monovalent H1N1 vaccine</p> <p>2 Weeks pre-vaccine 0.44 (0.25–0.76) Day of vaccination 1.83 (0.68–4.90) 1–3 Day post vaccine 1.08 (0.51–2.28) 4–7 Days post vaccine 0.70 (0.31–1.57) 0–7 Days post vaccine 0.99 (0.61–1.60)</p> <p>Incidence rate ratio (IRR) estimates for the onset of a convulsion episode in relation to the timing of monovalent H1N1 vaccine</p> <p>Dose 1</p> <p>2 Weeks pre-vaccine: 0.37 (0.20–0.68) Day of vaccination: 1.52 (0.49–4.73) 1–3 Day post vaccine: 0.85 (0.35–2.04) 4–7 Days post vaccine: 0.77 (0.34–1.72) 0–7 Days post vaccine: 0.89 (0.53–1.52)</p> <p>Dose 2</p> <p>2 Weeks pre-vaccine: 1.24 (0.40–3.88) Day of vaccination: 5.24 (0.73–37.41) 1–3 Day post vaccine: 3.48 (0.86–14.07) 4–7 Days post vaccine: 0 0–7 Days post vaccine: 1.96 (0.62–6.14)</p>	Not reported

Table 19. Postmarketing studies of influenza vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Italian Multicenter Study Group for Drug and Vaccine Safety in Children, 2011 ¹¹³ Case-control	N=683 children aged 1 month to 18 years, hospitalized through the emergency departments of eight pediatric hospitals/wards in Italy	2009 Monovalent H1N1, Seasonal influenza unspecified	Age and chronic diseases; the ORs of A-H1N1 and seasonal vaccine were each adjusted for the other influenza vaccine	OR of influenza-like illness Any flu vaccine 2.7 (1.6 to 4.7) A-H1N1 1.3 (0.6 to 3.1) Seasonal vaccine 2.1 (1.1 to 4.1)	Not reported
Baxter, 2012 ¹¹⁴ Retrospective cohort	43,702 LAIV recipients, 53,366 matched unvaccinated controls, 43,702 TIV recipients Age: 5 to 17 years, Setting: Kaiser Permanente health system	LAIV, TIV, October 2003 – March 2008	Relative risks (RR) were calculated as the ratio of the incidence rates of the two comparison groups without adjustment for any covariate. Hazard ratios (HR) were also calculated adjusting for matching factors and seasonal changes in background rates.	The incidence rates of SAEs overall and by specific diagnosis were not significantly higher or lower in the LAIV recipients relative to control groups in any comparison.	Children aged 5 to 8 vaccinated with LAIV had higher risk of acute GI event in 21 days (HR 1.36, 10.05 - 1.76) and 42 days (HR 1.30, 1.08 - 1.78) than unvaccinated cohort same age. Children aged 5 to 8 also had higher risk of acute respiratory tract event in 21 days (HR 1.12, 1.00 - 1.25) and 42 days (HR 1.15, 1.06 - 1.24) than unvaccinated cohort same age.

Table 19. Postmarketing studies of influenza vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Glanz et al. 2011 ¹¹⁵ Self-controlled case series	N=66,283 who received trivalent inactivated influenza vaccine (TIV); Location=U.S.; Age=24-59 months; Setting=Seven U.S. managed care organizations (Vaccine Safety Datalink)	TIV, October 2002 to March 2006	Calendar month (season) and age	<p>Medically Attended Events That Met the Screening Criteria in Risk Windows of 0 to 2, 1 to 14, and 1 to 42 Days After Vaccination</p> <p>Non-confirmed Cases From Electronic Data Analysis</p> <p>Potentially serious</p> <p>Nervous system disorder: 6.32 (0.96-41.65), Cardiac event: 3.56 (0.55-22.89) Hypotension: 5.52 (0.71-43.07)</p> <p>Gastrointestinal tract disorder: 2.75 (1.07-7.09)</p> <p>Cellulitis and skin reaction: 3.06 (0.89-10.53)</p> <p>Potentially less serious and common</p> <p>Rash: 2.33 (0.68-7.93)</p> <p>Limb soreness: 3.56 (1.30-9.75)</p> <p>Fever: 1.40 (1.09-1.80)</p> <p>Gastrointestinal tract symptoms (vomiting and diarrhea): 1.52 (1.18-1.95)</p> <p>Medical Record-Confirmed Cases</p> <p>Potentially serious</p> <p>Gastrointestinal tract disorder: 7.70 (1.11-53.52)</p> <p>Cellulitis and skin reaction: 3.27 (0.36-29.70)</p> <p>Potentially less serious and common</p> <p>Rash: 1.94 (0.44-8.63)</p> <p>Fever: 1.71 (1.64-1.80)</p> <p>Gastrointestinal tract symptoms (vomiting and diarrhea): 1.18 (1.10-1.25)</p>	Not reported
Morgan et al. 2011 ¹¹⁷ Self-controlled case series	N= 169 children with urea cycle disorders (USD); Location=U.S. Age=0-18 years;	A number of vaccines were analyzed but influenza (unspecified) was only vaccine reported on	Age	<p>Hyperammonemic episodes (HAE): Relative Incidences</p> <p>Risk Period: Days After Vaccination 1–7: 2.31 (0.73–7.30) 8–21: 0.78 (0.19–3.12) 1–21: 1.28 (0.52–3.15)</p>	Not reported

Table 19. Postmarketing studies of influenza vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Hambidge et al. 2011 ⁶⁹ Matched case-control (and self-controlled case series)	N=1,294 (269 cases of hospitalization of sickle cell crisis, 1025 controls); Location=United States; Age=6 months to 17 years; Setting=8 managed care organizations that comprise the Vaccine Safety Datalink	TIV , 1999-2006	Cases/controls matched on age category, gender, Vaccine Safety Datalink site, and season	Case-control study OR (95% CI) of hospitalization TIV: 1.3 (0.8–2.2) Self-controlled All children: 1.21 (0.75–1.95) Boys: 1.07 (0.50–2.28) Girls: 1.33 (0.72–2.44) 6-23 months: 1.23 (0.25–6.04) 60 mo to 17 yr: 1.38 (0.83–2.29)	Not reported
Benichimol, et al. 2013, ¹¹⁶ Self-controlled case series	N=26602; Location=Ontario, Canada; Age=< 19 years; Setting=Ontario Crohn's and Colitis Cohort (OCCC), a population-based registry of pediatric IBD patients derived from provincial health administrative data	Influenza, unspecified, 1999-2010	Self-controlled and also matched controls. Each IBD case was matched to 5 (or 4 where a fifth could not be found) controls according to gender, provincial administrative health region in which the subject resided, and date of birth.	SCCS Analysis to Assess Risk of Increased Health Services Utilization in the Postvaccine Period in Children With IBD and Non-IBD Matched Controls Overall all-cause health services utilization (hospitalizations + ED visits + outpatient visits) RI in IBD Patients, (95 CI) Days 3–14: 1.19 (0.88–1.59) . Days 15–30: 0.83 (0.61–1.13) Days 31–45: 0.96 (0.71–1.29) Days 46–60: 0.81 (0.58–1.12) Days 61–75: 0.94 (0.69–1.26) . Days 76–90: 0.79 (0.57–1.09) Days 91–180: 0.99 (0.85–1.16) . Pooled day 3–180: 0.95 (0.84–1.07) . Pooled day 15–180: 0.92 (0.82–1.04) RI in Controls, (95 CI) Days 3–14: 0.64 (0.47–0.89) Days 15–30: 0.95 (0.75–1.20) Days 31–45: 0.68 (0.52–0.91) Days 46–60: 0.93 (0.73–1.19) Days 61–75: 0.87 (0.68–1.11) Days 76–90: 0.91 (0.71–1.16)	None

Table 19. Postmarketing studies of influenza vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				<p>Days 91–180: 0.96 (0.85–1.09) Pooled day 3–180: 0.90 (0.82–0.98) Pooled day 15–180: 0.91 (0.83–1.00)</p> <p>RIR of Cases Versus Controls, (95 CI) Days 3–14: 1.60 (1.05–2.44) .03 Days 15–30: 0.74 (0.51–1.08) .12 Days 31–45: 1.18 (0.79–1.76) .42 Days 46–60: 0.73 (0.49–1.08) .12 Days 61–75: 0.91 (0.63–1.33) .64 Days 76–90: 0.74 (0.50–1.09) .13 Days 91–180: 0.85 (0.71–1.02) .09 Pooled day 3–180: 0.89 (0.78–1.02) .09 Pooled day 15–180: 0.85 (0.74–0.97) .02</p> <p>Hospitalizations (all causes)</p> <p>RI in IBD Patients, (95 CI) Days 3–14: 0.79 (0.18–3.37) .75 Days 15–30: 1.14 (0.39–3.31) .82 Days 31–45: 0.60 (0.14–2.55) .49 Days 46–60: 0.59 (0.14–2.49) .47 Days 61–75: 2.01 (0.86–4.69) .11 Days 76–90: 0.57 (0.13–2.43) .40 Days 91–180: 0.69 (0.35–1.36) .43</p> <p>ED visits (all causes)</p> <p>RI in IBD Patients, (95 CI) Days 3–14: 0.73 (0.27–2.03) Days 15–30: 0.89 (0.41–1.95) Days 31–45: 0.72 (0.29–1.80) Days 46–60: 1.57 (0.81–3.07) Days 61–75: 0.98 (0.42–2.26) Days 76–90: 0.99 (0.43–2.31) Days 91–180: 1.12 (0.73–1.72)</p> <p>RI in Controls, (95 CI) Days 3–14: 0.58 (0.21–1.58) Days 15–30: 1.12 (0.58–2.16)</p>	

Table 19. Postmarketing studies of influenza vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				<p>Days 31–45: 0.94 (0.45–1.94) Days 46–60: 1.35 (0.73–2.47) Days 61–75: 0.98 (0.50–1.96) Days 76–90: 0.76 (0.35–1.64) Days 91–180: 1.02 (0.72–1.45)</p> <p>RIR of Cases Versus Controls, (95 CI) Days 3–14: 1.21 (0.30–4.94) Days 15–30: 0.83 (0.31–2.24) Days 31–45: 0.80 (0.26–2.50) Days 46–60: 1.09 (0.46–2.59) Days 61–75: 0.88 (0.31–2.52) Days 76–90: 1.17 (0.38–3.55) Days 91–180: 0.94 (0.57–1.56)</p> <p>SCCS Analysis of IBD-Related Health Services Utilization (Hospitalizations + ED Visits + Outpatient Visits)</p> <p>RI, 95 CI, Days 3–14: 1.05 (0.68–1.63) Days 15–30: 0.45 (0.26–0.80) Days 31–45: 0.68 (0.42–1.11) Days 46–60: 0.89 (0.58–1.36) Days 61–75: 0.68 (0.43–1.10) Days 76–90: 0.81 (0.52–1.26) Days 91–180: 0.87 (0.70–1.09) Pooled days 3–180: 0.81 (0.68–0.96) Pooled days 15–180: 0.78 (0.66–0.94)</p>	

Table 19. Postmarketing studies of influenza vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Tse et al. 2012, Self-controlled risk interval, current vs. historical vaccine design ¹¹²	N=206,174 children vaccinated with TIV in 8 U.S. MCOs ; Age=6-59 months;	TIV, PCV13, Fall 2010	Adjustment for TIV or PCV13	Febrile seizures, Incidence rate ratios, self-controlled risk interval design First dose TIV IRR: 4.0 (2.1-6.2) First dose TIV, any dose PCV13 TIV IRR: 2.4 (1.2-4.7) PCV13 IRR: 2.5 (1.3-4.7)	None

CI = confidence interval; ED = emergency department; GPRD = general practice research database; HR = hazard ratio; IRR = incidence rate ratio; LAIV = live attenuated influenza vaccine; Mo = month; OR = odds ratio; RR = relative risk; SAEs = serious adverse events; TIV = trivalent influenza; USD = urea cycle disorders; Yr = year

Note: Additional study details presented in Appendix C evidence tables.

Haemophilus Influenza Type B (Hib) Vaccine

We identified three trials of the *Haemophilus influenza* type B (Hib) vaccine in children;¹¹⁸⁻¹²⁰ one was set in the United States, the other two in Asia. Details are presented in Table 20. Results of the U.S. trial (N = 5,190) indicated that vaccination agents Hib was associated with redness (OR 2.71, 95% CI 1.57, 4.67) and swelling (OR 9.44, 95% CI 4.90, 18.19), but not associated with hospitalizations. Vaccination was not associated with high fever in either the U.S. trial or a trial in the Philippines. A trial in Vietnam¹¹⁸ found the vaccine was not associated with any serious adverse events, including convulsion, diarrhea, fungal infection or GERD. No other AEs were associated with vaccination. In sum, strength of evidence is moderate that no serious AEs are associated with Hib vaccine in the short term. Regarding long term, we identified no post-licensure studies that met our inclusion criteria.

Table 20. Vaccinated versus unvaccinated children or adolescents: Hib vaccine

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Capeding M. R. Z. et al.,1996 ¹²⁰ Philippines	Controlled Clinical Trial	3	Sample size : 174, Mean age: 6.9 months, Age range: 5 – 8 months, Percent female: 37%	<i>Haemophilus Influenza</i> type b (Hib) protein conjugate, Routine Vaccines, Pedvax-Hib, Merck, PRP-OMP polysaccharide coupled to an outer membrane protein of <i>Neisseria meningitidis</i> group B. Lot 0957V., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 6-8 Weeks Dose2: 10-12 Weeks Dose3: 14-16 Weeks	Fever greater than or equal to 38 C: OR 1.246 (0.467-3.323)
Santosham M. et al.,1991 ¹¹⁹ United States	Controlled Clinical Trial	4	Sample size : 5,190, Mean age: 54.6 days, Age range: 35 – 196 days, Percent female: 49.4%	<i>Haemophilus Influenza</i> type b (Hib) protein conjugate, Routine Vaccines, Pedvax HIB, Merck, OMPC lots 1072, 1080, and 1085. After reconstitution with 0.1ml of diluent, each 0.5m of vaccine contained 15 micrograms of <i>H. influenzae</i> polysaccharide and 131 to 272 micrograms of group B meningococcal OMPC., Adjuvant: Aluminum, Preservative: Thimerosal, Delivery: Intramuscular	Dose1: 42-90 Days Dose2: 70-146 Days	Areas of redness measuring less than 2.54 cm in diameter: OR 2.713 (1.574-4.676)** Areas if swelling measuring less than 2.54 cm: OR 9.446 (4.905-18.19)** Conjunctivitis: OR 0.628 (0.408-0.968)** Fever above 38.9 C: OR 1.059 (0.685-1.638) Hospitalizations 30 days after vaccination: OR 0.986 (0.748-1.299) Viral infections: OR 0.285 (0.13-0.627)**

Table 20. Vaccinated versus unvaccinated children or adolescents: Hib vaccine (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Huu, T.N. et al. 2013 ¹¹⁸ Vietnam	Controlled Clinical Trial	7	Sample size : 300, Mean age: 8.7, Age range: 6 - 12, Percent female: 43.3%	<i>Haemoph. Influen.</i> type b (Hib) protein conjugate, Routine Vaccines , Experimental: Synflorix Routine: Infanrix hexa , GlaxoSmithKline , PHiD-CV (Synflorix™, GlaxoSmithKline, Rixensart, Belgium) contained 1µg of each capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23Fand 3µg of serotype 4 capsular polysaccharide conjugated individually to NTHi protein D; 3µg of serotype18C capsular polysaccharide conjugated to tetanus toxoid; and 3µg of serotype 19F capsular polysaccharide conjugated to diphtheria toxoid. Routine: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™,GlaxoSmithKline, Rixensart, Belgium) contained=30 IU of diphtheria toxoid,=40 IU of tetanus toxoid, 25µgofpertussis t , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Intramuscular	Dose1: 0 Days Dose2: 28-42 Days Dose3: 28-42 Days	SAE- convulsion: OR 0.332 (0.055-2.017) SAE- diarrhea: OR 0.503 (0.07-3.621) SAE- fungal infection: OR 0.25 (0.022-2.791) SAE- gastro-esophageal reflux disease: OR 0.505 (0.031-8.159) SAEs (total): OR 0.75 (0.259-2.169)

CI = confidence interval; Hib = *Haemophilus influenza* Type b; OR = odds ratio;

Note: Additional study details presented in Appendix C evidence tables.

Measles-Mumps-Rubella (MMR)

The IOM committee found the evidence “convincingly supports” causal relationships in the pediatric population between MMR and the following: measles inclusion body encephalitis in immunocompromised patients; febrile seizures;¹²¹⁻¹²⁸ and anaphylaxis. The IOM committee found the evidence “favors acceptance” of a causal relationship between MMR and transient arthralgia in the pediatric population.¹²⁹⁻¹³⁵ They found the evidence “favors rejection” of a causal relationships between MMR and autism in the pediatric population.¹³⁶⁻¹⁴⁰ Finally, the IOM committee found the evidence is “inadequate to accept or reject” a causal relationship in the pediatric population between MMR and the following: encephalitis, encephalopathy, afebrile seizures, cerebellar ataxia, acute disseminated encephalomyelitis, transverse myelitis, optic neuritis, neuromyelitis optica, MS onset, and chronic arthropathy.

In addition, a causal relationship between the Urabe Strain of mumps and aseptic meningitis has been shown; there is no evidence to link Jeryl Lynn™ strain, commonly used in the United States, to this adverse event.

We identified no additional trials and four postmarketing studies of MMR in children published after the IOM searches. Study designs included self-controlled case series and case-control. The studies were conducted in England, Denmark, Italy, Canada, and the United States. Data are displayed in Table 21.

Purpura

Andrews et al. (2012)¹⁴¹ studied 343 cases of thrombocytopenic purpura (TP) in children aged 12 to 23 months between 1990 and 2007. Vaccination status was ascertained using review of the immunization registry and health outcomes from hospital discharge data. This study presented data from both a case-control design and a self-controlled case series. The self-controlled case series was adjusted for age only. The results indicate that the relative risk of TP was significant 14-27 days (England: RR 3.13, 95% CI 1.44, 6.79; Denmark: RR 2.75, 95% CI 1.61, 4.69) after immunization and 0- 42 days after immunization in both England (RR 1.92, 95% CI 1.02, 3.59) and Denmark (RR 2.01, 95% CI 1.34, 2.99). The data from Denmark were used in a model adjusting for age (1-month intervals), calendar period (one year intervals), gender, place of birth, ethnicity of mother (Danish or not), and maternal age at birth. Similar results were obtained with a significant relative risk of TP at 14-27 days (RR 2.54, CI 95% 1.47, 4.37) and 0-42 days (RR 1.85, 95% CI 1.23, 2.78) after immunization with MMR.

Bertuola et al. (2010)¹⁴² studied 2,311 children from four pediatric hospitals in Italy between November 1999 and December 2007. The sample included 387 cases (mean age: 4.9 years) of idiopathic thrombocytic purpura (ITP) and 1,924 controls (mean age: 5.7 years) who had gastroduodenal lesions or neurological disorders. Vaccination with MMR was confirmed using physician self-report, and health outcomes were ascertained using emergency department and hospital records. Analysis adjusted for age and use of NSAIDs, acetaminophen, antibacterials, mucolytics, and corticosteroids. There was a statistically significant association between vaccination with MMR and ITP (OR 2.4, 95% CI 1.2, 4.7). Results were also significant for use of each medication except corticosteroids.

The VSD was used to study the association between several vaccines and ITP.¹⁴³ (Details are displayed in Table 29 on studies of multiple vaccines.) MMR was associated with ITP in infants 12 to 19 months old (OR 5.48, 95% CI 1.61, 18.64).

Hospitalization or ER visits

In a self-controlled case series study, Wilson et al. (2011)¹⁴⁴ studied 413,957 Canadian children who were vaccinated against MMR at 12–18 months of age between 2006 and 2009. Vaccination status was ascertained by a review of records from the Ontario Health Insurance Plan database. Health outcomes were verified using national databases like the Discharge Abstract Database and the National Ambulatory Care Registration System. Data were analyzed using a fixed effects Poisson regression model. The results show that the relative risk of hospitalization/ED use was significant on days 4–12 (RR 1.33, 95% CI 1.29–1.38) following the 12-month vaccination, and during days 10 to 12 after the 18-month vaccination.

Autism

In a case-control study of 189 young adults with Autism Spectrum Disorder and 224 controls, Uno et al. 2012¹⁴⁵ found that childhood receipt of mumps-measles-rubella (MMR) vaccine was not associated with an increased rate of new onset autism (OR 1.10, 95% CI 0.64, 1.90).

Summary

The IOM found that evidence “convincingly supports” a causal relationship between MMR and anaphylaxis in children allergic to ingredients, and an association of MMR vaccine with febrile seizures. We reviewed and agree with these determinations; thus, we rate the strength of evidence as high.

MMR vaccination was associated with thrombocytopenic purpura in children in the short term after vaccination. Strength of evidence is moderate, as findings have been consistent and odds ratios similar in three European countries, Canada and the United States.

A large post-licensure study found that MMR vaccination is associated with increased emergency department visits within two weeks. This is consistent with the IOM’s findings that MMR vaccine is associated with febrile seizures.

The IOM found that the evidence is “inadequate to accept or reject” a causal relationship in the pediatric population between MMR and the following: encephalitis, encephalopathy, afebrile seizures, meningitis, cerebellar ataxia, acute disseminated encephalomyelitis, transverse myelitis, optic neuritis, neuromyelitis optica, MS onset, and chronic arthropathy. We reviewed the IOM evidence and agree that evidence is insufficient to determine an association. The IOM findings favor rejection of a causal relationship between MMR vaccination and autism. We judge the strength of evidence as high based on a review of their findings and later published case-control study which reported no association.

Table 21. Postmarketing studies of measles-mumps-rubella (MMR) vaccine in children and adolescents

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Andrews et al., 2012 ¹⁴¹ Prospective cohort, also analyzed as self-controlled case series	N=343 cases of thrombocytopenic purpura (TP); Location=England, Denmark; Age=12–23 months;	MMR	Age Cohort study: Models were fitted just adjusting for age (1-month intervals) and calendar period (1 year intervals), and also adjusting for other covariates: child's gender, place of birth (classified according to degree of urbanization), ethnicity of mother (Danish or not), mother's age at birth (using age categories: ≤19, 20–24, 25–29, 30–34, 35–39, ≥40)	<p>Relative incidence of TP after MMR vaccination in children aged 12–23 months in England using the self-controlled case series method (SCCS) and in Denmark using the SCCS and cohort methods</p> <p>Self-Controlled Case Series Period after MMR (days) 0–13 England: 1.10 (0.33–3.71) Denmark: 1.38 (0.68–2.78) 14–27 England: 3.13 (1.44–6.79) Denmark: 2.75 (1.61–4.69) 28–42 England: 1.53 (0.58–4.03) Denmark: 1.94 (1.04–3.62) 0–42 England: 1.92 (1.02–3.59) Denmark: 2.01 (1.34–2.99)</p> <p>Cohort (Denmark) Period after MMR (days) 0–13: 1.32 (0.65–2.68) 14–27: 2.54 (1.47–4.37) 28–42: 1.72 (0.92–3.22) 0–42: 1.85 (1.23–2.78)</p>	Not reported

Table 21. Postmarketing studies of measles-mumps-rubella (MMR) vaccine in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Bertuola et al., 2010 ¹⁴² Case-control	N=2,311 (387 cases, 1924 controls); Location=Italy; Age=Mean (SD) case/control: 4.9 (3.5) / 5.7 (4.9); Setting=Four pediatric hospitals: Department of Paediatrics, University of Padua; Giannina Gaslini Pediatric Hospital, Genoa; Bambino Gesu Hospital, Rome; Santobono-Pausilipon Pediatric Hospital, Naples	MMR	Age and use of multiple medications	OR 95% CI for idiopathic thrombocytopenic purpura (ITP): MMR 2.4 (1.2-4.7)	Not reported

Table 21. Postmarketing studies of measles-mumps-rubella (MMR) vaccine in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Wilson et al., 2011 ¹⁴ ⁴ Self-controlled case series	N=413,957; Location=Ontario, Canada; Age=12 and 18 months;	Live MMR	None in the model	<p>Relative incidence of combined endpoint (hospital admission or emergency room visit) following 12 month vaccination, comparison is 20 to 28 days after vaccination.</p> <p>Risk interval: Relative Incidence (95% CI)</p> <p>Day 4: 1.15 (1.06–1.25) Day 5: 1.19 (1.10–1.29) Day 6: 1.20 (1.11–1.31) Day 7: 1.20 (1.10–1.30) Day 8: 1.62 (1.50–1.74) Day 9: 2.04 (1.91–2.17) Day 10: 1.84 (1.72–1.97) Day 11: 1.72 (1.60–1.84) Day 12: 1.32 (1.22–1.43) Days 4 to 12** (Combined risk interval): 1.33(1.29–1.38)</p> <p>Relative incidences of individual endpoints (emergency room visit, hospital admission, death) during highest risk interval compared to control period.</p> <p>12 months Emergency visits: 1.34 (1.29–1.39) Admissions: 1.08 (0.93–1.25)</p> <p>18 months Emergency visits: 1.25 (1.18–1.34) Admissions: 1.23 (0.94–1.59)</p>	Not reported

Table 21. Postmarketing studies of measles-mumps-rubella (MMR) vaccine in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Uno et al. 2012 ¹⁴⁵ Case-control	N=413 (189 Autism Spectrum Disorder (ASD) cases, 224 controls); Location=Kanto area, Japan; Age=22.6 years (mean); Setting=Cases were patients of the Yokohama Psycho-Developmental Clinic (YPDC). Controls were volunteers from area schools.	MMR, diphtheria-pertussis-tetanus vaccine (DPT); the polio vaccine. Study did not specify whether DPT was acellular and did not specify whether polio was inactivated. Only MMR was included in controlled analyses.	Maternal hypertension, low Apgar score, obstetrical vacuum extraction or forceps delivery Cases/controls matched by sex and year of birth	Odds ratio for ASD: 1.10 (0.64–1.90)	Maternal hypertension: 4.19 (0.46–38.57) Low Apgar score: 2.06 (0.18–22.12) Obstetrical vacuum extraction or forceps delivery: 0.98 (0.50–1.92)

CI = confidence interval; ITP = idiopathic thrombocytopenic purpura; MMR = measles-mumps-rubella; OR = odd ratio; SCCS = self-controlled case series; SD = standard deviation; TP = thrombocytopenic purpura

Note: Additional study details presented in Appendix C evidence tables.

Rotavirus Vaccines: RotaTeq and Rotarix

Vaccines against rotavirus were not included in the 2011 IOM report on adverse effects of vaccines. We identified 35 eligible trials of rotavirus vaccine.¹⁴⁶⁻¹⁷⁷ We excluded several trials because the dosage was not comparable to that of the current product. We also excluded studies of Rotashield, which was withdrawn from the market in 1999 because of concerns regarding risk of intussusception.

Participants in the accepted studies received 2-3 oral administered doses of Rotarix (18 studies) or RotaTeq (15 studies). Most participants were between 4 and 20 months of age. Studies were conducted in North America, South America, Europe, and Asia. The number of participants ranged from 100 to over 60,000. In general, neither Rotarix nor RotaTeq was associated with increased risk of AEs other than cough, runny nose or irritability. The only exception was an association of RotaTeq with respiratory and thoracic disorders in a trial of children with HIV in Sub-Saharan Africa.¹⁵⁷ Data from the studies are displayed in Table 22.

Table 22. Vaccinated versus unvaccinated children: rotavirus vaccines

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Armah G. E. et al.,2010 ¹⁴⁶ Ghana, Kenya, Mali	Controlled Clinical Trial	5	Sample size: 5,560, Age range: 4 - 12, Conditions: HIV	Rotavirus, RotaTeq, Merck, 2x10 ⁷ infectious units per reassortant rotavirus, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Bronchiolitis: OR 1 (0.063-16.002) Bronchopneumonia: OR 1.669 (0.398-6.989) Gastroenteritis: OR 1 (0.51-1.964) One or more serious adverse event: OR 0.933 (0.61-1.425) Other: OR 0.714 (0.226-2.253) Pneumonia: OR 1.302 (0.57-2.974) Respiratory tract infection: OR 0.6 (0.143-2.512) Upper respiratory tract infection: OR 0.5 (0.045-5.518)
Block S. L. et al.,2007 ¹⁴⁷ United States, Finland	Controlled Clinical Trial	5	Sample size: 1,312, Age range: 6 - 13, Percent female: 47.8%	Rotavirus, RotaTeq, Merck, ©1.1X10 infectious U per dose. Pentavalent (G1-G4, and P[8]) human bovine(WC3) reassortant rotavirus vaccine (PRV), Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 4-10 Weeks Dose3: 8-20 Weeks	Bronchiolitis/bronchitis/bronchospasm: OR 1.162 (0.419-3.224) Decreased appetite: OR 1.015 (0.063-16.269) Dehydration: OR 0.253 (0.028-2.267) Gastroenteritis: OR 0.507 (0.046-5.605) Gastrointestinal system: OR 0.301 (0.083-1.1) Influenza: OR 0.507 (0.046-5.605) Pneumonia: OR 3.056 (0.317-29.453) Respiratory syncytial virus infection: OR 6.778 (0.03-1543.45) Respiratory: OR 1.905 (0.755-4.806) Serious Adverse Event: OR 0.783 (0.438-1.399)
Chang C.-C. et al.,2009 ¹⁴⁸ Taiwan	Controlled Clinical Trial	NC	Sample size: 189, Age range: 6 - 12, Percent female: 47.6%	Rotavirus, RotaTeq, Merck, five human-bovine reassortant rotaviruses, each of which contained the WC3 bovine strain backbone with different human viral surface proteins G1, G2, G3, G4 and P[8]. An estimated final concentration of 6.5 × 10 ⁷ IU to 1.2 × 10 ⁸ IU was included in a 2 mL dose solution, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 4-10 Weeks Dose3: 8-20 Weeks	Diarrhea: OR 2.015 (0.972-4.178) Fever, rectal temperature > 38.0°C: OR 0.875 (0.492-1.555) Irritable crying: OR 0.979 (0.06-15.882) Vomiting: OR 1.13 (0.392-3.252)

Table 22. Vaccinated versus unvaccinated children: rotavirus vaccines (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Christie C. D. C. et al.,2010 ¹⁴⁹ Jamaica	Controlled Clinical Trial	4	Sample size: 1,804, Mean age: 7.7, Age range: 6 - 12, Percent female: 48.4%	Rotavirus, Routine Vaccines, RotaTeq, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 2 Month Dose3: 2 Month	Bronchiolitis: OR 1.081 (0.475-2.463) Convulsions: OR 0.99 (0.139-7.044) Death: OR 0.329 (0.034-3.172) Femur fracture: OR 0.99 (0.062-15.854) Gastroenteritis: OR 0.99 (0.199-4.918) Otitis media: OR 1.322 (0.295-5.922) Urinary Tract Infection: OR 1.389 (0.439-4.393) Viral infections: OR 3.973 (0.443-35.62)
Dennehy P. H. et al.,2005 ¹⁵⁰ United States, Canada	Controlled Clinical Trial	6	Sample size: 529, Mean age: 8.7, Age range: 5 - 15, Percent female: 51%	Rotavirus, Routine Vaccines, RIX4414, GlaxoSmithKline, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 2 Month	Bronchiolitis: OR 0.502 (0.1-2.532) Hypovolemia/dehydration: OR 0.507 (0.031-8.187)
Goveia M. G. et al.,2007 ¹⁵¹ 11 countries	Controlled Clinical Trial	8	Sample size: 2,074, Mean age: NR, Age range: 6 - 12, Conditions: Premature babies	Rotavirus, RotaTeq, Merck, vaccine contained 5 live human-bovine reassortant rotaviruses, each consisting of the WC3 bovine strain expressing a viral surface protein corresponding to human rotavirus serotypes G1, G2, G3, G4, or P1A, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 4-10 Weeks Dose3: 4-10 Weeks	Apneic attack (extreme preemie): OR 1.056 (0.066-16.901) At least one SAE (extreme preemie): OR 0.702 (0.249-1.979) Bronchiolitis (all subjects, most frequent AE): OR 0.7 (0.354-1.383) Bronchiolitis (extreme preemie): OR 1.056 (0.148-7.509) Deaths (total, all subjects): OR 1.056 (0.148-7.509) Death due to SIDS (all subjects): OR 1.056 (0.066-16.901) Pneumonia (extreme preemie): OR 2.113 (0.191-23.345)
Grant L. R. et al.,2012 ¹⁵² United States	Controlled Clinical Trial	5	Sample size: 1,003, Age range: 6 - 12	Rotavirus, RotaTeq, Merck, PRV is a live, pentavalent, vaccine that contains human bovine (WC3 strain) reassortant rotaviruses expressing the G1, G2, G3, G4, and P[8] human rotavirus antigens, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 4-10 Weeks Dose3: 8-20 Weeks	Deaths, (Were outside of 42 day safety window and not associated with vaccine): OR 1.945 (0.176-21.517) Diarrhea, all events: OR 1.208 (0.939-1.555) Diarrhea, vaccine related: OR 1.113 (0.851-1.456) Fever, all events: OR 0.943 (0.736-1.21) Fever, vaccine related: OR 1.047 (0.804-1.364) Vomiting, all events: OR 1.097 (0.788-1.527) Vomiting, vaccine related: OR 1.384 (0.911-2.102)

Table 22. Vaccinated versus unvaccinated children: rotavirus vaccines (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Kawamura N. et al.,2011 ¹⁵³ Japan	Controlled Clinical Trial	4	Sample size: 764, Mean age: 7.7, Age range: 6 - 14, Percent female: 50%	Rotavirus, Rotarix, GlaxoSmithKline, Each dose (1ml) of the lyophilized RIX4414 vaccine (Rotarix TM) contained at least 10-6.0 median Cell Culture Infective Dose (CCID50) of live attenuated human rotavirus RIX4414 strain, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 1 Month	# of patients with any AE (31-day post vacc): OR 0.96 (0.71-1.299) Cough/runny nose: OR 1.045 (0.762-1.434) Diarrhea: OR 1.652 (0.866-3.153) Eczema: OR 1.299 (0.82-2.057) Fever: OR 1.421 (0.837-2.414) Irritability: OR 1.128 (0.835-1.523) Loss of appetite: OR 1.397 (0.895-2.179) Upper respiratory tract infection: OR 1.011 (0.61-1.678) Vomiting: OR 1.084 (0.706-1.664)
Kerdpanich A. et al.,2010 ¹⁵⁴ Thailand	Controlled Clinical Trial	9	Sample size: 400, Age range: 6 - 12	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, RIX4414 vaccine contained at least 106.0 cell culture infective dose 50 (CCID50) of the RIX4414 strain. CaCO3 buffer based reconstitution., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 2 Month	Loss of appetite: OR 0.487 (0.205-1.16) SAE - UTI: OR 0.145 (0.009-2.384)
Kim D. S. et al.,2008 ¹⁵⁵ Korea	Controlled Clinical Trial	3	Sample size: 178, Age range: 6 - 12, Percent female: 42.7%	Rotavirus, RotaTeq, Merck, PRV contained 5 WC3 reassortant rotaviruses, each consisting of the WC3 bovine strain with viral surface proteins corresponding to human rotavirus serotypes G1, G2, G3, G4, and P1A_8 suspended in a liquid sodium citrate and phosphate buffer at an aggregate viral titer of approximately 6.9 _ 10 ⁷ to 8.6 _ 10 ⁷ infectious units per dose., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 4-10 Weeks Dose3: 8-20 Weeks	One or more serious adverse events: OR 0.44 (0.141-1.373)

Table 22. Vaccinated versus unvaccinated children: rotavirus vaccines (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Kim J. S. et al.,2012 ¹⁵⁶ South Korea	Controlled Clinical Trial	5	Sample size: 684, Mean age: 8.8, Percent female: 45.3%	Rotavirus, Routine Vaccines, RIX4414, NR, >=10*6.0 median Cell Culture Infective Dose per ml, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 8 Weeks Dose2: 16 Weeks	Bronchiolitis (total study period): OR 0.409 (0.123-1.356) Bronchiolitis (unsolicited/31d): OR 0.77 (0.327-1.811) Gastroenteritis (total study period): OR 0.427 (0.113-1.61) Patients with unsolicited AE over 31d: OR 0.815 (0.565-1.176) URI (unsolicited/31d): OR 0.861 (0.371-2) gastroenteritis (unsolicited/31d): OR 0.843 (0.467-1.521) nasopharyngitis (unsolicited/31d): OR 0.563 (0.301-1.051)
Laserson K. F. et al.,2012 ¹⁵⁷ Kenya	Controlled Clinical Trial	7	Sample size: 297, Age range: 0 - 12, Percent female: 51.8%, Conditions: HIV	Rotavirus, RotaTeq, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Gastrointestinal disorders: OR 1.534 (0.968-2.431) General disorders and administration site conditions: OR 0.97 (0.599-1.57) Infections: OR 0.684 (0.332-1.412) Infections Dose 2: OR 0.524 (0.301-0.912)** One of more serious adverse events: OR 0.581 (0.286-1.179) Respiratory, thoracic and mediastinal disorders: OR 337.733 (45.817-2489.554)**
Madhi S. A. et al.,2010 ¹⁵⁸ South Africa and Malawi	Controlled Clinical Trial	3	Sample size: 4,939, Mean age: 6.4 Percent female: 49.6%, Conditions: HIV	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, Calcium carbonate buffer, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Bronchiolitis: OR 1.027 (0.563-1.871) Bronchopneumonia: OR 0.995 (0.601-1.647) Deaths: OR 0.959 (0.661-1.393) Gastroenteritis: OR 0.779 (0.584-1.039) Overall SAE: OR 0.823 (0.68-0.995)** Pneumonia: OR 0.818 (0.564-1.185) Sepsis: OR 1.234 (0.722-2.11)

Table 22. Vaccinated versus unvaccinated children: rotavirus vaccines (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Narang A. et al.,2009 ¹⁵⁹ India	Controlled Clinical Trial	5	Sample size: 363, Mean age: 8.7, Age range: 8 - 10, Percent female: 47.1%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, Vaccine contained at least 106.0 median cell culture infectious dose (CCID50) of the vaccine strain per dose. The placebo contained the same constituents as the study vaccine but without the virus component. The lyophilized vaccine and placebo were reconstituted with a diluent containing Calcium Carbonate as a buffer, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 1 Month	Cough/runny nose: OR 1.515 (0.276-8.315) Cough/runny nose: OR 4.472 (2.02-9.902)** Diarrhea: OR 1 (0.218-4.597) Diarrhea: OR 0.89 (0.366-2.164) Fever: OR 0.675 (0.346-1.319) GE episodes from dose 1 to one month post-dose 2: OR 0.94 (0.433-2.04) Irritability: OR 0.242 (0.031-1.913) Irritability: OR 2.316 (1.135-4.723)** Loss of appetite: OR 1.136 (0.5-2.584) Serious adverse event: OR 1.473 (0.241-8.988) Vomiting: OR 0.093 (0.034-0.256)**
Omenaca F. et al.,2012 ¹⁶⁰ France, Portugal, Poland and Spain	Controlled Clinical Trial	6	Sample size: 1,009, Mean age: 8.5, Age range: 5 - 14, Percent female: 49%, Conditions: Premature babies	Rotavirus, Rotarix, GlaxoSmithKline, A single dose of RIX4414 vaccine contained at least 106.0 median cell culture infective dose of the live-attenuated RIX4414 human rotavirus strain., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 30-83 Days	At least 1 unsolicited symptom: OR 0.602 (0.458-0.792)** At least 1 unsolicited symptom (grade 3): OR 0.285 (0.142-0.573)** At least 1 unsolicited symptom (vaccine-related): OR 0.608 (0.401-0.92)** infection - Gastroenteritis: OR 0.744 (0.341-1.625) infection - Upper resp infection: OR 0.649 (0.291-1.448)
Phua K. B. et al.,2005 ¹⁶¹ Singapore	Controlled Clinical Trial	3	Sample size: 2,464, Mean age: 13.3, Age range: 11 - 17, Percent female: 50.2%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, 10.7 ffu group. To produce RIX4414, the parent 89-12 vaccine strain was further passaged in Vero cells and cloned [18, 20]. The vaccine was a lyophilized preparation supplied in single-dose vials with calcium carbonate buffer for reconstitution. Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 1 Month	Severe Vomiting (Dose 1): OR 1 (0.312-3.203) Severe Vomiting (Dose 2): OR 1 (0.312-3.203)

Table 22. Vaccinated versus unvaccinated children: rotavirus vaccines (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Phua K. B. et al.,2009 ¹⁶² Hong Kong, Singapore, Thailand	Controlled Clinical Trial	8	Sample size: 10,708, Mean age: 11.6, Age range: 5 - 20, Percent female: 49.1%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, contained at least 106.0 median cell culture infectious dose (CCID50) of the vaccine strain per dose, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 1-2 Month	Death: OR 0.332 (0.035-3.195) Intussusception (from Dose 1 to age 2): OR 1.996 (0.601-6.632) Withdrawal due to AE: OR 0.581 (0.229-1.477)
Phua K. B. et al.,2012 ¹⁶³ Singapore, Hong Kong, Taiwan	Controlled Clinical Trial	1	Sample size: 8,407, Mean age: 35.3, Age range: 23 - 44, Percent female: 49%, Percent pregnant: Percent Pregnant: 0%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, reconstitution of lyophilized vaccine in calcium carbonate buffer to a concentration of at least 10*6.0 cell culture infective dose (CCID50) of live-attenuated virus (median), Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 1-2 Month	Intussusception: OR 1.983 (0.18-21.878) gastroenteritis (failed treatment?): OR 1.487 (0.248-8.905)
Rodriguez Z. M. et al.,2007 ¹⁶⁴ United States	Controlled Clinical Trial	1	Sample size: 1,358, Mean age: 9.35, Age range: 6 - 13, Percent female: 51.1%	Rotavirus, Routine Vaccines, RotaTeq, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 28-70 Days Dose3: 56-140 Days	Cough: OR 1.027 (0.748-1.41) Diarrhea: OR 0.711 (0.535-0.946)** Fever: OR 0.901 (0.728-1.115) Nasal congestion: OR 0.957 (0.699-1.311) Nasopharyngitis: OR 0.891 (0.664-1.197) Otitis media: OR 0.786 (0.561-1.103) Upper respiratory infection: OR 0.827 (0.647-1.056) Vomiting: OR 0.747 (0.528-1.055)
Ruiz-Palacios G. M. et al.,2006 ¹⁶⁵ Finland, Argentina, Brazil, Chile, Colombia, the Dominican Republic, Honduras, Mexico, Nicaragua, Panama, Peru, Venezuela	Controlled Clinical Trial	6	Sample size: 63,225, Mean age: 8.2, Percent female: 49%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, Contained 10.5 median cell-culture infective doses of the RIX4414 vaccine strain. Vaccine was reconstituted with 1.3 ml of liquid calcium carbonate buffer., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 2 Month Dose2: 4 Month	Death: OR 1.298 (0.872-1.932) Definite intussusception, 31 days or less after dose 1: OR 0.498 (0.045-5.493) Definite intussusception, 31 days or less after dose 2: OR 0.996 (0.288-3.441) Definite intussusception, 31 days or less after either dose: OR 0.854 (0.287-2.541) Definite intussusception, between dose 1 and visit 3: OR 0.56 (0.248-1.268) Hospitalization: OR 0.877 (0.8-0.961)** Serious adverse events: OR 0.879 (0.804-0.962)**

Table 22. Vaccinated versus unvaccinated children: rotavirus vaccines (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Sow S. O. et al., 2012 ¹⁶⁶ Vietnam, Bangladesh, Ghana, Kenya, Mali	Controlled Clinical Trial	5	Sample size: 1,960, Mean age: NR, Age range: 6 - 14, Percent female: 48.3%	Rotavirus, RotaTeq, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Bronchiolitis: OR 1.002 (0.063-16.044) Deaths: OR 0.6 (0.143-2.518) One or more serious adverse events: OR 0.834 (0.254-2.742) Pneumonia: OR 0.667 (0.111-4.003)
Steele A. D. et al., 2010 ¹⁶⁷ South Africa	Controlled Clinical Trial	4	Sample size: 475, Mean age: 6.3	Rotavirus, Rotarix, GlaxoSmithKline, RIX4414 developed from 89-12 parent vaccine strain that was cloned and passaged on Vero cells. Viral concentration of 1 dose contained at least 1x10 ^{6.0} medial cell culture infective dose and lyophilized vaccine was reconstituted with calcium carbonate as buffer, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 10 Weeks Dose2: 14 Weeks	Serious adverse events (any): OR 1.011 (0.336-3.046)
Steele A. D. et al., 2011 ¹⁶⁸ South Africa	Controlled Clinical Trial	5	Sample size: 100, Mean age: 7, Age range: 6 - 10, Percent female: 53%, Conditions: HIV	Rotavirus, Rotarix, GlaxoSmithKline, Each dose of the vaccine contained at least 106.0 median cell culture infective dose (CCID 50) of the active virus strain. Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 1 Month Dose3: 1 Month	At least 1 Grade 3 unsolicited symptom w/in 31 d): OR 1 (0.425-2.352) Bronchopneumonia: OR 1.872 (0.512-6.848) Bronchopneumonia - Grade 3: OR 1 (0.236-4.242) Cough: OR 1.43 (0.622-3.286) Fatality: OR 0.621 (0.203-1.899) GE: OR 2.136 (0.503-9.068) GE - Grade 3: OR 2.087 (0.365-11.949) Irritability: OR 1.17 (0.39-3.515) Oral candidiasis - Grade 3: OR 2.087 (0.365-11.949)
Tregnaghi M. W. et al., 2011 ¹⁶⁹ Argentina, Brazil, Colombia, Dominican Republic, Honduras, and Panama	Controlled Clinical Trial	4	Sample size: 6,568, Mean age: 8.6, Age range: 6 - 12	Rotavirus, Rotarix, GlaxoSmithKline, Contained at least 106.0 median Cell Culture Infective Dose (CCID50) of live attenuated human rotavirus RIX4414 strain. The lyophilized vaccine was reconstituted with the supplied buffer before oral administration., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 1-2 Month	Bronchiolitis: OR 1.178 (0.874-1.588) Intussusception: OR 1 (0.183-5.464) Death: OR 2.503 (0.548-11.436) Gastroenteritis: OR 0.727 (0.529-1)** Pneumonia: OR 1 (0.699-1.43)

Table 22. Vaccinated versus unvaccinated children: rotavirus vaccines (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Vesikari T. et al.,2004 ¹⁷⁰ Finland	Controlled Clinical Trial	5	Sample size: 405, Mean age: 8.3, Age range: 6 - 12	Rotavirus, Rotarix, GlaxoSmithKline, The vaccine was a lyophilized product; it was reconstituted with a diluent containing calcium carbonate as buffer. Each reconstituted vaccine dose contained 104.7 focus forming units of the RIX4414 strain rotavirus vaccine, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 2 Month Dose2: 4 Month	Diarrhea, Dose 1: OR 1.652 (0.685-3.984) Diarrhea: OR 2.042 (0.538-7.745) Fever greater than or equal to 38.0°C, Dose 2: OR 1.11 (0.694-1.773) Fever greater than or equal to 38.0°C, Dose 1: OR 1.103 (0.578-2.105) Irritability, Dose 1: OR 1.088 (0.715-1.654) Irritability: OR 1.276 (0.845-1.928) Loss of appetite, Dose 1: OR 1.542 (0.914-2.602) Vomiting, Dose 1: OR 1.879 (0.788-4.48) Vomiting: OR 0.645 (0.299-1.393)
Vesikari T. et al.,2006 ¹⁷¹ Finland	Controlled Clinical Trial	5	Sample size: 1,946, Age range: 2 - 8	Rotavirus, NR, Low-potency pentavalent RotaTeq G1, G2, G3, G4, P1A 2.41×106., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 4-8 Weeks Dose3: 8-16 Weeks	Post-vaccination fever greater than or equal to 38.1 C rectally after dose 1: OR 1.479 (0.982-2.229) Post-vaccination fever greater than or equal to 38.1 C rectally after dose 2: OR 1.171 (0.788-1.74) Post-vaccination fever greater than or equal to 38.1 C rectally after dose 3: OR 1.286 (0.873-1.894)
Vesikari T. et al.,2006 ¹⁷² 11 countries	Controlled Clinical Trial	8	Sample size: 69,274, Mean age: 9.8, Age range: 6 - 12, Percent female: 49.3%	Rotavirus, RotaTeq, Merck, Pentavalent, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 4-10 Weeks Dose3: 4-10 Weeks	Not calculable
Vesikari T. et al.,2011 ¹⁷³ Finland	Controlled Clinical Trial	3	Sample size: 250, Mean age: 9.1, Age range: 6 - 12, Percent female: 50%	Rotavirus, Rotarix, GlaxoSmithKline, RIX4414 oral suspension (liquid formulation). Contained at least 10-6median cell culture infective dose (CCID50) of live attenuated RIX4414 human rotavirus strain. The liquid formulation of RIX4414 contained sucrose as excipient and the content of sucrose in the liquid formulation is higher than one in the lyophilized formulation., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 1 Month	Cough/runny nose: OR 0.959 (0.477-1.927) Diarrhea: OR 0.49 (0.066-3.639) Fever: OR 1.652 (0.381-7.173) Irritability: OR 1.199 (0.582-2.47) Loss of appetite: OR 0.778 (0.334-1.814) Vomiting: OR 1.098 (0.404-2.984)

Table 22. Vaccinated versus unvaccinated children: rotavirus vaccines (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Vesikari T. et al.,2004 ¹⁷⁴ Belgium, Germany	Controlled Clinical Trial	5	Sample size: 59, Age range: 1 - 44	Rotavirus, Rotarix, GlaxoSmithKline, Derived from the parent strain 89-12 single dose of a minimum of 10(6.1) focus forming unit (ffu) of RIX4414 or placebo, with prior administration of Mylanta® as buffer, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days	Not calculable
Zaman K. et al.,2009 ¹⁷⁵ Bangladesh	Controlled Clinical Trial	7	Sample size: 294, Mean age: 6.1, Age range: 6 - 7, Percent female: 53.4%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, 10.5 median cell culture infective dose of the G1P strain., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	fever: rectal temperature =38 °C: OR 0.3 (0.13-4-0.675)** Any diarrhea: =6/day: OR 0.66 (0.074-5.862) Gastroenteritis: OR 0.49 (0.03-8.001) Loss of appetite: OR 1.138 (0.553-2.341) Unsolicited symptoms: OR 0.603 (0.272-1.336) Vomiting: =1 episode of forceful emptying of partially digested stomach contents =1 h after feeding within a day: OR 1.377 (0.564-3.364)
Zaman K. et al.,2010 ¹⁷⁶ Bangladesh and Vietnam	Controlled Clinical Trial	8	Sample size: 2,035, Mean age: 8.9, Age range: 5.9 - 25.9, Percent female: 47%	Rotavirus, RotaTeq, Merck, Pentavalent rotavirus vaccine containing 5 human-bovine reassortant rotaviruses with the WC3 bovine strain as backbone and viral surface proteins corresponding to human rotavirus serotypes G1, G2 G3, G4, P1A[8], Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Death: OR 0.75 (0.167-3.36)
Zaman K. et al.,2012 ¹⁷⁷ Bangladesh	Controlled Clinical Trial	5	Sample size: 1,136, Mean age: 8.2, Percent female: 48.6%	Rotavirus, Routine Vaccines, RotaTeq, GlaxoSmithKline, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Accidental drowning: OR 1 (0.062-16.027) Acute diarrhea: OR 1 (0.062-16.027) All Serious Adverse Events: OR 0.939 (0.47-1.878) Death, All causes: OR 3.011 (0.312-29.031) Pneumonia: OR 0.728 (0.331-1.599)
Sow, S.O. et al. 2012 ¹⁷⁸ Sub-Saharan Africa (Ghana, Kenya and Mali)	Controlled Clinical Trial	2	Sample size: 1960, Mean age: 48, Age range: 0 - 14, Percent female: 48%	Rotavirus, RotaTeqTM , Merck, Not reported , Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Bronchiolitis: OR 1.002 (0.063-16.044) Pneumonia: OR 0.667 (0.111-4.003) Total deaths: OR 0.6 (0.143-2.518)

Table 22. Vaccinated versus unvaccinated children: rotavirus vaccines (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Lau, Y.L. et al. 2013 ¹⁷⁹ China	Controlled Clinical Trial	1	Sample size: 3025, Mean age: 11.6, Age range: 6 - 12, Percent female: Not reported%	Rotavirus, RotarixTM , GlaxoSmithKline , Each dose of the lyophilized formulation of RIX4414 (RotarixTM, GlaxoSmithKline, Belgium) vaccine contained at least 106.0 median cell culture infectious dose (CCID50) of live, attenuated human G1P rotavirus. The RIX4414 vaccine was reconstituted in a calcium carbonate buffer before oral administration. , Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 2 Month Dose2: 4 Month	Gastroenteritis-related symptoms requiring <=1 hospitalization: OR 0.793 (0.616-1.021) Intussusception: OR 2.001 (0.366-10.943)
Zaman, K. et al. 2012 ¹⁸⁰ Bangladesh	Controlled Clinical Trial	2	Sample size: 1136, Mean age: NR, Age range: 4 - 12	Rotavirus, RotaTeq, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 4 Weeks Dose3: 4 Weeks	Acute diarrhea: OR 1 (0.062-16.027) Death: OR 1 (0.201-4.976) Pneumonia: OR 0.728 (0.331-1.599)

AE = adverse event; CCID = cell culture infective dose; CI = confidence interval; FFU = focus forming unit; H = Hour; HIV = human immunodeficiency virus; IU = international unit; OR = odds ratio; PRV = pentavalent rotavirus vaccine; SAE = serious adverse events

Note: Additional study details presented in Appendix C evidence tables.

We found five post-licensure studies of vaccines against rotavirus (Buttery, 2011; Yih, 2013; Velazquez, 2012; Patel, 2011; Shui, 2012).¹⁸¹⁻¹⁸⁵ The studies were set in Australia (Buttery, 2011), United States (Shui, 2012; Yih, 2013), Mexico (Velazquez, 2012; Patel, 2011) and Brazil (Patel, 2011). All studied intussusception, as an earlier brand of rotavirus vaccine (Rotashield) was withdrawn from the market in 1999 due to concerns about this AE. Studies are displayed in Table 23.

Intussusception

Buttery et al. (2011)¹⁸¹ studied children under the age of 24 months who received either RotaTeq (N=296,023) or Rotarix (N=302,455) between July 2007 and December 2008. Vaccination status was ascertained through a national vaccination registry. Health outcomes were collected using active surveillance: the Australian Pediatric Surveillance Unit (APSU), the Pediatric Active Enhanced Disease Surveillance (PAEDS), and from the active surveillance of four major tertiary pediatric hospitals. Relative risk ratios were estimated to compare observed and expected cases of intussusception by age. For the RotaTeq vaccine, in the 1-7 days post vaccination period, the risk of intussusception was significant after the first dose (RR 5.26, 95% CI 1.09, 15.4) but insignificant after the second and third doses. The overall relative risk of intussusception was insignificant (RR 1.15, 95% CI 0.37, 2.68) during this period. There was a similar decreasing trend in the risk of intussusception with each dose in the 21-day period after vaccination; only dose one had a significant association (RR 3.51, 95% CI 1.29, 7.64). In children vaccinated with Rotarix, risk of intussusception was insignificant for all doses; the overall relative risk was 1.58 (95% CI 0.51, 3.69) for the 7-day post vaccination period and 1.37 (95% CI 0.73, 2.34) for the 21-day period.

In a self-controlled case series, Velazquez et al. (2012)¹⁸² studied 698 infants (age< 1 year) with intussusception between January 2008 and October 2010 in Mexico. Use of the Rotarix vaccine was confirmed using immunization cards or a review of all available medical records. In the absence of medical records, vaccination status was ascertained using parent/guardian reported data. Active surveillance identified cases of intussusception through reviews of admission and discharge logs from hospitals, emergency departments, pediatric, surgery and radiology wards. Episodes of intussusception were confirmed using radiography, surgery, or post mortem examination. Data were modeled using a conditional Poisson regression and adjusted for age as a potential confounder. The relative incidence of intussusception was significant after dose 1 during the 0-6 days (RR 6.49, 95% CI 4.17, 10.09), 0-15 days (RR 3.24, 95% CI 2.15, 4.87), and 0-30 days (RR 1.75, 95% CI 1.24, 2.48) post vaccination periods. The risk of intussusception after dose 2 was not significant for all three post vaccination periods studied.

Patel et al. (2011)¹⁸³ studied 2,665 infants (615 cases of intussusception, 2,050 controls), 45-245 days of age from 53 hospitals in seven states in Brazil and from 16 hospitals in 10 states in Mexico. This study reports two sets of results, one as a case-control study and the other as a self-controlled case series. Vaccination with Rotarix was ascertained by a review of medical records, and cases of intussusception were verified by a review of clinical records. Data were analyzed using a conditional logistic regression model that was matched by date of birth, and also controlled for age and sex. For the children studied in Mexico, the likelihood of intussusception in the case-control analysis was significant (OR 5.8, 95% CI 2.6, 13.0) at 1-7 days but not at 8-14 days or 15-21 days after vaccination. After the second dose, the likelihood of intussusception was significant 8-14 days (OR 2.3, 95% CI 1.2, 4.4) days after vaccination but not in the other periods. The case-control analysis of data from the children in Brazil showed no significant relationship between vaccine and

intussusception at any time period after dose 1, but showed a significant association (OR 1.9, 95% CI 1.1, 3.4) within 1-7 days after dose 2.

The results of Patel's self-controlled case series analyses¹⁸³ showed a significant association of Rotarix with intussusception in 1-7 days after the first dose (OR 5.3, 95% CI 3.0, 9.3) and 8-14 days (OR 2.2, 95% CI 1.2, 4.2) and 15-21 days (OR 2.2, 95% CI 1.2, 4.0) after the second dose in children in Mexico. In Brazil, the association with intussusception after the first dose of Rotarix was insignificant at each time period, but significant (OR 2.6, 95% CI 1.3, 5.2) 1-7 days after the second dose.

Two post-licensure studies were recently conducted in the U.S. Shui, 2012¹⁸⁴ analyzed VSD data on 786,725 doses of RotaTeq and found no association with intussusception at any time after vaccination. However, a recent analysis of data from the U.S. Post-Licensure Rapid Immunization Safety Monitoring (PRISM) program¹⁸⁵ found that RotaTeq was associated with intussusception after Dose 1 and Rotarix associated with this AE after Dose 2. The RotaTeq analysis had higher statistical power, as that vaccine was administered to orders of magnitude more children than Rotarix. Estimated rate of intussusception was 1.1 to 1.5 cases per 100,000 doses of RotaTeq and 5.1 cases per 100,000 doses of Rotarix.

Summary

Vaccines against rotavirus were not included in the 2011 IOM report.

Both RotaTeq and Rotarix were associated with cough, runny nose and irritability in children. There is moderate strength evidence from several RCTs for these mild, short-term adverse events.

In clinical trials, there was no association between either of the two currently available vaccines (RotaTeq and Rotarix) and any serious adverse events, including intussusception.

A high quality epidemiological study (N = 296,023) conducted in Australia found RotaTeq associated with intussusception in children 1 to 21 days following the first of three required doses. While a study of the U.S. VSD found no association, a large high quality U.S. study also found RotaTeq associated with intussusception after the first dose. Estimated rate of intussusception was 1.1 to 1.5 cases per 100,000 doses.

Two case-control studies conducted in Latin America found an association with intussusception in children following the first of two required doses of Rotarix. One study estimated Rotarix increases risk by 3.7 (95% CI 1.2, 7.3) additional cases per 100,000 person/years in Mexico. The other Latin American study estimated risk as one case per 51,000 vaccines in Mexico and one case per 68,000 vaccines in Brazil. A large high quality study in the United States found Rotarix associated with intussusception after Dose 2; rate was 5.1 cases per 100,000 doses.

Given the totality of scientific findings, the strength of evidence is moderate for an association of intussusception with both Rotateq and Rotarix. Although no cases were reported in over 30 well-designed clinical trials conducted around the world, such trials are not powered to detect adverse events that occur so infrequently. The most recent post-licensure study used the strongest design yet and included all cases from eight large U.S. HMOs. This study supports findings from the 2011 epidemiological study of over 500,000 children in Australia and two small studies conducted in Latin America.

Table 23. Postmarketing studies of rotavirus vaccines in children

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Buttery et al., 2011 ¹⁸¹ Observed /expected analysis	Children under 24 months old receiving RotaTeq (N=296,023) or Rotarix (302,455) in Australia; Active surveillance mechanisms	Two states used RotaTeq, two states used Rotarix	No control for confounders	<p>Observed and expected cases of intussusception by age in months in jurisdictions delivering RotaTeq</p> <p>1–7 days post-vaccine Dose 1: 5.26 (1.09, 15.4) Dose 2: 1.33 (0.16, 4.82) Dose 3: 0.00 (0.00, 2.16) Total: 1.15 (0.37, 2.68)</p> <p>1–21 days post-vaccine Dose 1: 3.51 (1.29, 7.64) Dose 2: 0.67 (0.14, 1.94) Dose 3: 0.00 (0.00, 0.89) Total: 0.77 (0.37, 1.41)</p> <p>Observed and expected cases of intussusception by age in months in jurisdictions delivering Rotarix</p> <p>1–7 days post-vaccine Dose 1: 3.45 (0.71, 10.1) Dose 2: 1.05 (0.13, 3.80) Total: 1.58 (0.51, 3.69)</p> <p>1–21 days post-vaccine Dose 1: 1.53 (0.42, 3.92) Dose 2: 0.88 (0.29, 2.05) Total: 1.37 (0.73, 2.34)</p>	Not reported
Velázquez et al., 2012 ¹⁸² Self-controlled case-series	N=698 infants < 1 year old in Mexico with intussusception Active surveillance across hospitals in Mexico from the Mexican Institute of Social Security	Rotarix	Age	<p>Relative Incidence</p> <p>Dose and risk period (days after vaccination)</p> <p>Dose 1, 0–30 days: 1.75 (1.24–2.48) Dose 2, 0–30 days: 1.06 (0.75–1.48)</p> <p>Dose 1, 0–15 days: 3.24 (2.15–4.87) Dose 2, 0–15 days: 1.06 (0.69–1.61)</p> <p>Dose 1, 0–6 days: 6.49 (4.17–10.09) Dose 2, 0–6 days: 1.29 (0.80–2.11)</p>	Not reported

Table 23. Postmarketing studies of rotavirus vaccines in children (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Patel et al., 2011 ¹⁸³ Case-control (also did self-controlled case-series)	N=2,665 (615 cases of intussusception, 2050 controls); Location=Mexico, Brazil; Age=45-245 days; Setting=53 hospitals in 7 states in Brazil and at 16 hospitals in 10 states in Mexico	RV1, Rotarix	Matched by date of birth, also controlled for age, sex	<p>OR (95% CI) for intussusception (Case-control)</p> <p>Mexico</p> <p>Either dose, any time before reference date 1.0 (0.6–1.7)</p> <p>First dose</p> <p>1–7 days: 5.8 (2.6–13.0) 8–14 days: 1.0 (0.4–2.9) 15–21 days: 0.8 (0.3–2.1)</p> <p>Second dose</p> <p>1–7 days: 1.1 (0.6–2.2) 8–14 days: 2.3 (1.2–4.4) 15–21 days: 2.0 (1.0–3.8)</p> <p>Brazil</p> <p>Either dose, any time before reference date 1.7 (0.9–2.9)</p> <p>First dose</p> <p>1–7 days: 1.4 (0.4–4.8) 8–14 days: 1.6 (0.5–4.7) 15–21 days: 0.6 (0.1–2.2)</p> <p>Second dose</p> <p>1–7 days: 1.9 (1.1–3.4) 8–14 days: 0.9 (0.5–1.8) 15–21 days: 0.8 (0.4–1.6)</p> <p>OR (95% CI) for intussusception (Self-controlled case-series)</p> <p>Mexico</p> <p>First dose</p> <p>1–7 days: 5.3 (3.0–9.3) 8–14 days: 1.1 (0.5–2.7) 15–21 days: 0.9 (0.3–2.2)</p> <p>Second dose</p> <p>1–7 days: 1.8 (0.9–3.8) 8–14 days: 2.2 (1.1–4.2) 15–21 days: 2.2 (1.2–4.0)</p> <p>Brazil</p> <p>First dose</p> <p>1–7 days: 1.1 (0.3–3.3) 8–14 days: 1.3 (0.5–3.4)</p>	Not reported

Table 23. Postmarketing studies of rotavirus vaccines in children (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				15–21 days: 0.2 (0.0–1.4) Second dose 1–7 days: 2.6 (1.3–5.2) 8–14 days: 1.4 (0.7–3.0) 15–21 days: 0.9 (0.4–2.0)	
Shui I. M. et al., 2012 ¹⁸⁴ Cohort	Children receiving RotaTeq in U.S. (N=786,725 total doses, which included 309,844 first doses) Mean age: NR Age range: 4 – 34 weeks	RotaTeq		RR (95% CI) for intussusception vs. concurrent comparison group administered any other vaccine. All doses 1 to 7 days 0.90 (0.10 – 11.08) 1 to 30 days 0.95 (0.37 – 2.63) Dose 1 1 to 7 days Undefined (0.01, Undefined) 1 to 30 days Undefined (0.22, Undefined) Dose 2 1 to 7 days 0.00 (0.00 – 17.30) 1 to 30 days 0.36 (0.07 – 1.65) Dose 3 1 to 7 days 1.57 (0.08 – 92.75) 1 to 30 days 1.57 (0.34 – 9.72)	
Yih, et al. 2013, ¹⁸⁵ Self-controlled risk interval (SCRI) and a cohort design	N=124 total cases, 613,000 infant-years; Location=U.S.; Age=5-36.9 weeks; Setting=Post-Licensure Rapid Immunization Safety Monitoring program (PRISM), participants were members of Mini-Sentinel Data Partners Aetna, HealthCore, or Humana	RotaTeq, Rotarix	SCRI: age Cohort: age, sex, Data Partner, and exposure status	Case counts and risk estimates (RR, 95% CI) for Brighton Level 1 confirmed intussusception after RotaTeq, risk estimates incorporate a correction factor for cases lacking charts (which make up 22% of the total by dose, study design, and age adjustment. Attributable potential cases ascertained). Pre-specified: Tate age-adjustment Post-hoc: PRISM age-adjustment SCRI, Risk Window 1-7 days Dose 1 Pre-specified: 9.1, 2.2-39 Post-hoc: 7.0, 1.7-29 Dose 2 Pre-specified: 1.8, 0.4-7.2	Not reported

Table 23. Postmarketing studies of rotavirus vaccines in children (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				<p>Post-hoc: 1.8, 0.4-7.2</p> <p>Dose 3 Pre-specified: 2.2, 0.5-9.7 Post-hoc: 2.3, 0.5-10</p> <p>All Pre-specified: 3.3, 1.5-7.4 Post-hoc: 3.0, 1.4-6.8</p> <p>SCRI, Risk Window 1-21 days</p> <p>Dose 1 Pre-specified: 4.2, 1.1-16 Post-hoc: 3.4, 0.9-13</p> <p>Dose 2 Pre-specified: 1.0, 0.3-3.1 Post-hoc: 1.0, 0.3-3.1</p> <p>Dose 3 Pre-specified: 1.0, 0.2-3.9 Post-hoc: 1.0, 0.2-4.0</p> <p>All Pre-specified: 1.6, 0.8-3.3 Post-hoc: 1.5, 0.7-3.1</p> <p>Cohort</p> <p>Dose 1 Pre-specified: 2.6, 1.2-5.8 Post-hoc: 2.9, 1.4-6.0</p> <p>Dose 2 Pre-specified: 0.9, 0.4-2.2 Post-hoc: 0.8, 0.3-2.0</p> <p>Dose 3 Pre-specified: 0.9, 0.4-2.2</p>	

Table 23. Postmarketing studies of rotavirus vaccines in children (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				<p>Post-hoc: 0.9, 0.4-2.2</p> <p>All</p> <p>Pre-specified: 1.3, 0.8-2.1</p> <p>Post-hoc: 1.3, 0.8-2.1</p> <p>Table 3. Case counts and risk estimates for Brighton Level 1 confirmed intussusception after Rotarix, by dose, study design, and age adjustment.</p> <p>Pre-specified: Tate age-adjustment</p> <p>Post-hoc: PRISM age-adjustment</p> <p>SCRI, Risk Window 1-7 days</p> <p>Dose 1</p> <p>Pre-specified: infinity</p> <p>Post-hoc: none</p> <p>Dose 2</p> <p>Pre-specified: 3.5, 0.5-25</p> <p>Post-hoc: 3.6, 0.5-25</p> <p>Dose 3</p> <p>Pre-specified: 5.7, 0.9-34</p> <p>Post-hoc: 5.5, 0.9-33</p> <p>SCRI, Risk Window 1-21 days</p> <p>Dose 1</p> <p>Pre-specified: infinity</p> <p>Post-hoc: none</p> <p>Dose 2</p> <p>Pre-specified: 1.7, 0.3-10</p> <p>Post-hoc: 1.7, 0.3-10</p>	

Table 23. Postmarketing studies of rotavirus vaccines in children (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				<p>Dose 3 Pre-specified: 2.3, 0.4-13 Post-hoc: 2.3, 0.4-13</p> <p>Cohort</p> <p>Dose 1 Pre-specified: 2.9, 0.4-22 Post-hoc: 3.2, 0.4-23</p> <p>Dose 2 Pre-specified: 5.1, 1.6-16 Post-hoc: 4.6, 1.5-15</p> <p>Dose 3 Pre-specified: 3.8, 1.4-10 Post-hoc: 3.7, 1.4-10</p>	

CI = confidence interval; OR = odds ratio

Note: Additional study details presented in Appendix C evidence tables.

Hepatitis B Vaccine

Although no epidemiological studies were identified by the IOM, mechanistic evidence “favored acceptance” of a causal relationship between the vaccine and anaphylaxis in yeast-sensitive individuals. The IOM found insufficient evidence to accept or reject a causal relationship with any other AEs. A 2002 IOM review on Hepatitis B vaccine and demyelinating neurological disorders concluded that the evidence “favors rejection” of a causal relationship with incident MS or MS relapse.⁹⁸

We found no trials and one postmarketing study of Hepatitis B vaccine in children or adolescents. Data from this study are displayed in Table 24.

Autism

Gallagher and Goodman (2010)¹⁸⁶ conducted a secondary analysis of 7,074 boys, age 3 to 17 years, born prior to 1999, using the National Health Interview Survey through 2002. Vaccination status and health outcomes were reported by parents in an interview with trained interviewers who asked them to gather vaccination records in advance. Data were analyzed using a logistic regression adjusted for race/ethnicity, two-parent household, and maternal education. Result was significant for the risk of autism in children who received their first dose of Hepatitis B vaccine during the first month of life (OR 3.00, 95% CI 1.11, 8.13), compared with those who received the vaccination after the first month of life or not at all. Significant protective factors included non-Hispanic white ethnicity (OR 0.36, 95% CI 0.15, 0.88), and belonging to a household with two parents (OR 0.30, 95% CI 0.12, 0.75). It is unclear why the authors selected “first month of life” as the only vaccination time period studied, without presenting analyses for other time periods or comparing “ever vaccinated” with “never vaccinated.”

The IOM found “insufficient” evidence of association of Hepatitis B vaccine with any short or long term adverse events in children. Our findings support that conclusion. Based on the newly identified study discussed above, there is insufficient evidence of an association of the Hepatitis B with autism in children.

Table 24. Postmarketing study of Hepatitis B vaccine in children and adolescents

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Gallagher and Goodman, 2010 ¹⁸⁶ Cross-sectional	N=7,074 (30 with autism, 7,044 without autism); Location=U.S.; Age=boys 3 through 17 years born prior to 1999; Used National Health Interview Survey data	Hepatitis B	Race/ethnicity, two-parent household, maternal education	OR (95% CI) of autism diagnosis Received first dose of Hepatitis B vaccine during first month of life, compared with receipt after first month of life or not at all OR=3.00 (1.11-8.13)	Non-Hispanic white: 0.36 (0.15-0.88) Two-parent household 0.30 (0.12-0.75) Maternal education, high school or higher 2.32 (0.85-6.30)

CI = confidence interval; OR = odds ratio

Note: Additional study details presented in Appendix C evidence tables.

HPV

The IOM committee studied the HPV vaccine, which is administered to adolescents and young adults in the United States. Except where noted below, studies did not report specific AEs by age. The IOM committee found the evidence “favors acceptance” of a causal relationship between the HPV vaccine and anaphylaxis. The IOM committee found the evidence is “inadequate to accept or reject” causal relationships between the HPV vaccine and the following: ADEM, transverse myelitis, neuromyelitis optica, MS, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, brachial neuritis, amyotrophic lateral sclerosis, transient arthralgia, pancreatitis, thromboembolic events, and hypercoagulable states.

We found thirteen additional reports of trials of the HPV vaccine in children and adolescents; eleven¹⁸⁷⁻¹⁹³ were original trials, and two^{194,195} were longitudinal follow ups of clinical trials. Data from these studies are displayed in Table 25. Participants were between 7 and 27 years of age and received either placebo or three doses of vaccine (either Cervarix or Gardasil). The trials were conducted in North America, South America, Asia, Europe, Australia, and Africa. Most participants were female; one trial¹⁸⁷ with a later follow-up¹⁹³ was conducted in males. That trial found a significant association between vaccination with Gardasil and respiratory and thoracic disorders in the 15 days post-vaccination (OR 20.78, 95% CI 7.09, 60.89). One study of Gardasil¹⁹⁰ included only children with HIV; that trial found no AEs associated with vaccination.

A trial of 208 females in Korea¹⁹¹ found an association between Cervarix and medically significant adverse conditions (OR 1.94, 95% CI 1.23, 3.07). Cervarix was associated with the following Grade 3 (severe) adverse events: arthralgias (OR 2.68, 95% CI 1.29, 5.59), fatigue (OR 1.96, 95% CI 1.39, 2.77), GI symptoms (OR 2.41, 95% CI 1.39, 4.19), and rash (OR 2.67, 95% CI 1.23, 5.80). (In this study, Grade 3 events were defined as severe enough to prevent normal daily activity.)

A Cervarix trial conducted in Taiwan, Germany, Honduras, Panama, and Columbia¹⁹⁶ followed girls aged 10 to 14 for 48 months post-vaccination. The vaccine was not associated with serious adverse events in the short or long term. However, only girls who had received the vaccine were followed long term; therefore, there is no control group for the follow-up phase of the study, and long-term safety could not be evaluated versus control. A trial conducted in West Africa¹⁹⁷ did not find an association between Cervarix and onset of chronic disease (OR 0.49, 95% CI 0.29-1.23). A small trial (N = 67) in Bangladesh¹⁹⁸ found Cervarix associated with “any adverse event” in the five days after each of the three doses. Adverse events included fever, headache, GI symptoms, and injection site issues. The most common AE was pain at the injection site; this was reported by 50% of vaccinees after Dose 1 and 72% after Dose 2.

A strong association between Gardasil and “vaccine related adverse events” was found in a Korean trial.¹⁹⁹ during seven months follow-up. There was no difference in rate of serious AEs between vaccine and placebo group. Again, the most common AE was pain at injection site, reported by 72.6% of vaccinees.

We identified a secondary analysis²⁰⁰ of data on young black women enrolled in two double-blind placebo-controlled trials of Gardasil (N = 706) in North America, South America, and Europe. This report presented results separately for women who became pregnant within the follow-up period that ranged from three to four years; they comprised one quarter of the study participants. Receipt of vaccine was associated with spontaneous abortion (miscarriage): in the vaccine group 19 of 307 pregnancies resulted in spontaneous abortion, compared to seven of 393 pregnancies in the placebo groups. Of note, HPV vaccine is not recommended for pregnant

women. Study participants were required to be on birth control and were tested for pregnancy before each of the three required vaccinations. Anyone testing positive was excused from the study.

Table 25. Vaccinated versus unvaccinated adolescents: HPV vaccine

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Block S. L. et al., 2010 ¹⁸⁸ Asia, Europe, Latin America, North America	Controlled Clinical Trial	7	Sample size : 21,480, Mean age: NR, Age range: 9 - 26, Percent female: 94%	Human papillomavirus (HPV), Gardasil/Silgard, Merck, HPV-6/11/16/18, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 0 Days Dose2: 2 Month Dose3: 6 Month	Cardiac: OR 2.472 (0.257-23.766) Death: OR 1.295 (0.502-3.341) Discontinuation due to AE: OR 1.099 (0.596-2.025) Gastrointestinal: OR 1.648 (0.302-8.998) Infections/infestations: OR 1.295 (0.662-2.532) Injury/poisoning/procedural: OR 0.669 (0.398-1.123) Musculoskeletal/connective tissue: OR 0.412 (0.037-4.543) Neoplasms benign malignant, unspecified: OR 0.824 (0.052-13.172) Nervous system: OR 0.824 (0.238-2.846) Pregnancy/puerperium/perinatal: OR 0.736 (0.463-1.17) Psychiatric: OR 1.236 (0.206-7.397) Renal/urinary: OR 0.824 (0.116-5.849) Reproductive system/breast: OR 0.824 (0.206-3.294) Respiratory/thoracic/mediastinal: OR 1.03 (0.276-3.836) Vascular: OR 164.803 (0-178246427.81)
De Carvalho N. et al., 2010 ¹⁹⁴ Brazil	Controlled Clinical Trial, Follow-up	3	Sample size : 433, Mean age: 26.5, Percent female: 100%, Percent Pregnant: 9.5%	Human papillomavirus (HPV), Cervarix, GlaxoSmithKline, 20 µg of HPV-16 L1 virus-like particle and 20 µg of HPV-18 L1 virus-like particle. Each type of virus-like particle was produced on <i>Spodoptera frugiperda</i> Sf-9 and <i>Trichoplusia ni</i> Hi-5 cell substrate with AS04 adjuvant containing 500 µg aluminum hydroxide and 50 µg 3-deacylated monophosphoryl lipid A (MPL, Corixa, Montana, USA) provided in a monodose vial, Adjuvant: ASO 4-Aluminum, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 Month Dose3: 6 Month	Medically significant adverse event (any): OR 1.344 (0.641-2.816)

Table 25. Vaccinated versus unvaccinated adolescents: HPV vaccine (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Giuliano A. R. et al., 2011 ¹⁹³ 18 countries	Controlled Clinical Trial, follow-up	4	Sample size : 3,895, Mean age: 20.5, Age range: 15 - 27, Percent female: 0%	Human papillomavirus (HPV), Gardasil or Silgard, Merck, Quadrivalent HPV types 6, 11, 16, 18. Low-dose contained 20 ug type 6, 40 ug type 11, 40 ug type 16, 20 ug type 18, with 225 ug aluminum adjuvant. Adjuvant: Aluminum, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 2 Month Dose3: 6 Month	Death (entire study period): OR 0.3 (0.082-1.091)
Khatun S. et al., 2012 ¹⁹² Bangladesh	Controlled Clinical Trial	2	Sample size : 67, Mean age: 12, Age range: 9 - 13, Percent female: 100%	Human papillomavirus (HPV), Cervarix, GlaxoSmithKline, HPV16/18 ASO4-adjuvanted cervical cancer vaccine. Purified L1 VLPs of HPV16/18 at 20/20- g per dose formulated on ASO4 adjuvant comprising 500 gm of aluminum hydroxide and 50 gm of 3-deacylated monopods phage lipid A, Adjuvant: ASO 4, Preservative: Not reported, Delivery: Not reported	Dose1: 0 Days Dose2: 1 Month Dose3: 6 Month	Not calculable

Table 25. Vaccinated versus unvaccinated adolescents: HPV vaccine (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Kim S. C. et al.,2011 ¹⁹¹ Korea	Controlled Clinical Trial	8	Sample size : 208, Mean age: 22, Age range: 15 - 25, Percent female: 100%	Human papillomavirus (HPV), Cervarix, GlaxoSmithKline, HPV-16/18 contained 20 mcg each of HPV-16 and -18 L1 (structural protein of HPV) virus like particle, adjuvanted with the proprietary immunostimulant ASO4 adjuvant system (comprising 3-O desacyl-4(1)-MPL [50 mcg] adsorbed on aluminum hydroxide [Al(OH)3, 500 mcg]), Adjuvant: ASO 4-Aluminum, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 Month Dose3: 6 Month	Medical significant adverse condition: OR 1.942 (1.227-3.073)** New onset chronic diseases: OR 0.41 (0.199-0.846)** Solicited - Arthralgias (Grade 3): OR 2.682 (1.287-5.591)** Solicited - Fatigue (Grade 3): OR 1.959 (1.388-2.766)** Solicited - Fevers (Grade 3): OR 1.725 (0.355-8.377) Solicited - GI symptoms (Grade 3): OR 2.405 (1.381-4.19)** Solicited - Headache (Grade 3): OR 1.633 (1.101-2.422)** Solicited - Myalgia (Grade 3): OR 2.275 (1.582-3.272)** Solicited - Rash (Grade 3): OR 2.668 (1.228-5.8)** Solicited - Urticaria (Grade 3): OR 2.156 (0.608-7.651) Unsolicited - Breast and reproductive system: OR 2.651 (0.763-9.208) Unsolicited - Infections and infestations: OR 2.149 (0.927-4.983) Unsolicited - any AE (Grade 3): OR 0.078 (0.026-0.232)**
Levin M. J. et al.,2010 ¹⁹⁰ U.S. (not stated explicitly)	Controlled Clinical Trial	7	Sample size : 126, Mean age: NR, Age range: 7 - 12, Conditions: HIV	Human papillomavirus (HPV), Gardasil, Merck, Quadrivalent human papillomavirus (QHPV) (types 6, 11, 16, 18) recombinant vaccine, 0.5 mL, intramuscular, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 8 Weeks Dose3: 24 Weeks	Ear and eye and respiratory system: OR 0.305 (0.019-5.034) Laboratory abnormality: OR 0.935 (0.094-9.343) Systemic reactions: OR 0.617 (0.054-7.053)
Li R. et al.,2012 ¹⁸⁹ China	Controlled Clinical Trial	4	Sample size : 600, Mean age: 24.6, Age range: 9.0 - 45.8, Percent female: 83.3%	Human papillomavirus (HPV), Gardasil/Silgard, Merck, Says to see ref 19. But ref 19 is of a different trial where multiple formulations were used. Cannot ascertain useful information., Adjuvant: Not Reported, Preservative: Not Reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 2 Month Dose3: 6 Month	Systemic AE (any): OR 1.122 (0.81-1.553) Systemic AE (vaccine-related): OR 1.066 (0.747-1.522)

Table 25. Vaccinated versus unvaccinated adolescents: HPV vaccine (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Moreira Jr E. D. et al.,2011 ¹⁸⁷ 18 countries including Brazil, Germany, Mexico, U.S., South Africa, Australia, Canada	Controlled Clinical Trial	7	Sample size : 4,065, Mean age: NR, Age range: 16 - 26, Percent female: 0%	Human papillomavirus (HPV), Gardasil/Silgard, Merck, Quadrivalent HPV (type6/11/16/18) L1 VLP vaccine with amorphous aluminum hydroxyphosphate sulfate (AAHS) adjuvant, Adjuvant: Aluminum, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 2 Month Dose3: 6 Month	Death (entire study period): OR 0.3 (0.083-1.093) Dizziness(1-15 days): OR 1.061 (0.555-2.027) Gastrointestinal Disorders(1-15 days): OR 1.049 (0.81-1.359) General Disorders(1-15 days): OR 0.953 (0.761-1.194) Influenza (1-15 days): OR 0.958 (0.625-1.469) Injury, Poisoning and Procedural Complications(1-15 days): OR 1.259 (0.734-2.162) Musculoskeletal and Connective Tissue Disorders(1-15 days): OR 1.232 (0.844-1.801) Nasopharyngitis(1-15 days): OR 0.881 (0.585-1.328) Nervous System Disorders(1-15 days): OR 0.889 (0.729-1.084) Oropharyngeal pain(1-15 days): OR 1.032 (0.654-1.63) Pharyngitis(1-15 days): OR 1.106 (0.602-2.033) Respiratory, Thoracic And Mediastinal Disorders(1-15 days): OR 20.774 (7.088-60.889)** Skin And Subcutaneous Tissue Disorders(1-15 days): OR 0.84 (0.497-1.421) Upper respiratory tract infection(1-15 days): OR 1.361 (0.761-2.434) Discontinuation due to SAE (entire study period): OR 0.3 (0.083-1.093)
Roteli-Martins C. M. et al.,2012 ¹⁹⁵ Brazil	Controlled Clinical Trial, follow-up	NC	Sample size : 436, Mean age: 26.5, Age range: 15 - 25, Percent female: 100%, Percent Pregnant: 17%	Human papillomavirus (HPV), HPV-16/18, GlaxoSmithKline, Described in another study, Adjuvant: ASO 4, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 Month Dose3: 6 Month	Medically Significant Adverse Events: OR 1.721 (0.998-2.97) New Onset Autoimmune Disease: OR 0.955 (0.133-6.84) New Onset Chronic Disease: OR 2.42 (0.464-12.609) Serious Adverse Events: OR 1.382 (0.516-3.699)

Table 25. Vaccinated versus unvaccinated adolescents: HPV vaccine (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Schwarz, T.F. et al. 2012 ¹⁹⁶ Taiwan, Germany, Honduras, Panama, and Colombia	Controlled Clinical Trial	NC	Sample size : 588, Mean age: 12, Percent female: 100%, Percent pregnant: Percent Pregnant: 5%	Human papillomavirus (HPV) , HPV-16/18 AS04-adjuvanted vaccine, GlaxoSmithKline, Each dose of the HPV-16/18 vaccine consisted of 20 ⑧g each of HPV-16 and HPV-18 L1 proteins, self-assembled as virus-like particles, adjuvanted with the Adjuvant System AS04 (comprising 500 ⑧g of aluminum hydroxide and 50⑧g of MPL), Adjuvant: ASO4, Preservative: Not reported, Delivery: Not reported	Dose1: 0 Days Dose2: 1 Month Dose3: 6 Month	New onset chronic disease: OR 2.822 (1.818-4.38)**
Sow, P. S. et al. 2013 ¹⁹⁷ Senegal, Tanzania	Controlled Clinical Trial	5	Sample size : 676, Mean age: 16.9, Age range: 10 - 25, Percent female: 100%	Human papillomavirus (HPV) , Cervarix , GlaxoSmithKline, Each dose of HPV-16/18 AS04-adjuvanted vaccine Cervarix ® (GlaxoSmithKline Vaccines) contained 20 µg each of HPV-16 and HPV-18 L1 virus like particles, 50 µ g of 3-O-desacyl-4'- monophosphoryl lipid A, and 500 µ g of Al(OH)3, Adjuvant: Aluminum, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 Month Dose3: 5 Month	Medically significant condition: OR 0.745 (0.518-1.07) New onset autoimmune disease: OR 0.5 (0.07-3.573) New onset chronic disease: OR 0.49 (0.209-1.148) SAE: OR 0.595 (0.288-1.229)

Table 25. Vaccinated versus unvaccinated adolescents: HPV vaccine (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Khatun, S. et al. 2012 ¹⁹⁸ Bangladesh	Controlled Clinical Trial	4	Sample size : 67, Mean age: NR, Age range: 9 - 13, Percent female: 100%	Human papillomavirus (HPV), Cervarix , GlaxoSmithKline , In this preparation, the L1 protein of each HPV type is expressed via a recombinant baculo virus vector. The VLPs of each HPV type are produced separately and consist of purified L1 VLPs of HPV-16/18 at 20/20-g per dose formulated on AS04 adjuvant comprising 500 gm of aluminum hydroxide and 50 gm of 3-deacylated monopods phage lipid ., Adjuvant: ASO 4 , Preservative: Not reported, Delivery: Not reported	Dose1: 0 Days Dose2: 1 Dose3: 6	Any AE after 1st dose: OR 16 (4.043-63.326)** Any AE after 2nd dose: OR 53.778 (9.89-292.432)** Any AE after 3rd dose: OR 81 (12.938-507.104)**
Kang, S. et al. 2008 ¹⁹⁹ Korea	Controlled Clinical Trial	4	Sample size : 176, Mean age: 16.6, Age range: 9 - 23, Percent female: 100%	Human papillomavirus (HPV) , Gardasil , Merck , Mixture of four recombinant HPV type-specific VLPs consisting of the L1 major capsid proteins of HPV 6,11, 16, and 18 synthesized in <i>Saccharomyces cerevisiae</i> . The four VLP types were purified and adsorbed onto amorphous aluminum hydroxyphosphate sulfate adjuvant. , Adjuvant: Aluminum , Preservative: Not reported , Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 Month Dose3: 6 Month	Vaccine related AE: OR 154.063 (20.474-1159.27)**

Table 25. Vaccinated versus unvaccinated adolescents: HPV vaccine (continued)

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Clark, L.R. et al. 2013 ²⁰⁰ Europe, Latin America, North America	Controlled Clinical Trial. Long-term follow-up	3	Sample size : 700, Mean age: 20, Age range: 16 - 24, Percent female: 100%, Percent pregnant: Percent Pregnant: 25%	Human papillomavirus (HPV) , Not reported. Quadrivalent vaccine targeting HPV-6/11 , Gardasil, Merck Sharp & Dohme, Corp. , Quadrivalent vaccine targeting HPV-6/11/16/18 , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Intramuscular	Dose1: 0 Days Dose2: Month 2 Dose3: Month 6	Abnormal live birth: OR 0.766 (0.182-3.23) Congenital or other anomaly - live birth: OR 1.281 (0.08-20.564) Number of fetal losses: OR 7.876 (2.694-23.025)** One or more injection-site AE: OR 1.384 (1.024-1.871)** One or more systemic AE: OR 1.362 (0.988-1.876) Spontaneous abortion: OR 0.798 (0.44-1.447) Vaccine-related systemic AE: OR 1.414 (0.977-2.046)

AAHS = amorphous aluminum hydroxyphosphate sulfate; AE = adverse event; Al(OH)₃ = aluminium hydroxide; CI = confidence interval; GI = gastrointestinal; HIV = human immunodeficiency virus; HPV = human papillomavirus; MPL = monophosphoryl lipid; OR = odds ratio; QHPV = quadrivalent human papillomavirus; SAE = serious adverse events

**Statistically significant.

Note: Additional study details presented in Appendix C evidence tables.

We found three postmarketing studies of HPV in adolescents / young adults published after the IOM report and one long-term follow-up of trial participants. Data from the studies are presented in Table 26.

Various Illnesses

Between August 2006 and March 2008, Chao et al. (2012)²⁰¹ followed 189,629 females, aged 9 to 26 years, who had received the HPV vaccine from two MCOs. Immunization with HPV vaccine was ascertained by a review of health records and health outcomes were identified through electronic health records followed by in-depth case review by a panel of experts. Data were analyzed to generate incidence rate ratio (IRR) estimates of onset of select autoimmune conditions in the vaccinated group compared to unvaccinated female populations of similar age. Vaccinated patients had a significantly lower incidence of juvenile rheumatoid arthritis (IRR 0.36, 95% CI 0.14, 0.71) and Type 1 diabetes (IRR 0.54, 95% CI 0.45, 0.70), they had a higher incidence of Hashimoto's disease (IRR 2.02, 95% CI 1.65, 2.60); the authors report that an investigation of a temporal relationship and biological plausibility revealed no consistent evidence of a safety signal.

Gee et al. (2011)²⁰² studied the administration of 600,558 doses of HPV4 in females age 9 to 26 years in seven large MCOs between August 2006 and October 2009. Vaccination status and health outcomes were confirmed using weekly standardized data files from participating MCOs. Case ascertainment was limited to the first episode in a particular time period. Data were analyzed using Poisson based maximized sequential probability ratio test (MaxSPRT) and a logistic regression model (appendicitis only). The logistic regression was adjusted for sex, age, and seasonality. No statistically significant increased risk for any of the pre-specified adverse events (appendicitis, Guillain Barré Syndrome, seizures, stroke, syncope, venous thromboembolism) was detected after vaccination.

Klein and colleagues²⁰³ analyzed data from enrollees in a California MCO who had received either Gardasil or Cervarix. Over 44,000 females received all three recommended doses. Fifty medical categories had significantly elevated ORs during at least one risk interval. Patient chart review found that most diagnoses existed before vaccination or that diagnostic workups were initiated at vaccine visit. Experts judged that only skin infections within two weeks of vaccine (OR, 1.8; 95% CI, 1.3-2.4) and syncope on day of vaccination (OR, 6.0; 95% CI, 3.9-9.2) were likely associated with the vaccine.

Summary

Short term adverse events including fever, headache, GI symptoms, and injection site issues were associated with HPV vaccine consistently in double-blind placebo-controlled trials. The most common adverse event was pain at the injection site; strength of evidence is high for this association due to the overwhelming consistency of results. Strength of evidence is moderate for the others listed.

A large high quality post-licensure study conducted in the U.S. found that HPV vaccine was associated with skin infection within two weeks and syncope on day of vaccination. SOE is moderate due to low risk of bias and strong study design.

The IOM found evidence “favors acceptance” of a causal relationship between the HPV vaccine and anaphylaxis in children and adolescents who may be allergic to ingredients. Our review of the IOM supports this finding; thus, strength of evidence is rated moderate.

We found moderate strength evidence that HPV vaccine is not associated with onset of juvenile rheumatoid arthritis or Type 1 diabetes. Although we identified only one post-licensure study on these diseases, the study included hundreds of thousands of doses and used computerized medical records to confirm vaccination and outcomes. We found insufficient evidence that HPV vaccine may be associated with onset of Hashimoto's disease, as the one study that investigated a temporal relationship and biological plausibility revealed no consistent evidence of a safety signal.

Strength of evidence is moderate that HPV vaccine is not associated with appendicitis, Guillain Barré Syndrome, seizures, stroke, or venous thromboembolism, based on a well-designed study of over 600,000 doses administered to patients in US HMOs.

A secondary analysis of long-term follow-up data on young black women who participated in two controlled trials of HPV vaccine reported an association with spontaneous abortion of pregnancies within three to four years of vaccination. There is insufficient evidence to conclude causality; however, this signal should be investigated in other data sets.

The IOM found that the evidence is “inadequate to accept or reject” causal relationships between HPV vaccine and the following: ADEM, transverse myelitis, neuromyelitis optica, MS, chronic inflammatory demyelinating polyneuropathy, brachial neuritis, amyotrophic lateral sclerosis, transient arthralgia, pancreatitis, thromboembolic events, and hypercoagulable states. We reviewed their findings and agree with their conclusions. Thus, strength of evidence is rated insufficient to determine association of these sequelae with vaccination.

Table 26. Postmarketing studies of HPV vaccine in children and adolescents

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Chao et al. 2012 ²⁰¹ Prospective cohort	N=189,629 females who received HPV Age=9–26 years; Setting=Two managed care organizations in California	HPV4 - Gardasil	Not reported	Incidence rate ratio (IRR) and 95% confidence interval (CI) of select autoimmune conditions in the vaccinated vs. non-vaccinated female populations of similar age in Kaiser Permanente Southern California Rheumatologic/autoimmune: Immune thrombocytopenia: 1.24 (0.91–2.02) Systemic lupus erythematosus: 1.10 (0.71–1.66) Rheumatoid arthritis: 0.70 (0.41–1.60) Juvenile rheumatoid arthritis: 0.36 (0.14–0.71) Autoimmune hemolytic anemia - excluded Endocrine: Type 1 diabetes: 0.54 (0.45–0.70) Hashimoto's disease: 2.02 (1.65–2.60) Graves' disease: 0.76 (0.42–1.10) Neurological/ophthalmic: Multiple sclerosis: 1.37 (0.74–3.20) Other demyelinating diseases of central nervous system: 0.71 (0.38–2.13) Optic neuritis: 1.45 (1.00–2.91) Uveitis: 1.28 (0.53–6.39)	Not reported
Gee et al. 2011 ²⁰² Prospective cohort	N=600,558 doses of HPV4; Females age 9–26 years in 7 large managed care organizations (MCOs) in U.S.	HPV4 - Gardasil	Logistic regression: sex, age, and seasonality	No statistically significant increased risk for any of the pre-specified adverse events (Appendicitis, Guillain Barré Syndrome, Seizures, Stroke, Syncope, Venous Thromboembolism) after vaccination was detected.	Not reported

Table 26. Postmarketing studies of HPV vaccine in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Klein, et al. 2012, ²⁰³ , Retrospective cohort	N=189,629; Location=California; Age=9-26 years; Setting=Kaiser Permanente in California	HPV4 - Gardasil	None	<p>ORs Following HPV4 Vaccination in the Combined ED/Hospital Setting, All Doses Combined</p> <p>Viral infection Days 1-60 Risk Interval: 1.1 (0.9-1.3) Days 1-14 Risk Interval: 1.5 (1.2-2.0)</p> <p>Attention-deficit, conduct, and disruptive behavior disorders Days 1-60 Risk Interval: 1.5 (1.2-2.0) Days 1-14 Risk Interval: 1.5 (1.0-2.3)</p> <p>Disease of nervous system and sense organs Days 1-60 Risk Interval: 1.0 (0.9-1.1) Days 1-14 Risk Interval: 1.2 (1.0-1.3)</p> <p>Ear conditions Days 1-60 Risk Interval: 1.2 (1.0-1.5) Days 1-14 Risk Interval: 1.5 (1.1-1.9)</p> <p>Disorders of peripheral nervous system Days 1-60 Risk Interval: 2.1 (1.0-4.2) Days 1-14 Risk Interval: 2.1 (0.8-5.7)</p> <p>Diseases of circulatory system Days 1-60 Risk Interval: 1.1 (1-1.3) Days 1-14 Risk Interval: 1.2 (1.0-1.5)</p> <p>Diseases of heart Days 1-60 Risk Interval: 1.1 (0.1-1.3) Days 1-14 Risk Interval: 1.3 (1.0-1.6)</p> <p>COPD and bronchiectasis Days 1-60 Risk Interval: 1.5 (1-2.2) Days 1-14 Risk Interval: 1.8 (1.1-3.2)</p>	None

Table 26. Postmarketing studies of HPV vaccine in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				<p>Asthma Days 1-60 Risk Interval: 1.2 (1.1-1.4) Days 1-14 Risk Interval: 1.21 (1-1.47)</p> <p>Disease of skin and subcutaneous tissue Days 1-60 Risk Interval: 1.0 (0.8-1.1) Days 1-14 Risk Interval: 1.5 (1.2-1.9)</p> <p>Skin and subcutaneous tissue infections Days 1-60 Risk Interval: 1.1 (0.9-1.4) Days 1-14 Risk Interval: 1.8 (1.3-2.4)</p> <p>Cellulitis and abscess Days 1-60 Risk Interval: 1.1 (0.8-1.4) Days 1-14 Risk Interval: 1.6 (1.2-2.3)</p> <p>Diseases of musculoskeletal system and connective tissue Days 1-60 Risk Interval: 1.1 (1-1.2) Days 1-14 Risk Interval: 1.2 (1.0-1.4)</p> <p>Spondylosis, disc intervertebral disorders, back problems Days 1-60 Risk Interval: 1.1 (0.9-1.3) Days 1-14 Risk Interval: 1.4 (1.0-1.8)</p> <p>Congenital anomalies Days 1-60 Risk Interval: 1.6 (1.1-2.3) Days 1-14 Risk Interval: 2.5 (1.6-4.0)</p> <p>Other congenital anomalies Days 1-60 Risk Interval: 1.8 (1.1-3.0) Days 1-14 Risk Interval: 3.6 (2.0-6.3)</p> <p>Fever of unknown origin Days 1-60 Risk Interval: 1.1 (0.9-1.4) Days 1-14 Risk Interval: 1.5 (1.0-2.1)</p>	

Table 26. Postmarketing studies of HPV vaccine in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				<p>Lymphadenitis Days 1-60 Risk Interval: 1.0 (0.6-1.8) Days 1-14 Risk Interval: 2.3 (1.2-4.4)</p> <p>Diabetes mellitus Days 1-60 Risk Interval: 2.2 (1.1-4.4) Days 1-14 Risk Interval: 2.5 (1.0-6.4)</p> <p>Attention-deficit disorder Days 1-60 Risk Interval: 1.7 (1.1-2.8) Days 1-14 Risk Interval: 2.1 (1.1-4.1)</p> <p>Personality disorders Days 1-60 Risk Interval: 1.8 (0.9-3.4) Days 1-14 Risk Interval: 2.8 (1.3-6.4)</p> <p>Disorders of teeth and jaw Days 1-60 Risk Interval: 1.1 (0.6-2.1) Days 1-14 Risk Interval: 2.6 (1.2-5.6)</p> <p>Congenital anomalies Days 1-60 Risk Interval: 1.7 (1.0-2.8) Days 1-14 Risk Interval: 2.7 (1.4-5.3)</p> <p>Other congenital anomalies Days 1-60 Risk Interval: 2.3 (1.1-5.0) Days 1-14 Risk Interval: 5.1 (2.2-11.9)</p>	

CI = confidence interval; HPV = human papillomavirus; IRR = incidence rate ratio; MCOs = managed care organizations

Note: Additional study details presented in Appendix C evidence tables.

Varicella

The IOM committee found evidence “convincingly supports” causal relationships in children between varicella virus vaccine and the following: disseminated Oka VZV without other organ involvement; disseminated Oka VZV with subsequent infection resulting in pneumonia,²⁰⁴ meningitis, or hepatitis in individuals with demonstrated immunodeficiencies; vaccine strain viral reactivation without other organ involvement; vaccine strain viral reactivation with subsequent infection resulting in meningitis or encephalitis;²⁰⁵ and anaphylaxis.²⁰⁴

The IOM committee found the evidence is “inadequate to accept or reject” a causal relationship between the varicella virus vaccine and the following: seizures, ADEM, transverse myelitis, Guillain-Barré syndrome, small fiber neuropathy, onset or exacerbation of arthropathy, and thrombocytopenia.

We found one new study in children (Table 27). Barbosa, 2012²⁰⁶ randomized 54 Brazilian children with systemic lupus erythematosus (SLE) to placebo or vaccine, and also vaccinated 28 healthy children who were matched controls. The authors reported no difference in AEs between placebo and control groups. Data on specific AEs was not provided.

Summary

Based on our review of the IOM findings, there is high strength evidence that vaccination of immunocompromised children against varicella is associated with disseminated Oka VZV with or without subsequent infection resulting in pneumonia,²⁰⁴ meningitis, or hepatitis. There is insufficient evidence regarding association of varicella virus vaccine and seizures, ADEM, transverse myelitis, Guillain-Barré syndrome, small fiber neuropathy, onset or exacerbation of arthropathy, and thrombocytopenia.

Based on one small controlled trial of vaccine in Brazilian children, there is insufficient evidence to determine whether varicella vaccine is safe in children with SLE.

Table 27. Vaccinated versus unvaccinated children and adolescents: varicella vaccine

Author- Year- Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Barbosa, C.M..et al. 2012 ²⁰⁶ Brazil	Controlled Clinical Trial	4	Sample size : 134, Mean age: 15, Age range: 5 - 18, Percent female: 78%	Varicella, Biken, Aventis Pasteur, >=1000 plaque forming units of virus/0.5 mL. Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days	Incalculable. Authors stated no difference in AEs

CI = confidence interval; HIV = human immunodeficiency virus; OR = odds ratio; NR = not reported

Note: Additional study details presented in Appendix C evidence tables.

Diphtheria Toxoid, Tetanus Toxoid, and Acellular Pertussis-Containing Vaccines

The IOM studied diphtheria toxoid, tetanus toxoid, and acellular pertussis-containing vaccines alone and in combination, in both children and adults. The IOM committee did not find evidence that “favors acceptance” of causal relationships for any conditions. They found the evidence “favors rejection” of a causal relationship between type 1 diabetes and vaccines containing diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens.²⁰⁷⁻²¹¹ The IOM committee found the evidence is “inadequate to accept or reject” causal relationships between diphtheria toxoid-, tetanus toxoid- or acellular pertussis-containing vaccine and the following: infantile spasms; seizures; cerebellar ataxia; autism; ADEM; transverse myelitis; MS relapse in children; serum sickness; immune thrombocytopenic purpura; and SIDS.

We found no additional studies in children published after the IOM search date; our review of their findings leads to a rating of moderate strength of evidence for each of the associations they investigated.

Meningococcal Vaccine

The IOM found the evidence “convincingly supports” a causal relationship with anaphylaxis in children who may be allergic to ingredients. The committee found the evidence “inadequate to accept or reject” causal relationships between meningococcal vaccine and the following: encephalitis, encephalopathy, ADEM, transverse myelitis, MS, Guillain-Barré syndrome, CIDP, and chronic headache. The IOM conclusion does not differentiate between meningococcal conjugate or meningococcal polysaccharide vaccine.

We found two studies of quadrivalent meningococcal conjugate vaccine in children (Table 28)^{212,213} published after the IOM report. A trial in Saudi Arabia found no statistical association with Grade 2 or 3 fever, malaise, myalgia or headache in the short term. A trial in the United States and South America²¹³ found vaccination was not associated with severe change in eating habits, severe irritability, severe persistent crying, severe sleepiness or urticaria in the year following vaccination. Per the findings of the IOM, strength of evidence is moderate that meningococcal vaccine may cause anaphylaxis in children who are allergic to ingredients. Strength of evidence is insufficient to determine an association between meningococcal vaccine and the serious adverse events encephalitis, encephalopathy, ADEM, transverse myelitis, MS, Guillain-Barré syndrome, CIDP, and chronic headache. Strength of evidence is insufficient to determine association with less serious events such as headache, irritability, and urticaria.

Table 28. Vaccinated versus unvaccinated studies of meningococcal vaccines in children and adolescents

Author-Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Khalil, M. et al. 2012 ²¹² Saudi Arabia	Controlled Clinical Trial	4	Sample size : 238, Mean age: 6.3, Age range: 5 - 8, Percent female: 55.0%	Meningococcal conjugate , Menactra, PA , Sanofi , Quadrivalent (A, C, Y, and W-135) meningococcal diphtheria toxoid-conjugate vaccine , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Intramuscular	Dose1: 0 Days	Grade 2-3 Fever: OR 1.508 (0.389-5.842) Grade 2-3 Headache: OR 1.113 (0.099-12.453) Grade 2-3 Malaise: OR 4.027 (0.487-33.3) Grade 2-3 Myalgia: OR 2.255 (0.248-20.507) SAE - Headache (unsolicited AE): OR 0.553 (0.034-8.949)
Klein, N.P. et al. 2012 ²¹³ U.S., Colombia, Argentina	Controlled Clinical Trial	2	Sample size : 1508, Mean age: 65.5, Age range: 55 - 89, Percent female: 47.8%	Meningococcal conjugate, Routine Vaccines , NR (likely Novartis, the trial sponsor) , Lyophilized Men A component with liquid MenC/W/Y component, Each dose contained 10micrograms of MenA oligosaccharides and 5microgram each of MenC, MenW-135, and MenY conjugated to CRM197 (~50microgram) , Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 2 Month Dose3: 2 Month	Severe change in eating habits (12m): OR 3.574 (0.439-29.129) Severe change in eating habits (6m): OR 0.507 (0.102-2.519) Severe irritability (12m): OR 0.675 (0.233-1.955) Severe irritability (6m): OR 3.06 (0.367-25.49) Severe persistent crying (12m): OR 0.761 (0.214-2.707) Severe sleepiness (12m): OR 0.507 (0.102-2.519) Severe sleepiness (6m): OR 3.06 (0.367-25.49) Urticaria (12m): OR 0.507 (0.102-2.519) Urticaria (6m): OR 0.888 (0.259-3.048)

CI = confidence interval; NR = not reported; OR = odds ratio

Note: Additional study details presented in Appendix C evidence tables.

Studies of Multiple Vaccines

Allergies/Asthma

We identified five postmarketing studies on allergic symptoms, wheezing, or asthma, that were not included in the IOM report. These, along with all studies of multiple vaccines in children, are displayed in Table 29. A study in the Netherlands using parent questionnaires to ascertain vaccination status and health outcomes found no association between receipt of a combined DTP-IPV vaccine and asthma, hay fever, eczema, food allergy or atopic disorders (Bernsen, 2006).²¹⁴ A case-control study of over 2,000 children with atopic dermatitis and a family history of allergy in twelve Western countries (Gruber, 2008)²¹⁵ found newborns immunized against polio had higher odds (OR 2.60, 95% CI 1.08, 6.25) of sensitivity to food allergens. This relationship did not hold for those immunized against polio later in life. The study also found that a significant relationship between Hepatitis B vaccine in the first 6 months of life with elevated total IgE (OR 1.48, 95% CI 1.03, 2.13). Varicella vaccine seemed to have a protective effect against elevated total IgE. A German study (Mommers, 2004)²¹⁶ found no relationship between vaccination against pertussis, measles, rubella, or Hib and atopic disease. A self-controlled case series of premature infants born in the United States (Mullooly, 2007)²¹⁷ found no increased risk of wheezing and lower respiratory syndrome associated with DTaP, inactivated polio virus (IPV), Hib, varicella, PCV7, MMR, or TIV vaccination. In fact, some of the vaccines had a protective effect in the week after vaccination. Finally, Thomson²¹⁸ found no association of MMR vaccine with asthma in an Australian cohort. (Two diphtheria-tetanus vaccines not currently used in the United States were also studied; no association with asthma was found.)

Seizures

Sun, 2012²¹⁹ examined national registry data on over 378,000 children who received a combined DTaP-IPV-Hib vaccine in Denmark from 2003-2009. They assessed the association of vaccination with febrile seizures, controlling for birth circumstances, demographics, and family history of epilepsy. In both a cohort analysis and self-controlled case series (SCCS), risk of febrile seizures on the day of vaccination was significant (cohort – first vaccination, HR 6.02, 95% CI 2.86, 12.65; cohort – second vaccination, HR 3.94, 95% CI 2.18, 7.10; SCCS - first vaccination, HR 6.49, 95% CI 3.10, 13.61; SCCS – second vaccination, HR 3.97, 95% CI 2.20, 7.16). An American study (Chen, 1997)²²⁰ investigated the relationship between DTP and MMR vaccines and seizures in children from four HMOs in the United States. For DTP, the relative risk for seizures was elevated on the day of vaccination (RR 2.20, 95% CI 1.50, 3.40). For MMR, the risk was elevated on days 4 to 7 (RR 1.80, 95% CI 1.20, 2.70) and 8 to 14 (RR 2.50, 95% CI 2.20, 3.30) after vaccination. The authors also investigated the relationship between Td vaccination and emergency department visit or hospitalization. They found that risk of emergency department visit was elevated within 14 days of vaccination.

Gold, 2010²²¹ also studied the relationship between DTP and MMR vaccines and seizures. They used Australian registry data and medical records to ascertain vaccination status and health outcomes. For MMR, the risk for seizures was elevated between days 6 to 11 after exposure (IRR 2.11 95% CI 1.43, 3.10). For DTP, the risk was not elevated during any time period studied.

Bell's Palsy

A small self-controlled case series of 233 Bell's Palsy cases in Northern California (Rowhani, 2012)²²² found no association with vaccination with TIV or Hepatitis B vaccine.

Guillain-Barre Syndrome (GBS)

Velentgas and colleagues²²³ were tasked with investigating the association between meningococcal conjugate vaccine and GBS in children and adolescents enrolled in five MCOs in the United States. Between March 2005 and August 2008, there were no reported cases of GBS within 42 days following vaccination with MCV4. The same was true for Tdap, Td, and Tetanus vaccination. There was one case each for MPSV4 and HPV; there were two cases reported for TIV and Hepatitis B vaccine. The authors calculated the attributable risks per one million vaccinations as displayed in Table 29 below.

Leukemia

Groves and colleagues²²⁴ included 439 children in nine Midwest and Mid-Atlantic states with lymphoblastic leukemia in a case-control analysis to investigate any possible relationship with oral or injected polio vaccine, diphtheria-tetanus pertussis vaccine, MMR, Hib, or Hepatitis B vaccine. Controls were selected using random-digit dialing, which resulted in controls of higher SES than the 439 cases. Analysis controlled for age at censoring, year of birth, sex, race, family income, parental education and attendance at daycare and/or preschool. Data collection forms were completed by mothers using vaccination records. None of the vaccines were associated with leukemia.

The relationship between vaccination and leukemia was also assessed in a case-control study of children enrolled in a large HMO in Northern California. (Ma, 2005)²²⁵ Cases were matched on date of birth, sex, and race / ethnicity. Analysis also controlled for maternal education and family income. Vaccination and diagnosis were ascertained through medical records. None of the vaccines investigated (DPT, polio vaccine, MMR, Hib, Hepatitis B vaccine) were associated with increased risk of leukemia.

The Cross-Canada Childhood Leukemia Study (MacArthur, 2008)²²⁶ was a case control study which found no association between vaccines against mumps, measles, rubella, diphtheria, tetanus, pertussis, polio, or Hepatitis B and leukemia. Vaccinations were administered from 1990 to 1994. Data was acquired through population registries. Analysis adjusted for maternal education, annual household income, ethnicity, maternal age at birth, and number of residences since birth. Multivariate models relied on strata formed by the following matching factors: province, gender, and age.

Finally, a case-control study of over 14,000 children born in Texas (Pagaoa, 2011)²²⁷ found no association between DTaP, IPV, MMR, Hib, Hepatitis B, and Varicella vaccines and acute lymphoblastic leukemia using data from cancer registry and medical records. Analysis adjusted for sex, child's birth year, child's ethnicity, child's birth weight, mother's age at child's birth.

Diabetes

Hummel²²⁸ conducted a secondary analysis of data from the BABYDIAB study in Germany to investigate the possible association of many factors (breast feeding, vaccinations, environmental, infections) and development of islet antibodies before the age of two. They included vaccines for Hib, measles, mumps, and rubella (separately) in their analyses; no association with the vaccines was found.

Purpura

A recent analysis investigated possible relationships between Hib, PCV, MMR, DTaP, TIV, Hepatitis A, varicella, and meningococcal vaccines and immune thrombocytopenic purpura (ITP) in children enrolled in five U.S. HMOs. (O’Leary, 2012)¹⁴³ In children from 12 to 19 months of age, MMR vaccine was associated with purpura (IRR 5.48, 95% CI 1.61, 18.64). None of the vaccines were associated with purpura in children aged two to six years. Purpura was associated with vaccination against Hepatitis A in children aged 7 to 17 years (IRR 23.14, 95% CI 3.59, 149.30) and a vaccination against varicella in children aged 11 to 17 years (IRR 12.14, 95% CI 1.10, 133.96).

Encephalitis

Pahud, 2012 investigated whether various factors were associated with encephalitis in California children and adolescents.²²⁹ Of 1,434 cases, immunization records were requested for over 800 and received for only 246. Of these, 136 were excluded due to incomplete records or no vaccinations in the one-year observation period. In the 110 encephalitis cases included, there was no association with either measles virus-containing vaccines or pertussis antigen-containing vaccines.

Summary

Strength of evidence is insufficient to determine an association between polio vaccine in newborns and sensitivity to food allergens. Strength of evidence is also insufficient to determine an association between Hepatitis B vaccine in the first 6 months of life and elevated total IgE. Strength of evidence is based on associations reported in one medium size study (N = 2,173) of children with a family history of food allergy living in 12 countries in multiple continents.

Strength of evidence of association of DTaP-IPV-Hib vaccination with febrile seizures in children in the short-term is moderate, based on a very large, high quality study.

There is high strength evidence that MMR, DTaP, Td, Hib, Hepatitis B, and polio vaccine vaccinations are not associated with childhood leukemia.. This rating is based on four high quality case-control studies that consistently found no association. All studies had low risk of bias and adjusted for important confounders in their analyses.

In the short-term, purpura was associated with vaccination against Hepatitis A in children aged 7 to 17 years, vaccination against varicella in children aged 11 to 17, and MMR in children from 12 to 19 months of age. Strength of evidence is moderate. Cases were rare (one or two per age group), and the majority were mild.

Table 29. Postmarketing studies of multiple vaccines in children and adolescents

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Bernsen et al. 2006 ²¹⁴ Retrospective Cohort	N=1,875; Location=Netherlands; Age=8-12 years; Setting=Orthodox Reformed (Protestant) primary schools	DTP-IPV (diphtheria-tetanus-pertussis-(inactivated) poliomyelitis vaccination)	A variable was included in the multivariate model if it changed the univariate point estimate by at least 10%. Following confounders were assessed: Season of birth; Birth order; Gender; Gestational age; Birth weight; Age of the mother at the time of delivery; Exposure to smoking (prenatally, during the first year of life and currently); Breast feeding for four months or more (yes/no); Housing in the first year of life (rural and living on a farm with livestock/rural, other/city); Pet keeping (furry pets or birds yes/no) during the first year of life and currently; Day care starting at age 6 months or less (yes/no); Current age; Asthma and/or allergy of the parents and/or siblings; Highest educational level of the parents; Family income; Current level of urbanization (five levels); Living on a farm with livestock (yes/no); Sibship size; Mold in the child's bedroom in the past year; Frequent (more than 5 days/week) consumption of fruit (yes/no) (raw or cooked) vegetables (yes/no) anti-oxidants (yes/no); unskimmed dairy products (yes/no) wholegrain bread (yes/no); Frequent (at least 1 day/week) consumption of fish; Frequent exercise (school gym at least once a week and playing games with physical activity for at least half an hour a day and either being a member of a sporting club or	OR (95% CI) for Atopic disorders Asthma: 1.04 (0.76–1.42) Hay fever: 0.79 (0.55–1.12) Eczema: 0.87 (0.66–1.14) Food allergy: 1.13 (0.71–1.81) Any atopic disorder: 1.00 (0.80–1.24) OR (95% CI) for Physician diagnosed atopic disorders Asthma: 1.03 (0.72–1.46) Hay fever: 1.06 (0.59–1.90) Eczema: 0.96 (0.73–1.25) Food allergy: 1.13 (0.71–1.81) Any atopic disorder: 1.04 (0.82–1.31)	Not reported

Table 29. Postmarketing studies of multiple vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
			walking or cycling from home to school vice versa for at least 1 h a day); Body mass index; Hib vaccination.		
Gruber et al. 2008 ²¹⁵ Retrospective cohort	N=2,173 (cases with atopic dermatitis and family history of allergy); Location=12 countries, Australia, Austria, Belgium, Czech Republic, France, Germany, Italy, the Netherlands, Poland, South Africa, Spain, and the UK; Age=1-2 years; Setting=97 study centers in 10 European countries, South Africa and Australia	Diphtheria, tetanus, pertussis, polio, <i>Haemophilus influenzae</i> Type B, Hepatitis B, mumps, measles, rubella, varicella, BCG, meningococci and pneumococci	Total assessed: country, age, gender, birth weight, maternal age, family history of atopy, presence of siblings, breastfeeding, parental smoking, day care, exposure to pet animals and SCORAD total index	OR (95% CI) for IgE-sensitivity to aeroallergens Infants immunized against Hepatitis B at birth were less likely to be IgE-sensitized to aeroallergens (adjusted Hepatitis B at birth: 0.54 (0.32, 0.90)) Hepatitis B immunization later on in life: NS OR (95% CI) for sensitivity to food allergens Newborns immunized against polio: 2.60 (1.08–6.25.) Immunization against polio later in life: NS OR (95% CI) for elevated total IgE Hepatitis B vaccine (first 6 months): R 1.48 (1.03–2.13), (0.12–0.93)	Not reported
Mommers et al. 2004, ²¹⁶ Case-control	N=510; Location=Dutch-German borderland; Age=7-8 years; Setting=Study on respiratory health in children conducted in the Dutch-German borderland, involving the Municipal Health Services of Kreis Heinsberg,	Bacille Calmette-Guérin (BCG), pertussis, measles/mumps, rubella, and <i>Haemophilus influenzae</i> type b (Hib)	Gender, birth order, country of residence, socioeconomic status, breastfeeding, exposure to environmental tobacco smoke, home dampness, pets, and childhood infections (measles, mumps, rubella, varicella, and scarlet fever). Analyses stratified according to country of residence or respiratory status were additionally performed.	Odds Ratios and 95% Confidence Intervals for Association Between Risk Factors and Atopic Disease Pertussis Respiratory symptoms 0.83 (0.45–1.52) Allergic sensitization 0.89 (0.47–1.70) Sensitized against grasses 0.84 (0.38–1.84) Sensitized against HDM 1.02 (0.46–2.25) Measles	Gender (male vs. female) Respiratory symptoms 1.68 (1.13–2.49) Allergic sensitization 2.68 (1.76–4.09) Sensitized against grasses 3.44 (2.05–5.76) Sensitized against HDM 2.90 (1.69–4.96) Birth order Only younger siblings

Table 29. Postmarketing studies of multiple vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
	Germany and of the Westelijke Mijnstreek, the Netherlands			Respiratory symptoms 0.93 (0.30–2.90) Allergic sensitization 1.51 (0.43–5.35) Sensitized against grasses 2.85 (0.45–18.08) Sensitized against HDM 1.93 (0.38–9.95) Rubella Respiratory symptoms 1.17 (0.65–2.10) Allergic sensitization 0.85 (0.46–1.57) Sensitized against grasses 0.75 (0.36–1.56) Sensitized against HDM 0.89 (0.41–1.92) Hib Respiratory symptoms 1.39 (0.60–3.19) Allergic sensitization 0.74 (0.30–1.79) Sensitized against grasses 0.55 (0.19–1.58) Sensitized against HDM 1.14 0.33–3.89 Frequencies of BCG, Pertussis, Measles, Rubella, and Hib Vaccination in Children With Respiratory Symptoms and in Sensitized Children Respiratory symptoms Pertussis: 0.85 (0.60–1.19) Measles: 0.86 (0.36–2.06) Rubella: 0.94 (0.64–1.38) Hib: 1.14 (0.82–1.58)	Respiratory symptoms 1.06 (0.54–2.08) Allergic sensitization 0.57 (0.29–1.13) Sensitized against grasses 0.52 (0.24–1.12) Sensitized against HDM 0.74 (0.30–1.83) 1 older sibling Respiratory symptoms 0.91 (0.47–1.76) Allergic sensitization 0.47 (0.24–0.92) Sensitized against grasses 0.44 (0.20–0.95) Sensitized against HDM 0.75 (0.31–1.82) 2 older siblings Respiratory symptoms 1.63 (0.74–3.60) Allergic sensitization 0.40 (0.18–0.91) Sensitized against grasses .40 (0.16–1.02) Sensitized against HDM 0.69 (0.24–1.97) >2 older siblings Respiratory symptoms 0.95 (0.30–3.02) Allergic sensitization 0.33 (0.09–1.15) Sensitized against grasses 0.20 (0.04–1.13)

Table 29. Postmarketing studies of multiple vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				Allergic sensitization Pertussis: 1.04 (0.73–1.47) Measles: 1.59 (0.61–4.17) Rubella: 0.80 (0.54–1.19) Hib: 0.94 (0.67–1.32)	Sensitized against HDM 0.29 (0.05–1.71)
Mullooly et al. 2007 ²¹⁷ Case-control	N=1,074 (844 atopy cases, 230 controls); Location=West Coast; Age=6-16 years; Setting=Kaiser Permanente Northwest (KPNW) HMO	DTP, MMR, HBV, IPV, HIB	Covariates associated with atopy at p < 0.20 in bivariate analyses were included in the regression models. controls for age at skin test, gender, race, maternal/family history of atopy, low birth weight, maternal age at birth, breast feeding at 2 months, household smoking, dogs in home, calendar period of skin test (1978–93, 1994–99, 2000–01)	OR (95% CI) for atopy All cases versus all controls No. of pertussis doses 1.06 (0.89–1.27) No. of measles doses 0.85 (0.56–1.29) No. of HIB doses 0.93 (0.81–1.08) No. of HBV doses 1.15 (0.88–1.49) All cases versus asthma controls No. of pertussis doses 0.98 (0.74–1.29) No. of measles doses 0.80 (0.42–1.53) No. of HIB doses 0.88 (0.73–1.07) No. of HBV doses 1.04 (0.75–1.45) Asthma cases versus asthma controls No. of pertussis doses 0.95 (0.71–1.29) No. of measles doses 0.69 (0.36–1.35) No. of HIB doses 0.88 (0.72–1.08) No. of HBV doses 1.05 (0.73–1.50)	Not reported

Table 29. Postmarketing studies of multiple vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Thomson et al. 2010 ²¹⁸ Prospective cohort	N=488; Location=Australia; Age=2-6 years (outcomes ascertained at 6 years); Setting=Melbourne Atopy Cohort Study (MACS), an ongoing prospective cohort study initiated in 1989	Triple antigen [diphtheria, tetanus and pertussis (DTP)], combined diphtheria and tetanus (CDT), measles mumps rubella (MMR)	Parental socio-demographics, allergic disease, parental smoking history; parental education; gender of child and older siblings, pet ownership of at least one dog and/or cat	RR (95% CI) for Asthma Triple antigen (DTP) 1st year: 4.75 (0.88, 25.58) 2nd year: 0.74 (0.56, 0.96) Combined diphtheria and tetanus 1st year 1.88 (1.28, 2.77) 2nd year 1.00 (0.57, 1.74) Measles mumps rubella 2nd year 0.78 (0.61, 1.00)	RR (95% CI) for Asthma Socio-demographics child Gender (male) 1.61 (1.21, 2.14) Older siblings (at least 1) 1.27 (1.17, 1.38) Characteristics mother Asthma 1.43 (1.07, 1.90) Eczema 1.32 (1.02, 1.72) Drug allergy 1.33 (1.02, 1.74) Characteristics father Asthma 1.34 (1.01, 1.79) Allergic rhinitis 1.37 (1.04, 1.81) Parent's education, parents' marital status, pet ownership: NS
Sun et al. 2012 ²¹⁹ Prospective cohort study and self-controlled case series	N=378,834 (cohort study), 7,811 children with febrile seizures (cases); Location=Denmark; Age=0-7 years; Cohort was identified by using information from the Danish Civil Registry	DTaP-IPV-Hib	Cohort: child's sex, multiple births, calendar year of birth, season, gestational age, birth weight, parity of the mother, parental history of epilepsy, maternal education, and family income at the time of birth. Season was included as a time-varying variable. SCCS: age of the child (1-week interval) and the season of the observation period	Cohort analysis - Adjusted HR Time After DTaP-IPV-Hib Vaccination First Vaccination 0 days: 6.02 (2.86-12.65) 1-3 days: 1.38 (0.58-3.31) 4-7 days: 0.41 (0.10-1.69) 0-7 days: 1.64 (0.93-2.88) Second Vaccination 0 days: 3.94 (2.18-7.10) 1-3 days: 1.57 (0.91-2.72) 4-7 days: 0.52 (0.23-1.18) 0-7 days: 1.36 (0.93-1.98) Third Vaccination 0 days: 1.07 (0.73-1.57) 1-3 days: 0.89 (0.70-1.14) 4-7 days: 1.06 (0.87-1.28) 0-7 days: 0.99 (0.86-1.15) SCCS analysis Relative IR	Differences between boys and girls not significant.

Table 29. Postmarketing studies of multiple vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				<p>Time After DTaP-IPV-Hib Vaccination</p> <p>First Vaccination</p> <p>0 days: 6.49 (3.10-13.61)</p> <p>1-3 days: 1.47 (0.62-3.50)</p> <p>4-7 days: 0.44 (0.11-1.81)</p> <p>0-7 days: 1.65 (0.94-2.90)</p> <p>Second Vaccination</p> <p>0 days: 3.97 (2.20-7.16)</p> <p>1-3 days: 1.52 (0.88-2.64)</p> <p>4-7 days: 0.49 (0.22-1.11)</p> <p>0-7 days: 1.32 (0.90-1.92)</p> <p>Third Vaccination</p> <p>0 days: 1.07 (0.73-1.57)</p> <p>1-3 days: 0.89 (0.70-1.14)</p>	
Chen et al. 1997 ²²⁰ Prospective cohort	N=~242,000 Location=U.S.; Age=0-6 years; Setting=Vaccine Safety Datalink (VSD) project (4 HMOs, Group Health Cooperative (GHC) of Puget Sound in Washington, Northwest Kaiser Permanente (NWK) in Oregon, Northern California Kaiser (NCK), and Southern California Kaiser (SCK) Permanente	DTP, MMR,	stratified by HMO and birth date, adjusted for other vaccines	<p>Relative risk (and 95% confidence interval) of seizures and persistent seizure disorders</p> <p>DTP</p> <p>Interval days post vaccination</p> <p>0 days: 2.20 (1.50-3.40)</p> <p>1-3 days: 1.00 (0.70-1.40)</p> <p>4-7 days: 0.80 (0.50-1.00)</p> <p>8-14 days: 0.85 (0.60-0.90)</p> <p>15-30 days: 0.84 (0.70-0.90)</p> <p>MMR</p> <p>Interval days post vaccination</p> <p>0 days: 0.80 (0.30-1.90)</p> <p>1-3 days: 0.50 (0.20-1.00)</p> <p>4-7 days: 1.80 (1.20-2.70)</p> <p>8-14 days: 2.50 (2.20-3.30)</p> <p>15-30 days: 1.00 (0.90-1.20)</p> <p>On crude analysis, a possible association was found 8 to 14 days after vaccination MMR. After adjustment the association with MMR persisted (2.42 (1.8-3.2)).</p>	Not reported

Table 29. Postmarketing studies of multiple vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Gold et al. 2010 ²²¹ Self Controlled Case Series	N= 323 cases of febrile seizures Location=South Australia; Age=0-7 years;	MMR, DTP	SCCS method accounted for exposure period and age	IRR for febrile seizures MMR vaccine Exposure period -1 to -14 days: 0.58 (0.33–1.02) Exposure period 6 to 11 days: 2.11 (1.43–3.10) Exposure period 15 to 35 days: 0.90 (0.65–1.25) DTP vaccine Exposure period -1 to -14 days: 0.56 (0.33–0.94) Exposure period 0 to 3 days: 0.59 (0.24–1.45) Exposure period 4 to 7 days: 0.94 (0.46–1.91) Exposure period 8 to 14 days: 0.93 (0.54–1.62)	Not reported
Rowhani-Rahbar et al. 2012 ²²² Case-centered	N=233 cases of Bell's Palsy; Age=<=18 years; Setting=Kaiser Permanente Northern California population	TIV, Hepatitis B	Not reported	OR, 95% CI TIV Days 1-14: 1.0 (0.2, 5.0) Days 1-28: 0.7 (0.2, 2.8) Days 29-56: 1.2 (0.3, 4.8) Hep B Days 1-14: 1.3 (0.4, 4.5) Days 1-28: 0.8 (0.2, 2.4) Days 29-56: 0.9 (0.3, 2.6)	Not reported

Table 29. Postmarketing studies of multiple vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Groves et al. 1999 ²²⁴ Case-control	N=878; Location=nine Midwestern and Mid-Atlantic states; Age=0-14 years; Setting=Patients with acute lymphoblastic leukemia (ALL), diagnosed between 1989 and 1993. Subjects who resided in Illinois, Indiana, Iowa, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, or Wisconsin at the time of diagnosis were eligible for the vaccination component of the study.	Oral or injected poliovirus vaccine, trivalent diphtheria–tetanus–pertussis vaccine, bivalent diphtheria–tetanus vaccine, bivalent tetanus–diphtheria vaccine, monovalent tetanus vaccine, trivalent measles–mumps–rubella vaccine, <i>Haemophilus influenzae</i> group b (Hib) vaccines, Hepatitis B virus vaccine and other vaccines	Age at censoring, year of birth, sex, race, family income, parental education and attendance at day-care and/or preschool	Effect of vaccination (ever vs. never) on subsequent risk of childhood acute lymphoblastic leukemia (439 matched pairs) OR (95% CI) Measles–mumps–rubella: 1.19 (0.67–2.10) Oral poliovirus: 1.05 (0.41–2.67) Diphtheria–tetanus–pertussis: 0.66 (0.27–1.65) Tetanus (all): 0.75 (0.26–2.16) Diphtheria (all): 0.75 (0.26–2.16) <i>Haemophilus influenzae</i> b (Hib): 0.73 (0.50–1.06) (Presumptive) polysaccharide vaccine: 1.13 (0.64–1.98) (Presumptive) conjugate vaccine: 0.57 (0.36–0.89)	Not reported
Ma et al. 2005, ²²⁵ Case-control	N=732; Location=California; Age=0-14 years; Setting=Northern California Childhood Leukemia Study (major pediatric clinical centers)	DPT, polio, MMR, Hib, Hepatitis B	Matched on date of birth, sex, mother's race and Hispanic status Adjusted for maternal education and annual household income	Vaccinations and the risk of childhood leukemia—adjusted odds ratios Each dose before the reference date DPT Leukemia: 0.97 (0.74, 1.28) ALL: 0.96 (0.72, 1.28) Polio Leukemia: 1.14 (0.88, 1.47) ALL: 1.08 (0.82, 1.41) MMR Leukemia: 1.06 (0.69, 1.63) ALL: 0.87 (0.55, 1.37) Hib Leukemia: 0.81 (0.68, 0.96)	Not reported

Table 29. Postmarketing studies of multiple vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				ALL: 0.81 (0.66, 0.98) Hepatitis B Leukemia: 0.97 (0.77, 1.23) ALL: 1.01 (0.78, 1.31)	
MacArthur et al. 2008 ²²⁶ Case-control	N=798; Location=Canada; Age=0-15 years; Setting=Canadian pediatric oncology centers and population-based cancer registries	Measles, mumps, and rubella (MMR), diphtheria, tetanus, and pertussis (DTP), poliomyelitis, hepatitis, or Bacillus Calmette-Guerin (BCG)	Maternal education, annual household income, ethnicity, maternal age at birth, and number of residences since birth. Multivariate models relied on strata formed by the following matching factors: province, gender, and age.	Vaccinations in childhood and risk of childhood leukemia, the Cross-Canada Childhood Leukemia Study, 1990–1994 OR (95% CI) Mumps: 0.83 (0.39-1.75) Measles 0.88 (0.41-1.90) Rubella 0.85 (0.42-1.70) Diphtheria 0.85 (0.29-2.49) Pertussis 0.71 (0.27-1.85) Tetanus 0.74 (0.27-2.03) Polio 0.90 (0.35-2.29) Hepatitis 1.09 (0.34-3.52) Other vaccine 0.81 (0.58-1.13)	Not reported
Pagaoa et al. 2011 ²²⁷ Case-control	N=14,000 (2,800 cancer cases, 11,200 controls); Location=Texas; Age=2 to 17 years; Setting=Texas Cancer Registry combined with birth certificate data to identify eligible participants	DTaP, IPV, MMR, Hib, Hepatitis B, Varicella Zoster, 4-3-1 (Four doses of DTaP, 3 doses of IPV, 1 dose of MMR), 4-3-1-3 (Four doses of DTaP, 3 doses of IPV, 1 dose of MMR, 3 doses of Hib), 4-3-1-3-3, 4-3-1-3-3-1	Stratified analyses with infant sex, race/ethnicity, maternal age at birth, birth weight, and parity. Subjects matched on sex and birth year Adjusted for sex, child's birth year, child's ethnicity, child's birth weight, mother's age at child's birth	No associations found between any vaccine and any type of cancer.	Not reported

Table 29. Postmarketing studies of multiple vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Hummel et al. 2000 ²²⁸ Prospective cohort	N=823; Location=Germany; Age=0-2 years; Setting=German BABYDIAB Study	Bacille Calmette-Guérin [BCG]); Haemophilus influenzae (HIB); diphtheria, tetanus, and pertussis (DTP); poliomyelitis; tick-born encephalitis (TBE); and measles, mumps, and rubella (MMR)	Not reported	Risk (odds ratio) for developing islet antibodies with respect to environmental factors. (Estimates from figure) Hib: 1.4 (0.07-4.00) Measles: 1.6 (0.07-7.00) Mumps: 1.2 (0.08-3.50) Rubella: 1.3 (0.07-4.00)	Not reported
O'Leary et al. 2012 ¹⁴³ Retrospective cohort	N=1.8 million from 5 managed care organizations; Location=Colorado, Hawaii, Georgia, Northern CA, Massachusetts; Age=6 weeks to 17 years;	MMR, Hepatitis A, varicella, Tdap, Hib	Not reported	IRR for immune thrombocytopenic purpura (ITP) 6 wk to 11 mo Hib, PCV: Not significant (NS) 6 to 23 mo TIV: NS 12 to 19 mo MMR: 5.48 (1.61, 18.64) MMRV, DTaP, Hib, PCV: NS 12 to 23 mo Hep A: NS 2 to 6 years TIV, Hep A: NS 4 to 6 years MMR, VAR, DTaP, IPV: NS 7 to 17 years Hep A: 23.14 (3.59, 149.30) TIV: NS 11 to 17 years VAR: 12.14 (1.10, 133.96) Tdap: 20.29 (3.12, 131.83) HPV, MCV: NS	Not reported

Table 29. Postmarketing studies of multiple vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Pahud et al. 2012 Case-centered method	N=110 encephalitis cases; Location=CA; Age= 6 months to 18 years	Many analyzed, measles virus-containing vaccines and pertussis antigen containing vaccines reported	Not reported	Association with pre-defined risk windows Measles virus-containing vaccines 5–15 days: OR=1.31 (0.30–5.77) Pertussis antigen-containing vaccines 0–3 days: OR=1.37 (0.33–5.78)	Not reported
Velentgas et al. 2012, ²²³ Retrospective cohort study	N=12.6 million; Location=U.S.; Age=11 to 21 years Setting: Five U.S. health plans	Meningococcal conjugate vaccine (MCV4); meningococcal polysaccharide vaccine (MPSV4), tetanus–diphtheria–acellular–pertussis vaccine (Tdap), tetanus and diphtheria vaccine (Td), tetanus, hepatitis B (HepB), human papillomavirus (HPV), and influenza vaccination	None	Incidence and attributable risk of GBS , per millions vaccinations MCV4 Cumulative incidence; one sided upper CI: 0; 2.09 Attributable risk: 0; 1.46 MPSV4 Cumulative incidence; one sided upper CI: 7.79; 37.00 Attributable risk: 7.16; 36.37 Tdap Cumulative incidence; one sided upper CI: 0; 2.49 Attributable risk: 0; 1.86 Td Cumulative incidence; one sided upper CI: 0; 8.02 Attributable risk: 0; 7.39 Tetanus Cumulative incidence; one sided upper CI: 0; 106.20 Attributable risk: 0; 105.57 Influenza Cumulative incidence; one sided upper CI: 3.49; 11.00 Attributable risk: 2.86; 10.37 HepB	None

Table 29. Postmarketing studies of multiple vaccines in children and adolescents (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
				Cumulative incidence; one sided upper CI: 8.04; 38.10 Attributable risk: 7.40; 37.47 HPV Cumulative incidence; one sided upper CI: 3.42; 10.80 Attributable risk: 2.79; 10.17	

BCG = Bacillus Calmette–Guérin; CI = confidence interval; CDT = combined diphtheria and tetanus; DTP = diphtheria, tetanus and pertussis; DTP-IPV = diphtheria-tetanus-pertussis-(inactivated) poliomyelitis vaccination; GHC = Group Health Cooperative; HBV = hepatitis B vaccine; HDM = house dust mite; Hep A = hepatitis A; Hib = *Haemophilus influenzae* Type b; HMO = health maintenance organization; HPV = human papillomavirus; IPV = polio vaccine; IRR = incidence rate ratio; ITP = immune thrombocytopenic purpura; MACS = Melbourne Atopy Cohort Study; MCV = measles-containing vaccine; MMR = measles, mumps, rubella; NCK = Northern California Kaiser; NWK = Northwest Kaiser Permanente; OR = odds ratio; SCCS = self-controlled case series; SCK = Southern California Kaiser; TBE = tick-born encephalitis; VAR = varicella; VSD = vaccine safety datalink

Note: Additional study details presented in Appendix C evidence tables.

Key Question 3: What is the evidence that vaccines recommended for pregnant women²⁵ are safe both for the woman and for her fetus/infant?

- a. What AEs are collected in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?
- b. What AEs are reported in clinical studies (phases I–IV) and in observational studies containing a control/comparison group?

Table 30 lists AEs collected or reported in studies of vaccines in pregnant women, abstracted verbatim. We interpreted “collected” to mean those specified a priori by investigators, while “reported” were any AEs reported by participants. The list does not imply an association with vaccination, as it contains AEs regardless of whether they were reported in vaccinated or unvaccinated study participants. Later we describe the studies further and assess association.

Table 30. Adverse events collected or reported in studies of pregnant women

Vaccine	Adverse Event
Influenza (inactive)	<ul style="list-style-type: none"> • Chest tightness or difficulty breathing • Cough • Death • Fever • Infant: Dermatitis contact • Infant: Hyperbilirubinemia neonatal • Infant: Respiratory distress • Infant: Seborrheic dermatitis • Infant: Upper respiratory tract infection • Malaise • Maternal: At least one adverse event • Maternal: Fever, cough, runny nose, nasal congestion, and skin itching • Maternal: Severe adverse event • Myalgia/Arthralgia • Small for gestational age • Sore throat, hoarseness, or pain swallowing • Stillbirth • Swelling of the face
Influenza - monovalent H1N1	<ul style="list-style-type: none"> • 5min APGAR score <7 • Allergy • Auricle defect • Chest infection • Chest pain • Cleft palate • Clubfoot • Congenital anomalies • Coryza • Cough • Death • Diarrhea • Downs Syndrome • Dyspnea • Ebstein's anomaly

Table 30. Adverse events collected or reported in studies of pregnant women (continued)

Vaccine	Adverse Event
	<ul style="list-style-type: none">• Fetal death• Flu-like symptoms• Gestational diabetes• Headache• Hip dysplasia• Hydrocephalus• Hypertension• Hypospadias• Imperforate lacrimal duct• Infections• Inferior vena cava (IVC) syndrome• Intrauterine Growth Restriction (IUGR)• Laryngomalacia• Limb pain• Malaise• Mild pulmonary artery stenosis• Miscarriage• Myalgia• Nausea, Influenza, Pain, viral infection• Neonatal death (1st, 2nd and 3rd Tri)• Neonatal pathologies• Pelvic kidney• Persistent arterial duct• Pharyngitis• Premature rupture of membranes (PROM)• Prematurity• Preterm birth• Preterm labor• Pulmonary valve stenosis• Pyelitic dilatation• Pyrexia• Rash• Right pyelitic hypotension• Sinusitis• Skin tag on finger• Small for gestational age• Spontaneous abortion (1st, 2nd and 3rd Tri)• Stillbirth (01st, 2nd and 3rd Tri)• Talipes calcaneus• Trisomy 21#• Umbilical hernia• Unilateral cryptorchidism• Varus equinus• Ventriculomegaly• Very preterm (<32w)

IUGR = intrauterine growth restriction; IVC = inferior vena cava; PROM = premature rupture of membranes

Key Question 3 – Pregnant Women (Continued):

- c. What AEs are associated with these vaccines in women?
 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 3. For each AE associated with a particular vaccine, what are the risk factors for the AE (including age, sex, race/ethnicity, genotype, underlying medical condition, whether the vaccine is administered individually or in a combination vaccine product, the schedule of vaccine administration, adjuvants, and medications administered concomitantly)?
- d. What AEs are associated with these vaccines in the fetus/infant?
 1. For each AE associated with a particular vaccine, what is the average severity (grade 1/mild; grade 2/moderate; grades 3 and 4/severe)?
 2. For AEs without statistically significant associations with a particular vaccine, what is the level of certainty?^a
 3. For each AE associated with a particular vaccine, what are risk factors for the AE (including age, gender, race/ethnicity, genotype, underlying medical condition, whether vaccine administered individually or in a combination vaccine product, vaccine schedule of administration, adjuvants, medications administered)?

Influenza Vaccines

We identified four studies comparing vaccinated and unvaccinated pregnant women; the results are displayed in Table 31. A cohort study by Lin et al in Taiwan²³⁰ compared 396 pregnant women who received AdimFlu-S influenza A (monovalent H1N1) between October 2009 and February 2010 with unvaccinated pregnant women; no difference in SAEs was

^a Level of certainty was operationalized as the 95-percent confidence interval surrounding the risk or odds estimate—i.e., the statistical significance.

reported. A comparison of the medical records of the age-matched groups showed that significantly fewer women in the vaccinated group experienced at least one adverse event during the study period compared to unvaccinated women (OR 0.37, 95% CI 0.22, 0.68). One statistically significant adverse event difference in the infants was observed: hyperbilirubinemia was much less common in the vaccinated group (OR 0.08, 95% CI 0.03, 0.2).

A Canadian cohort study²³¹ by Fell and colleagues included 55,570 pregnant women who delivered a single baby during the 2009/2010 influenza season. Women vaccinated during pregnancy with monovalent H1N1 influenza vaccines were statistically less likely to experience a fetal death (OR 0.60, 95% CI 0.44-0.81), preterm birth defined as below 37 weeks gestational age (OR 0.92, 95% CI 0.85, 0.98), infants small for their gestational age (OR 0.74, 95% CI 0.66, 0.83), or delivering infants before gestation week 32 (OR 0.72, 95% CI 0.58, 0.88). Richards²³² also studied receipt of monovalent H1N1 by pregnant women. Receipt of vaccination was associated with lower risk of low birth weight and premature infants.

Nordin²³³ used the VSD to assess the safety of TIV in pregnant women. No cases of GBS, transverse myelitis, optic neuritis, or Bell's Palsy were reported in the 42 days post-vaccination in this cohort of over 200,000 women. No association between the vaccine and serious adverse events was found. Infant outcomes were not studied.

Table 31. Cohort comparison studies of influenza vaccines in pregnant women

Author-Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Fell D. B. et al., 2012 ²³¹ Canada	Cohort	4	Sample size : 55,570, Mean age: NR, Age range: <18 - 40+	Influenza - monovalent H1N1, NR, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 0 Days	5min APGAR score <7: OR 0.925 (0.794-1.078) Fetal Death: OR 0.595 (0.439-0.806)** Preterm birth (<37w): OR 0.915 (0.853-0.981)** Small for gestational age: <10th percentile: OR 0.836 (0.788-0.887)** Small for gestational age: <3rd percentile: OR 0.74 (0.66-0.829)** Very preterm (<32w): OR 0.717 (0.584-0.879)**
Lin T. H. et al., 2012 ²³⁰ Taiwan	Cohort	7	Sample size : 396, Mean age: 32.4,	Influenza (inactivated), AdimFlu-S®, Adimmune Corporation, Taichung, Taiwan, The vaccine evaluated in this study was produced by Adimmune Corporation (Taichung, Taiwan) using standard techniques for the production of seasonal inactivated influenza vaccines. The vaccine is a monovalent, unadjuvanted, inactivated, split-virus vaccine. One shot (0.5ml) of AdimFlu-Influenza (H1N1) vaccine contains 15 µg of New York Medical College X-179A reassortant of the A/California/7/2009 (H1N1) like strain. Adjuvant: Adjuvant Free, Preservative: Not reported, Delivery: Intradermal	Dose1: 0 Days	Infant: Dermatitis contact: OR 1.882 (0.682-5.194) Infant: Hyperbilirubinemia neonatal: OR 0.083 (0.032-0.214)** Infant: Respiratory distress: OR 0.66 (0.183-2.375) Infant: Seborrheic dermatitis: OR 2.042 (0.605-6.895) Infant: Upper respiratory tract infection: OR 0.742 (0.253-2.18) Maternal: At least one adverse event: OR 0.371 (0.202-0.68)**
Dodds, L. et al. 2012 ²³⁴ Canada	Cohort	NC	Sample size: 9,647, Age range: <20 - >=35,	Influenza (inactivated), NR, Not reported, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 0 Days	Composite outcome: OR 0.823 (0.636-1.067) Low birth weight: OR 0.702 (0.547-0.901)** Preterm birth: OR 0.842 (0.689-1.028) Small for gestational age <10th percentile: OR 0.749 (0.614-0.914)** Term low birth weight: OR 0.751 (0.488-1.154)

Table 31. Cohort comparison studies of influenza vaccines in pregnant women (continued)

Author-Year-Country	Study Design	McHarm Score	Population	Vaccine	Timing	OR, 95% CI, Versus Unvaccinated Group
Nordin, J.D. et al. 2013 ²³³ USA	Cohort	NC	Sample size: 223,898, Mean age: 30.8, Age range: 14 — 49	Influenza (inactivated) , NR, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 0 days	Altered mental status (3 day f/u): OR 1.329 (0.69-2.563) Autonomic disorders (42d f/u): OR 0.487 (0.054-4.361) Meningoencephalitis (42 d): OR 5.849 (0.608-56.235) Peripheral neuropathy or neuritis (42 d): OR 1.95 (0.876-4.34) cellulitis (3 day f/u): OR 0.928 (0.437-1.972)
Richards, J.L. et al. 2013 ²³² U.S.	Cohort	2	Sample size : 3,327, Mean age: 31.2, Age range: NR	Influenza (inactivated), Influenza - monovalent H1N1, NR, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 0 days	Low Birth weight (<2500g): OR 0.706 (0.522-0.956)** Pre-term birth (27-36 wk): OR 0.602 (0.461-0.787)** Preterm Birth (27-33 wk): OR 0.505 (0.297-0.859)** Preterm Birth (34-36 wk): OR 0.657 (0.486-0.889)** Small for gestational age: OR 1.144 (0.868-1.508)

CI = confidence interval; NR = not reported; OR = odds ratio

**Statistically significant.

Note: Additional study details presented in Appendix C evidence tables.

Post-licensure studies are displayed in Table 32. One study (Omer, 2011)²³⁵ on TIV included 4,168 pregnant women and their newborns followed during the 2004/05 and 2005/06 flu seasons in the United States. Vaccination status and health outcomes were ascertained using self-reported data. The analysis adjusted for potential confounders including various types of influenza activity periods, maternal health, and demographic variables. Results showed that infants born during the influenza vaccine season to women who were vaccinated were less likely to be premature compared to infants born in the same period to unvaccinated mothers (adjusted OR 0.60, 95% CI 0.38, 0.94). This relationship increased (adjusted OR 0.44, 95% CI 0.26, 0.73) during periods of local influenza activity, and was at its greatest during periods of widespread influenza activity. Results also indicate that during widespread influenza activity periods, newborns of vaccinated mothers had 69% lower odds of being small for gestational age (adjusted OR 0.31, 95% CI 0.13, 0.75) compared with newborns of unvaccinated mothers. Irving²³⁶ used VSD to conduct a case-control study of miscarriage; no association with TIV was found.

Regarding monovalent H1N1, (Xu, 2012)²³⁷ studied data obtained from 198 pregnant women who enrolled before 20 weeks of gestation in the U.S. Vaccine and Medication in Pregnancy Surveillance System study. The aim of this study was not to assess the effect of H1N1 on childbirth outcomes, but to illustrate the use of survival analysis methods. Data were analyzed using time-independent (naive) and time-dependent covariate Cox models to account for left-truncation (due to possible enrollment later than conception). The model was adjusted for time of vaccine exposure (1st, 2nd trimester), previous spontaneous abortion events, maternal smoking habits, age, and the presence of asthma. Vaccination was not statistically associated with spontaneous abortions during any trimester.

Summary

We found moderate strength evidence that neither monovalent H1N1 vaccine nor trivalent inactivated vaccine (TIV) is associated with serious adverse events in pregnant women or their offspring. Several studies report that these vaccines decrease the risk of adverse pregnancy outcomes.

Table 32. Postmarketing studies of influenza vaccines in pregnant women

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Omer et al. 2011 ²³⁵ Retrospective cohort	4,168 pregnant women and their newborns enrolled in Georgia Pregnancy Risk Assessment Monitoring System (PRAMS), mean age not reported but 11.5% were <19, 12.5% were >35, and 76% were 19-35. Recruitment occurred in the flu seasons of 2004-2006.	TIV	Influenza activity period (pre-influenza activity period, periods of least local/regional influenza activity, period of widespread influenza activity) maternal variables (age, multiple births, medical risk factors, labor/delivery complications, birth defects, smoking during pregnancy, hypertension, insurance coverage, maternal diabetes, use of multivitamins, alcohol use during pregnancy, black race, education, marital status) Covariates were tested for the separate multivariate models by testing which potential confounders moved the relationship between immunization and birth outcome closer to 1.	Prematurity was defined as birth < 37 weeks gestation; SGA was defined as birth weight <10th percentile for gestational age. Infants born during the putative vaccine season to women who were vaccinated were less likely to be premature compared to infants born in the same period to unvaccinated mothers (adjusted OR 0.60, 95% CI 0.38 to 0.94) During the period of local influenza activity, this relationship increased (adjusted OR 0.44, 95% CI 0.26 to 0.73) During the widespread influenza activity period, this relationship was greatest: adjusted OR 0.80, 95% CI 0.11. to 0.74) Also during the widespread influenza activity period, compared with newborns of unvaccinated mothers, newborns of vaccinated mothers had 69% lower odds of being SGA (adjusted OR 0.31, 0.13 to 0.75).	Not reported
Irving, et al. 2013, ²³ ⁶ Case-control	N=486 (243 cases, 243 controls); Location=U.S.; Age=18-44 years; Setting=six health care organizations in the Vaccine Safety Datalink	Influenza TIV	Maternal age, health care utilization, maternal diabetes, parity	Odds of Influenza Vaccination in Cases of Early Pregnancy Loss in Varying Exposure Windows as Compared With Control Group Participants Adjusted ORs, 95% CI, p-value Primary analysis Exposed 1-28 d before reference date: 1.23 (0.53-2.89), 0.63 Exposed more than 28 d before reference date: 1.24 (0.54-2.86), 0.61 Secondary analysis Exposed while pregnant 0.80 (0.36-1.78), 0.58 Exposed before pregnant 2.34 (0.86-6.33), 0.10	None

Table 32. Postmarketing studies of influenza vaccines in pregnant women (continued)

Author / Year / Study Design	Population	Vaccines	Adjusted for These Confounders	Results Regarding Vaccine	Results Regarding Risk Factors
Xu et al. 2012 ²³⁷ Retrospective cohort	198 pregnant women who enrolled before 20 weeks gestation; U.S./Vaccine and Medication in Pregnancy Surveillance System study	H1N1	Vaccine exposure (1st or 2nd trimester) Previous spontaneous abortion (SAB) events (0, 1, 2, >=3) smoking maternal age asthma Dependent variable: Spontaneous abortion (SAB)	Spontaneous abortion (SAB) RR (time-independent): 1.13(0.13, 10.24) RR (time-dependent): 1.13(0.13, 10.24) Vaccination during 1st trimester (n=119) SAB RR (time-independent): 0.48(0.08, 2.70) RR (time-dependent): 0.79(0.19, 3.23) Vaccination during 2nd trimester (by definition, fetal loss>20weeks is still-birth, not SAB)(n=34) No. SAB: 0 Vaccination during 1st or 2nd trimester (n=153) SAB RR (time-independent): 0.58(0.10, 3.24) RR (time-dependent): 0.97(0.24, 3.94)	Not reported

CI = confidence interval; OR = odds ratio; PRAMS = Pregnancy Risk Assessment Monitoring System; RR = risk ratio; SAB = spontaneous abortion; SGA = small for gestational age

Note: Additional study details presented in Appendix C evidence tables.

Summary and Discussion

At the request of AHRQ and the Office of the Assistant Secretary for Health (OASH) we conducted an assessment of the evidence for the safety of vaccines recommended for routine use in the United States among adults, children, and pregnant women, according to ACIP guidelines. We conducted an extensive literature search for clinical trials and observational studies meeting our inclusion criteria: cohort studies comparing vaccinated and unvaccinated groups, case-control studies, self-controlled case series, and multivariate risk factor analyses. In this chapter, we describe the limitations of our review and present our conclusions. We also include a section on Research Gaps.

Limitations

Our literature search procedures were extensive; however, some unpublished trial results may not have been identified. An independent Scientific Resource Center (SRC) under contract with AHRQ requested Scientific Information Packets (SIPs) from the manufacturers of all vaccines routinely recommended in the United States. (The research team was prohibited from contacting manufacturers directly.) Only two companies responded; both manufacture vaccines against seasonal influenza.

We excluded non-English language studies. Although we were considering only vaccines approved for use in the United States, it is possible relevant epidemiological studies have been published in non-English journals.

An important limitation common to systematic reviews is the quality of the original studies included. We used a quality-rating instrument³² developed by another Evidence-based Practice Center specifically to evaluate studies reporting harms. The scores are presented in the results tables and taken into consideration when rating the strength of the evidence. Studies that reported timing and severity, and defined AEs using standard, precise definitions were rated higher than those that did not. Epidemiological studies that used medical records to ascertain vaccination and health outcomes were also rated higher than those that relied on patient or parent report. Strengths and weaknesses of studies vary according to their design. Cohort studies of vaccines may use multivariate analyses to control for confounding factors, but they cannot capture potential differences between those who get vaccinated and those who do not. Self-controlled case series control for patient characteristics that do not change over time (gender, race-ethnicity, genetics) but cannot capture factors that are time-related. This is especially important when studying vaccinations of infants and toddlers.

Studies using passive surveillance such as the U.S. Vaccine Adverse Event Reporting System (VAERS),¹⁶ are crucial in identifying signals regarding adverse events post-licensure. However, because by definition they do not consider the rate of such events in non-vaccinated populations, they are not designed to assess a statistical association between a vaccine and an adverse event, so they were excluded from this project. Thus, there may be important adverse event signals not identified in this report that warrant future research.

We included controlled trials that used formulations currently approved in the United States. We tried to exclude Phase II studies that used dosages that were never licensed and/or formulations available only in other countries. Some studies reported the potency of the vaccines under study in a different manner or unit than that reported in other studies or the product materials. We assessed these findings to the best of our capabilities. We point out discrepancies in our results text.

Except where explicitly stated in the text, controlled trials of vaccines are conducted in healthy patients. Thus, persons who may be more susceptible to AEs may be excluded from trials, yet eligible to receive a vaccine after it is licensed. In addition, trials are generally underpowered to detect very rare events. For example, a trial of 1,000 patients may not detect an AE with an expected incidence of one in 5,000. Trials may also be underpowered to assess risk factors for the AEs they do detect.

Post-licensure epidemiological studies are conducted to investigate possible associations between vaccines and AEs reported in passive surveillance or multiple case reports. Such studies often do not limit their investigation to a particular brand or formulation. They may lump vaccines against a specific disease together. For example, a study might investigate the effect of “seasonal influenza vaccines” in general. Formulations of seasonal influenza vaccines change each season, the vaccine comes in inactivated or live form, and a particular batch may or may not contain a strain of H1N1. It is difficult to assess the applicability of studies that do not report specific details about vaccines.

In many studies, the severity of AEs was not reported. Our researchers coded the severity according to CATAE classification when possible. Severity is listed in our tables where available.

Most studies did not investigate potential risk factors for AEs that were found to be associated with vaccination.

Some post-licensure surveys use patient or parent recall for ascertainment of vaccination or health outcomes, rather than medical records. Subjects may not have copies of their vaccination or medical records, introducing recall bias. Advanced health information technology (HIT) systems that contain vaccination and medical records can make surveys unnecessary, leading to higher quality studies. In the United States, the CDC's Vaccine Safety Datalink (VSD) uses data obtained through such systems at nine large health care organizations, enabling very high quality studies. Nations with single payer healthcare often have electronic registries, which allow epidemiological studies of entire populations.

Conclusions

Table 33 summarizes our conclusions, given the caveats described in the Limitations section. The second column displays the strength of evidence (SOE) regarding statistical association of each vaccine type with key AEs.

Table 33. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Adults			
Diphtheria Toxoid, Tetanus Toxoid, and Acellular Pertussis Vaccines (Td, Tdap)	High - anaphylaxis	Evidence “convincingly supports” a causal relationship between the tetanus toxoid vaccine and anaphylaxis.	We identified two additional trial in adults. No AEs were associated with vaccine.
Hepatitis A Vaccine	Insufficient- acute disseminated encephalomyelitis, transverse myelitis, MS, Guillain-Barré Syndrome, chronic inflammatory disseminated polyneuropathy, Bells' Palsy, anaphylaxis, and autoimmune hepatitis	Evidence is “inadequate to accept or reject” any causal relationships with AEs the committee was tasked with investigating: acute disseminated encephalomyelitis, transverse myelitis, MS, Guillain-Barré Syndrome, chronic inflammatory demyelinating polyneuropathy, Bells' Palsy, anaphylaxis, and autoimmune hepatitis.	We identified one additional post-licensure study; there was no association of the vaccine with any adverse events or onset of medical conditions.

Table 33. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Hepatitis B Vaccine	<p>Insufficient - optic neuritis, first demyelinating event, Guillain-Barré Syndrome, SLE, onset or exacerbation of vasculitis, polyarteritis nodosa, and onset or exacerbation of rheumatoid arthritis</p> <p>Moderate – No association with MS onset or exacerbation</p> <p>Moderate – anaphylaxis in patients allergic to yeast</p>	<p>Although no epidemiological studies were identified on anaphylaxis, mechanistic evidence “favors acceptance” of a causal relationship between the vaccine and anaphylaxis in yeast-sensitive individuals.</p> <p>Epidemiological studies of the following AEs in adults had evidence “inadequate to accept or reject” a causal relationship: optic neuritis, first demyelinating event, Guillain-Barré Syndrome, SLE, onset or exacerbation of vasculitis, polyarteritis nodosa, and onset or exacerbation of rheumatoid arthritis.</p> <p>A 2002 IOM review on Hep B vaccine and demyelinating neurological disorders concluded that the evidence “favors rejection” of a causal relationship with incident MS or MS relapse.</p> <p>No epidemiological studies of the following AEs in adults were found, evidence is also “inadequate to accept or reject” a causal relationship: encephalitis, encephalopathy, acute disseminated encephalomyelitis ADEM, transverse myelitis, neuromyelitis optica, chronic inflammatory demyelinating polyneuropathy, brachial neuritis, erythema nodosum, onset or exacerbation of psoriatic arthritis, onset or exacerbation of reactive arthritis, and fibromyalgia.</p>	No additional studies met our inclusion criteria.

Table 33. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Influenza Vaccines	<p>High – arthralgia, myalgia, malaise, fever, pain at injection site, anaphylaxis</p> <p>High – 2009 Monovalent H1N1 vaccine with Guillain-Barré Syndrome (GBS)</p> <p>High – No association with cardiovascular events in the elderly</p> <p>Insufficient - Multiple Sclerosis (MS) onset & exacerbation</p>	<p>Studied two forms of influenza vaccine: live attenuated form, administered intranasally (LAIV), and inactivated form (TIV), administered intramuscularly.</p> <p>Evidence “convincingly supports” a causal relationship between influenza vaccines and anaphylaxis in persons allergic to egg or gelatin. However, in recent years, manufacturers have reduced the egg protein content.</p>	<p>Many clinical trials reported that influenza vaccines are associated with arthralgia, myalgia, malaise, fever, and pain in the short-term in adults. These adverse events (AEs) were not considered serious; severity was graded mild to moderate. Odds of experiencing these events were 1.5 to 2 times higher in vaccinated patients than in unvaccinated. Risk factors were not discussed in the trials.</p> <p>A high quality meta-analysis found an association between 2009 monovalent H1N1 vaccine and Guillain-Barré Syndrome (GBS) in the 42 days post vaccination; results translate to about 1.6 excess cases per million vaccinated.</p> <p>Post-licensure studies have found inconsistent evidence associating influenza vaccines with onset or exacerbation of MS in adults.</p> <p>Post-licensure studies have found influenza vaccines are NOT associated with increased risk of cardiovascular or cerebrovascular events in the elderly.</p> <p>Post-licensure studies have shown that influenza vaccines are NOT associated with increased risk of serious AEs (SAEs) in renal patients.</p>
MMR Vaccine	<p>Moderate – No association with Type 1 diabetes</p> <p>Moderate - transient arthralgia in women</p> <p>Insufficient - MS onset, Guillain-Barré Syndrome, chronic arthralgia in women, and chronic arthritis and arthropathy in men.</p>	<p>Evidence “favors acceptance” of a causal relationship with transient arthralgia in women.</p> <p>Evidence is “inadequate to accept or reject” a causal relationship with MS onset, Guillain-Barré Syndrome, chronic arthralgia in women, and chronic arthritis and arthropathy in men.</p>	<p>MMR was NOT associated with onset of type 1 diabetes in adults in one large high quality epidemiological study. RR=0.71 (95% CI 0.61, 0.83)</p>

Table 33. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Pneumococcal Polysaccharide Vaccine	High – No association cardiovascular or cerebrovascular events in the elderly	Not covered	We found no placebo-controlled trials of the current formulation that reported adverse events data. (We did find trials of the current formulation that reported pneumonia or mortality; these were considered efficacy outcomes). Post-licensure studies of pneumococcal polysaccharide vaccine found vaccination was not associated with increased risk of cardiovascular events in older adults.
Zoster Vaccine	Moderate – injection site reactions, allergic reactions cellulitis possibly related to allergy	Recommended for U.S. adults over age 60; AEs specific to this age group were not covered.	In some reports of clinical trials, adverse events were reported only in categories such as “injection-related adverse events,” “systematic adverse events,” or “serious adverse events”. Vaccination was associated with injection site reactions. In post-licensure studies, vaccination was associated with cellulitis possibly related to allergy and allergic reactions, such as redness and swelling 1 to 7 days post vaccination. These mild AEs occurred in less than 1% of patients, and were more likely in the younger (aged 50-59) vaccinees. ^{85,86}
Children and Adolescents			
Diphtheria Toxoid, Tetanus Toxoid, and Acellular Pertussis-Containing Vaccines (DTaP, Td, Tdap)	Moderate - No association with type 1 diabetes Insufficient - infantile spasms, seizures, cerebellar ataxia, autism, ADEM, transverse myelitis, MS relapse, serum sickness, immune thrombocytopenic purpura, and SIDS.	Evidence “ favors rejection ” of a causal relationship between vaccines containing diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens and type 1 diabetes. Evidence is “ inadequate to accept or reject ” causal relationships between vaccination and the following: infantile spasms, seizures, cerebellar ataxia, autism, ADEM, transverse myelitis, MS relapse in children, serum sickness, immune thrombocytopenic purpura, and SIDS.	We found no additional studies that met our inclusion criteria.

Table 33. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Hepatitis B Vaccine	Insufficient – food allergy Moderate – No association with MS	Although no epidemiological studies were identified by the IOM, mechanistic evidence “ favored acceptance ” of a causal relationship between the vaccine and anaphylaxis in yeast-sensitive individuals. The IOM found evidence “ inadequate to accept or reject ” a causal relationship with any other AEs. A 2002 IOM report “ favors rejection ” of a causal relationship with MS onset or exacerbation.	Hepatitis B vaccine in the first 6 months of life was associated with elevated total IgE in a post-licensure study of children with a family history of food allergy, but not with clinical allergy ²¹⁵²¹⁵²¹⁶²¹⁶
Hib	Moderate – No association with Serious Adverse Events in short term	Not covered	No serious adverse events were associated in three high quality clinical trials.
HPV Vaccine	Moderate – No association with juvenile rheumatoid arthritis, Type 1 diabetes, appendicitis, Guillain Barré Syndrome, seizures, stroke, syncope, venous thromboembolism Moderate – anaphylaxis in persons with allergies, fever, headache, mild GI AEs, skin infection High – Pain at injection site Insufficient - ADEM, transverse myelitis, neuromyelitis optica, MS, onset of Hashimoto's disease, chronic inflammatory demyelinating polyneuropathy, brachial neuritis, amyotrophic lateral sclerosis, transient arthralgia, pancreatitis, thromboembolic events, and hypercoagulable states	Evidence “ favors acceptance ” of a causal relationship between the HPV vaccine and anaphylaxis. Evidence is “ inadequate to accept or reject ” causal relationships between HPV vaccines and the following: ADEM, transverse myelitis, neuromyelitis optica, MS, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, brachial neuritis, amyotrophic lateral sclerosis, transient arthralgia, pancreatitis, thromboembolic events, and hypercoagulable states.	A large post-licensure study found HPV vaccine was not associated with onset of juvenile rheumatoid arthritis or Type 1 diabetes. This study reported an IRR of 1.29 (95% CI 1.08, 1.56) of onset of Hashimoto's disease. However, investigation of a temporal relationship and biological plausibility revealed no consistent evidence of a safety signal. A large post-licensure study found HPV vaccine was NOT associated with Guillain Barré Syndrome, seizures, stroke, syncope, or venous thromboembolism. Several clinical trials found HPV vaccination associated with short-term severe pain at injection site. Trials also found vaccine associated with fever, headache, nausea and stomach ache. A secondary analysis including only black women who became pregnant within 3 to 4 years of receiving HPV vaccine in two trials reported a higher rate of spontaneous abortion in vaccinated subjects.

Table 33. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
	arthralgia, pancreatitis, thromboembolic events, spontaneous abortion, and hypercoagulable states		
Inactivated polio vaccine	Insufficient – food allergy	Not covered	One post-licensure study reported association between polio vaccine in newborns and sensitivity to food allergens.
Influenza Vaccines	<p>Moderate - mild gastrointestinal disorders, febrile seizures</p> <p>Low – No association with other Serious Adverse Events in the short term in children with cancer or who have received organ transplants</p> <p>Low - influenza-like symptoms</p> <p>Insufficient – asthma exacerbation (with live vaccine), ADEM, transverse myelitis</p>	<p>The IOM committee studied seasonal influenza vaccines. The influenza vaccine is administered in two forms: a live attenuated form, administered intranasally, and an inactivated form, administered intramuscularly.</p> <p>Evidence was “inadequate to accept or reject” a causal relationship in the pediatric population between seasonal influenza vaccines and the following: seizures, (ADEM), and transverse myelitis.</p> <p>Evidence was “inadequate to accept or reject” a causal relationship between live attenuated influenza vaccine (LAIV) and asthma exacerbation or reactive airway disease (RAD) episodes.</p>	<p>Seasonal influenza vaccines were NOT associated with any serious adverse events in the short term in children with malignancy, IBD, urea cycle disorders or children who had received organ transplant in post-licensure studies.</p> <p>Both seasonal influenza vaccines and monovalent H1N1 vaccine were associated with mild gastrointestinal disorders, such as vomiting and diarrhea in children in the short-term in several large post-licensure studies. One large study¹¹⁴¹¹⁴¹¹⁴¹¹⁵ found that younger vaccinated children (aged 5 to 8 years) were more likely to experience these symptoms than older vaccinated children (aged 9 to 17 years). (Children under 5 years of age were not included in that study).</p> <p>Both live and inactivated seasonal influenza vaccines were associated with influenza-like symptoms in children in the short term in multiple studies, while not associated in others. A large U.S. post-licensure study of children under age 5 years found TIV associated with febrile seizures. Risk was increased if PCV13 was administered concomitantly</p>

Table 33. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Measles-Mumps-Rubella	<p>High – No association with Autism Spectrum Disorders</p> <p>High - anaphylaxis in children with allergies, febrile seizures</p> <p>Moderate – Transient arthralgia</p> <p>Moderate - thrombocytopenic purpura</p> <p>Insufficient - encephalitis, encephalopathy, afebrile seizures, meningitis, cerebellar ataxia, acute disseminated encephalomyelitis, transverse myelitis, optic neuritis, neuromyelitis optica, MS onset, and chronic arthropathy</p>	<p>Evidence “convincingly supports” causal relationships with febrile seizures and, anaphylaxis. Evidence “convincingly supports” a causal relationship with measles inclusion body encephalitis in immunocompromised patients.</p> <p>Evidence “favors acceptance” of a causal relationship between MMR and transient arthralgia</p> <p>Evidence “favors rejection” of a causal relationship between MMR and autism.</p> <p>Evidence is “inadequate to accept or reject” a causal relationship with encephalitis, encephalopathy, afebrile seizures, cerebellar ataxia, acute disseminated encephalomyelitis, transverse myelitis, optic neuritis, neuromyelitis optica, MS onset, and chronic arthropathy.</p>	<p>Four additional postmarketing studies were identified. Vaccination was associated with thrombocytopenic purpura in the short term. MMR vaccination was associated with increased emergency department visits within two weeks; this is indirect support of the IOM’s findings that MMR vaccine is associated with febrile seizures.</p>
Meningococcal Vaccines (MCV4. MPSV)	<p>Moderate – anaphylaxis in children with allergies</p> <p>Insufficient - encephalitis, encephalopathy, ADEM, transverse myelitis, MS, Guillain-Barré syndrome, CIDP, chronic headache.</p>	<p>Evidence “convincingly supports” a causal relationship with anaphylaxis in children who may be allergic to ingredients.</p> <p>Evidence is “inadequate to accept or reject” causal relationships between meningococcal vaccine (unspecified) and the following: encephalitis, encephalopathy, ADEM, transverse myelitis, MS, Guillain-Barré syndrome, CIDP, and chronic headache.</p>	<p>Two new trials of quadrivalent meningococcal conjugate vaccines found no association with any AEs assessed.</p>

Table 33. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Miscellaneous & Combination Vaccines	<p>Moderate - DTaP-IPV-Hib vaccination with febrile seizures</p> <p>High – no association of childhood leukemia with MMR, DTaP, Td, Hib, Hep B, and polio vaccines</p> <p>Moderate – Hepatitis A, MMR, and varicella vaccine with purpura</p>	Not covered	<p>Association of DTaP-IPV-Hib vaccination with febrile seizures in children was found in a very large, high quality post-licensure study. Rate for first dose was estimated as 5.5 cases per 100,000 person/days. Rate for second dose was estimated as 5.7 cases per 100,000 person/days.</p> <p>Multiple large epidemiological studies have assessed MMR, DTaP, Td, Hib, Hep B, and polio vaccine and have found no association with childhood leukemia.</p> <p>In a large post-licensure study of over 1.8 million vaccines recipients, purpura was associated with vaccination against Hepatitis A in children aged 7 to 17 years, vaccination against varicella in children aged 11 to 17, and MMR in children from 12 to 19 months of age. These results were based on one or two cases per vaccine type/age group. According to the authors most cases were mild and acute.</p>
Pneumococcal Conjugate (PCV13)	Moderate – Febrile seizures	Not covered.	<p>A recent study using the U.S. Vaccine Safety Datalink (VSD) found an association with febrile seizures. Estimated rate for 16-month old patients is 13.7 cases per 100,000 doses for PCV13 without concomitant TIV, and 44.9 per 100,000 doses for concomitant TIV and PCV13.</p>

Table 33. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
Rotavirus Vaccines: RotaTeq and Rotarix	Moderate – intussusception	Not covered.	In clinical trials, there was no association between either of the two currently available vaccines (RotaTeq and Rotarix) and any serious adverse events, including intussusception, in the long or short-term. A high quality epidemiological study in Australia found RotaTeq was associated with intussusception 1 to 21 days following the first of three required doses in infants 1 to 3 months of age. Two case-control studies conducted in Latin America found an association of Rotarix with intussusception in children following the first of two required doses. Although one U.S. epidemiological study found no association, a recent analysis of the U.S. Post-Licensure Rapid Immunization Safety Monitoring (PRISM) program found both RotaTeq and Rotarix associated with intussusception in the short term. Estimated rate was 1.1 to 1.5 cases per 100,000 doses of RotaTeq and 5.1 cases per 100,000 doses of Rotarix.
Varicella Vaccine	High – anaphylaxis, disseminated Oka VZV without other organ involvement, disseminated Oka VZV with subsequent infection resulting in pneumonia, meningitis, or hepatitis in individuals with demonstrated immunodeficiencies, vaccine strain viral reactivation without other organ involvement, vaccine strain viral reactivation with subsequent infection resulting in meningitis or encephalitis	Evidence “convincingly supports” causal relationships between varicella virus vaccine and the following: disseminated Oka VZV without other organ involvement disseminated Oka VZV with subsequent infection resulting in pneumonia, meningitis, or hepatitis in individuals with demonstrated immunodeficiencies, vaccine strain viral reactivation without other organ involvement, vaccine strain viral reactivation with subsequent infection resulting in meningitis or encephalitis, and anaphylaxis. The evidence is “inadequate to accept or reject” a causal relationship between the vaccine and seizures, ADEM, transverse myelitis, Guillain-Barré syndrome, small fiber neuropathy, onset or exacerbation of arthropathy, and thrombocytopenia.	We identified one small trial in children with lupus (SLE); the trial reported no association with AEs.

Table 33. Summary: safety of vaccines used for routine immunization of adults (including pregnant women) and children (continued)

Vaccine	EPC Conclusions and Strength of Evidence	IOM Findings	Additional Findings From EPC
	Insufficient – seizures, ADEM, transverse myelitis, Guillain-Barré syndrome, small fiber neuropathy, onset or exacerbation of arthropathy, thrombocytopenia.		
Pregnant Women			
Influenza Vaccines	Moderate – No association with serious adverse events	Results not specific to pregnant women	Both monovalent H1N1 vaccine and seasonal influenza vaccine (inactivated) containing H1N1 strains were not associated with serious adverse events in pregnant women or their offspring in multiple trials and post-licensure studies. Studies report an association with lower risk of adverse pregnancy outcomes.

ADEM = acute disseminated encephalomyelitis; AEs = adverse events; CIDP = chronic inflammatory demyelinating polyneuropathy; DTaP = diphtheria, tetanus, and pertussis vaccine; EPC = Evidence-based Practice Center; GBS = Guillain-Barré Syndrome; Hep B = hepatitis B; Hib = Haemophilus influenzae type B; HPV = human papillomavirus; IOM = Institute of Medicine; LAIV = live attenuated influenza vaccine; MMR = measles, mumps, rubella vaccine; MS = multiple sclerosis; RAD = reactive airway disease; SIDS = sudden infant death syndrome; SLE = systemic lupus erythematosus; Td = tetanus-diphtheria; TIV = trivalent influenza vaccine; VZV = varicella-zoster virus

Research Gaps

Adults

There was insufficient evidence to determine whether influenza vaccines are associated with onset or exacerbation of MS.

A recent meta-analysis on 2009 monovalent H1N1 vaccine provided high strength evidence of association with Guillain Barré Syndrome in adults. As the vaccine is associated with only 1.6 excess cases per million vaccinated, it will be very difficult to assess risk factors.

The unknown association regarding MS and GBS and vaccines against hepatitis A, hepatitis B, and MMR presents a research gap; the IOM found evidence inadequate to accept or reject a causal relationship.

Some published vaccine trials were not specific in reporting AEs. Broad categories such as “injection-related adverse events,” “systemic adverse events,” “one or more adverse events” or “serious adverse events” were reported rather than specific AE. In addition, many studies reported on a list of pre-defined adverse events but did not rate the severity or provide enough information for our investigators to determine severity. Future trials of vaccines should report results with more granularity.

Children and Adolescents

There is insufficient evidence to determine any potential association between trivalent inactivated vaccine and asthma exacerbation, acute disseminated encephalomyelitis (ADEM), and transverse myelitis.

Febrile seizures were associated with MMR, influenza, and pneumococcal conjugate vaccines. Younger age was associated with increased risk in several studies. Large scale epidemiological studies could determine other patient risk factors.

A large post-licensure study found associations between both Rotarix and RotaTeq and intussusception in the short term following vaccination in U.S. children; patient risk factors were not reported.

Strong evidence for a lack of association of HPV vaccines with several serious medical conditions (juvenile rheumatoid arthritis, type 1 diabetes, GBS) has been found in large post-licensure studies. However, there is insufficient evidence regarding other serious conditions such as MS, chronic inflammatory demyelinating polyneuropathy, amyotrophic lateral sclerosis, and pancreatitis. Importantly, a recent analysis of long term follow-up data from two trials of Gardasil showed a possible increased risk of miscarriage of pregnancies within four years of vaccination among Black women. Large datasets from U.S. Managed Care Organizations (MCOs) include both immunizations and pregnancy records needed to investigate the potential relationship.

There is insufficient evidence to determine the possible association, if any, between vaccines such as DTaP, meningococcal vaccine, and varicella vaccine and the onset of nervous system conditions such as ADEM, transverse myelitis, MS, and GBS. Large scale epidemiological studies could provide additional data; however, as these medical conditions are extremely rare, it may be difficult to reach a level of evidence beyond “insufficient”.

Pregnant Women

There is moderate strength of evidence that inactivated influenza vaccine is not associated with serious adverse events in pregnant women or their offspring. Given the 2013 recommendation to administer the Tdap vaccine during every pregnancy, passive surveillance systems should be monitored regularly for AEs in this population. This is a particular concern for women with multiple pregnancies over a period of a few years.

A reliable system of tracking when in pregnancy the vaccine was given is extremely important. In addition, in any study of vaccines and pregnancy, follow-up of newborns should be sufficiently long, as not all adverse effects may be apparent immediately after birth. The need for large numbers of pregnant exposures is particularly important given the relative low frequency of some birth defects and defining which are causal to vaccine. In addition, little is known about the patient factors which may influence the effect of the vaccine. Another unknown is how vaccination in pregnancy may affect the newborn's immune system/reaction to newborn vaccinations. The Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) has components to monitor safety of maternally-administered vaccines and their effect on recipients and their offspring. VAMPSS is a collaboration of the American Academy of Asthma Allergy and Immunology, the Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego and the Sloane Epidemiology Center (SEC) at Boston University. The U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority contracted VAMPSS to perform safety monitoring of pandemic H1N1 influenza vaccine administered during the 2009 pandemic. As this report was being finalized, a VAMPSS study on the safety of H1N1 was released;^{238,239} the authors found no meaningful evidence of increase risk of major birth defects, miscarriage, or low birth weight for gestational age. Further, existing federal systems such as the VSD and/or PRISM could be potentially be used, as well.

General Methodological Observations

Advanced health information technology (HIT) systems that contain both vaccination and health outcome records can be used to conduct high quality epidemiological studies. In the United States, the VSD contains data obtained through such systems at nine very large MCOs. The FDA's Mini-Sentinel program also conducts active surveillance using electronic healthcare databases from MCOs. Nations with single payer healthcare systems often have electronic registries which allow very large epidemiological studies of entire populations. Studies using these databases have greater validity than studies that rely on surveys that use patient / parent recall for ascertainment of vaccination or health outcome. Not only are such surveys subject to recall bias, but there may be no way of determining the formulation or brand of vaccination.

Observational studies should be powered adequately to determine risk factors such as demographic and health characteristics of patients. Analysis should be stratified by formulation and brand of vaccine, if possible. This is especially true for influenza vaccine, which differs from season to season.

Independent abstraction and systematic reassessment of the studies included in the Institute of Medicine consensus report "Adverse Effects of Vaccines: Evidence and Causality" may be a useful future endeavor. Odds ratios could be calculated for each event reported in each trial and post-licensure study, and, where appropriate, meta-analysis conducted to calculate overall odds ratios for each AE and each vaccine type. If these studies were abstracted, the totality of data

could be statistically analyzed to explore additional hypotheses and issues beyond the scope of the current report.

References

1. Ten great public health achievements--United States, 1900-1999. *MMWR Morb Mortal Wkly Rep.* 1999 Apr 2;48(12):241-3. PMID: 10220250.
2. National, state, and local area vaccination coverage among children aged 19-35 months - United States, 2011. *MMWR Morb Mortal Wkly Rep.* 2012 Sep 7;61:689-96. PMID: 22951450.
3. National and state vaccination coverage among adolescents aged 13-17 years - United States, 2011. *MMWR Morb Mortal Wkly Rep.* 2012 Aug 31;61:671-7. PMID: 22932301.
4. Adult vaccination coverage--United States, 2010. *MMWR Morb Mortal Wkly Rep.* 2012 Feb 3;61(4):66-72. PMID: 22298302.
5. Influenza vaccination coverage among pregnant women --- United States, 2010-11 influenza season. *MMWR Morb Mortal Wkly Rep.* 2011 Aug 19;60(32):1078-82. PMID: 21849964.
6. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. *Vaccine.* 2007 Jun 28;25(27):5086-96. PMID: 17544181.
7. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2008 Incidence and Mortality Web-based Report Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. Atlanta (GA): 2012.
8. Centers for Disease Control and Prevention (CDC). Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women — Advisory Committee on Immunization Practices (ACIP), 2012. *MMWR Morb Mortal Wkly Rep.* February 22, 2013;62(7):131-5.
9. Marshall V, Baylor NW. Food and Drug Administration regulation and evaluation of vaccines. *Pediatrics.* 2011 May;127 Suppl 1:S23-30. PMID: 21502242.
10. Salmon DA, Pavia A, Gellin B. Editors' introduction: Vaccine safety throughout the product life cycle. *Pediatrics.* 2011 May;127 Suppl 1:S1-4. PMID: 21502245.
11. U.S. Food and Drug Administration (FDA). Postmarket Requirements and Commitments. 2013. <http://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm>. Accessed on June 06, 2013.
12. Nguyen M, Ball R, Midtun K, et al. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. *Pharmacoepidemiology & Drug Safety.* 2012 Jan;21 Suppl 1:291-7. PMID: 22262619.
13. Mini-Sentinel. 2011. http://www.mini-sentinel.org/about_us/. Accessed on June 06, 2013.
14. U.S. Food and Drug Administration (FDA). Vaccines, Blood & Biologics. 2013. <http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/ucm196251.htm>. Accessed on June 06, 2013.
15. Ball R, Horne D, Izurieta H, et al. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration. *Pediatrics.* 2011 May;127 Suppl 1:S31-8. PMID: 21502249.
16. Haber P, Iskander J, Walton K, et al. Internet-based reporting to the vaccine adverse event reporting system: A more timely and complete way for providers to support vaccine safety. *Pediatrics.* 2011 May;127(SUPPL. 1):S39-S44. PMID: 2011239116 MEDLINE PMID 21502243.
17. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. *Pediatrics.* 2011 May;127 Suppl 1:S45-53. PMID: 21502240.

18. LaRussa PS, Edwards KM, Dekker CL, et al. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network. *Pediatrics*. 2011 May;127 Suppl 1:S65-73. PMID: 21502239.
19. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *Lancet*. 1998 Feb 28;351(9103):637-41. PMID: 9500320.
20. Jansen VA, Stollenwerk N, Jensen HJ, et al. Measles outbreaks in a population with declining vaccine uptake. *Science*. 2003 Aug 8;301(5634):804. PMID: 12907792.
21. Retraction--Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *Lancet*. 2010 Feb 6;375(9713):445. PMID: 20137807.
22. Freed GL, Clark SJ, Hibbs BF, et al. Parental vaccine safety concerns. The experiences of pediatricians and family physicians. *Am J Prev Med*. 2004 Jan;26(1):11-4. PMID: 14700706.
23. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2011. *Ann Intern Med*. 2011;154(154):168-73.
24. CDC (Centers for Disease Control and Prevention). ACIP Recommendations Advisory Committee for Immunization Practices (ACIP) Available at: <http://www.cdc.gov/vaccines/pubs/acip-list.htm>. 2012.
25. CDC (Centers for Disease Control and Prevention). Guidelines for Vaccinating Pregnant Women. Available at: <http://www.cdc.gov/vaccines/pubs/preg-guide.htm>. March 2012.
26. Evidence Partners. DistillerSR. <http://systematic-review.net/>. 2011.
27. Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
28. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. *Emerg Med J*. 2003 Jan;20(1):54-60. PMID: 12533370.
29. Whitaker HJ, Farrington CP, Spiessens B, et al. Tutorial in biostatistics: the self-controlled case series method. *Statistics in Medicine*. 2006 May 30;25(10):1768-97. PMID: 16220518.
30. DHHS (U.S. Department of Health and Human Services). Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). 2009.
31. SAS/STAT software, Version 9.3 of the SAS System for [Unix]. Copyright © 2011 SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA.
32. Santaguida PL, Raina P. The Development of the McHarm Quality Assessment Scale for adverse events: Delphi Consensus on important criteria for evaluating harms. Available at: <http://hiru.mcmaster.ca/epc/mcharm.pdf>. 2008.
33. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. *J Clin Epidemiol*. 2010 May;63(5):513-23. PMID: 19595577.
34. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol*. 2011 Apr;64(4):401-6. PMID: 21208779.
35. Greene SK, Kulldorff M, Lewis EM, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. *Am J Epidemiol*. 2010 Jan 15;171(2):177-88. PMID: 19965887.
36. De Serres G, Skowronski DM, Guay M, et al. Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons. *Arch Intern Med*. 2004 Nov 8;164(20):2266-72. PMID: 15534165.

37. Hambidge SJ, Glanz JM, France EK, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. *JAMA*. 2006 Oct 25;296(16):1990-7. PMID: 17062862.
38. Scheifele DW, Duval B, Russell ML, et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. *Clin Infect Dis*. 2003 Apr 1;36(7):850-7. PMID: 12652385.
39. Skowronski DM, De Serres G, Scheifele D, et al. Randomized, double-blind, placebo-controlled trial to assess the rate of recurrence of oculorespiratory syndrome following influenza vaccination among persons previously affected. *Clin Infect Dis*. 2003 Oct 15;37(8):1059-66. PMID: 14523770.
40. Castro M, Dozor A, Fish J, et al. The safety of inactivated influenza vaccine in adults and children with asthma. *New England Journal of Medicine*. 2001;245(21):1529-36.
41. Kmiecik T, Arnoux S, Kobryna A, et al. Influenza vaccination in adults with asthma: safety of an inactivated trivalent influenza vaccine. *J Asthma*. 2007 Dec;44(10):817-22. PMID: 18097856.
42. Nicholson KG, Nguyen-Van-Tam JS, Ahmed AH, et al. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. *Lancet*. 1998 Jan 31;351(9099):326-31. PMID: 9652613.
43. Pedroza A, Huerta JG, Garcia Mde L, et al. The safety and immunogenicity of influenza vaccine in children with asthma in Mexico. *Int J Infect Dis*. 2009 Jul;13(4):469-75. PMID: 19084453.
44. Stenius-Aarniala B, Huttunen JK, Pyhala R, et al. Lack of clinical exacerbations in adults with chronic asthma after immunization with killed influenza virus. *Chest*. 1986 Jun;89(6):786-9. PMID: 3709244.
45. Tata LJ, West J, Harrison T, et al. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? *Thorax*. 2003 Oct;58(10):835-9. PMID: 14514932.
46. Langley JM, Aoki F, Ward BJ, et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. *Vaccine*. 2011 24;29(10):1921-8. PMID: 2011100418 MEDLINE PMID 21219987 (<http://www.ncbi.nlm.nih.gov/pubmed/21219987>).
47. Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. *Lancet*. 2011 Feb 26;377(9767):751-9. PMID: 21329971.
48. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. *Clinical Infectious Diseases*. 2010 Nov 1;51(9):997-1004. PMID: 20868284.
49. Iorio A, Basileo M, Marcucci M, et al. Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. *Archives of Internal Medicine*. 2010 Apr 12;170(7):609-16. PMID: 20386004.
50. Jackson LA, Gaglani MJ, Keyserling HL, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. *BMC Infectious Diseases*. 2010;10:71. PMID: 20236548.
51. Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok[REGISTERED]) against influenza in healthy adults: a randomized, placebo-controlled trial. *Vaccine*. 2011 Oct 13;29(44):7733-9. PMID: 21835220.
52. Talaat KR, Greenberg ME, Lai MH, et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. *Journal of Infectious Diseases*. 2010 1;202(9):1327-37. PMID: 201057959 MEDLINE PMID 20874515 .

53. Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. *Clinical Infectious Diseases*. 2011 Jan 1;52(1):128-37. PMID: 21148531.
54. Wang IK, Lin CL, Lin PC, et al. Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. *PLoS ONE* [Electronic Resource]. 2013;8(3):e58317. PMID: 23516462.
55. Baxter R, Bakshi N, Fireman B, et al. Lack of association of guillain-barre syndrome with vaccinations. *Clin Infect Dis*. 2013 Jul;57(2):197-204. PMID: 23580737.
56. Greene SK, Rett M, Weintraub ES, et al. Risk of Confirmed Guillain-Barre Syndrome Following Receipt of Monovalent Inactivated Influenza A (H1N1) and Seasonal Influenza Vaccines in the Vaccine Safety Datalink Project, 2009-2010. *American Journal of Epidemiology*. 2012 Jun 1;175(11):1100-9. PMID: 22582210.
57. Salmon DA, Proschan M, Forshee R, et al. Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. *Lancet*. 2013 Apr 27;381(9876):1461-8. PMID: 23498095.
58. Grimaldi-Bensouda L, Alperovitch A, Besson G, et al. Guillain-Barre syndrome, influenza-like illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. *American Journal of Epidemiology*. 2011 Aug 1;174(3):326-35. PMID: 21652600.
59. Crawford NW, Cheng A, Andrews N, et al. Guillain-Barre syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series. *Medical Journal of Australia*. 2012 Nov 19;197(10):574-8. PMID: 23163689.
60. Lee GM, Greene SK, Weintraub ES, et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. *American Journal of Preventive Medicine*. 2011 Aug;41(2):121-8. PMID: 21767718.
61. Isai A, Durand J, Le Meur S, et al. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. *Vaccine*. 2012 Nov 19;30(49):7123-9. PMID: 23022149.
62. Farez MF, Ysraelit MC, Fiol M, et al. H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study. *Multiple Sclerosis*. 2012 Feb;18(2):254-6. PMID: 21828198.
63. Tanner K, Roy N, Merrill RM, et al. Case-control study of risk factors for spasmodic dysphonia: A comparison with other voice disorders. *Laryngoscope*. 2012 May;122(5):1082-92. PMID: 22253036.
64. Siriwardena AN, Gwini SM, Coupland CAC. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. *CMAJ Canadian Medical Association Journal*. 2010 Oct 19;182(15):1617-23. PMID: 20855479.
65. Johnstone J, Loeb M, Teo KK, et al. Influenza vaccination and major adverse vascular events in high risk patients. *Circulation*. 2012;21.
66. Hedlund J, Christenson B, Lundbergh P, et al. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: A 1-year follow-up. *Vaccine*. 2003 August/September;21(25 26):3906-11. PMID: 2003442603 MEDLINE PMID 12922125 .
67. Gwini SM, Coupland CAC, Siriwardena AN. The effect of influenza vaccination on risk of acute myocardial infarction: self-controlled case-series study. *Vaccine*. 2011 Feb 1;29(6):1145-9. PMID: 21172383.
68. Garbe E, Andersohn F, Bronder E, et al. Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. *European Journal of Clinical Pharmacology*. 2012;68(5):821-32.

69. Hambidge SJ, Ross C, McClure D, et al. Trivalent inactivated influenza vaccine is not associated with sickle cell hospitalizations in adults from a large cohort. *Vaccine*. 2011 Oct 26;29(46):8179-81. PMID: 21930176.
70. Gilbertson DT, Guo H, Arneson TJ, et al. The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. *Nephrology Dialysis Transplantation*. 2011 Sep;26(9):2934-9. PMID: 21317410.
71. Hurst FP, Lee JJ, Jindal RM, et al. Outcomes associated with influenza vaccination in the first year after kidney transplantation. *Clinical Journal of The American Society of Nephrology: CJASN*. 2011 May;6(5):1192-7. PMID: 21511837.
72. Ting SCH, Crooks SW, South G. The effect of influenza vaccination on the incidence of chronic obstructive pulmonary disease exacerbations in the immediate postvaccination period. *Journal of Epidemiology & Community Health*. 2011 Feb;65(2):157-9. PMID: 19996358.
73. Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age. *Vaccine*. 2012 Apr 26;30(20):3053-60. PMID: 22425787.
74. Tseng HF, Slezak JM, Quinn VP, et al. Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men. *JAMA*. 2010 May 5;303(17):1699-706. PMID: 20442385.
75. Eurich DT, Johnstone JJ, Minhas-Sandhu JK, et al. Pneumococcal vaccination and risk of acute coronary syndromes in patients with pneumonia: population-based cohort study. *Heart*. 2012 Jul;98(14):1072-7. WOS:000305886300008.
76. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up. *BMC Public Health*. 2012;12:222. PMID: 22436146.
77. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. *New England Journal of Medicine*. 2004 Dec 16;351(25):2611-8. PMID: 15602021.
78. Macaladad N, Marcano T, Guzman M, et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. *Vaccine*. 2007 Mar 1;25(11):2139-44. PMID: 17250932.
79. Schmader KE, Levin MJ, Gnann JW, Jr., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. *Clinical Infectious Diseases*. 2012 Apr;54(7):922-8. PMID: 22291101.
80. Vermeulen JN, Lange JMA, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults \geq 60 years of age. *Vaccine*. 2012 Jan 20;30(5):904-10. PMID: 22154769.
81. Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. *Vaccine*. 2010 Jun 7;28(25):4204-9. PMID: 20416263.
82. Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. *Annals of Internal Medicine*. 2010 May 4;152(9):545-54. PMID: 20439572.
83. Murray AV, Reisinger KS, Kerzner B, et al. Safety and tolerability of zoster vaccine in adults \geq 60 years old. *Human Vaccines*. 2011 Nov;7(11):1130-6. PMID: 22048110.
84. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. *JAMA*. 2012 Jul 4;308(1):43-9. PMID: 22760290.
85. Tseng HF, Liu A, Sy L, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. *Journal of Internal Medicine*. 2012 May;271(5):510-20. PMID: 22026504.

86. Baxter R, Tran TN, Hansen J, et al. Safety of ZostavaxTM--a cohort study in a managed care organization. *Vaccine*. 2012 Oct 19;30(47):6636-41. PMID: 22963800.
87. Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. *Human Vaccines*. 2010 Apr;6(4):318-21. PMID: 20372089.
88. Ngan HYS, Cheung ANY, Tam KF, et al. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: Immunogenicity and safety in healthy Chinese women from Hong Kong. *Hong Kong Medical Journal*. 2010 2010;16(3):171-9. PMID: 2010451858 MEDLINE PMID 20519752 .
89. Bhatla N, Suri V, Basu P, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.[Erratum appears in *J Obstet Gynaecol Res*. 2010 Apr;36(2):466]. *Journal of Obstetrics & Gynaecology Research*. 2010 Feb;36(1):123-32. PMID: 20178538.
90. Lee S, Park WB, Shin K-H, et al. Immunogenicity and safety of a single intramuscular dose of a diphtheria-tetanus toxoid (Td) vaccine (GC1107) in Korean adults. *Vaccine*. 2011 Oct 13;29(44):7638-43. PMID: 21864613.
91. Eder L, Law T, Chandran V, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. *Arthritis Care and Research*. 2011 August;63(8):1091-7. PMID: 2011461623 MEDLINE PMID 21560259 .
92. Duderstadt SK, Rose CE, Jr., Real TM, et al. Vaccination and risk of type 1 diabetes mellitus in active component U.S. Military, 2002-2008. *Vaccine*. 2012 Jan 17;30(4):813-9. PMID: 22075092.
93. Yu O, Bohlke K, Hanson CA, et al. Hepatitis B vaccine and risk of autoimmune thyroid disease: A Vaccine Safety Datalink study. *Pharmacoepidemiology and Drug Safety*. 2007 July;16(7):736-45. PMID: 2007375340 MEDLINE PMID 17192842 .
94. Mitchell LA, Tingle AJ, MacWilliam L, et al. HLA-DR class II associations with rubella vaccine-induced joint manifestations. *J Infect Dis*. 1998 Jan;177(1):5-12. PMID: 9419163.
95. Ray P, Black S, Shinefield H, et al. Risk of chronic arthropathy among women after rubella vaccination. *Vaccine Safety Datalink Team. JAMA*. 1997 Aug 20;278(7):551-6. PMID: 9268275.
96. Slater PE, Ben-Zvi T, Fogel A, et al. Absence of an association between rubella vaccination and arthritis in underimmune postpartum women. *Vaccine*. 1995 Nov;13(16):1529-32. PMID: 8578837.
97. Tingle AJ, Mitchell LA, Grace M, et al. Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women. *Lancet*. 1997 May 3;349(9061):1277-81. PMID: 9142061.
98. IOM (Instituite of Medicine). *Immunization Safety Review: Multiple Immunizations and Immune Dysfunction*: The National Academies Press; 2002.
99. Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. *Clin Infect Dis*. 2004 Oct 1;39(7):920-7. PMID: 15472840.
100. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. *Pediatr Infect Dis J*. 2004 Feb;23(2):138-44. PMID: 14872180.
101. Gaglani MJ, Piedra PA, Riggs M, et al. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. *Pediatr Infect Dis J*. 2008 May;27(5):444-52. PMID: 18401289.
102. Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. *Pediatrics*. 2005 Sep;116(3):e397-407. PMID: 16140685.

103. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. *Pediatr Infect Dis J*. 2006 Oct;25(10):870-9. PMID: 17006279.
104. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. *N Engl J Med*. 2007 Feb 15;356(7):685-96. PMID: 17301299.
105. Englund JA, Walter E, Black S, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. *Pediatric Infectious Disease Journal*. 2010 Feb;29(2):105-10. PMID: 19934787.
106. Halasa N, Englund JA, Nachman S, et al. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. *Vaccine*. 2011 May 31;29(24):4110-5. PMID: 21496468.
107. Mallory RM, Malkin E, Ambrose CS, et al. Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials. *PLoS ONE [Electronic Resource]*. 2010;5(10):e13755. PMID: 21060780.
108. Madhi SA, Dittmer S, Kuwanda L, et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. *AIDS*. 2013 Jan 28;27(3):369-79. PMID: 23032417.
109. Greenhawt MJ, Spergel JM, Rank MA, et al. Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. *Annals of Allergy, Asthma, & Immunology*. 2012 Dec;109(6):426-30. PMID: 23176882.
110. Gotoh K, Ito Y, Suzuki E, et al. Effectiveness and safety of inactivated influenza vaccination in pediatric liver transplant recipients over three influenza seasons. *Pediatric Transplantation*. 2011 Feb;15(1):112-6. PMID: 21108713.
111. Stowe J, Andrews N, Bryan P, et al. Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: A database study. *Vaccine*. 2011 Nov;29(51):9467-72. WOS:000298529000009.
112. Tse A, Tseng HF, Greene SK, et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. *Vaccine*. 2012 Mar 2;30(11):2024-31. PMID: 22361304.
113. Italian Multicenter Study Group for D, Vaccine Safety in C. Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study. *BMJ Open*. 2011 Jan 1;1(2):e000167. PMID: 22021877.
114. Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. *Vaccine*. 2012 Apr 19;30(19):2989-98. PMID: 22386746.
115. Glanz JM, Newcomer SR, Hambidge SJ, et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. *Archives of Pediatrics & Adolescent Medicine*. 2011 Aug;165(8):749-55. PMID: 21810637.
116. Benchimol EI, Hawken S, Kwong JC, et al. Safety and utilization of influenza immunization in children with inflammatory bowel disease. *Pediatrics*. 2013 Jun;131(6):e1811-20. PMID: 23650306.
117. Morgan TM, Schlegel C, Edwards KM, et al. Vaccines are not associated with metabolic events in children with urea cycle disorders. *Pediatrics*. 2011 May;127(5):e1147-e53. PMID: 2011239006 MEDLINE PMID 21482610 .
118. Huu TN, Toan NT, Tuan HM, et al. Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable *Haemophilus influenzae* protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial. *BMC Infectious Diseases*. 2013;13:95. PMID: 23432812.

119. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of *Haemophilus influenzae* type b polysaccharide and *Neisseria meningitidis* outer-membrane protein complex. *New England Journal of Medicine*. 1991 Jun 20;324(25):1767-72. PMID: 1903846.
120. Capeding MRZ, Nohynek H, Pascual LG, et al. The immunogenicity of three *Haemophilus influenzae* type B conjugate vaccines after a primary vaccination series in Philippine infants. *American Journal of Tropical Medicine and Hygiene*. 1996;55(5):516-20. PMID: 1996357902 MEDLINE PMID 8940983 .
121. Andrews N, Stowe J, Miller E, et al. Post-licensure safety of the meningococcal group C conjugate vaccine. *Hum Vaccin*. 2007 Mar-Apr;3(2):59-63. PMID: 17312400.
122. Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. *N Engl J Med*. 2001 Aug 30;345(9):656-61. PMID: 11547719.
123. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. *The Vaccine Safety Datalink Team. Pediatrics*. 1997 Jun;99(6):765-73. PMID: 9164767.
124. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. *Lancet*. 1995 Mar 4;345(8949):567-9. PMID: 7619183.
125. Griffin MR, Ray WA, Mortimer EA, et al. Risk of seizures after measles-mumps-rubella immunization. *Pediatrics*. 1991 Nov;88(5):881-5. PMID: 1945626.
126. Miller E, Andrews N, Stowe J, et al. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. *Am J Epidemiol*. 2007 Mar 15;165(6):704-9. PMID: 17204517.
127. Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. *JAMA*. 2004 Jul 21;292(3):351-7. PMID: 15265850.
128. Ward KN, Bryant NJ, Andrews NJ, et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. *Pediatrics*. 2007 Aug;120(2):314-21. PMID: 17671057.
129. Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. *BMJ*. 1992 Apr 25;304(6834):1075-8. PMID: 1586818.
130. Davis RL, Marcuse E, Black S, et al. MMR immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. *The Vaccine Safety Datalink Team. Pediatrics*. 1997 Nov;100(5):767-71. PMID: 9346975.
131. Dos Santos BA, Ranieri TS, Bercini M, et al. An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. *Rev Panam Salud Publica*. 2002 Oct;12(4):240-6. PMID: 12431355.
132. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. *Ann Rheum Dis*. 2007 Oct;66(10):1384-7. PMID: 17284544.
133. LeBaron CW, Bi D, Sullivan BJ, et al. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. *Pediatrics*. 2006 Oct;118(4):1422-30. PMID: 17015532.
134. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. *Lancet*. 1986 Apr 26;1(8487):939-42. PMID: 2871241.
135. Virtanen M, Peltola H, Paunio M, et al. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. *Pediatrics*. 2000 Nov;106(5):E62. PMID: 11061799.

136. Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. *Vaccine*. 2001 Jun 14;19(27):3632-5. PMID: 11395196.
137. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. *N Engl J Med*. 2002 Nov 7;347(19):1477-82. PMID: 12421889.
138. Mrozek-Budzyn D, Kieltyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. *Pediatr Infect Dis J*. 2010 May;29(5):397-400. PMID: 19952979.
139. Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. *Lancet*. 2004 Sep 11-17;364(9438):963-9. PMID: 15364187.
140. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. *Lancet*. 1999 Jun 12;353(9169):2026-9. PMID: 10376617.
141. Andrews N, Stowe J, Miller E, et al. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. *Vaccine*. 2012 Apr 19;30(19):3042-6. PMID: 21699947.
142. Bertuola F, Morando C, Menniti-Ippolito F, et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. *Drug Safety*. 2010 Jan 1;33(1):65-72. PMID: 20000868.
143. O'Leary ST, Glanz JM, McClure DL, et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. *Pediatrics*. 2012 Feb;129(2):248-55. PMID: 22232308.
144. Wilson K, Hawken S, Kwong JC, et al. Adverse events following 12 and 18 month vaccinations: a population-based, self-controlled case series analysis. *PLoS ONE [Electronic Resource]*. 2011;6(12):e27897. PMID: 22174753.
145. Uno Y, Uchiyama T, Kurosawa M, et al. The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: The first case-control study in Asia. *Vaccine*. 2012 Jun 13;30(28):4292-8. PMID: 22521285.
146. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2010 Aug 21;376(9741):606-14. PMID: 20692030.
147. Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. *Pediatrics*. 2007 Jan;119(1):11-8. PMID: 17200266.
148. Chang C-C, Chang M-H, Lin T-Y, et al. Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. *Journal of the Formosan Medical Association*. 2009 Apr;108(4):280-5. PMID: 19369174.
149. Christie CDC, Duncan ND, Thame KA, et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. *Pediatrics*. 2010 Dec;126(6):e1499-506. PMID: 21115586.
150. Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. *Pediatric Infectious Disease Journal*. 2005 Jun;24(6):481-8. PMID: 15933555.
151. Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. *Pediatric Infectious Disease Journal*. 2007 Dec;26(12):1099-104. PMID: 18043445.
152. Grant LR, Watt JP, Weatherholtz RC, et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. *Pediatric Infectious Disease Journal*. 2012 Feb;31(2):184-8. PMID: 22252206.

153. Kawamura N, Tokoeda Y, Oshima M, et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. *Vaccine*. 2011;26(29):6335-41. PMID: 2011443943 MEDLINE PMID 21640780.
154. Kerdpanich A, Chokephaibulkit K, Watanaveeradej V, et al. Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent. *Human Vaccines*. 2010 March;6(3):254-62. PMID: 2010340035.
155. Kim DS, Lee TJ, Kang JH, et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. *Pediatric Infectious Disease Journal*. 2008 Feb;27(2):177-8. PMID: 18174862.
156. Kim JS, Bae CW, Lee KY, et al. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: A randomized, double-blind, placebo-controlled, phase IV study. *Human Vaccines and Immunotherapeutics*. 2012 June;8(6):806-12. PMID: 2012397541.
157. Laserson KF, Nyakundi D, Feikin DR, et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq([REGISTERED]), in Kenya, including among HIV-infected and HIV-exposed infants. *Vaccine*. 2012 Apr 27;30 Suppl 1:A61-70. PMID: 22520138.
158. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. *New England Journal of Medicine*. 2010 Jan 28;362(4):289-98. PMID: 20107214.
159. Narang A, Bose A, Pandit AN, et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. *Human Vaccines*. 2009 Jun;5(6):414-9. PMID: 19276664.
160. Omenaca F, Sarlangue J, Szenborn L, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. *Pediatric Infectious Disease Journal*. 2012 May;31(5):487-93. PMID: 22228231.
161. Phua KB, Quak SH, Lee BW, et al. Evaluation of RIX4414, A live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. *Journal of Infectious Diseases*. 2005 Sep;192:S6-S16. WOS:000231113500002.
162. Phua KB, Lim FS, Lau YL, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. *Vaccine*. 2009 Oct 9;27(43):5936-41. PMID: 19679216.
163. Phua KB, Lim FS, Lau YL, et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population. *Vaccine*. 2012 22;30(30):4552-7. PMID: 2012331314.
164. Rodriguez ZM, Goveia MG, Stek JE, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. *Pediatric Infectious Disease Journal*. 2007 Mar;26(3):221-7. PMID: 17484218.
165. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. *New England Journal of Medicine*. 2006 Jan 5;354(1):11-22. PMID: 16394298.
166. Sow SO, Tapia M, Haidara FC, et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. *Vaccine*. 2012 Apr 27;30 Suppl 1:A71-8. PMID: 22520140.
167. Steele AD, Reynders J, Scholtz F, et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. *Journal of Infectious Diseases*. 2010 Sep 1;202 Suppl:S93-100. PMID: 20684724.
168. Steele AD, Madhi SA, Louw CE, et al. Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa. *Pediatric Infectious Disease Journal*. 2011 Feb;30(2):125-30. PMID: 20842070.

169. Tregnaghi MW, Abate HJ, Valencia A, et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. *Pediatric Infectious Disease Journal*. 2011 June;30(6):e103-e8. PMID: 211306258 MEDLINE PMID 21378594 .
170. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. *Pediatric Infectious Disease Journal*. 2004 Oct;23(10):937-43. PMID: 15602194.
171. Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. *Vaccine*. 2006 May 29;24(22):4821-9. PMID: 16621194.
172. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. *New England Journal of Medicine*. 2006 Jan 5;354(1):23-33. PMID: 16394299.
173. Vesikari T, Karvonen A, Bouckenooghe A, et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. *Vaccine*. 2011 2011;29(11):2079-84. PMID: 201104676 MEDLINE PMID 21238572 (<http://www.ncbi.nlm.nih.gov/pubmed/21238572>).
174. Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. *Vaccine*. 2004 Jul 29;22(21-22):2836-42. PMID: 15246619.
175. Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. *Vaccine*. 2009 25;27(9):1333-9. PMID: 2009067202 MEDLINE PMID 19162114.
176. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2010 Aug 21;376(9741):615-23. PMID: 20692031.
177. Zaman K, Yunus M, El Arifeen S, et al. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. *Vaccine*. 2012 Apr 27;30 Suppl 1:A94-100. PMID: 22520143.
178. Sow SO, Tapia M, Haidara FC, et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. *Vaccine*. 2012 Apr 27;30 Suppl 1:A71-8. PMID: 22520140.
179. Lau YL, Nelson EA, Poon KH, et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. *Vaccine*. 2013 Apr 26;31(18):2253-9. PMID: 23499605.
180. Zaman K, Yunus M, El Arifeen S, et al. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. *Vaccine*. 2012 Apr 27;30 Suppl 1:A94-100. PMID: 22520143.
181. Buttery JP, Danchin MH, Lee KJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. *Vaccine*. 2011 Apr 5;29(16):3061-6. PMID: 21316503.
182. Velazquez FR, Colindres RE, Grajales C, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. *Pediatric Infectious Disease Journal*. 2012 Jul;31(7):736-44. PMID: 22695189.
183. Patel MM, Lopez-Collada VR, Bulhoes MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. *New England Journal of Medicine*. 2011 Jun 16;364(24):2283-92. PMID: 21675888.

184. Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. *JAMA*. 2012 Feb 8;307(6):598-604. PMID: 22318281.
185. Yih K, Lieu T, Kulldorff M, et al. Intussusception Risk After Rotavirus Vaccination in U.S. Infants. Available at: http://www.mini-sentinel.org/work_products/PRISM/Mini-Sentinel_PRISM_Rotavirus-and-intussusception-Report.pdf Mini-Sentinel Coordinating Center. June 2013.
186. Gallagher CM, Goodman MS. Hepatitis B Vaccination of Male Neonates and Autism Diagnosis, NHIS 1997-2002. *Journal of Toxicology and Environmental Health-Part a-Current Issues*. 2010;73(24):1665-77. WOS:000283878600002.
187. Moreira Jr ED, Palefsky JM, Giuliano AR, et al. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. *Human Vaccines*. 2011 July;7(7):768-75. PMID: 2011412543 MEDLINE PMID 21712645 .
188. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like particle vaccine. *Pediatric Infectious Disease Journal*. 2010 February;29(2):95-101. PMID: 2010088509 MEDLINE PMID 19952863.
189. Li R, Li Y, Radley D, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females. *Vaccine*. 2012 Jun 13;30(28):4284-91. PMID: 22433961.
190. Levin MJ, Moscicki A-B, Song L-Y, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. *Journal of Acquired Immune Deficiency Syndromes: JAIDS*. 2010 Oct;55(2):197-204. PMID: 20574412.
191. Kim SC, Song YS, Kim Y-T, et al. Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women. *Journal of Gynecologic Oncology*. 2011 Jun 30;22(2):67-75. PMID: 21860731.
192. Khatun S, Akram Hussain SM, Chowdhury S, et al. Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh. *Japanese Journal of Clinical Oncology*. 2012 Jan;42(1):36-41. PMID: 22194637.
193. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.[Erratum appears in N Engl J Med. 2011 Apr 14;364(15):1481]. *New England Journal of Medicine*. 2011 Feb 3;364(5):401-11. PMID: 21288094.
194. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. *Vaccine*. 2010 Aug 31;28(38):6247-55. PMID: 20643092.
195. Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: Up to 8.4 years of follow-up. *Human Vaccines and Immunotherapeutics*. 2012 March;8(3):381-8. PMID: 2012244555.
196. Schwarz TF, Huang LM, Medina DM, et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. *Journal of Adolescent Health*. 2012 Feb;50(2):187-94. PMID: 22265115.
197. Sow PS, Watson-Jones D, Kiviat N, et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women. *Journal of Infectious Diseases*. 2013 Jun 1;207(11):1753-63. PMID: 23242542.

198. Khatun S, Akram Hussain SM, Chowdhury S, et al. Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh. *Japanese Journal of Clinical Oncology*. 2012 Jan;42(1):36-41. PMID: 22194637.
199. Kang S, Kim KH, Kim YT, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. *Int J Gynecol Cancer*. 2008 Sep-Oct;18(5):1013-9. PMID: 17986242.
200. Clark LR, Myers ER, Huh W, et al. Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. *Journal of Adolescent Health*. 2013 Mar;52(3):322-9. PMID: 23299013.
201. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. *Journal of Internal Medicine*. 2012 Feb;271(2):193-203. PMID: 21973261.
202. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. *Vaccine*. 2011 Oct 26;29(46):8279-84. PMID: 21907257.
203. Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. *Archives of Pediatrics & Adolescent Medicine*. 2012 Dec;166(12):1140-8. PMID: 23027469.
204. Black S, Shinefield H, Ray P, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. *Pediatr Infect Dis J*. 1999 Dec;18(12):1041-6. PMID: 10608621.
205. Donahue JG, Kieke BA, Yih WK, et al. Varicella vaccination and ischemic stroke in children: is there an association? *Pediatrics*. 2009 Feb;123(2):e228-34. PMID: 19171574.
206. Barbosa CM, Terreri MT, Rosario PO, et al. Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. *Clinical & Experimental Rheumatology*. 2012 Sep-Oct;30(5):791-8. PMID: 22935227.
207. Blom L, Nystrom L, Dahlquist G. The Swedish childhood diabetes study. Vaccinations and infections as risk determinants for diabetes in childhood. *Diabetologia*. 1991 Mar;34(3):176-81. PMID: 1884889.
208. DeStefano F, Mullooly JP, Okoro CA, et al. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. *Pediatrics*. 2001 Dec;108(6):E112. PMID: 11731639.
209. Hviid A, Stellfeld M, Wohlfahrt J, et al. Childhood vaccination and type 1 diabetes. *N Engl J Med*. 2004 Apr 1;350(14):1398-404. PMID: 15070789.
210. Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. *Pediatr Infect Dis J*. 2010 Jul;29(7):613-7. PMID: 20190673.
211. Infections and vaccinations as risk factors for childhood type I (insulin-dependent) diabetes mellitus: a multicentre case-control investigation. EURODIAB Substudy 2 Study Group. *Diabetologia*. 2000 Jan;43(1):47-53. PMID: 10663215.
212. Khalil M, Al-Mazrou Y, Findlow H, et al. Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine. *Clinical & Vaccine Immunology: CVI*. 2012 Oct;19(10):1561-6. PMID: 22855388.

213. Klein NP, Reisinger KS, Johnston W, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.[Erratum appears in Pediatr Infect Dis J. 2012 Oct;31(10):1105]. Pediatric Infectious Disease Journal. 2012 Jan;31(1):64-71. PMID: 22094635.
214. Bernsen RMD, de Jongste JC, Koes BW, et al. Diphtheria tetanus pertussis poliomyelitis vaccination and reported atopic disorders in 8-12-year-old children. Vaccine. 2006 Mar 15;24(12):2035-42. PMID: 16368169.
215. Gruber C, Warner J, Hill D, et al. Early atopic disease and early childhood immunization--is there a link? Allergy. 2008 Nov;63(11):1464-72. PMID: 18925883.
216. Mommers M, Weishoff-Houben M, Swaen GM, et al. Infant immunization and the occurrence of atopic disease in Dutch and German children: a nested case-control study. Pediatr Pulmonol. 2004 Oct;38(4):329-34. PMID: 15334511.
217. Mullooly JP, Schuler R, Barrett M, et al. Vaccines, antibiotics, and atopy. Pharmacoepidemiology and Drug Safety. 2007 March;16(3):275-88. PMID: 2007140424 MEDLINE PMID 16794993 (<http://www.ncbi.nlm.nih.gov/pubmed/16794993>).
218. Thomson JA, Widjaja C, Darmaputra AAP, et al. Early childhood infections and immunisation and the development of allergic disease in particular asthma in a high-risk cohort: A prospective study of allergy-prone children from birth to six years. Pediatric Allergy & Immunology. 2010 Nov;21(7):1076-85. PMID: 20337970.
219. Sun YL, Christensen J, Hviid A, et al. Risk of Febrile Seizures and Epilepsy After Vaccination With Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, and Haemophilus Influenzae Type b. Jama-Journal of the American Medical Association. 2012 Feb;307(8):823-31. WOS:000300551300025.
220. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine safety datalink project: A new tool for improving vaccine safety monitoring in the United States. Pediatrics. 1997 June;99(6):765-73. PMID: 1997164925 MEDLINE PMID 9164767.
221. Gold M, Dugdale S, Woodman RJ, et al. Use of the Australian Childhood Immunisation Register for vaccine safety data linkage. Vaccine. 2010 Jun 11;28(26):4308-11. PMID: 20430123.
222. Rowhani-Rahbar A, Klein NP, Lewis N, et al. Immunization and bell's palsy in children: A case-centered analysis. American Journal of Epidemiology. 2012 1;175(9):878-85. PMID: 2012258839.
223. Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination. Pharmacoepidemiology & Drug Safety. 2012 Dec;21(12):1350-8. PMID: 22807266.
224. Groves FD, Gridley G, Wacholder S, et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. Br J Cancer. 1999 Sep;81(1):175-8. PMID: 10487630.
225. Ma X, Does MB, Metayer C, et al. Vaccination history and risk of childhood leukaemia. Int J Epidemiol. 2005 Oct;34(5):1100-9. PMID: 15951359.
226. MacArthur AC, McBride ML, Spinelli JJ, et al. Risk of childhood leukemia associated with vaccination, infection, and medication use in childhood: the Cross-Canada Childhood Leukemia Study. Am J Epidemiol. 2008 Mar 1;167(5):598-606. PMID: 18079130.
227. Pagaoa MA, Okcu MF, Bondy ML, et al. Associations between vaccination and childhood cancers in Texas regions. Journal of Pediatrics. 2011 June;158(6):996-1002. PMID: 2011270649 MEDLINE PMID 21227448 (<http://www.ncbi.nlm.nih.gov/pubmed/21227448>).
228. Hummel M, Fuchtenbusch M, Schenker M, et al. No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB study. Diabetes Care. 2000 Jul;23(7):969-74. WOS:000087890200017.

229. Pahud BA, Rowhani-Rahbar A, Glaser C, et al. Lack of association between childhood immunizations and encephalitis in California, 1998-2008. *Vaccine*. 2012 Jan 5;30(2):247-53. PMID: 22080172.
230. Lin TH, Lin SY, Lin CH, et al. AdimFlu-S((registered trademark)) influenza A (H1N1) vaccine during pregnancy: The Taiwanese Pharmacovigilance Survey. *Vaccine*. 2012 30;30(16):2671-5. PMID: 2012154620.
231. Fell DB, Sprague AE, Liu N, et al. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. *American Journal of Public Health*. 2012 Jun;102(6):e33-40. PMID: 22515877.
232. Richards JL, Hansen C, Bredfeldt C, et al. Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. *Clinical Infectious Diseases*. 2013 May;56(9):1216-22. PMID: 23378281.
233. Nordin JD, Kharbanda EO, Benitez GV, et al. Maternal safety of trivalent inactivated influenza vaccine in pregnant women. *Obstetrics & Gynecology*. 2013 Mar;121(3):519-25. PMID: 23635613.
234. Dodds L, Macdonald N, Scott J, et al. The association between influenza vaccine in pregnancy and adverse neonatal outcomes. *Journal of Obstetrics & Gynaecology Canada: JOGC*. 2012 Aug;34(8):714-20. PMID: 22947404.
235. Omer SB, Goodman D, Steinhoff MC, et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. *PLoS Med*. 2011 May;8(5):e1000441. PMID: 21655318.
236. Irving SA, Kieke BA, Donahue JG, et al. Trivalent inactivated influenza vaccine and spontaneous abortion. *Obstetrics & Gynecology*. 2013 Jan;121(1):159-65. PMID: 23262941.
237. Xu R, Luo Y, Chambers C. Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models. *Pharmacoepidemiology and Drug Safety*. 2012.
238. Louik C, Ahrens K, Kerr S, et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: exposure prevalence, preterm delivery, and specific birth defects. *Vaccine*. 2013 Oct 17;31(44):5033-40. PMID: 24016804.
239. Chambers CD, Johnson D, Xu R, et al. Risks and safety of pandemic h1n1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. *Vaccine*. 2013 Oct 17;31(44):5026-32. PMID: 24016809.
240. Johnstone J, Loeb M, Teo KK, et al. Influenza vaccination and major adverse vascular events in high-risk patients. *Circulation*. 2012 Jul 17;126(3):278-86. PMID: 22715472.
241. Hambidge SJ, Ross C, Glanz J, et al. Trivalent inactivated influenza vaccine is not associated with sickle cell crises in children. *Pediatrics*. 2012 Jan;129(1):e54-9. PMID: 22157132.
242. Kelly H, Carcione D, Dowse GK, et al. The vaccine-attributable risk for febrile convulsions following influenza vaccine. *Pediatric Infectious Disease Journal*. 2012 Jul;31(7):792. PMID: 22695195.
243. Klein NP, Massolo ML, Greene J, et al. Risk factors for developing apnea after immunization in the neonatal intensive care unit. *Pediatrics*. 2008 March;121(3):463-9. PMID: 2009129439 MEDLINE PMID 18310193 (<http://www.ncbi.nlm.nih.gov/pubmed/18310193>).
244. Klein NP, Aukes L, Lee J, et al. Evaluation of immunization rates and safety among children with inborn errors of metabolism. *Pediatrics*. 2011 May;127(5):e1139-e46. PMID: 2011239005 MEDLINE PMID 21482602 (<http://www.ncbi.nlm.nih.gov/pubmed/21482602>).
245. Mullooly JP, Schuler R, Mesa J, et al. Wheezing lower respiratory disease and vaccination of premature infants. *Vaccine*. 2011 Oct 13;29(44):7611-7. PMID: 21875634.

246. Andrews N, Stowe J, Wise L, et al. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. *Vaccine*. 2010 Oct; 18;28(44):7215-20. PMID: 20800702.
247. Matheson MC, Haydn Walters E, Burgess JA, et al. Childhood immunization and atopic disease into middle-age--a prospective cohort study. *Pediatric Allergy & Immunology*. 2010 Mar;21(2 Pt 1):301-6. PMID: 20003161.
248. Nakajima K, Dharmage SC, Carlin JB, et al. Is childhood immunisation associated with atopic disease from age 7 to 32 years? *Thorax*. 2007 Mar;62(3):270-5. PMID: 17090571.
249. Ray P, Black S, Shinefield H, et al. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age. *Vaccine*. 2011 Sep;29(38):6592-7. WOS:000295148800025.
250. Siberry GK, Williams PL, Lujan-Zilberman J, et al. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. *Pediatric Infectious Disease Journal*. 2010 May;29(5):391-6. PMID: 20431379.
251. Tokars JI, Lewis P, DeStefano F, et al. The risk of Guillain-Barre syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analyses. *Pharmacoepidemiology & Drug Safety*. 2012 May;21(5):546-52. PMID: 22407672.
252. Wise ME, Viray M, Sejvar JJ, et al. Guillain-Barre Syndrome During the 2009-2010 H1N1 Influenza Vaccination Campaign: Population-based Surveillance Among 45 Million Americans. *American Journal of Epidemiology*. 2012 Jun 1;175(11):1110-9. PMID: 22582209.
253. Yih WK, Lee GM, Lieu TA, et al. Surveillance for Adverse Events Following Receipt of Pandemic 2009 H1N1 Vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. *American Journal of Epidemiology*. 2012 Jun 1;175(11):1120-8. PMID: 22582207.
254. Phonrat B, Pitisuttithum P, Chamnanchanunt S, et al. Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais. *Vaccine*. 2013 Mar 1;31(11):1503-9. PMID: 23318149.
255. Whitehouse AJO, Maybery M, Wray JA, et al. No association between early gastrointestinal problems and autistic-like traits in the general population. *Developmental Medicine & Child Neurology*. 2011 May;53(5):457-62. PMID: 21418197.

Abbreviations/Acronyms

ACIP	Advisory Committee on Immunization Practices
ADEM	Acute disseminated encephalomyelitis
AEs	Adverse Events
AHRQ	Agency for Healthcare Research and Quality
ALL	Acute lymphoblastic leukemia
CAP	Community-acquired pneumonia
CCTs	Controlled Clinical Trials
CDC	Centers for Disease Control and Prevention
CER	Comparative Effectiveness Review
CI	Confidence Interval
CIDP	Chronic inflammatory demyelinating polyneuropathy
COPD	Chronic obstructive pulmonary disease
CTCAE	Common Terminology Criteria for Adverse Events
CVD	Cardiovascular Disease
DPT	Diphtheria–Pertussis–Tetanus vaccine
EPC	Evidence-based Practice Center
FDA	Food and Drug Administration
GBS	Guillain–Barré Syndrome
GERD	Gastroesophageal reflux disease
GI	Gastrointestinal
GPRD	General Practice Research Database (UK)
Hib	<i>Haemophilus influenzae</i> type b
HMO	Health Maintenance Organization
HPV	Human papillomavirus
HR	Hazard ratio
HZ	Herpes Zoster
ICD	International Classification of Diseases
IHD	Ischemic heart disease
ILI	Influenza-Like Illness
IOM	Institute of Medicine
IPD	Invasive pneumococcal disease
IPV	Inactivated polio vaccine
IRR	Incidence rate ratio
ITP	Idiopathic thrombocytopenic purpura
KQs	Key Questions
LAIV	Live attenuated influenza vaccine
MaxSPRT	Maximized sequential probability ratio test
MCO	Managed Care Organization

MCV	Meningococcal conjugate vaccine
MI	Myocardial infarction
MIV	Monovalent inactivated pandemic H1N1 vaccine
MMR	Measles, mumps, and rubella
MPSV	Meningococcal polysaccharide vaccine
MS	Multiple Sclerosis
NIH	National Institute of Health
OASH	Office of the Assistant Secretary for Health
OHSU	Oregon Health Sciences University
OR	Odds ratio
PAEDS	Pediatric Active Enhanced Disease Surveillance
PCV	Pneumococcal conjugate vaccine
PPV	Pneumococcal polysaccharide vaccination
PRAMS	Pregnancy Risk Assessment Monitoring System
PV	Pneumococcal vaccine
RAD	Reactive airway disease
RCTs	Randomized Controlled Trials
RR	Relative risk
SAE	Serious adverse events
SAS	Statistical Analysis System
SCCS	Self-controlled case series
SD	Standard deviation
SIDS	Sudden Infant Death Syndrome
SIPs	Scientific Information Packets
SLE	Systemic lupus erythematosus
SRC	Scientific Resource Center
Td	Tetanus, diphtheria
Tdap	Tetanus, diphtheria, and acellular pertussis vaccine
TEP	Technical Expert Panel
TIV	Trivalent influenza vaccine
TOO	Task Order Officer
TP	Thrombocytopenic purpura
USD	Urea cycle disorders
VAERS	Vaccine Adverse Event Reporting System
VICP	Vaccine Injury Compensation Program
VSD	Vaccine Safety Datalink
VZV	Varicella-Zoster Virus

Appendix A. Literature Search Strategy

Summary of Search Strategy – Vaccine Safety

Databases: MEDLINE (OVID), EMBASE, Web of Science, Cochrane SR, DARE, and CENTRAL to cover the existing clinical literature.

General approach: We combine search terms for the vaccine with general adverse event terms and specific adverse events.

We use generic vaccine terms as well as specific available vaccines. The list of specific adverse events for Influenza, Hib, Tetanus, Diphtheria, Pertussis, Varicella, Human Papillomavirus, Measles-Mumps-Rubella, Meningococcal, Hepatitis A, and Hepatitis B was based on the Institute of Medicine (IOM) 2011 report, Vaccine Adverse Event Reporting System (VAERS) data, and Food and Drug Administration (FDA) Mini-Sentinel data. The list of specific adverse events for Polio, Rotavirus, Zoster, and Pneumococcal (vaccines not covered by the IOM report) was based on VAERS, Mini-Sentinel, and HRSA information. General adverse event terms were used as a safeguard against missing new harms that have not yet been identified in existing summary reports.

We chose the search date of January, 2010 for the vaccines covered by the IOM report based on the IOM search date (August, 2010). For the remaining vaccines we searched without date restriction. Our search went through August 2013. Animal studies and editorials were excluded where possible. We combined Medical Subject Headings (MeSH) with free text terms in order to capture new publications not yet assigned controlled language in the electronic databases. The vaccine specific searches will de-duplicate within vaccines and across vaccines and combined in one master library. In addition, references of included studies, studies included in pertinent reviews and suggestions from clinical experts will be screened.

Vaccine Safety – Search Methodologies

LANGUAGE:

English

SEARCH STRATEGY:

NOTE:

“/” =MESH heading

“exp”=exploded MESH heading

“mp”=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier

“\$”= truncation/wild card

MMR:

measles mumps rubella vaccine/ or measles vaccine/ or (vaccination/ and measles/) or mumps vaccine/ or (vaccination/ and mumps/) or rubella vaccine/ or (vaccination/ and rubella/) or ((measles or mumps or rubella or mmr) adj5 (vaccin\$ or immuniz\$ or immunis\$)).mp. or ("triviaten berna" or priorix or trimovax or virivac or pluserix or proquad or "mmr 1" or "mmr 2" or "mmr I" or "mmr II" or mmrl or mmr2 or attenuvax or mumpsvax or meruvax).mp.

AND

safe\$.mp. or safety/ or (harm\$ or adverse or toxic or toxicity or toxicities).mp. or "side effect\$".mp. or death.mp. or mortality/ or anaphylaxis/ or anaphylactic shock/ or anaphyla\$.mp. or exp arthralgia/ or exp arthritis/ or arthropathy, neurogenic.mp. or exp arthropathy/ or arthritis.mp. or arthralgia.mp. or arthropath\$.mp. or autistic disorder/ or autism/ or infantile autism/ or asperger syndrome/ or rett syndrome/ or schizophrenia, childhood/ or child development disorders, pervasive/ or (childhood disintegrative disorder/ or pervasive development disorder.mp.) not otherwise specified/ or (autism or autistic or "pervasive development disorder\$").mp. or (rett syndrome or retts syndrome).mp. or (asperger syndrome or kanner syndrome or (child\$ adj5 schizophrenia)).mp. or (pervasive child\$ development\$ disorder\$ or disintegrative disorder\$).mp. or exp ataxia/ or ataxi\$.mp. or brachial plexus neuritis/ or brachial plexus neuritis.mp. or brachial neuritis.mp. or exp optic neuritis/ or optic neuritis.mp. or neuromyelitis optica.mp. or brachial neuralgia.mp. or amyotroph\$ neuralgi\$.mp. or (cervicobrachial neuralgi\$ or cervico-brachial neuralgi\$ or parsonage-turner syndrome or parsonage-aldren-turner syndrome or brachial neuritides or shoulder-girdle neuropath\$).mp. or brachial plexus neuritides.mp. or chronic fatigue syndrome/ or fatigue syndrome, chronic/ or fatigue syndrome\$.mp. or chronic fatigue.mp. or myalgic encephalomyelitis.mp. or fatigue disorder.mp. or (royal free disease or chronic remitting demyelinating disease\$ or disseminated neuropathy).mp. or Chronic inflammatory demyelinating polyneuropathy/ or polyradiculoneuropathy, chronic inflammatory demyelinating/ or exp multiple sclerosis/ or (polyneuropath\$ or polyradiculoneuropath\$ or multiple sclerosis).mp. or exp complex regional pain syndromes/ or exp complex regional pain syndrome/ or (complex regional pain or causalgia or reflex sympathetic dystrophy).mp. or seizures/ or Seizures, febrile/ or convulsion/ or exp epilepsies, myoclonic/ or spasms, infantile/ or Myoclonus epilepsy/ or myoclonus seizure/ or myoclonus/ or convulsion\$.ti,ab. or epileps\$.mp. or (myoclon\$ or spasm\$ or convuls\$ or seizure\$).mp. or exp encephalitis/ or exp encephalitis, viral/ or exp brain disease/ or encephal\$.ti,ab. or Encephalomyelitis.mp. or fibromyalgia/ or fibromyalg\$.mp. or fibrosis.mp. or fibrositides.mp. encephalopath\$.mp. or brain inflammation. or Myofascial pain syndrome.mp. or frozen shoulder/ or exp bursitis/ or shoulder impingement syndrome or exp synovitis/ or frozen shoulder.mp. or bursitis.mp. or synovitis.mp. or synovitides.mp. or bursitides.mp. or (Adhesive capsulitis or adhesive capsulitides or periarthritis or periarthritides).mp. or (shoulder impingement or subacromial impingement).mp. or exp hearing loss/ or (hearing adj2 loss).mp. or (deafness or hypoacusis or hypoacuses or hearing impairment).mp. or hepatitis/ or hepatitis.mp. or (Diabetes mellitus, type 1 or insulin dependent diabetes or insulin-dependent diabetes).mp. or (type 1 diabetes or type1 diabetes or juvenile onset diabetes or juvenile-onset diabetes).mp. or (iddm or brittle diabetes or autoimmune diabetes or ketosis-prone diabetes).mp. or (Meningitis or meningo\$ or meningeal or arachnoiditis or meningitides or pachymeningitis).mp. or pachymeningitides.mp. or myelitis, transverse.mp. or transverse myelitis.mp. or encephalomyelitis, acute disseminated/ or demyelinating.mp. or exp guillain-barre syndrome/ or "fisher\$ adj3 syndrome" or guillain barre.mp. or guillain-barre.mp. or myelitis.mp. or opsclonus myoclonus syndrome/ or opsclonus myoclonus syndrome.mp. or (dancing eyes dancing feet or opsclonus myoclonus ataxia or kinsbourne syndrome).mp. or exp inflammatory bowel diseases/ or inflammatory bowel disease\$.mp. or exp syncope/ or syncop\$.mp. or (fainting or (vasovagal adj5 (collapse or attack or shock or reaction\$)) or thrombocytopen\$).mp. or ((viral or virus) and infection\$ and (immunodeficien\$ or immunocompromis\$ or immunosuppress\$)).mp. or (spontaneous abort\$ or congenital abnormal\$).mp. or abnormalities, congenital/ OR Idiopathic thrombocytopenic purpura OR thrombocytopenic purpura, idiopathic/ OR Purpura, Thrombocytopenic, Idiopathic/ OR (tic OR tics).mp. OR exp lupus erythematosus, systemic/ or systemic lupus erythematosus.mp. or libman-sacks.mp. or systemic lupus.mp. OR arthritis, rheumatoid/ OR rheumatoid arthritis.mp. OR thromboembolism\$.mp. OR exp myocardial ischemia/ OR ischemic heart disease or "heart attack" or myocardial infarction or angina OR crohn\$.mp. OR ulcerative colitis.mp. OR reiter\$,mp. OR fibromyalgia/ or fibromyalg\$.mp. or fibrosis.mp. or fibrositides.mp. or "myofascial pain syndrome".mp. OR (uveitis or narcoleps\$ or stillbirth or stillborn or still-born or "systemic allergic reaction" or "polyarteritis nodosa" or stroke or strokes or "cerebrovascular accident" or "cerebrovascular accidents" or vasculitis).mp. OR ("ankylosing spondylitis" or "polymyalgia rheumatica" or "sudden infant

death").mp. or sudden infant death/ or sids.mp. or "cot death".mp. or "unexpected infant death".mp. or "serum sickness".mp.

NOT

editorials

VARICELLA/ZOSTER:

exp chickenpox vaccine/ or ((vaccines/ or vaccination/) and chickenpox/) or chickenpox vaccin\$.mp. or varicella vaccin\$.mp. or ((vaccin\$ or immuniz\$ or immunis\$).mp. and ((chicken pox or chickenpox or varicella).mp. or exp herpes zoster/ or zoster.mp. or shingles.mp.)) or varivax.mp. or varcel.mp. or varzos.mp. or varilrix.mp. or zostavax.mp.

AND

Safe\$.mp. or safety/ or (harm\$ or adverse or toxic or toxicity or toxicities).mp. or "side effect\$".mp. or death.mp. or mortality/ OR (viral adj3 reactiv\$).mp. or anaphylaxis/ or anaphylactic shock/ or anaphyla\$.mp. or exp arthralgia/ or exp arthritis/ or arthropathy, neurogenic.mp. or exp arthropathy/ or arthritis.mp. or arthralgia.mp. or arthropath\$.mp. or allergic OR allergy OR allergies {Including Related Terms} OR exp cerebellar ataxia/ or spinocerebellar ataxias/ or ataxia telangiectasia/ or machado-joseph disease/ or cerebellar ataxia\$.mp. or cerebellar incoordination\$.mp. or cerebellar dysmetria\$.mp. or hypermetria\$.mp. or adiadochokines\$.mp. or cerebellar hemiataxia\$.mp. or spinocerebellar ataxia\$.mp. or spinocerebellar atrophy.mp. or ataxia telangiectasi\$.mp. or machado-joseph.mp. or louis-bar syndrome.mp. or azorean disease.mp. OR exp myocardial infarction/ or exp stroke/ or exp death, sudden/ or cerebrovascular accident\$.mp. or myocardial infarction\$.mp. or heart attack\$.mp. or stroke.mp. or sudden death.mp. or Seizures, febrile/ or convulsion/ or exp epilepsies, myoclonic/ or spasms, infantile/ or Myoclonus epilepsy/ or myoclonus seizure/ or myoclonus/ or convulsion\$.ti,ab. or epileps\$.mp. or spasm\$.mp. or myoclon\$.mp. or seizure\$.mp. OR (((small fiber neuropath\$ or oka vzz or oka varicella).mp. or ((varicella zoster virus.mp. or herpesvirus 3, human/) and (immunosuppres\$ or immunocompromise\$ or immunodeficien\$).mp.) or disseminat\$.mp.) adj3 oka.mp.) or exp brain disease/ or encephal\$.mp. or encephalopath\$.mp. or brain inflammation.mp. or brain disease\$.mp. or brain disorder\$.mp. or exp encephalitis/ or exp encephalitis, viral/ OR (small fiber neuropath\$ or oka vzz or oka varicella).mp. OR (varicella zoster virus.mp. or herpesvirus 3, human/) and (immunosuppres\$ or immunocompromise\$ or immunodeficien\$).mp. OR (disseminat\$ adj3 oka).mp. or exp brain disease/ or encephal\$.mp. or encephalopath\$.mp. or brain inflammation.mp. or brain disease\$.mp. or brain disorder\$.mp. or exp encephalitis/ or exp encephalitis, viral/ OR (frozen shoulder/ or exp bursitis/ or shoulder impingement syndrome/ or exp synovitis/ or frozen shoulder.mp. or bursitis.mp. or synovitis.mp. or synovitides.mp. or bursitides.mp. or (Adhesive capsulitis or adhesive capsulitides or periarthritis or periarthritides).mp. or (shoulder impingement or subacromial impingement).mp. or varicella.mp.) adj3 hepatitis.mp. OR frozen shoulder/ or exp bursitis/ or shoulder impingement syndrome/ or exp synovitis/ or frozen shoulder.mp. or bursitis.mp. or synovitis.mp. or synovitides.mp. or bursitides.mp.

16-(Adhesive capsulitis or adhesive capsulitides or periarthritis or periarthritides or (shoulder impingement or subacromial impingement)).mp. OR (varicella adj3 hepatitis).mp. OR (Meningitis or meningo\$ or meningeal or arachnoiditis or meningitides or pachymeningitis or pachymeningitides).mp. or exp guillain-barre syndrome/ or myelitis, transverse.mp. or transverse myelitis.mp. or encephalomyelitis, acute disseminated/ or acute disseminated encephalomyelitis OR demyelinating.mp. or guillain barre.mp. or guillain-barre.mp. or fisher syndrome.mp. or fishers syndrome.mp. OR herpesvirus 3.mp. OR (vz adj2 virus).mp. OR ((varicella zoster virus or hhv-3 or ocular herpes zoster virus or chickenpox virus or herpesvirus varicellae) and (immunocompromis\$ or immunosuppre\$ or immunodeficien\$)).mp. OR exp pneumonia/ or pneumonia.mp. or lung inflammation.mp. or pulmonary inflammation.mp. OR exp syncope/ or syncop\$.mp. or fainting OR (vasovagal adj5 (collapse or attack or shock or reaction\$)).mp. OR exp lupus erythematosus, systemic/ or systemic lupus erythematosus.mp. or libman-sacks.mp. or systemic lupus.mp. OR exp thrombocytopenia/ or hemolytic-uremic syndrome/ or jacobsen distal 11q deletion syndrome/ or jacobsen distal 11q deletion.mp. or purpura, thrombocytopenic/ or thrombocytopenia, neonatal alloimmune/ or thrombocytopen\$.mp. or thrombopen\$.mp. OR (ramsey-hunt

or ramsey hunt or (hunt adj3 syndrome).mp. OR ((bell\$ adj2 palsy) or hemolytic-uremic syndrome or (spontaneous abort\$ or congenital abnormal\$)).mp. or abnormalities, congenital/ OR (Diabetes mellitus, type 1 or insulin dependent diabetes or insulin-dependent diabetes).mp. or (type 1 diabetes or type1 diabetes or juvenile onset diabetes or juvenile-onset diabetes).mp. or (iddm or brittle diabetes or autoimmune diabetes or ketosis-prone diabetes).mp. OR (tic OR tics).mp. OR uveitis OR narcolep\$.mp. OR rheumatoid arthritis.mp. OR live adj3 varicella.mp. OR (herpes zoster).mp. OR ataxia OR polyarteritis nodosa/ or polyarteritis nodosa.mp. or periarteritis nodosa.mp. or essential polyarteritis.mp. or necrotizing arteritis.mp. or smallfiber neuropath\$.mp. or small fiber neuropath\$.mp. OR vasculitis.mp. OR thromboembolism\$.mp. OR exp myocardial ischemia/ OR ischemic heart disease or "heart attack" or myocardial infarction or angina OR ankylosing spondylitis.mp. OR polymyalgia rheumatica.mp. OR fibromyalgia/ or fibromyalg\$.mp. or fibrosis.mp. or fibrositides.mp. or "myofascial pain syndrome".mp. OR sudden infant death/ or sudden infant death\$.mp. or sids.mp. or cot death.mp. or unexpected infant death.mp. OR serum sickness.mp.

NOT

Editorials

INFLUENZA:

influenza vaccines/ or (vaccination/ and influenza, human/) or flu vaccine.mp. or influenza vaccine\$.mp. OR (((vaccin\$ or immuniz\$ or immunis\$) and (influenza or flu or haemophilus b or haemophilus type b or haemophilus influenza\$ type b or hib)) or afluuria or agriflu or fluarix or flu-imune or flulaval or flumist or flushield or fluvirin or fluzone).mp.

AND

Safe\$.mp. or safety/ or (harm\$ or adverse or toxic or toxicity or toxicities).mp. or "side effect\$".mp. or death.mp. or mortality/ OR anaphylaxis/ or anaphylactic shock/ or anaphyla\$.mp. or exp arthralgia/ or exp arthritis/ or arthropathy, neurogenic.mp. or exp arthropathy/ or arthritis.mp. or arthralgia.mp. or arthropath\$.mp. OR (allergy or allergies or allergic).mp. OR asthma/ or status asthmaticus/ OR asthma\$.mp. or (bell\$ adj3 palsy).mp. or (facial adj3 paraly\$).mp. or (facial adj3 neuropath\$).mp. OR brachial plexus neuritis/ or brachial neuritis.mp. or brachial plexus neuritis.mp. or neuralgia.mp. or brachial plexus neuropath\$.mp. or small fiber neuropath\$.mp. OR exp myocardial infarction/ or exp stroke/ or exp death, sudden/ or cerebrovascular accident\$.mp. or myocardial infarction\$.mp. or heart attack\$.mp. or stroke.mp. or sudden death.mp. OR Chronic inflammatory demyelinating polyneuropathy/ or polyradiculoneuropathy, chronic inflammatory demyelinating/ or exp multiple sclerosis/ or (polyneuropath\$ or polyradiculoneuropath\$ or multiple sclerosis).mp. OR neuromyelitis optica/ or chronic remitting demyelinating disease.mp. or disseminated neuropathy.mp. OR neuromyelitis optica or optic neuritis).mp. or exp complex regional pain syndromes/ or exp complex regional pain syndrome/ or (complex regional pain or causalgia or reflex sympathetic dystrophy).mp. or seizures/ OR Seizures, febrile/ or convulsion/ or exp epilepsies, myoclonic/ or spasms, infantile/ or Myoclonus epilepsy/ or myoclonus seizure/ or myoclonus/ or convulsion\$.ti,ab. or epileps\$.mp. OR (myoclon\$ or spasm\$ or convuls\$ or seizure\$).mp. or exp encephalitis/ or exp encephalitis, viral/ OR exp brain disease/ or encephal\$.ti,ab. or encephalopath\$.mp. or brain inflammation.mp. OR encephalomyelitis.mp. or fibromyalgia/ or fibromyalg\$.mp. or fibrosis.mp. or fibrositides.mp. OR Myofascial pain syndrome.mp. or frozen shoulder/ or exp bursitis/ or shoulder impingement syndrome/ or exp synovitis/ or frozen shoulder.mp. or bursitis.mp. or synovitis.mp. or synovitides.mp. or bursitides.mp. or (Adhesive capsulitis or adhesive capsulitides or periarthritis or periarthritides).mp. OR (shoulder impingement or subacromial impingement).mp. or exp guillain-barre syndrome/ or myelitis, transverse.mp. or transverse myelitis.mp. or encephalomyelitis, acute disseminated/ or demyelinating.mp. or guillain barre.mp. or guillain-barre.mp. or myelitis.mp. or fisher syndrome.mp. or fishers syndrome.mp. OR oculorespiratory syndrome\$ or polyarteritis nodosa/ or polyarteritis nodosa.mp. or periarteritis nodosa.mp. or essential polyarteritis.mp. or necrotizing arteritis.mp. or small fiberneuropath\$.mp. or small fiber neuropath\$.mp. OR exp lupus erythematosus, systemic/ or systemic lupus erythematosus.mp. or libman-sacks.mp. or

systemic lupus.mp. OR exp syncope/ or syncop\$.mp. or fainting.mp. or (vasovagal adj5 (collapse or attack or shock or reaction\$)).mp. 23-vasculitis/ or vasculitis.mp. or vasculitides.mp. or angiitis.mp. or angioides.mp. or aortitis.mp. or arteritis.mp. or phlebitis.mp. or behcet syndrome.mp. or wegener granulomatosis.mp. or thrombophlebitis.mp. or papulosis.mp. or sickle cell.mp. OR (spontaneous abort\$ or congenital abnormal\$).mp. or abnormalities, congenital/ or congenital defect\$.mp. or stillbirth\$.mp. or stillborn.mp. or sudden infant death/ or sudden infant death\$.mp. or sids.mp. or cot death.mp. or unexpected infant death.mp. OR (Diabetes mellitus, type 1 or insulin dependent diabetes or insulin-dependent diabetes).mp. or (type 1 diabetes or type1 diabetes or juvenile onset diabetes or juvenile-onset diabetes).mp. or (iddm or brittle diabetes or autoimmune diabetes or ketosis-prone diabetes).mp. OR Idiopathic thrombocytopenic purpura OR thrombocytopenic purpura, idiopathic/ OR Purpura, Thrombocytopenic, Idiopathic/ OR (Tic OR tics).mp. OR uveitis OR narcolep\$.mp. OR rheumatoid arthritis.mp. OR birth adj3 defect\$.mp. OR thromboembolism\$.mp. OR exp myocardial ischemia/ OR ischemic heart disease or "heart attack" or myocardial infarction or angina OR eclampsia OR pre-eclampsia OR preeclampsia OR (preterm labor OR preterm labour).mp. OR "severe combined immune deficiency" OR ankylosing spondylitis.mp. OR polymyalgia rheumatica.mp. OR "serum sickness".mp. NOT Editorials

HEPATITIS A:

hepatitis a/ or hepatitis a vaccines/ or ((vaccination/ or vaccines/) and (hepatitis a/ or hepatitis a virus, human/)) or "hepatitis a vaccin\$".mp. or ((vaccin\$ or immuniz\$ or immunis\$ or immunolog\$) and "hepatitis a").mp. OR (havrix or vaqta or twinrix).mp.

AND

Safe\$.mp. or safety/ or (harm\$ or adverse or toxic or toxicity or toxicities).mp. or "side effect\$".mp. or death.mp. or mortality/ OR anaphylaxis/ or anaphylactic shock/ or anaphyla\$.mp. or allergy.mp. or allergies.mp. or allergic.mp. OR ((bell\$ adj2 palsy) or (facial adj2 paraly\$) or (facial adj2 neuropath\$)).mp. or Chronic inflammatory demyelinating polyneuropathy/ or "Chronic inflammatory demyelinating polyneuropathy".mp. or polyradiculoneuropathy, chronic inflammatory demyelinating/ or polyradiculoneuropathy.mp. or exp multiple sclerosis/ or "multiple sclerosis".mp. or "chronic remitting demyelinating disease\$".mp. or "disseminated neuropath\$".mp. OR frozen shoulder/ or exp bursitis/ or shoulder impingement syndrome/ or exp synovitis/ or frozen shoulder.mp. or bursitis.mp. or synovitis.mp. or synovitides.mp. or bursitides.mp. or (Adhesive capsulitis or adhesive capsulitides or periarthritis or periarthritides).mp. or (shoulder impingement or subacromial impingement).mp. OR hepatitis, autoimmune/ or autoimmune hepatitis/ or "autoimmune hepatitis".mp. OR myelitis, transverse.mp. or transverse myelitis.mp. or encephalomyelitis, acute disseminated/ OR acute disseminated encephalomyelitis or demyelinating.mp. or exp guillain-barre syndrome/ OR guillain barre.mp. or guillain-barre.mp. or "fisher syndrome".mp. or "fishers syndrome".mp. OR myelitis.mp. or exp syncope/ or syncop\$.mp. or fainting.mp. or (vasovagal adj5 (collapse or attack or shock or reaction\$)).mp. OR (seizure\$ or convuls\$ or spasm\$ or "birth defect\$" or spontaneous abort\$ or congenital abnormal\$).mp. or abnormalities, congenital/ or stillbirth\$.mp. or stillborn.mp. or "still-born".mp. or "sudden infant death".mp. or sids.mp. or "cot death\$".mp. or "unexpected infant death\$".mp. OR exp Purpura, Thrombocytopenic, Idiopathic/ or "idiopathic thrombocytopenic purpura".mp. OR tics/ or tic.mp. or tics.mp. or (uveitis or narcolep\$).mp. or exp lupus erythematosus, systemic/ or systemic lupus erythematosus.mp. or libman-sacks.mp. or systemic lupus.mp. or (rheumatoid arthritis or "polyarteritis nodosa").mp. OR (Diabetes mellitus, type 1 or insulin dependent diabetes or insulin-dependent diabetes or (type 1 diabetes or type1 diabetes or juvenile onset diabetes or juvenile-onset diabetes)).mp. OR (stroke or strokes or "cerebrovascular accident" or "cerebrovascular accidents" or vasculitis).mp. OR (thromboembolis\$ or exp myocardial ischemia/ OR ischemic heart disease or myocardial infarction or "heart attack" or angina or "ankylosing spondylitis" or "polymyalgia rheumatica"

or fibromyalgia or "serum sickness").mp. OR narcolep\$.mp. OR vasculitis OR fibromyalgia/ or fibromyalg\$.mp. or fibrositis.mp. or fibrositides.mp. OR Myofascial pain syndrome.mp.

NOT

Editorials

HEPATITIS B:

hepatitis b vaccines/ or ((vaccination/ or vaccines/) and (hepatitis b/ or hepatitis b virus/)) or "hepatitis b vaccin\$".mp. or ((vaccin\$ or immuniz\$ or immunis\$ or immunolog\$) and "hepatitis b").mp. or "engerix-b".mp. or "engerix b".mp. or "recombivax hb".mp. or "recombivax-hb".mp. or twinrix.mp. or hexavax.mp. or .mp.

AND

safe\$.mp. or safety/ or (harm\$ or adverse or toxic or toxicity or toxicities).mp. or "side effect\$".mp. or death.mp. or mortality/ OR anaphylaxis/ or anaphylactic shock/ or anaphyla\$.mp. or allergy.mp. or allergies.mp. or allergic.mp. OR exp arthralgia/ or exp arthritis/ or arthropathy, neurogenic.mp. or exp arthropathy/ or arthritis.mp. or arthralgia.mp. or arthropath\$.mp. OR rheumatoid arthritis/ or rheumatoid arthritis.mp. or brachial plexus neuritis/ or brachial neuritis.mp. or brachial plexus neuritis.mp. or neuralgia.mp. or brachial plexus neuropath\$.mp. or small fiber neuropath\$.mp. OR Chronic inflammatory demyelinating polyneuropathy/ or polyradiculoneuropathy, chronic inflammatory demyelinating/ or exp multiple sclerosis/ or (polyneuropath\$ or polyradiculoneuropath\$ or multiple sclerosis).mp. OR demyelinat\$.mp. OR neuromyelitis optica/ or chronic remitting demyelinating disease.mp. or disseminated neuropathy.mp. OR exp complex regional pain syndrome/ or exp complex regional pain syndromes/ or "complex regional pain".mp. or causalgia.mp. or "reflex sympathetic dystrophy".mp. OR Seizures, febrile/ or convulsion/ or exp epilepsies, myoclonic/ or spasms, infantile/ or Myoclonus epilepsy/ or myoclonus seizure/ or myoclonus/ or convulsions.ti,ab. or epileps\$.mp. or (myoclon\$ or spasm\$ or convuls\$ or seizure\$).mp. or exp epilepsy/ OR exp encephalitis/ or exp encephalitis, viral/ or exp brain disease/ or encephal\$.ti,ab. or encephalopath\$.mp. or brain inflammation.mp. or encephalomyelitis.mp. OR Brain Diseases/ OR erythema nodosum/ or "erythema nodosum".mp. or erythemat\$.mp. OR fibromyalgia/ or fibromyalg\$.mp. or fibrositis.mp. or fibrositides.mp. or "myofascial pain syndrome".mp. OR frozen shoulder/ or exp bursitis/ or shoulder impingement syndrome/ or exp synovitis/ or frozen shoulder.mp. or bursitis.mp. or synovitis.mp. or synovitides.mp. or bursitides.mp. or (Adhesive capsulitis or adhesive capsulitides or periarthritis or periarthritides).mp. or (shoulder impingement or subacromial impingement).mp. OR transverse myelitis.mp. or encephalomyelitis, acute disseminated/ or guillain barre.mp. OR guillian-barre.mp. OR myelitis.mp. or fisher syndrome.mp. or fishers syndrome.mp. OR myelitis.mp. or polyarteritis nodosa/ or polyarteritis nodosa.mp. or periarteritis nodosa.mp. or essential polyarteritis.mp. or necrotizing arteritis.mp. OR exp lupus erythematosus, systemic/ or systemic lupus erythematosus.mp. or libman-sacks.mp. or systemic lupus.mp. OR exp syncope/ or syncop\$.mp. or fainting.mp. or (vasovagal adj5 (collapse or attack or shock or reaction\$)).mp. OR vasculitis/ or vasculitis.mp. or vasculitides.mp. or angiitis.mp. or angiitides.mp. or aortitis.mp. or arteritis.mp. or phlebitis.mp. or behcet syndrome.mp. or wegener granulomatosis.mp. or thrombophlebitis.mp. OR Endarteritis/ OR (Diabetes mellitus, type 1 or insulin dependent diabetes or insulin-dependent diabetes or (type 1 diabetes or type1 diabetes or juvenile onset diabetes or juvenile-onset diabetes)).mp. OR exp thyroiditis, autoimmune/ or "autoimmune thyroid".mp. or "autoimmune thyroiditis".mp. or "auto-immune thyroid".mp. or "auto-immune thyroiditis".mp. OR (spontaneous abort\$ or congenital abnormal\$).mp. or abnormalities, congenital/ or congenital defect\$.mp. or stillbirth\$.mp. or stillborn.mp. or sudden infant death/ or sudden infant death\$.mp. or sids.mp. or cot death.mp. or unexpected infant death.mp. OR (tic or tics).mp. OR uveitis or narcolep\$ or birth defects or stroke or cerebrovascular accident\$ or thromboembolism\$ or exp myocardial ischemia/ OR ischemic heart disease or "heart attack" or myocardial infarction or angina or eclampsia or pre-eclampsia or preeclampsia or preterm or "pre-term" or "premature labor" or "premature labour" or reiter\$ or ankylosing spondylitis or polymyalgia rheumatica or "serum sickness").mp. OR exp Purpura,

Thrombocytopenic, Idiopathic/ or "idiopathic thrombocytopenic purpura".mp. OR (Meningitis or meningo\$ or meningeal or arachnoiditis or meningitides or pachymeningitis).mp. or pachymeningitides.mp. OR "severe combined immune deficiency"

NOT

Editorials

HUMAN PAPILLOMAVIRUS:

papillomavirus vaccines/ OR (vaccination/ AND (papillomaviridae/ OR papillomavirus infections/)) OR "papillomavirus vaccin\$" OR ((vaccin\$ OR immuniz\$) AND (papillomaviridae OR papillomavirus)) OR cervarix OR gardasil

AND

safe\$ OR harm\$ OR adverse OR toxic OR toxicity OR toxicities OR "side effect" OR "side effects" OR death OR mortality/ OR amyotrophic lateral sclerosis/ OR "amyotrophic lateral sclerosis" OR anaphylaxis/ OR anaphylactic shock/ OR anaphyla\$ OR allergic OR allergy OR allergies OR exp arthralgia/ OR exp arthritis/ OR arthropathy, neurogenic/ OR exp arthropathy/ OR arthritis OR arthralgia OR arthropath\$ OR brachial plexus neuritis/ OR "brachial neuritis" OR "brachial plexus neuritis" OR neuralgia OR brachial plexus neuropath\$ OR chronic inflammatory demyelinating polyneuropathy/ OR polyradiculoneuropathy, chronic inflammatory demyelinating/ OR exp multiple sclerosis/ OR neuromyelitis optica/ OR polyneuropath\$ OR polyradiculoneuropath\$ OR multiple sclerosis OR "neuromyelitis optica" OR OR seizures/ OR seizures, febrile/ or convulsion/ OR exp epilepsies, myoclonic/ OR spasms, infantile/ OR myoclonus epilepsy/ OR myoclonus seizure/ OR myoclonus/ OR convulsion\$.ti,ab. OR epileps\$ OR myoclon\$ OR spasm\$ OR convulsion\$ OR seizure\$ OR exp encephalitis/ OR exp encephalitis, viral/ OR encephalitis OR "brain inflammation" OR encephalomyelitis OR exp brain disease/ OR encephalopath\$.ti,ab. OR encephal\$ or "brain disease" OR "frozen shoulder" OR bursitis OR synovitis OR synovitides OR bursitides OR adhesive capsulitis OR adhesive capsulitides OR periarthritis OR periarthritides OR "shoulder impingement" OR "subacromial impingement" OR hypercoagulab\$ OR exp guillain barre syndrome/ OR "guillain barre" OR exp guillain-barre syndrome/ OR guillain-barre" OR myelitis, transverse/ OR "transverse myelitis" OR encephalomyelitis, acute disseminated/ OR "acute disseminated encephalomyelitis" OR "cerebrovascular accident" OR stroke OR myelitis OR encephalomyelitis OR demyelinating OR exp pancreatitis/ OR pancreatitis OR exp lupus erythematosus, systemic/ OR systemic lupus OR libman-sacks disease OR exp syncope/ OR syncope OR syncopes OR syncopal OR fainting OR (vasovagal adj (collapse OR attack OR shock OR reaction)) OR thromboembolism/ or thromboembol\$ OR hypercoagula\$ OR appendicitis OR "spontaneous abort\$" OR "congenital abnormal\$" OR abnormalities, congenital/ OR Diabetes mellitus, type 1 or insulin dependent diabetes or insulin-dependent diabetes or (type 1 diabetes or type1 diabetes or juvenile onset diabetes or juvenile-onset diabetes)).mp. OR Idiopathic thrombocytopenic purpura OR thrombocytopenic purpura, idiopathic/ OR Purpura, Thrombocytopenic, Idiopathic/ OR uveitis OR narcolep\$.mp. OR rheumatoid arthritis.mp. OR Fisher\$ adj syndrome.mp. OR oculorespiratory syndrome\$.mp. or polyarteritis nodosa/ or polyarteritis nodosa.mp. or periarteritis nodosa.mp. or essential polyarteritis.mp. or necrotizing arteritis.mp. or smallfiber neuropath\$.mp. or small fiber neuropath\$.mp. OR vasculitis OR exp myocardial ischemia/ OR ischemic heart disease or "heart attack" or myocardial infarction or angina OR Pancreatitis.mp. OR ankylosing spondylitis.mp. OR fibromyalgia/ or fibromyalg\$.mp. or fibrosis.mp. or fibrositides.mp. or "myofascial pain syndrome".mp. OR serum sickness.mp. OR Steril\$.mp. OR infertile\$.mp.

NOT

Editorials

DIPHTHERIA TOXOID-, TETANUS TOXOID-, AND ACELLULAR PERTUSSIS-CONTAINING VACCINES:

diphtheria-tetanus-acellular pertussis vaccines/ OR diphtheria pertussis tetanus vaccine/ OR tetanus toxoid/ OR "diphtheria-tetanus vaccine"/ OR ("diphtheria tetanus" OR "tetanus diphtheria" OR "tetanus and diphtheria" OR "diphtheria and tetanus").ti,ab. OR "tetanus toxoid".mp. OR DTaP.mp. OR TDaP.mp. OR (vaccin\$ adj5 (DT OR TD OR TT)).mp. OR "tetanus diphtheria acellular pertussis".mp. OR "tetanus diphtheria and acellular pertussis".mp. OR ((Diphtheria tetanus acellular pertussis" OR "tetanus diphtheria acellular pertussis" OR "diphtheria tetanus" OR "tetanus diphtheria" OR "tetanus toxoid" OR "tetanus and diphtheria" OR "diphtheria and tetanus" OR DTaP OR TDAP OR DT OR TD OR TT) adj5 (vaccin\$ OR immuniz\$) OR Tripedia OR Acelimune OR Infanrix OR hexavax OR "quattro virelon" OR decavac OR "acel-imune" OR "acel imune" OR certiva OR daptacel OR trihibit OR pediarix OR kinrix OR pentacel OR "tri-immunol" OR "tri immunol" OR adacel OR boostrix OR ditanrix

AND

safe\$ OR harm\$ OR adverse OR toxic OR toxicity OR "side effect" OR "side effects" OR death OR anaphylaxis/ OR anaphylactic shock/ OR anaphyla\$ OR allergic OR allergy OR allergies OR exp arthralgia/ OR exp arthritis/ OR arthropathy, neurogenic/ OR exp arthropathy/ OR arthritis OR arthralgia OR arthropath\$ OR exp arthritis, rheumatoid/ OR "rheumatoid arthritis" OR exp ataxia/ OR ataxia\$ OR "coordination impairment\$" OR dyssynergia OR "rubral tremor" OR autistic disorder/ OR autism/ OR infantile autism/ OR Asperger syndrome/ OR Rett syndrome/ OR schizophrenia, childhood/ OR child development disorders, pervasive/ OR childhood disintegrative disorder/ OR pervasive development disorder not otherwise specified/ OR autism OR autistic OR "kanner\$ syndrome" OR "autism spectrum" OR "rett\$ syndrome" OR "asperger\$ syndrome" OR "child\$ schizophrenia" OR "pervasive child\$ development\$ disorder\$" OR "pervasive development disorder\$" OR "disintegrative disorder?" OR bell palsy/ OR "bell\$ palsy" OR "facial paralys\$" OR "facial neuropath\$" OR chronic inflammatory demyelinating polyneuropathy/ OR polyradiculoneuropathy, chronic inflammatory demyelinating/ OR exp multiple sclerosis/ OR "chronic remitting demyelinating disease\$" OR "disseminated neuropathy" OR polyneuropath\$ OR polyradiculoneuropath\$ OR multiple sclerosis OR exp urticaria/ OR urticaria\$ OR hives OR angioedema OR exp complex regional pain syndrome/ OR exp complex regional pain syndromes/ OR "complex regional pain" OR causalgia OR "reflex sympathetic dystrophy" OR seizures/ OR seizures, febrile/ OR convulsion/ OR exp epilepsies, myoclonic/ OR spasms, infantile/ OR myoclonus epilepsy/ OR myoclonus seizure/ OR myoclonus/ OR convulsion\$.ti,ab. OR epileps\$ OR myoclon\$ OR spasm\$ OR convulsion\$ OR seizure\$ OR exp encephalitis/ OR exp encephalitis, viral/ OR encephalitis OR "brain inflammation" OR encephalomyelitis OR exp brain disease/ OR encephalopath\$.ti,ab. OR encephal\$ OR "brain disease" OR fibromyalgia/ OR fibromyalgia\$ OR fibrosis OR fibrositides OR "myofascial pain syndrome" OR frozen shoulder/ OR exp bursitis/ OR shoulder impingement syndrome/ OR exp synovitis/ OR "frozen shoulder" OR bursitis OR synovitis OR synovitides OR bursitides OR adhesive capsulitis OR adhesive capsulitides OR periarthritis OR periarthritides OR "shoulder impingement" OR "subacromial impingement" OR exp purpura, thrombocytopenic, idiopathic/ OR idiopathic thrombocytopenic purpura/ OR "idiopathic thrombocytopenic purpura\$" OR "werlhof\$ disease" OR "autoimmune thrombocytopenic purpura\$" OR "autoimmune thrombocytopenia\$" OR "thrombocytopen\$ purpura" OR diabetes mellitus, type 1/ OR "insulin dependent diabetes" OR "insulin-dependent diabetes" OR "type1 diabetes" OR "juvenile onset diabetes" OR "sudden-onset diabetes" OR IDDM OR "brittle diabetes" OR "autoimmune diabetes" OR "ketosis-prone diabetes" OR exp guillain barre syndrome/ OR "guillain barre" OR exp guillain- barre syndrome/ OR "guillain-barre" OR myelitis, transverse/ OR "transverse myelitis" OR encephalomyelitis, acute disseminated/ OR myelitis OR encephalomyelitis OR demyelinating OR Myocarditis/ OR myocarditis OR carditis or myocarditides OR pericarditis OR Opsoclonus-myoclonus syndrome/ OR ("Opsoclonus myoclonus syndrome" OR "dancing eyes dancing feet syndrome" OR "opsoclonus myoclonus ataxia" OR "kinsbourne syndrome" OR exp optic neuritis/ OR "optic neuritis" OR "optic neuritides" OR neuropapillitis OR neuropapillitides OR "retrobulbar neuritis" OR serum

sickness/ OR "serum sickness\$" OR "serum disease" OR "plasma sensitivity" OR sudden infant death/ OR "sudden infant death" OR SIDS OR "cot death" OR "unexpected infant death" OR exp syncope/ OR syncope OR syncopes OR syncopal OR fainting OR (vasovagal adj (collapse OR attack OR shock OR reaction)) OR "spontaneous abort\$" OR "congenital abnormal\$" OR abnormalities, congenital/ OR "congenital defect\$" OR stillbirth\$ OR stillborn OR exp meningitis/ OR meningitis OR "cranial nerve\$" OR paraly\$.mp. OR uveitis OR narcolep\$.mp. OR birth adj3 defect\$.mp. OR exp lupus erythematosus, systemic/ or systemic lupus erythematosus.mp. or libman-sacks.mp. or systemic lupus.mp. OR thrombocytopen\$.mp. OR Fisher\$ adj syndrome.mp. OR polyarteritis nodosa/ or polyarteritis nodosa.mp. or periarteritis nodosa.mp. or essential polyarteritis.mp. or necrotizing arteritis.mp. or smallfiber neuropath\$.mp. or small fiber neuropath\$.mp. OR exp stroke/ or exp death, sudden/ or cerebrovascular accident\$.mp. OR vasculitis OR thromboembolism\$.mp. OR exp myocardial ischemia/ OR ischemic heart disease or "heart attack" or myocardial infarction or angina OR eclampsia OR pre-eclampsia OR preeclampsia OR (preterm labor OR preterm labour).mp. OR ankylosing spondylitis.mp. OR polymyalgia rheumatica.mp. OR myoclonus OR "severe combined immune deficiency"

NOT

Editorials

MENINGOCOCCAL:

meningococcal vaccines/ OR MPSV4.mp. OR menomune.mp. OR MCV4.mp. or menactra.mp. OR ((vaccination/ or vaccines/) AND exp meningitis/)) OR mening\$ vaccin\$ OR ((vaccin\$ OR immuniz\$) AND meningitis))

AND

safe\$ OR harm\$ OR adverse OR toxic OR toxicity OR toxicities OR "side effect" OR "side effects" OR death OR mortality/ OR anaphylaxis/ OR anaphylactic shock/ OR anaphyla\$ OR allergic OR allergy OR allergies OR bell palsy/ OR "bell\$ palsy" OR "facial paralys\$" OR "facial neuropath\$" OR exp headache disorders/ OR (chronic adj2 headache\$) OR headache disorder\$ or headache syndrome\$ OR cephalgia syndrome\$ OR intractable headache\$ OR chronic inflammatory demyelinating polyneuropathy/ or polyradiculoneuropathy, chronic inflammatory demyelinating/ OR exp multiple sclerosis/ OR "chronic remitting demyelinating disease\$" OR "disseminated neuropathy" OR polyneuropath\$ OR polyradiculoneuropath\$ OR multiple sclerosis OR exp encephalitis/ OR exp encephalitis, viral/ OR encephalitis or brain inflammation or encephalomyelitis OR exp brain disease/ OR encephal\$.ti,ab. OR brain disease\$ or encephal\$ OR encephalomyelitis, acute disseminated OR "acute disseminated encephalomyelitis" OR myelitis, transverse/ OR "transverse myelitis" OR demyelinating OR encephalomyelitis OR frozen shoulder/ OR exp bursitis/ OR shoulder impingement syndrome/ OR exp synovitis/ OR "frozen shoulder" OR bursitis OR synovitis OR synovitides OR bursitides OR adhesive capsulitis OR adhesive capsulitides OR periarthritis OR periarthritides OR "shoulder impingement" OR "subacromial impingement" OR exp guillain barre syndrome/ OR "guillain barre" OR exp guillain-barre syndrome/ OR "guillain-barre" OR myelitis OR exp syncope/ OR syncope OR syncopes OR syncopal OR fainting OR (vasovagal adj (collapse OR attack OR shock OR reaction)) OR "spontaneous abort\$" OR "congenital abnormal\$" OR abnormalities, congenital/ OR thrombocytopenia\$ OR thrombopenia\$ OR seizures/ OR seizures, febrile/ OR convulsion/ OR exp epilepsies, myoclonic/ OR spasms, infantile/ OR myoclonus epilepsy/ OR myoclonus seizure/ OR myoclonus/ OR convulsion\$.ti,ab. OR epileps\$ OR myoclon\$ OR spasm\$ OR convulsion\$ OR seizure\$ OR purpura, schonlein-henoch/ OR "henoch-schonlein purpura\$" OR diabetes mellitus, type 1/ OR "insulin dependent diabetes" OR "insulin--dependent diabetes" OR "type1 diabetes" OR "juvenile onset diabetes" OR "sudden-onset diabetes" OR IDDM OR "brittle diabetes" OR "autoimmune diabetes" OR "ketosis-prone diabetes" OR Idiopathic thrombocytopenic purpura OR thrombocytopenic purpura, idiopathic/ OR Purpura, Thrombocytopenic, Idiopathic/ OR uveitis OR narcolep\$.mp. OR rheumatoid arthritis.mp. OR Fisher\$ adj syndrome.mp. OR (tic OR tics).mp. OR exp lupus erythematosus, systemic/ or systemic lupus erythematosus.mp. or libman-sacks.mp. or systemic lupus.mp. OR polyarteritis nodosa/ or polyarteritis nodosa.mp. or periarteritis

nodoso.mp. or essential polyarteritis.mp. or necrotizing arteritis.mp. OR exp stroke/ or exp death, sudden/ or cerebrovascular accident\$.mp. OR vasculitis OR thromboembolism\$.mp. OR exp myocardial ischemia/ OR ischemic heart disease or "heart attack" or myocardial infarction or angina OR vasculitis OR ankylosing spondylitis.mp. OR polymyalgia rheumatica.mp. OR fibromyalgia/ or fibromyalg\$.mp. or fibrositis.mp. or fibrositides.mp. or "myofascial pain syndrome".mp. OR "serum sickness".mp.

NOT

Editorials

POLIOVIRUS:

poliovirus Vaccine, Inactivated/ OR (polio\$AND (vaccine\$ OR vaccinate\$ OR vaccination\$ OR immuniz\$ OR immunis\$)) OR ipol OR poliovax OR hexavax OR "quattro virelon" OR pediarix OR kinrix OR pentacel OR orimune

AND

safe\$ OR harm\$ OR adverse OR toxic OR toxicity OR toxicities OR "side effect" OR "side effects" OR death OR mortality/ OR anaphylaxis/ OR anaphylactic shock/ OR anaphyla\$ OR exp ataxia/ OR ataxia\$ OR "coordination impairment\$" OR dyssynergia OR "rubral tremor" OR "gait adj3 disturb\$" OR allergic OR allergy OR allergies OR ((edema OR oedema) adj3 peripheral) OR exp urticaria/ OR urticaria\$ OR hives OR angioedema OR seizures/ OR seizures, febrile/ OR convulsion/ OR exp epilepsies, myoclonic/ OR spasms, infantile/ OR myoclonus epilepsy/ OR myoclonus seizure/ OR myoclonus/ OR convulsion\$.ti,ab. OR epileps\$ OR myoclon\$ OR spasm\$ OR convulsion\$ OR seizure\$ OR dyskinesia\$ OR "gaze palsy" OR hematochezia OR haematochezia OR hypotonia OR intussuscept\$ OR sudden infant death/ OR "sudden infant death" OR SIDS OR "cot death" OR "unexpected infant death" OR tremor OR exp syncope/ OR syncope OR syncopal OR fainting OR (vasovagal adj (collapse OR attack OR shock OR reaction)) OR wheez\$ OR asthma/ OR status asthmaticus/ OR asthma\$ OR "paralytic polio\$" OR "vaccine strain polio viral infection" OR "spontaneous abort\$" OR "congenital abnormal\$" OR abnormalities, congenital/ OR encephalomyelitis, acute disseminated OR "acute disseminated encephalomyelitis" OR exp guillain barre syndrome/ OR "guillain barre" OR exp guillain-barre syndrome/ OR "guillain-barre" OR myelitis, transverse/ OR "transverse myelitis" OR fibromyalgia/ OR fibromyalgia\$ OR fibrositis OR fibrositides OR thrombocytopenia\$ OR thrombopenia\$ OR diabetes mellitus, type 1/ OR "insulin dependent diabetes" OR "insulin-dependent diabetes" OR "type1 diabetes" OR "juvenile onset diabetes" OR "sudden-onset diabetes" OR IDDM OR "brittle diabetes" OR "autoimmune diabetes" OR "ketosis-prone diabetes" OR Idiopathic thrombocytopenic purpura OR thrombocytopenic purpura, idiopathic/ OR Purpura, Thrombocytopenic, Idiopathic/ OR (tic OR tics).mp. OR exp lupus erythematosus, systemic/ or systemic lupus erythematosus.mp. or libman-sacks.mp. or systemic lupus.mp. OR polyarteritis nodosa/ or polyarteritis nodosa.mp. or periarteritis nodosa.mp. or essential polyarteritis.mp. or necrotizing arteritis.mp. OR uveitis OR narcolep\$.mp. OR Fisher\$ adj syndrome.mp. OR ankylosing spondylitis.mp. OR polymyalgia rheumatica.mp. OR "serum sickness".mp.

NOT

editorials

PNEUMOCOCCAL:

pneumococcal vaccines/ OR (pneumonia/ OR pneumonia.ti,ab. OR pneumococ\$) AND (vaccine\$ OR vaccinate\$ OR vaccination\$ OR immuniz\$ OR immunis\$)) OR prevnar OR pneumovax OR "pnu-imune" OR "pnu imune" OR "pneumococcal polysaccharide\$"

AND

safe\$ OR harm\$ OR adverse OR toxic OR toxicity OR toxicities OR "side effect" OR "side effects" OR death OR mortality/ OR anaphylaxis/ OR anaphylactic shock/ OR anaphyla\$ OR exp ataxia/ OR ataxia\$ OR "coordination impairment\$" OR dyssynergia OR "gait adj3 disturb\$" OR allergic OR allergy OR

allergies OR ((edema OR oedema) adj3 peripheral) OR exp urticaria/ OR urticaria\$ OR hives OR angioedema OR seizures/ OR seizures, febrile/ OR convulsion/ OR exp epilepsies, myoclonic/ OR spasms, infantile/ OR myoclonus epilepsy/ OR myoclonus seizure/ OR myoclonus/ OR convulsion\$.ti,ab. OR epileps\$ OR myoclon\$ OR spasm\$ OR convulsion\$ OR seizure\$ OR dyskinesia\$ OR "gaze palsy" OR hematochezia OR haematochezia OR hypotonia OR intussuscept\$ OR sudden infant death/ OR "sudden infant death" OR SIDS OR "cot death" OR "unexpected infant death" OR tremor OR exp syncope/ OR syncope OR syncopes OR syncopal OR fainting OR (vasovagal adj (collapse OR attack OR shock OR reaction)) OR wheez\$ OR asthma/ OR status asthmaticus/ OR asthma\$ OR exp arthritis/ OR arthropathy, neurogenic/ OR exp arthropathy/ OR arthritis OR arthropath\$ OR chronic fatigue syndrome/ OR fatigue syndrome, chronic/ OR "fatigue syndrome\$" OR "chronic fatigue" OR "fatigue disorder" OR asthenia OR hyperhidrosis OR hypoesthesia\$ OR hypoesthesia\$ OR paraesthesia\$ OR paresthesia\$ OR "spontaneous abort\$" OR "congenital abnormal\$" OR abnormalities, congenital/ OR exp guillainbarre syndrome/ OR "guillain barre" OR myelitis, transverse/ OR "transverse myelitis" OR fibromyalgia/ OR fibromyalgia\$ OR fibrositis OR fibrositides OR thrombocytopenia\$ OR thrombopenia\$ OR serum sickness/ OR "serum sickness\$" OR "serum disease" OR "plasma sensitivity" OR encephalomyelitis, acute disseminated/ OR "acute disseminated encephalomyelitis" OR exp diabetes mellitus, type 1/ OR "insulin dependent diabetes" OR "insulin-dependent diabetes" OR "type1 diabetes" OR "juvenile onset diabetes" OR "sudden-onset diabetes" OR IDDM OR "brittle diabetes" OR "autoimmune diabetes" OR "ketosis-prone diabetes" OR Idiopathic thrombocytopenic purpura OR thrombocytopenic purpura, idiopathic/ OR Purpura, Thrombocytopenic, Idiopathic/ OR (tic OR tics).mp. OR uveitis OR narcolep\$.mp. OR Fisher\$ adj syndrome.mp. OR ankylosing spondylitis.mp. OR polymyalgia rheumatica.mp. OR exp lupus erythematosus, systemic/ or systemic lupus erythematosus.mp. or libman-sacks.mp. or systemic lupus.mp. OR exp polyarteritis nodosa/ or polyarteritis nodosa.mp. or periarteritis nodosa.mp. or essential polyarteritis.mp. or necrotizing arteritis.mp. OR rheumatoid arthritis.mp. OR thrombocytopen\$.mp. OR exp brain disease/ or encephal\$.ti,ab. or encephalopath\$.mp. or brain inflammation.mp. OR exp multiple sclerosis/ OR multiple sclerosis.mp. OR vasculitis OR exp stroke/ or exp death, sudden/ or cerebrovascular accident\$.mp. OR thromboembolism\$.mp. OR exp myocardial ischemia/ OR ischemic heart disease or "heart attack" or myocardial infarction or angina
NOT
editorials

ROTAVIRUS:

rotavirus vaccines/ OR rotavirus\$ C OR rotarix OR rotateq OR rotashield

AND

safe\$ OR harm\$ OR adverse OR toxic OR toxicity OR toxicities OR "side effect" OR "side effects" OR death OR mortality/ OR anaphylaxis/ OR anaphylactic shock/ OR anaphyla\$ OR urticaria/ OR urticaria\$ OR hives OR angioedema OR allergic OR allergy OR allergies OR intussuscept\$ OR sudden infant death/ OR "sudden infant death" OR SIDS OR "cot death" OR "unexpected infant death" OR seizures/ OR seizures, febrile/ OR convulsion/ OR exp epilepsies, myoclonic/ OR spasms, infantile/ OR myoclonus epilepsy/ OR myoclonus seizure/ OR myoclonus/ OR convulsion\$.ti,ab. OR epileps\$ OR myoclon\$ OR spasm\$ OR convulsion\$ OR seizure\$ OR dyskinesia\$ OR tremor\$ OR exp syncope/ OR syncope OR syncopes OR syncopal OR fainting OR (vasovagal adj (collapse OR attack OR shock OR reaction)) OR "spontaneous abort\$" OR "congenital abnormal\$" OR abnormalities, congenital/ OR encephalomyelitis, acute disseminated/ OR "acute disseminated encephalomyelitis" OR exp guillainbarre syndrome/ OR "guillain barre" OR myelitis, transverse/ OR "transverse myelitis" OR fibromyalgia/ OR fibromyalgia\$ OR fibrositis OR fibrositides OR "kawasaki disease\$" OR "kawasaki syndrome\$" OR exp meningitis/ OR meningitis OR exp encephalitis, viral/ OR encephalitis or brain inflammation or encephalomyelitis OR exp brain disease/ OR encephal\$.ti,ab. OR brain disease\$ OR encephal\$ OR myocarditis OR "gram-

negative sepsis" OR exp gastrointestinal hemorrhage/ OR "gastrointestinal bleeding" OR exp diabetes mellitus, type 1/ OR "insulin dependent diabetes" OR "insulin-dependent diabetes" OR "type1 diabetes" OR "juvenile onset diabetes" OR "sudden-onset diabetes" OR IDDM OR "brittle diabetes" OR "autoimmune diabetes" OR "ketosis-prone diabetes" OR Idiopathic thrombocytopenic purpura OR thrombocytopenic purpura, idiopathic/ OR Purpura, Thrombocytopenic, Idiopathic/ OR (tic OR tics).mp. OR intussuscept\$.mp OR exp lupus erythematosus, systemic/ or systemic lupus erythematosus.mp. or libman-sacks.mp. or systemic lupus.mp. OR rheumatoid arthritis.mp. OR Fisher\$ adj syndrome.mp. OR exp polyarteritis nodosa/ or polyarteritis nodosa.mp. or periarteritis nodosa.mp. or essential polyarteritis.mp. or necrotizing arteritis.mp. OR vasculitis OR ankylosing spondylitis.mp. OR polymyalgia rheumatica.mp. OR "serum sickness".mp.

NOT

editorials

HAEMOPHILUS INFLUENZA TYPE B:

haemophilus vaccines/ OR haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate [Supplementary Concept] OR ("haemophilus b" OR "haemophilus type b" OR "haemophilus influenzae type b" OR hib) AND (vaccine\$ OR vaccinate\$ OR vaccination\$ OR immuniz\$ OR immunis\$) OR acthib OR hiberix OR hibtiter OR omnihib OR pedvaxhib OR prohibit OR tetracoq

AND

safe\$ OR harm\$ OR adverse OR toxic OR toxicity OR toxicities OR "side effect" OR "side effects" OR death OR mortality/ OR anaphylaxis/ OR anaphylactic shock/ OR anaphyla\$ OR seizures/ OR seizures, febrile/ OR convulsion/ OR exp epilepsies, myoclonic/ OR spasms, infantile/ OR myoclonus epilepsy/ OR myoclonus seizure/ OR myoclonus/ OR convulsion\$.ti,ab. OR epileps\$ OR myoclon\$ OR spasm\$ OR convulsion\$ OR seizure\$ OR urticaria/ OR urticaria\$ OR hives OR angioedema OR allergic OR allergy OR allergies OR intussuscept\$ OR tremor\$ OR hypotoni\$ OR sudden infant death/ OR "sudden infant death" OR SIDS OR "cot death" OR "unexpected infant death" OR "spontaneous abort\$" OR "congenital abnormal\$" OR abnormalities, congenital/ OR encephalomyelitis, acute disseminated/ OR "acute disseminated encephalomyelitis" OR exp guillainbarre syndrome/ OR "guillain barre" OR myelitis, transverse/ OR "transverse myelitis" OR fibromyalgia/ OR fibromyalgia\$ OR fibrosis OR fibrositides OR (susceptib\$ adj3 hib) OR (susceptib\$ adj3 haemophilus) OR thrombocytopenia\$ OR thrombopenia\$ OR exp diabetes mellitus, type 1/ OR "insulin dependent diabetes" OR "insulin--dependent diabetes" OR "type1 diabetes" OR "juvenile onset diabetes" OR "sudden-onset diabetes" OR IDDM OR "brittle diabetes" OR "autoimmune diabetes" OR "ketosis-prone diabetes" OR Idiopathic thrombocytopenic purpura OR thrombocytopenic purpura, idiopathic/ OR Purpura, Thrombocytopenic, Idiopathic/ OR (tic OR tics).mp. OR uveitis OR narcolep\$.mp. OR exp lupus erythematosus, systemic/ or systemic lupus erythematosus.mp. or libman-sacks.mp. or systemic lupus.mp. OR rheumatoid arthritis.mp. OR Fisher\$ adj syndrome.mp. OR exp polyarteritis nodosa/ or polyarteritis nodosa.mp. or periarteritis nodosa.mp. or essential polyarteritis.mp. or necrotizing arteritis.mp. OR ankylosing spondylitis.mp. OR polymyalgia rheumatica.mp. OR "serum sickness".mp.

NOT

editorials

Appendix B. Data Abstraction Tools

Title and Abstract Screening Form

Order

(vaccine safety study, effectiveness study which may have AE data, systematic review with more potential includes, useful mechanistic study,
useful background paper including vaccines and pregnancy reviews, risk factor study, other source of potential includes, not sure)

- Order (Stop)

Exclude- wrong vaccine

(not Influenza, Tetanus, Diphtheria, Pertussis, Varicella, Zoster, Human Papillomavirus / HPV, Measles, Mumps, rubella / MMR, Pneumococcal (polysaccharide), Meningococcal, Hepatitis A, Hepatitis B, Rotavirus, Haemophilus influenza type b / Hib, inactivated Polio vaccine)

- Exclude-vaccine

Exclude-no data

(opinion pieces, study with no comparator including case studies and case series, study not on vaccination at all, animal studies)

- Exclude-no data

Exclude-other

(not English-language, meeting/conference abstract, other issues)

- Exclude-other

Exclude - Article could not be obtained

- Exclude-not found

Vaccine Safety Full-Text Inclusion Screening

Background:

- Very important background paper (REFERENCE MINE BELOW, HIT SUBMIT)
- Mechanistic study (REFERENCE MINE BELOW, HIT SUBMIT)

Excludes:

- Exclude-Participants (animal or in-vitro study) -
- Exclude-Outcome (no information on presence or absence of AE)
- Exclude-Language (not English)
- Exclude-Design, (no comparison of interest, case report, case series)
- Exclude-Other
- Exclude-Conference Abstract
- Exclude-Already included in IOM report
- Exclude- IOM exclusion

Needs Discussion (bring to meeting)

- ENTER REASON, THEN SUBMIT

Special interest studies where all groups were vaccinated (if one group got only "routine vaccines" go to next bold item)

We were going to research these issues of special interest to the TEP, but were unable due to resource constraints

- Pregnant women vs non-pregnant group
- High dose influenza vs other dose, in elderly
- Interdermal vs intramuscular administration of influenza vaccine
- Pneumococcal conjugate vaccine 13 (PCV13) vs Pneumococcal conjugate vaccine 7 (PCV7)
- Inactivated polio vaccine (IPV) vs Oral polio vaccine (OPV)
- Live attenuated influenza vaccine (LAIV) vs Trivalent influenza vaccine (TIV)
- Tetanus, diphtheria, acellular pertussis (TdaP) vs Tetanus, diphtheria (Td)
- Meningococcal conjugate vaccine (MCV4) vs meningococcal polysaccharide vaccine five (MPSV)

- Study of vaccine group vs. unvaccinated (or "routine vaccines") group (controlled trials, cohort studies comparing two groups)**
- Multivariate risk factor study (simultaneously analyzing more than 1 risk factor), case-control study (people with AE versus not), and self controlled studies**

Vaccines

(Study with human participants)

- DTaP
- Haemoph. Influen. type b (Hib)
- Hepatitis A
- Hepatitis B

- Human papillomavirus (HPV)
- Influenza (inactivated)
- Influenza (live)
- Measles, mumps, rubella (MMR)
- Meningococcal conjugate
- Meningococcal polysaccharide
- Pneumococcal conjugate
- Pneumococcal polysaccharide
- Polio (inactivated only)
- Rotavirus
- Td
- Tdap
- Varicella
- Zoster
- None of the above (REJECT)

Population (check all that apply)
(Study with human participants)

- Children (under age 12)
- Adolescents (12-18)
- Adults

- Elderly (65 and up)
- Immunocompromised only
- Pregnant

Calculated Exclusion (Vaccine and Population Combination)

- Exclude - No Relevant Groups (STOP SCREENING, HIT SUBMIT)
- Include - At least one relevant group

Vague: Vague Study with no information which adverse event was assessed (“safe”, “no AE occurred”)

- Vague

NOTES:

(i.e. where are the safety data if not in the results, special concerns):



Reference Mining:

- Which references should be ordered

Case Control, Self-Controlled Case Series, or Multivariate Risk Factor Analyses

Author/ Year	N/ Populatio n	Vaccines	Study Design	Selection bias	Attrition or non- response rate	Participation / Self-selection bias	Ascertainment of vaccination	Ascertainment of health outcome	Analysis Type	Statistical analysis of potential confounders	Period data collected	Study funder	Primary result regarding vaccine (s)	Results regarding risk factors	Commen t
Instructio ns	<i>Include sample size, location, age group, setting</i>	<i>List all analyzed</i>	<i>Retrospectiv e cohort or Prospective cohort or Case control</i>	<i>Entire population ? Or random sample? Or selected segment?</i>	<i>Lost to f/u, dropped out, etc</i>	<i>Do participants differ from non- participants?</i>	<i>Self-report, medical record, etc</i>	<i>Self-report, medical record, etc</i>	<i>cond. logistic regression etc</i>	<i>List all variables included in model</i>		<i>Usually listed at end of study</i>	<i>include 95% Confidence Interval, p value</i>	<i>if significant association , include 95% Confidence Interval, p value</i>	

Data Abstraction Form-Controlled Trials and Head-to-Head Cohort Comparisons

Study Details & Participation Information

Country

Study Design (CHECK ONE)

- Cohort study (comparing at least 2 cohorts)
- Controlled clinical trial
- Other (please specify)

Sample Size - Total

Length of follow-up

Mean Units

Range from to Units

Year study was conducted

to

Age

Mean Units

Range from to Units

Gender % Female**Pregnant Patients**

%

 yes no

Trimester

 First Second Third**Race and ethnicity (CHECK ALL THAT APPLY)** % White Latino Asian/PI Black / African American Native American Other Not reported

Medical Condition

- Asthma
 - Cancer
 - HIV
 - Inflammatory Bowel Disease
 - Lupus
 - Multiple Sclerosis
 - Premature babies
 - Rheumatoid Arthritis
 - Sickle Cell Anemia
 - Transplant patients (Specific Type)
 - Other 1 (Specify)
 - Other 2 (Specify)
 - None / not reported
-

Quality Assessment

McMaster Quality Assessment Scale for Harms (McHarm)

1. Were the harms PRE-DEFINED using standardized or precise definitions?

RATING

- Yes
 - No
 - Unsure
- [Clear Response](#)
2. Were SERIOUS events precisely defined?
- Yes
 - No
 - Unsure
- [Clear Response](#)

McMaster Quality Assessment Scale for Harms (McHarm)**RATING**

3. Were SEVERE events precisely defined?

- Yes
- No
- Unsure

[Clear Response](#)

4. Were the number of DEATHS in each study group specified OR were the reason(s) for not specifying them given?

- Yes
- No
- Unsure

[Clear Response](#)

5. Was the mode of harms collection specified as ACTIVE?

- Yes
- No
- Unsure

[Clear Response](#)

6. Was the mode of harms collection specified as PASSIVE?

- Yes
- No
- Unsure

[Clear Response](#)

7. Did the study specify WHO collected the harms?

- Yes
- No
- Unsure

[Clear Response](#)

8. Did the study specify the TRAINING or BACKGROUND of who ascertained the harms?

- Yes
- No
- Unsure

[Clear](#)

McMaster Quality Assessment Scale for Harms (McHarm)	RATING
9. Did the study specify the TIMING and FREQUENCY of collection of the harms?	<u>Response</u> <input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unsure
10. Did the author(s) use STANDARD scale(s) or checklist(s) for harms collection?	<u>Clear Response</u> <input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unsure
11. Did the authors specify if the harms reported encompass ALL the events collected or a selected SAMPLE?	<u>Clear Response</u> <input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unsure
12. Was the NUMBER of participants that withdrew or were lost to follow-up specified for each study group?	<u>Clear Response</u> <input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unsure
13. Was the TOTAL NUMBER of participants affected by harms specified for each study arm?	<u>Clear Response</u> <input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unsure
14. Did the author(s) specify the NUMBER for each TYPE of harmful event for each study group?	<u>Clear Response</u> <input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unsure

McMaster Quality Assessment Scale for Harms (McHarm)**RATING**[Clear Response](#)

15. Did the author(s) specify the type of analyses undertaken for harms data?

- Yes
- No
- Unsure

[Clear Response](#)

Vaccine Group 1**Sample Size****Enter all that apply:**

- DTaP
- Haemoph. Influen. type b (Hib) protein conjugate
- Hepatitis A
- Hepatitis B
- Human papillomavirus (HPV)
- Influenza (inactivated)
- Influenza (live)
- Influenza - monovalent H1N1
- Measles, mumps, rubella (MMR)
- Meningococcal conjugate
- Meningococcal polysaccharide
- Pneumococcal conjugate (PC7 vs PCV13)
- Pneumococcal polysaccharide PSV23 – (23-valent polysaccharide

vaccines)

- Polio (inactivated only)
- Rotavirus
- RotaTeq (RVS)
- Rotarix (RV1) (also known as RIX4414)
- Td
- Tdap
- Varicella
- Zoster
- Routine Vaccines
- Other Vaccine (please specify)

Brand Name(s)



Manufacturer



Age

 Units

to

Formulation



Dose 1 *Timing* *Units* *Dosage* *Units*

--	--	--

Dose 2 *Timing* *Units* *Dosage* *Units*

--	--	--

Dose 3 *Timing* *Units* *Dosage* *Units*

--	--	--

Dose 4 *Timing* *Units* *Dosage* *Units*

--	--	--

Dose 5 *Timing* *Units* *Dosage* *Units*

--	--	--

Adjuvants

- ASO 4
- Aluminum
- Adjuvant Free
- Not reported
- Other

Preservatives

- Thimerisol
- Phenol
- Preservative Free
- Not reported
- Other

Delivery route

- Intradermal
 - Intramuscular
 - Intravenous
 - Intranasal
 - Oral
 - Other (please specify)

Adverse Events

Adverse Event	#	%	System Category	Severity
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]

of patients with any AE

ANSWER The answer is **100**.

Any Severe Adverse Event

Vaccine Group 2

Sample Size

1

Enter all that apply:

- DTap
 - Haemoph. Influen. type b (Hib) protein conjugate
 - Hepatitis A

- Hepatitis B
- Human papillomavirus (HPV)
- Influenza (inactivated)
- Influenza (live)
- Influenza - monovalent H1N1
- Measles, mumps, rubella (MMR)
- Meningococcal conjugate
- Meningococcal polysaccharide
- Pneumococcal conjugate (PC7 vs PCV13)
- Pneumococcal polysaccharide PSV23 – (23-valent polysaccharide vaccines)
- Polio (inactivated only)
- Rotavirus
- RotaTeq (RVS)
- Rotarix (RV1) (also known as RIX4414)
- Td
- Tdap
- Varicella
- Zoster
- Routine Vaccines
- Other Vaccine (please specify)

Brand Name(s)



Manufacturer




Age

Units

to

Formulation



Dose 1 *Timing* *Units* *Dosage* *Units*

Dose 2 *Timing* *Units* *Dosage* *Units*

Dose 3 *Timing* *Units* *Dosage* *Units*

Dose 4 *Timing* *Units* *Dosage* *Units*

Dose 5 *Timing* *Units* *Dosage* *Units*

Adjuvants

ASO 4

- Aluminum
- Adjuvant Free
- No reported
- Other

Preservatives

- Thimerisol
- Phenol
- Preservative Free
- Not reported
- Other

Delivery route

- Intradermal
- Intramuscular
- Intravenous
- Intranasal
- Oral
- Other (please specify)

Adverse Events

Adverse Event	#	%	System Category	Severity
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
# of patients with any AE	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Any Severe Adverse Event	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Adverse Event	#	%	System Category	Severity

Vaccine Group 3

Sample Size

Enter all that apply:

- DTap
- Haemoph. Influen. type b (Hib) protein conjugate
- Hepatitis A
- Hepatitis B
- Human papillomavirus (HPV)
- Influenza (inactivated)
- Influenza (live)
- Influenza - monovalent H1N1
- Measles, mumps, rubella (MMR)
- Meningococcal conjugate
- Meningococcal polysaccharide
- Pneumococcal conjugate (PC7 vs PCV13)
- Pneumococcal polysaccharide PSV23 – (23-valent polysaccharide vaccines)
- Polio (inactivated only)
- Rotavirus
- RotaTeq (RVS)
- Rotarix (RV1) (also known as RIX4414)

- Td
- Tdap
- Varicella
- Zoster
- Routine Vaccines
- Other Vaccine (please specify)

Brand Name(s)

◀ ▶▲ ▼

Manufacturer

◀ ▶▲ ▼

Age

Units

to

Formulation

◀ ▶▲ ▼

Dose 1 *Timing Units Dosage Units*

Dose 2 *Timing Units Dosage Units*

Dose 3 *Timing* *Units* *Dosage* *Units*

Dose 4 *Timing* *Units* *Dosage* *Units*

Dose 5 *Timing* *Units* *Dosage* *Units*

Adjuvants

- ASO 4
- Aluminum
- Adjuvant Free
- No reported
- Other

Preservatives

- Thimerisol
- Phenol
- Preservative Free
- Not reported
- Other

Delivery route

- Intradermal
- Intramuscular
- Intravenous

- Intranasal
 - Oral
 - Other (please specify)

Adverse Events

Adverse Event	#	%	System Category	Severity
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]

of patients with any AE

[View Details](#) [Edit](#) [Delete](#)

Any Severe Adverse Event

“Unvaccinated” Comparison Group

Sample Size

1

- Placebo
 - Routine Vaccines
 - Nothing
 - Other (please specify)

If Placebo, does it include the same adjuvants, preservatives, formulations as the active group?

- Yes
 - No

(if no, please specify)

A horizontal scroll bar located at the bottom of the slide. It consists of a light gray track with a darker gray slider in the middle. On the left end of the track are two small square buttons with diagonal arrows pointing left and right. On the right end, there are three buttons: a top button with an upward arrow, a middle button with a downward arrow, and a bottom button with a rightward arrow.

Unsure

Adverse Events

Adverse Event	#	%	System Category	Severity

of patients with any AE

Three empty rectangular boxes arranged horizontally, intended for children to draw or write in.

Any Severe Adverse Event

COMMENTS / NOTES:

A screenshot of the Microsoft Word ribbon interface. The ribbon is at the top, featuring tabs for Home, Insert, Page Layout, References, Mailings, Formulas, Review, and View. Below the ribbon is a large white workspace. Along the bottom edge of the workspace is a decorative border consisting of a repeating pattern of small squares in light gray and white. In the bottom right corner, there is a small white rectangular button with a downward-pointing arrow icon.

Appendix C. Evidence Tables

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Baxter, 2012, Retrospective cohort ⁷³	Sample size: 60,996; Location: US; Age: 18-49; Setting: Kaiser Permanente Managed Care Health Plans	Ann Arbor Strain LAIV	Through Kaiser Permanente's immunization registries, approximately 20,000 individuals 18-49 years of age who were immunized from the 2003-2004 to 2007-2008 influenza seasons with LAIV as part of routine clinical practice were identified.	NA	These were participants of a health plan (i.e. insured).	Medical record	Medical records, healthcare utilization database	Cox proportional hazards model	Adjusted for: Matching factors, seasonal changes in background rates	2003-2008	MedImmune	The rate of hospitalization or death due to any condition within 180 days of vaccination with LAIV was lower than with TIV (1.46 vs 9.10; p < 0.01) or no vaccine (1.46 vs 3.36; p < 0.01). The incidence rate for any serious adverse event (SAE) within 21 days and 42 days of vaccination with LAIV was lower compared to no vaccination.	NR	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Baxter, et al. 2012, ⁸ Observational post-licensure (Phase IV) study; retrospective cohort	N=29,000; Location=California; Age=60+ years; Setting=Kaiser Permanente Northern California (KPNC), a US managed care organization	ZostavaxTM, a live, attenuated varicella-zoster virus vaccine	Entire population	Not really discussed. Study notes: From July 2006 through November 2007, 29,486 people 60 years of age or older were vaccinated with zoster vaccine at KPNC. Of them, 29,010 people had continuous KPNC membership for at least 180 days after vaccination, and were included in the study population.	Not discussed	Medical records. Detailed vaccination data are tracked and captured by the Kaiser Immunization Tracking System (KITS), one of the largest electronic tracking systems for immunization in the U.S. The KITS system collects, among other information, the patient's medical record number, date of vaccination, type of vaccine, route of administration, facility in which the vaccine was administered, manufacturer and vaccine lot number, and can be linked to other data sources to get additional information	Medical records. Subjects were followed for all postvaccination hospitalization and ED visits identified by International Classification of Diseases and Related Health Problems-9(ICD9) codes in the electronic medical records.	Exact conditional method with mid-probability adjustment	Self-controlled	2006-2007	This study was sponsored by Merck Sharp & Dohme, Corp. Trung Nam Tran and Patricia Saddier were full time employees of Merck Sharp & Dohme, Corp. at the time of the study.	Table 2. Health outcomes with elevated RR and statistically significant unadjusted p-value ($p<0.05$)(N=29,010). Coronary atherosclerosis and other heart disease 1.86 (1.09–3.15); $p=0.02$ Coronary atherosclerosis (ATS) 1.97 (1.11–3.49); $p=0.02$ Percutaneous transluminal coronary angioplasty (PTCA) 2.26 (1.19–4.27); $p=0.01$ Systemic lupus, erythematosus and connective tissue disorders 8.57 (1.08–212.11); $p=0.04$	None	Table 3 shows RR for subsets of individuals: diabetics, people with CHD, and people 80+ years.

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Duderstadt et al. 2012, Retrospective cohort ⁹²	N=2,385,102 active military personnel, including 1,074 cases of type 1 diabetes; Location=US; Age=17-35 years;	Hepatitis B, MMR, smallpox, typhoid, yellow fever	Entire population of Defense Medical Surveillance System. A total of 17,874 were excluded; if these exclusions differed systematically from those included, bias would be introduced into the study	Not applicable	Not discussed	Defense Medical Surveillance System	Defense Medical Surveillance System	Poisson regression	Receipt of multiple vaccines, age, race, sex, service branch, military grade, occupation, deployment, and calendar year	January 1 2002 to December 31 2008	Department of Defense	Risk Ratios for Diabetes Type 1 Hepatitis B: 0.83 (0.72, 0.95) MMR: 0.71 (0.61, 0.83)	Not reported	
Eder et al. 2011, Case-control ⁹¹	N=318 (159 Cases, 159 Controls); Location=Toronto; Age=Case/control, Mean (SD): 44.9 (13.1)/48.4 (13.3); Setting=Cases taken from University of Toronto Psoriatic Arthritis (PsA) cohort, clinic-based. Controls from Toronto Psoriasis Cohort	Hepatitis A and B, influenza, pneumococcus	Cases and controls selected from different populations. Cases were from a clinic-based group (PsA cohort) while controls were from another cohort of non-arthritis psoriasis patients. Study notes, "In order to minimize selection bias, psoriasis patients were recruited from several sources: dermatology clinics at Toronto Western Hospital and Women's College Hospital, (81.1%)	No attrition mentioned. In terms of recruitment, 190 PsA patients (cases) were identified, authors were unable to contact 29 (6 deceased), and 2 were excluded due to poor English language skills. Overall, 159 PsA patients (83.6%) were included in the study. 196 patients with psoriasis (controls) were approached for enrollment, of whom 159	Study did not note whether participants differed from nonparticipants.	Self-report through questionnaire	Clinical data were available from the cohorts' computerized databases	Logistic regression	Age, sex, duration and severity of psoriasis, and level of education.	Not reported	Krembil Foundation, Arthritis Society Spondyloarthritis Research Consortium of Canada National Research Initiative. Dr. Eder's work was supported by a fellowship grant from the Canadian Arthritis Network and by an Abbott Psoriatic Arthritis Fellowship . Ms.	OR (95% CI) of PsA: Hepatitis A: 0.70 (0.14–2.99), p=0.58 Hepatitis B: 1.50 (0.76–2.81), p=0.25 Pneumococcus: 1.40 (0.75–2.72), p=0.28 Flu: 1.0 (0.58–1.57), p=0.87	Not reported	Recall bias was a concern; those with arthritis may show higher recall of triggers. By approaching patients with a recent onset of arthritis, the study population had a short interval from the onset of PsA of approximately 3 years. Authors avoided linking environmental exposures and arthritis in the questionnaire, and requested

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
		community dermatologists, family medicine clinics in Toronto, and the general public in the greater Toronto area by advertising in local newspapers." However there are no details given for the recruitment of the two cohorts to determine if systematic biases resulted in non-comparable populations	completed the questionnaire.								Law's work was supported by a scholarship from the Canadian Arthritis Network. Dr. Chandran's work was supported by a Canadian Institutes of Health Research and Krembil Foundation.			information about events that occurred in the past 10 years. They also assessed recall bias by comparing reported information about exposure to infections and injuries with available data from a computerized database that stores medical records from 6 medical centers and outpatient clinics. The aim was to assess whether there has been underreporting of events by psoriasis patients. Overall, 3 of 3 patients with psoriasis reported a previous injury and 0 of 2 reported an infection. In the PsA group, only 1 of 3 reported an injury and 1 of 6

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
														reported an infection. Therefore, although these figures are small, it seems that recall bias is not a threat to the validity of the study, as the rates of reporting were not lower in the psoriasis group."
Eurich et al. 2012, Prospective cohort ⁷⁵	N=6171; Location=Edmonton (Alberta, Canada); Age=mean age 59 years; Setting=Population-based cohort of adults presenting with community-acquired pneumonia (CAP) in Edmonton	Pneumococcal polysaccharide vaccination (PPV)	Authors note a large protective effect against ACS events among patients receiving PPV during the acute pneumonia event was observed. Although this in itself is not improbable, the fact that no ACS events occurred within the first 2-4 weeks post discharge in this group suggests some selection bias was occurring, as PPV generally requires 2-4 weeks to initiate a reasonable	Of the 6874 cohort patients with CAP, authors excluded 310 (5%) who had PPV first administered during their initial CAP presentation and 393 (6%) who could not be linked to the administrative databases, resulting in a final study cohort of 6171 patients	Not discussed	PPV status was collected by trained staff masked to all study hypotheses. Receipt of vaccination was ascertained through multiple avenues including patient and proxy interview, medical record review, contact with primary care physicians and records from regional office of community health	Research nurses prospectively collected all clinically diagnosed ACS events in the emergency department and during hospitalization. Thereafter, ACS events were ascertained by linking patients to comprehensive provincial healthcare administrative databases	Multivariable Cox proportional hazard model	Pneumonia severity based on the PSI; comorbidities including chronic obstructive pulmonary disease, diabetes, ischemic heart disease (IHD); functional status, smoking status and cardiovascular and other medications Authors also completed a propensity (to receive PPV) score analysis	2000 to 2002	DTE receives salary support from Alberta Heritage Foundation for Medical Research (AHFMR) and the Canadian Institutes for Health Research (CIHR). SRM receives salary support from AHFMR and holds an endowed chair in	Adjusted HRs for fatal and non-fatal ACS events within 90 days according to pneumococcal vaccination status Primary analysis Death or ACS-related hospitalization: 0.42 (0.27 to 0.66), p=<0.001 Death: 0.92 (0.32 to 2.63), p=0.88 Hospitalization due to ACS: 0.35 (0.21 to 0.57), p=<0.001 Propensity score analysis Death or ACS-related hospitalization: 0.46 (0.28 to 0.73), p=0.001 Death: 1.51 (0.42 to 5.34),	None	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
			response. Also the majority of the cohort were older and antibody response is known to be poor in older populations with comorbidities Finally there may have been confounding by the healthy-user or healthy-vaccine effect, whereby more healthy or health-seeking patients are administered PPV compared with non-PPV patients								patient health management. TJM received Grants-in-aid from Capital Health; and unrestricted grants from Abbott Canada, Pfizer Canada and Janssen-Ortho Canada.	p=0.53 Hospitalization due to ACS: 0.36 (0.21 to 0.61), p=<0.001		
Farez et al. 2012, Self-controlled case series ⁶²	N=137 Multiple Sclerosis patients; Location=Argentina; Age=37 +/- 8 years (mean)	Influenza (monovalent Focetria, Novartis SRL, Italy or trivalent Istivac, Sanofi Pasteur, France)	Bias if cases differed from the general population in systematic ways (e.g., more or less likely to be vaccinated, doctors more likely to recommend vaccinations)	161 relapsing-remitting MS patients were identified from the database. 23 patients refused to participate and 2 had received other immunizations, leaving 137	Study notes patients excluded did not differ significantly from those included	Self-report	Database review	Poisson regression model	None given	1 January and 31 December 2010	Raul Carrea Institute for Neurological Research	30-day risk period: 0.86 (95% CI 0.20–3.62, p=0.836) 60-day risk period: 0.61 (95% CI 0.18–2.02, p=0.419) 90-day risk period: 0.51 (95% CI 0.18–1.47, p=0.211)	Not reported	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Garbe et al. 2012, Case-control ¹⁶⁸	N=1,200 (outpatient + inpatient). Influenza results presented just for outpatients where N=861; Location=Berlin, Germany; Age=18-92; Setting=Berlin hospitals, hematological practices, and laboratories	Influenza vaccine (Pneumococcal and poliomyelitis vaccine also assessed as causing 1 case each but ORs were Not reported.)	Cases and controls selected from the same hospitals using the same general procedures for interviews reducing the chance of selection bias occurring. Vaccines were not the only drugs study was interested in so diagnostic or surveillance biases lessened. Exposure misclassification was a minor concern because drug exposures were assessed 1 week before the index date	None	Study did not address	Self-report through face-to-face interviews and physician-provided information	Patients with ITP were identified through regular active inquiry in 2- to 3-week intervals in hospitals, hematological practices and laboratories. Diagnosis was additionally based on a face-to-face interview and physician-provided information. An advisory board assessed ambiguous cases.	Unconditional logistic regression	Model 1: age and sex ("single drug assessment") Model 2: age, sex and all drugs that were significant in the single drug assessment ("joint drug assessment")	October 2000 until March 2009	Cases were collected within the study "Berlin Case-Control Surveillance (FAKOS) of Serious Blood Dyscrasias", which was supported by a grant from the Federal Institute for Drugs and Medical Devices (Bonn, Germany).	OR (95% CI) of ITP Influenza, outpatient cases and controls: Model 1: 3.8 (1.5–9.1) Model 2: 4.0 (1.5–9.6)	Not reported	
Glanz et al. 2011, Self-controlled case series ¹¹⁵	N=66,283 who received trivalent inactivated influenza vaccine (TIV); Location=US; Age=24-59 months; Setting=Seven US managed care organizations (Vaccine	TIV	No info on systematic differences between sites in vaccine or outcome administration or ascertainment	Not discussed	Not discussed	VSD records review	Medical record review	Conditional Poisson regression	Calendar month (season) and age	2002-2006	Centers for Disease Control and Prevention	Medically Attended Events That Met the Screening Criteria in Risk Windows of 0 to 2, 1 to 14, and 1 to 42 Days After Vaccination Non-confirmed Cases From Electronic Data Analysis Potentially serious Nervous system disorder: 6.32 (0.96-41.65), p=0.06 Cardiac event: 3.56 (0.55-22.89), p=0.18	None given	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	Safety Datalink)											Hypotension: 5.52 (0.71-43.07), p=0.10 Gastrointestinal tract disorder: 2.75 (1.07-7.09), p=0.04 Cellulitis and skin reaction: 3.06 (0.89-10.53), p=0.08 Potentially less serious and common Rash: 2.33 (0.68-7.93), p=0.18 Limb soreness: 3.56 (1.30-9.75), p=0.01 Fever: 1.40 (1.09-1.80), p=0.01 Gastrointestinal tract symptoms (vomiting and diarrhea): 1.52 (1.18-1.95), p=0.001 Medical Record–Confirmed Cases Potentially serious Gastrointestinal tract disorder: 7.70 (1.11-53.52), p=0.04 Cellulitis and skin reaction: 3.27 (0.36-29.70), p=0.29 Potentially less serious and common Rash: 1.94 (0.44-8.63), p=0.38 Fever: 1.71 (1.64-1.80) Gastrointestinal tract symptoms (vomiting and diarrhea): 1.18 (1.10-1.25)		

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Greene et al. 2012, Self-controlled risk interval and case-centered analysis ⁵⁶	N=1.48 million doses Monovalent inactivated influenza vaccine (MIV) and seasonal trivalent inactivated influenza vaccine (TIV) during the 2009-2010 season	Monovalent inactivated influenza vaccine (MIV) and seasonal trivalent inactivated influenza vaccine (TIV)	Differences across sites in study participants and entry into medical care organizations may be relevant in terms of sampling bias	Not reported	Not reported	Electronic data and medical record review	Electronic data and medical chart review	Conditional Poisson regression for self-controlled analysis and logistic regression for case-centered analysis	Case-centered analyses by stratum of onset date, age, sex, site	2009–2010	Centers for Disease Control and Prevention	Relative Risk (self-controlled risk analysis) of Guillain-Barré Syndrome (GBS, RR, 95% CI) MIV Confirmed GBS 4.4 (1.3, 14.2) TIV Confirmed GBS: 1.3 (0.5, 3.8) Case-centered: The odds ratio for illness onset inside of the 42-day risk period versus outside of that period was 2.0 (95% CI: 0.5, 8.1).	None	
Grimaldi-Bensouda et al. 2011, Prospective case-control ⁵⁸	N=1225; Location=France; Age=Cases/Controls, Mean (SD): 48.6 (18.0)/50.7 (18.1); Setting=Cases drawn from all university and major regional hospital centers in metropolitan France known to have a large neurology clinic and	Influenza vaccines (seasonal and A/H1N1)	Hospital-based cases and controls from general practitioner lists. Diagnostic and surveillance approaches may differ such that hospital cases may have had better ascertainment of risk factors. Authors note that exposure misclassification may have occurred.	None	Not discussed	Self-report and objective confirmation obtained in a sample of 40% of cases and controls for the seasonal vaccination. The proportion was raised to 100% during the A/H1N1 vaccination program. Confirmation included copies of vaccination sheets, certificates, and other documentation.	A neurologist completed a detailed medical form - cases ascertained using an algorithm considering clinical, electrophysiologic, and cerebrospinal fluid data. Borderline cases were reviewed by independent and blinded experts	Conditional logistic regression	Cases/controls matched by age, gender, index date (calendar month), and region Receipt of other vaccines during the same time window, receipt of influenza vaccine in the past (before the time window considered), family history of autoimmune diseases,	March 2007 and June 2010. For the influenza A/H1N1 vaccine, analysis was restricted to the GBS cases that had occurred from commencement of the French national vaccination program on October 20, 2009, to 6 weeks after	LA-SER, GSK Biologicals, and Sanofi-Pasteur	All influenza vaccines (A/H1N1 + seasonal) First 6 weeks: 1.22 (0.45-3.32) 7 weeks to 3 months: 0.66 (0.27-1.65) 4 months to 6 months: 0.80 (0.34-1.88) Seasonal influenza vaccine only First 6 weeks: 1.30 (0.41-4.12) 7 weeks to 3 months: 0.60 (0.23-1.60) 4 months to 6 months: 0.69 (0.29-1.66) Influenza A/H1N1 vaccine only First 6 weeks: 0.92 (0.11-7.55) 7 weeks to 3 months:	Not reported	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	centers treating neurologic disease in children; Controls from registry of general practice patients across France								number of physician consultations in the previous year (0–2, 3–6, 7–12, or >=13), antibiotic or antiviral treatment in the previous 2 months, use of antipyretic agents in the previous 2 months.	the end of the vaccination campaign on March 31, 2010		1.08 (0.09-13.15)		
Gwini et al. 2011, Self-controlled case series ⁶⁷	N=8,180 cases of first acute myocardial infarction; Location=UK; Age=>=40 years;	Influenza	Population of study may differ from population as a whole in systematic ways that decrease generalizability	None	Not discussed	General Practice Research Database (GPRD)	General Practice Research Database (GPRD)	Conditional Poisson regression	Seasonality	2002-2007	Research for Patient Benefit Program of the National Institute for Health Research, United Kingdom	Incidence Rate Ratio Post-vaccination intervals 1-14 days: 0.68 (0.6-0.78) 15-28 days: 0.75 (0.66-0.86) 29-59 days: 0.82 (0.75-0.90) 60-90 days: 0.96 (0.87-1.07) 91-120 days: 0.98 (0.89-1.09) 121-180 days: 1.02 (0.95-1.10)		
Hambidge et al. 2011, Self-controlled case series ⁶⁹	N=348 adults with sickle cell disease in 8 MCOs in the US; (Vaccine Safety Datalink (VSD) cohort)	Influenza	Unclear about differences between sites in population selection, case and exposure ascertainment; differences between cases and other populations (e.g., cases may have been more	Not discussed	Not discussed	Medical record	Medical record	Conditional Poisson regression	Stratification by sex and age, adjustment for month within season	1991-2006	Centers for Disease Control and Prevention	Incidence rate ratios for sickle cell hospitalization All: 0.92 (0.66, 1.28), p=0.6 Males: 1.00 (0.59, 1.72), p=1.0 Females 0.87 (0.57, 1.31), p=0.5 18-49 yrs: 0.84 (0.57, 1.22), p=0.8 50-64 yrs: 1.51 (0.72, 3.18), p=0.3		

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
			likely to be vaccinated)										>=65 yrs: 0.94 (0.10, 8.55), p=1.0	
Hedlund et al. 2003, Prospective cohort ⁶⁶	N=100,242; Location=Stockholm County, Sweden; Age=>=65 years; Setting=All individuals in Stockholm County aged 65 years or older were invited to take part in a vaccination campaign against influenza and pneumococcal infection during 3 consecutive years, 1998–2000	Influenza and 23-valent pneumococcal vaccine (PV)	No randomization - vaccinated group may differ systematically in some fashion that makes them more likely to show adverse (or non-adverse) effects that are not related to the vaccine	Not discussed	Not discussed	Department of Communicable Disease Control and Prevention for Stockholm County database	Data on discharge diagnoses and mortality were obtained from the administrative database of Stockholm County Council	Poisson regression	Age and gender	1998-1999	Financial supported for this study was received from The Stockholm City Council, The Swedish Heart-Lung Foundation, The Swedish Society of Medicine, and Karolinska Institute.	Hospital admissions/100 000 individuals between 1 December 1998 and 30 November 1999 Influenza 0.68 (0.53-0.88), p=0.002 Pneumonia 0.78 (0.71-0.86), p=<0.0001 IPD: 0.46 (0.25-0.87), p=0.007 COPD: 1.04 (0.92-1.17), p=0.55 Cardiac failure: 0.95 (0.87-1.05), p=0.34	In-hospital mortality due to investigated diagnoses/100 000 individuals between 1 December 1998 and 30 November 1999 Influenza 1.20 (0.39-3.70), p=0.75 Pneumonia 0.55 (0.43-0.71), p=<0.0001 IPD: 0.53 (0.06-5.10), p=0.58 COPD: 0.53 (0.29-0.98), p=0.034 Cardiac failure: 0.72 (0.59-0.87), p=0.0007	None

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Hospital admissions/100 000 individuals per year between 1 December 1998 and 31 May 1999 Influenza: 0.66 (0.52-0.82), p=0.0002 Pneumonia: 0.72 (0.65-0.79), p=<0.0001 IPD: 0.47 (0.24-0.93), p=0.02 COPD: 1.07 (0.94-1.23), p=0.32 Cardiac failure: 0.90 (0.80-1.01), p=0.08 Hospital admissions/100 000 individuals per year between 1 June and 30 November 1999 Influenza: 1.36 (0.58-3.17), p=0.48 Pneumonia: 0.88 (0.77-1.00), p=0.05 IPD: 0.45 (0.15-1.32), p=0.20 COPD: 1.00 (0.87-1.15), p=0.98 Cardiac failure: 1.02 (0.93-1.11), p=0.69		
Hurst et al. 2011, Retrospective cohort ⁷¹	N=51,730 adult Medicare patients with renal transplant; Location=US; Age=>=65 years; 9,678 had claims for	Influenza	Entire population	Not reported	Not discussed	Medicare claims data	US Renal Data System (RDS) record review	Cox non-proportional hazards regression	Factors known to be independently associated with allograft loss (recipient age, black race, PRA 20%, dialysis vintage, diabetes mellitus,	2000-2006	Not specified	Vaccination in the first year after transplant was associated with lower risk of subsequent allograft loss and death Adjusted hazard ratio Allograft loss: 0.77 (0.69-0.85), p=0.001 Death: 0.82 (0.76-	Not reported	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment	
	influenza vaccine in the first year post transplant								congestive heart failure, ischemic heart disease, tobacco use, HLA matching, donor age of 50 years, donor black race, deceased-donor transplant, expanded criteria donor, delayed graft function, cold ischemic time of 24 hours, year of transplant, and induction/discharge immunosuppression. Others not specified for the relevant model but could include: older age, diabetes, later year of transplant, and tacrolimus or mycophenolate at discharge			0.89), p=0.001 Acute rejection in the first year was not associated with vaccination in the first 6 or 12 months after transplant Adjusted odds ratio Rejection in first 6 mo: 1.00 (0.88-1.14), p=0.965 Rejection in first 12 mo: 0.97 (0.89-1.07), p=0.569			
Johnstone et al. 2012, Prospective cohort ⁶⁵	N=31,546; Location=40 countries; Setting=Participants in the ONTARGE	Influenza, pneumococcal	Difficult to determine without more details on the original studies through which population	In total, 99.8% of participants were followed up until the primary outcome occurred or the	Not discussed	Self-report	All study outcomes were prospectively adjudicated by a central committee blinded to study	Logistic regression	Adjusted by propensity score for influenza vaccination (body mass index, age, sex,	2004 to 2007	This study was supported by a grant from Boehringer Ingelheim.	Association Between Influenza Vaccination and Risk of Major Adverse Vascular Events During the Influenza Season	Not reported	There was no association between pneumococcal vaccination and the primary	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	T/TRANSCE ND trials: at least 55 years old and a history of vascular disease or diabetes with document end-organ damage		drawn from	end of study			medication allocation and influenza vaccination status with the use of standardized criteria		ethnicity, education, vitamin use, smoking history, alcohol use, history of pneumococcal vaccination), history of coronary artery disease, diabetes mellitus, hypertension, stroke, admission to a nursing home, or use of aspirin, beta-blocker, lipid-lowering drug, angiotensin-converting enzyme inhibitor, or angiotensin II inhibitor		Dr Yusuf was supported by the Heart and Stroke Foundation of Ontario and a Senior Scientist Award from the Canadian Institutes of Health Research (CIHR). Dr Johnstone receives salary support from CIHR. Dr Loeb holds the Michael G. DeGroote Chair in Infectious Diseases at McMaster University	Cohort 2003-2004: 0.96 (0.73-1.27), p=0.79 2004-2005: 0.62 (0.50-0.77), p=<0.0001 2005-2006: 0.69 (0.53-0.91), p=0.009 2006-2007: 0.52 (0.42-0.65), p=<0.0001 Association Between Influenza Vaccination and Risk of the Major Adverse Vascular Events During the Non-influenza Season		outcome during any of the influenza seasons

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Deaths resulting from other causes: 0.33 (0.18–0.60), p=0.0004 2005–2006 Non-cardiovascular deaths: 0.21 (0.10–0.46), p=0.0001 Cancer deaths: 0.27 (0.10–0.69), p=0.0065 Deaths resulting from other causes: 0.14 (0.03–0.58), p=0.0070 2006–2007 Non-cardiovascular deaths: 0.27 (0.18–0.41), p=<0.0001 Cancer deaths: 0.17 (0.10–0.31), p=<0.0001 Deaths resulting from other causes: 0.47 (0.25–0.86), p=0.0137		
Siriwardena et al. 2010, Matched case-control ⁶⁴	N=78,706 (16,012 cases of myocardial infarction (MI), 62,964 controls); Location=UK; Age=40 to >=65; Setting=United Kingdom General Practice Research Database (GPRD), an extensively validated	Influenza; pneumococcal (study didn't specify types)	Possible biases in that those with risk factor for outcome may be more likely to be vaccinated, but confounders related to this were controlled for in multivariate analyses	Regression analyses dropped some participants due to missing data on risk factors such as smoking.	Not discussed	Data were extracted from the GPRD (assume by researchers). Virtually all patients in the database are registered with a general practitioner, and all health care attendances are recorded in the database. The database contains anonymized patient data that includes demographic	Data were extracted from the GPRD (assume by researchers). Cases were at least 40 years at the time of first acute myocardial infarction (fatal or nonfatal) had clinical records for over five and a half years (between Nov. 1, 2001, to May 31, 2007) and were identified using standardized (Read and	Conditional logistic regression	Model 1 adjusted for asthma or chronic obstructive pulmonary disease, chronic heart disease, stroke or transient ischemic attack, diabetes, splenectomy, chronic liver disease, chronic renal failure, immunosuppression and HIV, hyperlipidemia, family history	Cases identified from incident occurring between Nov. 1, 2001, to May 31, 2007.	This study was supported by funding from the Research for Patient Benefit Program of the National Institute for Health Research, United Kingdom	OR (95% CI) of acute MI Influenza vaccination within previous year: Model 1: 0.81 (0.77–0.85), p<0.001 Model 2: 0.83 (0.80–0.88) Pneumococcal vaccination within previous year: Model 1: 0.96 (0.91–1.02) Model 2: 0.98 (0.93–1.04) Pneumococcal vaccination results included in Appendix (www.cmaj.ca/cgi/co	None given, but subgroup results shows for the following categories: Influenza Vaccination in preceding yr: < 65 yr: Model 1: 0.81 (0.73–0.90) Model 2: 0.83 (0.75–0.92) ≥ 65 yr: Model 1: 0.79 (0.75–	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	computerized database, representative of and comprising 5% of the population of England and Wales.					information, diagnoses, medication, health-related behaviors, referrals and treatment outcomes. Influenza vaccination was defined as vaccination given in the year preceding the index date. Other exposures to influenza vaccination considered were influenza vaccination within the current vaccination season and early (i.e., between Sept. 1 and Nov. 15) or late vaccination (i.e., between Nov. 16 and Feb. 28 or 29, depending on the year). Patients were considered to have had a pneumococcal vaccination if they had ever received the pneumococcal vaccine before	Oxford Medical Information Systems [OXMIS]) codes.		of acute myocardial infarction, peripheral vascular disease, hypertension, smoking status, treatment with acetylsalicylic acid, treatment with statins, treatment with antihypertensives, and general practice consultations. Each type of vaccination was adjusted for the other type. Second set of models (Model 2) adjusted for all of the above variables as well as for body mass index, systolic blood pressure and total cholesterol using 10 multiply imputed data sets. (Systolic blood pressure, body mass index, and total cholesterol were not included in the main adjusted			ntent/full/cmaj.091891/DC1)	0.83) Model 2: 0.82 (0.78–0.86) Time since last vaccination at index date, months: 0–3 months: Model 1: 0.80 (0.74–0.86) Model 2: 0.84 (0.80–0.94) 3–6 months: Model 1: 0.82 (0.76–0.89) Model 2: 0.86 (0.85–0.99) 6–12 months: Model 1: 0.87 (0.81–0.94) Model 2: 0.91 (1.06–1.24) 12–60 months: Model 1: 1.12 (1.03–1.21) Model 2: 1.15 (0.88–1.20) ≥ 60 months: Model 1: 0.96 (0.82–1.13) Model 2: 1.03 Within-	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
						the index date. Combined vaccination was defined as pneumococcal vaccination ever combined with influenza vaccination in the year preceding the index date.			analyses owing to missing data (63%, 45% and 15% completeness respectively). Matched case-control, matched for: age, sex, general practice attended and calendar time (i.e., month corresponding to index date of acute myocardial infarction)				season vaccination Yes: Model 1: 0.80 (0.76–0.84) Model 2: 0.83 (0.79–0.87) Early within-season (Sept. to mid-Nov.): Model 1: 0.79 (0.75–0.83) Model 2: 0.82 (0.78–0.86) Late within-season (mid-Nov. to Feb.): Model 1: 0.88 (0.79–0.97) Model 2: 0.90 (0.82–1.00) Vaccination in previous yr, by month of index date: Sept. to Nov.: Model 1: 0.75 (0.68–0.83) Model 2: 0.77 (0.70–0.85) Dec. to Mar.: Model 1: 0.86 (0.79–0.93) Model 2: 0.88	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												(0.82–0.95) Apr. to Aug.: Model 1: 0.80 (0.73–0.86) Model 2: 0.84 (0.77–0.90) Pneumococcal < 65: Model 1: 0.83 (0.73–0.95) Model 2: 0.91 (0.79–1.05) ≥ 65: Model 1: 0.88 (0.83–0.93) Model 2: 0.97 (0.91–1.03)		
Tanner et al. 2012, Case-control ⁶³	N=286; Location=Utah; Age=20.4 to 92.5; Setting=The University of Utah Voice Disorders Center	Swine flu (Also assessed measles, mumps, and rubella separately - unsure if any of these are MMR)	Selected segment - University of Utah Voice Disorders Center	No details about dropping out over the course of the study, but study notes in the recruitment phase: Of the 192 patients approached and invited to participate, 150 individuals with SD completed the study (cases) Of the 160	Not reported	Self-report through questionnaire. Trained examiners administered the questionnaire to each participant and were periodically audited to ensure accuracy.	Voice disorder diagnosis was confirmed by a multidisciplinary team of professionals including a laryngologist and one of four speech-language pathologists. Diagnosis was assigned following a thorough evaluation including a detailed case history, auditory-perceptual	Logistic regression	Age, sex, race/ethnicity	Not reported	The work was supported in part by a University of Utah College of Health Research and Creative Grant	Vacc v. Nonvacc: 2.1 (0.9-5.0) Don't Know v. Nonvacc: 2.3 (1.3-4.1)	Not reported	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
				patients approached and invited to participate, 136 VC individuals completed the study (controls)			evaluation, and videolaryngoscopy, employing diagnostic criteria previously established and reported.							
Ting et al. 2011, Retrospective matched cohort (each pair included 1 vaccinated and 1 non-vaccinated COPD patient) ⁷²	586 patients with moderate to severe COPD identified in COPD Registers of 6 general practices in North Derbyshire UK. Age range 37-89 (median 68)	influenza	entire population of COPD patients in these 6-practices	n/a	n/a	medical record	medical record (spirometry records)	McNemar's test	controlled for environmental factors (weather, prevalence of respiratory viral pathogens)	10/2005-12/2005	NR	In the 14 days following vaccination, the control group had 21 COPD exacerbations cf. 11 in the vaccinated group (McNemar's p=0.11, not significant; OR 0.52 [95% CI 0.29, 1.14])		Study did NOT look at exacerbations by COPD stage or other risk factors.
Tseng et al. 2010, Prospective cohort ⁷⁴	N=84,170; Location=CA; Age=45-69 years; Setting=Kaiser Permanente Northern and Southern California health plans (California Men's Health Study)	Pneumococcal	Should be noted, participants who were vaccinated were significantly older than participants who were not vaccinated. Region, race/ethnicity, household income, education, and BMI also were associated significantly with vaccination status.	Study notes the mean (SD) length of follow-up was 4.7 (1.36) years. The unvaccinated group had relatively shorter length of followup	Not discussed	Immunization records were tracked by the Kaiser Immunization Tracking System	Electronic health records	Cox proportional hazards regression	Propensity score was created: age, race/ethnicity, region (northern vs southern California Kaiser Permanente), household income, education, BMI, cigarette smoking, physical activity level, sedentary for more than 6.5	2002-2007	This study was funded by California Cancer Research Program and Kaiser Permanent e.	Association of Pneumococcal Vaccination and Incidence of MI and Stroke Acute MI All men: 1.09 (0.98-1.21), p=0.13 Stroke All men: 1.14 (1.00-1.31), p=0.05	Association of Pneumococcal Vaccination and Incidence of MI and Stroke Age, y <65: 1.23 (1.08-1.40), p=0.001 >=65: 0.89 (0.80-1.01), p=0.10 High-risk groups Current	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
									hours per day outside of work, alcohol consumption, number of influenza vaccines received, calorie intake, fat intake, fruit and vegetable consumption, history of diabetes, history of high blood pressure, history of high cholesterol, history of peripheral artery disease, history of other heart diseases, history of stroke, history of acute MI, and the log scale transformed number of outpatient visits during the 5 years before baseline. Cigarette smoking was modeled through smoking status				smokers: 1.11 (0.83-1.47), p=0.48 Diabetes: 1.04 (0.87-1.24), p=0.51 Hypertension: 1.10 (0.97-1.25), p=0.16 Low-risk group: 0.98 (0.35-2.73), p=0.97 Influenza vaccine 0: 1.10 (0.70-1.72), p=0.69 1-10: 1.10 (0.97-1.26), p=0.14 >10: 1.00 (0.83-1.21), p=0.97	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Tseng et al. 2012, Case-centered and Self-controlled case series ⁸⁵	N=193,083 recipients of zoster vaccine in 8 US MCOs; Age=50 and older;	Zoster	VSD population - might be differences in case and exposure ascertainment across sites	Not discussed	Not discussed	Medical records	Authors used computerized data to identify any adult with a pre-specified event of interest or death	Case-centered: logistic regression SCCS: conditional Poisson regression	No additional confounders controlled for in models	1 January 2007 to 31 December 2008	Contract from the Centers for Disease Control and Prevention	Relative risk (RR) and 95% confidence interval (CI) of pre-specified adverse events within predefined risk windows following vaccination with a zoster vaccine Case-centered Day 1-14 Stroke: 1.03 (0.83–1.28) Acute myocardial infarction: 1.17 (0.92–1.48) Cardiomyopathy: 0.73 (0.51–1.03) Heart failure: 0.76 (0.46–1.24) Meningitis, encephalitis and encephalopathy: 0.54 (0.19–1.52) Ramsey-Hunt syndromes and Bell's palsy: 0.63 (0.29–1.38) Day 15-28 Stroke: 0.92 (0.73–1.16) Acute myocardial infarction: 1.04 (0.81–1.34) Acute Myocarditis: 8.98 (1.67–46.36) Cardiomyopathy: 1.11 (0.83–1.48) Heart failure: 1.08 (0.70–1.65) Meningitis, encephalitis and encephalopathy: 0.90	Not reported	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												(0.40–2.05) Day 29–42 Stroke: 1.06 (0.85–1.31) Acute myocardial infarction: 0.97 (0.75–1.26) Acute pericarditis: 1.04 (0.13–8.05) Acute Myocarditis: 17.18 (3.71–79.67) Cardiomyopathy: 1.00 (0.74–1.36) Heart failure: 0.95 (0.60–1.49) Meningitis, encephalitis and encephalopathy: 0.62 (0.23–1.69) Day 1–42 Stroke: 1.00 (0.87–1.15) Acute myocardial infarction: 1.07 (0.92–1.26) Acute pericarditis: 0.27 (0.03–2.22) Acute Myocarditis: 19.44 (3.58–105.68) Cardiomyopathy: 0.94 (0.77–1.14) Heart failure: 0.91 (0.68–1.21) Meningitis, encephalitis and encephalopathy: 0.66 (0.37–1.16) Mortality: 0.31 (0.23–0.40) Day 1–7 Cellulitis and infection: 1.30 (1.18–		

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												1.44) Allergic Reaction: 2.13 (1.87–2.40) SCCS Day 1-14 Cerebrovascular diseases: 0.94 (0.70–1.28) Acute myocardial infarction: 1.22 (0.87–1.73) Cardiomyopathy: 0.70 (0.45–1.10) Heart failure: 0.77 (0.41–1.46) Meningitis, encephalitis and encephalopathy: 0.80 (0.21–2.98) Ramsey-Hunt syndromes and Bell's palsy: 0.78 (0.29–2.09) Day 15-28 Cerebrovascular diseases: 1.03 (0.74–1.42) Acute myocardial infarction: 1.24 (0.85–1.79) Cardiomyopathy: 1.05 (0.69–1.59) Heart failure: 0.92 (0.51–1.63) Meningitis, encephalitis and encephalopathy: 0.86 (0.29–2.55) Day 29-42 Cerebrovascular diseases: 0.97 (0.71–1.30)		

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Acute myocardial infarction: 0.97 (0.67–1.39) Acute pericarditis: 1.00 (0.06–15.99) Acute Myocarditis: 3.00 (0.31–28.84) Cardiomyopathy: 0.86 (0.57–1.29) Heart failure: 0.64 (0.36–1.16) Meningitis, encephalitis and encephalopathy: 0.80 (0.21–2.98) Day 1-42 Cerebrovascular diseases: 0.99 (0.83–1.19) Acute myocardial infarction: 1.05 (0.86–1.29) Acute pericarditis: 0.50 (0.05–5.51) Acute Myocarditis: 5.00 (0.58–42.80) Cardiomyopathy: 0.94 (0.73–1.20) Heart failure: 0.88 (0.61–1.25) Meningitis, encephalitis and encephalopathy: 0.78 (0.39–1.56) Day 1-7 Cellulitis and infection: 1.10 (0.95–1.26) Allergic Reaction: 2.32 (1.85–2.91)		

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Uno et al. 2012, Case-control ¹⁴⁵	N=413 (189 ASD cases, 224 controls); Location=Kanto area, Japan; Age=22.6 years (mean); Setting=Cases were patients of the Yokohama Psycho-Developmental Clinic (YPDC). Controls were volunteers from area schools.	MMR, diphtheria-tetanus-pertussis-tetanus vaccine (DPT); the polio vaccine. Study did not specify whether DPT was acellular and did not specify whether polio was inactivated.	Selected segment - Kanto, Japan. Also, cases were patients of psycho-developmental clinic (may differ from cases that don't go to clinic)	89 of 1875 cases excluded because missing vaccine records. Additional 3 excluded because received vaccines overseas. 1429 cases born before 3/84 or after 5/92, leaving 354 cases. 189 cases could be matched to a control.	Not reported	Study notes that "vaccination history...collected based on the MCH handbook, which was routinely attached to each patient's file, were examined." Study did not note exactly who did the examining, but I assume it was the researchers.	Patients were diagnosed based on the (DSM-IV) and standardized criteria using the Diagnostic Interview for Social and Communication Disorder (DISCO). Another child psychiatrist or clinical psychologist conducted intellectual or developmental tests, such as the Psycho-Educational Profile-Revised and Wechsler Intelligence Scale for Children-Third Edition. After the interview and testing, the diagnosis was made by the team according to the DSM-IV criteria.	Conditional logistic regression	Maternal hypertension, low Apgar score, obstetrical vacuum extraction or forceps delivery	Study doesn't note when researchers collected data, but the universe of eligible participants included patients visiting the clinic between April 1997 (when the clinic opened) and March 2011.	A part of the study is the result of research grants from the Ministry of Health, Labor and Welfare of Japan, and "Integrated research on neuropsychiatric disorders" carried out under the Strategic Research Program for Brain Sciences by the Ministry of Education, Culture, Sports, Science and Technology of Japan	MMR: 1.10 (0.64–1.90), p=0.72	Maternal hypertension: 4.19 (0.46–38.57), p=0.21 Low Apgar score: 2.06 (0.18–22.12), p=0.57 Obstetrical vacuum extraction or forceps delivery: 0.98 (0.50–1.92), p=0.96	
Vila-Corcoles et al. 2012, Prospective cohort ⁷⁶	N=27,204 (8,981 vaccinated, 18,223 unvaccinated); Location=Spain; Age=71.7 (mean at	Pneumococcal (PPV23)	Paper did not provide details on recruitment - referred reader to another paper	None discussed	Not discussed	Review of the primary care centers' electronic clinical records	Computerized clinical record system Outcomes identified bases on ICD-9 codes with physician verification based on	Cox proportional hazards models	The following variables were considered in all the initial models: age, sex, number of outpatient visits to family physician in 12-months	Cohort members were followed from the start of the study (December 1, 2008) until the	This work was supported by a grant from the "Fondo de Investigación Sanitaria" of the	Multivariate hazard ratio (95% CI) CAP: 0.85 (0.62–1.15), p=0.287 AMI: 0.83 (0.56–1.22), p=0.347 Ischemic Stroke: 0.65 (0.42–0.99), p=0.048 Death from any cause: 0.88 (0.75–1.03),	Not reported	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	study start); Setting=nine primary care centers in the Health Region of Tarragona (a mixed residential-industrial urban area in the Mediterranean coast of Catalonia, Spain)						medical record review		before study start, influenza vaccination in prior autumn, history of coronary artery disease, history of stroke, history of chronic heart disease, chronic pulmonary disease, hypertension, hypercholesterolemia, obesity, diabetes mellitus, smoking status, alcoholism, chronic severe liver disease, chronic severe nephropathy, cancer, dementia and nursing-home residence. Age, sex and influenza vaccine status were judged epidemiologically relevant variables, being included in all the final models. Final Models: CAP: Adjusted for age, sex, number of	occurrence of any event, change in pneumococcal vaccination status, disenrollment from the primary care center, death, or until the end of first 12-month follow-up (November 30, 2009).	Instituto de Salud Carlos III [FIS 09/00043] of the Spanish Health Ministry	p=0.12		

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
									outpatient visits in prior year, influenza vaccination in prior year, chronic pulmonary disease, chronic heart disease, smoking and nursing-home resident AMI: Adjusted for age, sex, number of outpatient visits in prior year, influenza vaccination in prior year, history of coronary artery disease, chronic heart disease, diabetes mellitus, hypercholesterolemia, smoking (confounder) and nursing-home resident Ischemic Heart Disease: Adjusted for age, sex, number of outpatient visits in prior year, influenza vaccination in prior year, history of					

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment	
									coronary artery disease, history of stroke, smoking (confounder) and nursing-home resident Death from any cause: Adjusted for age, sex, number of outpatient visits in prior year, influenza vaccination in prior year, chronic pulmonary disease, chronic heart disease, diabetes mellitus, cancer, chronic nephropathy, dementia, hypertension, hypercholesterolemia, obesity, smoking, and nursing home-resident						
Yu et al. 2007, Case-control ⁹³	N=1,875 (355 Graves' disease cases, 418 Hashimoto's thyroiditis cases, 1,102 controls); Location=Vaccine	Hepatitis B vaccine, influenza, MMR, Hepatitis A, polio	Potential for those with disease to be more likely to receive vaccination or more likely to be assessed for vaccination. Also possible recall bias and	None	Not discussed	Vaccine information was collected from administrative immunization records, chart review, and telephone interviews with study subjects	Medical record review. Identified cases of Graves' disease and Hashimoto's thyroiditis on the basis of International Classification of Diseases, Ninth	Logistic regression	Controls were frequency-matched to cases by birth year, sex, and study site (HMO) All models adjusted for frequency-	January 1, 1999 through June 30, 2002	ID Biomedica l, Chiron Therapeutics and Vaccines, and Sanofi Pasteur; Study supported by the	OR (95% CI) for Graves' disease Main analysis Hepatitis B: 0.90 (0.62–1.32) Influenza: 1.07 (0.80–1.42) MMR: 0.59 (0.29–1.20) Hepatitis A: 0.70 (0.43–1.13)	Not reported		

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Safety Datalink Project: Group Health Cooperative, Seattle, WA; Northwest Kaiser Permanente, Portland, OR; and Kaiser Permanente of Northern California, Oakland, CA; Age=18–69 years; Setting=Three health maintenance organizations (HMOs)			exposure misclassification. Authors noted that case groups may have included some subjects with thyroid conditions other than Graves' disease or Hashimoto's thyroiditis.			Revision (ICD-9) codes for thyroid disease, associated with inpatient and outpatient medical encounters that were recorded in HMO administrative data systems.		matching variables (age groups, sex, site, and index year), personal and family history of autoimmune disease, smoking status, race, and education		Vaccine Safety Datalink contract with America's Health Insurance Plans, funded by the CDC	Polio: 1.29 (0.76–2.17) OR (95% CI) for Hashimoto's thyroiditis Main analysis Hepatitis B: 1.23 (0.87–1.73) Influenza: 1.15 (0.89–1.48) MMR: 1.50 (0.79–2.86) Hepatitis A: 0.97 (0.64–1.46) Polio: 1.17 (0.73–1.86)			
Zhang et al. 2012, Retrospective cohort ³⁴	N=463,541 (4,026 with ankylosing spondylitis, 66,751 with inflammatory bowel disease, 11,030 with psoriatic arthritis, 89,565 with psoriasis, and 292,169 with RA); Location=US; Age=74 years (mean	Zoster Herpes	Could not control for differences between those who received vaccinations and those who did not (e.g., those receiving vaccines may be a healthier population). Misclassification of medication exposure	Actual vaccine administration dates were unknown for 59% of patients, which resulted in the exclusion of these patients from safety analyses potentially introducing bias	Did not discuss	Database review	Database review (administrative claims from physicians or hospitalizations)	Proportional hazard regression	Sex, race, immune-mediated disease, time varying concurrent medications, and time-varying health care utilization (hospitalization and physician visits)	January 1, 2006, through December 31, 2009	Agency for Healthcare Research and Quality	HR (95% CI) for Herpes Zoster Incidence Using ICD-9-CM diagnosis code+pharmacy claim definition for HZ case (Def 1) HZ vaccination: 0.61 (0.52–0.71) Using ICD-9-CM diagnosis code only for HZ case (Def 2) HZ vaccination: 0.67 (0.59–0.75)	Sex Men [Reference] Women Def 1: 1.22 (1.17–1.28) Def 2: 1.21 (1.17–1.26) Race White [Reference] Black Def 1: 0.67 (0.62–0.73) Def 2: 0.69 (0.64–0.74) Other Def 1: 0.89	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	at study start); Setting=US Medicare beneficiaries											(0.81-0.97) Def 2: 0.89 (0.83-0.95)	Immune-mediated disease Rheumatoid arthritis [Reference] Ankylosing spondylitis Def 1: 0.98 (0.77-1.25) Def 2: 0.94 (0.77-1.13) Inflammatory bowel diseases Def 1: 1.03 (0.97-1.10) Def 2: 1.02 (0.97-1.07)	

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment			
												(0.95-1.05) Def 2: 1.25 (1.20-1.29) No. of physician visits in the previous 6 mo Def 1: 1.04 (1.04-1.04) Def 2: 1.04 (1.04-1.04) DMARDs, exclusive groups Non-biologic DMARDs [Reference] Anti-TNF biologics Def 1: 1.15 (1.08-1.23) Def 2: 1.10 (1.04-1.16)					

Evidence Table 1. Postmarketing studies: Adults

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
													Def 1: 1.79 (1.71-1.86) Def 2: 1.69 (1.64-1.75)	

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Barrett P. N. et al, 2011 US ⁴⁷	Controlled Clinical Trial	4	Sample size: 7250, Mean age: NR, Age range: 18 - 49	Influenza (inactivated), Baxter, Austria, contain 15 µg of haemagglutinin antigen from each of the three virus strains - A/Brisbane/59/2007 (A/H1N1), A/Uruguay/716/2007(A/Brisbane/10/2007-like) (A/H3N2), and B/Florida/4/2006 (B). The three virus strains were egg-derived wild-type strains provided by the National Institute for Biological Standards and Control (Potters Bar, UK)., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days	Any adverse event: 35% Any SAE: 0.8%, Sev: 3-5 Event: Arthralgia: 6%, Syscat: 15, Sev: 1-3 Event: Chills: 6%, Syscat: 8, Sev: 1-3 Event: Cough: 1%, Syscat: 22, Sev: 1-3 Event: Fatigue: 18%, Syscat: 8, Sev: 1-3 Event: Headache: 18%, Syscat: 8, Sev: 1-3 Event: Hyperhidrosis: 5%, Syscat: 8, Sev: 1-3 Event: Malaise: 14%, Syscat: 8, Sev: 1-3 Event: Myalgia: 18%, Syscat: 8, Sev: 1-3 Event: Oropharyngeal pain: 2%, Syscat: 7, Sev: 1-3 Event: Pyrexia: 2%, Syscat: 8, Sev: 1-3 Event: Death: 0.05%, Sev: 5	Arthralgia: OR 2.103 (1.666-2.655)** Chills: OR 2.239 (1.766-2.838)** Cough: OR 1.427 (0.862-2.361) Fatigue: OR 1.577 (1.382-1.8)** Headache: OR 1.396 (1.229-1.587)** Hyperhidrosis: OR 1.678 (1.306-2.155)** Malaise: OR 2.024 (1.736-2.36)** Myalgia: OR 3.281 (2.799-3.846)** Oropharyngeal pain: OR 1.626 (1.058-2.5)** Pyrexia: OR 2.271 (1.537-3.355)**
Bhatla N. et al.,2010 India ⁸⁹	Controlled Clinical Trial	7	Sample size: 337, Mean age: 28.4, Age range: 18 - 35, Percent female: 100%	Human papillomavirus (HPV), HPV-16/18 L1 virus-like particle (VLP) cervical ca, GlaxoSmithKline, HPV-16/18 L1 virus-like particle (VLP) cervical cancer vaccine containing the proprietary ASO4 (3-O-desacyl-4(1)-monophosphoryl lipid [MPL] [0 mcg MPL] adsorbed on aluminum [Al] hydroxide [500 mcg AL(+3)]) adjuvant system, Adjuvant: ASO 4-Aluminum, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Month Dose2: 1 Month Dose3: 6 Month	Any adverse event: 7.4% Any SAE: 1.1% Event: Acute appendicitis: 0.6%, Syscat: 7 Event: Lymph node tuberculosis: 0.6%, Syscat: 11 Event: Pain (Grade 3): 20.5%, Syscat: 17, Sev: 3 Event: Redness (>50 mm): 0.6%, Syscat: 23, Sev: 3 Event: Swelling (>50 mm): 2.9%, Syscat: 23, Sev: 3	Pain (Grade 3): OR 6.189 (2.634-14.54)** Redness (>50 mm): OR 1 (0.063-15.882)

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Frey S. et al,2010 US, Finland, Poland ⁴⁸	Controlled Clinical Trial	4	Sample size: 11404, Mean age: 33, Age range: 18 - 49, Percent female: 55%	Influenza (inactivated), Agrippal, Novartis, 15 mg of hemagglutinin per 0.5-mL dose of each virus strain recommended for the 2007–2008 Northern Hemisphere influenza season: A/Solomon Islands/3/2006 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 1 Days	Any SAE: 0.95% Event: Chills (mild-moderate): 5%, Syscat: 8, Sev: 1-2 Event: Malaise (mild-moderate): 7.5%, Syscat: 8, Sev: 1-2 Event: Myalgia (mild-moderate): 9%, Syscat: 8, Sev: 1-2 Event: Arthralgia (mild-moderate): 2.5%, Syscat: 15, Sev: 1-2 Event: Headache (mild-moderate): 15%, Syscat: 8, Sev: 1-2 Event: Sweating (mild-moderate): 2.5%, Syscat: 8, Sev: 1-2 Event: Fatigue (mild-moderate): 11%, Syscat: 8, Sev: 1-2 Event: Fever (mild-moderate): 1%, Syscat: 8, Sev: 1-2 Event: Withdrawal after AE: 0.03%, Sev: 1-2 Event: Death: 0.03%, Sev: 5	Headache (mild-moderate): OR 1 (0.881-1.134) Arthralgia (mild-moderate): OR 0.961 (0.722-1.279) Chills (mild-moderate): OR 1 (0.813-1.23) Death: OR 1.061 (0.066-16.969) Fatigue (mild-moderate): OR 1.112 (0.96-1.289) Fever (mild-moderate): OR 2.01 (1.159-3.487)** Malaise (mild-moderate): OR 1.27 (1.061-1.521)** Myalgia (mild-moderate): OR 1.314 (1.112-1.553)** Sweating (mild-moderate): OR 1 (0.749-1.335) Withdrawal after AE: OR 1.061 (0.066-16.969)
Iorio V et al.,2010 Italy ⁴⁹	Controlled Clinical Trial	4	Sample size: 104, Mean age: 71, Age range: 18 - NR, Percent female: 45.1%	Influenza (inactivated), Fluad, Novartis, Fujian/411/02 (influenza A[H3N2]), New Caledonia/20/99 (influenza A[H1N1]), and Shanghai/361/02 (influenza B), Adjuvant: Other adjuvant, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days Dose2: 42 Days	Any SAE: 0%, Syscat: 0 Event: Posttraumatic elbow hematoma: 0.96%, Syscat: 26, Sev: 1-3 Event: Gingival bleeding: 0.96%, Syscat: 7, Sev: 1-3 Event: Nosebleeds: 2.88%, Syscat: 22, Sev: 1-3 Event: Conjunctival hemorrhage: 0.96%, Syscat: 6, Sev: 1-3 Event: Bruising: 0%, Syscat: 12	Nosebleeds: OR 0.743 (0.162-3.403)

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Jackson L. A. et al., 2010 US ⁵⁰	Controlled Clinical Trial	7	Sample size: 7611, Mean age: 32.7, Age range: 18 - 49, Percent female: 60%, Percent pregnant: Percent Pregnant: 0.7%	Influenza (inactivated), Flulaval, ID Biomedical Corporation of Quebec (trademarked b, 15 µg of hemagglutinin(HA) antigen of each recommended influenza strain. Antigens for Season 1 (2005-2006) were A/New Caledonia/20/1999 (H1N1), A/New York/55/2004 (H3N2, A/California/7/2004-like), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like). Antigens for Season 2 (2006-2007) were A/New Caledonia/20/1999 (H1N1) virus, A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 0 Days	Any adverse event: 66% Any SAE: 1.1% Event: Fever: 3%, Syscat: 8, Sev: 1-3 Event: Myalgia/arthralgia: 18%, Syscat: 15, Sev: 1-3 Event: Malaise: 9%, Syscat: 8, Sev: 1-3 Event: Swelling of the face: 1%, Syscat: 8, Sev: 1-3 Event: Cough: 8%, Syscat: 22, Sev: 1-3 Event: Chest tightness or difficulty breathing: 3%, Syscat: 22, Sev: 1-3 Event: Sore throat, hoarseness, or pain swallowing: 9%, Syscat: 7, Sev: 1-3 Event: Death: 0%, Sev: 5	Chest tightness or difficulty breathing: OR 1.218 (0.938-1.581) Cough: OR 1.17 (0.982-1.396) Fever: OR 1.786 (1.278-2.496)** Myalgia/arthralgia: OR 1.979 (1.732-2.262)** Sore throat, hoarseness, or pain swallowing: OR 0.949 (0.809-1.112) Swelling of the face: OR 1.4 (0.915-2.143)
Johnstone, J. et al. 2012 ²⁴⁰ 40 countries	Cohort	2	Sample size : 31546, Mean age: 66 (approx), Age range: 55 - NR, Percent female: 29.9%	Influenza (inactivated) , NR , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Not reported	Dose1: NR	Event: Any major cardiovascular event (during flu season) : 1.1% , Syscat: 2 , Sev: 3-4 Event: Any major cardiovascular event (non flu season) : 0.94% , Syscat: 2 , Sev: 3-4 Event: Non cardiovascular deaths : 0.01% , Syscat: 2 , Sev: 4 Event: Cancer deaths : 0% , Sev: 4 Event: Deaths from other causes : 0.05% , Sev: 4	Any major cardiovascular event (during flu season): OR 1.082 (0.834-1.404) Any major cardiovascular event (during flu season): OR 1.082 (0.834-1.404) Any major cardiovascular event (non flu season): OR 0.887 (0.674-1.168) Any major cardiovascular event (non flu season): OR 0.887 (0.674-1.168) Deaths from other causes: OR 0.228 (0.028-1.856) Deaths from other causes: OR 0.228 (0.028-1.856) Non cardiovascular deaths: OR 0.133 (0.017-1.024) Non cardiovascular deaths: OR 0.133 (0.017-1.024)

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Langley J. M., et al. ²⁰¹¹ Canada ⁴⁶	Controlled Clinical Trial	4	Sample size: 1348, Mean age: 37.1, Age range: 18 - 64, Percent female: 54.2%	Influenza (inactivated), NR, Contains equal parts of three monovalent egg-grown, formalin-inactivated influenza antigens formulated with OMPs of N. meningitidis serogroup B strain 8047 at an initial ratio of OMP to haemagglutinin (HA) of 4:1. After diafiltration to remove detergents necessary to keep the OMPs in stable solution in the absence of antigen, the overall total protein to HA ratio in the final vaccine product is 2.5 to 5:1. The trivalent vaccine stock contained HA from each of A/New Caledonia/20/99 [H1N1], A/Panama/2007/99 [H3N2] and B/Shangdong/7/97 [H1N1]. Adjuvant: Not Reported, Preservative: Thimerisol, Delivery: Intranasal	Dose1: 0 Days Dose2: 14 Days	Any SAE: 0.219%, Syscat: 10, Sev: 3,4 Event: Shortness of breath (Grade 2/3): 0%, Syscat: 22, Sev: 3-5 Event: Lightheadedness/Dizziness (Grade2/3): 0%, Syscat: 17, Sev: 3-5 Event: New rash/itchy rash (Grade 2/3): 0%, Syscat: 10, Sev: 3-5 Event: Feverishness (Grade2/3): 0%, Syscat: 8, Sev: 3-5 Event: Burning/stinging nose (Grade2/3): 0%, Syscat: 8, Sev: 3-5 Event: Burning/stinging throat (Grade 2/3): 0%, Syscat: 8, Sev: 3-5 Event: Itching nose/throat/eyes (Grade 2/3): 0%, Syscat: 8, Sev: 3-5 Event: Temp >39C: 0%, Syscat: 8, Sev: 3-5	
Lee S. et al, ²⁰¹¹ Korea ⁹⁰	Controlled Clinical Trial	5	Sample size: 20, Mean age: 28.1, Age range: NR, Percent female: 0%	Td, SK Td Vaccine Inj, SK Chemicals, Seongnam, Korea, \geq 2 IU of diphtheria toxoid and \geq 20 IU of tetanus toxoid, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Days	Any adverse event: 80% Event: Serious adverse events: 0% Event: Hypoesthesia: 30%, Syscat: 17 Event: Hypoesthesia (vaccine-related): 20%, Syscat: 17	Hypoesthesia: OR 3.857 (0.326-45.572)
Macaladad N. et al., ²⁰⁰⁷ Brazil, Costa Rica, Colombia, Mexico, Peru and Venezuela and the Philippines ⁷⁸	Controlled Clinical Trial	2	Sample size: 21, Mean age: 38.1, Age range: 27 - 69, Percent female: 66.7%	Zoster, NR, 50,000 PFU/0.5 mL, Adjuvant: Not Reported, Preservative: Not reported, Delivery: injected	Dose1: 0 NR	Any adverse event: 37.5% Any SAE: 0% Event: Injection-site: 25.0%, Syscat: 8 Event: Systemic: 12.5% Event: Vaccine-related (Related to injection-site AE): 25.0%, Syscat: 8 Event: Injection-site (mild burning, erythema and pruritus): 25.0%, Syscat: 8, Sev: 2 Event: Serious vaccine-related AE: 0%	

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Madhi S. A. et al.,2011 South Africa ⁵³	Controlled Clinical Trial	3	Sample size: 189, Mean age: 36.3, Percent female: 84%, Conditions: HIV	Influenza (inactivated), Mutagrip, Sanofi, 15ugm each (per 0.5 ml) A/Solomon Islands/3/2006 (IVR-145), A/Brisbane/10/2007(IVR-147),B/Florida/4/2006, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: NR Dose2: NR Dose3: NR	Any adverse event: 14.4% Event: Pain: 8.3% Event: Redness: 2.1% Event: Swelling: 2.1% Event: Lump formation: 1.0% Event: Bruising: 0% Event: Itching: 3.1% Event: Rigors (muscle cramp): 0% Event: Fatigue: 1.0% Event: Headache: 3.1% Event: Fits (seizures): 0% Event: Myalgia: 3.1% Event: Arthralgia: 3.1% Event: Fever: 0%	Arthralgia: OR 0.694 (0.151-3.19) Fatigue: OR 0.179 (0.021-1.564) Headache: OR 0.936 (0.184-4.762) Itching: OR 2.872 (0.293-28.127) Lump formation: OR 0.464 (0.041-5.201) Myalgia: OR 1.42 (0.232-8.7) Pain: OR 1.955 (0.568-6.73) Redness: OR 1.895 (0.169-21.26)
Mills R. et a.,2010 US ⁸¹	Controlled Clinical Trial	5	Sample size: 101, Mean age: 67.8 (approx.), Age range: 50 - 93, Percent female: 59.4%	Zoster, Zostavax, Merck, Lyophilized zoster vaccine (~89,000 plaque-forming units[PFU]/dose at release), Adjuvant: Not Reported, Preservative: Not reported, Delivery: Subcutaneous	Dose1: 0 Days Dose2: 28 Days	Any adverse event: 52.0%, Syscat: 8 Any SAE: 0%, Sev: 3,4,5 Event: Overall - Injection site AEs: 45.9%, Syscat: 8 Event: Overall - Systemic AEs: 15.3%, Syscat: 8 Event: Overall - Vaccine related AEs: 2.0%, Syscat: 8 Event: Deaths: 0% Event: Stratum 1: 1 or more AEs: 54.4%, Syscat: 8 Event: Stratum 1: Injection site AEs: 47.1%, Syscat: 8 Event: Stratum 1: Systemic AEs: 13.2%, Syscat: 8 Event: Stratum 1: Vaccine related AEs: 1.5%, Syscat: 8 Event: Stratum 2: 1 or more AEs: 46.7%, Syscat: 8 Event: Stratum 2: Injection site AEs: 43.3%, Syscat: 8 Event: Stratum 2: Systemic AEs: 20.0%, Syscat: 8 Event: Stratum 2: Vaccine related AEs: 3.3%, Syscat: 8 Event: 50-59y: 1 or more AE: 47.4%, Syscat: 8 Event: 50-59y: Systemic AE: 5.3%, Syscat: 8 Event: 50-59y: Vaccine related AE: 0%, Syscat: 8 Event: >=60y: 1 or more AE: 53.2%, Syscat: 8 Event: >=60y: Systemic AE: 17.7%, Syscat: 8 Event: >=60y: Vaccine related AE: 2.5%, Syscat: 8	50-59y: Systemic AE: OR 0.245 (0.027-2.231) 50-59y: 1 or more AE: OR 1.899 (0.613-5.88) >=60y: Systemic AE: OR 1.664 (0.685-4.042) >=60y: 1 or more AE: OR 5.371 (2.609-11.054)** Overall - Injection site AEs: OR 19.841 (6.773-58.123)** Overall - Systemic AEs: OR 1.195 (0.537-2.659) Stratum 1: 1 or more AEs: OR 19.185 (5.673-64.881)** Stratum 1: Injection site AEs: OR 3.49 (1.674-7.277)** Stratum 1: Systemic AEs: OR 0.567 (0.236-1.364) Stratum 2: Injection site AEs: OR 14.943 (1.916-116.559)** Stratum 2: Systemic AEs: OR 6.383 (0.754-54.018) Stratum 2: 1 or more AEs: OR 8.058 (1.781-36.46)**

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Murray A. V. et al.,2011 US, Canada, Spain, Germany, UK ⁸³	Controlled Clinical Trial	4	Sample size: 11999, Mean age: 70.4, Age range: 60 - 99, Percent female: 58.6%	Zoster, Zostavax, Merck, Lyophilized ZV, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Subcutaneous	Dose1: 0	Any SAE: 5.7% Event: Blood/Lymphatic disorders(1-42d): 0%, Syscat: 1 Event: Cardiac disorders(1-42d): 0.3%, Syscat: 2 Event: GI disorders(1-42d): 0.1%, Syscat: 7 Event: Respiratory/Thoracic (1-42d): 0.1%, Syscat: 22 Event: Neoplasms(1-42d): 0.3%, Syscat: 16 Event: Nervous system (1-42d): 0.1%, Syscat: 17 Event: Psychiatric (1-42d): 0.0%, Syscat: 19 Event: Vaccine related SAEs (1-42d): 0.0%, Syscat: 6,15 Event: Death (1-42d): 0.1% Event: Blood/Lymphatic disorders(1-182d): .1%, Syscat: 1 Event: Cardiac disorders (1-182d): 1.2%, Syscat: 2 Event: GI disorders (1-182d): 0.6%, Syscat: 7 Event: Respiratory/Thoracic (1-182d): 0.5%, Syscat: 22 Event: Neoplasms (1-182d): 1.3%, Syscat: 16 Event: Nervous system(1-182d): 0.4%, Syscat: 17 Event: Psychiatric (1-182d): 0.1%, Syscat: 19 Event: Vaccine related SAEs(1-182d): 0.0% Event: Death (1-182d): 0.4%	Blood/Lymphatic disorders(1-182d): OR 1.253 (0.336-4.669) Cardiac disorders (1-182d): OR 1.016 (0.733-1.41) Cardiac disorders(1-42d): OR 1.002 (0.53-1.895) Death (1-182d): OR 1.417 (0.76-2.64) Death (1-42d): OR 1.203 (0.367-3.944) GI disorders (1-182d): OR 1.281 (0.787-2.085) GI disorders(1-42d): OR 1.337 (0.464-3.855) Neoplasms (1-182d): OR 1.317 (0.934-1.858) Neoplasms(1-42d): OR 1.672 (0.731-3.824) Nervous system(1-182d): OR 0.808 (0.476-1.369) Nervous system (1-42d): OR 0.716 (0.227-2.256) Psychiatric (1-182d): OR 60.2 (0.116-31171.904) Psychiatric (1-42d): OR 1.002 (0.141-7.118) Respiratory/Thoracic (1-182d): OR 1.123 (0.654-1.928) Respiratory/Thoracic (1-42d): OR 1.504 (0.424-5.333)

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Ngan H. Y. S. et al., 2010 Hong Kong ⁸⁸	Controlled Clinical Trial	7	Sample size: 300, Age range: 18 - 35, Percent female: 100%	Human papillomavirus (HPV), Cevarix, GlaxoSmithKline, Each dose (0.5 mL) of the HPV-16/18 vaccine contained 20 µg each of HPV-16 and -18 L1 (structural protein of HPV) virus-like particle (VLP) and adjuvant with a proprietary AS04 (3-O-desacyl-4'-monophosphoryllipid [50 µg] adsorbed on aluminium hydroxide [Al(OH)3, 500 µg], Adjuvant: ASO 4, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Month Dose2: 1 Month Dose3: 6 Month	Any adverse event: 90% Any SAE: 2% Event: Arthralgia: 8%, Syscat: 15, Sev: 1-3 Event: Fatigue: 42%, Syscat: 8, Sev: 1-3 Event: Fever: 6%, Syscat: 8, Sev: 1-3 Event: GI symptoms: 16%, Syscat: 7, Sev: 1-3 Event: Headache: 24%, Syscat: 8, Sev: 1-3 Event: Myalgia: 35%, Syscat: 8, Sev: 1-3 Event: Rash: 3%, Syscat: 10, Sev: 1-3 Event: Urticaria: 2%, Syscat: 10, Sev: 1-3	Arthralgia: OR 1.362 (0.556-3.336) Fatigue: OR 1.69 (1.049-2.721)** Fever: OR 0.734 (0.3-1.797) GI symptoms: OR 1.714 (0.86-3.415) Headache: OR 1.439 (0.822-2.519) Myalgia: OR 1.705 (1.031-2.82)** Rash: OR 3.062 (0.476-19.708) Urticaria: OR 1 (0.199-5.036)
Schmader K. E. et al., 2012 North America and Europe ⁷⁹	Controlled Clinical Trial	4	Sample size: 22439, Mean age: 54.8, Age range: 50 - 59, Percent female: 61.9%	Zoster, Zostavax, Merck, lyophilized ZV with stabilizers, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Subcutaneous	Dose1: 0 (Baseline)	Any adverse event: 72.8% Any SAE: 0.6% Event: 1 or more Injection-site AEs: 63.9% Event: 1 or more Systemic AEs: 35.4% Event: With vaccine-related AEs: 65.0% Event: Vaccine Related Injection site AEs: 63.9% Event: Vaccine relate systemic AEs: 6.7% Event: With vaccine related SAE: 0% Event: SAE with death: 0%	1 or more Injection-site AEs: OR 10.379 (9.722-11.081)** SAE with death: OR 0.334 (0.035-3.209) With vaccine-related AEs: OR 8.385 (7.882-8.922)** Vaccine relate systemic AEs: OR 0.43 (0.393-0.471)** With vaccine related SAE: OR 0.002 (0-0.013)** 1 or more Systemic AEs: OR 1.089 (1.031-1.151)**

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Simberkoff M. S. et al., 2010 US\$ ⁸²	Controlled Clinical Trial	7	Sample size: 38546, Mean age: NR, Age range: 60 - NR	Zoster, Merck, Median potency, 24600 plaque-forming units per dose, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Subcutaneous	Dose1: 0 Days	Any adverse event: 1.4%, Sev: 1-5 Any SAE: 1.68%, Sev: 3-5 Event: # of SAE (60-69y): 0.7%, Sev: 3-5 Event: # of SAE (>=70y): 0.98%, Sev: 3-5 Event: # of SAE (70-80y): 0.78%, Sev: 3-5 Event: # of SAE (>=80y): 0.2%, Sev: 3-5 Event: COSTART - Cardiovascular: 0.5%, Syscat: 2, Sev: 3-5 Event: COSTART - Digestive: 0.21%, Syscat: 7, Sev: 3-5 Event: COSTART - Musculoskeletal: 0.08%, Syscat: 15, Sev: 3-5 Event: COSTART - Nervous Sys: 0.18%, Syscat: 17, Sev: 3-5 Event: COSTART - Respiratory: 0.16%, Syscat: 22, Sev: 3-5 Event: COSTART - Sight/Sense: 0.02%, Syscat: 5,6, Sev: 3-5 Event: COSTART - Skin: 0.15%, Syscat: 23, Sev: 3-5 Event: COSTART - Genitourinary: 0.08%, Syscat: 20, Sev: 3-5 Event: COSTART - Endocrine: 0.01%, Syscat: 5, Sev: 3-5 Event: COSTART - Hemic/Lymphatic: 0.03%, Syscat: 1, Sev: 3-5 Event: COSTART - Metabolic/Nutritional: 0.03%, Syscat: 14, Sev: 3-5 Event: Diagnostic grp - Cancer: 0.27%, Syscat: 16, Sev: 3-5 Event: Diagnostic grp - Vascular (pathological): 0.41%, Syscat: 26, Sev: 3-5 Event: Diagnostic grp - Vascular (functional): .23%, Syscat: 26, Sev: 3-5	# of SAE (60-69y): OR 1.081 (0.847-1.38) # of SAE (70-80y): OR 0.909 (0.728-1.135) # of SAE (>=70y): OR 0.969 (0.793-1.185) # of SAE (>=80y): OR 1.301 (0.808-2.095) COSTART - Cardiovascular: OR 1.117 (0.835-1.496) COSTART - Digestive: OR 0.719 (0.481-1.075) COSTART - Endocrine: OR 0.25 (0.028-2.237) COSTART - Genitourinary: OR 0.941 (0.476-1.864) COSTART - Hemic/Lymphatic: OR 2.501 (0.485-12.894) COSTART - Metabolic/Nutritional: OR 1.667 (0.398-6.978) COSTART - Musculoskeletal: OR 1 (0.489-2.047) COSTART - Nervous Sys: OR 1.03 (0.642-1.652) COSTART - Respiratory: OR 0.973 (0.588-1.609) COSTART - Skin: OR 0.903 (0.542-1.506) Diagnostic grp - Cancer: OR 1.131 (0.76-1.683)

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Talaat K. R. et al.,2010 United States ⁵²	Controlled Clinical Trial	5	Sample size: 1313, Mean age: 56.5, Age range: 18 - 93, Percent female: 57.1%	Influenza - monovalent H1N1, CSL Limited, The 7.5-mgdoses were supplied in prefilled syringes that contained 7.5 mg of HA in 0.25 mL of thimerosal-free diluent., Adjuvant: Adjuvant Free, Preservative: Other, Delivery: Intramuscular	Dose1: NR Dose2: 21 Days	Event: Any systemic AE (Dose 1): 26%, Syscat: 8, Sev: 1-3 Event: Any systemic AE (Dose 2): 13%, Syscat: 8, Sev: 1-3 Event: Headache (Dose 1): 15%, Syscat: 8, Sev: 1-3 Event: Headache (Dose 2): 9%, Syscat: 8, Sev: 1-3 Event: Myalgia (Dose 1): 12%, Syscat: 8, Sev: 1-3 Event: Myalgia (Dose 2): 6%, Syscat: 8, Sev: 1-3 Event: Malaise (Dose 1): 8%, Syscat: 8, Sev: 1-3 Event: Malaise (Dose 2): 8%, Syscat: 8, Sev: 1-3 Event: Nausea (Dose 1): 4%, Syscat: 8, Sev: 1-3 Event: Nausea(Dose 2): 3%, Syscat: 8, Sev: 1-3 Event: Chills(Dose 1): 2%, Syscat: 8, Sev: 1-3 Event: Chills(Dose 2): 2%, Syscat: 8, Sev: 1-3 Event: Vomiting(Dose 1): 1%, Syscat: 8, Sev: 1-3 Event: Vomiting(Dose 2): 0.5%, Syscat: 8, Sev: 1-3 Event: Fever (Dose 1): 1%, Syscat: 8, Sev: 1-3 Event: Fever(Dose 2): 0.5%, Syscat: 8, Sev: 1-3	Any systemic AE (Dose 1): OR 1.176 (0.701-1.974) Any systemic AE (Dose 2): OR 0.562 (0.32-0.987)** Chills(Dose 1): OR 1 (0.208-4.801) Fever (Dose 1): OR 0.99 (0.11-8.922) Headache (Dose 1): OR 1.428 (0.719-2.835) Headache (Dose 2): OR 1 (0.464-2.154) Malaise (Dose 1): OR 1 (0.445-2.247) Malaise (Dose 2): OR 0.704 (0.341-1.452) Myalgia (Dose 1): OR 2.136 (0.885-5.159) Myalgia (Dose 2): OR 0.645 (0.29-1.437) Nausea (Dose 1): OR 1 (0.326-3.067) Nausea(Dose 2): OR 3.062 (0.39-24.025) Vomiting(Dose 1): OR 0.495 (0.089-2.744) Vomiting(Dose 2): OR 0.497 (0.045-5.549)
Treanor J. J. et al.,2011 USA ⁵¹	Controlled Clinical Trial	3	Sample size: 4648, Mean age: 32.5, Age range: 18 - 55, Percent female: 59%, Percent pregnant: Percent Pregnant: 0.8%	Influenza (inactivated), FluBlok, NR, The trivalent vaccine contained 45 mcg of each purified rHA0 derived from the A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 influenza viruses recommended for the 2007–2008 influenza season formulated with 0.005% Tween®-20 in 10mM sodiumphosphate buffer pH 7.0 ± 0.4 without a preservative, Adjuvant: Not Reported, Preservative: Preservative Free, Delivery: Intramuscular	Dose1: 0 Days	Any adverse event: 51.1% Any SAE: 1.5% Event: Fever (=100.4): 0.7%, Syscat: 8, Sev: 1-5 Event: Fatigue or lack of energy: 14.5%, Syscat: 8 Event: Shivering or chills: 3.0%, Syscat: 8 Event: Joint pain: 3.8%, Syscat: 15 Event: Muscle pain: 10.2%, Syscat: 15 Event: Headache: 14.9%, Syscat: 8 Event: Nausea: 5.5%, Syscat: 7 Event: Pain: 36.3%, Syscat: 8 Event: Bruising: 3.2%, Syscat: 12	Bruising: OR 1.258 (0.89-1.778) Fatigue or lack of energy: OR 1.004 (0.853-1.182) Fever (=100.4): OR 1.395 (0.665-2.928) Headache: OR 0.964 (0.821-1.131) Joint pain: OR 1.056 (0.779-1.432) Muscle pain: OR 1.585 (1.283-1.958)** Nausea: OR 1.173 (0.903-1.524) Pain: OR 6.686 (5.62-7.953)** Shivering or chills: OR 0.968 (0.692-1.354)

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Vermeulen J. N. et al.,2012 US and Netherlands ⁸⁰	Controlled Clinical Trial	5	Sample size: 210, Mean age: 68.7 (Tx); 70.7 (Placebo), Age range: 58 - 90, Percent female: 62.85%	Zoster, Zostavax, Merck, lyophilized ZV (~23,000 plaque forming unit [PFU]/0.5 mL), Adjuvant: Not Reported, Preservative: Not reported, Delivery: Subcutaneous	Dose1: 0 Days Dose2: 42 Days	Event: 1 or more AEs (Post Dose 1): 71.2% Event: With vaccine-related AEs (Post Dose 1): 52.9% Event: Systemic AEs (Post Dose 1): 12.5% Event: SAE (Post Dose 1): 0% Event: Discontinued due to a vaccine-related AE (Post dose 1): 1.9% Event: 1 or more AEs (Post dose 2): 76.5% Event: With vaccine-related AEs (Post Dose 2): 63.3% Event: Systemic AEs (Post Dose 2): 5.1% Event: Systemic AEs (PD #2) -Rash: 2.0%, Syscat: 10 Event: SAEs (Post dose 2): 5.1% Event: Discontinued due to vaccine related AE (Dose 2): 0%	1 or more AEs (Post Dose 1): OR 3.062 (1.732-5.412)** Systemic AEs (PD #2) -Rash: OR 2.019 (0.18-22.617) Systemic AEs (Post Dose 2): OR 0.825 (0.244-2.791) Systemic AEs (Post Dose 1): OR 14.696 (1.886-114.525)** 1 or more AEs (Post dose 2): OR 4.063 (2.278-7.243)** With vaccine-related AEs (Post Dose 1): OR 8.525 (4.179-17.389)** With vaccine-related AEs (Post Dose 2): OR 11.174 (5.461-22.867)**
Wang, I.K. et al. 2013 ⁵⁴ Taiwan	Cohort	5	Sample size : 4018, Mean age: 70/59 (vaccinated/nonvaccinate, Age range: 18 - 65+, Percent female: 51%, Conditions: ESRD	Influenza (inactivated) , Not specified , NR , Not reported , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Not reported	Dose1: Not reported	Event: Total hospitalization : 55% Event: Pneumonia/influenza-hospitalization : 17% , Syscat: 22 Event: Septicemia, bacteremia, and viremia-hospitalization : 12% , Syscat: 11 Event: Heart disease-hospitalization : 41% , Syscat: 2 Event: Respiratory Failure-hospitalization : 8% , Syscat: 22 Event: Intensive care unit admission-hospitalization : 2% Event: Mortality-hospitalization : 15%	Heart disease-hospitalization: OR 1.253 (1.072-1.465)** Intensive care unit admission-hospitalization: OR 0.341 (0.206-0.564)** Pneumonia/influenza-hospitalization: OR 1.238 (1.005-1.524)** Respiratory Failure-hospitalization: OR 0.963 (0.727-1.276) Septicemia, bacteremia, and viremia-hospitalization: OR 1.158 (0.916-1.464) Total hospitalization: OR 1.096 (0.94-1.277)

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Weinberg A. et al., 2010 US (No direct mentions) ⁸⁷	Cohort	1	Sample size: 82, Mean age: NR, Age range: 18 - 65, Percent female: 35.3%, Conditions: HIV	Varicella, Varivax, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 0 Weeks Dose2: 12 Weeks	Event: Dose1: Systemic rash (non-zosteriform): 3%, Syscat: 10, Sev: 1,2 Event: Dose 1: Pruritis: 3%, Syscat: 6, Sev: 1,2 Event: Dose 1: Adenopathy: 0%, Syscat: 26, Sev: 1,2 Event: Dose 1: Nose bleed: 0%, Sev: 1,2 Event: Dose 1: Influenza-like illness: 9%, Syscat: 8, Sev: 1,2 Event: Dose 1: Chest pain: 0%, Syscat: 2, Sev: 1,2 Event: Dose 1: Liver enzyme elevation: 0%, Syscat: 9, Sev: 1,2 Event: Dose 2: Systemic rash (non-zosteriform): 3%, Syscat: 10, Sev: 1,2 Event: Dose2: Pruritis: 0%, Syscat: 6, Sev: 1,2 Event: Dose2: Adenopathy: 0%, Syscat: 26, Sev: 1,2 Event: Dose2: Nose bleed: 3%, Sev: 1,2 Event: Dose2: Influenza-like illness: 0%, Syscat: 8, Sev: 1,2 Event: Dose2: Chest pain: 0%, Syscat: 2, Sev: 1,2 Event: Dose2: Liver enzyme elevation: 6%, Syscat: 9, Sev: 1,2	Dose 1: Influenza-like illness: OR 1.55 (0.242-9.94) Dose 1: Pruritis: OR 0.484 (0.042-5.618) Dose1: Systemic rash (non-zosteriform): OR 0.484 (0.042-5.618) Dose2: Liver enzyme elevation: OR 2.065 (0.178-23.943) Dose 2: Systemic rash (non-zosteriform): OR 1 (0.06-16.69)

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year- Country	Vaccine ²	Timing ²	Adverse Event ²	Control group	Adverse Events Control
Barrett P. N. et al.,2011 US ⁴⁷				Placebo Buffered saline	Any adverse event: 22%, Sev: 1-5 Any SAE: 0.7%, Sev: 3-5 Event: Arthralgia: 3%, Syscat: 15, Sev: 1-3 Event: Chills: 3%, Syscat: 8, Sev: 1-3 Event: Cough: 0.7%, Syscat: 22, Sev: 1-3 Event: Fatigue: 12%, Syscat: 8, Sev: 1-3 Event: Headache: 13%, Syscat: 8, Sev: 1-3 Event: Hiperhidrosis: 3%, Syscat: 8, Sev: 1-3 Event: Malaise: 227%, Syscat: 8, Sev: 1-3 Event: Myalgia: 6%, Syscat: 8, Sev: 1-3 Event: Oropharyngeal pain: 0.9%, Syscat: 7, Sev: 1-3 Event: Pyrexia: 1%, Syscat: 8, Sev: 1-3 Event: Death: 0%, Sev: 5 Event: Potentially placebo related SAE: 0.05%, Syscat: 26, Sev: 3
Bhatla N. et al.,2010 India ⁸⁹				Aluminum hydroxide (placebo) Contains only the aluminum hydrozide, no ASO4	Any adverse event: 13.4% Any SAE: 2.2% Event: Miscarriage: 0.6%, Syscat: 18, Sev: 5 Event: Bronchogenic cyst: 0.6%, Syscat: 22 Event: Cataract: 0.6%, Syscat: 6 Event: Pneumothorax of the left lung: 0.6%, Syscat: 22 Event: Pain (Grade 3): 4.0%, Syscat: 17, Sev: 3 Event: Redness (>50 mm): 0.6%, Syscat: 23, Sev: 3 Event: Swelling (>50 mm), Syscat: 23, Sev: 3
Frey S. et al.,2010 US, Finland, Poland ⁴⁸	Influenza (inactivated), Optaflu, Novartis, 15 mg of hemagglutinin per 0.5-mL dose of each virus strain recommended for the 2007–2008 Northern Hemisphere influenza season: A/Solomon Islands/3/2006 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 1 Days	Any SAE: 1.1% Event: Chills (mild-moderate), Syscat: 8, Sev: 1-2 Event: Malaise (mild-moderate): 7.5%, Syscat: 8, Sev: 1-2 Event: Myalgia (mild-moderate), Syscat: 8, Sev: 1-2 Event: Arthralgia (mild-moderate): 3.5%, Syscat: 15, Sev: 1-2 Event: Headache (mild-moderate): 15%, Sev: 1-2 Event: Sweating (mild-moderate), Sev: 1-2 Event: Fatigue (mild-moderate): 10%, Syscat: 8, Sev: 1-2 Event: Fever (mild-moderate): 1%, Syscat: 8, Sev: 1-2 Event: Withdraw after AE: .1%, Sev: 1-2 Event: Death: .1%, Sev: 5 AE: 0%	Placebo Unsure of adjuvants, preservatives and formulations	Any SAE: 0.97% Event: Chills (mild-moderate): 5%, Sev: 1-2 Event: Malaise (mild-moderate): 6%, Sev: 1-2 Event: Myalgia (mild-moderate): 7%, Sev: 1-2 Event: Arthralgia (mild-moderate): 2.6%, Sev: 1-2 Event: Headache (mild-moderate): 15%, Sev: 1-2 Event: Sweating (mild-moderate): 2.5%, Sev: 1-2 Event: Fatigue (mild-moderate), Sev: 1-2 Event: Fever (mild-moderate): 0.5%, Sev: 1-2 Event: Withdraw after AE (mild-moderate): 0.03%, Sev: 1-2 Event: Death (mild-moderate): .03%, Sev: 5

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year- Country	Vaccine ²	Timing ²	Adverse Event ²	Control group	Adverse Events Control
Iorio A. et al.,2010 Italy ⁴⁹				Placebo	Any SAE: 0%, Syscat: 0 Event: Nosebleeds: 3.85%, Syscat: 22, Sev: 1-3 Event: Bruising: 0.96%, Syscat: 12, Sev: 1-3 Event: Posttraumatic elbow hematoma: 0%, Syscat: 26 Event: Gingival bleeding: 0%, Syscat: 7 Event: Conjunctival hemorrhage: 0%, Syscat: 6
Jackson L. A. et al.,2010 US ⁵⁰				Placebo saline placebo injection	Any adverse event: 44% Any SAE: 1.0% Event: Fever: 1%, Syscat: 8, Sev: 1-3 Event: Myalgia/arthritis: 10%, Syscat: 15, Sev: 1-3 Event: Swelling of the face: 1.0%, Syscat: 8, Sev: 1-3 Event: Cough: 7.0%, Syscat: 22, Sev: 1-3 Event: Chest Tightness/Difficulty breathing: 3.0%, Syscat: 22, Sev: 1-3 Event: Sore throat, hoarseness or pain on swallowing: 9.0%, Syscat: 7, Sev: 1-3 Event: Death (road accident): .03%, Sev: 5 AE: 0%
Johnstone, J. et al. 2012 ²⁴⁰ 40 countries	Influenza (inactivated) , Adjuvant: Not Reported , Preservative: Not reported , Delivery:	Dose1: NR	Event: Any major cardiovascular event (during flu season) : 155% , Syscat: 2 , Sev: 3-4 Event: Any major cardiovascular event (non flu season) : 0.97% , Syscat: 2 , Sev: 3-4 Event: Non cardiovascular deaths : 0.23% , Sev: 4 Event: Cancer deaths : 0.1% , Sev: 4 Event: Deaths from other causes : 0.13% , Sev: 4 AE: 0.01% AE: 0% AE: 0%	Nothing	Event: Any major cardiovascular event (during flu season) : 1.0% , Syscat: 2 , Sev: 3-4 Event: Any major cardiovascular event (non flu season) : 1.05% , Syscat: 2 , Sev: 3-4 Event: Non cardiovascular deaths : 0.08% , Sev: 4 Event: Cancer deaths : 0.03% , Sev: 4 Event: Deaths from other causes : 0.01% , Sev: 4

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year- Country	Vaccine ²	Timing ²	Adverse Event ²	Control group	Adverse Events Control
Langley J. M. et al.,2011 Canada ⁴⁶	Influenza (inactivated), Contains equal parts of three monovalent egg-grown, formalin-inactivated influenza antigens formulated with OMPs of N. meningitidis serogroup B strain 8047 at an initial ratio of OMP to haemagglutinin (HA) of 4:1. After diafiltration to remove detergents necessary to keep the OMPs in stable solution in the absence of antigen, the overall total protein to HA ratio in the final vaccine product is 2.5 to 5:1. The trivalent vaccine stock contained HA from each of A/New Caledonia/20/99 [H1N1], A/Panama/2007/99 [H3N2] and B/Shangdong/7/97 [H1N1], Adjuvant: Not Reported, Preservative: Thimerisol, Delivery:	Dose1: 0 Days	Any SAE: 0% Event: Shortness of breath (Grade 2/3): 0%, Syscat: 22, Sev: 3-5 Event: Lightheadedness or dizziness (2/3): 0%, Syscat: 17, Sev: 3-5 Event: A new rash or a rash that has become itchy (2/3): 0%, Syscat: 10, Sev: 3-5 Event: Feverishness (Grade2/3): 0%, Syscat: 8, Sev: 3-5 Event: Burning/stinging nose (Grade2/3): 0%, Sev: 3-5 Event: Burning/stinging throat (Grade 2/3): 0%, Sev: 3-5 Event: Itching nose/throat/eyes (Grade 2/3): 0%, Syscat: 8, Sev: 3-5 Event: Temp >39C: 0%, Syscat: 8, Sev: 3-5 AE: 0% AE: 0% AE: 0%		Event: Shortness of breath (Grade 2/3): 0%, Syscat: 22, Sev: 3-5 Event: Lightheadedness or dizziness (2/3): 0%, Syscat: 17, Sev: 3-5 Event: A new rash or a rash that has become itchy (2/3): 0%, Syscat: 10, Sev: 3-5 Event: Feverishness: 0%, Syscat: 8, Sev: 3-5 Event: Temperature (>39C): 0%, Syscat: 8, Sev: 3-5 Event: Burning or stinging in the nose (2/3): 0%, Syscat: 8, Sev: 3-5 Event: Burning or stinging in the throat (2/3): 0%, Syscat: 8, Sev: 3-5 Event: Itching nose/throat eyes (2/3): 0%, Syscat: 8, Sev: 3-5
Lee S. et al.,2011 Korea ⁹⁰				Placebo Unsure of adjuvants, preservatives and formulations	Any adverse event: 40% Event: Serious adverse events (any): 0% Event: Hypoesthesia (any): 10%, Syscat: 17 Event: Hypoesthesia (vaccine-related): 0%, Syscat: 17
Macaladad N. et al.,2007 Brazil, Costa Rica, Colombia, Mexico, Peru and Venezuela and the Philippines ⁷⁸				Placebo Unsure of adjuvants, preservatives and formulations	Any adverse event: 0% Any SAE: 0% Event: Injection-site: 0%, Syscat: 8 Event: Systemic: 0% Event: Vaccine-related (Related to injection-site AE): 0%, Syscat: 8 Event: Injection-site (mild burning, erythema and pruritus): 0%, Syscat: 8, Sev: 2 Event: Serious vaccine-related AE: 0%

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year- Country	Vaccine ²	Timing ²	Adverse Event ²	Control group	Adverse Events Control
Madhi S. A. et al.,2011 South Africa ⁵³				Placebo Unsure of adjuvants, preservatives and formulations	Any adverse event: 9.9% Event: Pain: 4.4% Event: Redness: 1.1% Event: Swelling: 0% Event: Lump formation: 2% Event: Bruising: 0% Event: Itching: 1.1% Event: Rigors: 5% Event: Fatigue: 5.5% Event: Headache: 3.3% Event: Fits: 0% Event: Myalgia: 2.2% Event: Arthralgia: 4.4% Event: Fever: 1.1%
Mills R. et al.,2010 US ⁸¹				Nothing	Any adverse event: 17.7%, Syscat: 8 Any SAE: 0%, Syscat: 8, Sev: 3,4,5 Event: Overall: Injection site AE: 4.3%, Syscat: 8 Event: Overall: Systemic: 13.5%, Syscat: 8 Event: Overall: Vaccine related: 0%, Syscat: 8 Event: Overall: Deaths: 0% Event: Stratum1: With one or more AE: 22.7%, Syscat: 8 Event: Stratum1:Injection AE: 4.5%, Syscat: 8 Event: Stratum1:Systemic AE: 0%, Syscat: 8 Event: Stratum1:Vaccine AE: 0%, Syscat: 8 Event: Stratum2:With one or more AE: 6.7%, Syscat: 8 Event: Stratum2:Injection AE: 3.3%, Syscat: 8 Event: Stratum2:Systemic AE: 3.3%, Syscat: 8 Event: Stratum2:Vaccine AE: 0%, Syscat: 8 Event: 50-59y:With one or more AE: 26.3%, Syscat: 8 Event: 50-59y:Systemic AE: 21.1%, Syscat: 8 Event: 50-59y:Vaccine AE: 0%, Syscat: 8 Event: >=60y:With one or more AE: 15.6%, Syscat: 8 Event: >=60y:Systemic AE: 11.7% Event: >=60y:Vaccine AE: 0%, Syscat: 8

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year- Country	Vaccine ²	Timing ²	Adverse Event ²	Control group	Adverse Events Control
Murray A. V. et al.,2011 US, Canada, Spain, Germany, UK ⁸³				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any SAE: 5.0% Event: Blood/Lymphatic (1-42d): 0%, Syscat: 1 Event: Cardiac(1-42d): 0.3%, Syscat: 2 Event: GI(1-42d): 0.1%, Syscat: 7 Event: Neoplasms(1-42d): 0.2%, Syscat: 16 Event: Nervous system(1-42d): 0.1%, Syscat: 17 Event: Psychiatric(1-42d): 0.0%, Syscat: 19 Event: Respiratory(1-42d): 0%, Syscat: 22 Event: Vaccine SAE(1-42d): 0% Event: Death(1-42d): 0.1% Event: Blood/Lymphatic (1-182d): 0.1%, Syscat: 1 Event: Cardiac(1-182d): 1.2%, Syscat: 2 Event: GI(1-182d): 0.5%, Syscat: 7 Event: Neoplasm(1-182d): 1.0%, Syscat: 16 Event: Nervous(1-182d): 0.5%, Syscat: 17 Event: Psychiatric(1-182d): 0.1%, Syscat: 19 Event: Respiratory(1-182d): 0.4%, Syscat: 22 Event: Vaccine SAE(1-182d): 0.0% Event: Death(1-182d): 0.3%
Ngan H. Y. S. et al.,2010 Hong Kong ⁸⁸				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any adverse event: 77% Any SAE: 0.67%, Sev: 1-3 Event: Arthralgia: 6%, Syscat: 15, Sev: 1-3 Event: Fatigue: 30%, Syscat: 8, Sev: 1-3 Event: Fever: 8%, Syscat: 8, Sev: 1-3 Event: GI symptoms: 10%, Syscat: 7, Sev: 1-3 Event: Headache: 18%, Syscat: 8, Sev: 1-3 Event: Myalgia: 24%, Syscat: 8, Sev: 1-3 Event: Rash, Syscat: 10, Sev: 1-3 Event: Urticaria: 2%, Syscat: 10, Sev: 1-3
Schmader K. E. et al.,2012 North America and Europe ⁷⁹				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any adverse event: 41.5% Any SAE: 0.5% Event: With 1 or more injection site AEs: 14.4% Event: With 1 or more systemic AEs: 33.5% Event: Vaccine related AEs: 17.9% Event: Vaccine related injection site AEs: 14.4% Event: Vaccine related systemic AEs: 4.7% Event: Serious vaccine related AEs: 0% Event: SAE with death: .03% AE: 0%

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year- Country	Vaccine ²	Timing ²	Adverse Event ²	Control group	Adverse Events Control
Simberkoff M. S. et al.,2010 US ⁸²				Placebo Unsure of adjuvants, preservatives and formulations	Any adverse event: 1.4%, Sev: 1-5 Any SAE: 1.66%, Sev: 3-5 Event: # of SAE (60-69y): 0.65%, Sev: 3-5 Event: # of SAE (>=70y): 1.01%, Sev: 3-5 Event: # of SAE (70-80y): 0.86%, Sev: 3-5 Event: # of SAE (>=80y): 0.16%, Sev: 3-5 Event: Diagnostic grp - Cancer: 0.24%, Syscat: 16, Sev: 3-5 Event: Diagnostic grp - Vascular (pathological): 0.4%, Syscat: 26, Sev: 3-5 Event: Diagnostic grp - Vascular (functional): 86%, Syscat: 26, Sev: 3-5 Event: COSTART - Cardiovascular: 0.45%, Syscat: 2, Sev: 3-5 Event: COSTART - Digestive: 0.3%, Syscat: 7, Sev: 3-5 Event: COSTART - Endocrine: .02%, Syscat: 5, Sev: 3-5 Event: COSTART - Hemic/Lymphatic: 0.01%, Syscat: 1, Sev: 3-5 Event: COSTART - Metabolic/nutritional: 0.02%, Syscat: 14, Sev: 3-5 Event: COSTART - Musculoskeletal: 0.08%, Syscat: 15, Sev: 3-5 Event: COSTART - Nervous system: 0.18%, Syscat: 17, Sev: 3-5 Event: COSTART - Respiratory, Syscat: 22, Sev: 3-5 Event: COSTART - Skin: 0.16%, Syscat: 23, Sev: 3-5 Event: COSTART - Sight/Sense: 0%, Sev: 3-5 Event: COSTART - Genitourinary: .09%, Syscat: 20, Sev: 3-5

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
Talaat K. R. et al.,2010 United States ⁵²	Influenza - monovalent H1N1, CSL Limited, The 15mg dose was supplied in multidose vials of 60 mg of HA per milliliter with thimerosal 0.01% (wt/vol)., Adjuvant: Adjuvant Free, Preservative: Thimerisol, Delivery: Intramuscular	Dose1: NR NR Dose2: 21 Days	Event: Any systemic AE (Dose 1), Syscat: 8, Sev: 1-3 Event: Any systemic AE (Dose 2): 18%, Syscat: 8, Sev: 1-3 Event: Headache (Dose 1), Syscat: 8, Sev: 1-3 Event: Headache(Dose 2): 11%, Syscat: 8, Sev: 1-3 Event: Malaise(Dose 1): 14%, Sev: 1-3 Event: Malaise(Dose 2), Sev: 1-3 Event: Myalgia(Dose 1): 15%, Syscat: 8, Sev: 1-3 Event: Myalgia(Dose 2): 8%, Syscat: 8, Sev: 1-3 Event: Nausea(Dose 1): 5%, Syscat: 8, Sev: 1-3 Event: Nausea(Dose 2): 5%, Syscat: 8, Sev: 1-3 Event: Chills(Dose 1): 3%, Syscat: 8, Sev: 1-3 Event: Chills(Dose 2): 3%, Syscat: 8, Sev: 1-3 Event: Vomiting(Dose 1): 1%, Syscat: 8, Sev: 1-3 Event: Vomiting(Dose 2): 3%, Syscat: 8, Sev: 1-3 Event: Fever(Dose 1): 1%, Syscat: 8, Sev: 1-3 Event: Fever(Dose 2): 1%, Sev: 1-3 AE: 4%	Placebo Placebo was supplied in multidose vials containing vaccine diluent and thimerosal 0.01% (wt/vol). The 7.5microgram vaccine did not have thimerosal.	Event: Any systemic AEs (Dose 1): 23%, Syscat: 8, Sev: 1-3 Event: Any systemic AEs (Dose 2): 21%, Syscat: 8, Sev: 1-3 Event: Headache (Dose 1): 11%, Syscat: 8, Sev: 1-3 Event: Headache (Dose 2): 9%, Syscat: 8, Sev: 1-3 Event: Malaise (Dose 1): 8%, Syscat: 8, Sev: 1-3 Event: Malaise (Dose 2): 11%, Syscat: 8, Sev: 1-3 Event: Myalgia (Dose 1), Syscat: 8, Sev: 1-3 Event: Myalgia (Dose 2): 9%, Syscat: 8, Sev: 1-3 Event: Nausea (Dose 1): 4%, Syscat: 8, Sev: 1-3 Event: Nausea (Dose 2): 2%, Syscat: 8, Sev: 1-3 Event: Chills (Dose 1): 1%, Syscat: 8, Sev: 1-3 Event: Chills (Dose 2): 2%, Syscat: 8, Sev: 1-3 Event: Vomiting (Dose 1): 0%, Syscat: 8, Sev: 1-3 Event: Vomiting (Dose 2): 2%, Syscat: 8, Sev: 1-3 Event: Fever (Dose 1): 1%, Syscat: 8, Sev: 1-3 Event: Fever (Dose 2): 1%, Syscat: 8, Sev: 1-3
Treanor J. J. et al.,2011 USA ⁵¹				Placebo Saline injection	Any adverse event: 31.6% Any SAE: 1.3% Event: Fever (=100.4): 0.5%, Syscat: 8, Sev: 1-5 Event: Fatigue or lack of energy: 14.5%, Syscat: 8 Event: Shivering or chills: 3.1%, Syscat: 8 Event: Joint pain: 3.6%, Syscat: 15 Event: Muscle pain: 6.7%, Syscat: 15 Event: Headache: 15.4%, Syscat: 8 Event: Nausea: 181%, Syscat: 7 Event: Pain: 7.9%, Syscat: 8 Event: Bruising: 2.6%, Syscat: 12

Evidence Table 2. Vaccinated versus unvaccinated: Adults

Author- Year- Country	Vaccine ²	Timing ²	Adverse Event ²	Control group	Adverse Events Control
Vermeulen J. N. et al.,2012 US and Netherlands ⁸⁰				Placebo Unsure of adjuvants, preservatives and formulations	Event: 1 or more AE (Dose 1): 43.8% Event: With vaccine-related AEs (Dose 1): 11.4% Event: Systemic AEs (Dose 1): 1.0% Event: SAEs (Dose 1): 0% Event: Discontinued due to vaccine AE (Dose 1): 0% Event: With one or more AE (Dose 2): 39.6% Event: With vaccine-related AEs (Dose 2): 6% Event: Systemic AE (Dose 2): 5.9% Event: Rash: 1%, Syscat: 10 Event: SAEs (Dose 2): 0% Event: Discontinued due to vaccine AE (Dose 2): 0%
Wang, I.K. et al. 2013 ⁵⁴ Taiwan				Nothing	Event: Total hospitalization : 53% Event: Pneumonia/influenza-hospitalization : 14% , Syscat: 22 Event: Septicemia, bacteremia, and viremia : 11% , Syscat: 11 Event: Heart disease : 36% , Syscat: 2 Event: Respiratory Failure : 8% , Syscat: 22 Event: Intensive care unit admission : 6% Event: Mortality : 18% AE: .56%
Weinberg A. et al.,2010 US (No direct mentions) ⁸⁷				Placebo Unsure of adjuvants, preservatives and formulations	Event: Dose 1: Systemic rash (non-zosteriform): 6%, Syscat: 10, Sev: 1,2 Event: Dose 1: Pruritis: 6%, Syscat: 6, Sev: 1,2 Event: Dose 1: Adenopathy: 3%, Syscat: 26, Sev: 1,2 Event: Dose 1: Nose bleed: 0%, Syscat: Not sure, Sev: 1,2 Event: Dose 1: Influenza-like illness: 6%, Syscat: 8, Sev: 1,2 Event: Dose 1: Chest pain: 3%, Syscat: 2, Sev: 1,2 Event: Dose 1: Liver enzyme elevation: 1%, Syscat: 9, Sev: 1,2 Event: Dose 2:Systemic rash (non-zosteriform): 3%, Syscat: 10, Sev: 1,2 Event: Dose 2: Pruritis: 3%, Syscat: 6, Sev: 1,2 Event: Dose 2: Adenopathy: 0%, Syscat: 26, Sev: 1,2 Event: Dose 2: Nose bleed: 0%, Syscat: Not sure, Sev: 1,2 Event: Dose 2: Influenza-like illness: 3%, Syscat: 8, Sev: 1,2 Event: Dose 2: Chest pain: 0%, Syscat: 2, Sev: 1,2 Event: Dose 2: Liver enzyme elevation: 3%, Syscat: 9, Sev: 1,2

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Andrews et al. 2012, Prospective cohort, also analyzed as self-controlled case series ¹⁴¹	N=343 cases of thrombocytopenic purpura (TP); Location=England, Denmark; Age=12–23 months;	MMR	In England, regional immunization registers, where ethical and data custodian permissions had been obtained for linkage, were used which cover a birth cohort of about 60,000. No discussion of whether those who gave permission may have systematically differed from those who did not.	Not discussed	Not discussed	Database review: immunization registry data	Database review: national TP coded hospital discharge data	Cohort: Poisson regression	Age Cohort study: Models were fitted just adjusting for age (1-month intervals) and calendar period (1 year intervals), and also adjusting for other covariates: child's gender, place of birth (classified according to degree of urbanization), ethnicity of mother (Danish or not), mother's age at birth (using age categories: ≤19, 20–24, 25–29, 30–34, 35–39, ≥40)	England: 1996–2007 Denmark: 1990–2007	The VAESCO consortium is funded by the European Centre for Disease Prevention and Control	Relative incidence of TP after MMR vaccination in children aged 12–23 months in England using the self-controlled case series method (SCCS) and in Denmark using the SCCS and cohort methods Self Controlled Case Series Period after MMR (days) 0–13 England: 1.10 (0.33–3.71) Denmark: 1.38 (0.68–2.78) 14–27 England: 3.13 (1.44–6.79) Denmark: 2.75 (1.61–4.69) 28–42 England: 1.53 (0.58–4.03) Denmark: 1.94 (1.04–3.62) 0–42 England: 1.92 (1.02–3.59) Denmark: 2.01 (1.34–2.99) Cohort (Denmark) Period after MMR (days) 0–13: 1.32 (0.65–2.68) 14–27: 2.54 (1.47–4.37) 28–42: 1.72 (0.92–	None	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												3.22) 0-42: 1.85 (1.23–2.78)		
Baxter, 2012, Retrospective cohort ¹¹⁴	43,702 LAIV recipients, 53,366 matched unvaccinated controls, 43,702 TIV recipients Age: 5 to 17 years, Setting: Kaiser Permanente health system	LAIV, TIV, unvaccinated comparison group	Included all LAIV vaccine recipients in database	NA	NA	Medical record	Medical record	Cox proportional hazards model	Relative risks (RR) were calculated as the ratio of the incidence rates of the two comparison groups without adjustment for any covariate. Hazard ratios (HR) were also calculated adjusting for matching factors and seasonal changes in background rates.	October 2003 to March 2008	MedImmune	The incidence rates of serious adverse events (SAEs) overall and by specific diagnosis were not significantly higher or lower in the LAIV recipients relative to control groups in any comparison.	Children aged 5 to 8 vaccinated with LAIV had higher risk of acute GI event in 21 days (HR 1.36, 10.05 - 1.76) and 42 days (HR 1.30, 1.08 - 1.78) than unvaccinated cohort same age. Children aged 5 to 8 also had higher risk of acute respiratory tract event in 21 days (HR 1.12, 1.00 - 1.25) and 42 days (HR 1.15, 1.06 - 1.24) than unvaccinated cohort same age.	
Benchimol, et al. 2013, ¹¹⁶ Self-controlled case series	N=26602; Location=Ontario, Canada; Age=< 19 years; Setting=Ontario Crohn's and	Influenza	IBD cases	Not discussed or none	Not discussed	Immunization codes were obtained from the Ontario Health Insurance Plan (OHIP) database,	Review of health administrative data.	SCCS: relative incidence estimation	Self-controlled and also matched controls. Each IBD case was matched to 5 (or 4 where a fifth could not be	1999-2010	Dr Benchimol is supported by a Career Development Award from the Canadian Child Health Clinician	TABLE 2 SCCS Analysis to Assess Risk of Increased Health Services Utilization in the Postvaccine Period in Children With IBD and Non-IBD Matched Controls	None	RI=relative incidence RIR=ratio RI of cases to controls

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	Colitis Cohort (OCCC), a population-based registry of pediatric IBD patients derived from provincial health administrative data								found) controls according to gender, provincial administrative health region in which the subject resided, and date of birth.		Scientist Program. Dr Kwong is supported by a Clinician Scientist Award from the Department of Family and Community Medicine, University of Toronto. Dr Wilson holds the Canada Research Chair in Public Health Policy. The Institute for Clinical Evaluative Sciences receives funding from the Ontario Ministry of Health and Long-Term Care	Overall all-cause health services utilization (hospitalizations + ED visits + outpatient visits) RI in IBD Patients, (95CI) p-value Days 3–14: 1.19 (0.88–1.59).26 Days 15–30: 0.83 (0.61–1.13).23 Days 31–45: 0.96 (0.71–1.29).78 Days 46–60: 0.81 (0.58–1.12).20 Days 61–75: 0.94 (0.69–1.26).66 Days 76–90: 0.79 (0.57–1.09).15 Days 91–180: 0.99 (0.85–1.16).89 Pooled day 3–180: 0.95 (0.84–1.07).38 Pooled day 15–180: 0.92 (0.82–1.04).19 RI in Controls, (95CI) p-value Days 3–14: 0.64 (0.47–0.89).007 Days 15–30: 0.95 (0.75–1.20).65 Days 31–45: 0.68 (0.52–0.91).008 Days 46–60: 0.93 (0.73–1.19).56 Days 61–75: 0.87 (0.68–1.11).26 Days 76–90: 0.91 (0.71–1.16).44 Days 91–180: 0.96 (0.85–1.09).56		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Pooled day 3–180: 0.90 (0.82–0.98) .018 Pooled day 15–180: 0.91 (0.83–1.00) .055 RIR of Cases Versus Controls, (95CI) p-value Days 3–14: 1.60 (1.05–2.44) .03 Days 15–30: 0.74 (0.51–1.08) .12 Days 31–45: 1.18 (0.79–1.76) .42 Days 46–60: 0.73 (0.49–1.08) .12 Days 61–75: 0.91 (0.63–1.33) .64 Days 76–90: 0.74 (0.50–1.09) .13 Days 91–180: 0.85 (0.71–1.02) .09 Pooled day 3–180: 0.89 (0.78–1.02) .09 Pooled day 15–180: 0.85 (0.74–0.97) .02 Hospitalizations (all causes) RI in IBD Patients, (95CI) p-value Days 3–14: 0.79 (0.18–3.37) .75 Days 15–30: 1.14 (0.39–3.31) .82 Days 31–45: 0.60 (0.14–2.55) .49 Days 46–60: 0.59 (0.14–2.49) .47 Days 61–75: 2.01 (0.86–4.69) .11 Days 76–90: 0.57		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												(0.13–2.43) .40 Days 91–180: 0.69 (0.35–1.36) .43 No data other categories ED visits (all causes) RI in IBD Patients, (95CI) p-value Days 3–14: 0.73 (0.27–2.03) .55 Days 15–30: 0.89 (0.41–1.95) .77 Days 31–45: 0.72 (0.29–1.80) .48 Days 46–60: 1.57 (0.81–3.07) .18 Days 61–75: 0.98 (0.42–2.26) .96 Days 76–90: 0.99 (0.43–2.31) .99 Days 91–180: 1.12 (0.73–1.72) .60 RI in Controls, (95CI) p-value Days 3–14: 0.58 (0.21–1.58) .28 Days 15–30: 1.12 (0.58–2.16) .74 Days 31–45: 0.94 (0.45–1.94) .86 Days 46–60: 1.35 (0.73–2.47) .33 Days 61–75: 0.98 (0.50–1.96) .97 Days 76–90: 0.76 (0.35–1.64) .49 Days 91–180: 1.02 (0.72–1.45) .91 RIR of Cases Versus Controls, (95CI) p-		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												value Days 3–14: 1.21 (0.30–4.94) .79 Days 15–30: 0.83 (0.31–2.24) .72 Days 31–45: 0.80 (0.26–2.50) .70 Days 46–60: 1.09 (0.46–2.59) .85 Days 61–75: 0.88 (0.31–2.52) .81 Days 76–90: 1.17 (0.38–3.55) .78 Days 91–180: 0.94 (0.57–1.56) .81	TABLE 3 SCCS Analysis of IBD- Related Health Services Utilization (Hospitalizations + ED Visits + Outpatient Visits) RI, 95CI, p-value Days 3–14: 1.05 (0.68–1.63) .82 Days 15–30: 0.45 (0.26–0.80) .006 Days 31–45: 0.68 (0.42–1.11) .12 Days 46–60: 0.89 (0.58–1.36) .58 Days 61–75: 0.68 (0.43–1.10) .11 Days 76–90: 0.81 (0.52–1.26) .35 Days 91–180: 0.87 (0.70–1.09) .24 Pooled days 3–180: 0.81 (0.68–0.96) .014 Pooled days 15–180: 0.78 (0.66–0.94)	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												.007		
Bernsen et al. 2006, ²¹⁴ Study says observational cross-sectional study - they are collecting information on exposures and outcomes at the same time, but assessing childhood vaccination in the first year of life and "ever had" diseases but also current adverse events so study is prospective in some cases but difficult to tease apart	N=1875; Location=Netherlands; Age=8-12 years; Setting=Orthodox Reformed (Protestant) primary schools	DTP-IPV (diphtheria-tetanus-pertussis-(inactivated) poliomyelitis vaccination)	Information biases based on self-reported data. Physician-diagnosed outcomes introduce bias due to populations systematically differing between those who see doctors versus those who do not. Study assessed the possibility of selection bias due to low response rates of schools and children and determined that the chances were small	A total of 1875 children returned the questionnaire (a response rate of 42%), of which three questionnaires were excluded because of missing vaccination status).	Did not discuss	Self-report (questionnaires)	Self-report (questionnaires) Blood samples were taken for objective assessment of outcome. 72% of the participants gave informed consent for a blood sample (73.6% of the vaccinated, and 70.3% of the unvaccinated children). From these children a random stratified sample of 100 children were selected. On the basis of the objective allergy data of 100 children and other relevant variables, authors imputed the objective allergy for the remaining 1773 children	Logistic regression	A variable was included in the multivariate model if it changed the univariate point estimate by at least 10%. Following confounders were assessed: Season of birth; Birth order; Gender; Gestational age; Birth weight; Age of the mother at the time of delivery; Exposure to smoking (prenatally, during the first year of life and currently); Breast feeding for four months or more (yes/no); Housing in the first year of life (rural and living on a farm with livestock/rural, other/city); Pet keeping (furry pets or birds yes/no) during	Autumn 2003–Spring 2004	Not reported	OR (95% CI) for Atopic disorders Asthma: 1.04 (0.76–1.42) Hay fever: 0.79 (0.55–1.12) Eczema: 0.87 (0.66–1.14) Food allergy: 1.13 (0.71–1.81) Any atopic disorder: 1.00 (0.80–1.24) OR (95% CI) for Physician diagnosed atopic disorders Asthma: 1.03 (0.72–1.46) Hay fever: 1.06 (0.59–1.90) Eczema: 0.96 (0.73–1.25) Food allergy: 1.13 (0.71–1.81) Any atopic disorder: 1.04 (0.82–1.31)	Not reported	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
									the first year of life and currently; Day care starting at age 6 months or less (yes/no); Current age; Asthma and/or allergy of the parents and/or siblings; Highest educational level of the parents; Family income; Current level of urbanization (five levels); Living on a farm with livestock (yes/no); Sibship size; Mold in the child's bedroom in the past year; Frequent (more than 5 days/week) consumption of fruit (yes/no) (raw or cooked) vegetables (yes/no) anti-oxidants (yes/no) unskimmed dairy products (yes/no) whole meal bread					

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
									(yes/no); Frequent (at least 1 day/week) consumption of fish; Frequent exercise (school gym at least once a week and playing games with physical activity for at least half an hour a day and either being a member of a sporting club or walking or cycling from home to school vice versa for at least 1 h a day); Body mass index; Hib vaccination. In all models family size, education and atopic history of parents or siblings proved to be confounders					

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Bertuola et al. 2010, Case-control ¹⁴²	N=2,311 (387 cases, 1924 controls); Location=Italy; Age=Mean (SD) case/control : 4.9 (3.5) / 5.7 (4.9); Setting=Four pediatric hospitals: Department of Pediatrics, University of Padua; Giannina Gaslini Pediatric Hospital, Genova; Bambino Gesu Hospital, Rome; Santobono-Pausilipon Pediatric Hospital, Naples	MMR	Both cases and controls chosen from a population of hospitalized children lessening the chance of selection bias	None	NA	Physician interview (self-report)	Information on the reason for hospital admission came from pediatric emergency department records. Final diagnosis was retrieved from the clinical records after discharge.	Logistic regression	Age and use of drugs	November 1999 to December 2007	Italian Medicines Agency	OR 95% CI for ITP: MMR 2.4 (1.2-4.7)	Not reported	
Buttery et al. 2011, Observed/expected analysis ¹⁸¹	Children under 24 months old receiving RotaTeq (N=296,023) or, Rotarix (302,455)in Australia; Active surveillance	Two states used RotaTeq, two states used Rotarix	Rotavirus vaccination was introduced under the Australian National Immunization Program (NIP) in July 2007 and has a high coverage rate (90–95% for	None - study depended on active ascertainment of cases	Not discussed	Records from the Australian Childhood Immunization Register (ACIR). Vaccination status was confirmed from written records and/or by linkage to a Surveillance of	Active surveillance through the Australian Pediatric Surveillance Unit (APSU) and Pediatric Active Enhanced Disease Surveillance (PAEDS) study.	Relative risk estimation	No control for confounders	1st July 2007 to 31st December 2008	National Health and Medical Research Council; the Department of Health and Ageing, Commonwealth Government of Australia;	Observed and expected cases of intussusception by age in months in jurisdictions delivering RotaTeq 1–7 days post-vaccine Dose 1: 5.26 (1.09, 15.4) Dose 2: 1.33 (0.16,	None	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	mechanisms		most infant vaccines. The eligible population for the study covers nearly all infants. Study notes, "there is potential for bias in the estimation of both the observed cases and the background incidence rate due to limitations in the data sources used in the calculations. It is important to consider the size and direction of these possible biases but we consider them unlikely to account for the observed excess cases." Differences in surveillance methods between the two mechanisms may have led to biases in estimation of exposure and outcome (underestimates)			national vaccination registry (ACIR) in PAEDS cases	registered pediatricians and surgeons across Australia (APSU) and surveillance of four major tertiary pediatric hospitals across Australia.				the Sydney Medical School, University of Sydney; CSL Limited (CSL) and GlaxoSmithKline. The PAEDS pilot study is funded by the Department of Health and Ageing, Commonwealth Government of Australia.	4.82) Dose 3: 0.00 (0.00, 2.16) Total: 1.15 (0.37, 2.68) 1–21 days post-vaccine Dose 1: 3.51 (1.29, 7.64) Dose 2: 0.67 (0.14, 1.94) Dose 3: 0.00 (0.00, 0.89) Total: 0.77 (0.37, 1.41) Observed and expected cases of intussusception by age in months in jurisdictions delivering Rotarix 1–7 days post-vaccine Dose 1: 3.45 (0.71, 10.1) Dose 2: 1.05 (0.13, 3.80) Total: 1.58 (0.51, 3.69) 1–21 days post-vaccine Dose 1: 1.53 (0.42, 3.92) Dose 2: 0.88 (0.29, 2.05) Total: 1.37 (0.73, 2.34)		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
			. There may have been overestimation of incidence rate.											
Chao et al. 2012, Prospective cohort ²⁰¹	N=189,629 females who received HPV Age=9–26 years; Setting=Two managed care organizations in California	HPV4	Women receiving HPV vaccines may differ systematically from women who do not in susceptibility to outcome or likelihood of having outcome causing bias. Or there might be diagnoses biases where doctors look for adverse events more closely following vaccinations.	Not discussed	Not discussed	Health records review	MCO record review. Review of all safety data emerging from this study was carried out by an independent scientific committee, the Safety Review Committee (SRC). Cases were identified through electronic health records and then In-depth case review by a panel of experts.	Incidence rate ratio estimation	None	08/2006 and 03/2008	Merck & Co.	Incidence rate ratio (IRR) and 95% confidence interval (CI) of select autoimmune conditions in the vaccinated vs. non-vaccinated female populations of similar age in Kaiser Permanente Southern California Rheumatologic / autoimmune Immune thrombocytopenia: 1.24 (0.91–2.02) Systemic lupus erythematosus: 1.10 (0.71–1.66) Rheumatoid arthritis: 0.70 (0.41–1.60) Juvenile rheumatoid arthritis: 0.36 (0.14–0.71) Autoimmune haemolytic anaemia - excluded Endocrine Type 1 diabetes: 0.54 (0.45–0.70) Hashimoto's disease: 2.02 (1.65–2.60) Graves' disease: 0.76 (0.42–1.10) Neurological / ophthalmic	None	cluster of disease onset in relation to vaccination timing, dose sequence or age was found for any autoimmune condition. None of the estimated IRR was significantly elevated except Hashimoto's disease [IRR=1.29, 95% confidence interval: 1.08–1.56]. Further investigation of temporal relationship and biological plausibility revealed no consistent evidence for a safety signal for autoimmune thyroid

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment	
												Multiple sclerosis: 1.37 (0.74–3.20) Other demyelinating diseases of central nervous system: 0.71 (0.38–2.13) Optic neuritis: 1.45 (1.00–2.91) Uveitis: 1.28 (0.53–6.39)			conditions. The SRC and the investigator's identified no autoimmune safety concerns in this study
Chen et al. 1997, Prospective cohort ²²⁰	N=~242,000 (MMR, DTP, though I'm unsure on this) 12,626 and 3,379 for 10-12 year olds and 14-16 year olds respectively for Td); Location=US; Age=0-6 years; Setting=Vaccine Safety Datalink (VSD) project (4 HMOs, Group Health Cooperative (GHC) of Puget Sound in Washington, Northwest Kaiser Permanente (NWK) in Oregon,	DTP, MMR, Td, Hib (example analytic studies)	Entire population of VSD, but no detail of potential differences between sites in ascertainment or vaccination procedures	Not discussed	Not discussed	VSD record review	International Classification of Diseases (ICD)-9 codes for all hospitalizations and emergency department visits are compiled for the VSD study cohort	Cox regression model (DTP and MMR and seizures)	MMR/DTP - stratified by HMO and birth date, adjusted for other vaccines Age (Td)	1991-1994	Not reported (assume CDC)	Relative risk and 95% confidence interval of seizures and persistent seizure disorders following DTP and MMR vaccinations in the Vaccine Safety Datalink Project (estimates from figure) DTP Interval (days post vaccination) 0 days: 2.20 (1.50-3.40) 1-3 days: 1.00 (0.70-1.40) 4-7 days: 0.80 (0.50-1.00) 8-14 days: 0.85 (0.60-0.90) 15-30 days: 0.84 (0.70-0.90) MMR Interval (days post vaccination) 0 days: 0.80 (0.30-1.90) 1-3 days: 0.50 (0.20-1.00) 4-7 days: 1.80 (1.20-	Not reported	Article discusses the VSD generally and then gives a couple examples of the analytic capabilities which are abstracted here	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	Northern California Kaiser (NCK), and Southern California Kaiser (SCK) Permanente											2.70) 8-14 days: 2.50 (2.20-3.30) 15-30 days: 1.00 (0.90-1.20) On crude analysis, a possible association was found 8 to 14 days after vaccination with both Hib (1.40 (1.2-1.8)) and MMR (2.30 (1.9-2.9)) vaccines. After adjustment there was no association between Hib and seizures (0.90 (0.7-1.2)), whereas the association with MMR persisted (2.42 (1.8-3.2)). Rates of Hospitalization and Emergency Department Visits After Tetanus-Diphtheria (Td) Toxoid Vaccination by Age: Vaccine Safety Datalink Project Within 7 days of Td Hospitalization: 1.53 (0.65–3.48), p=0.38 Emergency department visit: 1.49 (0.98–2.23), p=0.06 Emergency department visit: 0.93 (0.40–2.11), p=0.99		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Within 14 days of Td Hospitalization: 1.47 (0.74–2.90), p=0.31 Emergency department visit: 1.46 (1.05–2.01), p=0.03 Emergency department visit: 1.42 (0.80–2.47), p=0.25 Within 30 days of Td Hospitalization: 1.53 (0.85–2.72), p=0.18 Emergency department visit: 1.23 (0.96–1.58), p=0.11 Emergency department visit: 1.03 (0.66–1.60), p=0.96		
Gallagher and Goodman 2010, Cross-sectional ¹⁸⁶	N=7074 (30 with autism, 7044 without autism); Location=US; Age=boys 3 through 17 years born prior to 1999; Setting=National Health Interview Survey	Hepatitis B	Study notes, a greater proportion of children without autism diagnosis had vaccination records. (Observations without a vaccination record were excluded so autism diagnosis prevalence may be underestimated.) Incomplete and	Patients with missing values for outcome, exposure, or risk factor variables were excluded from analyses	Study did not discuss	Self-report with trained interviewers	Self-report with trained interviewers	Logistic regression	Race/ethnicity, two-parent household, maternal education	1997 through 2002	Unfunded	OR (95% CI) of autism diagnosis Received first dose of hepatitis B vaccine during first month of life OR=3.00 (1.11–8.13), p=0.031	Non-Hispanic white: 0.36 (0.15–0.88), p=0.025 Two-parent household 0.30 (0.12–0.75), p=0.010 Maternal education, high school or higher 2.32 (0.85–6.30), p=0.099	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
			missing data may introduce bias in the analysis											
Gee et al. 2011, Prospective cohort ²⁰²	N=600,558 doses of HPV4; Females age 9-26 years in 7 large managed care organizations (MCOs) in US	HPV4	Entire population of females in 7 MCOs meeting certain requirements. Unsure how generalizable to larger population outside of the 7 MCOs. Also unknown how sites differ from one another in patient population. For unexposed cohort - possible ascertainment biases where those who got vaccinated might have been monitored more closely for adverse events	Not discussed	Not discussed	Weekly standardized data files from participating MCOs.	Weekly standardized data files from participating MCOs. Case ascertainment was limited to the first episode in a particular time period.	Poisson based maximized sequential probability ratio test (maxSPRT) Logistic regression (appendicitis only)	Logistic regression: sex, age, and seasonality	Between August 2006 and October 2009	Centers for Disease Control and Prevention	No statistically significant increased risk for any of the pre-specified adverse events (Appendicitis, Guillain–Barré Syndrome, Seizures, Stroke, Syncope, Venous Thromboembolism) after vaccination was detected.	None	
Gilbertson et al. 2011, Prospective cohort ⁷⁰	N=118,533 Medicare patients who initiated hemodialysis before August 1, 2003 and were alive through October 31, 2005; Location= US	Influenza, pneumococcal	Vaccinated may be healthier cohort than unvaccinated or may reflect population with better quality of care	Not discussed	Not discussed	Claims records	Unclear - patients were followed up, but unclear if claims records were searched	Cox proportional hazards	Patient demographics, doesn't specify but variables assessed include age, sex, race, primary cause of end-stage renal disease, dialysis duration, comorbid conditions.	Patients identified from 2003-2005, followed from 2005-2006	Fresenius Medical Care	Relative risk of mortality (Table 2) Pneumococcal vacc: 0.94 (0.90–0.98), p=0.005 Influenza vacc (both seasons): 0.77 (0.73–0.81), p=<0.0001	Vaccine associated with lower mortality. Higher risk of mortality if older, longer on dialysis, have comorbid conditions.	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	Age=>18 years;								Also controlled for influenza vaccination.					
Gold et al. 2010, Self-Controlled Case Series ²²¹	N= 323 cases of febrile seizures Location=South Australia; Age=0-7 years;	MMR, DTP	Approximately 98% of all newborns are registered on the immunization database within 12 months. Outcomes from hospital data (2 major hospitals). No indication if patients were more or less representative of the general population.	Amongst the 174,136 hospital admissions, there were 35,590 admissions (20.4%) without any ICD-codes or Complaint Codes. However adverse events were carefully identified from the admission description text field using broad criteria for inclusion. Authors note "it is unlikely that we either underestimated or overestimated the number of true adverse events."	Not discussed	Australian Childhood Immunization Register (ACIR)	Database review: data were derived from two sources; the Open Architecture Clinical Information System Clinical Reporting Repository (OACIS CRR), which contains hospital admissions data and emergency department data and the Women and Children's Hospital (WCH) database and Flinders Medical Center	Within-subjects Poisson regression	SCCS method accounted for exposure period and age	1997-2002	Department of Health, South Australia, under the Human Services Research and Innovation Programme	IRR for febrile seizures MMR vaccine Exposure period -1 to -14 days: 0.58 (0.33-1.02), p=0.06 Exposure period 6 to 11 days: 2.11 (1.43-3.10), p=<0.001 Exposure period 15 to 35 days: 0.90 (0.65-1.25), p=0.54 DTP vaccine Exposure period -1 to -14 days: 0.56 (0.33-0.94), p=0.03 Exposure period 0 to 3 days: 0.59 (0.24-1.45), p=0.25 Exposure period 4 to 7 days: 0.94 (0.46-1.91), p=0.86 Exposure period 8 to 14 days: 0.93 (0.54-1.62), p=0.80	None given	
Groves et al. 1999, Case-control ²²⁴	N=878; Location=nine Midwestern and Mid-Atlantic states; Age=0-14 years;	Oral or injected poliovirus vaccine, trivalent diphtheria-tetanus-pertussis vaccine,	Author notes, controls selected using random-digit dialing were more likely to be offspring of parents with higher	Mothers of 96% of eligible cases and 75% of eligible controls from the nine states completed an initial telephone	Not discussed	Data collection forms were completed by the mothers using vaccination records from physicians or by the	Case ascertainment described in another study	Conditional logistic regression	Age at censoring, year of birth, sex, race, family income, parental education and attendance at day-care	Patient diagnosis between 1989 and 1993. Unsure when data was collected.	Not reported	Effect of vaccination (ever vs never) on subsequent risk of childhood acute lymphoblastic leukemia (439 matched pairs) Measles-mumps-	Not reported	Kleinerman et al, 1997. Kleinerman RA, Linet MS, Hatch EE, Wacholder S, Tarone RE,

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	Setting=Patients with ALL, diagnosed between 1989 and 1993, were enrolled in the study. Subjects who resided in Illinois, Indiana, Iowa, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, or Wisconsin at the time of diagnosis were eligible for the vaccination component of the study.	bivalent diphtheria-tetanus vaccine, bivalent tetanus-diphtheria vaccine, monovalent tetanus vaccine, trivalent measles-mumps-rubella vaccine, Haemophilus influenza group b (Hib) vaccines, hepatitis B virus vaccine and other vaccines	education and/or family income compared with cases. However, while this may explain the tendency of the controls to have more vaccinations, the association between conjugate Hib vaccine and ALL persisted after statistical adjustment for family income and parental education, and no such inverse association was observed for any other vaccine.	interview, and mothers of 788 (98%) and 699 (97%) eligible cases and controls, respectively, participated in a subsequent in-person interview. In the third component, vaccination data were provided by mothers (based on vaccination records from physicians) or obtained directly from the physicians of 630 (79.9%) cases and 550 (78.7%) controls, representing overall participation rates of 70.1% for cases and 50.4% for controls.		physicians themselves.			and/or preschool	After 1993, before 1999 when study was published.		rubella: 1.19 (0.67–2.10) Oral poliovirus: 1.05 (0.41–2.67) Diphtheria-tetanus-pertussis: 0.66 (0.27–1.65) Tetanus (all): 0.75 (0.26–2.16) Diphtheria (all): 0.75 (0.26–2.16) Haemophilus influenza b (Hib): 0.73 (0.50–1.06) (Presumptive) polysaccharide vaccine: 1.13 (0.64–1.98) (Presumptive) conjugate vaccine: 0.57 (0.36–0.89)		Severson RK, Kaune WT, Friedman DR, Haines CM, Muirhead CR, Boice JD and Robison LL (1997) Magnetic field exposure assessment in a case-control study of childhood leukemia. Epidemiology 8: 575–583. Details case ascertainment
Gruber et al. 2008, Retrospective cohort ²¹⁵	N=2173 (cases with atopic dermatitis and family history of allergy); Location=12 countries, Australia,	Diphtheria, tetanus, pertussis, polio, Haemophilus influenza Type B, hepatitis B, mumps, measles,	Participants recruited into a randomized clinical trial but no real details given. Results for this paper taken from screening population	Eleven children with all immunization data missing were excluded from further analyses but no differences discussed	Not discussed	Recorded from immunization cards	Scoring atopic dermatitis (SCORAD) tool administered by trained investigators for atopic dermatitis severity	Logistic regression	Total assessed: country, age, gender, birth weight, maternal age, family history of atopy, presence of siblings, breastfeeding, All IgE	March 2002 and March 2004	UCB Pharma, Brussels, Belgium	OR (95% CI) for IgE-sensitivity to aeroallergens Infants immunized against hepatitis B at birth were less likely to be IgE-sensitized to aeroallergens (adjusted Hepatitis B	Not reported	ORs are also presented in figure 2

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	Austria, Belgium, Czech Republic, France, Germany, Italy, the Netherlands, Poland, South Africa, Spain, and the UK; Age=1-2 years; Setting=97 study centers in 10 European countries, South Africa and Australia	rubella, varicella, BCG, meningococci and pneumococci	before randomization occurred.				measurements were performed in three central laboratories with the Pharmacia ImmunoCAP fluorescence enzyme immunoassay technology		parental smoking, day care, exposure to pet animals and SCORAD total index			at birth: 0.54 (0.32, 0.90), p = 0.018 No effect was seen for hepatitis B immunization later on in life. OR (95% CI) for sensitivity to food allergens Newborns immunized against polio: 2.60 (1.08–6.25,) p = 0.032 Immunization against polio later in life: NS OR (95% CI) for elevated total IgE hepatitis B vaccine (first 6 months): R 1.48 (1.03–2.13), p = 0.034 OR (95% CI) for elevated total IgE varicella immunization in the first year: 0.27 (0.08–0.87), p = 0.028 varicella immunization in the 3 months before screening: 0.28 (0.14–0.56), p = 0.0003 varicella immunization since birth: 0.37 (0.21–0.65), p = 0.0005		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment	
												rubella immunization since birth: 0.79 (0.63–0.99), p = 0.043 pneumococci immunization since birth: 0.49 (0.27–0.92), p = 0.027 No significant association of vaccination status and atopy (as defined by any positive IgE test) was found.			

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Hambidge et al. 2011, Matched case-control (and self-controlled case series) ²⁴¹	N=1294 (269 cases of hospitalization on sickle cell crisis, 1025 controls); Location=United States; Age=6 months to 17 years; Setting=8 managed care organizations that comprise the Vaccine Safety Datalink	TIV (trivalent inactivated influenza)	For the case-control study possible bias in that children hospitalized for SCA, might be more likely to get vaccine (did not seem to be a factor in this study because of self-controlled case series results). Authors note that children classified as not receiving vaccine may have received vaccine outside of their MCO. Attempt to retrieve outside records varied by MCO. Decrease in temperatures during flu season is known trigger for pain crisis. This could possibly introduce a temporal bias in the analysis."	Analysis was limited to periods when most TIV was administered, between October 1 and January 31 of each influenza season. This resulted in the removal of 3 TIV-exposed children who were vaccinated in the months of February or March. Two cases could not be matched to a control and were removed for analysis.	Not discussed	Record review from Vaccine Safety Datalink dataset	Medical records of potential cases were reviewed to confirm hospitalization for sickle cell crises	Conditional logistic regression	Cases/controls matched on age category, gender, Vaccine Safety Datalink site, and season	1999 to 2006	Centers for Disease Control and Prevention through America's Health Insurance Plans	Case-control study OR (95% CI) of hospitalization TIV: 1.3 (0.8–2.2) Self-controlled All children: 1.21 (0.75–1.95), p=0.43 Boys: 1.07 (0.50–2.28), p=0.86 Girls: 1.33 (0.72–2.44), p=0.36 6-23 months: 1.23 (0.25–6.04), p=0.80 60 mo to 17 yr: 1.38 (0.83–2.29), p=0.22	Not reported	
Hummel et al. 2000, Prospective cohort ²²⁸	N=823; Location=Germany; Age=0-2 years; Setting=German BABYDIA B Study	Bacille Calmette-Guérin [BCG]; haemophilus influenza (HIB); diphtheria,	Study design described in another paper (See comment box)	From 1989 until the time of analysis (1999), 1,002 of 1,553 offspring recruited at birth had reached the	Not discussed	Structured questionnaires	Direct measurement	Odds ratios were calculated as the ratio of the proportion of offspring with islet antibodies in	None mentioned	1989-1999	Work was supported by grants from the Bundesministerium für Forschung, Bildung und	Figure 2. Risk (odds ratio) for developing islet antibodies with respect to environmental factors. (Estimates from figure)	None given	Ziegler AG, Hummel M, Schenker M, Bonifacio E: Antibody appearance and risk for the

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	tetanus, and pertussis (DTP); poliomyelitis; tick-born encephalitis (TBE); and measles, mumps, and rubella (MMR)		age of 2 years; 823 (82%) participated in the 2-year follow-up visit and were included into this analysis.	Completed questionnaires were returned from 626 offspring (76.1%). Information concerning total duration of breast-feeding, exclusive time of breast-feeding, vaccinations, and infections was missing from 110, 137, 56, and 68 offspring, respectively				those with breast-feeding times greater and less than 3 months and in those with and without a vaccination event.			Technologie	Hib: 1.4 (0.07-4.00) Measles: 1.6 (0.07-7.00) Mumps: 1.2 (0.08-3.50) Rubella: 1.3 (0.07-4.00)		development of childhood diabetes in offspring of parents with type 1 diabetes: the German BABYDIAB Study. Diabetes 48:460–468, 1999
Italian Multicenter Study Group for Drug and Vaccine Safety in Children, 2011, Case-control ¹¹³	N=683 children aged 1 month to 18 years, hospitalized through the emergency departments of eight pediatric hospitals/wards in Italy	A-H1N1 Seasonal influenza	Potentially some selective recruitment of vaccinated children that should have been attenuated by enrolling cases on a specified day of the week	Aside from initial exclusions, no attrition discussed	Not discussed	Parental report	Active surveillance. Both clinically defined and laboratory confirmed hospitalizations for Influenza Like Illness (ILI) were considered. Adverse events ascertained through parental report	Logistic regression	Age and chronic diseases; the ORs of A-H1N1 and seasonal vaccine were each adjusted for the other influenza vaccine	November 2009 to August 2010	Italian Medicines Agency	OR of influenza-like illness Any flu vaccine 2.7 (1.6 to 4.7) A-H1N1 1.3 (0.6 to 3.1) Seasonal vaccine 2.1 (1.1 to 4.1)	Not reported	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Kelly et al. 2012, Retrospective cohort ²⁴²	N=104,076 children presenting to Perth hospitals with febrile convulsion	Influenza	Entire population was assessed though unknown if hospital cases differed systematically in the 9 hospitals assessed from other area hospitals	Not discussed	Not discussed	Unknown	Emergency Department Information from 9 Perth hospitals	Risk estimation	None	March to April 2010	No funding to disclose	The 49-day risk of emergency department presentation for a febrile convolution following Fluvax was $38/11,963 = 32/10,000$. The risk in those who had not received Fluvax was $61/92,113 = 7/10,000$. The VAR, calculated as the risk difference, is thus estimated as 25/10,000 children	None given	
Klein et al. 2008, Prospective cohort ²⁴³	N=497; Location=C A; Age=27.3 weeks (mean gestational age); Setting=NICU database in the Northern California Kaiser Permanente Medical Care Program	Polio vaccines (IPV and oral poliovirus vaccine), diphtheria/tetanus/pertussis vaccine (either DTP or DTaP vaccine), Hib vaccine, HBV vaccine, Streptococcus pneumoniae vaccine (pneumococcal conjugate vaccine), and trivalent influenza vaccine.	Study notes that the apnea observed in the post immunization period may not reflect an adverse response to immunization but may be attributable to normal variations in apnea occurrence in this NICU population. Clinicians may not have vaccinated infants perceived to be at risk for a vaccine-related adverse event	557 (74.4%) received 1 vaccine and were eligible for chart abstraction. Sixty of those 557 eligible infants (10.7%) were not reviewed, for the following reasons: missing charts (n 15), charts missing significant data (n 7), infants not at KPMCP on day 53 (n 37), and significant congenital anomalies (n 1)	Not discussed	Database record review	Neonatal Minimum Data Set, medical records review. To evaluate apnea after discharge from the NICU, we examined hospital and emergency department visits for apnea diagnoses captured within the KPMCP electronic medical record during the 2 weeks after hospital discharge	Multivariate logistic regression	Desaturations and/or bradycardia, SNAP-II of >10, Receiving caffeine, Gestational age, Weight of 2000 g, Age of 67 d, Female gender	1997-2003	Vaccine Safety Datalink contract with America's Health Insurance Plans, funded by the Centers for Disease Control and Prevention	Multivariate Model Predicting Apnea During the 48-Hour Period After Immunization With Pre-immunization Apnea Apnea: 25.5 (9.0–71.9), p=0.0001 Desaturations and/or bradycardia: 1.4 (0.7–2.7), p=0.33 SNAP-II of >10: 3.4 (1.2–9.3), p=0.02 Receiving caffeine: 1.7 (0.8–3.3), p=0.15 Gestational age: 1.1 (0.9–1.2), p=0.40 Weight of 2000 g: 2.0 (0.98–4.1), p=0.06 Age of 67 d: 2.2 (1.1–4.4), p=0.03 Female gender: 1.0 (0.6–1.8), p=0.96	None	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
		Infants born earlier in the study period might have received the combination DTP/Hib or DTaP/Hib vaccines, whereas those born later might have received DTaP/IPV/HBV vaccine"	until the infants were without apnea for a period of time. This bias, similar to the healthy vaccine phenomenon, would result in a healthier pre immunization population, compared with a similar, unvaccinated, NICU population									Without Pre-immunization Apnea Desaturations and/or bradycardia: 1.4 (0.7–2.7), p=0.30 SNAP-II of >10: 4.2 (1.2–14.3), p=0.02 Receiving caffeine: 1.5 (0.7–3.2), p=0.25 Gestational age: 1.1 (0.9–1.2), p=0.38 Weight of 2000 g: 2.1 (1.0–4.5), p=0.05 Age of 67 d: 2.3 (1.1–4.8), p=0.03 Female gender: 1.1 (0.6–2.0), p=0.85		
Klein et al. 2011, Case-control ²⁴⁴	N= 1,617, including 77 cases with inborn metabolic disorders and 1,540 controls; Age= <=18 years; Setting=Northern California Kaiser Permanente (KPNC)	Dtwp, Dtap, MMR, oral poliovirus vaccine, inactivated poliovirus vaccine, hepatitis B, and Haemophilus influenza type B vaccine (study lumps together)	Entire HMO population. Possible biases if cases treated differently in regards to vaccination versus those without Inborn Error of Metabolism (IEM)	We identified 249 individuals with a single IEM ICD-9 code from 1990 to 2007 who were born at KPNC and had continuous membership until 2 years of age, which decreased to 131 when requiring 2 separate IEM ICD-9 codes. We excluded an additional 54 individuals after medical record review for a final immunization rates study population of 77 IEM	Not discussed	Medical records	Medical records	Poisson regression	None beyond matching variables (gender, birth month and year, and birth facility)	1990 to 2007	Contract with America's Health Insurance Plans from the Centers for Disease Control and Prevention	There were few differences in percentage of children with IEM who were up to date at 2 years of age for receipt of vaccines according to recommended schedule when compared to matched health controls. One exception was that children with "chronic" IEM were less likely to have received all recommended dose of polio, hepatitis B, and MMR by age two.	Risk of hospitalization during post vaccination days 0 to	None

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
				subjects and 1,540 matched control subjects.								14 was elevated among 1 to 4 year old children in the "sickest" group of IEM cases RR 4.2, 95% CI 1.2 - 15.1.		
Ma et al. 2005, Case-control ²²⁵	N=732; Location=C alifornia; Age=0-14 years; Setting=Northern California Childhood Leukemia Study (major pediatric clinical centers)	DPT, polio, MMR, Hib, Hepatitis B	Details given in other papers, but there is a detailed protocol for control selection. Only issue is with hospital case selection if the hospital cases differed systematically from the general population controls	Approximately 85% of the eligible cases consented to participate. 82.5% of controls were eligible.	Did not discuss	Records obtained from parents or physicians	Ascertainment from pediatric clinical centers within 72 hours of diagnosis	Conditional logistic regression	Matched on date of birth, sex, mother's race and Hispanic status Adjusted for maternal education and annual household income	1995-2002	National Institute of Environmental Health Sciences	Table 4: Vaccinations and the risk of childhood leukemia—adjusted odds ratios Each dose before the reference date DPT Leukemia: 0.97 (0.74, 1.28) ALL: 0.96 (0.72, 1.28) Polio Leukemia: 1.14 (0.88, 1.47) ALL: 1.08 (0.82, 1.41) MMR Leukemia: 1.06 (0.69, 1.63) ALL: 0.87 (0.55, 1.37) Hib Leukemia: 0.81 (0.68, 0.96) ALL: 0.81 (0.66, 0.98) Hepatitis B Leukemia: 0.97 (0.77, 1.23)	Not reported	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												ALL: 1.01 (0.78, 1.31)		
MacArthur et al. 2008, Case-control ²²⁶	N=798; Location=Canada; Age=0-15 years; Setting=Canadian pediatric oncology centers and population-based cancer registries	Measles, mumps, and rubella (MMR), diphtheria, tetanus, and pertussis (DTP), poliomyelitis, hepatitis, or Bacillus Calmette-Guerin (BCG)	Cases from pediatric oncology treatment centers in each of the five provinces. And population-based cancer registries. Controls were area residents.	Initial contact with potential controls was by letter, followed by telephone contact. In total, 449 cases and 675 controls were identified as possible subjects. Of these, 445 cases and 526 controls eligible for inclusion in the study were successfully contacted. A total of 399 case-control pairs agreed to participate, resulting in contact participation rates of 90 percent for eligible cases and 76 percent for eligible controls.	Study notes, "Inherent in our case-control study is the possibility of selection or recall bias, as well as exposure misclassification, since information was not always corroborated with the index child's vaccination or medical records."	Standardized, personal interviews conducted in the home with the child's parents or guardians. Immunization data were recorded from the child's vaccination record if available at the time of interview. Otherwise, parents were asked to recall their child's immunization history	Participants meeting these criteria were ascertained through pediatric oncology treatment centers in each of the five provinces. Population-based cancer registries were also used for case ascertainment in all provinces except Quebec.	Conditional logistic regression	Maternal education, annual household income, ethnicity, maternal age at birth, and number of residences since birth.	1990-1994	Funding for this study was provided by the National Health Research and Development Program of Health Canada and the Canadian Electricity Association. Additional funding for one of the authors (A. C. M.) was provided by a research unit infrastructure grant from the Michael Smith Foundation for Health Research	Vaccinations in childhood and risk of childhood leukemia, the Cross-Canada Childhood Leukemia Study, 1990–1994	Mumps: 0.83 (0.39-1.75) Measles 0.88 (0.41-1.90) Rubella 0.85 (0.42-1.70) Diphtheria 0.85 (0.29-2.49) Pertussis 0.71 (0.27-1.85) Tetanus 0.74 (0.27-2.03) Polio 0.90 (0.35-2.29) Hepatitis 1.09 (0.34-3.52) Other vaccine 0.81 (0.58-1.13)	None given

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Mommers et al. 2004, Case-control ²¹⁶	N=510; Location=Dutch-German borderland; Age=7-8 years; Setting=Participants in a longitudinal study on respiratory health in children was conducted in the Dutch-German borderland, involving the Municipal Health Services of Kreis Heinsberg, Germany and of the Westelijke Mijnstreek, the Netherlands	Bacille Calmette-Guerin (BCG), pertussis, measles/mumps, rubella, and Haemophilus influenza type b (Hib)	Vaccinated and unvaccinated children may differ in other respects than those accounted for in the regression models. Authors note that for instance, atopic parents may be more reluctant to vaccinate their children than nonatopic parents. In the data however, the authors found no evidence of selective avoidance of vaccination of their child by parents with self-reported asthma	In 1995, parents of all 5,052 children born between November 30, 1989–December 1, 1990 and living in the study area were invited to participate. Parents of 3,871 children (76.6%) returned the completed questionnaire on respiratory symptoms and diagnosis. A second survey was conducted in 1997; 218 children (5.6%) were lost to follow-up because they had moved out of the study area or were unlocatable. Of the remaining 3,653 children, 2,884 (78.9%) completed the 1997 questionnaire. Children with respiratory symptoms as well as controls were selected based	Not discussed	Data on vaccination status and childhood infections were obtained from the Youth Health Care Department of the participating Municipal Health Services. In the Netherlands, vaccination status was registered during routine checkups of children. In Germany, vaccination status was registered during the checkup of school beginners at age 5–6 years.	Parental questionnaires were sent for self-completion. In the presence of one or both parents, completeness of the questionnaire was checked by an assistant of the Municipal Health Service, and blood samples were taken for immunological analysis.	Multivariate logistic regression	Gender, birth order, country of residence, socioeconomic status, breastfeeding, exposure to environmental tobacco smoke, home dampness, pets, and childhood infections (measles, mumps, rubella, varicella, and scarlet fever). Analyses stratified according to country of residence or respiratory status were additionally performed.	1995-1997	European Union; Euregio Maas-Rhine; Land Northrhine-Westphalia; Province of Limburg; Counties of Heinsberg, Midden-Limburg, and Westelijke Mijnstreek.	Odds Ratios and 95% Confidence Intervals for Association Between Risk Factors and Atopic Disease Pertussis Respiratory symptoms 0.83 (0.45–1.52) Allergic sensitization 0.89 (0.47–1.70) Sensitized against grasses 0.84 (0.38–1.84) Sensitized against HDM 1.02 (0.46–2.25) Measles Respiratory symptoms 0.93 (0.30–2.90) Allergic sensitization 1.51 (0.43–5.35) Sensitized against grasses 2.85 (0.45–18.08) Sensitized against HDM 1.93 (0.38–9.95) Rubella Respiratory symptoms 1.17 (0.65–2.10) Allergic sensitization 0.85 (0.46–1.57) Sensitized against grasses 0.75 (0.36–1.56) Sensitized against HDM 0.74 (0.30–1.83) 0.89 (0.41–1.92)	Gender (male vs. female) Respiratory symptoms 1.68 (1.13–2.49) Allergic sensitization 2.68 (1.76–4.09) Sensitized against grasses 3.44 (2.05–5.76) Sensitized against HDM 2.90 (1.69–4.96) Birth order Only younger siblings Respiratory symptoms 1.06 (0.54–2.08) Allergic sensitization 0.57 (0.29–1.13) Sensitized against grasses 0.52 (0.24–1.12) Sensitized against HDM 0.74 (0.30–1.83)	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
				on the answers given in the first and second surveys. The parents of 775 (76.0%) 7–8-year-old children returned the completed questionnaire.								Hib Respiratory symptoms 1.39 (0.60–3.19) Allergic sensitization 0.74 (0.30–1.79) Sensitized against grasses 0.55 (0.19–1.58) Sensitized against HDM 1.14 0.33–3.89 Frequencies of BCG, Pertussis, Measles, Rubella, and Hib Vaccination in Children With Respiratory Symptoms and in Sensitized Children Respiratory symptoms Pertussis: 0.85 (0.60–1.19) Measles: 0.86 (0.36–2.06) Rubella: 0.94 (0.64–1.38) Hib: 1.14 (0.82–1.58) Allergic sensitization Pertussis: 1.04 (0.73–1.47) Measles: 1.59 (0.61–4.17) Rubella: 0.80 (0.54–1.19) Hib: 0.94 (0.67–1.32)		1 older sibling Respiratory symptoms 0.91 (0.47–1.76) Allergic sensitization 0.47 (0.24–0.92) Sensitized against grasses 0.44 (0.20–0.95) Sensitized against HDM 0.75 (0.31–1.82) 2 older siblings Respiratory symptoms 1.63 (0.74–3.60) Allergic sensitization 0.40 (0.18–0.91) Sensitized against grasses 0.40 (0.16–1.02) Sensitized against HDM 0.69 (0.24–1.97) >2 older siblings Respiratory

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
													symptoms 0.95 (0.30–3.02) Allergic sensitization 0.33 (0.09–1.15) Sensitized against grasses 0.20 (0.04–1.13) Sensitized against HDM 0.29 (0.05–1.71)	
Morgan et al. 2011, Self-controlled case series ¹¹⁷	N= 169 children with urea cycle disorders (USD); Location=US Age=0-18 years;	A number of vaccines were analyzed but influenza was only specific vaccine reported on	Self-controls.	Not discussed	169 patients were enrolled and records obtained for 112. There were no statistically significant differences between patients with and without vaccination records in the types of UCDs, onset of hyperammonemia in first 30 days of life, or hospital	Clinical records	Clinical records	Conditional Poisson regression	Age	February 6, 2006, to July 31, 2009	America's Health Insurance Plans under contract from the Centers for Disease Control and Prevention	Influenza only: Relative Incidences (Table 4) Risk Period: Days After Vaccination 1–7: 2.31 (0.73–7.30) 8–21: 0.78 (0.19–3.12) 1–21: 1.28 (0.52–3.15)	Not reported	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment	
						where care was provided. Factors associated with unobtainable vaccination records included older mean age of patient at enrollment and the occurrence of HAEs during the study period.									
Mullooly et al. 2007, Case-control ²¹⁷	N=1074 (844 atopy cases, 230 controls); Location=West Coast; Age=6-16 years; Setting=Kaiser Permanente Northwest (KPNW) HMO	DTP, MMR, HBV, IPV, HIB	Cases and controls drawn from same population and underwent same allergen test. Some tests were incomplete so there may have been some outcome misclassification.	Of the 1287 continuously eligible children referred to allergy clinics during 1987-2001, 1150 (89%) had records of skin tests. We excluded 14 patients with a skin test because of serious chronic conditions or treatments, which left 1136 study-eligible patients. Eight hundred forty-four (74%) had	Not discussed	Vaccinations were abstracted from electronic medical records (EMR) and from paper-based medical charts	Atopy or atopic predisposition in early childhood was determined according to skin-prick test results from ages 6-16 years	Logistic regression	Covariates associated with atopy at p < 0.20 in bivariate analyses were included in the regression models. controls for age at skin test, gender, race, maternal/family history of atopy, low birth weight, maternal age at birth, breast feeding at 2 months, household smoking, dogs in home,	Study participants eligible if skin tested for inhalant allergens during 1987-2001 and enrolled in KPNW since birth	Supported in part by CDC through a subcontract with America's Health Insurance Plans (AHIP)	OR (95% CI) for atopy All cases versus all controls No. of pertussis doses 1.06 (0.89-1.27) No. of measles doses 0.85 (0.56-1.29) No. of HIB doses 0.93 (0.81-1.08) No. of HBV doses 1.15 (0.88-1.49) All cases versus asthma controls No. of pertussis doses 0.98 (0.74-1.29) No. of measles doses 0.80 (0.42-1.53) No. of HIB doses 0.88 (0.73-1.07) No. of HBV doses	Not reported		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
				a positive skin test for at least one allergen and were classified as atopy cases. Sixty-two of the 292 with no positive skin tests were tested for two or fewer allergens and were excluded from the study as having indeterminate atopy status, leaving 230 non-atopic controls. Atopy cases accounted for 79% (844) of the 1074 eligible study subjects.					calendar period of skin test (1978–93, 1994–99, 2000–01)			1.04 (0.75–1.45) Asthma cases versus asthma controls No. of pertussis doses 0.95 (0.71–1.29) No. of measles doses 0.69 (0.36–1.35) No. of HIB doses 0.88 (0.72–1.08) No. of HBV doses 1.05 (0.73–1.50)		
Mullooly et al. 2011, Self-controlled case series ²⁴⁵	N=18,628; Location=US; Age=0-16 months; Setting=Infants born at five health maintenance organizations	Hepatitis B, DTaP, HiB, IPV, MMR, Varicella, PCV7, TIV	HMO study population, possible generalizability issues if population differed from general	Authors note ascertainment of infants with complex medical condition indicator ICD-9 codes was likely incomplete (e.g., omitted renal failure), however misclassification does not threaten the validity of results since	Not discussed	HMO database record review	Database record review: ICD-9 coded database records. Random samples of medical charts of non-fragile premature infants with wheezing lower respiratory diseases (WLRD). ICD-9-CM codes were abstracted to assess the positive predictive value	Cox proportional hazard regression	age, seasonal circulation of respiratory viruses (RSV, Rhinovirus), and frequency of well-baby visits (WBV), and linear and quadratic age effects	The study population of premature infants born into the HMOs during 1997–2002 was followed for the first 16 months of life	Subcontract with America's Health Insurance Plans (AHIP) from the Centers for Disease Control and Prevention (CDC).	Adj HR of WLRD, non-fragile 1–7 days HBV: 0.59 (0.49–0.72) DTaP: 0.68 (0.58–0.81) HiB: 0.68 (0.58–0.8) IPV: 0.61 (0.5–0.75) MMR: 0.55 (0.41–0.74) Varicella: 0.61 (0.45–0.83) PCV7: 0.72 (0.59–0.87) TIV: 0.47 (0.29–0.78)	None	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment	
				there was no evidence of increased wheezing lower respiratory diseases (WLRD) risk in either population			(PPV) of diagnosis codes and the accuracy of medical-care encounter sequences as proxies for WLRD onsets					8–14 days HBV: 0.84 (0.72–0.98) DTaP: 0.97 (0.85–1.11) HiB: 0.96 (0.84–1.09) IPV: 0.91 (0.78–1.07) MMR: 0.68 (0.52–0.88) Varicella: 0.71 (0.53–0.94) PCV7: 0.95 (0.8–1.12) TIV: 0.73 (0.48–1.09)		15–30 days HBV: 0.95 (0.85–1.05) DTaP: 1.08 (0.99–1.19) HiB: 1.05 (0.96–1.15) IPV: 1.04 (0.93–1.16) MMR: 0.83 (0.69–1.00) Varicella: 0.92 (0.76–1.11) PCV7: 1.09 (0.98–1.23) TIV: 0.94 (0.71–1.25)	31–44 days HBV: 0.88 (0.78–0.98) DTaP: 0.96 (0.87–1.06) HiB: 0.95 (0.86–1.05) IPV: 0.89 (0.79–1) MMR: 0.86 (0.71–

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment	
												1.05) Varicella: 0.90 (0.74–1.11) PCV7: 0.95 (0.84– 1.07) TIV: 0.75 (0.53– 1.06)	Adj HR fragile 1–7 days HBV: 0.73 (0.62– 0.86) DTaP: 0.66 (0.56– 0.77) HIB: 0.65 (0.55– 0.76) IPV: 0.67 (0.56– 0.81) MMR: 0.58 (0.43– 0.79) Varicella: 0.55 (0.39–0.77) PCV7: 0.61 (0.5– 0.75) TIV: 0.87 (0.63– 1.21)	8–14 days HBV: 0.87 (0.74– 1.01) DTaP: 0.82 (0.71– 0.95) HIB: 0.83 (0.73– 0.96) IPV: 0.88 (0.74– 1.03) MMR: 0.82 (0.63– 1.07) Varicella: 0.84 (0.64–1.11) PCV7: 0.84 (0.7– 1.00) TIV: 1.05 (0.78– 1.41)	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												15–30 days HBV: 0.97 (0.87–1.07) DTaP: 0.97 (0.89–1.07) HIB: 0.99 (0.9–1.09) IPV: 0.96 (0.86–1.08) MMR: 0.90 (0.74–1.08) Varicella: 0.86 (0.7–1.05) PCV7: 0.99 (0.88–1.12) TIV: 1.00 (0.79–1.26) 31–44 days HBV: 0.93 (0.83–1.04) DTaP: 0.96 (0.87–1.06) HIB: 0.97 (0.88–1.07) IPV: 0.99 (0.88–1.11) MMR: 0.92 (0.76–1.13) Varicella: 1.01 (0.82–1.23) PCV7: 1.01 (0.89–1.14) TIV: 0.98 (0.75–1.27)		
O'Leary et al. 2012, Retrospective cohort ¹⁴³	N=1.8 million from 5 managed care organizations; Location=Colorado, Hawaii, Georgia, Northern CA,	MMR, Hepatitis A, varicella, Tdap, Hib	Study did not discuss if any biases may have existed in the populations included in the managed care databases versus those who were not o differences in diagnosing	Not discussed	Not discussed	Medical record	Potential ITP cases were identified by using diagnostic codes and platelet counts. All cases were verified by chart review.	Self-controlled care series	None reported	2000 to 2009	Kaiser Permanente with funds provided by the Food and Drug Administration	IRR for immune thrombocytopenic purpura (ITP) 6 wk to 11 mo Hib: 0.53 (0.14, 1.94), p=0.33 PCV: 0.58 (0.15, 2.18), p=0.42 6 to 23 mo TIV: 2.69 (0.81, 8.88), p=0.11 12 to 19 mo	None reported	Authors: ITP is unlikely after early childhood vaccines other than MMR. Because of the small number of exposed

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	Massachusetts; Age=6 weeks to 17 years;		practices across the five sites									MMR: 5.48 (1.61, 18.64), p=0.006 MMRV: 2.87 (0.78, 10.56), p=0.11 DTaP: 1.00 (0.21, 4.81), p=0.99 Hib: 0.75 (0.16, 3.63), p=0.72 PCV: 0.72 (0.14, 3.97), p=0.70 12 to 23 mo Hep A: 0.22 (0.03, 1.82), p=0.16 2 to 6 years TIV: 1.86 (0.41, 8.38), p=0.42 Hep A: 1.14 (0.34, 3.86), p=0.83 4 to 6 years MMR: 3.06 (0.42, 22.30), p=0.27 VAR: 4.39 (0.46, 41.65), p=0.20 DTaP: 2.57 (0.53, 12.37) p=0.24 IPV: 1.37 (0.23, 8.32), p=0.73 7 to 17 years Hep A: 23.14 (3.59, 149.30), p=0.001 TIV: 5.95 (0.54, 65.96), p=0.15 11 to 17 years VAR: 12.14 (1.10, 133.96), p=0.04 HPV: 9.71 (0.87, 108.92), p=0.07 MCV: 6.02 (0.64, 56.18), p=0.12 Tdap: 20.29 (3.12, 131.83), p=0.002		cases and potential confounding, the possible association of ITP with hepatitis A, varicella, and tetanus-diphtheria-acellular pertussis vaccines in older children requires further investigation.

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Pagaoa et al. 2011, Case-control ¹²⁷	N=14,000(2 800 cancer cases, 11,200 controls); Location=Texas; Age=2 to 17 years; Setting=Texas Cancer Registry combined with birth certificate data to identify eligible participants	DTaP, IPV, MMR, Hib, Hepatitis B, Varicella Zoster, 4-3-1 (Four doses of DTaP, 3 doses of IPV, 1 dose of MMR), 4-3-1-3 (Four doses of DTaP, 3 doses of IPV, 1 dose of MMR, 3 doses of Hib), 4-3-1-3-3, 4-3-1-3-3-1	Cancer patients may differ from the general population in certain ways that make them systematically different (e.g., more likely to be vaccinated)	3871 cancer cases assessed originally, a total of 2800 were included	Not discussed	Rates from the Texas Department of State Health Services, validated with vaccination records; also data gotten from state's active surveillance systems	Texas Cancer Registry	Multilevel mixed-effects regression model	Stratified analyses with infant sex, race/ethnicity, maternal age at birth, birth weight, and parity. Subjects matched on sex and birth year Adjusted for sex, child's birth year, child's ethnicity, child's birth weight, mother's age at child's birth	1995 to 2006	Not listed	OR (95% CI) for total cancer cases DTaP: 0.92 (0.80-1.07), p=0.28 IPV: 0.93 (0.81-1.07), p=0.30 MMR: 0.92 (0.82-1.02), p=0.11 Hib: 0.84 (0.70-1.00), p=0.05 4-3-1: 0.90 (0.80-1.03), p=0.13 4-3-1-3: 0.98 (0.87-1.11), p=0.78 OR (95% CI) for acute lymphoblastic leukemia DTaP: 0.82 (0.63-1.06), p=0.12 IPV: 0.83 (0.63-1.09), p=0.17 MMR: 0.87 (0.71-1.08), p=0.21 Hib: 0.58 (0.42-0.82), p=0.002 4-3-1: 0.77 (0.60-1.00), p=0.05 4-3-1-3: 1.04 (0.74-1.47), p=0.80 OR (95% CI) for Non-Hodgkin Lymphoma DTaP: 0.88 (0.58-1.32), p=0.53 IPV: 1.01 (0.59-1.74), p=0.98 MMR: 0.99 (0.63-1.55), p=0.96 Hib: 0.65 (0.26-1.59), p=0.34 4-3-1: 0.98 (0.59-1.64), p=0.95 4-3-1-3: 1.18 (0.70-1.98), p=0.54 OR (95% CI) for	None reported	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Medulloblastoma DTaP: 1.11 (0.71-1.73), p=0.65 IPV: 1.49 (0.89-2.52), p=0.13 MMR: 1.10 (0.70-1.72), p=0.68 Hib: 1.45 (0.75-2.80), p=0.28 4-3-1: 1.39 (0.85-2.27), p=0.19 4-3-1-3: 1.46 (0.90-2.36), p=0.12 County-level vaccination rates: OR (95% CI) for total cancer cases DTaP: 1.20 (0.90-1.60), p=0.21 IPV: 0.88 (0.74-1.05), p=0.17 MMR: 1.10 (0.84-1.45), p=0.48 Hib: 0.92 (0.82-1.04), p=0.18 Hepatitis B: 0.81 (0.67-0.98), p=0.03 Varicella Zoster: 1.03 (0.92-1.16), p=0.60 4-3-1: 1.00 (0.89-1.11), p=0.93 4-3-1-3-3: 0.90 (0.74-1.09), p=0.28 4-3-1-3-3-1: 0.98 (0.88-1.10), p=0.77 OR (95% CI) for acute lymphoblastic leukemia DTaP: 1.02 (0.61-1.72), p=0.92 IPV: 0.67 (0.49-0.92), p=0.01 MMR: 0.84 (0.51-1.39), p=0.49		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Hib: 0.76 (0.54-1.08), p=0.13 Hepatitis B: 0.63 (0.46-0.88), p=0.006 Varicella Zoster: 1.07 (0.78-1.47), p=0.67 4-3-1: 0.73 (0.51-1.06), p=0.10 4-3-1-3-3: 0.62 (0.44-0.87), p=0.007 4-3-1-3-3-1: 0.77 (0.50-1.17), p=0.22 OR (95% CI) for Non-Hodgkin Lymphoma DTaP: 2.34 (0.93-5.90), p=0.07 IPV: 0.73 (0.31-1.72), p=0.47 MMR: 2.81 (1.27-6.22), p=0.01 Hib: 0.98 (0.59-1.64), p=0.94 Hepatitis B: 0.77 (0.32-1.81), p=0.54 Varicella Zoster: 0.97 (0.58-1.62), p=0.91 4-3-1: 1.13 (0.71-1.82), p=0.60 4-3-1-3-3: 1.22 (0.40-3.69), p=0.72 4-3-1-3-3-1: 0.84 (0.51-1.38), p=0.49 OR (95% CI) for Medulloblastoma DTaP: 1.43 (0.44-4.63), p=0.55 IPV: 1.47 (0.73-2.96), p=0.28 MMR: 1.20 (0.37-3.88), p=0.76 Hib: 1.62 (1.00-2.62), p=0.05		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Hepatitis B: 1.39 (0.67-2.91), p=0.38 Varicella Zoster: 0.90 (0.54-1.51), p=0.70 4-3-1: 1.14 (0.60-2.18), p=0.69 4-3-1-3-3: 1.58 (0.76-3.30), p=0.22 4-3-1-3-3-1: 1.12 (0.58-2.17), p=0.74		
Pahud et al. 2012, Case-centered method ²²⁹	N=110 encephalitis cases; Location=C A; Age= 6 months to 18 years	Many analyzed, measles virus-containing vaccines and pertussis antigen containing vaccines reported	Of 1,434 cases, immunization records were requested for over 800 and received for only 246. 136 were excluded due to incomplete immunization records or because no vaccines were given in the 1 year observation period, leaving 110 for analysis. If nonparticipants differed in systematic ways then bias will be introduced though we do not know which direction the bias would go	Not discussed	Not discussed	Immunization records request	Medical record review	Logistic regression	None reported	Between July 1998 and December 2008	America's Health Insurance Plans (AHIP) Vaccine Safety Fellowship program under contract from the Centers for Disease Control and Prevention (CDC)	Association with pre-defined risk windows Measles virus-containing vaccines 5-15 days: OR=1.31 (0.30-5.77) Pertussis antigen-containing vaccines 0-3 days: OR=1.37 (0.33-5.78)	None reported	
Patel et al. 2011, Case-control (also did self-controlled case-series) ¹⁸³	N=2665 (615 cases of intussusception, 2050 controls);	RV1, Rotarix	Neighborhood controls - possible differences in risk factors or exposure	A total of 615 infants with intussusception (285 in Mexico and 330 in Brazil)	Not discussed	Medical records review	Clinical record review	Conditional logistic regression	Matched by date of birth, also controlled for age, sex	August 2008 through August 2010	GAVI Alliance under a collaborative agreement with the	OR (95% CI) for intussusception (Case-control) Rotavirus vaccination	Not reported	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	Location=Mexico, Brazil; Age=45-245 days; Setting=53 hospitals in 7 states in Brazil and at 16 hospitals in 10 states in Mexico		ascertainment between cases and controls Possible misclassification; Case and control status was not concealed from the interviewers so there may have been some differences in the effort made by the interviewers with respect to ascertaining vaccination history (misclassification)	and 2050 controls (739 in Mexico and 1311 in Brazil) were enrolled. Of these, 594 case patients (97%) and 2033 controls (99%) had a history of vaccination as confirmed by a vaccination card.							Program for Appropriate Technology in Health (PATH) and in part by the U.S. Department of Health and Human Services	Mexico Either dose, any time before reference date 1.0 (0.6–1.7) First dose 1–7 days: 5.8 (2.6–13.0) 8–14 days: 1.0 (0.4–2.9) 15–21 days: 0.8 (0.3–2.1) Second dose 1–7 days: 1.1 (0.6–2.2) 8–14 days: 2.3 (1.2–4.4) 15–21 days: 2.0 (1.0–3.8) Brazil Either dose, any time before reference date 1.7 (0.9–2.9) First dose 1–7 days: 1.4 (0.4–4.8) 8–14 days: 1.6 (0.5–4.7) 15–21 days: 0.6 (0.1–2.2) Second dose 1–7 days: 1.9 (1.1–3.4) 8–14 days: 0.9 (0.5–1.8) 15–21 days: 0.8 (0.4–1.6) OR (95% CI) for intussusception (Case-series) Rotavirus vaccination		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Mexico First dose 1–7 days: 5.3 (3.0–9.3) 8–14 days: 1.1 (0.5–2.7) 15–21 days: 0.9 (0.3–2.2) Second dose 1–7 days: 1.8 (0.9–3.8) 8–14 days: 2.2 (1.1–4.2) 15–21 days: 2.2 (1.2–4.0) Brazil First dose 1–7 days: 1.1 (0.3–3.3) 8–14 days: 1.3 (0.5–3.4) 15–21 days: 0.2 (0.0–1.4) Second dose 1–7 days: 2.6 (1.3–5.2) 8–14 days: 1.4 (0.7–3.0) 15–21 days: 0.9 (0.4–2.0)		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Rowhani-Rahbar et al. 2012, Case-centered ²²²	N=233 cases of Bell's Palsy; Age=<=18 years; Setting=Kaiser Permanente Northern California population	TIV, Hepatitis B	Bias if cases differed from the general population in systematic ways (e.g., more or less likely to be vaccinated, doctors more likely to recommend vaccinations)	977 children originally identified, after exclusions 233 included in final sample.	Not discussed	Database review	Database record review, reviewed and adjudicated by an otolaryngologist	Logistic regression	None	2001 through 2006	Centers for Disease Control and Prevention	OR, 95% CI TIV Days 1-14: 1.0 (0.2, 5.0) Days 1-28: 0.7 (0.2, 2.8) Days 29-56: 1.2 (0.3, 4.8) Hep B Days 1-14: 1.3 (0.4, 4.5) Days 1-28: 0.8 (0.2, 2.4) Days 29-56: 0.9 (0.3, 2.6)	None	
Stowe et al. 2011, Self-controlled case series ¹¹¹	N=2,366 cases of convulsions; Location=UK; Age=Under 10 years; Used General Practice Research Database (GPRD)	Monovalent H1N1 influenza vaccine during the 2009/10 influenza season or seasonal TIV	Data from General Practitioners, bias may occur if population differs from general (e.g., more likely to get vaccinations or diagnoses or better care)	The children were followed up for an average of 5.1 years each (range 0.3–10.0 years) but attrition not discussed	Not discussed	Medical records	Medical records	Conditional Poisson regression	Age, period and season	May 2000 to April 2010	Not specified, study notes J. Stowe is funded from a grant from the Department of Health Policy Research Programs	Incidence rate ratio (IRR) estimates for the onset of a convulsion episode in relation to the timing of influenza vaccination and type of vaccine administered Vaccine, Period, IRR TIV 2 Weeks pre-vaccine: 1.00 (0.70–1.42) Day of vaccination: 1.23 (0.39–3.83) 1–3 Day post vaccine: 0.98 (0.47–2.07) 4–7 Days post vaccine: 0.96 (0.50–1.86) 0–7 Days post vaccine: 1.00 (0.64–1.59) Monovalent H1N1 vaccine	Not reported	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												2 Weeks pre-vaccine 0.44 (0.25–0.76) Day of vaccination 1.83 (0.68–4.90) 1–3 Day post vaccine 1.08 (0.51–2.28) 4–7 Days post vaccine 0.70 (0.31–1.57) 0–7 Days post vaccine 0.99 (0.61–1.60) Incidence rate ratio (IRR) estimates for the onset of a convulsion episode in relation to the timing of monovalent H1N1 vaccine Dose 1 2 Weeks pre-vaccine: 0.37 (0.20–0.68) Day of vaccination: 1.52 (0.49–4.73) 1–3 Day post vaccine: 0.85 (0.35–2.04) 4–7 Days post vaccine: 0.77 (0.34–1.72) 0–7 Days post vaccine: 0.89 (0.53–1.52) Dose 2 2 Weeks pre-vaccine: 1.24 (0.40–3.88) Day of vaccination: 5.24 (0.73–37.41) 1–3 Day post vaccine: 3.48 (0.86–14.07)		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												4-7 Days post vaccine: 0 0-7 Days post vaccine: 1.96 (0.62-6.14)		
Sun et al. 2012, Prospective cohort study and self-controlled case series ²¹⁹	N=378,834 (cohort study), 7811 children with febrile seizures (cases); Location=Denmark; Age=0-7 years; Cohort was identified by using information from the Danish Civil Registry	DTaP-IPV-Hib	Both inpatients and outpatients were included in the register system lessening chance of selection bias. Children with missing values on vaccination remained in the reference cohort and tended to bias the association toward the null hypothesis. Authors note, "Any misclassification of febrile seizures or epilepsy is likely to be non-differential and cause a bias of the HR toward the null hypothesis, but we expect this bias to be small."	Study had almost complete follow-up of all children born in Denmark during a 6-year period due to nationwide registries	Study indicated there should be little difference	Information on vaccinations was obtained from reports submitted from general practitioners (GPs) to the Danish Health Insurance Registry	Information on febrile seizures and epilepsy was obtained from the Danish National Hospital Register.	Cohort study: Cox proportional hazard SCCS: conditional Poisson regression	Cohort: child's sex, multiple births, calendar year of birth, season, gestational age, birth weight, parity of the mother, parental history of epilepsy, maternal education, and family income at the time of birth. Season was included as a time-varying variable. SCCS: age of the child (1-week interval) and the season of the observation period	2003-2009	Lundbeck Foundation. Dr Sun also received support from the Lennart Grams Memorial Foundation. The data recruitment was supported by grants from the Danish Medical Research Council, NordForsk, and Seventh Framework Programme (FP7) grant from the European Research Council.	Cohort analysis - Adjusted HR Time After DTaP-IPV-Hib Vaccination First Vaccination 0 days: 6.02 (2.86-12.65) 1-3 days: 1.38 (0.58-3.31) 4-7 days: 0.41 (0.10-1.69) 0-7 days: 1.64 (0.93-2.88) Second Vaccination 0 days: 3.94 (2.18-7.10) 1-3 days: 1.57 (0.91-2.72) 4-7 days: 0.52 (0.23-1.18) 0-7 days: 1.36 (0.93-1.98) Third Vaccination 0 days: 1.07 (0.73-1.57) 1-3 days: 0.89 (0.70-1.14) 4-7 days: 1.06 (0.87-1.28) 0-7 days: 0.99 (0.86-1.15) SCCS analysis Relative IR Time After DTaP-IPV-Hib Vaccination	Differences between boys and girls not significant.	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												First Vaccination 0 days: 6.49 (3.10-13.61) 1-3 days: 1.47 (0.62-3.50) 4-7 days: 0.44 (0.11-1.81) 0-7 days: 1.65 (0.94-2.90) Second Vaccination 0 days: 3.97 (2.20-7.16) 1-3 days: 1.52 (0.88-2.64) 4-7 days: 0.49 (0.22-1.11) 0-7 days: 1.32 (0.90-1.92) Third Vaccination 0 days: 1.07 (0.73-1.57) 1-3 days: 0.89 (0.70-1.14) 4-7 days: 1.06 (0.87-1.28) 0-7 days: 0.99 (0.86-1.15)		
Thomson et al. 2010, Prospective cohort ²¹⁸	N=488; Location=Australia; Age=2-6 years (outcomes ascertained at 6 years); Setting=Melbourne Atopy Cohort Study (MACS), an ongoing prospective cohort study initiated in	Triple antigen [diphtheria, tetanus and pertussis (DTP)], combined diphtheria and tetanus (CDT), measles mumps rubella (MMR)	Study notes, "Loss to follow-up is a potential issue for prospective studies as selective loss to follow-up may bias the results. It is not possible to test whether loss to follow-up has influenced the associations reported as information on outcomes reported as information on outcomes in	By 6 yr of age, 488 (79%) of the original birth cohort of 620 remained, representing a cumulative loss to follow-up of 21%. At initial recruitment, 19 of the 620 were lost to follow up. 24 were lost to follow up at 1 year old data collection and	Not assessed	Parental report	Parental report of consistent symptoms and/or physician/doctor diagnosis	Linear regression	Parental socio-demographics, allergic disease, parental smoking history; parental education; gender of child and older siblings, pet ownership of at least one dog and/or cat	The MACS recruited 620 infants born between February 1990 and November 1994	MACS was initially supported by Nestle' Australia, while the Asthma Foundation of Victoria supported the 10-yr follow-up.	RR (95% CI) for Asthma Triple antigen (DTP) 1st year: 4.75 (0.88, 25.58) 2nd year: 0.74 (0.56, 0.96) Combined diphtheria and tetanus 1st year 1.88 (1.28, 2.77) 2nd year 1.00 (0.57, 1.74) Measles mumps rubella 2nd year 0.78 (0.61, 0.94 (0.67,	RR (95% CI) for Asthma Socio-demographic child Gender (male) 1.61 (1.21, 2.14) Older siblings (at least 1) 1.27 (1.17, 1.38) Characteristics mother Education (tertiary) 0.94 (0.67,	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	1989		those lost to follow-up is not available. However, it seems unlikely that selective attrition has had a major impact as the rate of follow-up was relatively high being almost 80% by 6 yr which is the strength of the study."	another 89 were loss to follow up at the two year old data collection. Reason for loss to follow up were not provided.								1.00)	1.31) Marital status (married) 0.75 (0.45, 1.24) Smoking (never) 0.70 (0.47, 1.03) Asthma 1.43 (1.07, 1.90) Eczema 1.32 (1.02, 1.72) Allergic rhinitis 0.87 (0.65, 1.17) Food allergy 1.14 (0.84, 1.53) Drug allergy 1.33 (1.02, 1.74) Characteristics father Education (tertiary) 1.11 (0.78, 1.58) Smoking (never) 0.99 (0.71, 1.40) Asthma 1.34 (1.01, 1.79) Eczema 1.16 (0.84, 1.61) Allergic rhinitis 1.37 (1.04,	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
													1.81) Food allergy 0.73 (0.50, 1.08) Drug allergy 0.89 (0.44, 1.81) Pet ownership Dog 0.84 (0.61, 1.14) Cat 1.05 (0.78, 1.42)	
Tse et al. 2012, Self-controlled risk interval, current vs. historical vaccine design ¹¹²	N=206,174 children vaccinated with TIV in 8 US MCOs ; Age=6-59 months;	TIV, PCV13	Bias if cases differed from the general population in systematic ways (e.g., more or less likely to be vaccinated, doctors more likely to recommend vaccinations)	Not discussed	Not discussed	Database record review	Medical record review	Maximized sequential probability ratio test (MaxSPRT) for the self-controlled risk interval design; Poisson-based conditional MaxSPRT (CMaxSPRT) for the current vs. historical design	Adjustment for TIV or PCV13	2010-2011	Centers for Disease Control and Prevention	Incidence rate ratios, self-controlled risk interval design First dose TIV IRR: 4.0 (2.1-6.2) First dose TIV, any dose PCV13 TIV IRR: 2.4 (1.2-4.7) PCV13 IRR: 2.5 (1.3-4.7)	None	
Velázquez et al. 2012, Self-controlled case-series ¹⁸²	N=698 infants < 1 year old in Mexico with intussusception Active surveillance across hospitals in	Rotarix	Bias if cases differed from the general population in systematic ways (e.g., more or less likely to be vaccinated, doctors more likely to recommend vaccinations)	None	Total of 751 infants enrolled and 698 included. No discussion of differences between participants and non-	Review of records, confirmed by review of Expanded Program on Immunization cards. If direct review of Expanded Program on Immunization	Review of hospital admission and discharge logs, and emergency department, pediatric ward, surgery and radiology files. Episodes of intussusception were classified as	Conditional Poisson regression	Age	January 2008 and October 2010	Not listed, many authors were GlaxoSmithKline employees	Relative Incidence Dose and risk period (days after vaccination) Dose 1, 0-30 days: 1.75 (1.24–2.48), p=0.001 Dose 2, 0-30 days: 1.06 (0.75–1.48), p=0.75 Dose 1, 0-15 days:	Not reported	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	Mexico from the Mexican Institute of Social Security				participants	cards was not possible, vaccination history was confirmed from available clinical files (medical charts or the IMSS database). If this was not possible, vaccination history was confirmed through parent/guardian recall.	definite according to the case definition developed by the Brighton Collaboration Working Group for Intussusception, and were confirmed by radiography, surgery or postmortem examination					3.24 (2.15–4.87), p=<0.001 Dose 2, 0-15 days: 1.06 (0.69–1.61), p=0.79 Dose 1, 0-6 days: 6.49 (4.17–10.09), p=<0.001 Dose 2, 0-6 days: 1.29 (0.80–2.11), p=0.29		
Wilson et al. 2011, Self-controlled case series ¹⁴⁴	N=413,957; Location=Ontario, Canada; Age=12 and 18 months;	Live MMR	Newborn Screening Ontario dataset captures over 99% of births	Not applicable	Not applicable	Database record review: pediatric vaccination was identified using the Ontario Health Insurance Plan (OHIP) database	The Canadian Institute for Health Information's (CIHI) Discharge Abstract Database (DAD) was used to ascertain hospital admission. CIHI's National Ambulatory Care Registration System (NACRS) was used to ascertain ER visits, the Canadian Triage and Acuity Score (CTAS) rating and the diagnosis made by the most responsible physician for the visit. The Registered Persons Database	fixed effects Poisson regression	None in the model	2006-2009	Canadian Foundation for Innovation, the Population Health Improvement Research Network (PHIRN), and by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC)	Relative incidence of combined endpoint (hospital admission or emergency room visit) following 12 month vaccination. Risk interval: Relative Incidence (95% CI), P value Day 4: 1.15 (1.06–1.25), p=0.0008 Day 5: 1.19 (1.10–1.29), p=0.0001 Day 6: 1.20 (1.11–1.31), p=0.0001 Day 7: 1.20 (1.10–1.30), p=0.0001 Day 8: 1.62 (1.50–1.74), p=0.0001 Day 9: 2.04 (1.91–2.17), p=0.0001 Day 10: 1.84 (1.72–1.97), p=0.0001 Day 11: 1.72 (1.60–1.84)), p=0.0001	None given	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
							was used to ascertain cases of death.					Day 12: 1.32 (1.22–1.43), p=0.0001 Days 4 to 12** (Combined risk interval): 1.33(1.29–1.38), p=0.0001 Relative incidences of individual endpoints (emergency room visit, hospital admission, death) during highest risk interval compared to control period. 12 months Emergency visits: 1.34 (1.29–1.39) Admissions: 1.08 (0.93–1.25) 18 months Emergency visits: 1.25 (1.18–1.34) Admissions: 1.23 (0.94–1.59) Relative incidence of combined endpoint (hospital admission or emergency room visit) following 18 month vaccination Risk interval: Relative Incidence (95% CI), P value Days 10: 1.31 (1.19–1.45), p=0.0001 Days 11: 1.26 (1.14–1.39), p=0.0001 Days 12: 1.34 (1.21–1.47), p=0.0001 Days 10 to 12		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												(Combined risk interval): 1.25 (1.17-1.33), p=0.0001		
Yih, et al. 2013, ¹⁸⁵ Self-controlled risk interval (SCRI) and a cohort design	N=124 total cases, 613,000 infant-years; Location=U.S.; Age=5-36.9 weeks; Setting=Post-Licensure Rapid Immunization Safety Monitoring program (PRISM), participants were members of Mini-Sentinel Data Partners Aetna, HealthCore, or Humana	RotaTeq, Rotarix	Self-controlled, however physicians may have screened cases more heavily knowing about their vaccination status. Sensitivity analysis revealed this to be not a major contributor to any increased risk	343 potential cases of intussusception were identified in the electronic data. Of these, 267 (78%) had medical record review, and 124 were considered Level 1 on Brighton levels of diagnostic certainty. Charts for the non-reviewed 76 potential cases (22%) were unobtainable due to inability to locate the provider, provider refusal to participate, or there being no record of the patient at the provider	Risk estimates generally decreased with the addition of Brighton Level 2 cases and with the addition of cases for which charts were not obtained; but estimates that were statistically significant in the primary analysis generally retained their significance, and in fact some of the Rotarix estimates became statistically significant with the addition of these cases lacking charts. The attenuation	Claims data and medical record review	Claims data with adjudication	SCRI: logistic regression Cohort: Poisson regression	SCRI: age Cohort: age, sex, Data Partner, and exposure status	January 2004 to September 2011	FDA	Table 2. Case counts and risk estimates (RR, 95% CI) for Brighton Level 1 confirmed intussusception after RotaTeq, risk estimates incorporate a correction factor for cases lacking charts (which make up 22% of the total by dose, study design, and age adjustment). Attributable potential cases ascertained). Pre-specified: Tate age-adjustment Post-hoc: PRISM age-adjustment SCRI, Risk Window 1-7 days Dose 1 Pre-specified: 9.1, 2.2-39 Post-hoc: 7.0, 1.7-29 Dose 2 Pre-specified: 1.8, 0.4-7.2 Post-hoc: 1.8, 0.4-7.2 Dose 3 Pre-specified: 2.2, 0.5-9.7 Post-hoc: 2.3, 0.5-10	None	

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participati on bias	Ascertainmen t of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
				of observed risk is not surprising, as we would expect greater misclassification of the outcome to be introduced by the addition of these unconfirmed potential cases, tending to cause bias toward the null. Furthermore, it is not clear that the validity of our risk estimate increases through the addition of Level 2 cases where there is less diagnostic certainty.								All Pre-specified: 3.3, 1.5-7.4 Post-hoc: 3.0, 1.4-6.8 SCRI, Risk Window 1-21 days Dose 1 Pre-specified: 4.2, 1.1-16 Post-hoc: 3.4, 0.9-13 Dose 2 Pre-specified: 1.0, 0.3-3.1 Post-hoc: 1.0, 0.3-3.1 Dose 3 Pre-specified: 1.0, 0.2-3.9 Post-hoc: 1.0, 0.2-4.0 All Pre-specified: 1.6, 0.8-3.3 Post-hoc: 1.5, 0.7-3.1 Cohort Dose 1 Pre-specified: 2.6, 1.2-5.8 Post-hoc: 2.9, 1.4-6.0 Dose 2 Pre-specified: 0.9, 0.4-2.2 Post-hoc: 0.8, 0.3-		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												2.0 Dose 3 Pre-specified: 0.9, 0.4-2.2 Post-hoc: 0.9, 0.4-2.2 All Pre-specified: 1.3, 0.8-2.1 Post-hoc: 1.3, 0.8-2.1 Table 3. Case counts and risk estimates for Brighton Level 1 confirmed intussusception after Rotarix, by dose, study design, and age adjustment. Pre-specified: Tate age-adjustment Post-hoc: PRISM age-adjustment SCRI, Risk Window 1-7 days Dose 1 Pre-specified: infinity Post-hoc: none Dose 2 Pre-specified: 3.5, 0.5-25 Post-hoc: 3.6, 0.5-25 Dose 3 Pre-specified: 5.7, 0.9-34		

Evidence Table 3. Postmarketing studies: Children-adolsecents

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Post-hoc: 5.5, 0.9-33 SCRI, Risk Window 1-21 days Dose 1 Pre-specified: infinity Post-hoc: none Dose 2 Pre-specified: 1.7, 0.3-10 Post-hoc: 1.7, 0.3-10 Dose 3 Pre-specified: 2.3, 0.4-13 Post-hoc: 2.3, 0.4-13 Cohort Dose 1 Pre-specified: 2.9, 0.4-22 Post-hoc: 3.2, 0.4-23 Dose 2 Pre-specified: 5.1, 1.6-16 Post-hoc: 4.6, 1.5-15 Dose 3 Pre-specified: 3.8, 1.4-10 Post-hoc: 3.7, 1.4-10		

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Andrews N. et al.,2010 UK ²⁴⁶	Cohort	1	Sample size: 118200, Mean age: NR, Age range: 1 - 12	Haemoph. Influenza. type b (Hib) protein conjugate, DTwP, NR, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: NR	Any adverse event: 29.6% Event: Crying: 3.7%, Syscat: 8 Event: Diarrhea: 17.9%, Syscat: 7 Event: Feeding problem: 2.3%, Syscat: 7 Event: Fever: 6.8%, Syscat: 8 Event: Vaccine reaction: 0.3%, Syscat: 10 Event: Vomiting: 11.9%, Syscat: 8 Event: Convulsion/fit/seizure: 0.6%, Syscat: 17 Event: Apnea/collapse/cyanosis/pallor: 0.2%, Syscat: 17,8	
Armah G. E. et al.,2010 Ghana, Kenya, Mali ¹⁴⁶	Controlled Clinical Trial	5	Sample size: 5560, Age range: 4 - 12, Conditions: HIV	Rotavirus, RotaTeq, Merck, 2×10 ⁷ infectious units per reassortant rotavirus, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Event: One or more serious adverse event: 1.5% Event: Death: 0%, Syscat: 8 Event: Pyrexia: <0.1%, Syscat: 8 Event: Sudden infant death syndrome: 0%, Syscat: 8 Event: Bronchiolitis: <0.1%, Syscat: 11 Event: Bronchopneumonia: 0.2%, Syscat: 11 Event: Gastroenteritis: 0.6%, Syscat: 11 Event: Otis media acute: 0%, Syscat: 11 Event: Pneumonia: 0.5%, Syscat: 11 Event: Respiratory tract infection: 0.1%, Syscat: 11 Event: Upper respiratory tract infection: <0.1%, Syscat: 11 Event: Other: 0.2% Event: Vomiting: <0.1%, Syscat: 7	Bronchiolitis: OR 1 (0.063-16.002) Bronchopneumonia: OR 1.669 (0.398-6.989) Gastroenteritis: OR 1 (0.51-1.964) One or more serious adverse event: OR 0.933 (0.61-1.425) Other: OR 0.714 (0.226-2.253) Pneumonia: OR 1.302 (0.57-2.974) Respiratory tract infection: OR 0.6 (0.143-2.512) Upper respiratory tract infection: OR 0.5 (0.045-5.518)
Barbosa, C.M..et al. 2012 ²⁰⁶ Brazil	Controlled Clinical Trial	4	Sample size : 134, Mean age: 15, Age range: 5 - 18, Percent female: 78%	Varicella , Biken , Aventis Pasteur , >=1000 plaque forming units of virus/0.5 mL , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Intramuscular	Dose1: 0 Days	Any adverse event : 42.9% , Syscat: 8, 7 , Sev: 1 Event: Herpes zoster (45 day f/u) : 0% , Syscat: 23	

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Block S. L. et al.,2007 United States, Finland ¹⁴⁷	Controlled Clinical Trial	5	Sample size: 1312, Age range: 6 - 13, Percent female: 47.8%	Rotavirus, RotaTeq, Merck, ©1.1X10 infectious U per dose. Pentavalent (G1–G4, and P[8]) humanbovine(WC3) reassortant rotavirus vaccine (PRV), Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Weeks Dose2: 4-10 Weeks Dose3: 8-20 Weeks	Any adverse event: 88.3% Event: Serious Adverse Event: .03% Event: Gastrointestinal system: 0.46%, Syscat: 7 Event: Abdominal pain: 0%, Syscat: 7 Event: Constipation: 0%, Syscat: 7 Event: Decreased appetite: 0.15%, Syscat: 14 Event: Dehydration: 0.15%, Syscat: 14 Event: Gastroenteritis: 0.15%, Syscat: 7 Event: Hematochezia: 0%, Syscat: 7 Event: General Body: 0.46%, Syscat: 8 Event: Fever, greater than or equal to 102.5 F: 0.31%, Syscat: 8 Event: SIDS: 0.15%, Syscat: 8 Event: Nervous system: 0.31%, Syscat: 17 Event: Meningitis: 0.15%, Syscat: 11 Event: Partial seizures: 0.15%, Syscat: 17 Event: Respiratory: 2%, Syscat: 22 Event: Bronchiolitis/bronchitis/bronchospasm: 1.23%, Syscat: 22 Event: Influenza: 0.15%, Syscat: 22 Event: Pertussis: 0%, Syscat: 22 AE: 3%, Syscat: 22 Event: Respiratory syncytial virus infection: 1%, Syscat: 22 Event: Upper respiratory tract infection: 0%, Syscat: 22	Bronchiolitis/bronchitis/bronchospasm : OR 1.162 (0.419-3.224) Decreased appetite: OR 1.015 (0.063-16.269) Dehydration: OR 0.253 (0.028-2.267) Gastroenteritis: OR 0.507 (0.046-5.605) Gastrointestinal system: OR 0.301 (0.083-1.1) Influenza: OR 0.507 (0.046-5.605) Respiratory syncytial virus infection: OR 6.778 (0.03-1543.45) Respiratory: OR 1.905 (0.755-4.806) Serious Adverse Event: OR 0.783 (0.438-1.399)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Block S. L. et al.,2010 Asia, Europe, Latin America, North America ¹⁸⁸	Controlled Clinical Trial	7	Sample size: 21480, Mean age: NR, Age range: 9 - 26, Percent female: 94%	Human papillomavirus (HPV), Gardasil/Silgard, Merck, HPV-6/11/16/18, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 1 Days Dose2: 2 Month Dose3: 6 Month	Event: Blood/lymphatic system: 0.03%, Syscat: 1, Sev: 3,4,5 Event: Cardiac: 0.03%, Syscat: 2, Sev: 3,4,5 Event: Gastrointestinal: 0.03%, Syscat: 7, Sev: 3,4,5 Event: Hepatobiliary: 0.02%, Syscat: 9, Sev: 3,4,5 Event: Infections/infestations: 0.2%, Syscat: 11, Sev: 3,4,5 Event: Injury/poisoning/procedural: 0.2%, Syscat: 12, Sev: 3,4,5 Event: Musculoskeletal/connective tissue: 0.01%, Syscat: 15, Sev: 3,4,5 Event: Neoplasms benign malignant, unspecified: 0.01%, Syscat: 16, Sev: 3,4,5 Event: Nervous system: 0.04%, Syscat: 17, Sev: 3,4,5 Event: Pregnancy/puerperium/perinatal: 0.3%, Syscat: 18, Sev: 3,4,5 Event: Psychiatric: 0.03%, Syscat: 19, Sev: 3,4,5 Event: Renal/urinary: 0.02%, Syscat: 20, Sev: 3,4,5 Event: Reproductive system/breast: 0.03%, Syscat: 21, Sev: 3,4,5 Event: Respiratory/thoracic/mediastinal: 0.04%, Syscat: 22, Sev: 3,4,5 Event: Vascular: 0.03%, Syscat: 26, Sev: 3,4,5 Event: Serious systemic AE: 0.9% Event: Death: 0.1%, Sev: 5 Event: Discontinuation due to AE: 0.2%	Cardiac: OR 2.472 (0.257-23.766) Death: OR 1.295 (0.502-3.341) Discontinuation due to AE: OR 1.099 (0.596-2.025) Gastrointestinal: OR 1.648 (0.302-8.998) Infections/infestations: OR 1.295 (0.662-2.532) Injury/poisoning/procedural: OR 0.669 (0.398-1.123) Musculoskeletal/connective tissue: OR 0.412 (0.037-4.543) Neoplasms benign malignant, unspecified: OR 0.824 (0.052-13.172) Nervous system: OR 0.824 (0.238-2.846) Pregnancy/puerperium/perinatal: OR 0.736 (0.463-1.17) Psychiatric: OR 1.236 (0.206-7.397) Renal/urinary: OR 0.824 (0.116-5.849) Reproductive system/breast: OR 0.824 (0.206-3.294) Respiratory/thoracic/mediastinal: OR 1.03 (0.276-3.836) Vascular: OR 164.803 (0-178246427.81)
Capeding M. R. Z. et al.,1996 Philippines ¹²⁰	Controlled Clinical Trial	3	Sample size: 174, Mean age: 6.9, Age range: 5 - 8, Percent female: 37%	Haemoph. influenza. type b (Hib) protein conjugate, Routine Vaccines, Pedvax-Hib, Merck, PRP-OMP polysaccharide coupled to an outer membrane protein of Neisseria meningitidis group B. Lot 0957V., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 6-8 Weeks Dose2: 10-12 Weeks Dose3: 14-16 Weeks	Event: Serious adverse reactions: 0% Event: Fever greater than or equal to 38 C: 26%, Syscat: 8	Fever greater than or equal to 38 C: OR 1.246 (0.467-3.323)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Chang C.-C. et al.,2009 Taiwan ¹⁴⁸	Controlled Clinical Trial	NC	Sample size: 189, Age range: 6 - 12, Percent female: 47.6%	Rotavirus, RotaTeq, Merck, five human-bovine reassortant rotaviruses, each of which contained the WC3 bovine strain backbone with different human viral surface proteins G1, G2, G3, G4 and P[8]. An estimated final concentration of 6.5×10^7 IU to 1.2×10^8 IU was included in a 2 mL dose solution, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Weeks Dose2: 4-10 Weeks Dose3: 8-20 Weeks	Event: Fever, rectal temperature > 38.0°C: 53.7%, Syscat: 8 Event: Intussusception: 0%, Syscat: 7 Event: Diarrhea: 26.3%, Syscat: 7 Event: Vomiting: 8.4%, Syscat: 7 Event: Irritable crying: 1.1%, Syscat: 8	Diarrhea: OR 2.015 (0.972-4.178) Fever, rectal temperature > 38.0°C: OR 0.875 (0.492-1.555) Irritable crying: OR 0.979 (0.06-15.882) Vomiting: OR 1.13 (0.392-3.252)
Christie C. D. C. et al.,2010 Jamaica ¹⁴⁹	Controlled Clinical Trial	4	Sample size: 1804, Mean age: 7.7, Age range: 6 - 12, Percent female: 48.4%	Rotavirus, Routine Vaccines, RotaTeq, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Month Dose2: 2 Month Dose3: 2 Month	Any SAE: 4.8%, Sev: 4-5 Event: Death: 0.11%, Sev: 5 Event: Bronchiolitis: 1.3%, Syscat: 22, Sev: 1-3 Event: Urinary Tract Infection: 0.8%, Syscat: 20, Sev: 1-3 Event: Otitis media: 0.4%, Syscat: 4, Sev: 1-3 Event: Gastroenteritis: 0.3%, Syscat: 7, Sev: 1-3 Event: Bronchopneumonia: 0.6%, Syscat: 22, Sev: 1-3 Event: Viral infections: 0.4%, Syscat: 11, Sev: 1-3 Event: Convulsions: 0.2%, Syscat: 17, Sev: 1-3 Event: Anemia: 0.2%, Syscat: 1, Sev: 1-3 Event: Anal fissure: 0.2%, Syscat: 7, Sev: 1-3 Event: Asthma: 0.2%, Syscat: 22, Sev: 1-3 Event: Upper resp infection: 0.2%, Syscat: 22, Sev: 1-3 Event: Femur fracture: 0.1%, Syscat: 12, Sev: 1-3 Event: Intussusception: 0%, Syscat: 22, Sev: 1-3	Bronchiolitis: OR 1.081 (0.475-2.463) Convulsions: OR 0.99 (0.139-7.044) Death: OR 0.329 (0.034-3.172) Femur fracture: OR 0.99 (0.062-15.854) Gastroenteritis: OR 0.99 (0.199-4.918) Otitis media: OR 1.322 (0.295-5.922) Urinary Tract Infection: OR 1.389 (0.439-4.393) Viral infections: OR 3.973 (0.443-35.62)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Clark, L.R. et al. 2013 ²⁰⁰ Europe, Latin America, North America	Controlled Clinical Trial	3	Sample size : 700, Mean age: 20, Age range: 16 - 24, Percent female: 100%, Percent pregnant: Percent Pregnant: 25%	Human papillomavirus (HPV) , Not reported. Quadrivalent vaccine targeting HPV-6/11 , Gardasil, Merck Sharp & Dohme, Corp. , Quadrivalent vaccine targeting HPV-6/11/16/18 , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Intramuscular	Dose1: Day 1 Days Dose2: Month 2 Month Dose3: Month 6 Month	Any SAE : 1.7% Event: One or more injection-site AE : 49% , Syscat: 8 Event: One or more systemic AE : 35.8% Event: Vaccine-related systemic AE : 23.8% Event: Serious vaccine-related AE : 0% Event: Abnormal live birth : 3% , Syscat: 18 Event: Congenital or other anomaly - live birth : 1% , Syscat: 18 Event: Other medical condition - live birth : 2% , Syscat: 18 Event: Number of fetal losses : 24.2% , Syscat: 18 Event: Spontaneous abortion : 20% , Syscat: 18 Event: Late fetal death : 0% , Syscat: 18 Event: Elective abortion : 17.4% , Syscat: 18	Abnormal live birth: OR 0.766 (0.182-3.23) Congenital or other anomaly - live birth: OR 1.281 (0.08-20.564) Number of fetal losses: OR 7.876 (2.694-23.025)** One or more injection-site AE: OR 1.384 (1.024-1.871)** One or more systemic AE: OR 1.362 (0.988-1.876) Spontaneous abortion: OR 0.798 (0.44-1.447) Vaccine-related systemic AE: OR 1.414 (0.977-2.046)
De Carvalho N. et al.,2010 Brazil ¹⁹⁴	NA	3	Sample size: 433, Mean age: 26.5, Percent female: 100%, Percent pregnant: Percent Pregnant: 9.5%	Human papillomavirus (HPV), Cervarix, GlaxoSmithKline, 20 µg of HPV-16 L1 virus-like particle and 20 µg of HPV-18 L1 virus-like particle. Each type of virus-like particle was produced on <i>Spodoptera frugiperda</i> Sf-9 and <i>Trichoplusia ni</i> Hi-5 cell substrate with AS04 adjuvant containing 500 µg aluminum hydroxide and 50 µg 3-deacylated monophosphoryl lipid A (MPL, Corixa, Montana, USA) provided in a monodose vial., Adjuvant: ASO 4-Aluminum, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Month Dose2: 1 Month Dose3: 6 Month	Any SAE: 1.8% Event: Medically significant adverse event (any): 8.1% Event: New onset chronic disease: 0% Event: New onset autoimmune disease: 0%	Medically significant adverse event (any): OR 1.344 (0.641-2.816)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Dennehy P. H. et al.,2005 United States, Canada ¹⁵⁰	Controlled Clinical Trial	6	Sample size: 529, Mean age: 8.7, Age range: 5 - 15, Percent female: 51%	Rotavirus, Routine Vaccines, RIX4414, GlaxoSmithKline, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Month Dose2: 2 Month	Any adverse event: 4.72% Event: Fever: 0%, Syscat: 8 Event: Hypovolemia/dehydration: 0.47%, Syscat: 14, Sev: Serious Event: Meningitis: 0%, Syscat: 11, Sev: Serious Event: Petit mal seizures: 0%, Syscat: 17, Sev: Serious Event: Leukocytosis: 0%, Syscat: 1, Sev: Serious Event: Pyelonephritis: 0.94%, Syscat: 20, Sev: Serious Event: Kidney cyst: 0.47%, Syscat: 20, Sev: Serious Event: Bronchiolitis: 1.42%, Syscat: 22, Sev: Serious Event: Wheezing: 0%, Syscat: 22, Sev: Serious Event: Pneumonia: 0%, Syscat: 22, Sev: Serious Event: Asthma: 0.47%, Syscat: 22, Sev: Serious Event: Other respiratory illness: 0%, Syscat: 22, Sev: Serious Event: Gastroenteritis: 0.94%, Syscat: 7, Sev: Serious Event: GERD: 0%, Syscat: 7, Sev: Serious Event: Mesenteric adenitis: 0%, Syscat: 7, Sev: Serious	Bronchiolitis: OR 0.502 (0.1-2.532) Hypovolemia/dehydration: OR 0.507 (0.031-8.187)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Englund J. A. et al.2010 US ¹⁰⁵	Controlled Clinical Trial	6	Sample size: 1375, Mean age: 9.1, Age range: 2 - 7	Influenza (inactivated), Fluzone, Sanofi, 0.25 mL dose contained 7.5 g hemagglutinin (HA) of A/New Caledonia/20/99(H1N1); A/New York/55/2004 (H3N2), and B/Jiangsu/10/2003, Adjuvant: Not Reported, Preservative: Preservative Free, Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 Month	Any adverse event: 93.4%, Sev: 1-3 Any SAE: 1.9%, Sev: 2-3 Event: Fever >=38C (Dose 1): 11.2%, Syscat: 8, Sev: 1-3 Event: Any irritability (Dose 1): 80%, Syscat: 8, Sev: 1-3 Event: Decreased appetite (Dose 1): 39%, Syscat: 8, Sev: 1-3 Event: Any emesis (Dose 1): 15%, Syscat: 8, Sev: 1-3 Event: Abnormal crying (Dose 1): 62%, Syscat: 8, Sev: 1-3 Event: Any drowsiness (Dose 1): 67%, Syscat: 8, Sev: 1-3 Event: Fever >=38C (Dose 2): 2.3%, Syscat: 8, Sev: 1-3 Event: Any irritability (Dose 2): 55%, Syscat: 8, Sev: 1-3 Event: Decreased appetite (Dose 2): 22%, Syscat: 8, Sev: 1-3 Event: Any emesis (Dose 2): 11%, Syscat: 8, Sev: 1-3 Event: Abnormal crying (Dose 2): 41%, Syscat: 8, Sev: 1-3 Event: Any drowsiness (Dose 2): 41%, Syscat: 8, Sev: 1-3 Event: Death: 0.1%, Sev: 5	Abnormal crying (Dose 1): OR 1 (0.794-1.26) Abnormal crying (Dose 2): OR 1.042 (0.83-1.31) Any drowsiness (Dose 1): OR 1.093 (0.863-1.384) Any emesis (Dose 1): OR 1.294 (0.926-1.808) Any emesis (Dose 2): OR 0.193 (0.146-0.256)** Any irritability (Dose 1): OR 1.128 (0.858-1.483) Any irritability (Dose 2): OR 0.922 (0.736-1.156) Decreased appetite (Dose 1): OR 0.883 (0.703-1.109) Decreased appetite (Dose 2): OR 0.944 (0.723-1.234) Fever >=38C (Dose 1): OR 0.952 (0.67-1.352) Fever >=38C (Dose 2): OR 0.596 (0.313-1.135)
Giuliano A. R. et al.,2011 18 countries ¹⁹³	Controlled Clinical Trial	4	Sample size: 3895, Mean age: 20.5, Age range: 15 - 27, Percent female: 0%	Human papillomavirus (HPV), Gardasil or Silgard, Merck, Quadrivalent HPV types 6, 11, 16, 18. Low-dose contained 20 ug type 6, 40 ug type 11, 40 ug type 16, 20 ug type 18, with 225 ug aluminum adjuvant. (from reference for Villa, 2005, which is study ID 20223), Adjuvant: Aluminum, Preservative: Not reported, Delivery: Intramuscular	Dose1: 1 Days Dose2: 2 Month Dose3: 6 Month	Any adverse event: 69.2% Event: Serious vaccine-related events (entire study period): 0% Event: Death (entire study period): 0.2%, Sev: 5 Event: Serious vaccine-related events (first 15 days): 0% Event: Death (first 15 days): 0%	Death (entire study period): OR 0.3 (0.082-1.091)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Gotoh K. et al.,2011 Japan ¹¹⁰	Cohort	1	Sample size: 101, Mean age: 9.8, Percent female: 51.5%, Conditions: Transplant	Influenza (inactivated), NR, 15 µg hemagglutinin per 0.5 mL of each of the following influenza strains: A/New Caledonia/20/99 (H1N1), A/Hiroshima/52/2005 (H3N2), and B/Malaysia/2506/2004 in the 2006–2007 season; A/Solomon Islands/3/2006 (H1N1), A/Hiroshima/52/2005 (H3N2), and B/Malaysia/2506/2004 in the 2007–2008 season; and A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2), and B/Florida/4/2006 in the 2008–2009 season. These inactivated vaccines did not contain adjuvant., Adjuvant: Adjuvant Free, Preservative: Not reported, Delivery: Not reported	Dose1: 0 Days	Any SAE: 0% Event: Acute allograft rejection: 0%, Syscat: 10 Event: Acute febrile illness: 21.2%, Syscat: 8 Event: Flu virus infection: 6.1%, Syscat: 10	Acute febrile illness: OR 0.421 (0.16-1.11) Flu virus infection: OR 0.819 (0.143-4.703)
Goveia M. G. et al.,2007 11 countries ¹⁵¹	Controlled Clinical Trial	8	Sample size: 2074, Mean age: NR, Age range: 6 - 12, Conditions: Premature babies	Rotavirus, RotaTeq, Merck, vaccine contained 5 live human-bovine reassortant rotaviruses, each consisting of the WC3 bovine strain expressing a viral surface protein corresponding to human rotavirus serotypes G1, G2, G3, G4, or P1A, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 4-10 Weeks Dose3: 4-10 Weeks	Any SAE: 5.5% Event: Bronchiolitis (all subjects, most frequent AE): 1.4%, Syscat: 22, Sev: 3-4 Event: Intussusception (all subjects, confirmed): 0%, Syscat: 7, Sev: 3-4 Event: hematochezia (all subjects): 0%, Syscat: 1, Sev: 3-4 Event: Deaths (total, all subjects): 0.2%, Sev: 5 Event: Death due to SIDS (all subjects): 0.1%, Sev: 5 Event: At least one SAE (extreme preemie): 8.1%, Sev: 3-4 Event: Bronchiolitis (extreme preemie): 2.7%, Syscat: 22, Sev: 3-4 Event: Pneumonia (extreme preemie): 2.7%, Syscat: 22, Sev: 3-4 Event: Apneic attack (extreme preemie): 1.4%, Syscat: 22, Sev: 3-4	Apneic attack (extreme preemie): OR 1.056 (0.066-16.901) At least one SAE (extreme preemie): OR 0.702 (0.249-1.979) Bronchiolitis (all subjects, most frequent AE): OR 0.7 (0.354-1.383) Bronchiolitis (extreme preemie): OR 1.056 (0.148-7.509) Deaths (total, all subjects): OR 1.056 (0.148-7.509) Death due to SIDS (all subjects): OR 1.056 (0.066-16.901) Pneumonia (extreme preemie): OR 2.113 (0.191-23.345)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Grant L. R et al.,2012 United States ¹⁵²	Controlled Clinical Trial	5	Sample size: 1003, Age range: 6 - 12	Rotavirus, RotaTeq, Merck, PRV is a live, pentavalent, vaccine that contains humanbovine (WC3 strain) reassortant rotaviruses expressing the G1, G2, G3, G4, and P[8] human rotavirus antigens, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Weeks Dose2: 4-10 Weeks Dose3: 8-20 Weeks	Event: Vomiting, vaccine related: 11.4%, Syscat: 7 Event: Diarrhea, vaccine related: 31.8%, Syscat: 7 Event: Fever, vaccine related: 33.2%, Syscat: 8 Event: Intussusception: 0%, Syscat: 7 Event: Deaths, (Were outside of 42 day safety window and not associated with vaccine): 0.39% Event: Vomiting, all events: 17.5%, Syscat: 7 Event: Diarrhea, all events: 43.0%, Syscat: 7 Event: Fever, all events: 54.2%, Syscat: 8	Deaths, (Were outside of 42 day safety window and not associated with vaccine): OR 1.945 (0.176-21.517) Diarrhea, all events: OR 1.208 (0.939-1.555) Diarrhea, vaccine related: OR 1.113 (0.851-1.456) Fever, all events: OR 0.943 (0.736-1.21) Fever, vaccine related: OR 1.047 (0.804-1.364) Vomiting, all events: OR 1.097 (0.788-1.527) Vomiting, vaccine related: OR 1.384 (0.911-2.102)
Greenhawt, M.J. et al. 2012 ¹⁰⁹ US	Controlled Clinical Trial	1	Sample size : 143, Mean age: NR, Age range: 14 - 17, Percent female: 36.7%, Conditions: Egg allergy	Influenza (inactivated) , Fluzone , Sanofi , Formulation had ovo-albumin content of 0.1 microgram per 0.5 ml dose , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Not reported	Dose1: 0 Days Dose2: 30 mins NR	Syscat: Not clear Event: Localized urticaria : 35.7% , Syscat: 23 Event: Systemic urticaria : 35.7% , Syscat: 23 Event: Oro-facial angioedema : 42.8% , Syscat: 23 Event: Throat itching : 21.4% , Syscat: 7 Event: Throat swelling : 14.3% , Syscat: 7 Event: Stridor : 7.1% , Syscat: 22 Event: Cough : 21.4% , Syscat: 22 Event: Dyspnea : 14.3% , Syscat: 22 Event: Wheezing : 14.3% , Syscat: 22 Event: Hypotension : 7.1% , Syscat: 26 Event: Vomiting : 64.3% , Syscat: 7 Event: Abdominal pain : 21.4% , Syscat: 7	Dyspnea: OR 0.117 (0.02-0.693)** Hypotension: OR 0.577 (0.047-7.119) Localized urticaria: OR 1.019 (0.232-4.466) Oro-facial angioedema: OR 1.8 (0.407-7.957) Stridor: OR 0.577 (0.047-7.119) Systemic urticaria: OR 0.494 (0.116-2.105) Throat itching: OR 1.273 (0.214-7.582) Throat swelling: OR 2.667 (0.216-32.961) Wheezing: OR 2.667 (0.216-32.961)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Halasa N. et al.,2011 US ¹⁰⁶	Controlled Clinical Trial	2	Sample size: 20, Mean age: 12.2, Age range: 5 - 17, Percent female: 45%, Conditions: Cancer	Influenza (live), MedImmune, 2005-2005 prep: 106.5-7.5 TCID50 per dose for each of the following strains: A/New Caledonia/20/99 (A/NC/20/99; A/H1N1), A/Wyoming/3/2003(A/Fujian/4 11/02-like, A/Fuj/411/02; A/H3N2), and B/Jilin/20/2003(B/Shanghai/36 1/2002-like, Yam88 lineage; B/Yam/166/98; B2005-2006: contained an identical A/H1N1 strain, but the A/H3N2 isolate was updated to A/California/7/2004(A/Cal/7/0 4) and the B strain was replaced with B/Jiangsu/10/2003(B/Shanghai/ 361/2002-like, Yam88 lineage; B/Yam/166/98; B, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intranasal	Dose1: 0 Days	Any adverse event: 88.9% Any SAE: 0% Event: Fever >=100C (0-42 days): 22.2%, Syscat: 8, Sev: 1-3 Event: Runny nose: 77.8%, Syscat: 22, Sev: 1-3 Event: Sore throat: 22.2%, Syscat: 22, Sev: 1-3 Event: Cough: 11.1%, Syscat: 22, Sev: 1-3 Event: Vomiting: 44.4%, Syscat: 8, Sev: 1-3 Event: Headache: 44.4%, Syscat: 8, Sev: 1-3 Event: Muscle ache: 0%, Syscat: 15, Sev: 1-3 Event: Chills: 11.1%, Syscat: 8, Sev: 1-3 Event: Tiredness: 44.4%, Syscat: 8, Sev: 1-3 Event: Irritability: 0%, Syscat: 8, Sev: 1-3 Event: Rash: 0%, Syscat: 10, Sev: 1-3 Event: Febrile neutropenia: 0%, Syscat: 1, Sev: 1-3	Chills: OR 0.259 (0.022-3.063) Cough: OR 0.259 (0.022-3.063) Fever >=100C (0-42 days): OR 0.375 (0.051-2.772) Headache: OR 0.286 (0.045-1.821) Runny nose: OR 1.556 (0.244-9.913) Sore throat: OR 0.25 (0.034-1.819) Tiredness: OR 0.444 (0.074-2.66) Vomiting: OR 1.556 (0.244-9.913)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Huu, T.N. et al. 2013 ¹¹⁸ Vietnam	Controlled Clinical Trial	7	Sample size : 300, Mean age: 8.7, Age range: 6 - 12, Percent female: 43.3%	Haemoph. Influen. type b (Hib) protein conjugate, Routine Vaccines , Experimental: SynflorixRoutine: Infarix hexa , GlaxoSmithKline , PHiD-CV (Synflorix™, GlaxoSmithKline, Rixensart,Belgium) contained 1µg of each capsular polysaccharideof pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23Fand 3µg of serotype 4 capsular polysaccharide conju-gated individually to NTHi protein D; 3µg of serotype 18C capsular polysaccharide conjugated to tetanus tox-oid; and 3µg of serotype 19F capsular polysaccharideconjugated to diphtheria toxoid. Routine: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™,GlaxoSmithKline, Rixensart, Belgium) contained=30 IUof diphtheria toxoid,=40 IU of tetanus toxoid, 25µgofpertussis t , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Intramuscular	Dose1: 0 Days Dose2: 28-42 Days Dose3: 28-42 Days	Event: SAEs (total) : 4.5% , Syscat: See below , Sev: 2-3 Event: SAE- convulsion : 1.0% , Syscat: 17 , Sev: 2-3 Event: SAE- diarrhea : 1.0% , Syscat: 7 , Sev: 2-3 Event: SAE-bronchiolitis : 1.0% , Syscat: 22 , Sev: 2-3 Event: SAE- autoimmune thrombocytopenia : 0.5% , Syscat: 1 , Sev: 2-3 Event: SAE- upper respiratory tract infection : 0.5% , Syscat: 22 , Sev: 2-3 Event: SAE- gastro-oesophageal reflux disease : 0.5% , Syscat: 7 , Sev: 2-3 Event: SAE - hydronephrosis : 0.5% , Syscat: 20 , Sev: 2-3 Event: SAE- fungal infection : 0.5% , Syscat: 11 , Sev: 2-3 Event: SAE - Kawasaki ' s disease : 0.5% , Syscat: 1 , Sev: 2-3 Event: SAE - coagulopathy : 0.5% , Syscat: 1 , Sev: 2-3	SAE- convulsion: OR 0.332 (0.055-2.017) SAE- diarrhea: OR 0.503 (0.07-3.621) SAE- fungal infection: OR 0.25 (0.022-2.791) SAE- gastro-oesophageal reflux disease: OR 0.505 (0.031-8.159) SAEs (total): OR 0.75 (0.259-2.169)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Kang, S. et al. 2008 ¹⁹⁹ Korea	Controlled Clinical Trial	4	Sample size : 176, Mean age: 16.6, Age range: 9 - 23, Percent female: 100%	Human papillomavirus (HPV) , Gardasil , Merck , Mixture of four recombinant HPV type-specific VLPs consisting of the L1 major capsid proteins of HPV 6,11, 16, and 18 synthesized in <i>Saccharomyces cerevisiae</i> .The four VLP types were purified and adsorbed onto amorphous aluminum hydroxyphosphate sulfate adjuvant. , Adjuvant: Aluminum , Preservative: Not reported , Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 Month Dose3: 6 Month	Any adverse event : 77.8% , Syscat: 8, 23 , Sev: 1 Any SAE : 2.5% , Syscat: 8 , Sev: 3 Event: Vaccine related AE : 72.6% , Syscat: 8, 23 , Sev: 1 Event: SAE - death : 0.8% , Sev: 4 Event: Vaccine related SAE : 0% Event: Discontinued due to AE : 8.23% , Syscat: 12 , Sev: 4 Event: Discontinued due to vaccine related AE : 0% Event: Discontinued due to SAE : 0% Event: Discontinued due to vaccine related SAE : 0%	Vaccine related AE: OR 154.063 (20.474-1159.27)**
Kawamura N. et al.,2011 Japan ¹⁵³	Controlled Clinical Trial	4	Sample size: 764, Mean age: 7.7, Age range: 6 - 14, Percent female: 50%	Rotavirus, Rotarix, GlaxoSmithKline, Each dose (1ml) of the lyophilized RIX4414 vaccine (Rotarix TM) contained at least 10-6.0 median Cell Culture Infective Dose (CCID50) of live attenuated human rotavirus RIX4414 strain, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Month Dose2: 1 Month	Any adverse event: 75.8% Any SAE: 14.2% Event: # of patients with any AE (31-day post vacc): 54.9% Event: Eczema: 14.2%, Syscat: 23 Event: Upper respiratory tract infection: 9.8%, Syscat: 22 Event: Cough/runny nose: 35%, Syscat: 22, Sev: 1 Event: Diarrhea: 8%, Syscat: 7 Event: Fever: 11%, Syscat: 8 Event: Irritability: 53%, Syscat: 8 Event: Loss of appetite: 16%, Syscat: 8 Event: Vomiting: 15%, Syscat: 7	# of patients with any AE (31-day post vacc): OR 0.96 (0.71-1.299) Cough/runny nose: OR 1.045 (0.762-1.434) Diarrhea: OR 1.652 (0.866-3.153) Eczema: OR 1.299 (0.82-2.057) Fever: OR 1.421 (0.837-2.414) Irritability: OR 1.128 (0.835-1.523) Loss of appetite: OR 1.397 (0.895-2.179) Upper respiratory tract infection: OR 1.011 (0.61-1.678) Vomiting: OR 1.084 (0.706-1.664)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Kerdpanich A. et al.,2010 Thailand ¹⁵⁴	Controlled Clinical Trial	9	Sample size: 400, Age range: 6 - 12	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, RIX4414 vaccine contained at least 106.0 cell culture infective dose 50 (CCID50) of the RIX4414 strain. CaCO3 buffer based reconstitution., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Month Dose2: 2 Month	Any adverse event: <4% Any SAE: 2.3%, Syscat: 7,8,20,26, Sev: 3-4 Event: SAE - Gastroenteritis: 0.57%, Syscat: 7, Sev: 3-4 Event: SAE - UTI: 0.57%, Syscat: 20, Sev: 3-4 Event: SAE- Neonatal hypertension: 0.57%, Syscat: 26, Sev: 3-4 Event: SAE - Escherichia UTI: 0.57%, Syscat: 20, Sev: 3-4 Event: Loss of appetite: 23%, Syscat: 8, Sev: 3-4 Event: Fatality: 0%, Sev: 5	Loss of appetite: OR 0.487 (0.205-1.16) SAE - UTI: OR 0.145 (0.009-2.384)
Khalil, M. et al. 2012 ²¹² Saudi Arabia	Controlled Clinical Trial	4	Sample size : 238, Mean age: 6.3, Age range: 5 - 8, Percent female: 55.0%	Meningococcal conjugate , Menactra, PA , Sanofi , Quadrivalent (A, C, Y, and W-135) meningococcal diph-theria toxoid-conjugate vaccine , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Intramuscular	Dose1: 0 Days	Event: Grade 2-3 Fever : 5.2% , Syscat: 8 , Sev: 2-3 Event: Grade 2-3 Headache : 1.3% , Syscat: 8 , Sev: 2-3 Event: Grade 2-3 Malaise : 4.5% , Syscat: 8 , Sev: 2-3 Event: Grade 2-3 Myalgia : 2.6% , Syscat: 8 , Sev: 2-3 Event: SAE - Upper respiratory infection (unsolicited AE) : 0.6% , Syscat: 22 , Sev: 3 Event: SAE - Headache (unsolicited AE) : 0.6% , Syscat: 8 , Sev: 3	Grade 2-3 Fever: OR 1.508 (0.389-5.842) Grade 2-3 Headache: OR 1.113 (0.099-12.453) Grade 2-3 Malaise: OR 4.027 (0.487-33.3) Grade 2-3 Myalgia: OR 2.255 (0.248-20.507) SAE - Headache (unsolicited AE): OR 0.553 (0.034-8.949)
Khatun, S. et al. 2012 ¹⁹⁸ Bangladesh	Controlled Clinical Trial	4	Sample size : 67, Mean age: NR, Age range: 9 - 13, Percent female: 100%	Human papillomavirus (HPV) , Cervarix , GlaxoSmithKline , In this preparation, the L1protein of each HPV type is expressed via a recombinantbaculo virus vector. The VLPs of each HPV type are produced separately and consist of purified L1 VLPs of HPV-16/18 at 20/20-g per dose formulated on AS04 adjuvant comprising 500 gm of aluminum hydroxide and 50 gm of 3-deacylated monopods phage lipid A . , Adjuvant: ASO 4 , Preservative: Not reported , Delivery: Not reported	Dose1: 0 Days Dose2: 1 Dose3: 6	Any SAE : 0% Event: Any AE after 1st dose : 80% , Syscat: 8, 7 Event: Any AE after 2nd dose : 88% , Syscat: 8, 7 Event: Any AE after 3rd dose : 90% , Syscat: 8, 7 Event: SAE : 0%	Any AE after 1st dose: OR 16 (4.043-63.326)** Any AE after 2nd dose: OR 53.778 (9.89-292.432)** Any AE after 3rd dose: OR 81 (12.938-507.104)**

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Kim D. S. et al.,2008 Korea ¹⁵⁵	Controlled Clinical Trial	3	Sample size: 178, Age range: 6 - 12, Percent female: 42.7%	Rotavirus, RotaTeq, Merck, PRV contained 5 WC3 reassortant rotaviruses, each consisting of the WC3 bovine strain with viral surface proteins corresponding to human rotavirus serotypes G1, G2, G3, G4, and P1A_8 suspended in a liquid sodium citrate and phosphate buffer at an aggregate viral titer of approximately 6.9 – 10 ⁷ to 8.6 – 10 ⁷ infectious units per dose., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Weeks Dose2: 4-10 Weeks Dose3: 8-20 Weeks	Event: One or more serious adverse events: 5.3% Event: Intussusception: 0%, Syscat: 7 Event: Vaccine-related serious adverse event: 0.87%	One or more serious adverse events: OR 0.44 (0.141-1.373)
Kim J. S. et al.,2012 South Korea ¹⁵⁶	Controlled Clinical Trial	5	Sample size: 684, Mean age: 8.8, Percent female: 45.3%	Rotavirus, Routine Vaccines, RIX4414, NR, >=10*6.0 median Cell Culture Infective Dose per ml, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 8 Weeks Dose2: 16 Weeks	Any adverse event: 72.6% Any SAE: 3.3% Event: Patients with unsolicited AE over 31d: 29.1% Event: nasopharyngitis (unsolicited/31d): 5.7%, Syscat: 22 Event: URI (unsolicited/31d): 3.9%, Syscat: 22 Event: Bronchiolitis (unsolicited/31d): 3.5%, Syscat: 22 Event: gastroenteritis (unsolicited/31d): 8.3%, Syscat: 7 Event: Bronchiolitis (total study period): 1.2%, Syscat: 22 Event: Gastroenteritis (total study period): 1.0%, Syscat: 7	Bronchiolitis (total study period): OR 0.409 (0.123-1.356) Bronchiolitis (unsolicited/31d): OR 0.77 (0.327-1.811) Gastroenteritis (total study period): OR 0.427 (0.113-1.61) Patients with unsolicited AE over 31d: OR 0.815 (0.565-1.176) URI (unsolicited/31d): OR 0.861 (0.371-2) gastroenteritis (unsolicited/31d): OR 0.843 (0.467-1.521) nasopharyngitis (unsolicited/31d): OR 0.563 (0.301-1.051)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Kim, S. C. et al.,2011 Korea ¹⁹¹	Controlled Clinical Trial	8	Sample size: 208, Mean age: 22, Age range: 15 - 25, Percent female: 100%	Human papillomavirus (HPV), Cervarix, GlaxoSmithKline, HPV-16/18 contained 20 mcg each of HPV-16 and -18 L1 (structural protein of HPV) virus like particle, adjuvanted with the proprietary immunostimulant ASO4 adjuvant system (comprising 3-O desacyl-4(1)-MPL [50 mcg] adsorbed on aluminium hydroxide [Al(OH) ₃ , 500 mcg]), Adjuvant: ASO 4-Aluminum, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Month Dose2: 1 Month Dose3: 6 Month	Event: Unsolicited - Infections and infestations, Syscat: 11 Event: Unsolicited - Breast and reproductive system, Syscat: 21 Event: Unsolicited - any AE (Grade 3), Sev: 3 Event: Medical significant adverse condition Event: New onset chronic diseases Event: Solicited - Arthralgias (Grade 3): 10.7%, Syscat: 15, Sev: 3 Event: Solicited - Fatigue (Grade 3): 49.0%, Syscat: 8, Sev: 3 Event: Solicited - Fevers (Grade 3): 1.6%, Syscat: 8, Sev: 3 Event: Solicited - GI symptoms (Grade 3): 17.5%, Syscat: 7, Sev: 3 Event: Solicited - Headache (Grade 3): 29.6%, Syscat: 17, Sev: 3 Event: Solicited - Myalgia (Grade 3): 44.1%, Syscat: 15, Sev: 3 Event: Solicited - Rash (Grade 3): 9.6%, Syscat: 23, Sev: 3 Event: Solicited - Urticaria (Grade 3): 3.0%, Syscat: 23, Sev: 3	Medical significant adverse condition: OR 1.892 (0.846-4.233) New onset chronic diseases: OR 0.374 (0.11-1.272) Solicited - Arthralgias (Grade 3): OR 3.12 (1.423-6.845)** Solicited - Fevers (Grade 3): OR 1.698 (0.343-8.402) Solicited - GI symptoms (Grade 3): OR 3.342 (1.759-6.352)** Solicited - Headache (Grade 3): OR 5.063 (2.405-10.658)** Solicited - Rash (Grade 3): OR 3.024 (1.328-6.886)** Solicited - Urticaria (Grade 3): OR 2.167 (0.596-7.877) Unsolicited - Breast and reproductive system: OR 2.731 (0.767-9.718) Unsolicited - Infections and infestations: OR 2.317 (0.96-5.589) Unsolicited - any AE (Grade 3): OR 0.06 (0.02-0.183)**

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Klein, N.P. et al. 2012 ²¹³ U.S., Colombia, Argentina	Controlled Clinical Trial	2	Sample size : 1508, Mean age: 65.5, Age range: 55 - 89, Percent female: 47.8%	Meningococcal conjugate, Routine Vaccines , NR (likely Novartis, the trial sponsor) , Lyophilized Men A component with liquid MenCWY component, Each dose contained 10micrograms of MenA oligosaccharides and 5microgram each of MenC, MenW-135, and MenY conjugated to CRM197 (~50microgram) , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Intramuscular	Dose1: 0 Month Dose2: 2 Month Dose3: 2 Month	Event: Urticaria (6m) : 1% , Syscat: 23 , Sev: 2-3 Event: Urticaria (12m) : <1% , Syscat: 23 , Sev: 2-3 Event: Severe change in eating habits (6m) : <1% , Syscat: 8 , Sev: 2-3 Event: Severe change in eating habits (12m) : 1% , Syscat: 8 , Sev: 2-3 Event: Severe sleepiness (6m) : 1% , Syscat: 8 , Sev: 2-3 Event: Severe sleepiness (12m) : <1% , Syscat: 8 , Sev: 2-3 Event: Severe persistent crying (6m) : <1% , Syscat: 8 , Sev: 2-3 Event: Severe persistent crying (12m) : 1% , Syscat: 8 , Sev: 2-3 Event: Severe irritability (6m) : 1% , Syscat: 8 , Sev: 2-3 Event: Severe irritability (12m) : 1% , Syscat: 8 , Sev: 2-3 Event: Severe vomiting (6m) : 0% , Syscat: 7 , Sev: 2-3 Event: Severe vomiting (12m) : <1% , Syscat: 7 , Sev: 2-3 Event: Severe diarrhea (6m) : <1% , Syscat: 7 , Sev: 2-3 Event: Severe diarrhea (12m) : 1% , Syscat: 7 , Sev: 2-3 Event: SAE- Death : 0% , Syscat: 0 , Sev: 2-3 Event: SAE- Kawasaki disease (after 3rd dose of MenC) : <1% , Syscat: 1 , Sev: 2-3 Event: SAE - partial complex seizures (after 2nd dose of Men C) : <1% , Syscat: 17 , Sev: 2-3 Event: SAE - Febrile convulsions (after 3rd dose of MenC) : <1% , Syscat: 17 , Sev: 2-3	Severe change in eating habits (12m): OR 3.574 (0.439-29.129) Severe change in eating habits (6m): OR 0.507 (0.102-2.519) Severe irritability (12m): OR 0.675 (0.233-1.955) Severe irritability (6m): OR 3.06 (0.367-25.49) Severe persistent crying (12m): OR 0.761 (0.214-2.707) Severe sleepiness (12m): OR 0.507 (0.102-2.519) Severe sleepiness (6m): OR 3.06 (0.367-25.49) Urticaria (12m): OR 0.507 (0.102-2.519) Urticaria (6m): OR 0.888 (0.259-3.048)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Laserson K. F. et al.,2012 Kenya ¹⁵⁷	Controlled Clinical Trial	7	Sample size: 297, Age range: 0 - 12, Percent female: 51.8%, Conditions: HIV	Rotavirus, RotaTeq, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Any adverse event: 93.2% Event: One of more serious adverse events: 9.5%, Sev: Serious Event: Infections: 9.5%, Syscat: 11, Sev: Serious Event: Respiratory, thoracic and mediastinal disorders: 0%, Syscat: 22, Sev: Serious Event: General disorders and administration site conditions: 0%, Syscat: 8, Sev: Serious Event: Death: 0%, Syscat: 8 Event: Infections: 71.4%, Syscat: 11, Sev: Serious Event: Respiratory, thoracic and mediastinal disorders: 69.4%, Syscat: 22, Sev: Serious Event: General disorders and administration site conditions: 66%, Syscat: 8, Sev: Serious Event: Gastrointestinal disorders: 60.5%, Syscat: 7, Sev: Serious Event: Nervous system disorders: 0%, Syscat: 17, Sev: Serious Event: Reproductive system and breast disorders: 0.7%, Syscat: 21, Sev: Serious	Gastrointestinal disorders: OR 1.534 (0.968-2.431) General disorders and administration site conditions: OR 0.97 (0.599-1.57) Infections: OR 0.684 (0.332-1.412) Infections: OR 0.524 (0.301-0.912)** One of more serious adverse events: OR 0.581 (0.286-1.179) Respiratory, thoracic and mediastinal disorders: OR 337.733 (45.817-2489.554)**
Lau, Y.L. et al. 2013 ¹⁷⁹ China	Controlled Clinical Trial	1	Sample size : 3025, Mean age: 11.6, Age range: 6 - 12, Percent female: Not reported%	Rotavirus , RotarixTM , GlaxoSmithKline , Each dose of the lyophilized formulation of RIX4414 (RotarixTM, GlaxoSmithKline, Belgium) vaccine contained at least 106.0 median cell culture infectious dose (CCID50) of live, attenuated human G1P rotavirus. The RIX4414 vaccine was reconstituted in a calcium carbonate buffer before oral administration. , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Oral	Dose1: 2 Month Dose2: 4 Month	Any SAE : 29% Event: Intussusception : 0.3% , Syscat: 7 Event: Gastroenteritis-related symptoms requiring <=1 hospitalization : 8% , Syscat: 7	Gastroenteritis-related symptoms requiring <=1 hospitalization: OR 0.793 (0.616-1.021) Intussusception: OR 2.001 (0.366-10.943)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Levin M. J. et al.,2010 US (not stated explicitly) ¹⁹⁰	Controlled Clinical Trial	7	Sample size: 126, Mean age: NR, Age range: 7 - 12, Conditions: HIV	Human papillomavirus (HPV), Gardasil, Merck, Quadrivalent human papillomavirus (QHPV) (types 6, 11, 16, 18) recombinant vaccine, 0.5 mL, intramuscular, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intramuscular	Dose1: 0 Weeks Dose2: 8 Weeks Dose3: 24 Weeks	Any adverse event: 29% Any SAE: 2%, Sev: 4 Event: Ear and eye and respiratory system: 1%, Syscat: 4, 5, 22 Event: Laboratory abnormality: 3%, Syscat: 13 Event: Systemic reactions: 2% Event: (Injection site reactions) Event: (Other)	Ear and eye and respiratory system: OR 0.305 (0.019-5.034) Laboratory abnormality: OR 0.935 (0.094-9.343) Systemic reactions: OR 0.617 (0.054-7.053)
Li R. et.al.,2012 China ¹⁸⁹	Controlled Clinical Trial	4	Sample size: 600, Mean age: 24.6, Age range: 9.0 - 45.8, Percent female: 83.3%	Human papillomavirus (HPV), Gardasil/Silgard, Merck, Says to see ref 19. But ref 19 is of a different trial where multiple formulations were used. Cannot ascertain useful information., Adjuvant: Not Reported, Preservative: Not Reported, Delivery: Intramuscular	Dose1: 1 Days Dose2: 2 Month Dose3: 6 Month	Any adverse event: 50.7% Event: Serious AE (any): 0% Event: Serious AE (vaccine-related): 0% Event: Severe pruritus: 0%, Syscat: 23, Sev: Serious Event: Systemic AE (any): 42.7% Event: Systemic AE (vaccine-related): 28.7%	Systemic AE (any): OR 1.122 (0.81-1.553) Systemic AE (vaccine-related): OR 1.066 (0.747-1.522)
Madhi S. A. et al.,2010 South Africa and Malawi ¹⁵⁸	Controlled Clinical Trial	3	Sample size: 4939, Mean age: 6.4 in placebo and rotarix gro, Percent female: 49.6%, Conditions: HIV	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, Calcium carbonate buffer, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Event: Overall SAE: 9.7% Event: Gastroenteritis: 3.8%, Syscat: 7, Sev: Serious Event: Pneumonia: 2.3%, Syscat: 22, Sev: Serious Event: Bronchopneumonia: 1.4%, Syscat: 22, Sev: Serious Event: Bronchiolitis: 1%, Syscat: 22, Sev: Serious Event: Sepsis: 1.4%, Syscat: 11, Sev: Serious Event: Deaths: 2.5% Event: Intussception: 0.03%, Syscat: 7 Event: Vaccine-related AEs: 0.1%	Bronchiolitis: OR 1.027 (0.563-1.871) Bronchopneumonia: OR 0.995 (0.601-1.647) Deaths: OR 0.959 (0.661-1.393) Gastroenteritis: OR 0.779 (0.584-1.039) Overall SAE: OR 0.823 (0.68-0.995)** Pneumonia: OR 0.818 (0.564-1.185) Sepsis: OR 1.234 (0.722-2.11)
Madhi, S.A. et al. 2013 ¹⁰⁸ South Africa	Controlled Clinical Trial	4	Sample size : 410, Mean age: 23.8, Age range: 6 - 59, Percent female: 59%	Influenza (inactivated) , VAXIGRIP , Sano?-Aventis , Adjuvant: Adjuvant Free , Preservative: Not reported , Delivery: Intramuscular	Dose1: Not reported Dose2: 1 month later Month	Any SAE : 0% Event: Pain at site of injection : 2.3% , Syscat: 8 Event: Fever at least 37.5o C : 4.2% , Syscat: 8 Event: Induration at injection site : 2.3% , Syscat: 8 Event: Weakness : 4.5% , Syscat: 8	Uncalcuable

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Moreira Jr E. D. et al.,2011 18 countries including Brazil, Germany, Mexico, US, South Africa, Australia, Canada ¹⁸⁷	Controlled Clinical Trial	7	Sample size: 4065, Mean age: NR, Age range: 16 - 26, Percent female: 0%	Human papillomavirus (HPV), Gardasil/Silgard, Merck, Quadrivalent HPV (type6/11/16/18) L1 VLP vaccine with amorphous aluminum hydroxyphosphatesulfate (AAHS) adjuvant, Adjuvant: Aluminum, Preservative: Not reported, Delivery: Intramuscular	Dose1: 1 Days Dose2: 2 Month Dose3: 6 Month	Any adverse event: 69.2% Any SAE: 0.4%, Sev: 3-5 Event: Death (entire study period): 0.2%, Sev: 5 Event: Discontinuation due to AE (entire study period): 0.3%, Sev: 1-5 Event: Discontinuation due to SAE (entire study period): 0.2%, Sev: 3-5 Event: 1 or more systemic AE (1-15 days): 31.7%, Sev: 1-3 Event: Influenza (1-15 days): 2.2%, Syscat: 11, Sev: 1-3 Event: Nasopharyngitis(1-15 days): 2.3%, Syscat: 11, Sev: 1-3 Event: Pharyngitis(1-15 days): 1.1%, Syscat: 11, Sev: 1-3 Event: Upper respiratory tract infection(1-15 days): 1.4%, Syscat: 11, Sev: 1-3 Event: Injury, Poisoning and Procedural Complications(1-15 days): 1.5%, Syscat: 12, Sev: 1-3 Event: Musculoskeletal and Connective Tissue Disorders(1-15 days): 3.1%, Syscat: 15, Sev: 1-3 Event: Nervous System Disorders(1-15 days): 10.6%, Syscat: 17, Sev: 1-3 Event: Dizziness(1-15 days): 1.0%, Syscat: 17, Sev: 1-3 Event: Respiratory, Thoracic And Mediastinal Disorders(1-15 days): 3.6%, Syscat: 22, Sev: 1-3 Event: Oropharyngeal pain(1-15 days): 2.0%, Syscat: 22, Sev: 1-3 Event: Gastrointestinal Disorders(1-15 days): 6.4%, Syscat: 7, Sev: 1-3 Event: General Disorders(1-15 days): 8.3%, Sev: 1-3 Event: Skin And Subcutaneous Tissue Disorders(1-15 days): 1.3%, Sev: 1-3	Death (entire study period): OR 0.3 (0.083-1.093) Dizziness(1-15 days): OR 1.061 (0.555-2.027) Gastrointestinal Disorders(1-15 days): OR 1.049 (0.81-1.359) General Disorders(1-15 days): OR 0.953 (0.761-1.194) Influenza (1-15 days): OR 0.958 (0.625-1.469) Injury, Poisoning and Procedural Complications(1-15 days): OR 1.259 (0.734-2.162) Musculoskeletal and Connective Tissue Disorders(1-15 days): OR 1.232 (0.844-1.801) Nasopharyngitis(1-15 days): OR 0.881 (0.585-1.328) Nervous System Disorders(1-15 days): OR 0.889 (0.729-1.084) Oropharyngeal pain(1-15 days): OR 1.032 (0.654-1.63) Pharyngitis(1-15 days): OR 1.106 (0.602-2.033) Respiratory, Thoracic And Mediastinal Disorders(1-15 days): OR 20.774 (7.088-60.889)** Skin And Subcutaneous Tissue Disorders(1-15 days): OR 0.84 (0.497-1.421) Upper respiratory tract infection(1-15 days): OR 1.361 (0.761-2.434) Discontinuation due to SAE (entire study period): OR 0.3 (0.083-1.093)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Narang A. et al.,2009 India ¹⁵⁹	Controlled Clinical Trial	5	Sample size: 363, Mean age: 8.7, Age range: 8 - 10, Percent female: 47.1%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, Vaccine contained at least 106.0 median cell culture infectious dose (CCID50) of the vaccine strain per dose. The placebo contained the same constituents as the study vaccine but without the virus component. The lyophilized vaccine and placebo were reconstituted with a diluent containing Calcium Carbonate as a buffer., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Month Dose2: 1 Month	Event: Serious adverse event: 2.61% Event: SAE, lower respiratory tract infection: 1.74%, Syscat: 11 Event: SAE, pneumonia: 0.87%, Syscat: 11 Event: GE episodes from dose 1 to one month post-dose 2: 12.6%, Syscat: 7 Event: Cough/runny nose: 3%, Syscat: 22, Sev: 3 Event: Diarrhea: 3%, Syscat: 7, Sev: 3 Event: Fever: 1%, Syscat: 8, Sev: 3 Event: Irritability: 1%, Syscat: 8, Sev: 3 Event: Loss of appetite: 1%, Syscat: 14, Sev: 3 Event: Vomiting: 4%, Syscat: 7, Sev: 3 Event: Cough/runny nose: 28%, Syscat: 22, Sev: 1-5 Event: Diarrhea: 9%, Syscat: 7, Sev: 1-5 Event: Fever: 16%, Syscat: 8, Sev: 1-5 Event: Irritability: 24%, Syscat: 8, Sev: 1-5 Event: Loss of appetite: 12%, Syscat: 14, Sev: 1-5 Event: Vomiting: 16%, Syscat: 7, Sev: 1-5	Cough/runny nose: OR 1.515 (0.276-8.315) Cough/runny nose: OR 4.472 (2.02-9.902)** Diarrhea: OR 1 (0.218-4.597) Diarrhea: OR 0.89 (0.366-2.164) Fever: OR 0.675 (0.346-1.319) GE episodes from dose 1 to one month post-dose 2: OR 0.94 (0.433-2.04) Irritability: OR 0.242 (0.031-1.913) Irritability: OR 2.316 (1.135-4.723)** Loss of appetite: OR 1.136 (0.5-2.584) Serious adverse event: OR 1.473 (0.241-8.988) Vomiting: OR 0.093 (0.034-0.256)**
Omenaca F. et al.,2012 France, Portugal, Poland and Spain ¹⁶⁰	Controlled Clinical Trial	6	Sample size: 1009, Mean age: 8.5, Age range: 5 - 14, Percent female: 49%, Conditions: Premature babies	Rotavirus, Rotarix, GlaxoSmithKline, A single dose of RIX4414 vaccine contained at least 106.0 median cell culture infective dose of the live-attenuated RIX4414 human rotavirus strain., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 30-83 Days	Any SAE: 5.1% Event: At least 1 unsolicited symptom: 29.3% Event: At least 1 unsolicited symptom (grade 3): 1.9%, Syscat: 8,7 Event: At least 1 unsolicited symptom (vaccine-related): 8.5% Event: Intussusception: 0%, Syscat: 7 Event: Death: 0%, Sev: 5 Event: infection - Gastroenteritis: 2.4%, Syscat: 11 Event: infection - Upper resp infection: 2.1%, Syscat: 11	At least 1 unsolicited symptom: OR 0.602 (0.458-0.792)** At least 1 unsolicited symptom (grade 3): OR 0.285 (0.142-0.573)** At least 1 unsolicited symptom (vaccine-related): OR 0.608 (0.401-0.92)** infection - Gastroenteritis: OR 0.744 (0.341-1.625) infection - Upper resp infection: OR 0.649 (0.291-1.448)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Phua K. B. et al.,2005 Singapore ¹⁶¹	Controlled Clinical Trial	3	Sample size: 2464, Mean age: 13.3, Age range: 11 - 17, Percent female: 50.2%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, 10.7 ffu group. To produce RIX4414, the parent 89-12vaccine strain was further passaged in Vero cells and cloned [18,20]. The vaccine was a lyophilized preparation supplied in single-dose vials with calcium carbonate buffer for reconstitution., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 1 Month	Any SAE: 6.27% Event: SAE - Intussusception: 0%, Syscat: 7, Sev: 2-4 Event: Severe Fever (Dose 1): 0%, Syscat: 8, Sev: 2-4 Event: Severe Fever (Dose 2): 0%, Syscat: 8, Sev: 2-4 Event: Severe Vomiting (Dose 1): 1%, Syscat: 7, Sev: 2-4 Event: Severe Vomiting (Dose 2): 1%, Syscat: 7, Sev: 2-4 Event: Severe Diarrhea (Dose 1): 0%, Syscat: 7, Sev: 2-4 Event: Severe Diarrhea (Dose 2): 0%, Syscat: 7, Sev: 2-4	Severe Vomiting (Dose 1): OR 1 (0.312-3.203) Severe Vomiting (Dose 2): OR 1 (0.312-3.203)
Phua K. B. et al.,2009 Hong Kong, Singapore, Thailand ¹⁶²	Controlled Clinical Trial	8	Sample size: 10708, Mean age: 11.6, Age range: 5 - 20, Percent female: 49.1%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, contained at least 106.0 median cell culture infectious dose (CCID50) of the vaccine strain per dose, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Dose2: 1-2 Month	Event: Intussusception (within 31 days post vaccination): 0%, Syscat: 7, Sev: 1-4 Event: Intussusception (from Dose 1 to age 2): 0.15%, Syscat: 7, Sev: 1-4 Event: Death: 0.02%, Sev: 5 Event: Withdrawal due to AE: 0.13%	Death: OR 0.332 (0.035-3.195) Intussusception (from Dose 1 to age 2): OR 1.996 (0.601-6.632) Withdrawal due to AE: OR 0.581 (0.229-1.477)
Phua K. B. et al.,2012 Singapore, Hong Kong, Taiwan ¹⁶³	Controlled Clinical Trial	1	Sample size: 8407, Mean age: 35.3, Age range: 23 - 44, Percent female: 49%, Percent pregnant: Percent Pregnant: 0%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, reconstitution of lyophilized vaccine in calcium carbonate buffer to a concentration of at least 10*6.0 cell culture infective dose (CCID50) of live-attenuated virus (median), Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: NR Dose2: 1-2 Month	Any adverse event: 0.24% Event: Intussusception: 7% Event: gastroenteritis (failed treatment?): 7% Event: Kawasaki disease: 1%	Intussusception: OR 1.983 (0.18-21.878) gastroenteritis (failed treatment?): OR 1.487 (0.248-8.905)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Rodriguez Z. M. et al.,2007 United States ¹⁶⁴	Controlled Clinical Trial	1	Sample size: 1358, Mean age: 9.35, Age range: 6 - 13, Percent female: 51.1%	Rotavirus, Routine Vaccines, RotaTeq, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 28-70 Days Dose3: 56-140 Days	Any adverse event: 82.3% Event: Diarrhea: 14.7%, Syscat: 7 Event: Vomiting: 9.4%, Syscat: 7 Event: Fever: 46.5%, Syscat: 8 Event: Upper respiratory infection: 23.6%, Syscat: 11 Event: Nasopharyngitis: 14.7%, Syscat: 11 Event: Otitis media: 10.1%, Syscat: 11 Event: Cough: 13.1%, Syscat: 22 Event: Nasal congestion: 13.0%, Syscat: 22 Event: Intussusception: 0.15%, Syscat: 7	Cough: OR 1.027 (0.748-1.41) Diarrhea: OR 0.711 (0.535-0.946)** Fever: OR 0.901 (0.728-1.115) Nasal congestion: OR 0.957 (0.699-1.311) Nasopharyngitis: OR 0.891 (0.664-1.197) Otitis media: OR 0.786 (0.561-1.103) Upper respiratory infection: OR 0.827 (0.647-1.056) Vomiting: OR 0.747 (0.528-1.055)
Roteli-Martins C. M. et al.,2012 Brazil ¹⁹⁵	#10119 f/u	NC	Sample size: 436, Mean age: 26.5, Age range: 15 - 25, Percent female: 100%, Percent pregnant: Percent Pregnant: 17%	Human papillomavirus (HPV), HPV-16/18, GlaxoSmithKline, Described in another study, Adjuvant: ASO 4, Preservative: Not reported, Delivery: Reported in previous study	Dose1: 0 Month Dose2: 1 Month Dose3: 6 Month	Event: New Onset Chronic Disease: 2.2% Event: New Onset Autoimmune Disease, Syscat: 10 Event: Serious Adverse Events: 4.5% Event: Medically Significant Adverse Events: 17.9%	Medically Significant Adverse Events: OR 1.721 (0.998-2.97) New Onset Autoimmune Disease: OR 0.955 (0.133-6.84) New Onset Chronic Disease: OR 2.42 (0.464-12.609) Serious Adverse Events: OR 1.382 (0.516-3.699)
Ruiz-Palacios G. M. et al.,2006 Finland, Argentina, Brazil, Chile, Colombia, the Dominican Republic, Honduras, Mexico, Nicaragua, Panama, Peru, Venezuela ¹⁶⁵	Controlled Clinical Trial	6	Sample size: 63225, Mean age: 8.2, Percent female: 49%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, Contained 10.5 median cell-culture infective doses of the RIX4414 vaccine strain. Vaccine was reconstituted with 1.3 ml of liquid calcium carbonate buffer., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 2 Month Dose2: 4 Month	Event: Serious adverse events: 2.93% Event: Death: 0.18%, Syscat: 8, Sev: 5 Event: Hospitalization: 2.8% Event: Definite intussusception, 31 days or less after either dose: 0.02%, Syscat: 7 Event: Definite intussusception, 31 days or less after dose 1: 0%, Syscat: 7 Event: Definite intussusception, 31 days or less after dose 2: 0.02%, Syscat: 7 Event: Definite intussusception, between dose 1 and visit 3: 0.03%, Syscat: 7	Death: OR 1.298 (0.872-1.932) Definite intussusception, 31 days or less after dose 1: OR 0.498 (0.045-5.493) Definite intussusception, 31 days or less after dose 2: OR 0.996 (0.288-3.441) Definite intussusception, 31 days or less after either dose: OR 0.854 (0.287-2.541) Definite intussusception, between dose 1 and visit 3: OR 0.56 (0.248-1.268) Hospitalization: OR 0.877 (0.8-0.961)** Serious adverse events: OR 0.879 (0.804-0.962)**

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Santosham M. et al.,1991 United States ¹¹⁹	Controlled Clinical Trial	4	Sample size: 5190, Mean age: 54.6, Age range: 35 - 196, Percent female: 49.4%	Haemoph. influenza. type b (Hib) protein conjugate, Routine Vaccines, PedvaxHIB, Merck, OMPC lots 1072,1080, and 1085. After reconstitution with 0.1ml of diluent, each 0.5m of vaccine contained 15 micrograms of H. influenza polysaccharide and 131 to 272 micrograms of group B meningococcal OMPC., Adjuvant: Aluminum, Preservative: Thimerisol, Delivery: Intramuscular	Dose1: 42-90 Days Dose2: 70-146 Days	Event: Viral infections: 0.5%, Syscat: 11 Event: Conjunctivitis: 2%, Syscat: 6 Event: Areas of redness measuring less than 2.54 cm in diameter: 3.3%, Syscat: 8 Event: Areas if swelling measuring less than 2.54 cm: 6.2%, Syscat: 8 Event: Hospitalizations 30 days after vaccination: 4.02% Event: Fever above 38.9 C: 1.63%, Syscat: 8	Areas of redness measuring less than 2.54 cm in diameter: OR 2.713 (1.574-4.676)** Areas if swelling measuring less than 2.54 cm: OR 9.446 (4.905-18.19)** Conjunctivitis: OR 0.628 (0.408-0.968)** Fever above 38.9 C: OR 1.059 (0.685-1.638) Hospitalizations 30 days after vaccination: OR 0.986 (0.748-1.299) Viral infections: OR 0.285 (0.13-0.627)**
Schwarz, T.F. et al. 2012 ¹⁹⁶ Taiwan, Germany, Honduras, Panama, and Colombia	Controlled Clinical Trial	NC	Sample size : 588, Mean age: 12, Percent female: 100%, Percent pregnant: Percent Pregnant: 5%	Human papillomavirus (HPV) , HPV-16/18 AS04-adjuvanted vaccine , GlaxoSmithKline , Each dose of the HPV-16/18 vaccine consisted of 20 @g each of HPV-16 andHPV-18 L1 proteins, self-assembled as virus-like particles, adjuvanted with the Adjuvant System AS04 (comprising 500 @g of aluminum hydroxide and 50@g of MPL). , Adjuvant: ASO 4 , Preservative: Not reported , Delivery: Not reported	Dose1: 0 Month Dose2: 1 Month Dose3: 6 Month	Any SAE : 8% Event: New onset chronic disease : 9% , Syscat: NG Event: Medically significant condition : 51% , Syscat: NG	New onset chronic disease: OR 2.822 (1.818-4.38)**

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Shui I. M. et al.,2012 US ¹⁸⁴	Cohort	1	Sample size: 117575, Mean age: NR, Age range: 4 - 34	Rotavirus, RotaTeq, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 2 Month Dose3: 2 Month	Event: Intussusception - All doses (1-30d risk period), Syscat: 7 Event: Intussusception - All doses (1-7d risk period), Syscat: 7 Event: Intussusception - 1 dose (1-30d risk period), Syscat: 7 Event: Intussusception - 1 dose (1-7d risk period), Syscat: 7 Event: Intussusception - 2 dose (1-30d risk period), Syscat: 7 Event: Intussusception - 2 dose (1-7d risk period), Syscat: 7 Event: Intussusception - 3 dose (1-30d risk period), Syscat: 7 Event: Intussusception - 3 dose (1-7d risk period), Syscat: 7	Intussusception - 2 dose (1-30d risk period): OR 0.396 (0.106-1.473) Intussusception - 3 dose (1-30d risk period): OR 0.989 (0.247-3.954) Intussusception - 3 dose (1-7d risk period): OR 0.989 (0.09-10.907) Intussusception - All doses (1-30d risk period): OR 0.865 (0.363-2.063) Intussusception - All doses (1-7d risk period): OR 0.742 (0.124-4.439)
Sow S. O. et al.,2012 Vietnam, Bangledash, Ghana, Kenya, Mali ¹⁶⁶	Controlled Clinical Trial	5	Sample size: 1960, Mean age: NR, Age range: 6 - 14, Percent female: 48.3%	Rotavirus, RotaTeq, Merck, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Event: One or more serious adverse events: 0.5% Event: Serious vaccine-related adverse events: 0% Event: Deaths: 0.3%, Syscat: 8 Event: Bronchiolitis: 0.1%, Syscat: 11 Event: Meningitis: 0.1%, Syscat: 11 Event: Meningitis pneumococcal: 0.1%, Syscat: 11 Event: Pneumonia: 0.2%, Syscat: 11	Bronchiolitis: OR 1.002 (0.063-16.044) Deaths: OR 0.6 (0.143-2.518) One or more serious adverse events: OR 0.834 (0.254-2.742) Pneumonia: OR 0.667 (0.111-4.003)
Sow, P. S. et al. 2013 ¹⁹⁷ Senegal, Tanzania	Controlled Clinical Trial	5	Sample size : 676, Mean age: 16.9, Age range: 10 - 25, Percent female: 100%	Human papillomavirus (HPV) , Cervarix , GlaxoSmithKline , Each dose of HPV-16/18 AS04-adjuvanted vaccine Cervarix ® (GlaxoSmithKline Vaccines) contained 20 µg each of HPV-16 and HPV-18 L1 viruslike particles, 50 µg of 3-O-desacyl-4'-monophosphoryl lipid A, and 500 µg of Al(OH)3. , Adjuvant: Aluminum , Preservative: Not reported , Delivery: Intramuscular	Dose1: 0 Days Dose2: 1 Month Dose3: 5 Month	Event: Death : 0% Event: SAE : 3.8% Event: AE leading to premature discontinuation : 0% Event: Medically significant condition : 69.3% Event: New onset chronic disease : 2.4% Event: New onset autoimmune disease : .4% , Syscat: 10	Medically significant condition: OR 0.745 (0.518-1.07) New onset autoimmune disease: OR 0.5 (0.07-3.573) New onset chronic disease: OR 0.49 (0.209-1.148) SAE: OR 0.595 (0.288-1.229)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Steele A. D. et al.,2010 South Africa ¹⁶⁷	Controlled Clinical Trial	4	Sample size: 475, Mean age: 6.3	Rotavirus, Rotarix, GlaxoSmithKline, RIX4414 developed from 89-12 parent vaccine strain which was cloned and passaged on Vero cells. Viral concentration of 1 dose contained at least 1x10e6.0 medial cell culture infective dose and lyophilised vaccine was reconstituted with calcium carbonate as buffer, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 10 Weeks Dose2: 14 Weeks	Any adverse event: 70% Event: Serious adverse events (any): 5.3% Event: Serious adverse events (vaccine-related): 0% Event: Deaths (vaccine-related): 0% Event: Deaths (any): 1.1% Event: Intussusception: 0%	Serious adverse events (any): OR 1.011 (0.336-3.046)
Tregnaghi M. W. et al.,2011 Argentina, Brazil, Colombia, Dominican Republic, Honduras, and Panama ¹⁶⁹	Controlled Clinical Trial	4	Sample size: 6568, Mean age: 8.6, Age range: 6 - 12	Rotavirus, Rotatix, GlaxoSmithKline, Contained at least 106.0 median Cell Culture Infective Dose (CCID50) of live attenuated human rotavirus RIX4414 strain. The lyophilized vaccine was reconstituted with the supplied buffer before oral administration., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 1-2 Month	Any SAE: 11.5%, Sev: 3-5 Event: Bronchiolitis: 3.4%, Syscat: 22, Sev: 3-4 Event: Gastroenteritis: 2.2%, Syscat: 7, Sev: 3-4 Event: Pneumonia: 2.1%, Syscat: 22, Sev: 3-4 Event: Intussusception: 0.1%, Syscat: 7, Sev: 3-4 Event: Death: 0.2%, Sev: 5	Bronchiolitis: OR 1.178 (0.874-1.588) Intussusception: OR 1 (0.183-5.464) Death: OR 2.503 (0.548-11.436) Gastroenteritis: OR 0.727 (0.529-1)** Pneumonia: OR 1 (0.699-1.43)
Vesikari T. et al.,2004 Finland ¹⁷⁰	Controlled Clinical Trial	5	Sample size: 405, Mean age: 8.3, Age range: 6 - 12	Rotavirus, Rotarix, GlaxoSmithKline, The vaccine was a lyophilized product; it was reconstituted with a diluent containing calcium carbonate as buffer. Each reconstituted vaccine dose contained 104.7 focus forming units of the RIX4414 strain rotavirus vaccine, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: 2 Month Dose2: 4 Month	Event: Fever greater than or equal to 38.0°C, Dose 1: 12%, Syscat: 8 Event: Diarrhea, Dose 1: 8%, Syscat: 7 Event: Vomiting, Dose 1: 9%, Syscat: 7 Event: Irritability, Dose 1: 62%, Syscat: 8 Event: Loss of appetite, Dose 1: 24%, Syscat: 14 Event: Fever greater than or equal to 38.0°C, Dose 2: 27%, Syscat: 8 Event: Diarrhea: 4%, Syscat: 7 Event: Vomiting: 6%, Syscat: 7 Event: Irritability: 59%, Syscat: 8 Event: Loss of appetite: 24%, Syscat: 14 Event: Intussusception, Syscat: 7	Diarrhea, Dose 1: OR 1.652 (0.685-3.984) Diarrhea: OR 2.042 (0.538-7.745) Fever greater than or equal to 38.0°C, Dose 2: OR 1.11 (0.694-1.773) Fever greater than or equal to 38.0°C, Dose 1: OR 1.103 (0.578-2.105) Irritability, Dose 1: OR 1.088 (0.715-1.654) Irritability: OR 1.276 (0.845-1.928) Loss of appetite, Dose 1: OR 1.542 (0.914-2.602) Vomiting, Dose 1: OR 1.879 (0.788-4.48) Vomiting: OR 0.645 (0.299-1.393)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Vesikari T. et al.,2006 Finland ¹⁷¹	Controlled Clinical Trial	5	Sample size: 1946, Age range: 2 - 8	Rotavirus, NR, Low-potency pentavalent G1, G2, G3, G4, P1A 2.41×106., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Weeks Dose2: 4-8 Weeks Dose3: 8-16 Weeks	Event: Post-vaccination fever greater than or equal to 38.1 C rectally after dose 1: 27%, Syscat: 8 Event: Post-vaccination fever greater than or equal to 38.1 C rectally after dose 2: 27%, Syscat: 8 Event: Post-vaccination fever greater than or equal to 38.1 C rectally after dose 3: 30%, Syscat: 8 Event: Intussusception: 0.4%, Syscat: 7 Event: Deaths: 0%	Post-vaccination fever greater than or equal to 38.1 C rectally after dose 1: OR 1.479 (0.982-2.229) Post-vaccination fever greater than or equal to 38.1 C rectally after dose 2: OR 1.171 (0.788-1.74) Post-vaccination fever greater than or equal to 38.1 C rectally after dose 3: OR 1.286 (0.873-1.894)
Vesikari T. et al.,2006 11 countries ¹⁷²	Controlled Clinical Trial	8	Sample size: 69274, Mean age: 9.8, Age range: 6 - 12, Percent female: 49.3%	Rotavirus, RotaTeq, Merck, Pentavalent, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 4-10 Weeks Dose3: 4-10 Weeks	Any SAE: 2.4%, Syscat: 3-4 Event: Intussusception (total): 0.03%, Syscat: 7 Event: Intussusception (within 42 day of any dose): 0.02%, Syscat: 7 Event: Intussusception related Death: 0%, Syscat: 7 Event: Total deaths: 0.07%, Sev: 5 Event: Death due to SIDS: 0.02%, Sev: 5	
Vesikari T. et al.,2011 Finland ¹⁷³	Controlled Clinical Trial	3	Mean age: 9.1, Age range: 6 - 12, Percent female: 50%	Rotavirus, Rotarix, GlaxoSmithKline, RIX4414 oral suspension (liquid formulation). Contained at least 10-6 median cell culture infective dose (CCID50) of live attenuated RIX4414 human rotavirus strain. The liquid formulation of RIX4414 contained sucrose as excipient and the content of sucrose in the liquid formulation is higher than one in the lyophilized formulation., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days Dose2: 1 Month	Event: Cough/runny nose: 39%, Syscat: 22 Event: Diarrhea: 2%, Syscat: 7 Event: Fever: 8%, Syscat: 8 Event: Irritability: 69%, Syscat: 8 Event: Loss of appetite: 18%, Syscat: 8 Event: Vomiting: 14.2%, Syscat: 7	Cough/runny nose: OR 0.959 (0.477-1.927) Diarrhea: OR 0.49 (0.066-3.639) Fever: OR 1.652 (0.381-7.173) Irritability: OR 1.199 (0.582-2.47) Loss of appetite: OR 0.778 (0.334-1.814) Vomiting: OR 1.098 (0.404-2.984)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Zaman K. et al.,2009 Bangladesh ¹⁷⁵	Controlled Clinical Trial	7	Sample size: 294, Mean age: 6.1, Age range: 6 - 7, Percent female: 53.4%	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, 10.5 median cell culture infective dose of the G1P strain., Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Event: Unsolicited symptoms: 67% Event: Death due to severe pneumonia and cardi respiratory and renal failure 16 days after dose 1: 1.03%, Syscat: 8 Event: Gastroenteritis: 1.03%, Syscat: 7 Event: Any diarrhea: =6/day: 2%, Syscat: 7, Sev: 3 Event: fever: rectal temperature =38 °C: 15%, Syscat: 8, Sev: 3 Event: fever: rectal temperature >39.5 °C: 3%, Syscat : 8, Sev: 1-5 Event: Irritability: 48%, Syscat: 8, Sev: 1-5 Event: Irritability: ying that could not be comforted/prevented normal activity: 2%, Syscat: 8, Sev: 3 Event: Loss of appetite: 38%, Syscat: 14, Sev: 1-5 Event: Vomiting: =1 episode of forceful emptying of partially digested stomach contents =1 h after feeding within a day: 22%, Syscat: 7, Sev: 1-5 Event: Vomiting: =3 episodes/day: 7%, Syscat: 7, Sev: 1-5	fever: rectal temperature =38 °C OR 0.3 (0.134-0.675)** Any diarrhea: =6/day: OR 0.66 (0.074-5.862) Gastroenteritis: OR 0.49 (0.03-8.001) Loss of appetite: OR 1.138 (0.553-2.341) Unsolicited symptoms: OR 0.603 (0.272-1.336) Vomiting: =1 episode of forceful emptying of partially digested stomach contents =1 h after feeding within a day: OR 1.377 (0.564-3.364)
Zaman K. et al.,2010 Bangladesh and Vietnam ¹⁷⁶	Controlled Clinical Trial	8	Sample size: 2035, Mean age: 8.9, Age range: 5.9 - 25.9, Percent female: 47%	Rotavirus, RotaTeq, Merck, Pentavalent rotavirus vaccine containing 5 human-bovine reassortant rotaviruses with the WC3 bovine strain as backbone and viral surface proteins corresponding to human rotavirus serotypes G1, G2 G3, G4, P1 A[8], Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Any SAE: 2.5% Event: Death: 0.3%, Sev: 5 Event: Serious adverse events (vaccine-related): 0%	Death: OR 0.75 (0.167-3.36)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Zaman K. et al.,2012 Bangladesh ¹⁷⁷	Controlled Clinical Trial	5	Sample size: 1136, Mean age: 8.2, Percent female: 48.6%	Rotavirus, Routine Vaccines, RotaTeq, GlaxoSmithKline, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Event: Acute diarrhea: 0.18%, Syscat: 7, Sev: Serious Event: Bronchiolitis: 0.53%, Syscat: 11, Sev: Serious Event: Umbilical infection: 0%, Syscat: 11, Sev: Serious Event: Pneumonia: 1.94%, Syscat: 11, Sev: Serious Event: Head injury: 0.18%, Syscat: 12, Sev: Serious Event: All Serious Adverse Events: 2.82%, Sev: Serious Event: Death, All causes: 0.53%, Syscat: 8, Sev: 5 Event: Death, CMV infection: 0.18%, Sev: 5 Event: Death, Pneumonia: 0.18%, Sev: 5 Event: Death, Hepatoblastoma: 0%, Sev: 5 Event: Death, UTI and sepsis: 0% Event: Accidental drowning: 0.18%, Sev: 5	Acute diarrhea: OR 1 (0.062-16.027) All Serious Adverse Events: OR 0.939 (0.47-1.878) Death, All causes: OR 1 (0.201-4.976) Pneumonia: OR 0.728 (0.331-1.599)

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
Andrews N. et al.,2010 UK ²⁴⁶	Haemoph. influenza. type b (Hib) protein conjugate, Polio (inactivated only), Tdap, Pediacel, Sanofi, Adjuvant: Not Reported, Preservative: Not reported, Delivery:	Dose1: NR	Any adverse event: 30.4% Event: Crying: 2223%, Syscat: 8 Event: Diarrhea: 18.4%, Syscat: 7 Event: Feeding Problem: 2.55%, Syscat: 7 Event: Fever: 7.2%, Syscat: 8 Event: Vaccine reaction: 0.1% Event: Vomiting: 11.88% Event: Convulsion/fit/seizure: 0.4%, Syscat: 17 Event: Apnea/collapse/cyanosis/pallor: 0.2%, Syscat: 17,8 AE: 0% AE: 0% AE: 0%		
Armah G. E. et al.,2010 Ghana, Kenya, Mali ¹⁴⁶				Placebo, Routine Vaccines Placebo includes same adjuvants, preservatives, formulations as the active group	Event: One or more serious adverse event: 1.7% Event: Vomiting: 0%, Syscat: 7 Event: Death: 0.1%, Syscat: 8 Event: Pyrexia: 0%, Syscat: 8 Event: Sudden infant death syndrome: <0.1%, Syscat: 8 Event: Bronchiolitis: <0.1%, Syscat: 11 Event: Bronchopneumonia: 17%, Syscat: 11 Event: Gastroenteritis: 0.6%, Syscat: 11 Event: Otitis media acute: <0.1%, Syscat: 11 Event: Pneumonia: 0.4%, Syscat: 11 Event: Respiratory tract infection: 0.2%, Syscat: 11 Event: Upper respiratory tract infection: 0.1%, Syscat: 11 Event: Other: 0.3%
Barbosa, C.M..et al. 2012 ²⁰⁶ Brazil	Varicella , Biken , Aventis-Pasteur , >=1000 plaque forming units of virus/0.5 mL , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Intramuscular	Dose1: 0 Days	Any adverse event : 46.4% , Syscat: 7, 8 , Sev: 1 Event: Herpes Zoster : 0% , Syscat: 23	Nothing	Any adverse event : 23.1% , Syscat: 7,8 , Sev: 1 Event: Herpes zoster : 3.8% , Syscat: 23
Block S. L. et al.,2007 United States, Finland ¹⁴⁷				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any adverse event: 89.8% Event: Serious Adverse Event: .04% Event: Gastrointestinal system: 1.52%, Syscat: 7 Event: Abdominal pain: 0.15%, Syscat: 7 Event: Constipation: 0.15%, Syscat: 7

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
					<p>Event: Decreased Appetite: 0.15%, Syscat: 14 Event: Dehydration: 0.61%, Syscat: 14 Event: Gastroenteritis: 1%, Syscat: 7 Event: Hematochezia: 0.15%, Syscat: 7 Event: General body: 0%, Syscat: 8 Event: Fever, greater than or equal to 102.5 F: 0%, Syscat: 8 Event: SIDS: 0%, Syscat: 8 Event: Nervous system: 0%, Syscat: 17 Event: Mengitis: 0%, Syscat: 11 Event: Partial Seizures: 0%, Syscat: 17 Event: Respiratory system, Syscat: 22 Event: Bronchiolitis/bronchitis/bronchospasm: 1.06%, Syscat: 22 Event: Influenza: 0.3% Event: Pertussis: .45%, Syscat: 22 Event: Pneumonia: 0.15%, Syscat: 22 Event: Respiratory syncytial virus infection: 1%, Syscat: 22 Event: Upper respiratory tract infection: 1%, Syscat: 22 AE: 0% AE: 0%</p>
Block S. L. et al.,2010 Asia, Europe, Latin America, North America ¹⁸⁸				Placebo There was an aluminum and a non-aluminum containing placebo.	Event: Blood/lymphatic system: 0%, Syscat: 1, Sev: 3,4,5 Event: Cardiac: 0.1%, Syscat: 2, Sev: 3,4,5 Event: Gastrointestinal: 0.2%, Syscat: 7, Sev: 3,4,5 Event: Hepatobiliary: 0%, Syscat: 9, Sev: 3,4,5 Event: Infections/infestations: 0.1%, Syscat: 11, Sev: 3,4,5 Event: Injury/poisoning/procedural: 0.3%, Syscat: 12, Sev: 3,4,5 Event: Musculoskeletal/connective tissue: 1%, Syscat: 15, Sev: 3,4,5 Event: Neoplasms benign malignant, unspecified: 0.01%, Syscat: 16, Sev: 3,4,5 Event: Nervous system: 0.05%, Syscat: 17, Sev:

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
					3,4,5 Event: Pregnancy/puerperium/perinatal: 0.4%, Syscat: 18, Sev: 3,4,5 Event: Psychiatric: 0.02%, Syscat: 19, Sev: 3,4,5 Event: Renal/urinary: 0.02%, Syscat: 20, Sev: 3,4,5 Event: Reproductive system/breast: 0.04%, Syscat: 21, Sev: 3,4,5 Event: Respiratory/thoracic/mediastinal: 0.04%, Syscat: 22, Sev: 3,4,5 Event: Vascular: 0.02%, Syscat: 26, Sev: 3,4,5 Event: serious systemic AE: 1.1%, Sev: 3,4,5 Event: Death: 0.1%, Sev: 5 Event: Discontinuation due to AE: 0.2%
Capeding M. R. Z. et ak.,1996 Philippines ¹²⁰	:			Routine Vaccines	Event: Serious adverse reactions: 0% Event: Irritability: 22%, Syscat: 8 Event: Fever: 22%, Syscat: 8
Chang C.-C. et al.,2009 Taiwan ¹⁴⁸				Placebo Unsure of adjuvants, preservatives and formulations	Event: Fever, rectal temperature > 38.0°C: 57%, Syscat: 8 Event: Intussusception: 0%, Syscat: 7 Event: Diarrhea: 15.1%, Syscat: 7 Event: Vomiting: 7.5%, Syscat: 7 Event: Irritable crying: 1.1%, Syscat: 8
Christie C. D. C. et al.,2010 Jamaica ¹⁴⁹				Placebo Unsure of adjuvants, preservatives and formulations	Any SAE: 3.5%, Sev: 4-5 Event: Death: 0.33%, Sev: 5 Event: Bronchiolitis: 1.2%, Syscat: 22, Sev: 1-3 Event: UTI: 0.6%, Syscat: 20, Sev: 1-3 Event: Otitis media: 0.3%, Syscat: 4, Sev: 1-3 Event: Gastroenteritis: 0.3%, Syscat: 7, Sev: 1-3 Event: Bronchopneumonia: 0%, Syscat: 22, Sev: 1-3 Event: Viral infections: 2%, Syscat: 11, Sev: 1-3 Event: Convulsions: 0.2%, Syscat: 17, Sev: 1-3 Event: Anemia: 0%, Syscat: 1, Sev: 1-3 Event: Anal fissure: 0%, Syscat: 7, Sev: 1-3 Event: Asthma: 0%, Syscat: 22, Sev: 1-3 Event: URI: 0%, Syscat: 22, Sev: 1-3 Event: Femur fracture: 0.1%, Syscat: 12, Sev: 1-3 Event: Intussusception: 0.2%, Syscat: 7, Sev: 1-3
Clark, L.R. et al. 2013 ²⁰⁰ Europe, Latin America, North				Placebo Unsure of adjuvants, preservatives and formulations	Any SAE : 1.6% Event: One or more injection-site AE : 41% , Syscat: 8 Event: One or more systemic AE : 29.1%

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
America					Event: Vaccine-related systemic AE : 18.2% Event: Serious vaccine-related AE : 0% Event: Abnormal live birth : 4.5% , Syscat: 18 Event: Congenital or other anomaly - live birth : 1% , Syscat: 18 Event: Other medical condition - live birth : 30% , Syscat: 18 Event: Number of fetal losses : 27% , Syscat: 18 Event: Spontaneous abortion : 6% , Syscat: 18 Event: Late fetal death : 3% , Syscat: 18 Event: Elective abortion : 18% , Syscat: 18
De Carvalho N. et al.,2010 Brazil ¹⁹⁴				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any SAE: 2.4% Event: Medically significant adverse event (any): 6.2% Event: New onset chronic disease: 0% Event: New onset autoimmune disease: 0%
Dennehy P. H. et al.,2005 United States, Canada ¹⁵⁰	Rotavirus, Routine Vaccines, RIX4414, GlaxoSmithKline, Adjuvant: Not Reported, Preservative: Not reported, Delivery:	Dose1: 0 Month Dose2: 2 Month	Any adverse event: 3.83% Event: Fever: 0%, Syscat: 8, Sev: Serious Event: Hypovolemia/dehydration: 0%, Syscat: 14, Sev: Serious Event: Meningitis: 0.48%, Syscat: 11, Sev: Serious Event: Petit mal seizures: .48%, Syscat: 17, Sev: Serious Event: Leukocytosis: 0%, Sev: Serious Event: Pyelonephritis: 0%, Sev: Serious Event: Kidney cyst: 0%, Syscat: 20, Sev: Serious Event: Bronchiolitis: .48%, Syscat: 22, Sev: Serious Event: Wheezing: 0%, Syscat: 22, Sev: Serious Event: Pneumonia: .5%, Syscat: 22, Sev: Serious Event: Asthma: 0%, Syscat: 22, Sev: Serious Event: Other respiratory illness: 0%, Syscat: 22, Sev: Serious Event: Gastroenteritis: 0%, Syscat: 7, Sev: Serious Event: GERD: 0%, Syscat: 7, Sev: Serious Event: Mesenteric adenitis, Syscat: 7, Sev: Serious	Placebo, Routine Vaccines Unsure of adjuvants, preservatives and formulations	Any adverse event: 9.26% Event: Fever: 0.93%, Syscat: 8, Sev: Serious Event: Hypovolemia/dehydration: 0.93%, Syscat: 14, Sev: Serious Event: Meningitis: 0%, Syscat: 11, Sev: Serious Event: Petit mal seizures: 0%, Syscat: 17, Sev: Serious Event: Leukocytosis: 1.85%, Syscat: 1, Sev: Serious Event: Pyelonephritis: 0%, Syscat: 20, Sev: Serious Event: Kidney cyst: 3%, Syscat: 20, Sev: Serious Event: Bronchiolitis: 2.78%, Syscat: 22, Sev: Serious Event: Wheezing: 0.93%, Syscat: 22, Sev: Serious Event: Pneumonia: .93%, Syscat: 22, Sev: Serious Event: Asthma: 0%, Syscat: 22, Sev: Serious Event: Other respiratory illness: 0.93%, Syscat: 22, Sev: Serious Event: Gastroenteritis: 0%, Syscat: 7, Sev: Serious Event: GERD: 0%, Syscat: 7, Sev: Serious Event: Mesenteric adenitis, Syscat: 7, Sev: Serious

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
			Event: Mesenteric adenitis: 1%, Syscat: 7, Sev: Serious AE: 0% AE: 0% AE: 0%		
Englund J. A. et al., 2010 US ¹⁰⁵				Placebo 0.25 mL sterile with 0.9% sodium chloride	<p>Any adverse event: 92.7%, Sev: 1-3 Any SAE: 1.5%, Sev: 2-3 Event: Fever $\geq 38C$ (Dose 1): 11.7%, Syscat: 8, Sev: 1-3 Event: Any irritability (Dose 1): 78%, Syscat: 8, Sev: 1-3 Event: Decreased appetite (Dose 1): 42%, Syscat: 8, Sev: 1-3 Event: Any emesis (Dose 1): 12%, Syscat: 8, Sev: 1-3 Event: Abnormal crying (Dose 1): 62%, Syscat: 8, Sev: 1-3 Event: Any drowsiness (Dose 1): 65%, Syscat: 8, Sev: 1-3 Event: Fever $\geq 38C$ (Dose 2), Syscat: 8, Sev: 1-3 Event: Any irritability (Dose 2): 57%, Syscat: 8, Sev: 1-3 Event: Decreased appetite (Dose 2): 23%, Syscat: 8, Sev: 1-3 Event: Any emesis (Dose 2): 9.4%, Syscat: 8, Sev: 1-3 Event: Abnormal crying (Dose 2): 39%, Syscat: 8, Sev: 1-3 Event: Any drowsiness (Dose 2): 40%, Syscat: 8, Sev: 1-3 Event: Death: 0%, Sev: 5</p>
Giuliano A. R. et al., 2011 18 countries ¹⁹³				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	<p>Any adverse event: 64.2% Event: Serious vaccine-related events (entire study period): 0% Event: Death (entire study period): 0.5%, Sev: 5 Event: Serious vaccine-related events (first 15 days): 0% Event: Death (first 15 days): 0%</p>
Gotoh K. et al., 2011 Japan ¹¹⁰				Nothing	<p>Any SAE: 0% Event: Acute allograft rejection: 2.8%, Syscat: 10 Event: Acute febrile illness: 31.0%, Syscat: 8</p>

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
Goveia M. G. et al.,2007 11 countries ¹⁵¹				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Event: Influenza virus infection: 5.6%, Syscat: 10 Any SAE: 5.8%, Sev: 3-4 Event: Bronchiolitis: 2.0%, Syscat: 22, Sev: 3-4 Event: Intussusception (confirmed): 0%, Syscat: 7, Sev: 3-4 Event: hematochezia: 0.09%, Syscat: 1, Sev: 3-4 Event: Deaths (total): 0.19%, Sev: 5 Event: Deaths due to SIDS: 0.09%, Sev: 5 Event: At least 1 SAE (extreme preemie): 9.8%, Sev: 3-4 Event: Bronchiolitis (extreme preemie): 1%, Syscat: 22, Sev: 3-4 Event: Pneumonia (extreme preemie): 1.1%, Syscat: 22, Sev: 3-4 Event: Apneic attack (extreme preemie): 1.1%, Syscat: 22, Sev: 3-4
Grant L. R. et al.,2012 United States ¹⁵²				Placebo Unsure of adjuvants, preservatives and formulations	Event: Vomiting, vaccine related: 8.5%, Syscat: 7 Event: Diarrhea, vaccine related: 29.7%, Syscat: 7 Event: Fever, vaccine related: 32.3%, Syscat: 8 Event: Intussusception: 0%, Syscat: 7 Event: Deaths (outside of 42 day follow-up safety window and not assoc with vaccine): 0.2% Event: Vomiting, all events: 16.3%, Syscat: 7 Event: Diarrhea, all events: 275%, Syscat: 7 Event: Fever, all events: 55.9%, Syscat: 8
Greenhawt, M.J. et al. 2012 ¹⁰⁹ US				Placebo Unsure of adjuvants, preservatives and formulations	Event: Localized urticaria : 35.2% , Syscat: 23 Event: Systemic urticaria : 52.9% , Syscat: 23 Event: Orofacial angioedema : 29.4% , Syscat: 23 Event: Throat itching : 17.6% , Syscat: 7 Event: Throat swelling : 5.9% , Syscat: 7 Event: Stridor : 11.7% , Syscat: 22 Event: Cough : 1% , Syscat: 22 Event: Dyspnea : 5.9% , Syscat: 22 Event: Wheezing : 11.7% , Syscat: 22 Event: Hypotension : 5.9% , Syscat: 26 Event: Vomiting : 58.8% , Syscat: 7 Event: Abdominal pain : 11.7% , Syscat: 7
Halasa N. et al.,2011 US ¹⁰⁶				Placebo Unsure of adjuvants, preservatives and	Any adverse event: 90% Any SAE: 0% Event: Fever >100C: 40%, Syscat: 8, Sev: 1-3

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
				formulations	Event: Runny nose: 30%, Syscat: 22, Sev: 1-3 Event: Sore throat: 10%, Syscat: 22, Sev: 1-3 Event: Cough: 30%, Syscat: 22, Sev: 1-3 Event: Vomiting: 30%, Syscat: 8, Sev: 1-3 Event: Headache: 70%, Syscat: 8, Sev: 1-3 Event: Muscle aches: 3%, Syscat: 15, Sev: 1-3 Event: Chills: 30%, Syscat: 8, Sev: 1-3 Event: Tiredness: 60%, Syscat: 8, Sev: 1-3 Event: Irritability: 10%, Syscat: 8, Sev: 1-3 Event: Rash: 20%, Syscat: 10, Sev: 1-3 Event: Febrile neutropenia: 20%, Syscat: 1, Sev: 1-3
Huu, T.N. et al. 2013 ¹¹⁸ Vietnam				Routine Vaccines	Event: SAE (total) : 6.0% , Syscat: See below , Sev: 2-3 Event: SAE-bronchiolitis : 3.0% , Syscat: 22 , Sev: 2-3 Event: SAE-diarrhea : 2.0% , Syscat: 7 , Sev: 2-3 Event: SAE-fungal infection : 2.0% , Syscat: 11 , Sev: 2-3 Event: SAE- urinary tract infection : 1.0% , Syscat: 11, 20 , Sev: 2-3 Event: SAE- gastro- oesophageal reflux diseas : 1.0% , Syscat: 7 , Sev: 2-3 Event: SAE - oral candidiasis : 1% , Syscat: 11 , Sev: 2-3 Event: SAE - viral infection : 1.0% , Syscat: 11 , Sev: 2-3
Kang, S. et al. 2008 ¹⁹⁹ Korea				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any adverse event : 71.2% , Syscat: 8, 23 , Sev: 1 Any SAE : 0% Event: SAE- Pharyngitis : 1.7% , Syscat: 22 , Sev: 3 Event: Vaccine related SAE : 0% Event: Discontinued due to AE : 0% Event: Discontinued due to vaccine related AE : 0% Event: Discontinued due to SAE : 0% Event: Discontinued due to vaccine related SAE : 0%
Kawamura N . et al.,2011 Japan ¹⁵³				Placebo Unsure of adjuvants, preservatives and formulations	Any adverse event: 73.5(8-daypostvacc)% Any SAE: 17.1% Event: # of patients with any AE (31-day post vacc): 56.0% Event: Eczema: 11.3%, Syscat: 23 Event: Upper respiratory tract infection: 9.7%, Syscat: 22

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
					Event: Cough/runny nose (8-day post vacc): 34%, Syscat: 22, Sev: 1 Event: Diarrhea (8-day post vacc): 5%, Syscat: 7 Event: Fever (8-day post vacc): 8%, Syscat: 8 Event: Irritability (8-day post vacc), Syscat: 8 Event: Loss of appetite (8-day post vacc): 12%, Syscat: 8 Event: Vomiting (8-day post vacc): 14%, Syscat: 7
Kerdpanich A. et al., 2010 Thailand ¹⁵⁴	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, RIX4414 vaccine contained at least 106.0 cell culture infective dose 50 (CCID50) of the RIX4414 strain. Water base reconstitution., Adjuvant: Not Reported, Preservative: Not reported, Delivery:	Dose1: 0 Month Dose2: 2 Month	Any adverse event: <4% Any SAE: 2.87%, Syscat: 8,22,23, Sev: 3-4 Event: SAE- infantile colic: 1%, Syscat: 8, Sev: 3-4 Event: SAE- pneumonia: 1.15%, Syscat: 22, Sev: 3-4 Event: SAE -pharygontisilitis: 0.57%, Syscat: 22, Sev: 3-4 Event: SAE- cellulitis: .57%, Syscat: 23, Sev: 3-4 Event: Loss of appetite: 2%, Sev: 3-4 Event: Fatality: 0%, Sev: 5 AE: 1% AE: 0% AE: 0%	Placebo, Routine Vaccines, Water Placebo includes same adjuvants, preservatives, formulations as the active group	Any adverse event: <4%, Sev: 3 Any SAE: 7.69%, Syscat: 22,20,8, Sev: 3-4 Event: SAE - Bronchiolitis: 3.85%, Syscat: 22, Sev: 3-4 Event: SAE - UTI: 3.85%, Syscat: 20, Sev: 3-4 Event: Loss of appetite: 38%, Syscat: 8 Event: Fatality: 0%, Sev: 5
Khalil, M. et al. 2012 ²¹² Saudi Arabia				Routine Vaccines , They had no prior MPSV4, they got the MCV only	Event: Grade 2/3- Fever : 3.5% , Syscat: 8 , Sev: 2-3 Event: Grade 2/3- Headache : 1.2% , Syscat: 8 , Sev: 2-3 Event: Grade 2/3- Malaise : 1.2% , Syscat: 8 , Sev: 2-3 Event: Grade 2/3- Myalgia : 1.2% , Syscat: 8 , Sev: 2-3 Event: SAE - Upper respiratory tract infection (unsolicited) : 1.2% , Syscat: 22 , Sev: 3 Event: SAE- Pharyngitis (unsolicited) : 1.2% , Syscat: 22 , Sev: 3
Khatun, S. et al. 2012 ¹⁹⁸ Bangladesh				Nothing	Any SAE : 0% Event: Any AE after 1st dose : 20% , Syscat: 8, 7 Event: Any AE after 2nd dose : 12% , Syscat: 8, 7 Event: Any AE after 3rd dose : 10% , Syscat: 8, 7 Event: SAE : 0%
Kim D. S. et	:			Placebo	Event: One or more serious adverse event: 11.1%

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
al.,2008 Korea ¹⁵⁵				Unsure of adjuvants, preservatives and formulations	Event: Intussusception: 0%, Syscat: 7
Kim J. S. et al.,2012 South Korea ¹⁵⁶				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any adverse event: 76.7% Any SAE: 7.4% Event: Patients with unsolicited AE over 31d: 33.5% Event: nasopharyngitis (unsolicited/31d): 9.7%, Syscat: 22 Event: URI (unsolicited/31d): 4.5%, Syscat: 22 Event: Bronchiolitis (unsolicited/31d): 4.5%, Syscat: 22 Event: gastroenteritis (unsolicited/31d): 9.7%, Syscat: 7 Event: Bronchiolitis (total study period): 2.8%, Syscat: 22 Event: Gastroenteritis (total study period): 2.3%, Syscat: 7 AE: 1.31%
Kim S. C. et al.,2011 Korea ¹⁹¹				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Event: Unsolicited - Infections and infestations: 10.5%, Syscat: 11 Event: Unsolicited - Breast and reproductive system: 4.48%, Syscat: 21 Event: Unsolicited -any AE (Grade 3): 32.8%, Sev: 3 Event: Medical significant adverse condition: 13.4% Event: New onset chronic diseases: 8.96% Event: Solicited - Arthralgias (Grade 3): 13.4%, Syscat: 15, Sev: 3 Event: Solicited - Fatigue (Grade 3): 2%, Syscat: 8, Sev: 3 Event: Solicited - Fever (Grade 3): 2.99%, Syscat: 8, Sev: 3 Event: Solicited - GI Symptoms (Grade 3): 25.4%, Syscat: 7, Sev: 3 Event: Solicited - Headache (Grade 3): 64%, Syscat: 17, Sev: 3 Event: Solicited - Myalgia (Grade 3): 80.6%, Syscat: 15, Sev: 3 Event: Solicited - Rash (Grade 3): 11.9%, Syscat: 23, Sev: 3 Event: Solicited - Urticaria (Grade 3): 4.48%, Syscat: 23, Sev: 3

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
Klein, N.P. et al. 2012 ²¹³ U.S., Colombia, Argentina				Routine Vaccines	<p>Event: Urticaria (6m) : 1% , Syscat: 23 , Sev: 2-3</p> <p>Event: Urticaria (12m) : 1% , Syscat: 23 , Sev: 2-3</p> <p>Event: Severe change in eating habits (6m) : 1% , Syscat: 8 , Sev: 2-3</p> <p>Event: Severe change in eating habits (12m) : <1% , Syscat: 8 , Sev: 2-3</p> <p>Event: Severe sleepiness (6m) : <1% , Syscat: 8 , Sev: 2-3</p> <p>Event: Severe sleepiness (12m) : 1% , Syscat: 8 , Sev: 2-3</p> <p>Event: Severe persistent crying (6m) : 1% , Syscat: 8 , Sev: 2-3</p> <p>Event: Severe persistent crying (12m) : <1% , Syscat: 8 , Sev: 2-3</p> <p>Event: Severe irritability (6m) : 1% , Syscat: 8 , Sev: 2-3</p> <p>Event: Severe irritability (12m) : <1% , Syscat: 8 , Sev: 2-3</p> <p>Event: Severe diarrhea (6m) : <1% , Syscat: 7 , Sev: 2-3</p> <p>Event: Severe diarrhea (12m) : <1% , Syscat: 7 , Sev: 2-3</p> <p>Event: SAE-Death : 0% , Sev: 2-3</p> <p>Event: SAE- Kawasaki disease : 0% , Syscat: 1 , Sev: 2-3</p> <p>Event: SAE- partial complex seizures : 0% , Syscat: 17 , Sev: 2-3</p> <p>Event: SAE- convulsions : 0% , Syscat: 17 , Sev: 2-3</p>
Laserson K. F. et al.,2012 Kenya ¹⁵⁷				Placebo, Routine Vaccines Unsure of adjuvants, preservatives and formulations	<p>Any adverse event: 98%</p> <p>Event: One or more serious adverse event: 15.3%</p> <p>Event: Infections: 13.3%, Syscat: 11, Sev: Serious</p> <p>Event: Respiratory, thoracic and mediastinal disorders: 0.7%, Syscat: 22, Sev: Serious</p> <p>Event: General disorders and administration site conditions: 0.7%, Syscat: 8, Sev: Serious</p> <p>Event: Death: 0.7%</p> <p>Event: Infections: 82.7%, Syscat: 11, Sev: Serious</p> <p>Event: Respiratory, thoracic, and mediastinal disorders: 100%, Syscat: 22, Sev: Serious</p> <p>Event: General disorders and administration site conditions: 66.7%, Syscat: 8, Sev: Serious</p> <p>Event: Gastrointestinal disorders: 50.0%, Syscat: 7, Sev: Serious</p>

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
					Event: Nervous system disorders: 2.7%, Syscat: 17, Sev: Serious Event: Reproductive system and breast disorders: 0%, Syscat: 22, Sev: Serious
Lau, Y.L. et al. 2013 ¹⁷⁹ China				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any SAE : 32% Event: Intussusception : 0.1% , Syscat: 7 Event: Gastroenteritis-related symptoms requiring <=1 hospitalization : 10% , Syscat: 7
Levin M. J. et al.,2010 US (not stated explicitly) ¹⁹⁰				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any adverse event: 23% Any SAE: 0% Event: Ear and eye and respiratory system: 3%, Syscat: 4, 6, 22 Event: Laboratory abnormality: 3%, Syscat: 13 Event: Systemic reactions: 3% Event: (Injection site reactions) Event: (Other)
Li R. et al.,2012 China ¹⁸⁹				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any adverse event: 44.0% Event: Serious AE (any): 0.3% Event: Serious AE (vaccine-related): 0% Event: Severe pruritus: 0%, Syscat: 23 Event: Systemic AE (any): 39.9% Event: Systemic AE (vaccine-related): 27.5%
Madhi S. A. et al.,2010 South Africa and Malawi ¹⁵⁸				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Event: Overall SAE: 11.5%, Sev: Serious Event: Gastroenteritis: 4.8%, Syscat: 7, Sev: Serious Event: Pneumonia: 2.8%, Syscat: 22, Sev: Serious Event: Sepsis: 1.2%, Syscat: 11, Sev: Serious Event: Bronchopneumonia: 1.4%, Syscat: 22, Sev: Serious Event: Bronchiolitis: 1%, Syscat: 22, Sev: Serious Event: Vaccine-related AEs: 43% Event: Deaths: 2.6%
Madhi, S.A. et al. 2013 ¹⁰⁸ South Africa				Placebo Unsure of adjuvants, preservatives and formulations	Any SAE : 0%
Moreira Jr E. D. et al.,2011 18 countries including Brazil,	:			Placebo Placebo includes same adjuvants, preservatives, formulations as the active	Any adverse event: 64.2% Any SAE: 0.6% Event: Death (entire study): 0.5%, Sev: 5 Event: discontinued due to an adverse experience

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
Germany, Mexico, US, South Africa, Australia, Canada ¹⁸⁷				group	<p>(entire study): 0.7%, Sev: 1-5 Event: discontinued due to SAE(entire study): 0.5%, Sev: 3-5 Event: Gastrointestinal Disorders (1-15 days): 6.2%, Syscat: 7, Sev: 1-5 Event: General Disorders (1-15 days): 8.7%, Syscat: 8, Sev: 1-5 Event: Infections and Infestations (1-15 days): 9.6%, Syscat: 11, Sev: 1-5 Event: Influenza (1-15 days): 50%, Syscat: 11, Sev: 1-5 Event: Nasopharyngitis (1-15 days): 2.6%, Syscat: 11, Sev: 1-5 Event: Pharyngitis (1-15 days): 1.0%, Syscat: 11, Sev: 1-5 Event: Upper respiratory tract infection (1-15 days): 1.0%, Syscat: 11, Sev: 1-5 Event: Injury, Poisoning and Procedural (1-15 days) Complications: 1.2%, Syscat: 12, Sev: 1-5 Event: Musculoskeletal and Connective Tissue Disorders (1-15 days): 2.6%, Syscat: 15, Sev: 1-5 Event: Nervous System Disorders (1-15 days): 11.8%, Syscat: 17, Sev: 1-5 Event: Dizziness (1-15 days): 0.9%, Syscat: 17, Sev: 1-5 Event: Respiratory, Thoracic And Mediastinal Disorders (1-15 days): 3.5%, Syscat: 22, Sev: 1-5 Event: Oropharyngeal pain (1-15 days): 1.9%, Syscat: 22, Sev: 1-5 Event: Skin And Subcutaneous Tissue Disorders (1-15 days): 1.6%, Sev: 1-5</p>
Narang A. et al., 2009 India ¹⁵⁹				Placebo, Routine Vaccines Unsure of adjuvants, preservatives and formulations	Event: Serious adverse events: 1.79% Event: SAE, bronchiolitis: 0.89%, Syscat: 22 Event: SAE, parotitis: 0.89%, Syscat: 11 Event: GE episodes from dose 1 to one month post-dose 2: 13.3%, Syscat: 7 Event: Cough/runny nose: 2%, Syscat: 22, Sev: 3 Event: Diarrhea: 3%, Syscat: 7, Sev: 3 Event: Fever, Syscat: 8, Sev: 3 Event: Irritability: 4%, Syscat: 8, Sev: 3 Event: Loss of appetite: 0%, Syscat: 14, Sev: 3 Event: Vomiting: 5%, Syscat: 7, Sev: 3 Event: Cough/runny nose: 31%, Syscat: 22, Sev: 1-5

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
					Event: Diarrhea: 8%, Syscat: 7, Sev: 1-5 Event: Fever: 10%, Syscat: 8, Sev: 1-5 Event: Irritability: 22%, Syscat: 8, Sev: 1-5 Event: Loss of appetite: 12%, Syscat: 14, Sev: 1-5 Event: Vomiting: 7.5%, Syscat: 7, Sev: 1-5
Omenaca F. et al.,2012 France, Portugal, Poland and Spain ¹⁶⁰	:			Placebo includes same adjuvants, preservatives, formulations as the active group	Event: At least 1 SAE: 6.2% Event: At least 1 unsolicited symptom: 40.7% Event: At least 1 unsolicited symptom (Grade 3): 6.5%, Syscat: 8,7, Sev: 3 Event: At least 1 unsolicited symptom (vaccine related): 13.3% Event: Death - Bronchiolitis: 0.29%, Sev: 5 Event: Intussception: 0%, Syscat: 7 Event: infection - Gastroenteritis, Syscat: 11 Event: infection - upper resp infection: 3.2%, Syscat: 11
Phua K. B. et al.,2005 Singapore ¹⁶¹	Rotavirus, Routine Vaccines, Rotarix, GlaxoSmithKline, 10.2 ffu group. To produce RIX4414, the parent 89–12 vaccine strain was further passaged in Vero cells and cloned [18,20]. The vaccine was a lyophilized preparation supplied in single-dose vials with calcium carbonate buffer for reconstitution., Adjuvant: Not Reported, Preservative: Not reported, Delivery:	Dose1: 0 Days Dose2: 1 Month	Any SAE: 8.33% Event: SAE - Intussception (likely related to vaccine), Syscat: 7, Sev: 2-4 Event: Severe Fever (Dose 1): 1%, Syscat: 8, Sev: 2-4 Event: Severe Fever (Dose 2), Syscat: 8, Sev: 2-4 Event: Severe Vomiting (Dose 1): 2%, Syscat: 7, Sev: 2-4 Event: Severe Vomiting (Dose 2): 2%, Sev: 2-4 Event: Severe Diarrhea (Dose 1), Sev: 2-4 Event: Severe Diarrhea (Dose 2): 0%, Syscat: 7, Sev: 2-4 AE: 0%	Placebo, Routine Vaccines Unsure of adjuvants, preservatives and formulations	Any SAE: 6.12% Event: SAE- Intussusception (likely unrelated to vaccine): 1%, Syscat: 7, Sev: 2-4 Event: Severe Fever (Dose 1): 0%, Syscat: 8, Sev: 2-4 Event: Severe Fever (Dose 2): 1%, Syscat: 8, Sev: 2-4 Event: Severe Vomiting (Dose 1): 1%, Syscat: 7, Sev: 2-4 Event: Severe Vomiting (Dose 2): 1%, Syscat: 7, Sev: 2-4 Event: Severe Diarrhea (Dose 1): 0%, Syscat: 7, Sev: 2-4 Event: Severe Diarrhea (Dose 2), Syscat: 7, Sev: 2-4
Phua K. B. et al.,2009 Hong Kong, Singapore, Thailand ¹⁶²	:			Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Sev: 3-5 Event: Intussusception (w/in 31 days post vaccination): 0%, Syscat: 7, Sev: 1-4 Event: Intussusception (Dose 1 to age 2): 0.07%, Syscat: 7, Sev: 1-4 Event: Death (entire study period): 0.06%, Sev: 5 Event: Withdrawal due to AE: 0.22%
Phua K. B. et al.,2012				Placebo, Routine Vaccines Placebo includes same	Any adverse event: 0.26% Event: Intussusception: 0.02%

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
Singapore, Hong Kong, Taiwan ¹⁶³				adjuvants, preservatives, formulations as the active group	Event: gastroenteritis: 0.05%
Rodriguez Z.M. et al., 2007 ¹⁶⁴ United States				Placebo, Routine Vaccines Unsure of adjuvants, preservatives and formulations	Any adverse event: 87.1% Event: Diarrhea: 19.5%, Syscat: 7 Event: Vomiting: 12.2%, Syscat: 7 Event: Fever: 49.1%, Syscat: 8 Event: Upper respiratory infection: 27.2%, Syscat: 11 Event: Nasopharyngitis: 16.2%, Syscat: 11 Event: Otitis media: 12.5%, Syscat: 11 Event: Cough, Syscat: 22 Event: Nasal congestion: 13.5%, Syscat: 22
Roteli-Martins C. M et al., 2012 Brazil ¹⁹⁵				Placebo Unsure of adjuvants, preservatives and formulations	Event: New Onset Chronic Disease: 0.9% Event: New Onset Autoimmune Disease, Syscat: 10 Event: Serious Adverse Events: 3.3% Event: Medically Significant Adverse Events: 11.3%
Ruiz-Palacios G. M. et al., 2006 Finland, Argentina, Brazil, Chile, Colombia, the Dominican Republic, Honduras, Mexico, Nicaragua, Panama, Peru, Venezuela ¹⁶⁵				Placebo, Routine Vaccines Placebo includes same adjuvants, preservatives, formulations as the active group	Event: Serious adverse event between dose 1 and visit 3: 3.32% Event: Hospitalization: 3.18%, Sev: 3, 4 Event: Death: 0.14%, Syscat: 8, Sev: 5 Event: Deinite intussusception, 31 days or less after either dose: 0.02%, Syscat: 7 Event: Deinite intussusception, 31 days or less after dose 1: 0.01%, Syscat: 7 Event: Deinite intussusception, 31 days or less after dose 2: 0.02%, Syscat: 7 Event: Deinite intussusception, between dose 1 and visit 3: .05%, Syscat: 7 AE: 0%
Santosham M. et al.1991 United States ¹¹⁹				Placebo, Routine Vaccines Unsure of adjuvants, preservatives and formulations	Event: Viral infections: 1.6%, Syscat: 11 Event: Conjunctivitis: 3.1%, Syscat: 6 Event: Areas of redness measuring less than 2.54 cm in diameter: 1.2%, Syscat: 8 Event: Areas of swelling measuring less than 2.54 cm in diameter: 0.7%, Syscat: 8 Event: Hospitalizations 30 days after vaccination: 4.07% Event: Fever above 38.9 C: 1.54%, Syscat: 8
Schwarz, T.F. et				Routine Vaccines	Any SAE : 3%

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
al. 2012 ¹⁹⁶ Taiwan, Germany, Honduras, Panama, and Colombia					Event: New onset chronic disease : 3% , Syscat: NG Event: Medically significant condition : 26% , Syscat: NG

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Shui I. M. et al.,2012 US ¹⁸⁴				Routine Vaccines	<p>Event: Intussusception - All doses (1-30d risk period), Syscat: 7</p> <p>Event: Intussusception - All doses (1-7d risk period), Syscat: 7</p> <p>Event: Intussusception - 1 dose (1-30d risk period), Syscat: 7</p> <p>Event: Intussusception - 1 dose (1-7d risk period), Syscat: 7</p> <p>Event: Intussusception - 2 dose (1-30d risk period), Syscat: 7</p> <p>Event: Intussusception - 2 dose (1-7d risk period), Syscat: 7</p> <p>Event: Intussusception - 3 dose (1-30d risk period): 1%, Syscat: 7</p> <p>Event: Intussusception - 3 dose (1-7d risk period), Syscat: 7</p>
Sow S. O. et al.,2012 Vietnam, Bangladesh, Ghana, Kenya, Mali ¹⁶⁶				Placebo Unsure of adjuvants, preservatives and formulations	<p>Event: One or more serious adverse events: 0.6%</p> <p>Event: Serious vaccine-related adverse events: 0.2%</p> <p>Event: Deaths: 0.5%, Syscat: 8</p> <p>Event: Bronchiolitis: 0.1%, Syscat: 11</p> <p>Event: Meningitis: 0%, Syscat: 11</p> <p>Event: Meningitis pneumococcal: 3%, Syscat: 11</p> <p>Event: Pneumonia: 3%, Syscat: 11</p>
Sow, P. S. et al. 2013 ¹⁹⁷ Senegal, Tanzania				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	<p>Event: Death : 0%</p> <p>Event: SAE : 6.2%</p> <p>Event: AEs leading to premature discontinuation : 0%</p> <p>Event: Medically significant condition : 75.2%</p> <p>Event: New onset chronic disease : 4.9%</p> <p>Event: New onset autoimmune disease : 0.9% , Syscat: 10</p>
Steele A. D. et al.,2010 South Africa ¹⁶⁷	Rotavirus, Rotarix, GlaxoSmithKline, RIX4414 developed from 89-12 parent vaccine strain which was cloned and passaged on Vero cells. Viral concentration of 1 dose contained at least 1x10e6.0 medial cell culture infective dose and lyophilized vaccine was reconstituted with calcium carbonate as buffer, Adjuvant: Not Reported, Preservative: Not Reported	Dose1: 6 Weeks Dose2: 10 Weeks Dose3: 14 Weeks	Any adverse event: 54%, Sev: N,N Event: Serious adverse events (any): 9% Event: Serious adverse events (vaccine-related): 0% Event: Death (vaccine-related): 0% Event: Death (any): 0.5% Event: Intussusception: 0% AE: 0% AE: 0% AE: 0%	Placebo, Routine Vaccines Placebo includes same adjuvants, preservatives, formulations as the active group	<p>Any adverse event: 59%</p> <p>Event: Serious adverse events (any): 5.2%</p> <p>Event: Serious adverse-events (vaccine-related): 1%, Syscat: 7, Sev: Serious</p> <p>Event: Death (vaccine-related): 0%</p> <p>Event: Death (any): 0%</p> <p>Event: Intussusception: 0%</p>

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents

Tregnaghi M. W. et al.,2011 Argentina, Brazil, Colombia, Dominican Republic, Honduras, and Panama ¹⁶⁹				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any SAE: 12.1%, Sev: 3-5 Event: Bronchiolitis: 2.9%, Syscat: 22, Sev: 3-4 Event: Gastroenteritis: 3.0%, Syscat: 7, Sev: 3-4 Event: Pneumonia: 2.1%, Syscat: 22, Sev: 3-4 Event: Intussusception: 0.1%, Syscat: 7, Sev: 3-4 Event: Death: 0.1%, Sev: 5
Vesikari T. et al.,2004 Finland ¹⁷⁰				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Event: Fever greater than or equal to 38.0°C, Dose 1: 11%, Syscat: 8 Event: Diarrhea, Dose 1: 5%, Syscat: 7 Event: Vomiting, Dose 1: 5%, Syscat: 7 Event: Irritability, Dose 1: 60%, Syscat: 8 Event: Loss of appetite, Dose 1: 17%, Syscat: 14 Event: Fever greater than or equal to 38.0°C: 25%, Syscat: 8 Event: Diarrhea, Dose 2, Syscat: 7 Event: Vomiting, Dose 2: 9%, Syscat: 7 Event: Irritability, Dose 2: 53%, Syscat: 8 Event: Loss of appetite, Dose 2: 20%, Syscat: 14 Event: Intussusception: 0%, Syscat: 7
Vesikari T. et al.,2006 Finland ¹⁷¹	:			Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Event: Post-vaccination fever greater than or equal to 38.1 C rectally after dose 1, Syscat: 8 Event: Post-vaccination fever greater than or equal to 38.1 C rectally after dose 2, Syscat: 8 Event: Post-vaccination fever greater than or equal to 38.1 C rectally after dose 3, Syscat: 8
Vesikari T. et al.,2006 11 countries ¹⁷²				Placebo Unsure of adjuvants, preservatives and formulations	Any SAE: 2.5% Event: Intussusception (total) Event: Intussusception w/in 42 days of any dose Event: Intussusception related death: 0%, Sev: 5 Event: Deaths (all): 0.1%, Sev: 5 Event: Death due to SIDS, Sev: 5
Vesikari T. et al.,2011 Finland ¹⁷³	Rotavirus, Rotarix, GlaxoSmithKline, lyophilized formulation (1 ml after reconstitution with calcium carbonate buffer). Contained at least 10-6median cell culture infective dose (CCID50) of live attenuated RIX4414 human rotavirus strain, Adjuvant: Not Reported, Preservative: Not rep	Dose1: 0 Days Dose2: 1 Month	Event: Cough/runny nose, Syscat: 22 Event: Diarrhea: 5.5%, Syscat: 7 Event: Fever, Syscat: 8 Event: Irritability: 66%, Syscat: 8 Event: Loss of appetite: 20% Event: Vomiting AE: 6%	Placebo Unsure of adjuvants, preservatives and formulations	Event: Cough/runny nose: 40%, Syscat: 22 Event: Diarrhea: 4%, Syscat: 7 Event: Fever: 5%, Syscat: 8 Event: Irritability: 65%, Syscat: 8 Event: Loss of appetite: 22%, Syscat: 8 Event: Vomiting: 13.1%, Syscat: 7

Evidence Table 4. Vaccinated versus unvaccinated: Children-adolescents					
Zaman K. et al.,2010 Bangladesh and Vietnam ¹⁷⁶				Placebo, Routine Vaccines Placebo includes same adjuvants, preservatives, formulations as the active group	Any SAE: 0.2% Event: Death: 0.4% Event: Serious adverse event (vaccine-related): 0%
Zaman K. et al.,2012 Bangladesh ¹⁷⁷				Placebo, Routine Vaccines Unsure of adjuvants, preservatives and formulations	Event: Acute diarrhea: 0.18%, Syscat: 7, Sev: Serious Event: Bronchiolitis: 0%, Syscat: 11, Sev: Serious Event: Umbilical infection: 0.18%, Syscat: 11, Sev: Serious Event: Pneumonia: 2.64%, Syscat: 11, Sev: Serious Event: Head injury: 0%, Syscat: 12, Sev: Serious Event: All Serious adverse events: 2.99%, Sev: Serious Event: Death, all causes: 0%, Syscat: 8, Sev: 5 Event: Death, CMV infection: 0%, Sev: 5 Event: Death, Pneumonia: 0%, Sev: 5 Event: Death, Hepatoblastoma: .18%, Sev: 5 Event: Death, UTI sepsis: 0.18%, Sev: 5 Event: Death, Accidental drowning: 0.18%, Sev: 5
Zaman K., et al.,2009 Bangladesh ¹⁷⁵				Placebo, Routine Vaccines Unsure of adjuvants, preservatives and formulations	Event: Unsolicited symptoms: 77.1% Event: Gastroenteritis: 2.08%, Syscat: 7 Event: Any diarrhea: =6/day: 3%, Syscat: 7, Sev: 3 Event: Fever: rectal temperature =38 ? C: 37%, Syscat: 8, Sev: 1-5 Event: Loss of appetite: 35%, Syscat: 14, Sev: 1-5 Event: Vomiting: =1 episode of forceful emptying of partially digested stomach contents =1 h after feeding within a day: 17%, Syscat: 7, Sev: 1-5

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Baxter, et al. 2013, ⁵⁵ Case-centered and cohort	N=415 cases; Location=California; Age=48.5 years (mean), 5-87 years (range); Setting=Kaiser Permanente Northern California (KPNC)	Influenza (TIV), 23-valent pneumococcal polysaccharide, IPV, Tdap, I-typoid, Hepatitis A, Hepatitis B, Td	Medical reviewer aware of study hypothesis, may have influenced case selection	Of the 892 potential cases for which medical records were available, 114 were rejected by the MRAs, and 242 were rejected by the reviewing neurologist, either as incompatible with GBS or because of not enough information or no weakness found in chart review. Of the 550 confirmed cases, 415 were incident within the study period, and patients were KPNC members at the time of GBS onset, so were eligible for inclusion in the analysis	Not discussed	Medical record review	Medical record review	Case-centered: Logistic regression model with a case-centered specification Cohort: Poisson regression	Case-centered: Age and sex matching for expected odds Cohort: age	1995-2006	This work was supported by a subcontract with America's Health Insurance Plans under contract 200-2002-00732 from the CDC, as a part of the Vaccine Safety Datalink.	Table 2. Odds Ratio of Vaccination in a 6- or 10-Week Risk Interval Before Onset of Guillain-Barre Syndrome, Using a Case-Centered Analysis Design OR, 95% CI, p-value 6-week Risk Interval IPV: 7.19 (0.18-281.03), 0.245 Tdap: None (0.16 to NE), 0.249 PPV-23: 0.72 (0.11-2.87), 0.722 Hep A: 2.22 (0.30-10.63), 0.36 Hep B: 0.43 (0.02-2.56), 0.455 Td: 1.43 (0.33-4.56), 0.558 TIV: 1.11 (0.39-3.08), 0.83 10-week Risk Interval IPV: 4.15 (0.11-163.38), 0.39 Tdap: None (.09 to NE), 0.377 PPV-23: 0.44 (0.07-1.72), 0.281 Hep A: 2.00 (0.39-8.74), 0.366 Hep B: 0.24 (0.01-1.46), 0.15	None	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Td: 1.14 (0.32-3.29), 0.783 TIV: 0.99 (0.33-2.70), 0.991 Table 3. Number of Guillain-Barre Syndrome Cases and Crude Rates per 100 000 Person-Years (Cohort analysis) Relative rate, 95% CI, p-value 1.3, (0.75-2.26), 0.35		
Crawford, et al., 2012 ⁵⁹ , Self-controlled case series	N=44 Location=Victoria, Australia Age=48 (median); 7-95 years (range) Setting=An active surveillance system for GBS was established in 10 hospitals in Victoria	Monovalent H1N1 vaccine (Panvax, CSL Limited) TIV (Fluvax, CSL Limited; Vaxigrip, Sanofi Pasteur; Influvac, Abbott)	GBS cases only	Sixty-six cases of probable GBS were identified in the 12-month study period. Three cases were excluded, leaving 63 GBS episodes in 62 individuals. Of these, nine were excluded, as on review they did not meet diagnostic criteria for GBS. Four further confirmed cases were excluded, as the date of	Not discussed	Research assistants obtained informed consent once “possible” GBS cases were identified. A detailed immunisation history was then obtained from study participants and their primary health care physician (following patient consent)	Standard and pseudolikelihood methods	None, self-controlled design	September 30, 2009 to September 30, 2010	This study was funded by CSL Ltd as part of postmarketing surveillance, with financial support for study nurses at each site.	Table 3: Pandemic (H1N1) 2009 influenza A immunisation and Guillain-Barré syndrome: relative incidence (RI) estimates from the self-controlled case series with a 42-day postvaccination risk window Base: 3.41 (0.78-14.97) No seasonal trivalent influenza vaccine: 3.39 (0.77-14.91) No period adjustment: 2.92 (0.75-11.31) Three 2-week	Table 3: Pandemic (H1N1) 2009 influenza A immunisation and Guillain-Barré syndrome: relative incidence (RI) estimates from the self-controlled case series with a 42-day postvaccination risk window Base: 3.41 (0.78-14.97) No seasonal trivalent influenza vaccine: 3.39 (0.77-14.91) No period adjustment: 2.92 (0.75-11.31) Three 2-week	None	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
				onset of symptoms predicated the availability of the monovalent H1N1 vaccine. In six cases, data were only available from the hospital medical record (ie, neither the patient nor primary care physician were available). These cases with incomplete immunisation histories were excluded from the primary analysis, leaving 44 cases.								periods 0–13 days: 3.74 (0.41–34.05) 14–27 days: 3.35 (0.38–29.64) 28–41 days: 3.19 (0.35–28.67) Only Brighton level 1–2 cases: 3.99 (0.82–19.55) Include unconfirmed cases: 2.71 (0.62–11.85) Include incomplete vaccine history: 3.25 (0.75–14.21) Include incomplete vaccine history and second episode: 3.34 (0.76–14.59) Include all: 2.25 (0.54–9.37)		
Irving, et al. 2013, ²³⁶ Case-control	N=486 (243 cases, 243 controls); Location=US; Age=18-44 years; Setting=six health care organizations in the Vaccine Safety Datalink	Influenza (TIV)	No data on possible case ascertainment or vaccine administration differences across health plans	Three hundred eighty-six potential cases of spontaneous abortion were identified electronically; 255 cases were confirmed by medical record review and matched to control group participants. After excluding six	Not discussed	Medical record review	Medical record review	Conditional logistic regression	Maternal age, health care utilization, maternal diabetes, parity	Autumn of 2005 or 2006	Funded through a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732, from the Centers for Disease Control and Prevention	Table 3. Odds of Influenza Vaccination in Cases of Early Pregnancy Loss in Varying Exposure Windows as Compared With Control Group Participants Adjusted ORs, 95% CI, p-value Primary analysis Exposed 1–28 d before reference	None	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
				pairs with unknown vaccination status, one pair with an invalid LMP, and five pairs with fetal demise at less than 5 weeks of gestation, 243 pairs were included in the final analysis.							(CDC).	date: 1.23 (0.53-2.89), 0.63 Exposed more than 28 d before reference date: 1.24 (0.54-2.86), 0.61 Secondary analysis Exposed while pregnant 0.80 (0.36-1.78), 0.58 Exposed before pregnant 2.34 (0.86-6.33), 0.10		
Isai et al., 2012 ⁶¹ , cross-sectional in that both exposure and outcome are ascertained at the same time, but outcomes are ascertained following vaccination in EudraVigilance database	N=50,221 adverse events; Location=European Union; Age=Unknown; Setting=EudraVigilance database	Flu vaccines: Cantagrip, Cultura, Celvapan, Fluval, Focetria, Pandemrix, Panenza	Unsure if EudraVigilance contains AEs from all authorized medicines	Not discussed	Not discussed	Database review	Database review	No statistical comparisons	None	October 1, 2009 to 31 December 31, 2010	Not reported	Analysis 1 included all cases as reported. Analysis 2 used cases assessed as certain, probable or possible according to WHO Causality assessment and available Brighton Collaboration definitions Using analysis 1, the reporting ratio calculated as the percentage of autoimmune ADRs amongst all reported ADRs shows comparable results for nonadjuvanted (0.94% [0.64–1.24]) and adjuvanted (0.60% [0.53–0.67]) vaccines.	None	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												The calculation using analysis 2 (restricted analysis) included 15 cases of autoimmune disorders for nonadjuvanted vaccines and 121 cases for adjuvanted ones. The reporting ratio was 0.37% (0.18–0.56) and 0.26% (0.22–0.31), respectively. For the calculation of reporting rates using the estimated number of vaccinees as the denominator, analysis 1 resulted in a reporting rate of 9.98 (6.81–13.16) per million for nonadjuvanted vaccines and of 6.87 (6.06–7.68) per million for adjuvanted vaccines. Using analysis 2, the reporting rates were respectively 3.94 (1.95–5.94) and 3.01 (2.47–3.55) per million.		
Klein, et al. 2012, ²⁰³ , Retrospective cohort	N=189,629; Location=California; Age=9–26 years; Setting=Kai	Quadrivalent human papillomavirus vaccine (HPV4)	Entire population	Not discussed	Not discussed	Electronic medical record review	Electronic medical record review	Conditional logistic regression	None	2006–2008	This study was funded by Merck & Co.	Table 2. Summary of HCUP Categories With Elevated ORs Following HPV4 Vaccination in the Combined	None	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	Sutter Permanente in California											ED/Hospital Setting, All Doses Combined Viral infection Days 1-60 Risk Interval: 1.1 (0.9-1.3) Days 1-14 Risk Interval: 1.5 (1.2-2.0) Attention-deficit, conduct, and disruptive behavior disorders Days 1-60 Risk Interval: 1.5 (1.2-2.0) Days 1-14 Risk Interval: 1.5 (1.0-2.3) Disease of nervous system and sense organs Days 1-60 Risk Interval: 1.0 (0.9-1.1) Days 1-14 Risk Interval: 1.2 (1.0-1.3) Ear conditions Days 1-60 Risk Interval: 1.2 (1.0-1.5) Days 1-14 Risk Interval: 1.5 (1.1-1.9) Disorders of peripheral nervous system		

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment				
												Days 1-60 Risk Interval: 2.1 (1.0-4.2) Days 1-14 Risk Interval: 2.1 (0.8-5.7)	Diseases of circulatory system Days 1-60 Risk Interval: 1.1 (1-1.3) Days 1-14 Risk Interval: 1.2 (1.0-1.5)	Diseases of heart Days 1-60 Risk Interval: 1.1 (0.1-1.3) Days 1-14 Risk Interval: 1.3 (1.0-1.6)	COPD and bronchiectasis Days 1-60 Risk Interval: 1.5 (1-2.2) Days 1-14 Risk Interval: 1.8 (1.1-3.2)	Asthma Days 1-60 Risk Interval: 1.2 (1.1-1.4) Days 1-14 Risk Interval: 1.21 (1-1.47)	Disease of skin and subcutaneous tissue Days 1-60 Risk Interval: 1.0 (0.8-	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												1.1) Days 1-14 Risk Interval: 1.5 (1.2-1.9) Skin and subcutaneous tissue infections Days 1-60 Risk Interval: 1.1 (0.9-1.4) Days 1-14 Risk Interval: 1.8 (1.3-2.4) Cellulitis and abscess Days 1-60 Risk Interval: 1.1 (0.8-1.4) Days 1-14 Risk Interval: 1.6 (1.2-2.3) Diseases of musculoskeletal system and connective tissue Days 1-60 Risk Interval: 1.1 (1-1.2) Days 1-14 Risk Interval: 1.2 (1.0-1.4) Spondylosis, disc intervertebral disorders, back problems Days 1-60 Risk Interval: 1.1 (0.9-1.3) Days 1-14 Risk		

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Interval: 1.4 (1.0-1.8) Congenital anomalies Days 1-60 Risk Interval: 1.6 (1.1-2.3) Days 1-14 Risk Interval: 2.5 (1.6-4.0) Other congenital anomalies Days 1-60 Risk Interval: 1.8 (1.1-3.0) Days 1-14 Risk Interval: 3.6 (2.0-6.3) Fever of unknown origin Days 1-60 Risk Interval: 1.1 (0.9-1.4) Days 1-14 Risk Interval: 1.5 (1.0-2.1) Lymphadenitis Days 1-60 Risk Interval: 1.0 (0.6-1.8) Days 1-14 Risk Interval: 2.3 (1.2-4.4) Diabetes mellitus Days 1-60 Risk Interval: 2.2 (1.1-4.4) Days 1-14 Risk		

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Interval: 2.5 (1.0-6.4) Attention-deficit disorder Days 1-60 Risk Interval: 1.7 (1.1-2.8) Days 1-14 Risk Interval: 2.1 (1.1-4.1) Personality disorders Days 1-60 Risk Interval: 1.8 (0.9-3.4) Days 1-14 Risk Interval: 2.8 (1.3-6.4) Disorders of teeth and jaw Days 1-60 Risk Interval: 1.1 (0.6-2.1) Days 1-14 Risk Interval: 2.6 (1.2-5.6) Congenital anomalies Days 1-60 Risk Interval: 1.7 (1.0-2.8) Days 1-14 Risk Interval: 2.7 (1.4-5.3) Other congenital anomalies Days 1-60 Risk Interval: 2.3 (1.1-5.0)		

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Days 1-14 Risk Interval: 5.1 (2.2-11.9)		
Lee et al. 2011, Self-controlled design or a current versus historical comparison ⁶⁰	N=4,512,366 flu doses in eight U.S. managed care organizations; Age=6 mos to >=65 years;	H1N1 monovalent inactivated (MIV) and live, attenuated (LAMV) vaccines separate from seasonal trivalent inactivated (TIV) and live, attenuated (LAIV) influenza vaccines	Comprehensive population group	Not discussed	Not discussed	Medical record review	Medical record review. For Guillain-Barré syndrome (GBS), all cases were adjudicated by at least two neurologists	SCRI: maximized sequential probability ratio test (MaxSPRT) Current versus historical comparison: Either the Poisson-based MaxSPRT or the Poisson-based conditional MaxSPRT (CMaxSPRT) was used logistic regression	Case-centered logistic regression: case date, age group, gender, and site.	2009-2010	Centers for Disease Control	No significant associations were noted during sequential analyses for Guillain-Barré syndrome, most other neurologic outcomes, and allergic and cardiac events. For MIV, a statistical signal was observed for Bell's palsy for adults aged >=25 years on March 31, 2010, using the self-controlled approach. Subsequent analyses revealed no significant temporal cluster. Case-centered logistic regression adjusting for seasonality demonstrated an OR for Bell's palsy of 1.26 (95% CI=0.97, 1.63).	None	
Matheson et al. 2010, Prospective cohort ²⁴⁷	N=5,556 members of Tasmanian Longitudinal Health Study, Age=7 to 44 yrs;	Diphtheria, Tetanus, Pertussis, Polio, Smallpox	Representative sample of Tasmania residents	At this follow-up, 88.1% (n = 7,562) were traced. A postal survey was sent to all traced participants and a response rate of 78.4% (n = 5,729)	Not discussed	School medical records which contained parent reported immunization history	Questionnaire - self-report	Multivariable regression models were used to estimate relative risks while adjusting for confounders. Cox regression	Multivariate: Sex, birthplace and history of bacterial infection, parental smoking, and parental asthma, history of viral infection, birth	2004	National Health and Medical Research Council of Australia, Clifford Craig Foundation of Tasmania and Victorian & Tasmanian	Associations with immunization (Adjusted RR) Current asthma at age 44 Diphtheria: 0.93 (0.71, 1.22) Tetanus: 1.05 (0.81, 1.38) Pertussis: 0.87 (0.68, 1.12)	None	Giles GG, Lickiss N, Gibson HB. Respiratory symptoms in Tasmanian adolescents: a follow up of the 1961 birth cohort.

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
				was achieved. This analysis is based on questionnaire data collected in 1968 and follow-up in 2004. School medical record data were available for 5,556 (97%) of 5,729.				was used to estimate the association between childhood immunizations and asthma developing after the age of 7 yrs	order and social class in 2004. We also investigated any effect modification related to having childhood asthma by age 7 yrs. Cox: sex, bacterial infections, birth order and social class in 1968. The Cox model with asthma onset after the age of 21 yrs as the outcome was also adjusted for adult smoking, and socio-economic status in adult life		Asthma Foundations	Polio: 0.92 (0.69, 1.24) DTP: 0.92 (0.73, 1.16) Eczema by age 44 Diphtheria: 1.05 (0.92, 1.20) Tetanus: 1.07 (0.94, 1.21) Pertussis: 0.99 (0.88, 1.12) Polio: 1.03 (0.89, 1.18) DTP: 1.04 (0.93, 1.16) Food allergy by age 44 Diphtheria: 1.09 (0.81, 1.47) Tetanus: 1.03 (0.78, 1.35) Pertussis: 1.11 (0.84, 1.47) Polio: 1.11 (0.80, 1.53) DTP: 1.02 (0.80, 1.30) Hay fever by age 44 Diphtheria: 1.02 (0.92, 1.12) Tetanus: 1.03 (0.94, 1.13) Pertussis: 1.03 (0.93, 1.13) Polio: 1.04 (0.93, 1.16) DTP: 1.05 (0.97, 1.15) Association between immunization and incident asthma from age 8 to age 44		Aust N Z J Med 1984; 14: 631-7. Jenkins MA, Hopper JL, Bowes G, Carlin JB, Flander LB, Giles GG. Factors in childhood as predictors of asthma in adult life. BMJ 1994; 309: 90-3.

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												(Adjusted HR, 8-44 years) Diphtheria: 1.07 (0.83,1.39) Tetanus: 1.13 (0.88,1.45) Pertussis: 1.04 (0.82,1.32) Polio: 1.19 (0.89,1.60) DTP: 1.05 (0.85,1.31)		
Nakajima et al. 2007, Prospective cohort ²⁴⁸	N=8443; Location=Tasmania; Age=7-30 years; Setting=Primary schools (Tasmanian Asthma Study, a prospective population-based cohort study which started in 1968)	Diphtheria, tetanus, pertussis, polio (Study notes in Australia, there were two forms of polio vaccine—the Salk (injected polio vaccine) which was commonly used before the introduction of Sabin (oral polio vaccine) in 1966.	Children born in the UK, US, New Zealand, Canada or South Africa were more likely to have been immunized against diphtheria, pertussis and polio than those born in Tasmania. Study notes parental health attitudes might have affected both seeking a diagnosis of an atopic condition and having their children vaccinated, which might have contributed to the risk of atopic conditions being associated with	Subjects were lost to follow-up at each stage of the study. In 1968 99% response rate; In 1974 87.2% response rate; In 1991 74.7% response rate	Not discussed	School medical records filled out by parents	Parental report	Multiple logistic regression	Sex, birthplace, history of bacterial infection, parental smoking, parental asthma, history of viral infection, birth order and history of pneumonia Asthma after 13 years: Sex, parental asthma Eczema after 7 years: Age 7 years asthma status, sex, parental asthma, parental smoking Food allergy after 7 years:	Authors collected information from the 1968 survey and the 1974 and 1991 follow-up studies.	The 1968 and 1974 studies were funded by the Tasmanian Asthma Foundation and the 1991 study was funded by the National Health Medical Research Council. Computerization of the 1974 study was funded by the Victorian Asthma Foundation.	OR (95% CI) for asthma by age 7 years Diphtheria: 1.33 (1.06-1.68), p=0.01 Tetanus: 1.16 (0.94-1.43), p=0.16 Pertussis: 1.19 (0.96-1.47), p=0.11 Polio: 1.05 (0.83-1.32), p=0.69 OR (95% CI) for asthma by age 13 years Diphtheria: 1.28 (0.98-1.66), p=0.07 Tetanus: 1.18 (0.89-1.55), p=0.24 Pertussis: 1.11 (0.91-1.37), p=0.31 Polio: 1.03 (0.79-1.35), p=0.84 OR (95% CI) for eczema by age 7 years Diphtheria: 1.53 (1.13-2.07), p=0.01 Tetanus: 1.53 (1.15-2.04), p=0.01	Not reported	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
		vaccination. Such a detection bias is more likely with eczema, given that eczema is more likely to develop in early childhood, during which timeframe childhood immunizations are given. The observed associations may also suggest that there is a higher likelihood of childhood immunizations in those already at greater risk of atopic disease. However the authors did not believe this to be the case. Potential recall biases and differential misclassification of exposure							Age 7 years asthma status, sex, parental smoking Hay fever after 7 years: Age 7 years asthma status, sex, parental smoking, feeding in 1st 3 months			Pertussis: 1.46 (1.10-1.93), p=0.01 Polio: 1.36 (1.00-1.87), p=0.05 OR (95% CI) for food allergy by age 7 years Diphtheria: 1.47 (1.04-2.07), p=0.03 Tetanus: 1.26 (0.93-1.71), p=0.14 Pertussis: 1.39 (1.01-1.91), p=0.04 Polio: 1.44 (1.00-2.07), p=0.05 OR (95% CI) for hay fever by age 7 years Diphtheria: 1.20 (0.94-1.53), p=0.15 Tetanus: 1.05 (0.84-1.31), p=0.67 Pertussis: 1.10 (0.88-1.38), p=0.42 Polio: 0.88 (0.69-1.12), p=0.30 OR (95% CI) for asthma after age 13 years Diphtheria: 0.58 (0.26-1.27), p=0.17 Tetanus: 0.79 (0.32-1.96), p=0.61 Pertussis: 0.57 (0.30-1.09), p=0.09 Polio: 0.50 (0.22-1.10), p=0.08 OR (95% CI) for eczema after age 7 years Diphtheria: 0.68 (0.36-1.29), p=0.24		

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Tetanus: 0.76 (0.38-1.52), p=0.44 Pertussis: 0.57 (0.35-0.93), p=0.03 Polio: 0.76 (0.39-1.48), p=0.43 OR (95% CI) for food allergy after age 7 years Diphtheria: 1.50 (0.81-2.79), p=0.20 Tetanus: 0.98 (0.54-1.75), p=0.94 Pertussis: 0.88 (0.57-1.35), p=0.55 Polio: 1.02 (0.57-1.83), p=0.94 OR (95% CI) for hay fever after age 7 years Diphtheria: 1.19 (0.75-1.89), p=0.45 Tetanus: 1.09 (0.67-1.78), p=0.72 Pertussis: 0.96 (0.67-1.38), p=0.83 Polio: 0.78 (0.47-1.28), p=0.32		
Ray et al. 2011, Prospective cohort and case-control ²⁴⁹	N=1,660 (415 Rheumatoid arthritis cases, 1245 controls) Location=C A; Age=15-59 years; Setting=Kaiser Permanente Northern CA	Hepatitis B, influenza	Cases and controls from the same HMO population. Cases more likely to be African American or Latino than controls. Controls more likely to have missing data for race.	None noted	Not discussed	Database record review and medical record review	Medical record review	Cohort study: Poisson regression. Case control: conditional logistic regression	Cohort study: adjusted for age, sex, race, number of health care visits within 1 year Case-control: sex, race, number of utilization visits. Matched on age and utilization	1997 to 1999	Centers for Disease Control and Prevention Vaccine Safety Datalink Project	RR from cohort study 90 Day Exposure Interval Hepatitis B: 1.44 (0.46, 4.51), p=0.53 Influenza: 0.72 (0.45, 114), p=0.16 180 Day Exposure Interval Hepatitis B: 1.67 (0.74, 3.77), p=0.22 Influenza: 1.36 (1.03, 1.80), p=0.03 365 Day Exposure	Not reported	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	members											Interval Hepatitis B: 1.23 (0.58, 2.63), p=0.59 Influenza: 1.34 (1.06, 1.69), p=0.01 OR from case-control study 90 Day Exposure Interval Hepatitis B: 1.5 (0.4, 5.2), p=0.55 Influenza: 0.7 (0.4, 1.2), p=0.14 180 Day Exposure Interval Hepatitis B: 2.0 (0.8, 5.1), p=0.14 Influenza: 1.1 (0.8, 1.6), p=0.57 365 Day Exposure Interval Hepatitis B: 1.4 (0.6, 3.1), p=0.39 Influenza: 1.1 (0.9, 1.5), p=0.43 730 Day Exposure Interval Hepatitis B: 1.0 (0.5, 2.1), p=0.91 Influenza: 1.1 (0.8, 1.4), p=0.59		
Siberry et al. 2010, ²⁵⁰ Phase I/II open label safety and immunogenicity trial with no control group	N=305 HIV positive adolescents; Age=11–24 years; Setting=27 US sites of the IMPAACT network	MCV4	Eligibility criteria for were: (1) age of 11 to 24 years; (2) on stable antiretroviral therapy (ART) or not receiving ART for at least 90 days prior to vaccination; (3) no personal or	324 original participants, 305 final	Subjects included in the immunogenicity analysis (n = 305) were similar to those not included except that	Vaccines were administered by authors	Observation and self-report	Multivariable logistic regression	Not reported	Between July and October of 2007	National Institute of Allergy and Infectious Diseases cooperative agreement #5 U01 AI41110 with the Pediatric AIDS Clinical	No subjects had GBS. Two subjects had AEs grade >= 3 or higher. Authors ruled out any possible association with MCV4 vaccine.	Lower CD4 count more likely to experience AEs.	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
			family history of Guillain-Barré Syndrome (GBS); and (4) no meningococcal polysaccharide vaccine within last 2 years and no MCV4 at any time		those not included were less likely to be receiving HAART						Trials Group (PACTG) and #1 U01 AI068616 with the IMPAACT Group			
Tokars et al. 2012, Self-controlled analyses ²⁵¹	N= 379 Guillain-Barré Syndrome (GBS) patients; Location=10 US states/metro areas; Age=1-84 years; From Centers for Disease Control and Prevention Emerging Infections Program active, population-based surveillance dataset	H1N1 vaccines	Biases if cases differed from the general population in terms of for example being more likely to be vaccinated	None	Not reported	Self-report or medical record	Active ascertainment through network of neurologists, hospital discharge data and review of medical charts	Conditional Poisson regression	Tested interactions: age group, sex, mode of administration (injected, intranasal, or unknown), whether seasonal influenza vaccine had been received in the 42 days prior to H1N1 vaccine receipt, and the EIP site reporting the data	2009-2010	Not reported	Relative risk Overall: 2.1 (1.2, 3.5) Sex Male: 2.3 (1.2, 4.7) Female: 1.8 (0.8, 3.9) Vaccine type Inactivated: 2.2 (1.3, 3.9) Live attenuated: 1.3 (0.1, 14.1) Unknown: 1.4 (0.2, 9.0) Seasonal vaccine	RRs Age (years) 0.5-24: 3.0 (1.0, 9.1) 25-49: 2.0 (0.7, 5.5) 50-64: 2.1 (0.8, 5.6) ≥65: 1.5 (0.5, 4.3) RRs Age (years) 0.5-24: 3.0 (1.0, 9.1) 25-49: 2.0 (0.7, 5.5) 50-64: 2.1 (0.8, 5.6) ≥65: 1.5 (0.5, 4.3) Sex Male: 2.3 (1.2, 4.7) Female: 1.8 (0.8, 3.9) Vaccine type Inactivated: 2.2 (1.3, 3.9) Live attenuated: 1.3 (0.1, 14.1) Unknown: 1.4 (0.2, 9.0) Seasonal vaccine	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
													within 42 days before H1N1 vaccine No: 2.4 (1.3, 4.5) Yes: 1.6 (0.6, 4.0)	
Velentgas et al. 2012, ²²³ Retrospective cohort study	N=12.6 million; Location=U.S.; Age=11- to 21-year-olds; Setting:Five US health plans	Meningococcal conjugate vaccine (MCV4); meningococcal polysaccharide vaccine (MPSV4), tetanus–diphtheria–acellular–pertussis vaccine (Tdap), tetanus and diphtheria vaccine (Td), tetanus, hepatitis B (HepB), human papillomavirus (HPV), and influenza vaccination	Entire population	Not discussed	Not discussed	Automated claims and enrollment data were used to identify vaccinations. Authors identified MCV4 (ACYW-135-D, Menactra W), meningococcal polysaccharide vaccine (MPSV4), tetanus–diphtheria–acellular–pertussis vaccine (Tdap), tetanus and diphtheria vaccine (Td), tetanus, hepatitis B (HepB), human papillomavirus (HPV), and influenza vaccinations and their associated dates of	Inpatient and outpatient medical claims were searched to identify instances of the ICD-9 code 357.0 (i.e. GBS). Medical charts for potential GBS cases were requested by the health plans from the hospital of treatment or other provider, such as a neurologist, rehabilitation hospital, or primary care provider. Photocopies of relevant sections of the medical record were obtained for adjudication review. GBS case adjudication was performed by a panel of three neurologists under the oversight of one	Incidence rate estimation	None	2005-2008	This study was funded by a contract from Sanofi-Pasteur to Harvard Pilgrim Health Care.	. Risk and attributable risk of GBS after vaccination, according to vaccine type MCV4 Cumulative incidence; one sided upper CI: 0; 2.09 Attributable risk: 0; 1.46 MPSV4 Cumulative incidence; one sided upper CI: 7.79; 37.00 Attributable risk: 7.16; 36.37 Tdap Cumulative incidence; one sided upper CI: 0; 2.49 Attributable risk: 0; 1.86 Td Cumulative incidence; one sided upper CI: 0; 8.02 Attributable risk: 0; 7.39	None	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
						administration using Current Procedural Terminology, Healthcare Common Procedure Coding System, or ICD-9 procedure codes as present in the medical claims data.	of the authors (A.A.A.).					Tetanus Cumulative incidence; one sided upper CI: 0; 106.20 Attributable risk: 0; 105.57 Influenza Cumulative incidence; one sided upper CI: 3.49; 11.00 Attributable risk: 2.86; 10.37 HepB Cumulative incidence; one sided upper CI: 8.04; 38.10 Attributable risk: 7.40; 37.47 HPV Cumulative incidence; one sided upper CI: 3.42; 10.80 Attributable risk: 2.79; 10.17		
Wise et al. 2012, Retrospective cohort ²⁵²	N=408 Guillain–Barré syndrome (GBS) cases; Location=US; Age=0-65+ (no average measures given); Setting=10 sites of the Emerging	Inactivated and live attenuated influenza A (H1N1) 2009 monovalent vaccines (in study referred to collectively as pH1N1 vaccine)	No details on recruitment for EIP, but study focused on entire population	707 suspected GBS cases 282 did not meet Brighton criteria (40%) Of the remaining 425, 14 were excluded due to GBS onset prior to 10/1/09 Medical records reviewed for	Not discussed	Dates of receipt of pH1N1 vaccine and 2009–2010 seasonal influenza vaccine (hereafter referred to as seasonal vaccine) were recorded from vaccination cards, vaccine	Active, population-based surveillance for GBS cases. Trained surveillance officers reviewed medical records to gather standardized information on patient characteristics, clinical presentation, and	Estimation of incidence rate ratios using Mantel-Haenszel method	Age (stratification) Age specific RR were adjusted for sex	October 1, 2009, and May 31, 2010	Not reported	RR (95% CI) of GBS (confirmed and probable) pH1N1 vaccine <25: 1.67 (0.58-3.22) 25+: 1.54 (0.90-2.25) Overall: 1.57 (1.02-2.21) Seasonal vaccine <25: 1.78 (0.59-3.48)	Not reported	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
	Infections Program (EIP): California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee			411 GBS cases 408 vaccinated		registries, or providers administering the vaccine, or via self-report (as recorded in the medical record or telephone interview) if a documented source was not available	medical history for every suspected GBS case.					25+: 1.36 (0.84-1.91) Total: 1.43 (0.94-1.89)		
Yih et al. 2012, ²⁵³ Self-controlled risk interval, case-centered, and current-vs.-historical comparison. For GBS and most other outcomes, the SCRI design was used. Case-centered approach was used to adjust for seasonality. For selected rare outcomes, current vs.-historical comparison methods were used	N=3,040,363 doses; Location=US; Age=2-49 years; Setting=Post-Licensure Rapid Immunization Safety Monitoring (PRISM) system. Five health insurance and associated companies with 38 million members and 9 state/city immunization registries contributed records	Monovalent pandemic 2009 H1N1 influenza vaccine	Comprehensive set of data from health insurance companies. No control group	To avoid bias related to time lag in the accrual of health insurance claims data, authors used outcome data only for vaccinations given up to dates in January or February, ensuring nearly complete follow-up through both the risk and control periods.	Not discussed	Insurance company records	Data on outcomes came from insurance claims. For GBS, there was GBS medical record review by experts	SCRI: conditional Poisson regression Case-centered method for GBS: Logistic regression Current-vs.-historical: logistic regression	Case-centered: data partner, sex, and age group Current v historical: data partner, sex, and age group	2009-2010	Food and Drug Administration through America's Health Insurance Plans under Centers for Disease Control and Prevention contract	Risks of Health Outcomes of Interest Occurring After Receipt of a First Dose of Inactivated or Not-Otherwise-Specified 2009 H1N1 Influenza Vaccine: A 95% CI was used for anaphylaxis; 99% CIs were used for all other outcomes shown in the table, to account for multiple testing SCRI analysis Demyelinating disease: 1.01 (0.86-1.20), 0.84 Peripheral nervous system disorders 6 months-24 years: 1.17 (0.84-1.63), 0.24 >=25 years: 0.99 (0.92-1.05), 0.61 Bell's palsy	None	

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												6 months–24 years: 1.21 (0.54-2.69), 0.54 ≥25 years: 1.23 (0.88-1.73), 0.12 Other cranial nerve disorders ≥25 years: 1.07 (0.89-1.28), 0.35 Allergic reactions ≥6 months: 1.17 (0.92-1.49), 0.10 Hemorrhagic stroke 6 months–24 years: 1.13 (0.46-2.82), 0.72 ≥25 years: 0.85 (0.62-1.16), 0.18 Ischemic stroke 6 months–24 years: 2.17 (0.61-7.73), 0.12 ≥25 years: 0.92 (0.77-1.10), 0.23 Seizures 6 months–24 years: 0.55 (0.22-1.37), 0.09 ≥25 years: 0.50 (0.15-1.65), 0.13 Current-vs.-historical analysis Demyelinating disease 6 months–24 years: 0.95 (0.54-1.68), 0.82 Encephalitis/myelitis/encephalomyelitis ≥6 months: 0.85 (0.28-2.54), 0.69 Other cranial nerve		

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												disorders 6 months–24 years: 0.85 (0.55-1.32), 0.35 Ataxia ≥6 months: 0.72 (0.41-1.28), 0.14 Anaphylaxis ≥ 6 months: 0.75 (0.29-1.90), 0.54 2009 H1N1 Vaccines Without Proximate Seasonal Influenza Vaccine SCRI analysis Demyelinating disease ≥25 years: 1.00 (0.79-1.28), 0.98 Peripheral nervous system disorders 6 months–24 years: 0.88 (0.50-1.55), 0.57 ≥25 years: 1.12 (1.01-1.23), 0.003 Bell's palsy 6 months–24 years: 1.25 (0.37-4.24), 0.64 ≥25 years: 1.65 (1.03-2.64), 0.006 Other cranial nerve disorders ≥25 years: 1.07 (0.82-1.40), 0.51 Allergic reactions ≥6 months: 1.06 (0.71-1.60), 0.69 Hemorrhagic stroke 6 months–24 years:		

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												1.00 (0.23-4.42), 1.00 >=25 years: 0.93 (0.59-1.45), 0.66 Ischemic stroke 6 months-24 years: 2.50 (0.29-21.6), 0.27 >=25 years: 0.88 (0.69-1.13), 0.18 Seizures 6 months-24 years: 0.25 (0.03-1.92), 0.08 >= 25 years: 0.44 (0.09-2.09), 0.18 Current-vs.-historical analysis Demyelinating disease 6 months-24 years: 0.82 (0.40-1.68), 0.47 Encephalitis/myelitis/encephalomyelitis >= 6 months: 0.62 (0.15-2.49), 0.37 Other cranial nerve disorders 6 months-24 years: 0.87 (0.51-1.49), 0.52 Ataxia >=6 months: 0.67 (0.35-1.29), 0.12 Anaphylaxis >=6 months: 0.67 (0.22-2.00), 0.47 2009 H1N1 Vaccines With		

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												Concomitantly Administered Seasonal Influenza Vaccine SCRI analysis Demyelinating disease >=25 years: 1.48 (0.80-2.72), 0.10 Peripheral nervous system disorders 6 months–24 years: 1.50 (0.56-4.01), 0.29 >=25 years: 1.12 (0.88-1.43), 0.22 Bell's palsy 6 months–24 years: 4.00 (0.22-71.2), 0.21 >=25 years: 1.33 (0.43-4.15), 0.51 Other cranial nerve disorders >=25 years: 1.72 (0.97-3.07), 0.02 Allergic reactions >= 6 months: 2.41 (1.15-5.07), 0.002 Hemorrhagic stroke 6 months–24 years: 2.00 (0.21-18.6), 0.42 >=25 years: 1.13 (0.32-3.93), 0.81 Ischemic stroke 6 months–24 years: 2.00 (0.09-46.9), 0.57 >=25 years: 1.05 (0.49-2.25), 0.88 Seizures 6 months–24 years:		

Evidence Table 5. Postmarketing studies: Mixed population

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
												1.00 (0.12-8.19), 1.00 Current-vs.-historical analysis Demyelinating disease 6 months–24 years: 1.04 (0.31-3.45), 0.93 Encephalitis/myelitis/encephalomyelitis ≥6 months: 3.45 (0.70-17.0), 0.05 Other cranial nerve disorders 6 months–24 years: 0.86 (0.32-2.34), 0.70 Ataxia ≥ 6 months: 1.01 (0.22-4.60), 0.98 Anaphylaxis ≥6 months: 1.20 (0.16-9.04), 0.86		

Evidence Table 6. Vaccinated versus unvaccinated: Mixed population

Author- Year-Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Mallory R. M et al., 2010 US ¹⁰⁷	Controlled Clinical Trial	3	Mean age: 9, Age range: 2 - 17, Percent female: 51%	Influenza - monovalent H1N1, not reported, MedImmune, derived by genetic reassortment of the hemagglutinin and neuraminidase genes from the wild-type A/California/7/2009 virus and the remaining 6 gene segments from an attenuated master donor virus (in sucrose phosphate buffer and egg allantoic fluid, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Intranasal	Dose1: 1 Days Dose2: 29 Days	Event: # with any AE Dose 1: 18.1% Event: # with any AE Dose 2: 13.7% Event: Blood and lymphatic system Dose 1, Syscat: 1 Event: Blood and lymphatic system Dose 2, Syscat: 1 Event: Ear and labyrinth Dose 1, Syscat: 4 Event: Ear and labyrinth Dose 2, Syscat: 4 Event: Eye Dose 1, Syscat: 6 Event: Eye Dose 2, Syscat: 6 Event: GI Dose 1, Syscat: 7 Event: GI Dose 2, Syscat: 7 Event: General disorders and administration site conditions Dose 1, Syscat: 8 Event: General disorders and administration site conditions Dose 2, Syscat: 8 Event: Immune system Dose 1, Syscat: 10 Event: Immune system Dose 2, Syscat: 10 Event: Infections and infestations Dose 1, Syscat: 11 Event: Infections and infestations Dose 2, Syscat: 11 Event: Injury, poisoning, procedural complications Dose 1, Syscat: 12 Event: Injury, poisoning, procedural complications Dose 2, Syscat: 12	# with any AE Dose 1: OR 1.103 (0.537-2.267) # with any AE Dose 2: OR 0.985 (0.448-2.167) Ear and labyrinth Dose 2: OR 0.251 (0.015-4.066) GI Dose 1: OR 1.017 (0.367-2.818) GI Dose 2: OR 0.882 (0.281-2.774) Infections and infestations Dose 1: OR 0.756 (0.149-3.834) Infections and infestations Dose 2: OR 1.821 (0.404-8.219) Injury, poisoning, procedural complications Dose 2: OR 0.759 (0.078-7.414)
Vesikari T. et al., 2004 Belgium, Germany ¹⁷⁴	Controlled Clinical Trial	5	Sample size: 59, Age range: 1 - 44	Rotavirus, Rotarix, GlaxoSmithKline, Derived from the parent strain 89-12 single dose of a minimum of 10(6.1) focus forming unit (ffu) of RIX4414 or placebo, with prior administration of Mylanta® as buffer, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Oral	Dose1: 0 Days	Any adverse event: 0% Any SAE: 0%	

Evidence Table 6. Vaccinated versus unvaccinated: Mixed population

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
Mallory R. M. et al.,2010 US ¹⁰⁷			Event: Musculoskeletal and connective tissue Dose 1: 2%, Syscat: 15 Event: Musculoskeletal and connective tissue Dose 2, Syscat: 15 Event: Nervous System Dose 1, Syscat: 17 Event: Nervous System Dose 2, Syscat: 17 Event: Respiratory, thoracic, and mediastinal Dose 1 Event: Respiratory, thoracic, and mediastinal Dose 2 Event: Skin and subcutaneous tissue Dose 1, Syscat: 23 Event: Skin and subcutaneous tissue Dose 2, Syscat: 23 Syscat: 1		Event: # with any AE Dose 1: 16.7% Event: # with any AE Dose 2: 13.6% Event: Blood and lymphatic system Dose 1, Syscat: 1 Event: Blood and lymphatic system: 0%, Syscat: 1 Event: Ear and labyrinth Dose 1: 0%, Syscat: 4 Event: Ear and labyrinth Dose 2: 1.52%, Syscat: 4 Event: Eye Dose 1: 0%, Syscat: 6 Event: Eye Dose 2: 0%, Syscat: 6 Event: GI Dose 1: 7.58%, Syscat: 7 Event: GI Dose 2: 6.1%, Syscat: 7 Event: General disorders and administration site conditions Dose 1: 0%, Syscat: 8 Event: General disorders and administration site conditions Dose 2: 0%, Syscat: 8 Event: Immune System Dose 1: 0%, Syscat: 10 Event: Immune System Dose 2: 0%, Syscat: 10 Event: Infections and infestations Dose 1, Syscat: 11 Event: Infections and infestations Dose 2: 3.03%, Syscat: 11 Event: Injury, poisoning, procedural complications Dose 1: 0% Event: Injury, poisoning, procedural complications Dose 2***: 1.5%, Syscat: 12
Phonrat, B. et al. 2013 ²⁵⁴ Thailand				Placebo Placebo includes same adjuvants, preservatives, formulations as the active group	Any adverse event : 69.5% Any SAE : 0% Event: SAE : 0% Event: Arthalgia (1st immunization) : 2.07(ofcases)% , Syscat: 15 Event: Arthalgia (2nd immunization) : 2.41(ofcases)% , Syscat: 15
Vesikari T. et al.,2004 Belgium, Germany ¹⁷⁴	Rotavirus, Rotarix, GlaxoSmithKline, Derived from the parent strain 89-12. 10.7 ffu or 10.4 ffu of RIX4414 or placebo administered with prior administration of Maalox® as buffer., Adjuvant: Not Reported, Preservative: Not reported, Delivery:	Dose1: 0 Days	Event: At least 1 solicited AE (10.7 ffu group) Event: At least 1 solicited AE (10.4 ffu group): 0% AE: 0%	Placebo Unsure of adjuvants, preservatives and formulations	Event: at least 1 solicited SAE (1-3 yr): 100% Event: Any SAE (18-44 yr): 0%

Evidence Table 7. Postmarketing studies: Pregnant women

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
Omer,2011, Retrospective cohort ³³⁵	4,168 pregnant women and their newborns enrolled in Georgia Pregnancy Risk Assessment Monitoring System (PRAMS), mean age not reported but 11.5% were <19, 12.5% were >35, and 76% were 19-35. Recruitment occurred in the flu seasons of 2004-2006.	Inactivated influenza	PRAMS is a selected segment intended to oversample black women and women who gave birth to Small for Gestational Age (SGA) babies; within PRAMS, black women are significantly less likely to get influenza vaccine	Not applicable	Yes, see selection bias	Self-report	Self-report	logistic regression	Influenza activity period (pre-influenza activity period, periods of least local/regional influenza activity, period of widespread influenza activity) maternal variables (age, multiple births, medical risk factors, labor/delivery complications, birth defects, smoking during pregnancy, hypertension, insurance coverage, maternal diabetes, use of multivitamins, alcohol use during pregnancy, black race, education, marital status) Covariates were tested for the separate multivariate models by testing which potential confounders moved the relationship between	Following 2004-2005 and 2005-2006 influenza seasons	Emory University, National Foundation for Infectious Diseases	Prematurity was defined as birth < 37 weeks gestation; SGA was defined as birth weight <10th percentile for gestational age. Infants born during the putative vaccine season to women who were vaccinated were less likely to be premature compared to infants born in the same period to unvaccinated mothers (adjusted OR 0.60, 95% CI 0.38 to 0.94) During the period of local influenza activity, this relationship increased (adjusted OR 0.44, 95% CI 0.26 to 0.73)) During the widespread influenza activity period, this relationship was greatest: adjusted OR 0.80, 95% CI 0.11. to 0.74) Also during the widespread influenza activity period, compared with newborns of unvaccinated mothers, newborns of vaccinated mothers had 69% lower odds of being SGA (adjusted OR	NA	Maternal immunization is associated with reduced likelihood of prematurity and SGA except during the pre-influenza activity period.

Evidence Table 7. Postmarketing studies: Pregnant women

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment
									immunization and birth outcome closer to 1.			0.31, 0.13 to 0.75).		
Whitehouse et al. 2011, Prospective cohort ²⁵⁵	N=804 participants from the Western Australian Pregnancy Cohort; Location=Australia; Age=infants followed up to 20 years;	MMR	Study assessed autism scores in low and high income groups and found no differences (because those in the study tended to be more socially advantaged). Authors note, "our inclusion criterion for the gastrointestinal group – presentation to hospital, general practitioner, or clinic with gastrointestinal symptoms – may have biased this sample towards families more inclined to seek health services rather than children in actual need of assistance"	Data available for 37.6% of the 2,138 children whose whereabouts were still known (2,868 in original cohort)	Study noted that participant's differed from birth cohort in that they were: more likely to have mothers who had completed secondary school at the time of pregnancy and to come from families who lived above the income 'poverty' threshold.	Parental report	Self-report (questionnaire)	Bivariate analyses	Primary purpose was to study association of early GI problems and ASD	Recruitment from 1989 to 1992, followed for 20 years	National Health and Medical Research Council, Raine Medical Research Foundation, University of Western Australia, the University of Western Australia Faculty of Medicine, Dentistry and Health Sciences, Telethon Institute for Child Health Research, and the Women's and Infants Research Foundation	Mean autism quotient (AQ) did not differ between those who had received MMR, those who had received measles and mumps vaccine, and those who had received neither. p =0.65	None	
Xu et al. 2012, retrospective cohort ²³⁷	n=198 pregnant women who enrolled before 20 weeks gestation; US/Vaccine and Medication	H1N1	Self-selected population (women who contacted the system)	n/a	Participants were all pregnant women	n/r	n/r	time-independent (naive) and time-dependent covariate Cox models to account for left-truncation	vaccine exposure (1st or 2nd trimester) Previous spontaneous abortion (SAB) events (0, 1, 2, >=3) smoking	n/r	DHHS	Controls (n=40, no vaccine) No. SAB: 4 SAB rate: 34% Vaccination between LMP and date of conception(n=5) No. SAB: 1 SAB rate: 25%	Data not shown, although none of the confounders was associated with enrollment time	Aim of this study was not to assess effect of H1N1 on SAB rate but to illustrate use of survival

Evidence Table 7. Postmarketing studies: Pregnant women

Author, Year, Study Design	Population studied	Vaccines included	Selection Bias	Attrition, non-response	Participation bias	Ascertainment of vaccination status	Ascertainment of health outcome	Analysis conducted	Adjusted for these potential confounders	Period data collected	Study funder	Primary results regarding vaccine	Any risk factor findings	Comment	
	in Pregnancy Surveillance System study						(due to possible enrollment later than conception) and vaccine exposure timing	maternal age asthma Dependent variable: SAB				RR (time-independent): 1.13(0.13, 10.24) RR (time-dependent): 1.13(0.13, 10.24) Vaccination during 1st trimester (n=119) No. SAB: 4 SAB rate: 18.6% RR (time-independent): 0.48(0.08, 2.70) RR (time-dependent): 0.79(0.19, 3.23) Vaccination during 2nd trimester (by definition, fetal loss>20weeks is still-birth, not SAB)(n=34) No. SAB: 0 Vaccination during 1st or 2nd trimester (n=153) No. SAB: 4 SAB rate: 16.5% RR (time-independent): 0.58(0.10, 3.24) RR (time-dependent): 0.97(0.24, 3.94)			analysis methods to study effects of vaccines on SAB

Evidence Table 7. Postmarketing studies: Pregnant women

Author- Year- Country	Study Design	McHarm Score	Population	Vaccine1	Timing1	Adverse Event1	OR, 95% CI, versus unvaccinated group
Dodds, L. et al. 2012 ²³⁴ Canada	Cohort	NC	Sample size : 9647, Age range: <20 - >=35, Percent female: 100%	Influenza (inactivated) , NR , Not reported , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Not reported	Dose1: NG	Event: Small for gestational age <10th percentile : 6.6% , Syscat: 18 Event: Low birth weight : 4% , Syscat: 18 Event: Term low birth weight : 1.4% , Syscat: 18 Event: Preterm birth : 6.5% , Syscat: 18 Event: Composite outcome : 3.7% , Syscat: 18	Composite outcome: OR 0.823 (0.636-1.067) Low birth weight: OR 0.702 (0.547-0.901)** Preterm birth: OR 0.842 (0.689-1.028) Small for gestational age <10th percentile: OR 0.749 (0.614-0.914)** Term low birth weight: OR 0.751 (0.488-1.154)
Fell D. B. et al.,2012 Canada ²³¹	Cohort	4	Sample size: 55570, Mean age: NR, Age range: <18 - 40+, Percent female: 100%	Influenza - monovalent H1N1, NR, Adjuvant: Not Reported, Preservative: Not reported, Delivery: Not reported	Dose1: NR	Event: Preterm birth (<37w): 5.9%, Syscat: 18, Sev: 1 Event: Very preterm (<32w): 0.6%, Syscat: 18, Sev: 2 Event: Small for gestational age: <10th percentile: 8.3%, Syscat: 18, Sev: 2 Event: Small for gestational age: <3rd percentile: 2%, Syscat: 18, Sev: 3-4 Event: 5min APGAR score <7: 1.19%, Syscat: 18 Event: Fetal Death: 0.26%, Syscat: 18, Sev: 5	5min APGAR score <7: OR 0.925 (0.794-1.078) Fetal Death: OR 0.595 (0.439-0.806)** Preterm birth (<37w): OR 0.915 (0.853-0.981)** Small for gestational age: <10th percentile: OR 0.836 (0.788-0.887)** Small for gestational age: <3rd percentile: OR 0.74 (0.66-0.829)** Very preterm (<32w): OR 0.717 (0.584-0.879)**
Lin T. H. et al.,2012 Taiwan ²³⁰	Cohort	7	Sample size: 396, Mean age: 32.4 (exposed), Percent female: 100%	Influenza (inactivated), AdimFlu-S®, Adimmune Corporation, Taichung, Taiwan, The vaccine evaluated in this study was produced by Adimmune Corporation (Taichung, Taiwan) using standard techniques for the production of seasonal inactivated influenza vaccines. The vaccine is a monovalent, unadjuvanted, inactivated, split-virus vaccine. One shot	Dose1: 0 Days	Any adverse event: 35.6% Event: Infant: Hyperbilirubinemia neonatal: 2.5%, Syscat: 13 Event: Infant: Dermatitis contact: 5.4%, Syscat: 23 Event: Infant: Upper respiratory tract infection: 3.0%, Syscat: 22 Event: Infant: Seborrheic dermatitis: 4.0%, Syscat: 23 Event: Infant: Respiratory distress: 2.0%, Syscat: 22 Event: Maternal: Fever, cough, runny nose, nasal congestion, and skin itching: 2.0%, Syscat: 8 Event: Maternal: At least one adverse event: 8.6% Event: Maternal: Severe adverse event: 0%	Infant: Dermatitis contact: OR 1.882 (0.682-5.194) Infant: Hyperbilirubinemia neonatal: OR 0.083 (0.032-0.214)** Infant: Respiratory distress: OR 0.66 (0.183-2.375) Infant: Seborrheic dermatitis: OR 2.042 (0.605-6.895) Infant: Upper respiratory tract infection: OR 0.742 (0.253-2.18) Maternal: At least one adverse event: OR 0.371 (0.202-0.68)**

				(0.5ml) of AdimFlu-S®influenza A (H1N1) vaccine contains 15 µg of New York Medical College X-179A reassortant of the A/California/7/2009 (H1N1) like strain. Adjuvant: Adjuvant Free, Preservative: Not reported, Delivery: Intradermal			
Nordin, J.D. et al. 2013 ²³³ USA	Cohort	1	Sample size : 223898, Mean age: 30.8, Age range: 14 - 49, Percent female: 100%, Percent pregnant: Percent Pregnant: 100%	Influenza (inactivated) , NR , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Not reported	Dose1: NR NR	<p>Any adverse event : 0.077% , Sev: (3 d f/u, full cohort)</p> <p>Event: cellulitis (3 day f/u) : 1.3% , Syscat: 23</p> <p>Event: seizures (3 day f/u) : 0.1% , Syscat: 17</p> <p>Event: Altererd mental status (3 day f/u) : 2% , Syscat: 19</p> <p>Event: Autonomic disorders (42d f/u) : 0.1% , Syscat: 17</p> <p>Event: Cranial nerve disorders (42 d) : 0% , Syscat: 17</p> <p>Event: Degeneration of CNS (42 d) : 0.1% , Syscat: 17</p> <p>Event: Demyelinating disease (42 d) : 0.1% , Syscat: 17</p> <p>Event: Peripheral neuropathy or neuritis (42 d) : 1.6% , Syscat: 17</p> <p>Event: Guillan Barre syndrome (42 d) : 0% , Syscat: 17</p> <p>Event: Meningoencephalitides (42 d) : 0.4% , Syscat: 17</p> <p>Event: Movement disorders (42 d) : 0% , Syscat: 17</p> <p>Event: Myoneural disorders (42 d) : 0.1% , Syscat: 17</p> <p>Event: Paralytic syndromes (42 d) : 0.1% , Syscat: 17</p> <p>Event: Psychoses (42 d) : 0.7% , Syscat: 19</p> <p>Event: Spinocerebellar disease (42 d) : 0% , Syscat: 17</p> <p>Event: Myocarditis/pericarditis (42 d) : 0.1% , Syscat: 2</p> <p>Event: Thrombocytopenia (42 d, full cohort)) : 10.4% , Syscat: 1</p> <p>Event: Any neurologic event (42 d, first trimester exposures) : 4.1% , Syscat: 17, 19</p> <p>Event: Any neurologic event (42d, full cohort) : 22% , Syscat: 17, 19</p> <p>Event: Thrombocytopenia (42d, first trimester exposure) : 6% , Syscat: 1</p> <p>Event: Any event (3d, first trimester exposure) :16%</p>	<p>Altererd mental status (3 day f/u): OR 1.329 (0.69-2.563)</p> <p>Autonomic disorders (42d f/u): OR 0.487 (0.054-4.361)</p> <p>Meningoencephalitides (42 d): OR 5.849 (0.608-56.235)</p> <p>Peripheral neuropathy or neuritis (42 d): OR 1.95 (0.876-4.34)</p> <p>cellulitis (3 day f/u): OR 0.928 (0.437-1.972)</p>

Evidence Table 7. Postmarketing studies: Pregnant women

Richards, J.L. et al. 2013 ²³² US	Cohort	2	Sample size : 3327, Mean age: 31.2, Age range: NR, Percent female: 100%	Influenza (inactivated), Influenza - monovalent H1N1 , NR , Adjuvant: Not Reported , Preservative: Not reported , Delivery: Not reported	Dose1: NR NR	Event: Pre-term birth (27-36 wk) : 7.6% , Syscat: 18 , Sev: 1,2 Event: Preterm Birth (27-33 wk) : 1.7% , Syscat: 18 , Sev: 1,2 Event: Preterm Birth (34-36 wk) : 6.0% , Syscat: 18 , Sev: 1,2 Event: Low Birth weight (<2500g) : 6.4% , Syscat: 18 , Sev: 1, 2 Event: Small for gestational age : 9.3% , Syscat: 18 , Sev: 1, 2	Low Birth weight (<2500g): OR 0.706 (0.522-0.956)** Pre-term birth (27-36 wk): OR 0.602 (0.461-0.787)** Preterm Birth (27-33 wk): OR 0.505 (0.297-0.859)** Preterm Birth (34-36 wk): OR 0.657 (0.486-0.889)** Small for gestational age: OR 1.144 (0.868-1.508)
---	--------	---	---	--	-----------------	---	---

Evidence Table 7. Postmarketing studies: Pregnant women

Author- Year- Country	Vaccine2	Timing2	Adverse Event2	Control group	Adverse Events Control
Dodds, L. et al. 2012 ²³⁴ Canada				Nothing	Event: Small for gestational age <10th percentile : 8.6% , Syscat: 18 Event: Low birth weight : 5.6% , Syscat: 18 Event: Term low birth weight : 1.9% , Syscat: 18 Event: Preterm birth : 7.7% , Syscat: 18 Event: Composite outcome : 4.5% , Syscat: 18
Fell D. B. et al. 2012 Canada ²³¹				Nothing	Event: Preterm birth (<37w): 6.41%, Syscat: 18, Sev: 1 Event: Very preterm (<32w): 0.84%, Syscat: 18, Sev: 2 Event: Small for gest age: <10th percentile: 9.77%, Syscat: 18, Sev: 2 Event: Small for gest age: <3rd percentile: 2.68%, Syscat: 18, Sev: 3-4 Event: 5min APGAR score <7: 1.28%, Syscat: 18 Event: Fetal death: 0.43%, Syscat: 18, Sev: 5
Lin T. H. et al., 2012 Taiwan ²³⁰	:			Nothing	Any adverse event: 49% Event: Infant: Hyperbilirubinemia neonatal: 22.8%, Syscat: 13 Event: Infant: Dermatitis contact: 2.9%, Syscat: 23 Event: Infant: Upper respiratory tract infection: 3.9%, Syscat: 22 Event: Infant: Seborrheic dermatitis: 1.9%, Syscat: 23 Event: Infant: Respiratory distress: 2.9%, Syscat: 22 Event: Maternal: At least one adverse event: 20.2% Event: Maternal: Severe adverse event: 0% AE: 0%
Nordin, J.D. et al. 2013 ²³³ USA				Nothing	Any adverse event : 6.8% , Sev: (3 d f/u, full cohort) Event: cellulitis (3 day f/u) : 1.4% , Syscat: 23 Event: seizures (3 day f/u) : 0% , Syscat: 17 Event: Altererd mental status (3 day f/u) : 1.5% , Syscat: 19 Event: Autonomic disorders (42d f/u) : .3% , Syscat: 17 Event: Cranial nerve disorders (42 d) : 0% , Syscat: 17 Event: Degeneration of CNS (42 d) : 0% , Syscat: 17 Event: Demyelinating disease (42 d) : 22% , Syscat: 17 Event: Peripheral neuropathy or neuritis (42 d) : 1.5% , Syscat: 17

				<p>Event: Guillan Barre syndrome (42 d) : .1% , Syscat: 17</p> <p>Event: Meningoencephalitides (42 d) : .2% , Syscat: 17</p> <p>Event: Movement disorders (42 d) : 0% , Syscat: 17</p> <p>Event: Myoneural disorders (42 d) : .1% , Syscat: 17</p> <p>Event: Paralytic syndromes (42 d) : .1% , Syscat: 17</p> <p>Event: Psychoses (42 d) : .4% , Syscat: 19</p> <p>Event: Spinocerebellar disease (42 d) : .1% , Syscat: 17</p> <p>Event: Myocarditis/pericarditis (42 d) : 0% , Syscat: 2</p> <p>Event: Thrombocytopenia (42 d, full cohort)) : 11.5%</p> <p>Event: Any neurologic event (42 d, first trimester exposures) : 3.8% , Syscat: 17</p> <p>Event: Any neurologic event (42d, full cohort) : 0.03% , Syscat: 17</p> <p>Event: Thrombocytopenia (42d, first trimester exposure) : 20% , Syscat: 1</p> <p>Event: Any event (3 d, first trimester exposure) : 31%</p> <p>AE: 0.02%</p> <p>AE: 0%</p>
Richards, J.L. et al. 2013 ²³² US			Nothing	<p>Event: Preterm birth (27-36wk) : 12.1% , Syscat: 18 , Sev: 1, 2</p> <p>Event: Preterm (27-33 wk) : 3.3% , Syscat: 18 , Sev: 1, 2</p> <p>Event: Preterm (34-36wk) : 8.8% , Syscat: 18 , Sev: 1, 2</p> <p>Event: Low birth weight (<2500g) : 8.8% , Syscat: 18 , Sev: 1, 2</p> <p>Event: Small for gestational age : 8.2% , Syscat: 18 , Sev: 1, 2</p>

Appendix D. Excluded Studies and Background Papers

Articles Could Not Be Obtained – 5

1. Blatter M. Open trial to evaluate the safety and immunogenicity of a fifth (booster) dose of diphtheria, tetanus, acellular pertussis vaccine in healthy children. Unpublished; Report No.: Internal clinical trial report (014). June 1996.
2. Fox S. Study confirms rotavirus vaccine-intussusception link. Infections in Medicine. 2001 Apr;18(4):182-. PMID: WOS:000168263900004.
3. Gustafsson L., Hallander H.O., Gothe fors L. An immunogenicity and safety study of combined adsorbed tetanus, low dose diphtheria and acellular pertussis vaccine (TdaP5v and TdaP1v) given as a school-leaving booster to 14–15-year old adolescents primed with a five-component acellular pertussis vaccine at 3, 5 and 12 months of age and a booster dose at 5 1/2 years of age. Unpublished. September 2011.
4. Santosham M, Hill J, Wolff M, et al. Erratum: Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk Native American population (The Pediatric Infectious Disease Journal, Vol. 10, February 1991, pp. 113-117). Pediatric Infectious Disease Journal. 1991 1991;10(5):369. PMID: 1991195710.
5. Taranger J., Trollfors B. Safety and immunogenicity of combined vaccines against diphtheria, tetanus, pertussis and polio at six years of age. Unpublished; 1996:January. Report No.: Internal clinical trial report (007B). January 1996.

Rejected for Participants (Animal or In-Vitro Study) – 20

1. Abraham E. Intranasal Immunization with Bacterial Polysaccharide Containing Liposomes Enhances Antigen-Specific Pulmonary Secretory Antibody-Response. *Vaccine*. 1992;10(7):461-8. PMID: WOS:A1992HV88400007.
2. Bellinzoni RC, Blackhall J, Baro N, et al. Efficacy of an inactivated oil-adjuvanted rotavirus vaccine in the control of calf diarrhoea in beef herds in Argentina. *Vaccine*. 1989 1989;7(3):263-8. PMID: 1989174507 MEDLINE PMID 2551102 (<http://www.ncbi.nlm.nih.gov/pubmed/2551102>).
3. Bucardo F, Rippinger CM, Svensson L, et al. Vaccine-derived NSP2 segment in rotaviruses from vaccinated children with gastroenteritis in Nicaragua. *Infection, Genetics and Evolution*. 2012 August;12(6):1282-94. PMID: 2012327099.
4. Choi NW, Estes MK, Langridge WHR. Mucosal immunization with a ricin toxin B subunit-rotavirus NSP4 fusion protein stimulates a Th1 lymphocyte response. *Journal of Biotechnology*. 2006 24;121(2):272-83. PMID: 2006012524 MEDLINE PMID 16181698 (<http://www.ncbi.nlm.nih.gov/pubmed/16181698>).
5. Cui YL, Zhang XM, Gong Y, et al. Immunization with DnaJ (hsp40) could elicit protection against nasopharyngeal colonization and invasive infection caused by different strains of *Streptococcus pneumoniae*. *Vaccine*. 2011 Feb;29(9):1736-44. PMID: WOS:000288058500003.
6. Dorea JG. Integrating experimental (in vitro and in vivo) neurotoxicity studies of low-dose thimerosal relevant to vaccines. *Neurochemical Research*. 2011 June;36(6):927-38. PMID: 2011250772 MEDLINE PMID 21350943 (<http://www.ncbi.nlm.nih.gov/pubmed/21350943>).
7. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. *Journal of Experimental Medicine*. 1969 Jun 1;129(6):1367-84. PMID: 4977283.
8. Hainisch EK, Brandt S, Shafti-Keramat S, et al. Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses. *Equine Veterinary Journal*. 2012 Jan;44(1):107-11. PMID: 21895749.
9. Iosef C, Van Nguyen T, Jeong KI, et al. Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes. *Vaccine*. 2002 15;20(13 14):1741-53. PMID: 2002110438 MEDLINE PMID: 11906761 (<http://www.ncbi.nlm.nih.gov/pubmed/11906761>).
10. Koyama S, Aoshi T, Tanimoto T, et al. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. *Science Translational Medicine*. 2010

2010;2(25):25ra4. PMID: 2010309645 MEDLINE
(<http://www.ncbi.nlm.nih.gov/pubmed/20424013>).

11. Nepper CA, Seastone CV. Mechanisms of Immunologic Paralysis by Pneumococcal Polysaccharide. Iv. Comparison of Polysaccharide and Whole Organisms. *Journal of Immunology*. 1964 Nov;93:867-71. PMID: 14239947.
12. Ranheim T, Mathis PK, Joelsson DB, et al. Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq (R)). *Journal of Virological Methods*. 2006 Feb;131(2):193-201. PMID: WOS:000235264500012.
13. Roldao A, Vieira HLA, Charpilienne A, et al. Modeling rotavirus-like particles production in a baculovirus expression vector system: Infection kinetics, baculovirus DNA replication, mRNA synthesis and protein production. *Journal of Biotechnology*. 2007 Oct;128(4):875-94. PMID: 2007113507 MEDLINE PMID 17289202
(<http://www.ncbi.nlm.nih.gov/pubmed/17289202>).
14. Rubin SA, Afzal MA. Neurovirulence safety testing of mumps vaccines--historical perspective and current status. *Vaccine*. 2011 Apr 5;29(16):2850-5. PMID: 21334386.
15. Shen Z, Lei H. Expression of hBD-2 induced by 23-valent pneumococcal polysaccharide vaccine, Haemophilus influenzae type b vaccine and split influenza virus vaccine. *Molecular Medicine Reports*. 2012 October;6(4):733-8. PMID: 2012488666.
16. Soto PC, Stein LL, Hurtado-Ziola N, et al. Relative Over-Reactivity of Human versus Chimpanzee Lymphocytes: Implications for the Human Diseases Associated with Immune Activation. *Journal of Immunology*. 2010 Apr;184(8):4185-95. PMID: WOS:000276625800020.
17. Spadaccini A, Virnik K, Ni YS, et al. Stable expression of a foreign protein by a replication-competent rubella viral vector. *Vaccine*. 2010 Feb;28(5):1181-7. PMID: WOS:000275122200008.
18. Thiele S, Borschewski A, Kuchler J, et al. Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions. *Clinical & Vaccine Immunology: CVI*. 2011 Jul;18(7):1058-66. PMID: 21562115.
19. Wise RP, Iskander J, Pratt RD, et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. *JAMA*. 2004 Oct 13;292(14):1702-10. PMID: 15479935.
20. Xu PL, Iwata M, Leong S, et al. Highly virulent strains of *Pseudomonas solanacearum* that are defective in extracellular-polysaccharide production. *Journal of Bacteriology*. 1990 Jul;172(7):3946-51. PMID: 2163393.

Rejected for Language (Not English) – 9

1. Benefits and risks of vaccination against papillomavirus human ORIGINAL (NON-ENGLISH) TITLE Beneficios y riesgos de la vacunacion contra el virus del papiloma humano. Ginecologia y Obstetricia de Mexico. 2011 December;79(12):803-7. PMID: 2012155624 MEDLINE PMID 22384535 (<http://www.ncbi.nlm.nih.gov/pubmed/22384535>).
2. Akazawa M. Economic analysis of vaccine programs. Japanese Journal of Clinical Pharmacology and Therapeutics. 2010 September;41(5):245-52. PMID: 2010626428.
3. Autret E, Jonville-Bera AP, Galy-Eyraud C, et al. [Thrombocytopenic purpura after isolated or combined vaccination against measles, mumps and rubella]. Therapie. 1996 Nov-Dec;51(6):677-80. PMID: 9164004.
4. Forster J. Current rotavirus vaccines. Efficacy and cost-effectiveness. Monatsschrift Kinderheilkunde. 2005 Sep;153(9):831-+. PMID: WOS:000232710300003.
5. Li YP, Zhang SM, Ye Q. Safety and immunogenicity of the diphtheria, tetanus, acellular pertussis plus hemophilus influenza type b combined vaccine (DTaP-Hib) to Chinese infants. Zhongguo ji hua mian yi = Chinese journal of vaccines and immunization. 2010 Apr;16(2):97-104.
6. Minodier P, Noel G, Blanc P, et al. Rotavirus vaccines and the risk of intussusception. Archives de Pediatrie. 2007 Jun;14(6):618-20. PMID: WOS:000247302100035.
7. Mrozek-Budzyn D, Majewska R, Kieltyka A, et al. [Lack of association between thimerosal-containing vaccines and autism]. ORIGINAL (NON-ENGLISH) TITLE Brak związku miedzy ekspozycja na szczepionki zawierajace tiomersal i rozwojem autyzmu u dzieci. Przeglad Epidemiologiczny. 2011 2011;65(3):491-5.
8. Yang SP, Li JY, Yan XX, et al. A review on adverse events following immunization of meningococcal vaccines. Chinese Journal of Evidence-Based Medicine. 2011 2011;11(12):1468-70. PMID: 2012080945.
9. Zahedpasha Y, Ahmadpour Kacho M, Pour Nasrollah M, et al. Immune response in preterm infants to hepatitis B vaccine. Journal of Babol University of Medical Sciences. 2011;13(4) PMID: 2011408656.

Rejected for Conference Abstract – 191

1. Global Advisory Committee on Vaccine Safety, 6-7 June 2006. Weekly Epidemiological Record. 2006 Jul 14;81(28):273-8. PMID: 16841398.
2. Global Advisory Committee on Vaccine Safety, 12-13 June 2007. Weekly Epidemiological Record. 2007 Jul 20;82(28-29):252-9. PMID: 17642098.
3. Global Advisory Committee on Vaccine Safety, 12-13 December 2007. Weekly Epidemiological Record. 2008 Jan 25;83(4):37-44. PMID: 18219807.
4. Global Advisory Committee on Vaccine Safety, 17-18 December 2008. Weekly Epidemiological Record. 2009 Jan 30;84(5):37-40. PMID: 19180768.
5. Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. Weekly Epidemiological Record. 2009 Aug 7;84(32):325-32. PMID: 19860024.
6. Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2010. Allergy, Asthma and Clinical Immunology. 2010;6(2):2010-11.
7. Pneumococcal immunization in older adults. Clinical Geriatrics. 2010 June;18(6):13-4. PMID: 2010389740.
8. Ackerman K, Cohen DC, Erickson RA. Hepatitis B Vaccination Induced Idiopathic Thrombocytopenic Purpura. Gastroenterology. 2011 May;140(5):S976-S. PMID: WOS:000290167304500.
9. Ahmed S, Perveen I. Safety, Immunogenicity and reactogenicity of recombinant hepatitis B vaccine Engerix(trademark)-B. Immunology. 2011 December;135 SUPPL. 1:81.
10. Al Qudah Z, Abukwaik W, Souayah N. Stroke after vaccination in United States. A report from the CDC/FDA vaccine adverse event reporting system. [1990-2010. Neurology. 2012;78(1):2012-04.
11. Ali AK. Vaccine-associated guillain-barre syndrome: A pharmacovigilance analysis of data in the United States' vaccine adverse event reporting system (1990-2009). Value in Health. 2011 May;14(3):A113-A4.
12. Allwin R, Gauer S, Roessel, et al. Efficacy and side effects of H1N1 vaccination in renal transplant and dialysis patients. Transplant International. 2011 September;24 SUPPL. 2:289.
13. Alvarez MM, Fernandez CG, Exposito AG. Antibody response to the standard hepatitis B vaccination in patients with rheumatoid arthritis and ankylosign spondylitis treated with infliximab. Arthritis and Rheumatism. 2011;63(10):1316.

14. Alvarez-Soria MJ, Hernandez-Gonzalez A, Carrasco-Garcia de Leon S, et al. Demyelinating disease and papillomavirus vaccine: Report of three cases. *Journal of Neurology*. 2010 June;257 SUPPL. 1:S119.
15. Andreas J, Jenke A, Weckelmann A, et al. Incidence, management and protective factors of intussusception in children: Results from a nationwide german surveillance. *Journal of Pediatric Gastroenterology and Nutrition*. 2009 May;48 SUPPL. 3:E52-E3.
16. Anh DD, Thiem VD, Hutagalung Y, et al. Immunogenicity, Reactogenicity and Safety of the Oral Live Attenuated Human Rotavirus Vaccine RIX4414(Rotarix (TM)) Oral Suspension (Liquid Formulation) in Vietnamese Infants. *International Journal of Infectious Diseases*. 2008 Dec;12:E147-E. PMID: WOS:000263287800365.
17. Aqua KA, Basu P, Petit RG. ADXS11-001 immunotherapy targeting HPV-E7: Preliminary safety data from two phase 2 studies in women with CIN 2/3 and with recurrent/refractory cervical cancer. *Journal of Immunotherapy*. 2011 November-December;34(9):700.
18. Autret-Leca E, Daubin C, Poggi P, et al. Pneumococcal conjugate vaccine: national monitoring of serious adverse effects. *Fundamental & Clinical Pharmacology*. 2009 Jun;23:88-. PMID: WOS:000268185600444.
19. Baluch A, Humar A, Egli A, et al. A randomized controlled trial of high-dose intradermal vs. standard intramuscular influenza vaccine in solid organ transplant recipients. *American Journal of Transplantation*. 2012 May;12 SUPPL. 3:53-4.
20. Benoit B, Claire PN, Vincent M, et al. Safety and Efficacy of an Inactivated, Unadjuvanted Vaccine Against the Novel Influenza A Variant (H1N1v) in Renal Transplant Recipients (INSERM C09-32, Transfluvac Study). *American Journal of Transplantation*. 2011 Apr;11:78-. PMID: WOS:000289318400160.
21. Bernal N, Alberto E, Hernandez M, et al. Safety and Reactogenicity of a 10-Valeant Pneumococcal Non-Typeable Haemophilus influenzae Protein D-Conjugate Vaccine (PHiD-CV) in Filipino Infants. *International Journal of Infectious Diseases*. 2008 Dec;12:E153-E. PMID: WOS:000263287800379.
22. Bharadwaj AS, Rathod A, Badheka A, et al. Vaccination Serology Status (Non-Pneumococcal and Non-Influenza) and Cardiovascular Mortality: Insights from Nhanes Iii. *Journal of the American College of Cardiology*. 2011 Apr;57(14):E556-E. PMID: WOS:000291695100557.
23. Black S, Shinefield H, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine (Wyeth-Lederle) in infancy. *Pediatric Research*. 1996 Apr;39(4):986-. PMID: WOS:A1996UD23800986.

24. Black SB, Shinefield HR, Hiatt RH, et al. Safety and Efficacy of Hboc Conjugate Haemophilus Influenzae Type-B Vaccine in 61,000 Infants. *Pediatric Research*. 1991 Jan;29(1):116-. PMID: WOS:A1991EP11000024.
25. Boen M, DeLeon D, Bennett CL, et al. Gardasil: A false sense of immunity? *Journal of Clinical Oncology*. 2010;28(15):2010-06.
26. Borba EF, Saad CGS, Calich ALG, et al. The novel pandemic influenza A (H1N1) 2009 vaccine: Low rate of Seroconversion after vaccination in systemic lupus erythematosus. *Arthritis and Rheumatism*. 2010;2010;62 SUPPL. 10:481.
27. Brauner S, Kvarnstrom M, Gorgen S, et al. Vaccination of patients with primary Sjogren's syndrome reveals hyperreactive B cell compartment with a skewed maturation pattern. *Annals of the Rheumatic Diseases*. 2011 March;70 SUPPL. 2:A67.
28. Broder K, Haber P, Miller E, et al. Detecting signals in the vaccine adverse event reporting system. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S358.
29. Brookhart SMA, Li J, Paeglow C, et al. Characterizing vaccine-associated risk using natural smoothing. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S260-S1.
30. Callejo D, Lopez-Polin A, Blasco JA. Cost utility of human papilloma virus vaccine in Spain. *Value in Health*. 2010 November;13(7):A258.
31. Camacho LH, Betts RF, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZV(HT)) in adults with hematologic malignancy (HM). *Blood*. 2010;116(21):2010-12.
32. Ceschi A, Ingram K, Curkovic I, et al. Adverse drug reactions: The most commonly involved drugs and organ systems in pharmacovigilance reports at the University Hospital Zurich. *British Journal of Clinical Pharmacology*. 2009 October;68 SUPPL. 1:50.
33. Chambers CD, Johnson DL, Xu R, et al. Challenges and design of a prospective, observational cohort study to assess the risk of spontaneous abortion following administration of human papillomavirus (HPV) bivalent (Types 16 and 18) recombinant vaccine. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S358.
34. Chambers CD, Schatz M, Mitchell AA, et al. The vaccines and medications in pregnancy surveillance system (VAMPSS): Launch of a new system for post-marketing surveillance. *Birth Defects Research Part A - Clinical and Molecular Teratology*. 2010 May;88(5):406.
35. Chenaf C, Zenut M, Eschalier A. Thrombocytopenic Purpura and vaccination: Where do we stand? *Fundamental and Clinical Pharmacology*. 2010 April;24 SUPPL. 1:73.

36. Chioato A, Noseda E, Stevens M, et al. Efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to secukinumab 150 mg: Preliminary study results. *Arthritis and Rheumatism*. 2011;63(10):1822.
37. Chlebna-Sokol D, Szynczewska E. Immunogenicity and Safety of Heptavalent Pneumococcal Conjugate Vaccine in Very Preterm Infants - Draft Report. *Acta Paediatrica*. 2009 Oct;98:101-2. PMID: WOS:000269862100263.
38. Cordero E, Perez-Ordonez A, Aydillo T, et al. Immunogenicity, efficacy, and safety of the pandemic influenza A/H1N1 vaccine in solid organ transplant recipients. *Clinical Microbiology and Infection*. 2011 May;17 SUPPL. 4:S48.
39. Cowan ML, Chon WJ, Josephson M, et al. Impaired response to influenza vaccination in kidney transplant recipients. *American Journal of Transplantation*. 2012 May;12 SUPPL. 3:S55.
40. Crespo M, Collado S, Mir M, et al. Renal patients showed a poor response to the 2009 pandemic new influenza a H1N1 virus vaccine. *Transplant International*. 2011 September;24 SUPPL. 2:42.
41. Dagan R, Kassis I, Sarov B, et al. Safety and Immunogenicity of Oral Rhesus Rotavirus Tetravalent Vaccine (Orrtv) in Neonates. *Pediatric Research*. 1991 Jan;29(1):117-. PMID: WOS:A1991EP11000026.
42. Daniel BS, Venugopal SS, Murrell DF. Complete resolution of chronic multiple verruca vulgaris treated with quadrivalent human papilloma virus (HPV) vaccine. *Australasian Journal of Dermatology*. 2011 May;52 SUPPL. 1:21.
43. Davies EG, Ashton L, McDermott E, et al. Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in ataxia telangiectasia: evidence of a genotype/phenotype correlation. *Clinical and Experimental Immunology*. 2008 Nov;154:115-6. PMID: WOS:000262727500218.
44. de Boer AW, McNeil S, Halperin SA, et al. Safety and Immunogenicity of a Novel Hepatitis B Vaccine Adjuvanted with Immunostimulatory Sequence (Iss) in Renal Predialysis and Dialysis Patients. *American Journal of Kidney Diseases*. 2010 Apr;55(4):A51-A. PMID: WOS:000276054500100.
45. De La Hoz F, Alvis N, Gamboa O, et al. Cost-effectiveness analysis of the introduction of the varicellavaccine in Colombia. *Value in Health*. 2011 May;14(3):A118.
46. De Lavallade H, Garland PL, Sekine T, et al. 2009 pandemic influenza A H1N1 vaccination in the patients with hematologic malignancies: Requirement for repeated dosing to optimize seroprotection. *Blood*. 2010;116(21):2010-12.
47. Del Pozo Garcia G, Gallego C, Gomez JJ, et al. Possible indicators of intussusception post-rotavirus vaccine. *Pediatric Radiology*. 2011 May;41 SUPPL. 1:S337-S8.

48. Dieleman J, Lecomte C, Schuemie M, et al. Safety of adjuvanted pandemic influenza vaccines: Background rate of narcolepsy in Europe. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S260.
49. Dieleman JP, Romio SS, de Vries CS, et al. Guillain-Barre Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccines - A Multinational Case Control Study in Europe. *Pharmacoepidemiology and Drug Safety*. 2011 Aug;20:S258-S9. PMID: WOS:000294946600573.
50. Dodds L, McNeil S, Scott J, et al. Influenza vaccination in pregnancy. *American Journal of Epidemiology*. 2011 1;173 SUPPL. 11:S40.
51. Doran I, Shaharabani H, Kariv R, et al. Influenza A H1N1 Vaccine is Safe and Effective in Patients With Inflammatory Bowel Disease (IBD) Treated With Thiopurines and TNF-alpha Blockers. *Gastroenterology*. 2011 May;140(5):S771-S2. PMID: WOS:000290167303427.
52. Doug BR, Xu Y, Zhang YL, et al. Efficacy and safety of 23-valent pneumococcal polysaccharide vaccine in prevention of lower respiratory tract infections in the Chinese elderly: A prospective concurrent controlled trial. *Chest*. 2005 Oct;128(4):148S-S. PMID: WOS:000232800300060.
53. Duan ZP, Zou HB, Chen Y, et al. Efficacy and Safety of Double Vs. Standard Dose Recombinant Hepatitis B Vaccine in Infants Born to Hbsag-Positive Mothers: An Interim Report of a Multi-Center, Randomized and Controlled Trial. *Hepatology*. 2011 Oct;54:884A-5A. PMID: WOS:000295578003329.
54. Farez MF, Ysraelit MC, Fiol M, et al. H1N1 vaccination does not increase risk of exacerbation in MS: A self-controlled case-series study. *Multiple Sclerosis*. 2011 October;17(10 SUPPL. 1):S133-S4.
55. Farinas-Alvarez C, Nunez-Viejo MA, Ansorena-Pool L, et al. Impact of pneumococcal vaccination in preventing invasive pneumococcal disease in Cantabria (SPAIN). *Clinical Microbiology and Infection*. 2011 May;17 SUPPL. 4:S243-S4.
56. Faure C, Koller A, Hartmann K, et al. Development of a large safety database using studies conducted during the clinical development and post-marketing of a virosomal aluminium-free hepatitis a vaccine. *Value in Health*. 2011 November;14(7):A285-A6.
57. Ferreira GLC, Almeida JM, Alena K. Implementation of panenza A(H1N1) 2009 pandemic vaccine pharmacovigilance plan. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S356-S7.
58. Fontaine H, Chazallon C, Mancini-Bourgine M, et al. Relapse after analogues treatment discontinuation is not prevented by DNA vaccination in chronic hepatitis B (ANRS HB 02 VAC-ADN). *Hepatology*. 2011 October;54 SUPPL. 1:1064A.

59. Franca ILA, Ribeiro ACM, Aikawa NE, et al. Influenza a H1N1/2009 vaccine in rheumatic disease patients under anti-TNF therapy: Safety and response. *Arthritis and Rheumatism*. 2011;63(10):2619.
60. Fremond ML, Duchamp M, Guerin V, et al. CD4 T-cell response to pandemic H1N1 specific vaccine after HSCT in pediatric recipients. *Blood*. 2010;116(21):2010-12.
61. Galindo CM, Rosillon D, Holick CN, et al. Post-marketing study of autoimmune diseases following vaccination with human papillomavirus bivalent (types 16 and 18) recombinant vaccine in females in the US: Rationale and design. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S359.
62. Garbe E, Andersohn F, Bronder E, et al. Association between drug use and acute immune thrombocytopenia in adults: Results from the berlin case-control surveillance study. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S147.
63. Geier DA, Young HA, Geier MR. Thimerosal exposure & increasing trends of premature puberty in the vaccine safety datalink. *Indian Journal of Medical Research*. 2010 April;131(4):500-7. PMID: 2010231604 MEDLINE PMID 20424300 (<http://www.ncbi.nlm.nih.gov/pubmed/20424300>).
64. George C, Taylor DN, Cathaud O. Electronic data capture (EDC) with digital pen and paper in a phase I clinical trial of a new influenza vaccine. *Journal of Clinical Pharmacology*. 2011 September;51(9):1332.
65. Gilbert CL, Klopfer SO, Schodel FP, et al. Immunogenicity and Safety of a Hepatitis B Vaccine Manufactured by a Modified Process in Healthy Adults 50-64 years of age and \geq 65 years of age. *Journal of the American Geriatrics Society*. 2011 Apr;59:S171-S2. PMID: WOS:000289524600500.
66. Goldstone S. Efficacy of the quadrivalent hpv vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men. *Sexually Transmitted Infections*. 2011 July;87 SUPPL. 1:A352.
67. Goss MA, Lievano F, Seminack M, et al. No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy: Five year pregnancy registry data. *Birth Defects Research Part A - Clinical and Molecular Teratology*. 2012 May;94(5):367.
68. Gregg M, Blackhouse G, Loeb M, et al. Economic evaluation of a cluster randomized controlled trial of an influenza immunization program directed at healthy children. *Value in Health*. 2012 June;15(4):A242.
69. Grimaldi-Bensouda L, Alperovitch A, Besson G, et al. Guillain-barre syndrome, influenza-like illnesses and influenza vaccination during seasons with and without circulating a/H1N1 viruses. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S259-S60.

70. Grimaldi-Bensouda L, Michel M, Viallard JF, et al. A multicenter case-control prospective study to assess the risk of immune thrombocytopenia (ITP) associated with vaccines in adults using the PGRx-ITP registry. *Blood*. 2011;118(21):2011-12.
71. Guissa VR, Aikawa NE, Sallum AM, et al. Influenza a H1N1/2009 vaccine in juvenile dermatomyositis: Reduced response in patients under immunosuppressive agents. *Arthritis and Rheumatism*. 2011;63(10):2020.
72. Haber P, Izurieta H, Patel M, et al. Intussusception reports following RotaTeq (TM) vaccination: Vaccine adverse event reporting system (VAERS), 3/2006-02/2007. *Pharmacoepidemiology and Drug Safety*. 2007 Aug;16:S61-S2. PMID: WOS:000248820200129.
73. Halperin SA, Gupta A, Jeanfreau R, et al. Clinical immunogenicity and reactogenicity of menveo(registered trademark) (MenACWY-CRM) versus menactra(registered trademark) (MCV4) in healthy 2-to-10-year-old children. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2010 Winter;21(4):184.
74. Han GR, Pan C, Jiang HX, et al. A PROSPECTIVE STUDY FOR THE EFFICACY AND SAFETY OF THE COMBINATION WITH 200 IU HBIG AND 20 UG RECOMBINANT HBV VACCINE FOR THE PREVENTION OF PERINATAL TRANSMISSION OF HEPATITIS B VIRUS (HBV) IN THE INFANTS BORN TO HBEAG plus AND HIGHLY VIREMIC MOTHERS. *Hepatology*. 2010 Oct;52(4):531A-2A. PMID: WOS:000288775600430.
75. Hansen J, Black S, Shinefield H, et al. Lack of association of seizures with receipt of seven valent pneumococcal conjugate vaccine (Prevnar (c), Wyeth). *Clinical Infectious Diseases*. 2001 Oct;33(7):1149-. PMID: WOS:000171226900381.
76. Harandi AA, Pakdaman H, Sahraian MA, et al. Infectious diseases, related vaccinations, and risk of multiple sclerosis later in life: A case-control study. *Neurology*. 2012;78(1):2012-04.
77. Harandi AM, Medaglini D, Shattock RJ. Vaccine adjuvants: A priority for vaccine research. *Vaccine*. 2010 Nov;28(12):2363-6. PMID: 2010132270 MEDLINE PMID 20064476 (<http://www.ncbi.nlm.nih.gov/pubmed/20064476>).
78. Harris K. A retrospective study of adverse drug reactions following the administration of influenza, pneumococcal and/or tetanus vaccines to geriatric nursing facility patients. *Journal of the American Geriatrics Society*. 2000 Aug;48(8):S129-S. PMID: WOS:000088887000538.
79. Harris MA, Shen H, Marion S, et al. Associations between viral infections and Parkinson's disease in a case-control study. *Movement Disorders*. 2011 May;26 SUPPL. 2:S51-S2.
80. Heijstek MW, Heijstek M, Ott De Bruin L, et al. Vaccinations in pediatric autoimmune and autoinflammatory diseases: A systematic literature review. *Clinical and Experimental Rheumatology*. 2011 March-April;29(2):453.

81. Hitchon CA, Peschken CA, Mailley T, et al. Environmental and genetic contributions to disease severity in north american natives with early inflammatory arthritis. *Arthritis and Rheumatism*. 2011;63(10):2139.
82. Hua W, Tiernan R, Steffey A, et al. Postmarketing safety review for rotarix1: Data from the vaccine adverse event reporting system (VAERS), April 2008-October 2009. *Pharmacoepidemiology and Drug Safety*. 2010 August;19 SUPPL. 1:S326-S7.
83. Huang WT, Chang S, Miller ER, et al. Safety assessment after recall of haemophilus influenzae type B (Hib) vaccine - United States, 2007-2008. *Pharmacoepidemiology and Drug Safety*. 2008 Aug;17:S116-S. PMID: WOS:000258420100265.
84. Huu TN, Phuong NTM, Toan NT, et al. Assessment of the immunogenicity and safety of Quinvaxem(registered trademark) (DTwP-HepB- Hib) against diphtheria, pertussis, tetanus, hepatitis B and diseases caused by *H. influenzae* among healthy Vietnamese children. *International Journal of Infectious Diseases*. 2012 June;16 SUPPL.1:e304-e5.
85. Huu TN, Toan NT, Tuan HM, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable *Haemophilus influenzae* protein D conjugate vaccine (PHiD-CV) co-administered with DTPa-HBV-IPV/Hib in Vietnamese infants. *International Journal of Infectious Diseases*. 2012 Jun;16:E304-E. PMID: WOS:000308353101314.
86. Huu TN, Toan NT, Tuan HM, et al. Safety and reactogenicity of the 10-valent pneumococcal nontypeable *Haemophilus influenzae* protein D conjugate vaccine (PHiD-CV) co-administered with DTPa-HBV-IPV/Hib in Vietnamese infants. *International Journal of Infectious Diseases*. 2012 June;16 SUPPL.1:e304.
87. Jessen H. HPV-Impfung bei Männern. *JDDG - Journal of the German Society of Dermatology*. 2012 June;10 SUPPL. 3:30.
88. Kang HY, Kim KH, Kim HM, et al. Public health and economic impact of rotavirus vaccination in Korea. *Value in Health*. 2010 November;13(7):A549.
89. Kemmeren JM, Timmer SS, Van Der Maas NAT, et al. Comparing the tolerability of a fifth dose of an acellular pertussis-containing booster vaccination in differently primed children. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S360-S1.
90. King J, Vink P, Farley J, et al. Safety and immunogenicity of 3 doses of a 5-valent pneumococcal conjugate vaccine (PCV) in HIV and non-HIV-infected children <2 yrs of age. *Pediatric Research*. 1996 Apr;39(4):1037-. PMID: WOS:A1996UD23801037.
91. Kivitz A, Schechtman J, Texter M, et al. Assessment of immune responses to pneumococcal and influenza vaccines in patients with rheumatoid arthritis receiving certolizumab pegol. *Arthritis and Rheumatism*. 2011;63(10):2011-11.

92. Koksal B, Ozbek O. Evaluation of the effects of influenza vaccination on asthma control in schoolage children. *Allergy: European Journal of Allergy and Clinical Immunology*. 2011 June;66 SUPPL. 94:665.
93. Kombo LA, Gerber MA, Pickering LK, et al. Intussusception, infection, and immunization: summary of a workshop on rotavirus. *Pediatrics*. 2001 Aug;108(2):E37. PMID: 11483847.
94. Kumar D, Lien D, Campbell P, et al. Safety and immunogenicity of quadrivalent human papillomavirus vaccine in solid organ transplant recipients. *American Journal of Transplantation*. 2010 April;10 SUPPL. 4:206.
95. Lapeyre-Mestre M, Saussier C, Dumolard C, et al. Guillain Barre Syndrome and A(H1N1) 2009 vaccination: A French case-control study. *Fundamental and Clinical Pharmacology*. 2011 April;25 SUPPL. 1:104.
96. Lawrence J, He S, Hille D, et al. A study of RotaTeqTM (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. *International Journal of Infectious Diseases*. 2012 June;16 SUPPL.1:e307.
97. Le NM, Ontaneda D, Moodley M, et al. Neuromyelitis optica: Disease onset in relationship with infections and vaccinations. *Journal of Neurology*. 2009 June;256 SUPPL. 2:S54.
98. Lepage AK, McIntyre RC, Kennedy SE, et al. Safety and reactogenicity of the human papilloma virus vaccine in kidney transplant patients. *Immunology and Cell Biology*. 2011 October;89(7):A22.
99. Li J, Daniel GW, Paeglow C, et al. Use of self-controlled risk-interval design in childhood vaccine safety. *SOURCE Pharmacoepidemiology and Drug Safety* (2011) 20 SUPPL. 1 (S242-S243). Date of Publication: August 2011 CONFERENCE NAME 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management CONFERENCE LOCATION Chicago, IL, United States CONFERENCE DATE 2011-08-14 to 2011-08-17. 2011.
100. Liu IF, Huang CC, Chan WL, et al. Effect of annual influenza vaccination on mortality and hospitalization in patients with chronic heart disease. *Journal of the American College of Cardiology*. 2011 5;57(14 SUPPL. 1):E598.
101. Loughlin J, Christopher Mast T, Wang FT, et al. A general safety evaluation of the pentavalent rotavirus vaccine. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S362.
102. Loughlin J, Florence W, Eng PM, et al. A post-marketing surveillance program for pentavalent rotavirus vaccine. *Pharmacoepidemiology and Drug Safety*. 2009 August;(2009) 18(S1):S27.

103. Loulergue P, Rousseau B, Mir O, et al. Immunogenicity and safety of two doses of AS03Aadjuvanted influenza A/H1N1 2009 vaccine in cancer patients on chemotherapy - VACANCE study. *Clinical Microbiology and Infection*. 2011 May;17 SUPPL. 4:S320.
104. Lu Y, Ashworth LA, Bousvaros A, et al. Immune response to human papillomavirus vaccine (Gardasil) in girls and young women with inflammatory bowel disease. *Gastroenterology*. 2011 May;140(5 SUPPL. 1):S158-S9.
105. Makris M, Polyzos K, Mavros M, et al. Safety of hepatitis B, pneumococcal, and meningococcal vaccines in pregnancy: Evaluation of the published evidence. *Clinical Microbiology and Infection*. 2011 May;17 SUPPL. 4:S405.
106. Manoff S, McFetridge R, Liss C, et al. Antibody Persistence 10 Years after 1st and 2nd Doses of 23-Valent Pneumococcal Polysaccharide Vaccine (PN23), and Immunogenicity and Safety of 2nd and 3rd Doses in Older Adults. *Journal of the American Geriatrics Society*. 2010 Apr;58:25-6. PMID: WOS:000276247100071.
107. Marman SE, Yousef E. Adverse reactions to Pneumovax pneumococcal vaccine-cases of hyperimmunization? *Journal of Allergy and Clinical Immunology*. 2007 Jan;119(1):S96-S. PMID: WOS:000251460400378.
108. Mehling M, Hilbert P, Fritz S, et al. Viral antigen-specific adaptive immune responses in fingolimod-treated MS patients. *Multiple Sclerosis*. 2010 October;16(10 SUPPL. 1):S28-S9.
109. Menschik VD, Martin D. Empirical bayesian data mining as an FDA tool for prospective early detection of novel safety signals in the vaccine adverse events reporting system (VAERS): A case study of febrile seizures after an influenza virus. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S241.
110. Miossi R, Fuller R, Moraes JCB, et al. Influenza H1N1 vaccination in mixed connective tissue disease: Effectiveness and safety independent of disease or therapy. *Arthritis and Rheumatism*. 2011;63(10):2011-11.
111. Mohty B, Bel M, Vukicevic M, et al. Immunogenicity and safety of the ASO3-adjuvanted A/09/H1N1 influenza vaccine in adult allogeneic haematopoietic stem cell transplantation recipients. *Bone Marrow Transplantation*. 2011 Apr;46:S21-S2. PMID: WOS:000289195400046.
112. Moro PL, Arana J, Cano M, et al. Clinical patterns of adverse events after high-dose influenza vaccine reported to the vaccine adverse event reporting system. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S362.
113. Mullane KM, Mullane MR, Wong BMY, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in adults with solid tumor malignancy (STM). *Journal of Clinical Oncology*. 2011;29(15):2011-06.

114. Mundt AJ. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-Year End-of-study analysis of the randomised, double-blind PATRICIA trial. International Journal of Radiation Oncology Biology Physics. 2012;82(3):1039-40. PMID: 2012064415.
115. Naleway A, Weintraub E, Riedlinger K, et al. CC5-02: A Descriptive Study of Vaccinations Occurring During Pregnancy, 2002-2006. Clinical Medicine & Research. 2012 Aug;10(3):187. PMID: 22904519.
116. Namkoong JM, Park GC, Hwang S, et al. Retransplantation for recurrent hepatitis A virus infection following liver transplantation for fulminant hepatitis A infection. Liver Transplantation. 2011 June;17 SUPPL. 1:S177-S8.
117. Nath K, Burel J, Pritchard AL, et al. Impaired immune response to influenza vaccination in chronic obstructive pulmonary disease. Internal Medicine Journal. 2011 September;41 SUPPL. 4:13.
118. Nkanza J, Lafleche J, Anyoti H, et al. Adverse events following immunization (AEFI) with human papillomavirus vaccine and hepatitis B vaccines in females aged 9 to 26 Years in Canada, 2006-2010. Canadian Journal of Infectious Diseases and Medical Microbiology. 2010 Winter;21(4):186.
119. Omenaca F, Merino JM, Tejedor JC, et al. Immunogenicity and Safety of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine (Phid-Cv) Following Primary and Booster Vaccination in Preterm-Born Children. Child Care Health and Development. 2010 Jan;36:78-9. PMID: WOS:000273636500169.
120. Oude Bruin LM, Heijstek M, Bijl M, et al. Vaccinations in pediatric patients receiving DMARDs, glucocorti-costerooids or biological therapy: A systematic literature review. Clinical and Experimental Rheumatology. 2011 March-April;29(2):444.
121. Ouwens M, Littlewood K, Sauboin C, et al. Impact of mmrv mass vaccination with or without a catch up program on the incidence of varicella complications in France. Value in Health. 2010 November;13(7):A430.
122. Parisi CAS, Maspero JF, Gervasoni ME, et al. Anaphylaxis to oral poliovirus vaccine in children with cow milk protein allergy. Journal of Allergy and Clinical Immunology. 2011 February;127(2 SUPPL. 1):AB248.
123. Parrino J, Marquez F, Fisher CL, et al. Safety, tolerability, and immunogenicity of zoster vaccine in patients on chronic/maintenance corticosteroids. Arthritis and Rheumatism. 2011;63(10):2011-11.
124. Pasoto SG, Calich ALG, Aikawa NE, et al. Antimalarials: A window of opportunity to improve the influenza A/H1N1 vaccine response in lupus patients under immunosuppressive agents. Arthritis and Rheumatism. 2011;63(10):2011-11.

125. Perez-Lloret S, Rey MV, Bondon-Guitton E, et al. Drugs related to Tourette-like syndrome: A case/non-case study in the French Pharmacovigilance database. *Movement Disorders*. 2012 June;27 SUPPL. 1:S440.
126. Prelog M, Schonlaub J, Zlamy M, et al. Reduced IgG antibody avidity in organ transplant recipients after varicella-zoster-virus vaccination. *Clinical Microbiology and Infection*. 2010 April;16 SUPPL. 2:S57.
127. Rahbar H, Abreu-Lanfranco O, Singh A, et al. Risk factors for readmissions in patients 65 or older admitted for pneumonia. *Journal of the American Geriatrics Society*. 2012 April;60 SUPPL. 4:S84-S5.
128. Rajeshwari K. Prevention of rotavirus gastroenteritis. *Indian Pediatrics*. 2006 November;43(11):1018. PMID: 2007132628.
129. Rennels MB, Edwards KM, Keyserling HL, et al. Immunogenicity and safety of 7-valent pneumococcal-CRM(197) conjugate vaccine. *Pediatric Research*. 1996 Apr;39(4):1082-. PMID: WOS:A1996UD23801082.
130. Riaz H, Denyer M. The efficacy of bivalent and tetravalent HPV vaccination against cervical intraepithelial neoplasia and persistent HPV 16 and 18 infection. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2012 June;119 SUPPL. 1:176-7.
131. Rohde KA, Moran JJM, Hayney MS. Effectiveness and safety of influenza vaccine in first six months post-lung transplant. *Pharmacotherapy*. 2011 October;31(10):439e.
132. Rossi JF, Caumes B, Cymbalista F, et al. Immunogenicity and safety of one dose of influenza A H1N1v 2009 adjuvanted vaccine for unpreviously treated patients with binet-stage a chronic lymphoid leukaemia of B-cell type (B-CLL): Result of a prospective study conducted in 9 French centers by the intergroupe Francnullais GOELAMS/GFLLC-MW. *Blood*. 2010;116(21):2010-12.
133. Rothberg M. Herpes zoster: is there a role for vaccination? *Clinical Microbiology and Infection*. 2010 April;16 SUPPL. 2:S52.
134. Rothova A, De Groot JDF, Mudrikova T. Reactivation of acute retinal necrosis after flu H1N1 vaccination. *British Journal of Ophthalmology*. 2011 February;95(2):291. PMID: 2011056354 MEDLINE PMID 20733030 (<http://www.ncbi.nlm.nih.gov/pubmed/20733030>).
135. Rousseau BJ, Loulergue P, Mir O, et al. Immunogenicity and Safety of Two Doses of As03a-Adjuvanted Influenza a H1n1v 2009 Vaccine in Cancer Patients on Chemotherapy - Vacancé Study. *Annals of Oncology*. 2010 Oct;21:399-400. PMID: WOS:000284592300521.

136. Rowhani-Rahbar A, Fireman B, Lewis N, et al. Use of the case-centered analytic method in epidemiologic studies of immunization safety. *American Journal of Epidemiology*. 2011;173 SUPPL. 11:S159.
137. Rowhani-Rahbar A, Klein NP, Dekker CL, et al. Biologically plausible risk intervals to assess febrile seizure following immunization with influenza and pneumococcal conjugate vaccines. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S243.
138. Saah A. An evaluation of the long-term effectiveness, immunogenicity, and safety of gardasil in previously vaccinated women. *Sexually Transmitted Infections*. 2011 July;87 SUPPL. 1:A357-A8.
139. Saddier P, Tran T, Ackerson B, et al. Importance of medical record review for database studies: Example of Febrile Convulsion (FC). *Pharmacoepidemiology and Drug Safety*. 2010 August;19 SUPPL. 1:S322.
140. Samad L, Bashir HE, Marven S, et al. Intussusception in the first year of life: A UK national surveillance study. *Archives of Disease in Childhood*. 2010 April;95 SUPPL. 1:A1.
141. Sambatakou H. Adverse effect of influenza A/H1N1 vaccination on endothelial function of HIV infected patients. *Clinical Microbiology and Infection*. 2011 May;17 SUPPL. 4:S647.
142. Sammon CJ, McGrohan A, Snowball J, et al. Swine flu vaccination in pregnancy and associated miscarriage risk. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S58-S9.
143. Santanello NC, Mast C, Loughlin J, et al. Cautionary example of potential exposure-based differential misclassification in a post-marketing vaccine safety study. *Pharmacoepidemiology and Drug Safety*. 2009 August;(2009) 18(S1):S26.
144. Sargsyan N, Balyan AY. Retrospective study of pentavalent vaccine administration in children. *New Armenian Medical Journal*. 2010 September;4(3):58.
145. Saussier CS, Hill CH, Castot AC. Number of Spontaneous Reports of Guillain-Barre Syndrome after Flu A(H1N1) Vaccination versus Expected Number in France. *Drug Safety*. 2010;33(10):920-. PMID: WOS:000282559300072.
146. Schilling A, Morgan T. High grade cervical dysplasia in young women after HPV vaccination. *Reproductive Sciences*. 2011 March;18(3 SUPPL. 1):87A-8A.
147. Schwarz TF, Pauksens K, Juergens C, et al. An Open-label Trial to Assess the Safety of 13-Valent Pneumococcal Conjugate Vaccine in Older Adults, Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine. *Journal of the American Geriatrics Society*. 2011 Apr;59:S30-S. PMID: WOS:000289524600086.

148. Scott P, Moss WJ, Gilani Z, et al. Safety and immunogenicity of measles vaccine in HIV-infected children: Systematic review and meta-analysis. International Journal of Infectious Diseases. 2010 Mar;14:E70-E1. PMID: WOS:000276298200166.
149. Shaikh AG, Termsarasab P, Nwankwo C, et al. Guillain-Barre Syndrome Following Swine Influenza Vaccination. Muscle & Nerve. 2011 Oct;44(4):656-. PMID: WOS:000295402000120.
150. Sheikh Z, Abukwaik W, Souayah N. Ataxia after vaccination in united states, a report from the CDC/FDA vaccine adverse event reporting system [1990-2010]. Neurology. 2012;78(1):2012-04.
151. Sheikh Z, Abukwaik W, Souayah N. Meningitis after vaccination in United States, a report from the CDC/FDA vaccine adverse event reporting system [1990-2010]. Neurology. 2012;78(1):2012-04.
152. Shinjo SK, Neto ML, Silva CA, et al. Pandemic unadjuvanted influenza a 2009 vaccine in adult dermatomyositis and polymyositis: Immunogenicity independent of therapy and no harmful effect in disease. Arthritis and Rheumatism. 2011;63(10):2011-11.
153. Sibunruang S. Two-site intradermal influenza vaccination in elderly. Clinical Microbiology and Infection. 2011 May;17 SUPPL. 4:S425-S6.
154. Small TN, Iovino CS, Abboud M, et al. Vaccine response in recipients of HLA mismatched unrelated double unit cord blood transplantation (CBT). Blood. 2010;116(21):2010-12.
155. Small TN, Jakubowski AA, Barker JN, et al. Safety and immunogenicity of the 13-valent protein-conjugated pneumococcal vaccine(PCV13) following related and unrelated hematopoietic stem cell transplantation (HCT). Blood. 2011;118(21):2011-12.
156. Smith K, Muther J, Duke A, et al. Antibody secreting cells arising after vaccination from anti-cardiolipin positive individuals can produce antibodies which are bi-specific and bind to both cardiolipin and the vaccinating antigen. Arthritis and Rheumatism. 2011;63(10):2011-11.
157. Smith LM, Srighanthan J, Poon KKY, et al. Quality of reporting of harms in randomized controlled trials: An example using human papillomavirus (HPV) vaccines. Pharmacoepidemiology and Drug Safety. 2010 August;19 SUPPL. 1:S82.
158. Sonmezler M, Tuncer Ertem G, Ucal Bakkal S, et al. The side effects of H1N1 pandemic vaccine in pregnant women and comparison to other healthcare workers. Clinical Microbiology and Infection. 2011 May;17 SUPPL. 4:S830.
159. Steffey A, Lizewski R, Sutherland A, et al. Acute pancreatitis after quadrivalent human papillomavirus vaccination: Reports to a post-marketing passive surveillance system, 2006-2009. Pharmacoepidemiology and Drug Safety. 2010 August;19 SUPPL. 1:S186.

160. Suryakiran PV, Vinals C, Vanfraechem K, et al. The human rotavirus vaccine rix4414 in infants: An integrated safety summary (ISS). *Acta Paediatrica, International Journal of Paediatrics*. 2011 December;100 SUPPL. 463:56-7.
161. Swamy GK. Phase II Study To Assess the Safety and Immunogenicity of Two Dose Levels of 2009 H1N1 Influenza Vaccine in Pregnant Women. *Reproductive Sciences*. 2011 Mar;18(3):235A-A. PMID: WOS:000291721701143.
162. Tan SJ, Chean R, Hurt A, et al. Follow-up response of renal transplant recipients to booster influenza a H1N1 vaccine. *Nephrology*. 2011 September;16 SUPPL. 1:78.
163. Trabert B, Graubard BI, Erickson RL, et al. Mumps, orchitis and testicular germ cell tumors: A cause for concern? *SOURCE American Journal of Epidemiology* (2011) 173 SUPPL. 11 (S165). Date of Publication: 1 Jun 2011 CONFERENCE NAME 3rd North American Congress of Epidemiology CONFERENCE LOCATION Montreal, QC, Canada CONFERENCE DATE 2011-06-21 to 2011-06-24. 2011.
164. Tran GMK, Gerbaud L, Caprani A. Auto-immune thrombocytopenia after Measles Mumps Rubella MMR vaccination: molecular mimicry of measles virus phosphoprotein with platelet gpIIb. *Retrovirology*. 2010 May;7:66-7. PMID: WOS:000278329600210.
165. Tricotel A, Fagot J, Tubert-Bitter P, et al. Human papillomavirus vaccine and autoimmune disorders: A cohort study of 5.8 millions of adolescents and young women. Two years follow-up results. *Fundamental and Clinical Pharmacology*. 2011 April;25 SUPPL. 1:101.
166. Tseng YR, Chen HL, Hu FC, et al. Symptomatic and fulminant hepatitis B in infancy after universal hepatitis B vaccination: Clinical outcome and risk factors. *Hepatology*. 2011 October;54 SUPPL. 1:703A.
167. Ulanova M, Hawdon N, Nix E, et al. Risk of invasive haemophilus influenzae type B (Hib) disease and response to Hib vaccine in patients with chronic renal failure. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2011 Spring;22 SUPPL. SA:20A.
168. Umapathi T. International collaborative safety monitoring for pandemic 2009 H1N1 vaccines: Estimation of the risk of Guillain-Barre syndrome-Singapore experience. *Journal of the Peripheral Nervous System*. 2011 September;16 SUPPL. 3:S137-S8.
169. Van Besouw NM, Zuijderwijk JM, Noorlander I, et al. Varicella zoster virus vaccination induces virus-specific class II restricted memory responses in seronegative kidney transplant recipients. *American Journal of Transplantation*. 2012 May;12 SUPPL. 3:193.
170. Van Der Maas N, Wesselo C, Phaff T, et al. Adverse events following bivalent human papillomavirus vaccination reported to the enhanced passive surveillance system of the Netherlands. *Pharmacoepidemiology and Drug Safety*. 2010 August;19 SUPPL. 1:S324.

171. Van Der Maas N, Zonnenberg-Hoff I, Kemmeren J, et al. Immediate occurring adverse events following bivalent human papillomavirus vaccination in the Netherlands. *Pharmacoepidemiology and Drug Safety*. 2010 August;19 SUPPL. 1:S329-S30.
172. Van Praet S, Puertolas PA, Alvarez SZ. Study on Pandemrix pharmacovigilance at CHU St. Pierre. *International Journal of Clinical Pharmacy*. 2011 April;33(2):379-80.
173. Vardeny O, Hermanson MP, Moran JM, et al. A randomized study of double-dose versus single-dose influenza vaccination in patients with heart failure. *Circulation*. 2011;124(21):2011-11.
174. Velazquez FR, Colindres R, Grajales C, et al. Postmarketing surveillance of intussusception following mass introduction of the human rotavirus vaccine in Mexico: An interim analysis. *Acta Paediatrica, International Journal of Paediatrics*. 2010 December;99 SUPPL. 462:92.
175. Verity C, Stellitano L, Winstone A, et al. Is guillain barre syndrome/fisher syndrome associated with swine 'flu vaccination in children? Results: from a UK-wide epidemiological study. *SOURCE Archives of Disease in Childhood* (2011) 96 SUPPL. 1 (A5-A6). Date of Publication: April 2011 CONFERENCE NAME Annual Conference of the Royal College of Paediatrics and Child Health, RCPCH 2011 CONFERENCE LOCATION Warwick, United Kingdom CONFERENCE DATE 2011-04-05 to 2011-04-07. 2011.
176. Vesikari T, Esposito S, Kimura A, et al. Immunogenicity of an investigational multicomponent meningococcal serogroup B vaccine in healthy infants at 2, 4 and 6 months of age. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2010 Winter;21(4):183.
177. Wade A, Crawford G, Pumford N, et al. Sensitivity of pro's in evaluating adverse events in people receiving influenza vaccination. *Value in Health*. 2011 November;14(7):A282.
178. Walker AM, Puenpatom T, Li J, et al. Search for new safety signals in the patterns of care following MMR vaccine. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S347-S8.
179. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States: A claims-based analysis. *Pharmacoepidemiology and Drug Safety*. 2009 August;(2009) 18(S1):S26.
180. Wang M, Khromava A, Mahmood A, et al. Pregnant women receiving tetanus-diphtheria-acellular pertussis (Tdap) vaccine: 6 Years of adacel vaccine pregnancy registry data. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S60-S1.
181. Wijnans E, Dieleman J, Voordouw A, et al. Estimating the effectiveness of pandemic influenza vaccination in a dutch population. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S363.

182. Winnick A, Mitsiev I, Diflo T, et al. The effects of H1N1 vaccination in liver transplantation. *Liver Transplantation*. 2011 June;17 SUPPL. 1:S94-S5.
183. Winston D, Mullane K, Boeckh M, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZV(HT)) in adults with allogeneic or autologous hematopoietic stem-cell transplants (HCT). *Biology of Blood and Marrow Transplantation*. 2011 February;17(2 SUPPL. 1):S273.
184. Wood D, Group WHOIC. WHO informal consultation on quality, safety and efficacy specifications for live attenuated rotavirus vaccines Mexico City, Mexico, 8-9 February 2005. *Vaccine*. 2005 Dec 1;23(48-49):5478-87. PMID: 16129525.
185. Wood N, Cannings K, Quinn H, et al. Rotavirus vaccines and intussusception: An increased risk. *Journal of Paediatrics and Child Health*. 2011 May;47 SUPPL. 2:16.
186. Yuki N, Ihara T, Ito S, et al. Do influenza vaccines induce anti-ganglioside antibodies? *Journal of the Peripheral Nervous System*. 2010 September;15(3):291.
187. Zaiem A, El Adii S, Kastalli S, et al. Adverse effect following immunization associated with diphtheria-tetanus-pertussis and oral poliomyelitis vaccine. *Drug Safety*. 2009;32(10):942.
188. Zangwill KM, Greenberg DP, Wong VK, et al. Safety and immunogenicity of two lots of pneumococcal conjugate vaccine in infants. *Pediatric Research*. 1996 Apr;39(4):1116-. PMID: WOS:A1996UD23801116.
189. Zhang J, Delzell ES, Xie F, et al. The use, safety and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases. *Pharmacoepidemiology and Drug Safety*. 2011 August;20 SUPPL. 1:S363-S4.
190. Zhang J, Xie F, Delzell ES, et al. Safety of zoster vaccine in individuals with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. *Arthritis and Rheumatism*. 2011;63(10):2011-11.
191. Zhang J, Xie FL, Delzell ES, et al. Safety of Zoster Vaccine in Individuals with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Disease. *Arthritis and Rheumatism*. 2011 Oct;63(10):S318-S. PMID: WOS:000297621501006.

Rejected for Adverse Events Not Assessed – 458

1. From the Centers for Disease Control and Prevention. Status report on the Childhood Immunization Initiative: national, state, and urban area vaccination coverage levels among children aged 19-35 months--United States, 1996. *JAMA*. 1997 Aug 27;278(8):622-3. PMID: 9272882.
2. Erratum: Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis- Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age (*Clinical Journal of Infectious Diseases and Medical Microbiology* (2007) 18, 4, (241-248)). *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2007 September/October;18(5):318. PMID: 2007589433.
3. FDA panel recommends continued use of rotarix and rotateq vaccines viral DNA contamination. *Formulary*. 2010 May;45(5):167. PMID: 2010397508.
4. Rotavirus vaccination and risk of intussusception: Investigation of a possible safety signal. *Australian Prescriber*. 2011 April;34(2):47. PMID: 2011237396.
5. Aaby P, Benn CS. Non-specific and sex-differential effects of routine vaccines: what evidence is needed to take these effects into consideration in low-income countries? *Human Vaccines*. 2011 Jan 1;7(1):120-4. PMID: 21278492.
6. Aaby P, Martins CL, Garly ML, et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. *British Medical Journal*. 2010 Nov;341PMID: WOS:000285090100006.
7. Abbott KC, Yuan CM, Lee JL. Nothing to sneeze at: Efficacy and cost-effectiveness of the influenza vaccine in patients receiving long-term dialysis. *American Journal of Kidney Diseases*. 2011 May;57(5):651-3. PMID: 2011205912 MEDLINE PMID 21496725 (<http://www.ncbi.nlm.nih.gov/pubmed/21496725>).
8. Abramson JS, Almquist JR, Jenkins RR, et al. Prioritisation of routine vaccines: a mistake for the USA. *The Lancet*. 2008 20080315/21;371(9616):881-2. PMID: 2008126512 MEDLINE PMID 18342670 (<http://www.ncbi.nlm.nih.gov/pubmed/18342670>).
9. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. *Pediatrics*. 2008 Mar;121(3):562-9. PMID: WOS:000253780100015.
10. Adegbola RA, Leach A, Mulholland K, et al. Antigenuria in Gambian infants following immunization with a *Haemophilus influenzae* type b polyribosylribitol phosphate-tetanus toxoid protein conjugate (PRP-T) vaccine. *Diagnostic Microbiology & Infectious Disease*. 1998 Sep;32(1):15-9. PMID: 9791752.

11. Ahlgren C, Oden A, Haghghi S, et al. The effect of live attenuated measles vaccine and measles infection on measles antibody levels in serum and CSF of multiple sclerosis patients. *Multiple Sclerosis*. 2010 October;16(10 SUPPL. 1):S28.
12. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. *Thorax*. 2006 Mar;61(3):189-95. PMID: 16227328.
13. Ali NK, Bhutta ZA. A review of rotavirus diarrhea in Pakistan: How much do we know? *Journal of the College of Physicians and Surgeons Pakistan*. 2003 1;13(5):297-301. PMID: 2003256170 MEDLINE PMID 12757686 (<http://www.ncbi.nlm.nih.gov/pubmed/12757686>).
14. AlonsoDeVelasco E, Verheul AF, Verhoef J, et al. *Streptococcus pneumoniae*: virulence factors, pathogenesis, and vaccines. *Microbiological Reviews*. 1995 Dec;59(4):591-603. PMID: 8531887.
15. Amador JJ, Vasquez J, Orozco M, et al. Rotavirus disease burden, Nicaragua 2001-2005: defining the potential impact of a rotavirus vaccination program. *International Journal of Infectious Diseases*. 2010 July;14(7):e592-e5. PMID: 2010324049 MEDLINE PMID 20022778 (<http://www.ncbi.nlm.nih.gov/pubmed/20022778>).
16. Ameratunga SN, Lennon DR, Entwistle B, et al. The immunogenicity of *Haemophilus influenzae*: Meningococcal protein conjugate vaccine in Polynesian and non-Polynesian New Zealand infants. *Journal of Paediatrics and Child Health*. 1997 1997;33(2):138-41. PMID: 1997158608 MEDLINE PMID 9145357 (<http://www.ncbi.nlm.nih.gov/pubmed/9145357>).
17. Anar C, Bicmen C, Yapioglu S, et al. Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease. *New Microbiologica*. 2010 Apr;33(2):117-27. PMID: WOS:000277651700003.
18. Anderson EL, Kennedy DJ, Geldmacher KM, et al. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. *Journal of Pediatrics*. 1996 May;128(5 Pt 1):649-53. PMID: 8627437.
19. Andrews N, Waight P, Yung CF, et al. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. *Journal of Infectious Diseases*. 2011 1;203(1):32-9. PMID: 2011084070 MEDLINE PMID 21148494 (<http://www.ncbi.nlm.nih.gov/pubmed/21148494>).
20. Andrews N, Waight PA, Borrow R, et al. Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. *PLoS ONE*. 2011;6(12)PMID: 2011662171.
21. Ansaldi F, Sticchi L, Durando P, et al. Decline in pneumonia and acute otitis media after the introduction of childhood pneumococcal vaccination in Liguria, Italy. *Journal of International Medical Research*. 2008 2008;36(6):1255-60. PMID: 2009188000 MEDLINE PMID 19094434 (<http://www.ncbi.nlm.nih.gov/pubmed/19094434>).

22. Anttila M, Eskola J, Ahman H, et al. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. *Vaccine*. 1999;17(15-16):1970-7. PMID: 10217596 MEDLINE PMID 10217596 (<http://www.ncbi.nlm.nih.gov/pubmed/10217596>).
23. Ardern-Holmes SL, Lennon D, Pinnock R, et al. Trends in hospitalization and mortality from rotavirus disease in New Zealand infants. *Pediatric Infectious Disease Journal*. 1999 July;18(7):614-9. PMID: 10440437 MEDLINE PMID 10440437 (<http://www.ncbi.nlm.nih.gov/pubmed/10440437>).
24. Arkwright PD, Patel L, Moran A, et al. Atopic eczema is associated with delayed maturation of the antibody response to pneumococcal vaccine. *Clinical and Experimental Immunology*. 2000;122(1):16-9. PMID: 1000364135 MEDLINE PMID 11012612 (<http://www.ncbi.nlm.nih.gov/pubmed/11012612>).
25. Auriel E, Gadoth A, Regev K, et al. Seasonal and H1N1v influenza vaccines in MS: safety and compliance. *Journal of the Neurological Sciences*. 2012 Mar 15;314(1-2):102-3. PMID: 22056469.
26. Auvinen A, Hakulinen T, Groves F. Haemophilus influenzae type B vaccination and risk of childhood leukaemia in a vaccine trial in Finland. *British Journal of Cancer*. 2000;83(7):956-8. PMID: 2000333622 MEDLINE PMID 10970701 (<http://www.ncbi.nlm.nih.gov/pubmed/10970701>).
27. Babu GR, Bhatnagar T. Influenza vaccination to elderly: Quantifying the potential role of unmeasured confounders through an example. *Internet Journal of Epidemiology*. 2010;9(1) PMID: 2011071658.
28. Bakir M, Yagci A, Ulger N, et al. Pharyngeal colonization with Haemophilus influenzae type b among healthy Turkish infants and children. *Pediatrics International*. 2002 Aug;44(4):381-6. PMID: 12139561.
29. Baldo V, Baldovin T, Pellegrini M, et al. Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents. *Clinical & Developmental Immunology*. 2010 PMID: WOS:000277714800001.
30. Balmer P, Orrow RB, Arkwright PD. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine. *Vaccine*. 2007 Aug;25(34):6321-5. PMID: WOS:000248955000006.
31. Barry DW, Mayner RE, Hochstein HD, et al. Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. *Am J Epidemiol*. 1976 Jul;104(1):47-59. PMID: 132867.

32. Baxendale HE, Keating SM, Johnson M, et al. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. *Vaccine*. 2010 Jul 5;28(30):4763-70. PMID: 20471437.
33. Bayard V, DeAntonio R, Contreras R, et al. Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama. *International Journal of Infectious Diseases*. 2012 February;16(2):e94-e8. PMID: 2012044273 MEDLINE PMID 22154592 (<http://www.ncbi.nlm.nih.gov/pubmed/22154592>).
34. Bedford HE, Elliman DAC. The adverse effects of vaccines - Fact and fiction. *Current Paediatrics*. 2002 2002;12(1):62-6. PMID: 2002014928.
35. Bennett EM, Domachowske JB. Progress in adolescent immunization. *Clinical Microbiology Newsletter*. 2007 1;29(19):143-8. PMID: 2007450065.
36. Beran J, Vesikari T, Wertzova V, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. *J Infect Dis*. 2009 Dec 15;200(12):1861-9. PMID: 19909082.
37. Berger F, Njamkepo E, Minaberry S, et al. Investigation on a pertussis outbreak in a military school: risk factors and approach to vaccine efficacy. *Vaccine*. 2010 Jul 19;28(32):5147-52. PMID: 20541009.
38. Bhatla N, Suri V, Basu P, et al. Erratum: Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women (The Journal of Obstetrics and Gynaecology Research 36:1 (123-132)). *Journal of Obstetrics and Gynaecology Research*. 2010 April;36(2):466. PMID: 2010197269.
39. Block SL, Busman TA, Paris MM, et al. Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media. *Pediatric Infectious Disease Journal*. 2004 Sep;23(9):834-8. PMID: 15361722.
40. Bloom DE, Canning D, Shenoy ES. The effect of vaccination on children's physical and cognitive development in the Philippines. *Applied Economics*. 2012;44(21):2777-83. PMID: WOS:000301540200010.
41. Bluestone CD. Pneumococcal conjugate vaccine - Impact on otitis media and otolaryngology. *Archives of Otolaryngology-Head & Neck Surgery*. 2001 Apr;127(4):464-7. PMID: WOS:000167936100022.
42. Blum MD, Dagan R, Mendelman PM, et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. *Vaccine*. 2000 May 8;18(22):2359-67. PMID: 10738092.

43. Bogaards JA, Coupe VMH, Xiridou M, et al. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. *Epidemiology*. 2011 July;22(4):505-15. PMID: 2011438768 MEDLINE PMID 21540743 (<http://www.ncbi.nlm.nih.gov/pubmed/21540743>).
44. Bolgiano B, Mawas F, Burkin K, et al. A retrospective study on the quality of Haemophilus influenzae type b vaccines used in the UK between 1996 and 2004. *Human Vaccines*. 2007 Sep-Oct;3(5):176-82. PMID: 17786035.
45. Bompuzzi R, Wildemann B. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. *Neurology*. 2010 Mar 9;74(10):864; author reply -5. PMID: 20211914.
46. Booy R, Hodgson SA, Slack MPE, et al. Invasive Haemophilus-Influenzae Type-B Disease in the Oxford Region (1985-91). *Archives of Disease in Childhood*. 1993 Aug;69(2):225-8. PMID: WOS:A1993LQ09400014.
47. Braeckman T, Van Herck K, Raes M, et al. Rotavirus Vaccines in Belgium Policy and Impact. *Pediatric Infectious Disease Journal*. 2011 Jan;30(1):S21-S4. PMID: WOS:000285795900005.
48. Breiman RF, Zaman K, Armah G, et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. *Vaccine*. 2012 27;30(SUPPL. 1):A24-A9. PMID: 2012230571 MEDLINE PMID 22520132 (<http://www.ncbi.nlm.nih.gov/pubmed/22520132>).
49. Bricks LF, Berezin E. Impact of pneumococcal conjugate vaccine on the prevention of invasive pneumococcal diseases. *Jornal de Pediatria*. 2006 July/August;82(SUPPL. 1):S67-S74. PMID: 2006533782 MEDLINE PMID 16721440 (<http://www.ncbi.nlm.nih.gov/pubmed/16721440>).
50. Brown B, Blas M, Cabral A, et al. Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers. *Vaccine*. 2012 16;30(13):2309-14. PMID: 2012130238 MEDLINE PMID 22306855 (<http://www.ncbi.nlm.nih.gov/pubmed/22306855>).
51. Buettcher M, Baer G, Bonhoeffer J, et al. Three-year surveillance of intussusception in children in Switzerland. *Pediatrics*. 2007 September;120(3):473-80. PMID: 2007433961 MEDLINE PMID 17766518 (<http://www.ncbi.nlm.nih.gov/pubmed/17766518>).
52. Burwen DR, La Voie L, Braun MM, et al. Evaluating adverse events after vaccination in the Medicare population. *Pharmacoepidemiology & Drug Safety*. 2007 Jul;16(7):753-61. PMID: 17385786.

53. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal Polysaccharide Vaccine Efficacy - an Evaluation of Current Recommendations. *Jama-Journal of the American Medical Association*. 1993 Oct;270(15):1826-31. PMID: WOS:A1993MB46400025.
54. Cai Y, Rodriguez S, Rameswaran R, et al. Production of pharmaceutical-grade plasmids at high concentration and high supercoiled percentage. *Vaccine*. 2010 23;28(8):2046-52. PMID: 2010119217 MEDLINE PMID 19896448 (<http://www.ncbi.nlm.nih.gov/pubmed/19896448>).
55. Campitelli MA, Rosella LC, Stukel TA, et al. Influenza vaccination and all-cause mortality in community-dwelling elderly in Ontario, Canada, a cohort study. *Vaccine*. 2010 Dec 16;29(2):240-6. PMID: 21044667.
56. Carmo GMID, Yen C, Cortes J, et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: A time-series analysis. *PLoS Medicine*. 2011;8(4):11. PMID: 2011240140.
57. Carty CL, Heagerty P, Nakayama K, et al. Inflammatory response after influenza vaccination in men with and without carotid artery disease. *Arterioscler Thromb Vasc Biol*. 2006 Dec;26(12):2738-44. PMID: 17023683.
58. Castilla J, Beristain X, Martinez-Artola V, et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. *Vaccine*. 2012 Jan;30(3):539-43. PMID: WOS:000301812300007.
59. Castilla J, Moran J, Martinez-Artola V, et al. Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009-2010: Cohort and case-control study. *Vaccine*. 2011 11;29(35):5919-24. PMID: 2011409529 MEDLINE PMID 21723358 (<http://www.ncbi.nlm.nih.gov/pubmed/21723358>).
60. Cavanaugh JS, Awi D, Mandy M, et al. Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic Vaccines Based on Hepatitis B Virus Surface Protein for Chronic HBV Infection. *PLoS ONE*. 2011 Feb;6(2) PMID: WOS:000287369200001.
61. Chan TC, Hung IFN, Luk JKH, et al. Efficacy of dual vaccination of pandemic H1N1 2009 influenza and seasonal influenza on institutionalized elderly: A one-year prospective cohort study. *Vaccine*. 2011 13;29(44):7773-8. PMID: 2011557539 MEDLINE PMID 21821084 (<http://www.ncbi.nlm.nih.gov/pubmed/21821084>).
62. Chan TC, Hung IFN, Luk JKH, et al. Prevention of Mortality and Pneumonia Among Nursing Home Older Adults by Dual Pneumococcal and Seasonal Influenza Vaccination During a Pandemic Caused by Novel Pandemic Influenza A (H1N1). *Journal of the American Medical Directors Association*. 2012.
63. Chang YC, Chou YJ, Liu JY, et al. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan - A representative population-based comparative study. *Journal of Infection*. 2012;65:231-8.

64. Chen RT, Rastogi SC, Mullen JR, et al. The vaccine adverse event reporting system (VAERS). *Vaccine*. 1994;12(6):542-50. PMID: 1994117962 MEDLINE PMID 8036829 (<http://www.ncbi.nlm.nih.gov/pubmed/8036829>).
65. Chen WH, El-Kamary SS. Vaccines for enteric infections. *Current Opinion in Gastroenterology*. 2012 January;28(1):18-23. PMID: 2012089077 MEDLINE PMID 22080824 (<http://www.ncbi.nlm.nih.gov/pubmed/22080824>).
66. Chen YE, Beasley S, Grimwood K. Intussusception and rotavirus associated hospitalisation in New Zealand. *Archives of Disease in Childhood*. 2005 October;90(10):1077-81. PMID: 2005448132 MEDLINE PMID 15964860 (<http://www.ncbi.nlm.nih.gov/pubmed/15964860>).
67. Cherian MP, Al-Kanani KA, Al Qahtani SS, et al. The rising incidence of type 1 diabetes mellitus and the role of environmental factors - Three decade experience in a primary care health center in Saudi Arabia. *Journal of Pediatric Endocrinology and Metabolism*. 2010;23(7):685-95. PMID: 2010493713 MEDLINE PMID 20857841 (<http://www.ncbi.nlm.nih.gov/pubmed/20857841>).
68. Chernin LR, Swender D, Hostoffer RW, Jr. Cracking the shell on egg-hypersensitive patients and egg-containing vaccines. *Journal of the American Osteopathic Association*. 2011 Oct;111(10 Suppl 6):S5-6. PMID: 22086894.
69. Chi R-C, Reiber GE, Neuzil KM. Influenza and pneumococcal vaccination in older veterans: results from the behavioral risk factor surveillance system. *Journal of the American Geriatrics Society*. 2006 Feb;54(2):217-23. PMID: 16460371.
70. Choo S, Zhang QB, Seymour L, et al. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. *Journal of Infectious Diseases*. 2000 Oct;182(4):1260-3. PMID: WOS:000089712100037.
71. Christenson B, Hedlund J, Lundbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. *European Respiratory Journal*. 2004 Mar;23(3):363-8. PMID: 15065822.
72. Christenson B, Pauksen K, Sylvan SPE. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. *Virology Journal*. 2008;5:52. PMID: 18442371.
73. Clark. Erratum: Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants (Journal of Pediatrics (February 2004) 144 (184-190)). *Journal of Pediatrics*. 2004 Apr;144(4):558. PMID: 2004161706.
74. Clark HF, Lawley D, Mallette LA, et al. Decline in Cases of Rotavirus Gastroenteritis Presenting to The Children's Hospital of Philadelphia after Introduction of a Pentavalent

Rotavirus Vaccine. Clinical and Vaccine Immunology. 2009 Mar;16(3):382-6. PMID: WOS:000263854200014.

75. Clark HF, Lawley D, Shrager D, et al. Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: Different dose response patterns to virus surface proteins VP7 and VP4. Pediatric Infectious Disease Journal. 2004 March;23(3):206-11. PMID: 2004121117 MEDLINE PMID 15014293 (<http://www.ncbi.nlm.nih.gov/pubmed/15014293>).
76. Conterno LO, da Silva Filho CR, Ruggeberg JU, et al. WITHDRAWN: Conjugate vaccines for preventing meningococcal C meningitis and septicaemia. Cochrane Database of Systematic Reviews. 2011(7):CD001834. PMID: 21735387.
77. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of Monovalent Rotavirus Vaccine (Rotarix) against Severe Diarrhea Caused by Serotypically Unrelated G2P[4] Strains in Brazil. Journal of Infectious Diseases. 2010 Feb;201(3):363-9. PMID: WOS:000273441000008.
78. Cortes JE, Curns AT, Tate JE, et al. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. New England Journal of Medicine. 2011 22;365(12):1108-17. PMID: 2011531196 MEDLINE PMID 21992123 (<http://www.ncbi.nlm.nih.gov/pubmed/21992123>).
79. Cortese MM, Staat MA, Weinberg GA, et al. Underestimates of intussusception rates among US infants based on inpatient discharge data: implications for monitoring the safety of rotavirus vaccines. Journal of Infectious Diseases. 2009 Nov 1;200 Suppl 1:S264-70. PMID: 19817607.
80. Couch RB. Lessons learned from clinical trials in 1976 and 1977 of vaccines for the Newly Emerged swine and Russian Influenza A/H1N1 viruses. Birkhauser Advances in Infectious Diseases. 2011;(359-371). Date of Publication(2011 Influenza Vaccines for the Future, Book Series Title: ISBN 9783034602785):volume. PMID: 2011373902.
81. Cowling BJ, Fang VJ, Nishiura H, et al. Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine. Clinical Infectious Diseases. 2012 15;54(12):1778-83. PMID: 2012305675.
82. Crocetti E, Arniani S, Bordoni F, et al. Effectiveness of influenza vaccination in the elderly in a community in Italy. European Journal of Epidemiology. 2001;17(2):163-8. PMID: WOS:000170953500010.
83. Crooks CJ, Prieto-Merino D, Evans SJW. Identifying adverse events of vaccines using a bayesian method of medically guided information sharing. Drug Safety. 2012 2012;35(1):61-78. PMID: 2011677228 MEDLINE PMID 22136183 (<http://www.ncbi.nlm.nih.gov/pubmed/22136183>).
84. Cunliffe NA, Witte D, Ngwira BM, et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: A randomized, double-blind, placebo controlled trial. Vaccine. 2012 27;30(SUPPL. 1):A36-A43. PMID: 2012230573 MEDLINE PMID 22520135 (<http://www.ncbi.nlm.nih.gov/pubmed/22520135>).

85. Czajka H, Schuster V, Zepp F, et al. Corrigendum to "A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra <trade>): Immunogenicity and safety profile" Vaccine 27 (2009) 6504-6511. Vaccine. 2010 6;28(52):8352. PMID: 2010666520.
86. Dagan R, Sikuler-Cohen M, Zamir O, et al. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatric Infectious Disease Journal. 2001 2001;20(10):951-8. PMID: 2001359896 MEDLINE PMID 11642629 (<http://www.ncbi.nlm.nih.gov/pubmed/11642629>).
87. Dalton CB, Cretikos MA, Durrheim DN, et al. Comparison of adult patients hospitalised with pandemic (H1N1) 2009 influenza and seasonal influenza during the "PROTECT" phase of the pandemic response. Medical Journal of Australia. 2010 15;192(6):357-8. PMID: 2010281127.
88. Das MK, Bhattacharyya N. Paediatric immunisation: Special emphasis on measles and MMR vaccinations. Journal of the Indian Medical Association. 2002 1;100(5):320-1. PMID: 2002365477 MEDLINE PMID 12418635 (<http://www.ncbi.nlm.nih.gov/pubmed/12418635>).
89. Dashefsky B, Wald E, Guerra N, et al. Safety, Tolerability, and Immunogenicity of Concurrent Administration of Haemophilus-Influenzae Type-B Conjugate Vaccine (Meningococcal Protein Conjugate) with Either Measles-Mumps-Rubella Vaccine or Diphtheria-Tetanus-Pertussis and Oral Poliovirus Vaccines in 14-Month-Old to 23-Month-Old Infants. Pediatrics. 1990 Apr;85(4):682-9. PMID: WOS:A1990CZ92900011.
90. Davies K, Woo P. Immunization in rheumatic diseases of childhood: An audit of the clinical practice of british paediatric rheumatology group members and a review of the evidence. Rheumatology. 2002 2002;41(8):937-41. PMID: 2002297972 MEDLINE PMID 12154212 (<http://www.ncbi.nlm.nih.gov/pubmed/12154212>).
91. Dennehy PH. Effects of vaccine on rotavirus disease in the pediatric population. Current Opinion in Pediatrics. 2012 February;24(1):76-84. PMID: 2012047095 MEDLINE PMID 22189398 (<http://www.ncbi.nlm.nih.gov/pubmed/22189398>).
92. Dennehy PH, Vesikari T, Matson DO, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq[REGISTERED] (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Human Vaccines. 2011 May;7(5):563-8. PMID: 21441783.
93. Desselberger U. Prospects for vaccines against rotaviruses. Reviews in Medical Virology. 1998 1998;8(1):43-52. PMID: 1998066826.
94. Desselberger U, Huppertz HI. Immune responses to rotavirus infection and vaccination and associated correlates of protection. Journal of Infectious Diseases. 2011 15;203(2):188-95. PMID: 2011085083 MEDLINE PMID 21288818 (<http://www.ncbi.nlm.nih.gov/pubmed/21288818>).

95. Dewan P, Gupta P. Burden of Congenital Rubella Syndrome (CRS) in India: A Systematic Review. *Indian Pediatrics*. 2012 May;8;49(5):377-99. PMID: 22700664.
96. Dey AK, Srivastava IK. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. *Expert Review of Vaccines*. 2011 February;10(2):227-51. PMID: 2011111488 MEDLINE PMID 21105782 (<http://www.ncbi.nlm.nih.gov/pubmed/21105782>).
97. D'Heilly S, Bauman WL, Nichol KL. Safety and acceptability of pneumococcal vaccinations administered in nontraditional settings. *American Journal of Infection Control*. 2002 Aug;30(5):261-8. PMID: 12163859.
98. Di Pasquale A, De Ridder M, Van Der Meeren O. Hepatitis B virus vaccine in chronic kidney diseases: Improved immunogenicity by adjuvants? Limits of a meta-analysis. *Vaccine*. 2012 17;30(38):5586. PMID: 2012458511.
99. Dodds L, McNeil SA, Fell DB, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. *Canadian Medical Association Journal*. 2007 Feb;176(4):463-8. PMID: WOS:000243991300014.
100. Driver C. Pneumonia part 2: signs, symptoms and vaccinations. *British Journal of Nursing*. 2012 Feb 23-Mar 7;21(4):245-9. PMID: 22398939.
101. Duclos P, Hofmann CA. Immunisation safety: A priority of the World Health Organization's Department of Vaccines and Biologicals. *Drug Safety*. 2001 2001;24(15):1105-12. PMID: 2002067895 MEDLINE PMID 11772144 (<http://www.ncbi.nlm.nih.gov/pubmed/11772144>).
102. Eberly MD, Gorman GH, Eide MB, et al. The effect of rotavirus immunization on rotavirus gastroenteritis hospitalization rates in military dependents. *Vaccine*. 2011 Jan;29(4):650-9. PMID: WOS:000286853500009.
103. Eglee Perez M, Glass R, Alvarez G, et al. Rhesus rotavirus-based quadrivalent vaccine is efficacious despite age, socioeconomic conditions and seasonality in Venezuela. *Vaccine*. 2000 22;19(7 8):976-81. PMID: 2000425530 MEDLINE PMID 11115724 (<http://www.ncbi.nlm.nih.gov/pubmed/11115724>).
104. Einollahi B. Immune response to hepatitis B vaccine in patients with chronic kidney disease. *Hepatitis Monthly*. 2011 October;11(10):781-2. PMID: 2011607112.
105. El Khoury AC, Mast TC, Ciarlet M, et al. Projecting the effectiveness of RotaTeq(registered trademark) against rotavirus-related hospitalizations and deaths in six Asian countries. *Human Vaccines*. 2011 May;7(5):506-10. PMID: 2011267189 MEDLINE PMID 21422820 (<http://www.ncbi.nlm.nih.gov/pubmed/21422820>).

106. Ellenberg SS, Braun MM. Monitoring the safety of vaccines: Assessing the risks. *Drug Safety*. 2002;25(3):145-52. PMID: 2002168642 MEDLINE PMID 11945111 (<http://www.ncbi.nlm.nih.gov/pubmed/11945111>).
107. Englund JA, Mbawuike IN, Hammill H, et al. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. *J Infect Dis*. 1993 Sep;168(3):647-56. PMID: 8354906.
108. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. *Arch Intern Med*. 1995 Nov 27;155(21):2336-40. PMID: 7487259.
109. Fasunla AJ. Challenges of tracheostomy in patients managed for severe tetanus in a developing country. *International Journal of Preventive Medicine*. 2010;1(3):176-81. PMID: 21566788.
110. Fedson DS. The clinical effectiveness of pneumococcal vaccination: A brief review. *Vaccine*. 1999;17(SUPPL. 1):S85-S90. PMID: 1999273477 MEDLINE PMID 10471188 (<http://www.ncbi.nlm.nih.gov/pubmed/10471188>).
111. Fedson DS, Liss C. Precise answers to the wrong question: Prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. *Vaccine*. 2004;25:22(8):927-46. PMID: 2004083344 MEDLINE PMID 15161070 (<http://www.ncbi.nlm.nih.gov/pubmed/15161070>).
112. Ferreyra L, Bustos D, Biganzoli P, et al. HHV-6 IgG4 isotype response following measles infection. *Journal of Medical Virology*. 2010;82(3):396-9. PMID: 2010074053 MEDLINE PMID 20087929 (<http://www.ncbi.nlm.nih.gov/pubmed/20087929>).
113. Ferris DG, Shulman L. Prevention of human papillomavirus in women of childbearing age. *Sexuality, Reproduction and Menopause*. 2010;8(2):PMID: 2010661372.
114. Findlow H, Southern J, Mabey L, et al. Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine. *Clinical and Vaccine Immunology*. 2006 Apr;13(4):507-10. PMID: WOS:000236962300011.
115. Finn A, Booy R, Moxon R, et al. Should the new pneumococcal vaccine be used in high-risk children? *Archives of Disease in Childhood*. 2002 Jul;87(1):18-21. PMID: 12089114.
116. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. *Pediatric Infectious Disease Journal*. 2003 Jan;22(1):10-6. PMID: WOS:000180455900002.
117. Firmansyah A, Dwipoerwantoro PG, Kadim M, et al. Improved growth of toddlers fed a milk containing synbiotics. *Asia Pacific Journal of Clinical Nutrition*. 2011;20(1):69-76. PMID: 21393113.

118. Fischer TK, Anh DD, Antil L, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. *Journal of Infectious Diseases*. 2005;192(10):1720-6. PMID: 2005506928 MEDLINE PMID 16235169 (<http://www.ncbi.nlm.nih.gov/pubmed/16235169>).
119. Fischer TK, Gentsch JR. Rotavirus typing methods and algorithms. *Reviews in Medical Virology*. 2004 March/April;14(2):71-82. PMID: 2004115475 MEDLINE PMID 15027000 (<http://www.ncbi.nlm.nih.gov/pubmed/15027000>).
120. Fischer TK, Viboud C, Parashar U, et al. Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993-2003. *Journal of Infectious Diseases*. 2007;195(8):1117-25. PMID: 2007168247 MEDLINE PMID 17357047 (<http://www.ncbi.nlm.nih.gov/pubmed/17357047>).
121. Fleming DM, Verlander NQ, Elliot AJ, et al. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. *Epidemiology and Infection*. 2010 September;138(9):1281-8. PMID: 2010544277 MEDLINE PMID 20109259 (<http://www.ncbi.nlm.nih.gov/pubmed/20109259>).
122. Flores AR, Szilagyi PG, Auinger P, et al. Estimated burden of rotavirus-associated diarrhea in ambulatory settings in the United States. *Pediatrics*. 2010 February;125(2):e191-e8. PMID: 2010090830 MEDLINE PMID 20100749 (<http://www.ncbi.nlm.nih.gov/pubmed/20100749>).
123. Forstner C, Plefka S, Tobudic S, et al. Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients. *Vaccine*. 2012 Aug;30(37):5449-52. PMID: 22749594.
124. Foster DA, Talsma A, Furumotodawson A, et al. Influenza Vaccine Effectiveness in Preventing Hospitalization for Pneumonia in the Elderly. *American Journal of Epidemiology*. 1992 Aug;136(3):296-307. PMID: WOS:A1992JR44600005.
125. Fox PG, Kumchum S. Caring for Myanmar refugees in Thailand. *International Nursing Review*. 1996 Sep-Oct;43(5):154-8. PMID: 8894842.
126. France EK, Smith-Ray R, McClure D, et al. Impact of maternal influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants. *Arch Pediatr Adolesc Med*. 2006 Dec;160(12):1277-83. PMID: 17146026.
127. Frasch CE, Hiner EE, Gross TP. Haemophilus b disease after vaccination with Haemophilus b polysaccharide or conjugate vaccine. *American Journal of Diseases of Children*. 1991 Dec;145(12):1379-82. PMID: 1669664.
128. French N, Gilks CF, Mujugira A, et al. Pneumococcal vaccination in HIV-1-infected adults in Uganda: Humoral response and two vaccine failures. *Aids*. 1998 Oct;12(13):1683-9. PMID: 998307537 MEDLINE PMID 9764789 (<http://www.ncbi.nlm.nih.gov/pubmed/9764789>).

129. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. *Lancet*. 2000 Jun 17;355(9221):2106-11. PMID: 10902624.
130. French Jr RW, Yeh S. The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults. *Expert Opinion on Biological Therapy*. 2012 January;12(1):63-77. PMID: 2011699976 MEDLINE PMID 22074323
(<http://www.ncbi.nlm.nih.gov/pubmed/22074323>).
131. Fritzell B, Fletcher MA. Pneumococcal polysaccharide-protein (CRM(197)) conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule. *Expert Review of Vaccines*. 2011 March;10(3):263-90. PMID: 2011179942 MEDLINE PMID 21434795
(<http://www.ncbi.nlm.nih.gov/pubmed/21434795>).
132. Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. *Vaccine*. 2008 Aug 5;26(33):4284-9. PMID: 18585831.
133. Gall RM, Witterick IJ, Shargill NS, et al. Control of bleeding in endoscopic sinus surgery: use of a novel gelatin-based hemostatic agent. *Journal of Otolaryngology*. 2002 Oct;31(5):271-4. PMID: 12512890.
134. Gatibelza ME, Laroye B, Lombard J, et al. Management of a ruptured infected abdominal aortic aneurysm and a spondylodiscitis due to *Gemella haemolysans*. *Annals of Vascular Surgery*. 2009 Jul-Aug;23(4):536.e13-7. PMID: 19110401.
135. Gattringer R, Winkler H, Roedler S, et al. Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants. *Transplant Infectious Disease*. 2011 Oct;13(5):540-4. PMID: WOS:000295837900018.
136. Giles ML, Visvanathan K, Lewin SR, et al. Chronic Hepatitis B Infection and Pregnancy. *Obstetrical & Gynecological Survey*. 2012 Jan;67(1):37-44. PMID: WOS:000300220300017.
137. Gilsdorf JR. *Haemophilus influenzae* type b vaccine. *Indian Journal of Pediatrics*. 1988 1988;55(2):218-24. PMID: 1988152330 MEDLINE PMID 3042621
(<http://www.ncbi.nlm.nih.gov/pubmed/3042621>).
138. Glanz JM, McClure DL, Magid DJ, et al. Parental refusal of varicella vaccination and the associated risk of varicella infection in children. *Archives of Pediatrics and Adolescent Medicine*. 2010 January;164(1):66-70. PMID: 2010021895 MEDLINE PMID 20048244
(<http://www.ncbi.nlm.nih.gov/pubmed/20048244>).

139. Gomez E, Zoth SC, Berinstein A. Plant-based vaccines for potential human application: A review. *Human Vaccines*. 2009;2009;5(11):738-44. PMID: 2010041001 MEDLINE PMID 19829054 (<http://www.ncbi.nlm.nih.gov/pubmed/19829054>).
140. Govaert TM, Sprenger MJ, Dinant GJ, et al. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. *Vaccine*. 1994 Oct;12(13):1185-9. PMID: 7839722.
141. Govaert TME, Thijs C, Masurel N, et al. The Efficacy of Influenza Vaccination in Elderly Individuals - a Randomized Double-Blind Placebo-Controlled Trial. *Jama-Journal of the American Medical Association*. 1994 Dec;272(21):1661-5. PMID: WOS:A1994PU75900024.
142. Greenberg DP, Vadheim CM, Partridge S, et al. Immunogenicity of Haemophilus-Influenzae Type-B Tetanus Toxoid Conjugate Vaccine in Young Infants. *Journal of Infectious Diseases*. 1994 Jul;170(1):76-81. PMID: WOS:A1994NR96500011.
143. Gross PA, Hermogenes AW, Sacks HS, et al. The Efficacy of Influenza Vaccine in Elderly Persons - a Metaanalysis and Review of the Literature. *Annals of Internal Medicine*. 1995 Oct;123(7):518-27. PMID: WOS:A1995RW49500008.
144. Guerra FA. Delays in immunization have potentially serious health consequences. *Pediatric Drugs*. 2007;2007;9(3):143-8. PMID: 2007268552 MEDLINE PMID 17523694 (<http://www.ncbi.nlm.nih.gov/pubmed/17523694>).
145. Gulland A. Rotavirus vaccine cuts deaths of Mexican babies from diarrhoea by 40%. *British Medical Journal*. 2010 Jan;340PMID: WOS:000274089400005.
146. Gurgel RQ, Ilozue C, Correia JB, et al. Impact of rotavirus vaccination on diarrhoea mortality and hospital admissions in Brazil. *Tropical Medicine and International Health*. 2011 September;16(9):1180-4. PMID: 2011431922 MEDLINE PMID 21749584 (<http://www.ncbi.nlm.nih.gov/pubmed/21749584>).
147. Guthridge S, McIntyre P, Isaacs D, et al. Differing serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate (PRP-OMPc) vaccine in Australian Aboriginal and Caucasian infants - implications for disease epidemiology. *Vaccine*. 2000 May;18(23):2584-91. PMID: WOS:000087151100013.
148. Gutzeit C, Raftery MJ, Peiser M, et al. Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction. *Journal of Immunology*. 2010 Jul 1;185(1):488-97. PMID: 20525895.
149. Hahne S, van den Hoek A, Baayen D, et al. Prevention of perinatal hepatitis B virus transmission in the Netherlands, 2003-2007: Children of Chinese mothers are at increased risk of breakthrough infection. *Vaccine*. 2012;21;30(9):1715-20. PMID: 2012084011 MEDLINE PMID 22210140 (<http://www.ncbi.nlm.nih.gov/pubmed/22210140>).

150. Hak E, Grobbee DE, Sanders EAM, et al. Rationale and design of CAPITA: A RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. *Netherlands Journal of Medicine*. 2008 October;66(9):378-83. PMID: 2008509996 MEDLINE PMID 18990781 (<http://www.ncbi.nlm.nih.gov/pubmed/18990781>).
151. Hak E, Hoes AW, Grobbee DE, et al. Conventional influenza vaccination is not associated with complications in working-age patients with asthma or chronic obstructive pulmonary disease. *American Journal of Epidemiology*. 2003 Apr 15;157(8):692-700. PMID: 12697573.
152. Halsey NA. Safety of combination vaccines: Perception versus reality. *Pediatric Infectious Disease Journal*. 2001 2001;20(11 SUPPL.):S40-S4. PMID: 2001402763 MEDLINE PMID 11704723 (<http://www.ncbi.nlm.nih.gov/pubmed/11704723>).
153. Halsey NA, Abramson JS, Chesney PJ, et al. Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine. *Pediatrics*. 1998 December;102(6):1483-91. PMID: 1998410974 MEDLINE PMID 9832589 (<http://www.ncbi.nlm.nih.gov/pubmed/9832589>).
154. Hanna JN, Gratten M, Tiley SM, et al. Pneumococcal vaccination: an important strategy to prevent pneumonia in Aboriginal and Torres Strait Island adults. *Australian and New Zealand Journal of Public Health*. 1997 Jun;21(3):281-5. PMID: WOS:A1997YK90600010.
155. Hattotuwa KL, Hind CR. Pneumococcal vaccine. *Postgraduate Medical Journal*. 1997 Apr;73(858):222-4. PMID: 9156124.
156. Healy P, Zochling J, March L. Immunisation of adult patients with rheumatic diseases. *Medicine Today*. 2008 June;9(6):69-71. PMID: 2008343790.
157. Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with haemophilus influenzae type b conjugate vaccine failure in childhood. *Clinical Infectious Diseases*. 2000 2000;31(4):973-80. PMID: 2001143513 MEDLINE PMID 11049779 (<http://www.ncbi.nlm.nih.gov/pubmed/11049779>).
158. Heffelfinger JD, Heckbert SR, Psaty BM, et al. Influenza vaccination and risk of incident myocardial infarction. *Hum Vaccin*. 2006 Jul-Aug;2(4):161-6. PMID: 17012887.
159. Heinonen S, Silvennoinen H, Lehtinen P, et al. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. *The Lancet Infectious Diseases*. 2011 Jan;11(1):23-9. PMID: 21106443.
160. Hendrickson DJ, Blumberg DA, Joad JP, et al. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine. *Pediatric Infectious Disease Journal*. 2008 November;27(11):1030-2. PMID: 2009248550 MEDLINE PMID 18845981 (<http://www.ncbi.nlm.nih.gov/pubmed/18845981>).

161. Hensley E, Briars L. Closer look at autism and the measles-mumps-rubella vaccine. *Journal of the American Pharmacists Association: JAPhA*. 2010 Nov-Dec;50(6):736-41. PMID: 21071320.
162. Heyse JF, Kaplan KM. The reactogenicity and immunogenicity of commercial *Haemophilus influenzae* type b conjugate vaccines. *European Journal of Pediatrics*. 2000 Dec;159(12):932-3. PMID: 11131356.
163. Hillman RJ, Giuliano AR, Palefsky JM, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. *Clinical & Vaccine Immunology: CVI*. 2012 Feb;19(2):261-7. PMID: 22155768.
164. Hillman RJ, Giuliano AR, Palefsky JM, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. *Clinical & Vaccine Immunology: CVI*. 2012 Feb;19(2):261-7. PMID: 22155768.
165. Hiner EE, Frasch CE. Spectrum of disease due to *Haemophilus influenzae* type b occurring in vaccinated children. *Journal of Infectious Diseases*. 1988 Aug;158(2):343-8. PMID: 3261314.
166. Hiner EE, Frasch CE. Spectrum of disease due to *Haemophilus influenzae* type b occurring in vaccinated children. *Journal of Infectious Diseases*. 1988 1988;158(2):343-8. PMID: 1988223249 MEDLINE PMID 3261314 (<http://www.ncbi.nlm.nih.gov/pubmed/3261314>).
167. Hoare S. HIV infection in children--impact upon ENT doctors. *International Journal of Pediatric Otorhinolaryngology*. 2003 Dec;67 Suppl 1:S85-90. PMID: 14662174.
168. Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. *Journal of Infectious Diseases*. 2011 Sep 15;204(6):845-53. PMID: 21846636.
169. Holmes SJ, Lucas AH, Osterholm MT, et al. Immunoglobulin deficiency and idiotype expression in children developing *Haemophilus influenzae* type b disease after vaccination with conjugate vaccine. The Collaborative Study Group. *JAMA*. 1991 Oct 9;266(14):1960-5. PMID: 1895474.
170. Hom J, Medwid K. The low rate of bacterial meningitis in children, ages 6 to 18 months, with simple febrile seizures. *Academic Emergency Medicine*. 2011 Nov;18(11):1114-20. PMID: 22092892.
171. Horst D, Ressing ME, Wiertz E. Exploiting human herpesvirus immune evasion for therapeutic gain: potential and pitfalls. *Immunology and Cell Biology*. 2011 Mar;89(3):359-66. PMID: WOS:000288539800007.
172. Hoshino Y, Wagner M, Yan XY, et al. Horizontal transmission of rhesus monkey rotavirus-based quadrivalent vaccine during a phase 3 clinical trial in Caracas, Venezuela.

Journal of Infectious Diseases. 2003 1;187(5):791-800. PMID: 2003102915 MEDLINE PMID 12599053 (<http://www.ncbi.nlm.nih.gov/pubmed/12599053>).

173. Hotopf M, David A, Hull L, et al. Role of vaccinations as risk factors for ill health in veterans of the Gulf war: Cross sectional study. British Medical Journal. 2000 20;320(7246):1363-7. PMID: 2000170967 MEDLINE PMID 10818024 (<http://www.ncbi.nlm.nih.gov/pubmed/10818024>).
174. Howard PF, McCaw JM, Richmond PC, et al. Virus detection and its association with symptoms during influenza-like illness in a sample of healthy adults enrolled in a randomised controlled vaccine trial. Influenza and other Respiratory Viruses. 2012.
175. Huebner RE, Mbelle N, Forrest B, et al. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatric Infectious Disease Journal. 2002 Nov;21(11):1004-7. PMID: WOS:000179254800004.
176. Hung IFN, Yuen KY. Dual pneumococcal and influenza vaccination in elderly patients with chronic illnesses: Protective benefits overestimated? Clinical Infectious Diseases. 2011 15;52(4):559. PMID: 2011105147.
177. Huo Z, Miles J, Harris T, et al. Effect of Pneumovax(registered trademark) II vaccination in high-risk individuals on specific antibody and opsonic capacity against specific and non-specific antigen. Vaccine. 2002 4;20(29 30):3532-4. PMID: 2002390467.
178. Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis.[Erratum appears in CMAJ. 2009 May 12;180(10):1038]. CMAJ Canadian Medical Association Journal. 2009 Jan 6;180(1):48-58. PMID: 19124790.
179. Hviid A, Svanstrom H. Antibiotic use and intussusception in early childhood. Journal of Antimicrobial Chemotherapy. 2009 Sep;64(3):642-8. PMID: WOS:000273181400028.
180. Hyser JM, Estes MK. Rotavirus vaccines and pathogenesis: 2008. Current Opinion in Gastroenterology. 2009 January;25(1):36-43. PMID: 2009031642 MEDLINE PMID 19114772 (<http://www.ncbi.nlm.nih.gov/pubmed/19114772>).
181. Inaba H, Hartford CM, Pei D, et al. Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. 2012 Jan;156(1):109-17. PMID: 22017512.
182. Inoue S, Watanuki Y, Kaneko T, et al. Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study. BMJ Open. 2011 Jan 1;1(1):e000105. PMID: 22021764.

183. Iskander JK, Miller ER, Chen RT. The role of the vaccine adverse event reporting system (VAERS) in monitoring vaccine safety. *Pediatric Annals*. 2004 September;33(9):599-606. PMID: 2004393883 MEDLINE PMID 15462575 (<http://www.ncbi.nlm.nih.gov/pubmed/15462575>).
184. Itzler R, Koch G, Matson DO, et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). *Bmc Pediatrics*. 2010;10:42. PMID: 20540778.
185. Jackowska T, Pluta J. Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens. *Archives of Medical Science*. 2012 Jun;8(3):542-8. PMID: WOS:000306150200024.
186. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. *N Engl J Med*. 2003 May 1;348(18):1747-55. PMID: 12724480.
187. Jackson LA, Peterson D, Dunn J, et al. A randomized placebo-controlled trial of acetaminophen for prevention of post-vaccination fever in infants. *PLoS ONE [Electronic Resource]*. 2011;6(6) PMID: 2011333756.
188. Jackson LA, Yu O, Nelson JC, et al. Injection site and risk of medically attended local reactions to acellular pertussis vaccine. *Pediatrics*. 2011 Mar;127(3):e581-7. PMID: 21300679.
189. Jacobs AL. Liability and maternal immunization: In utero injury claims in the VICP. *American Journal of Obstetrics and Gynecology*. 2012 September;207(3 SUPPL.):S63-S6. PMID: 2012497480.
190. Jacobson RM, Swan A, Adegbienro A, et al. Making vaccines more acceptable - Methods to prevent and minimize pain and other common adverse events associated with vaccines. *Vaccine*. 2001 21;19(17 19):2418-27. PMID: 2001113295 MEDLINE PMID 11257372 (<http://www.ncbi.nlm.nih.gov/pubmed/11257372>).
191. Jacobson RM, Zabel KS, Poland GA. The challenge of vaccine safety. *Seminars in Pediatric Infectious Diseases*. 2002 July;13(3):215-20. PMID: 2002294526 MEDLINE PMID 12199618 (<http://www.ncbi.nlm.nih.gov/pubmed/12199618>).
192. Jaffe S. New rotavirus vaccines on the horizon. *Scientist*. 2005 Feb;19(3):37-9. PMID: WOS:000227520100026.
193. Jatana SK, Nair MNG. Combination vaccines. *Medical Journal Armed Forces India*. 2007 April;63(2):167-71. PMID: 2007436684.
194. Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. *Lancet*. 2005 Oct;366(9492):1165-74. PMID: WOS:000232311300026.

195. Jiang T, Li X, Liu W, et al. Serum antibody response to the novel influenza A (H1N1) virus in the elderly. *Clinical Infectious Diseases*. 2010;15;50(2):285-6. PMID: 2010026203 MEDLINE PMID 20034356 (<http://www.ncbi.nlm.nih.gov/pubmed/20034356>).
196. Johns MC, Eick AA, Blazes DL, et al. Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel. *PLoS One*. 2010;5(5):e10722. PMID: 20502705.
197. Johnson B, Gargiullo P, Murphy TV, et al. Factors associated with bowel resection among infants with intussusception in the United States. *Pediatric Emergency Care*. 2012 Jun;28(6):529-32. PMID: 22653458.
198. Johnstone J, Eurich DT, Minhas JK, et al. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. *Clinical Infectious Diseases*. 2010 Jul 1;51(1):15-22. PMID: 20504233.
199. Jones RG, Bass JW, Weisse ME, et al. Antigenuria after immunization with *Haemophilus influenzae* oligosaccharide CRM(197) conjugate (HbOC) vaccine. *Pediatric Infectious Disease Journal*. 1991;1991;10(8):557-9. PMID: 1992016450 MEDLINE PMID 1891285 (<http://www.ncbi.nlm.nih.gov/pubmed/1891285>).
200. Jones T. Varivax Merck & Co. *Current Opinion in Investigational Drugs*. 2002;3(1):54-7. PMID: 2002187573 MEDLINE PMID 12054073 (<http://www.ncbi.nlm.nih.gov/pubmed/12054073>).
201. Jones TF, McMillian M, Boothe E, et al. Hospital discharge data for Guillain-Barre syndrome and influenza A (H1N1) vaccine adverse events. *Emerging Infectious Diseases*. 2010 Sep;16(9):1500-1. PMID: 20735949.
202. Justice FA, Nguyen LT, Tran SN, et al. Recurrent intussusception in infants. *Journal of Paediatrics and Child Health*. 2011 November;47(11):802-5. PMID: 2011636695 MEDLINE PMID 21435072 (<http://www.ncbi.nlm.nih.gov/pubmed/21435072>).
203. Kamboj KK, Kirchner HL, Kimmel R, et al. Significant variation in serotype-specific immunogenicity of the seven-valent *Streptococcus pneumoniae* capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein. *Journal of Infectious Diseases*. 2003 May 15;187(10):1629-38. PMID: 12721943.
204. Kansu E. Late effects of hematopoietic stem cell transplantation. *Hematology*. 2005 September/October;10(SUPPL. 1):238-44. PMID: 2005582014 MEDLINE PMID 16188682 (<http://www.ncbi.nlm.nih.gov/pubmed/16188682>).
205. Kapikian AZ, Hoshino Y, Chanock RM, et al. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. *Journal of Infectious Diseases*. 1996;1996;174(SUPPL. 1):S65-S72. PMID: 1996270930 MEDLINE PMID 8752293 (<http://www.ncbi.nlm.nih.gov/pubmed/8752293>).

206. Kapikian AZ, Vesikari T, Ruuska T, et al. An update on the 'Jennerian' and modified 'Jennerian' approach to vaccination of infants and young children against rotavirus diarrhea. *Advances in Experimental Medicine and Biology*. 1992;1992;327:59-69. PMID: 1993042520 MEDLINE PMID 1295353 (<http://www.ncbi.nlm.nih.gov/pubmed/1295353>).
207. Kapikian AZ, Wyatt RG, Levine MM. Oral administration of human rotavirus to volunteers: Indication of illness and correlates of resistance. *Journal of Infectious Diseases*. 1983;1983;147(1):95-106. PMID: 1983084078 MEDLINE PMID 6296243 (<http://www.ncbi.nlm.nih.gov/pubmed/6296243>).
208. Kaplan J. 1997 USPHS/IDSA report on the prevention of opportunistic infections in patients infected with human immunodeficiency virus. *Pediatrics*. 1998;1998;102(4 II):1064-85. PMID: 1998338714.
209. Karande S, Gogtay NJ, Kshirsagar NA. Improving Drug Safety Monitoring. *Indian Pediatrics*. 2003 December;40(12):1167-75. PMID: 2004003084 MEDLINE PMID 14722367 (<http://www.ncbi.nlm.nih.gov/pubmed/14722367>).
210. Kawakami K, Ohkusa Y, Kuroki R, et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. *Vaccine*. 2010 Oct 8;28(43):7063-9. PMID: 20723631.
211. Kelly HA, Grant KA, Fielding JE, et al. Pandemic influenza H1N1 2009 infection in Victoria, Australia: no evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009. *Vaccine*. 2011 Aug 26;29(37):6419-26. PMID: 21473950.
212. Kelso JM. Update on vaccination guidelines for allergic children. *Expert Review of Vaccines*. 2009 November;8(11):1541-6. PMID: 2009589592 MEDLINE PMID 19863246 (<http://www.ncbi.nlm.nih.gov/pubmed/19863246>).
213. Keyser JS, Derkay CS. *Haemophilus influenzae* type B epiglottitis after immunization with HbOC conjugate vaccine. *American Journal of Otolaryngology*. 1994 Nov-Dec;15(6):436-43. PMID: 7872480.
214. Kharbanda EO, Vazquez-Benitez G, Shi WX, et al. Assessing the safety of influenza immunization during pregnancy: the Vaccine Safety Datalink. *American Journal of Obstetrics & Gynecology*. 2012 Sep;207(3 Suppl):S47-51. PMID: 22920059.
215. Kidd S, Goodson JL, Aramburu J, et al. Poliomyelitis outbreaks in Angola genetically linked to India: risk factors and implications for prevention of outbreaks due to wild poliovirus importations. *Vaccine*. 2011 May 12;29(21):3760-6. PMID: 21440639.
216. King JC, Jr., Vink PE, Farley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency

virus and non-human immunodeficiency virus-infected children. *Pediatric Infectious Disease Journal*. 1996 Mar;15(3):192-6. PMID: 8852905.

217. Kling S. Vaccination and ethical issues. *Current Allergy and Clinical Immunology*. 2009 November;22(4):178-80. PMID: 2010015136.

218. Kobayashi M, Thompson J, Tollefson SJ, et al. Tetraivalent rhesus rotavirus vaccine in young infants. *Journal of Infectious Diseases*. 1994 1994;170(5):1260-3. PMID: 1994331314 MEDLINE PMID 7963722 (<http://www.ncbi.nlm.nih.gov/pubmed/7963722>).

219. Koivula I, Sten M, Leinonen M, et al. Clinical efficacy of pneumococcal vaccine in the elderly: A randomized, single-blind population-based trial. *American Journal of Medicine*. 1997 October;103(4):281-90. PMID: 1997329913 MEDLINE PMID 9382120 (<http://www.ncbi.nlm.nih.gov/pubmed/9382120>).

220. Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. *Lancet Oncology*. 2011 Sep;12(9):862-70. PMID: 21865087.

221. Krueger JG, Ochs HD, Patel P, et al. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: Results of a randomized, single blind study. *Journal of Investigative Dermatology*. 2008 November;128(11):2615-24. PMID: 2008485144 MEDLINE PMID 18496564 (<http://www.ncbi.nlm.nih.gov/pubmed/18496564>).

222. Kuehn BM. CDC panel recommends vaccine for smokers; reviews HPV safety data. *JAMA*. 2008 Dec 17;300(23):2713-4. PMID: 19088341.

223. Kuehn BM. FDA: Benefits of rotavirus vaccination outweigh potential contamination risk. *JAMA - Journal of the American Medical Association*. 2010 7;304(1):30-1. PMID: 2010376206 MEDLINE PMID 20606142 (<http://www.ncbi.nlm.nih.gov/pubmed/20606142>).

224. Kuehn BM. Immunization recommendations expanded for hepatitis B, HPV, pertussis vaccines. *JAMA - Journal of the American Medical Association*. 2012 28;307(13):1353-4. PMID: 2012198374 MEDLINE PMID 22474190 (<http://www.ncbi.nlm.nih.gov/pubmed/22474190>).

225. Kulkarni PS, Sapru A, Bavdekar A, et al. Immunogenicity of two diphtheria-tetanus-whole cell pertussis-hepatitis B vaccines in infants: A comparative trial. *Human Vaccines*. 2011 September;7(9):941-4. PMID: 2011552858.

226. Kwon S, Kim S, Cho M-h, et al. Neurologic complications and outcomes of pandemic (H1N1) 2009 in Korean children. *Journal of Korean Medical Science*. 2012 Apr;27(4):402-7. PMID: 22468104.

227. Kyaw MH, Bramley JC, Chalmers J, et al. Pneumococcal vaccination: opinion of general practitioners and hospital doctors in Scotland, 1999-2000. *Communicable Disease & Public Health*. 2001 Mar;4(1):42-8. PMID: 11467019.
228. Ladhani S, Heath PT, Ramsay ME, et al. Long-term immunological follow-up of children with haemophilus influenzae serotype b vaccine failure in the United Kingdom. *Clinical Infectious Diseases*. 2009 1;49(3):372-80. PMID: 2009376196 MEDLINE PMID 19580418 (<http://www.ncbi.nlm.nih.gov/pubmed/19580418>).
229. Lambert SB, Faux CE, Hall L, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. *Medical Journal of Australia*. 2009 Aug;191(3):157-60. PMID: WOS:000269171100012.
230. Lamontagne F, Garant M-P, Carvalho J-C, et al. Pneumococcal vaccination and risk of myocardial infarction. *CMAJ Canadian Medical Association Journal*. 2008 Oct 7;179(8):773-7. PMID: 18838452.
231. Lanata CF, Black RE, Del Aguila R, et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. *Journal of Infectious Diseases*. 1989 1989;159(3):452-9. PMID: 1989065893 MEDLINE PMID 2536789 (<http://www.ncbi.nlm.nih.gov/pubmed/2536789>).
232. Landrum ML, Hullsiek KH, Ganesan A, et al. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. *Aids*. 2010 February;24(4):545-55. PMID: 2010149504 MEDLINE PMID 19487908 (<http://www.ncbi.nlm.nih.gov/pubmed/19487908>).
233. Lanzieri TM, Linhares AC, Costa I, et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. *International Journal of Infectious Diseases*. 2011 March;15(3):e206-e10. PMID: 2011118561 MEDLINE PMID 21193339 (<http://www.ncbi.nlm.nih.gov/pubmed/21193339>).
234. Lashkari HP, El Bashir H. Immunisations among school leavers: is there a place for measles-mumps-rubella vaccine? 2010: Bulletin European sur les Maladies Transmissibles = European Communicable Disease Bulletin. 15(7), 2010 Apr 29. PMID: 20460082.
235. Laupland KB, Fisman DN. Zoster vaccination: A new opportunity for adult immunization. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2009 Winter;20(4):105-6. PMID: 2010033103.
236. Lazarsfeld R, Cavallario S. Two adult vaccination survey papers. *Vaccine*. 2010 14;28(22):3757. PMID: 2010278607 MEDLINE PMID 20427104 (<http://www.ncbi.nlm.nih.gov/pubmed/20427104>).
237. Lei T, Siu K-L, Kok K-H, et al. Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus. *Vaccine*. 2012 Mar 30;30(16):2605-10. PMID: 22342549.

238. Leonardi S, La Rosa M. Are Hepatitis B Virus and Celiac Disease Linked? *Hepatitis Monthly*. 2010 Sum;10(3):173-5. PMID: WOS:000280521500004.
239. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. *J Infect Dis*. 2008 Mar 15;197(6):825-35. PMID: 18419349.
240. Lewindon PJ, Harkness L, Lewindon N. Randomised controlled trial of sucrose by mouth for the relief of infant crying after immunisation. *Archives of Disease in Childhood*. 1998 May;78(5):453-6. PMID: 9659093.
241. Lewis KDC, Dallas MJ, Victor JC, et al. Comparison of two clinical severity scoring systems in two multi-center, developing country rotavirus vaccine trials in Africa and Asia. *Vaccine*. 2012 27;30(SUPPL. 1):A159-A66. PMID: 2012230588 MEDLINE PMID 22520126 (<http://www.ncbi.nlm.nih.gov/pubmed/22520126>).
242. Lewis RF, Kisakye A, Gessner BD, et al. Action for child survival: elimination of *Haemophilus influenzae* type b meningitis in Uganda. *Bulletin of the World Health Organization*. 2008 Apr;86(4):292-301. PMID: WOS:000255427100012.
243. Liang X, Zhang Y, Xu W, et al. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. *Journal of Infectious Diseases*. 2006 1;194(5):545-51. PMID: 2006416045 MEDLINE PMID 16897650 (<http://www.ncbi.nlm.nih.gov/pubmed/16897650>).
244. Licciardi PV, Balloch A, Russell FM, et al. Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization. *Vaccine*. 2010 14;28(22):3793-800. PMID: 2010278613 MEDLINE PMID 20362199 (<http://www.ncbi.nlm.nih.gov/pubmed/20362199>).
245. Linhares AC, Gabbay YB, Mascarenhas JDP, et al. Immunogenicity, safety and efficacy of tetrivalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. *Bulletin of the World Health Organization*. 1996 1996;74(5):491-500. PMID: 1997012640 MEDLINE PMID 9002329 (<http://www.ncbi.nlm.nih.gov/pubmed/9002329>).
246. Linhares AC, Lanata CF, Hausdorff WP, et al. Reappraisal of the Peruvian and Brazilian lower titer tetrivalent rhesus-human reassortant rotavirus vaccine efficacy trials: analysis by severity of diarrhea. *Pediatric Infectious Disease Journal*. 1999 Nov;18(11):1001-6. PMID: WOS:000083619500012.
247. Linhares AC, Stupka JA, Ciapponi A, et al. Burden and typing of rotavirus group A in Latin America and the Caribbean: Systematic review and meta-analysis. *Reviews in Medical Virology*. 2011 March;21(2):89-109. PMID: 2011169270.
248. Liu H. The changing landscape of global vaccine development and market potential. *BioPharm International*. 2007 October;20(10):115-24. PMID: 2007555743.

249. Liu IF, Huang CC, Chan WL, et al. Effects of annual influenza vaccination on mortality and hospitalization in elderly patients with ischemic heart disease: A nationwide population-based study. *Preventive Medicine*. 2012 June;54(6):431-3. PMID: 2012319341.
250. Long CB, Ramos I, Rastogi D, et al. Humoral and cell-mediated immune responses to monovalent 2009 influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk children. *Journal of Pediatrics*. 2012 Jan;160(1):74-81. PMID: 21840537.
251. Lopert R. Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children. *Eurosurveillance*. 2010 07;15(40):21. PMID: 2010680939.
252. Lopez-Macias C. Virus-like particle (VLP)-based vaccines for pandemic influenza: Performance of a VLP vaccine during the 2009 influenza pandemic. *Human Vaccines and Immunotherapeutics*. 2012 March;8(3):402-5. PMID: 2012244559.
253. Louik C, Chambers C, Jacobs D, et al. Influenza vaccine safety in pregnancy: can we identify exposures? *Pharmacoepidemiology & Drug Safety*. 2013 Jan;22(1):33-9. PMID: 22899209.
254. Macartney KK, Porwal M, Dalton D, et al. Decline in rotavirus hospitalisations following introduction of Australia's national rotavirus immunisation programme. *Journal of Paediatrics and Child Health*. 2011 May;47(5):266-70. PMID: WOS:000290865500006.
255. Madhi SA, Kirsten M, Louw C, et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: A randomized, double-blind, placebo-controlled trial. *Vaccine*. 2012 Apr;30:A44-A51. PMID: WOS:000304850100008.
256. Madhi SA, Kuwanda L, Cutland C, et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. *Pediatric Infectious Disease Journal*. 2005 May;24(5):410-6. PMID: WOS:000229226400003.
257. Magnus MC, Vestreheim DF, Nystad W, et al. Decline in Early Childhood Respiratory Tract Infections in the Norwegian Mother and Child Cohort Study After Introduction of Pneumococcal Conjugate Vaccination. *Pediatric Infectious Disease Journal*. 2012 Sep;31(9):951-5. PMID: WOS:000308197200021.
258. Malakoff D. Aluminum is put on trial as a vaccine booster. *Science*. 2000 26;288(5470):1323-4. PMID: 2000206728.
259. Mangtani P, Shah A, Roberts JA. Validation of influenza and pneumococcal vaccine status in adults based on self-report. *Epidemiology & Infection*. 2007 Jan;135(1):139-43. PMID: 16740194.

260. Manoff SB, Liss C, Caulfield MJ, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years. *J Infect Dis.* 2010 Feb 15;201(4):525-33. PMID: 20088694.
261. Mansoor O. DTPH vaccine. *N Z Med J.* 1994 Sep 28;107(986 Pt 1):382. PMID: 7936471.
262. Marchetti F, Assael B, Gabutti G, et al. Monitoring the rate of hospitalization before rotavirus immunization in Italy utilizing ICD9-CM regional databases. *Human Vaccines.* 2009 2009;5(3):172-6. PMID: 2009301634 MEDLINE PMID 18802404 (<http://www.ncbi.nlm.nih.gov/pubmed/18802404>).
263. Marlow RD, Finn A. The promise of immunisation against rotavirus. *Archives of Disease in Childhood.* 2012 August;97(8):736-40. PMID: 2012467186.
264. Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. *BMJ.* 2010;340:c1004. PMID: 20211953.
265. Mascarenhas JDP, Leite JPG, Gabbay YB, et al. Tetraivalent rhesus-human rotavirus vaccine (RRV-TV) in Belem, Brazil: Efficacy against prevailing P and G genotypes. *Journal of Tropical Pediatrics.* 2002 Oct;48(5):300-2. PMID: WOS:000178120600009.
266. Mato SP, Perrin K, Scardino D, et al. Evaluation of rotavirus vaccine effectiveness in a pediatric group practice. *American Journal of Epidemiology.* 2002 Dec;156(11):1049-55. PMID: WOS:000179603300009.
267. Matys K, Mallary S, Bautista O, et al. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. *Clinical & Vaccine Immunology: CVI.* 2012 Jun;19(6):881-5. PMID: 22518014.
268. Mazzone PJ, Mossad SB, Mawhorter SD, et al. The humoral immune response to influenza vaccination in lung transplant patients. *European Respiratory Journal.* 2001 Dec;18(6):971-6. PMID: WOS:000173857500012.
269. McKenney D, Pouliot KL, Wang Y, et al. Broadly protective vaccine for *Staphylococcus aureus* based on an in vivo-expressed antigen. *Science.* 1999 May 28;284(5419):1523-7. PMID: 10348739.
270. Meier P. Polio trial: An early efficient clinical trial. *Statistics in Medicine.* 1990 1990;9(1 2):13-6. PMID: 1990300272 MEDLINE PMID 2189187 (<http://www.ncbi.nlm.nih.gov/pubmed/2189187>).
271. Merlo HC, Vaid SK, Meyer A, et al. Is it safe to vaccinate children against varicella while they're in close contact with a pregnant woman? *Journal of Family Practice.* 2011 July;60(7):432-3. PMID: 2012088467.

272. Meszner Z, Balogh A, Banyai K, et al. The clinical burden of rotavirus disease: Retrospective analysis of infant and childhood gastroenteritis in seven countries in central and eastern Europe. *Pediatric Infectious Disease Journal*. 2008 January;27(1 SUPPL.):S33-S41. PMID: 2008008163.
273. Migasena S, Simasathien S, Samakoses R, et al. Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants. *Vaccine*. 1995 1995;13(2):168-74. PMID: 1995057755 MEDLINE PMID 7625111 (<http://www.ncbi.nlm.nih.gov/pubmed/7625111>).
274. Milanovic M, Stojanovich L, Djokovic A, et al. Influenza vaccination in autoimmune rheumatic disease patients. *Tohoku Journal of Experimental Medicine*. 2013;229(1):29-34. PMID: 23221145.
275. Mills OF, Rhoads GG. The contribution of the case-control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines. *Journal of Clinical Epidemiology*. 1996 Jun;49(6):631-6. PMID: 8656223.
276. Mishra D, John TJ. Hib, measles and varicella vaccine. *Indian Pediatrics*. 2000 2000;37(11):1279-81. PMID: 2000420113 MEDLINE PMID 11086320 (<http://www.ncbi.nlm.nih.gov/pubmed/11086320>).
277. Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. *Cochrane Database of Systematic Reviews*. 2013;1:CD000422. PMID: 23440780.
278. Moore SR, Lima AAM, Guerrant RL. Preventing 5 million child deaths from diarrhea in the next 5 years. *Nature Reviews Gastroenterology and Hepatology*. 2011 July;8(7):363-4. PMID: 2011375298.
279. Moore SW, Kirsten M, Muller EW, et al. Retrospective Surveillance of Intussusception in South Africa, 1998-2003. *Journal of Infectious Diseases*. 2010 Sep;202:S156-S61. PMID: WOS:000280623700021.
280. Morris SK, Awasthi S, Khera A, et al. Rotavirus mortality in India: Estimates based on a nationally representative survey of diarrhoeal deaths ORIGINAL (NON-ENGLISH) TITLE La mortalite du rotavirus en Inde: Estimations fondaes sur une enquete nationale representative des deces par diarrheae. *Bulletin of the World Health Organization*. 2012 October;90(10):720-7. PMID: 2012587233.
281. Moss SJ, Fenton AC, Toomey JA, et al. Responses to a Conjugate Pneumococcal Vaccine in Preterm Infants Immunized at 2, 3, and 4 Months of Age. *Clinical and Vaccine Immunology*. 2010 Nov;17(11):1810-6. PMID: WOS:000283651200021.

282. Moulton LH, Staat MA, Santosham M, et al. The protective effectiveness of natural rotavirus infection in an American Indian population. *Journal of Infectious Diseases*. 1998 Dec;178(6):1562-6. PMID: WOS:000077466700002.
283. Moyo S, Hawkridge T, Mahomed H, et al. Determining causes of mortality in children enrolled in a vaccine field trial in a rural area in the Western Cape Province of South Africa. *Journal of Paediatrics & Child Health*. 2007 Mar;43(3):178-83. PMID: 17316193.
284. Mrozek-Budzyn D, Kieltyka A, Majewska R, et al. Measles, mumps and rubella (MMR) vaccination has no effect on cognitive development in children - The results of the Polish prospective cohort study. *Vaccine*. 2013 May 24;31(22):2551-7. PMID: 23588083.
285. Muhsen K, Chodick G, Goren S, et al. The uptake of rotavirus vaccine and its effectiveness in preventing acute gastroenteritis in the community. *Vaccine*. 2010 Dec;29(1):91-4. PMID: WOS:000286345000014.
286. Muhsen K, Shulman L, Kasem E, et al. Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel A case-control study. *Human Vaccines*. 2010 Jun;6(6):450-4. PMID: WOS:000281998900012.
287. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. *Lancet*. 1997 Apr;349(9060):1191-7. PMID: WOS:A1997WW71700007.
288. Munos MK, Fischer Walker CL, Black RE. The effect of rotavirus vaccine on diarrhoea mortality. *International Journal of Epidemiology*. 2010 1;39(SUPPL. 1):i56-i62. PMID: 2012544833.
289. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. *Journal of the National Cancer Institute*. 2010 March;102(5):325-39. PMID: 2010160291 MEDLINE PMID 20139221 (<http://www.ncbi.nlm.nih.gov/pubmed/20139221>).
290. Musawi MA, Alhindi SJ, Abu-Elyazeed R, et al. Incidence of intussusception: Five-year hospital-based retrospective review. *Bahrain Medical Bulletin*. 2010;32(2) PMID: 2010396140.
291. Musher DM, Rueda AM, Nahm MH, et al. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. *Journal of Infectious Diseases*. 2008 1;198(7):1019-27. PMID: 2008439919 MEDLINE PMID 18710324 (<http://www.ncbi.nlm.nih.gov/pubmed/18710324>).
292. Naidus E, Damon L, Schwartz BS, et al. Experience with use of Zostavax (R) in patients with hematologic malignancy and hematopoietic cell transplant recipients. *American Journal of Hematology*. 2012 Jan;87(1):123-5. PMID: WOS:000298257700028.

293. Nates SV, Frias M, Belfiore S, et al. Effect on seroprevalence of anti-poliovirus antibodies and on vaccination coverage of the implementation of a DTwP-IPV-Hib vaccination programme in a South American city. *Epidemiology and Infection*. 2011 June;139(6):826-35. PMID: 2011270422 MEDLINE PMID 20587121 (<http://www.ncbi.nlm.nih.gov/pubmed/20587121>).
294. Navar-Boggan AM, Halsey NA, Golden WC, et al. Risk of fever and sepsis evaluations after routine immunizations in the neonatal intensive care unit. *Journal of Perinatology*. 2010 September;30(9):604-9. PMID: 2010478070 MEDLINE PMID 20182438 (<http://www.ncbi.nlm.nih.gov/pubmed/20182438>).
295. Nelson CM, Sutanto A, Gessner BD, et al. Age- and cause-specific childhood mortality in Lombok, Indonesia, as a factor for determining the appropriateness of introducing Haemophilus influenzae type b and pneumococcal vaccines. *Journal of Health, Population & Nutrition*. 2000 Dec;18(3):131-8. PMID: 11262765.
296. Ng SC, Woodrow S, Patel N, et al. Role of genetic and environmental factors in British twins with inflammatory bowel disease. *Inflammatory Bowel Diseases*. 2012 April;18(4):725-36. PMID: 2012167381 MEDLINE PMID 21557397 (<http://www.ncbi.nlm.nih.gov/pubmed/21557397>).
297. Nichol KL. Ten-year durability and success of an organized program to increase influenza and pneumococcal vaccination rates among high-risk adults. *American Journal of Medicine*. 1998 November;105(5):385-92. PMID: 1998399440 MEDLINE PMID 9831422 (<http://www.ncbi.nlm.nih.gov/pubmed/9831422>).
298. Nichol KL, MacDonald R, Hauge M. Side effects associated with pneumococcal vaccination. *American Journal of Infection Control*. 1997 Jun;25(3):223-8. PMID: 9202818.
299. Nightingale SL. Two new child vaccines licenced: Combination DTP and Haemophilus b conjugate vaccine. *Journal of the American Medical Association*. 1993 1993;269(19):2491. PMID: 1993135917.
300. Nokleby H. Vaccination and anaphylaxis. *Current Allergy and Asthma Reports*. 2006 February;6(1):9-13. PMID: 2006153479 MEDLINE PMID 16476188 (<http://www.ncbi.nlm.nih.gov/pubmed/16476188>).
301. Novadzki IM, Rosario Filho N. Anaphylaxis associated with the vaccine against measles, mumps and rubella. *Revista de Saude Publica*. 2010 Apr;44(2):372-6. PMID: 20339639.
302. Novadzki IM, Rosario N, Zanoni G, et al. Hypersensitivity reactions following measles-mumps-rubella vaccine and dextran-specific IgG response. *Allergologia et Immunopathologia*. 2010 November;38(6):341-3. PMID: 2010629506 MEDLINE PMID 20605313 (<http://www.ncbi.nlm.nih.gov/pubmed/20605313>).
303. Obaro S. Rotavirus vaccine efficacy in African and Asian countries. *The Lancet*. 2010 December;376(9756):1897. PMID: 2010669126.

304. Offit P, Plotkin SA, Halsey NA. Preventing harm from thimerosal in vaccines [3] (multiple letter). *Journal of the American Medical Association*. 2000;283(16):2104-5. PMID: 2000159072.
305. Offit PA. The rotavirus vaccine. *Journal of Clinical Virology*. 1998 December;11(3):155-9. PMID: 1999036534 MEDLINE PMID 9949951 (<http://www.ncbi.nlm.nih.gov/pubmed/9949951>).
306. Offit PA, Clark HF. The rotavirus vaccine. *Current Opinion in Pediatrics*. 1999;11(1):9-13. PMID: 1999069764 MEDLINE PMID 10084077 (<http://www.ncbi.nlm.nih.gov/pubmed/10084077>).
307. O'Grady KAF, Lee KJ, Carlin JB, et al. Increased risk of hospitalization for acute lower respiratory tract infection among Australian indigenous infants 5-23 months of age following pneumococcal vaccination: A cohort study. *Clinical Infectious Diseases*. 2010;150(7):970-8. PMID: 2010159432 MEDLINE PMID 20192729 (<http://www.ncbi.nlm.nih.gov/pubmed/20192729>).
308. Okabayashi T, Hanazaki K. Overwhelming postsplenectomy infection syndrome in adults - A clinically preventable disease. *World Journal of Gastroenterology*. 2008 Jan;14(2):176-9. PMID: WOS:000252417100003.
309. Ortqvist A, Berggren I, Insulander M, et al. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm county, Sweden. *Clinical Infectious Diseases*. 2011;15;52(10):1203-11. PMID: 2011229426 MEDLINE PMID 21507917 (<http://www.ncbi.nlm.nih.gov/pubmed/21507917>).
310. Ortqvist A, Granath F, Askling J, et al. Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. *European Respiratory Journal*. 2007 Sep;30(3):414-22. PMID: 17537767.
311. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. *Lancet*. 1998 Feb 7;351(9100):399-403. PMID: 9482293.
312. Osendarp SJM, Fuchs GJ, van Raaij JMA, et al. The effect of zinc supplementation during pregnancy on immune response to Hib and BCG vaccines in Bangladesh. *Journal of Tropical Pediatrics*. 2006 October;52(5):316-23. PMID: 2006499280 MEDLINE PMID 16621858 (<http://www.ncbi.nlm.nih.gov/pubmed/16621858>).
313. Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. *The Lancet Infectious Diseases*. 2012 January;12(1):36-44. PMID: 2011703325 MEDLINE PMID 22032844 (<http://www.ncbi.nlm.nih.gov/pubmed/22032844>).

314. Ott U, Sauerbrei A, Lange J, et al. Serological response to influenza A H1N1 vaccine (Pandemrix) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients. *Medical Microbiology & Immunology*. 2012 Aug;201(3):297-302. PMID: 22350187.
315. Otto S, Mahner B, Kadow I, et al. General non-specific morbidity is reduced after vaccination within the third month of life--the Greifswald study. *Journal of Infection*. 2000 Sep;41(2):172-5. PMID: 11023764.
316. Ozkaya E, Cambaz N, Kolsuz LD, et al. Vaccination coverage and risk factors for incomplete vaccination in children with recurrent wheeze. *Allergologia et Immunopathologia*. 2011 July-August;39(4):222-7. PMID: 2011403962 MEDLINE PMID 21208719 (<http://www.ncbi.nlm.nih.gov/pubmed/21208719>).
317. Pang XL, Joensuu J, Hoshino Y, et al. Rotaviruses detected by reverse transcription polymerase chain reaction in acute gastroenteritis during a trial of rhesus-human reassortant rotavirus tetravalent vaccine: implications for vaccine efficacy analysis. *Journal of Clinical Virology*. 1999 Jun;13(1-2):9-16. PMID: WOS:000081178600002.
318. Parashar UD, Bresee JS, Gentsch JR, et al. Rotavirus. *Emerging Infectious Diseases*. 1998 1998;4(4):561-70. PMID: 1998413712 MEDLINE PMID 9866732 (<http://www.ncbi.nlm.nih.gov/pubmed/9866732>).
319. Parashar UD, Glass RI. Rotavirus vaccines--early success, remaining questions. *New England Journal of Medicine*. 2009 Mar 12;360(11):1063-5. PMID: 19279338.
320. Parashar UD, Holman RC, Cummings KC, et al. Trends in intussusception-associated hospitalizations and deaths among US infants. *Pediatrics*. 2000 2000;106(6):1413-21. PMID: 2000432587 MEDLINE PMID 11099597 (<http://www.ncbi.nlm.nih.gov/pubmed/11099597>).
321. Parke JC, Schneerson R, Reimer C, et al. Clinical and Immunological Responses to Haemophilus-Influenzae Type-B-Tetanus Toxoid Conjugate Vaccine in Infants Injected at 3, 5, 7, and 18 Months of Age. *Journal of Pediatrics*. 1991 Feb;118(2):184-90. PMID: WOS:A1991EX30200003.
322. Parsons HK, Metcalf SC, Tomlin K, et al. Invasive pneumococcal disease and the potential for prevention by vaccination in the United Kingdom. *Journal of Infection*. 2007 May;54(5):435-8. PMID: 17052760.
323. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. *JAMA - Journal of the American Medical Association*. 2009 3;301(21):2243-51. PMID: 2009275023 MEDLINE PMID 19491186 (<http://www.ncbi.nlm.nih.gov/pubmed/19491186>).

324. Patel M, Pedreira C, De Oliveira LH, et al. Duration of protection of pentavalent rotavirus vaccination in Nicaragua. *Pediatrics*. 2012 August;130(2):e365-e72. PMID: 2012454508.
325. Paulke-Korinek M, Rendi-Wagner P, Kundi M, et al. Universal mass vaccination against rotavirus gastroenteritis: Impact on hospitalization rates in Austrian children. *Pediatric Infectious Disease Journal*. 2010 April;29(4):319-23. PMID: 2010197689 MEDLINE PMID 19935446 (<http://www.ncbi.nlm.nih.gov/pubmed/19935446>).
326. Pavli A, Maltezou HC. Travelling to Greece for the summer 2011 Special Olympics. *Travel Medicine and Infectious Disease*. 2011 May;9(3):135-41. PMID: 2011327241 MEDLINE PMID 21570357 (<http://www.ncbi.nlm.nih.gov/pubmed/21570357>).
327. Paximadi E, Karakasiliotis I, Mamuris Z, et al. Genomic analysis of recombinant Sabin clinical isolates. *Virus Genes*. 2006 April;32(2):203-10. PMID: 2006170622 MEDLINE PMID 16604453 (<http://www.ncbi.nlm.nih.gov/pubmed/16604453>).
328. Peltola H. Haemophilus influenzae type b disease and vaccination in Latin America and the Caribbean. *Pediatric Infectious Disease Journal*. 1997 Aug;16(8):780-7. PMID: WOS:A1997XR53200009.
329. Percheson PB, Trepanier P, Dugre R, et al. A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line. *Dev Biol Stand*. 1999;98:127-32; discussion 33-4. PMID: 10494965.
330. Perez N, Iannicelli JC, Girard-Bosch C, et al. Effect of probiotic supplementation on immunoglobulins, isoagglutinins and antibody response in children of low socio-economic status. *European Journal of Nutrition*. 2010 April;49(3):173-9. PMID: 2010220331 MEDLINE PMID 19838618 (<http://www.ncbi.nlm.nih.gov/pubmed/19838618>).
331. Perez-Schael I, Blanco M, Vilar M, et al. Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants. *Journal of Clinical Microbiology*. 1990 1990;28(3):553-8. PMID: 1990078477 MEDLINE PMID 2157737 (<http://www.ncbi.nlm.nih.gov/pubmed/2157737>).
332. Petersen J. HBV treatment and pregnancy. *Journal of Hepatology*. 2011 December;55(6):1171-3. PMID: 2011634955 MEDLINE PMID 21718670 (<http://www.ncbi.nlm.nih.gov/pubmed/21718670>).
333. Phommintikul A, Kuanprasert S, Wongcharoen W. Influenza vaccination reduced cardiovascular events in patients hospitalized with an acute coronary syndrome. *Annals of Internal Medicine*. 2011 20111115;155(10):JC5-. PMID: 2011626757.
334. Phommintikul A, Kuanprasert S, Wongcharoen W, et al. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. *European Heart Journal*. 2011 Jul;32(14):1730-5. PMID: 21289042.

335. Pierson DL, Mehta SK, Gilden D, et al. Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax immunization. *Journal of Infectious Diseases*. 2011 Jun 1;203(11):1542-5. PMID: 21592982.
336. Pilishvili T, Zell ER, Farley MM, et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. *Pediatrics*. 2010 Jul;126(1):e9-17. PMID: 20547641.
337. Pittman PR, Coonan KM, Gibbs PH, et al. Long-term health effects of repeated exposure to multiple vaccines. *Vaccine*. 2004 Sep;23(4):525-36. PMID: 2004471640 MEDLINE PMID 15530702 (<http://www.ncbi.nlm.nih.gov/pubmed/15530702>).
338. Pliaka V, Dedepsidis E, Kyriakopoulou Z, et al. Growth kinetic analysis of bi-recombinant poliovirus vaccine strains. *Virus Genes*. 2010 Apr;40(2):200-11. PMID: 20091423.
339. Pluta RM, Lymph C, Golub RM. Guillain-Barre syndrome. *JAMA - Journal of the American Medical Association*. 2011 Jan 19;305(3):319. PMID: 2011042009.
340. Pool V, Braun MM, Kelso JM, et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. *Pediatrics*. 2002 Dec;110(6):e71. PMID: 12456938.
341. Powell ND, Allen RG, Hufnagle AR, et al. Stressor-Induced Alterations of Adaptive Immunity to Vaccination and Viral Pathogens. *Immunology and Allergy Clinics of North America*. 2011 February;31(1):69-79. PMID: 2010647643 MEDLINE PMID 21094924 (<http://www.ncbi.nlm.nih.gov/pubmed/21094924>).
342. Puig-Barbera J, Diez-Domingo J, Hoyos SP, et al. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. *Vaccine*. 2004 Dec;23(3):283-9. PMID: WOS:000225778600004.
343. Rabbone I, Scaramuzza AE, Iafusco D, et al. Pandemic influenza vaccination coverage in children with type 1 diabetes: analysis from seven Italian centers. *Human Vaccines*. 2011 Dec;7(12):1291-2. PMID: 22108031.
344. Ratajczak HV. Theoretical aspects of autism: Causes-A review. *Journal of Immunotoxicology*. 2011 January-March;8(1):68-79. PMID: 2011082091 MEDLINE PMID 21299355 (<http://www.ncbi.nlm.nih.gov/pubmed/21299355>).
345. Rhorer J, Ambrose CS, Dickinson S, et al. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. *Vaccine*. 2009 Feb 11;27(7):1101-10. PMID: 19095024.
346. Robinson CG, Hernanz-Schulman M, Zhu Y, et al. Evaluation of anatomic changes in young children with natural rotavirus infection: is intussusception biologically plausible? *Journal of Infectious Diseases*. 2004 Apr 15;189(8):1382-7. PMID: 15073674.

347. Robke JT, Woods M, Heitz S. Pharmacist impact on pneumococcal vaccination rates through incorporation of immunization assessment into critical pathways in an acute care setting. *Hospital Pharmacy*. 2002 Oct;37(10):1050-4. PMID: 2002374438.
348. Rodenburg GD, van Gils EJM, Veenhoven RH, et al. Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses. *Vaccine*. 2010 Feb;28(5):1391-6. PMID: WOS:000275122200035.
349. Rogalewski A, Kraus J, Hasselblatt M, et al. Improvement of advanced postvaccinal demyelinating encephalitis due to plasmapheresis. *Neuropsychiatric Disease and Treatment*. 2007;3(6):987-91. PMID: 2008025711.
350. Rojas OL, Caicedo L, Guzman C, et al. Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine. *Viral Immunology*. 2007 Jun;20(2):300-11. PMID: WOS:000247717100008.
351. Rose J, Hawthorn RL, Watts B, et al. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: Model based analysis. *BMJ*. 2009 3;(2009) 339(7724):787-91. PMID: 2009523077.
352. Rowe IA, Parker R, Armstrong MJ, et al. Hepatitis A virus vaccination in persons with hepatitis C virus infection: Consequences of quality measure implementation. *Hepatology*. 2012;56(2):501-6.
353. Ruggeberg JU, Collins C, Clarke P, et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. *Vaccine*. 2007 Jan;25(2):264-71. PMID: WOS:000243614900005.
354. Russell FM, Balloch A, Tang MLK, et al. Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. *Vaccine*. 2009 Sep;27(41):5685-91. PMID: WOS:000270070400020.
355. Saaka M, Okoko BJ, Kohberger RC, et al. Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia. *Vaccine*. 2008 Jul;26(29-30):3719-26. PMID: WOS:000257649000023.
356. Santosham M, Rivin B, Wolff M, et al. Prevention of Haemophilus-Influenzae Type-B Infections in Apache and Navajo Children. *Journal of Infectious Diseases*. 1992 Jun;165:S144-S51. PMID: WOS:A1992HW74500048.
357. Schaffer SA, Husain S, Delgado DH, et al. Impact of Adjuvanted H1N1 Vaccine on Cell-Mediated Rejection in Heart Transplant Recipients. *American Journal of Transplantation*. 2011 Dec;11(12):2751-4. PMID: WOS:000297411800028.

358. Scheifele D, Bjornsen GL, Arcand T, et al. Antigenuria after receipt of Haemophilus b diphtheria toxoid conjugate vaccine. *Pediatric Infectious Disease Journal*. 1989 Dec;8(12):887-8. PMID: 2626290.
359. Schneider L, Weinberg A, Boguniewicz M, et al. Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls. *Journal of Allergy & Clinical Immunology*. 2010 Dec;126(6):1306-7.e2. PMID: 20889193.
360. Schneider LC, Insel RA, Howie G, et al. Response to a Haemophilus influenzae type b diphtheria CRM(197) conjugate vaccine in children with a defect of antibody production to Haemophilus influenzae type b polysaccharide. *Journal of Allergy and Clinical Immunology*. 1990;1990;85(5):948-53. PMID: 1990173492 MEDLINE PMID 2332568 (<http://www.ncbi.nlm.nih.gov/pubmed/2332568>).
361. Schonbeck Y, Sanders EAM, Hoes AW, et al. Rationale and design of the prevention of respiratory infections and management in children (PRIMAKid) study - A randomized controlled trial on the effectiveness and costs of combined influenza and pneumococcal vaccination in pre-school children with recurrent respiratory tract infections. *Vaccine*. 2005 Sep;23(41):4906-14. PMID: WOS:000232189500003.
362. Schutz K, Hughes RG, Parker A, et al. Kinetics of IgM and IgA Antibody Response to 23-Valent Pneumococcal Polysaccharide Vaccination in Healthy Subjects. *Journal of Clinical Immunology*. 2012.
363. Schwartz JL. The first rotavirus vaccine and the politics of acceptable risk. *Milbank Quarterly*. 2012 Jun;90(2):278-310. PMID: 22709389.
364. Scott JAG, Ojal J, Ashton L, et al. Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. *Clinical Infectious Diseases*. 2011 Oct;53(7):663-70. PMID: 21865175.
365. Scott JR, Millar EV, Lipsitch M, et al. Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in native American communities. *Journal of Infectious Diseases*. 2012;15;205(2):280-8. PMID: 2012001251 MEDLINE PMID 22128315 (<http://www.ncbi.nlm.nih.gov/pubmed/22128315>).
366. Shankar S, Dhiman P, Kumar PG. Early undifferentiated arthritis in India: A six month follow up study. *Indian Journal of Rheumatology*. 2010 September;5(3):118-23. PMID: 2010541421.
367. Sharts-Hopko NC. HIB: a new conjugate and a combination vaccine. *MCN Am J Matern Child Nurs*. 1994 Jan-Feb;19(1):56. PMID: 8201867.

368. Shaw RD, Fong KJ, Losonsky GA, et al. Epitope-specific immune responses to rotavirus vaccination. *Gastroenterology*. 1987;1987;93(5):941-50. PMID: 1988000635 MEDLINE PMID 2443417 (<http://www.ncbi.nlm.nih.gov/pubmed/2443417>).
369. Shehab ZM, Azimi P, Asmar BI, et al. Immunogenicity and reactogenicity of Haemophilus influenzae Type b - meningococcus group B outer membrane protein conjugate vaccine in children 2-60 months of age. *Scandinavian Journal of Infectious Diseases*. 1991;1991;23(6):763-9. PMID: 1992064809 MEDLINE PMID 1815340 (<http://www.ncbi.nlm.nih.gov/pubmed/1815340>).
370. Shih A, Quinley J, Lee T-K, et al. Assessing pneumococcal revaccination safety among New York State Medicare beneficiaries. *Public Health Reports*. 2002 Mar-Apr;117(2):164-73. PMID: 12357001.
371. Shin S, Anh DD, Zaman K, et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. *Vaccine*. 2012 Apr;30:A106-A13. PMID: WOS:000304850100016.
372. Shinefield HR, Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. *Pediatric Infectious Disease Journal*. 2000 April;19(4):394-7. PMID: 2000142098 MEDLINE PMID 10783042 (<http://www.ncbi.nlm.nih.gov/pubmed/10783042>).
373. Shinefield HR, Pichichero ME. Rotavirus vaccine (RotaTeq[®]): Profile report. *Drugs and Therapy Perspectives*. 2006;22(10):5-6. PMID: 2006453308.
374. Short JA, Van Der Walt JH, Zoanetti DC. Immunization and anesthesia - An international survey. *Paediatric Anaesthesia*. 2006 May;16(5):514-22. PMID: 2006182206 MEDLINE PMID 16677260 (<http://www.ncbi.nlm.nih.gov/pubmed/16677260>).
375. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. *Vaccine*. 2007 May;25(19):3816-26. PMID: WOS:000246419100010.
376. Silfverdal SA, Berg S, Hemlin C, et al. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine. *Vaccine*. 2009 Mar;27(10):1601-8. PMID: WOS:000264264600019.
377. Silk H, Zora J, Goldstein J, et al. Response to pneumococcal immunization in children with and without recurrent infections. *Journal of Asthma*. 1998;35(1):101-12. PMID: WOS:000072401900010.
378. Silvers LE, Ellenberg SS, Wise RP, et al. The epidemiology of fatalities reported to the Vaccine Adverse Event Reporting System 1990-1997. *Pharmacoepidemiology and Drug Safety*. 2001;2001;10(4):279-85. PMID: 2001395284 MEDLINE PMID 11760487 (<http://www.ncbi.nlm.nih.gov/pubmed/11760487>).

379. Simon JK, Ramirez K, Cuberos L, et al. Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. *Clinical and Vaccine Immunology*. 2011 March;18(3):355-61. PMID: 2011144853 MEDLINE PMID 21228137 (<http://www.ncbi.nlm.nih.gov/pubmed/21228137>).
380. Simpson CR, Ritchie LD, Robertson C, et al. Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study. *The Lancet Infectious Diseases*. 2012.
381. Sinisalo M, Vilpo J, Itala M, et al. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. *Vaccine*. 2007 Dec;26(1):82-7. PMID: WOS:000252490700010.
382. Siscovick DS, Raghunathan TE, Lin D, et al. Influenza vaccination and the risk of primary cardiac arrest. *Am J Epidemiol*. 2000 Oct 1;152(7):674-7. PMID: 11032163.
383. Skowronski DM, de Serres G, Crowcroft NS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: Four observational studies from Canada. *PLoS Medicine*. 2010;7(4) PMID: 2010257356.
384. Smith LM, Brassard P, Kwong JC, et al. Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an ontario cohort of grade 8 girls. *BMC Public Health*. 2011 Aug;11 PMID: WOS:000295379000001.
385. Smith-Norowitz TA, Wong D, Kusonruksa M, et al. Long term persistence of IgE anti-influenza virus antibodies in pediatric and adult serum post vaccination with influenza virus vaccine. *International Journal of Medical Sciences*. 2011 2011;8(3):239-44. PMID: 2011237366 MEDLINE PMID 21448311 (<http://www.ncbi.nlm.nih.gov/pubmed/21448311>).
386. Sood SK, Daum RS. Disease caused by *Haemophilus influenzae* type b in the immediate period after homologous immunization: Immunologic investigation. *Pediatrics*. 1990 1990;85(4 SUPPL.):698-704. PMID: 1990099883 MEDLINE PMID 2107522 (<http://www.ncbi.nlm.nih.gov/pubmed/2107522>).
387. Spackova M, Wiese-Posselt M, Dehnert M, et al. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. *Vaccine*. 2010 8;28(3):686-91. PMID: 2009621836 MEDLINE PMID 19874924 (<http://www.ncbi.nlm.nih.gov/pubmed/19874924>).
388. Staat MA, Cortese MM, Bresee JS, et al. Rhesus rotavirus vaccine effectiveness and factors associated with receipt of vaccine. *Pediatric Infectious Disease Journal*. 2006 Nov;25(11):1013-8. PMID: 17072123.
389. Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. *Br J Cancer*. 2007 May 7;96(9):1320-3. PMID: 17375045.

390. Stassen PM, Sanders JS, Kallenberg CG, et al. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. *Nephrol Dial Transplant*. 2008 Feb;23(2):654-8. PMID: 17913738.
391. Steele AD, Neuzil KM, Cunliffe NA, et al. Human rotavirus vaccine Rotarix(trademark) provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. *BMC Infectious Diseases*. 2012;12(213) PMID: 2012579883.
392. Stenius-Aarniala B, Huttunen JK, Pyhala R, et al. Lack of clinical exacerbations in adults with chronic asthma after immunization with killed influenza virus. *Chest*. 1986 Jun;89(6):786-9. PMID: 3709244.
393. Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). *Clin Dev Immunol*. 2006 Jun-Dec;13(2-4):373-5. PMID: 17162380.
394. Svanstrm H, Callrus T, Hviid A. Temporal data mining for adverse events following immunization in nationwide danish healthcare databases. *Drug Safety*. 2010 2010;33(11):1015-25. PMID: 2010563351 MEDLINE PMID 20925439 (<http://www.ncbi.nlm.nih.gov/pubmed/20925439>).
395. Swinler GH, Michaels D, Hussey GG. WITHDRAWN: Conjugate vaccines for preventing *Haemophilus influenzae* type B infections. *Cochrane Database of Systematic Reviews*. 2009(4):CD001729. PMID: 19821280.
396. Taddio A, Ilersich AL, Ipp M, et al. Physical interventions and injection techniques for reducing injection pain during routine childhood immunizations: Systematic review of randomized controlled trials and quasi-randomized controlled trials. *Clinical Therapeutics*. 2009 2009;31(SUPPL. 2):S48-S76. PMID: 2009495233 MEDLINE PMID 19781436 (<http://www.ncbi.nlm.nih.gov/pubmed/19781436>).
397. Takahashi K, Ohkusa Y, Kim J-Y. The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study. *BMC Health Services Research*. 2011;11:254. PMID: 21978107.
398. Tan TQ, Gerbie MV. Pertussis and patient safety: implementing Tdap vaccine recommendations in hospitals. *Joint Commission Journal on Quality & Patient Safety*. 2010 Apr;36(4):173-8. PMID: 20402374.
399. Temte JL. Should all children be immunised against hepatitis A? *British Medical Journal*. 2006 25;332(7543):715-8. PMID: 2006442504 MEDLINE PMID 16565129 (<http://www.ncbi.nlm.nih.gov/pubmed/16565129>).
400. Tenembaum S, Chitnis T, Ness J, et al. Acute disseminated encephalomyelitis. *Neurology*. 2007 April;68(16 SUPPL. 2):S23-S36. PMID: 2007196097 MEDLINE PMID 17438235 (<http://www.ncbi.nlm.nih.gov/pubmed/17438235>).

401. Tessmer A, Welte T, Schmidt-Ott R, et al. Influenza vaccination is associated with reduced severity of community-acquired pneumonia. *European Respiratory Journal*. 2011;38(1):147-53. PMID: 2011380784 MEDLINE PMID 21148226 (<http://www.ncbi.nlm.nih.gov/pubmed/21148226>).
402. Tomljenovic L, Shaw CA. No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil? *Journal of Internal Medicine*. 2012.
403. Tseng YT, Sun HY, Chang SY, et al. Seroprevalence of hepatitis virus infection in men who have sex with men aged 18-40 years in Taiwan. *Journal of the Formosan Medical Association*. 2012.
404. Usen S, Adegbola R, Mulholland K, et al. Epidemiology of invasive pneumococcal disease in the Western Region, The Gambia. *Pediatric Infectious Disease Journal*. 1998 Jan;17(1):23-8. PMID: WOS:000071617000005.
405. Valente C, Hinds J, Pinto F, et al. Decrease in Pneumococcal Co-Colonization following Vaccination with the Seven-Valent Pneumococcal Conjugate Vaccine. *PLoS ONE [Electronic Resource]*. 2012 Jan;7(1) PMID: WOS:000301357100048.
406. van den Biggelaar AHJ, Pomat W, Bosco A, et al. Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance. *Vaccine*. 2011;26;29(33):5414-20. PMID: 2011390305 MEDLINE PMID 21645573 (<http://www.ncbi.nlm.nih.gov/pubmed/21645573>).
407. van Gils EJM, Hak E, Veenhoven RH, et al. Effect of Seven-Valent Pneumococcal Conjugate Vaccine on *Staphylococcus aureus* Colonisation in a Randomised Controlled Trial. *PLoS ONE [Electronic Resource]*. 2011 Jun;6(6) PMID: WOS:000291612600007.
408. Van Holle L, Zeinoun Z, Bauchau V, et al. Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: A proof of concept study. *Pharmacoepidemiology and Drug Safety*. 2012 June;21(6):603-10. PMID: 2012338995.
409. Vandebrouaene M, Colebunders R, Mascartlemone F, et al. Equal IgG Antibody-Response to Pneumococcal Vaccination in All Stages of Human-Immunodeficiency-Virus Disease. *Journal of Infectious Diseases*. 1995 Aug;172(2):551-3. PMID: WOS:A1995RK46400033.
410. Verstraeten T, DeStefano F, Chen RT, et al. Vaccine safety surveillance using large linked databases: Opportunities, hazards and proposed guidelines. *Expert Review of Vaccines*. 2003 February;2(1):21-9. PMID: 2003192795 MEDLINE PMID 12901594 (<http://www.ncbi.nlm.nih.gov/pubmed/12901594>).
411. Vesikari T. Clinical trials of live oral rotavirus vaccines: the Finnish experience. *Vaccine*. 1993;11(2):255-61. PMID: 8382419.

412. Vesikari T. Rotavirus vaccine studies in Europe. *Acta Paediatrica, International Journal of Paediatrics, Supplement*. 1999;1999;88(426):9-13. PMID: 1999074634 MEDLINE PMID: 10088905 (<http://www.ncbi.nlm.nih.gov/pubmed/10088905>).
413. Vesikari T, Itzler R, Matson DO, et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). *International Journal of Infectious Diseases*. 2007 Nov;11 Suppl 2:S29-35. PMID: 18162243.
414. Vesikari T, Karvonen A, Ferrante SA, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq[REGISTERED], in Finnish infants up to 3[NON-BREAKING SPACE]years of age: the Finnish Extension Study. *European Journal of Pediatrics*. 2010 Nov;169(11):1379-86. PMID: 20559656.
415. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. *Lancet*. 2007;24;370(9601):1757-63. PMID: 2007564672 MEDLINE PMID: 18037080 (<http://www.ncbi.nlm.nih.gov/pubmed/18037080>).
416. Vesikari T, Prymula R, Schuster V, et al. Efficacy and Immunogenicity of Live-attenuated Human Rotavirus Vaccine in Breast-fed and Formula-fed European Infants. *Pediatric Infectious Disease Journal*. 2012 May;31(5):509-13. PMID: WOS:000303730400016.
417. Vesikari T, Ruuska T, Green KY, et al. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. *Pediatric Infectious Disease Journal*. 1992;1992;11(7):535-42. PMID: 1992228151 MEDLINE PMID: 1326741 (<http://www.ncbi.nlm.nih.gov/pubmed/1326741>).
418. Viboud C, Simonsen L. Does seasonal influenza vaccination increase the risk of illness with the 2009 A/H1N1 pandemic virus? *International Journal of Risk and Safety in Medicine*. 2011;2011;23(2):97-102. PMID: 2011468274.
419. Vidal K, Bucheli P, Gao Q, et al. Immunomodulatory effects of dietary supplementation with a milk-based wolfberry formulation in healthy elderly: A randomized, double-blind, placebo-controlled trial. *Rejuvenation Research*. 2012;1;15(1):89-97. PMID: 2012110336 MEDLINE PMID: 22352435 (<http://www.ncbi.nlm.nih.gov/pubmed/22352435>).
420. Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O, et al. Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. *BMC Public Health*. 2010;10:25. PMID: 20085658.
421. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Ineffectiveness of Pneumococcal Vaccination in Cardiovascular Prevention: The CAPAMIS Study. *JAMA Intern Med*. 2013 May;27:1-3. PMID: 23712335.

422. Visser A, Hoosen A. Combination vaccines in the South African setting. *Vaccine*. 2012;7;30(SUPPL.3):C38-C44. PMID: 2012515649.
423. Vlachopoulos C, Xaplanteris P, Sambatakou H, et al. Acute systemic inflammation induced by influenza A (H1N1) vaccination causes a deterioration in endothelial function in HIV-infected patients. *HIV Medicine*. 2011 November;12(10):594-601. PMID: 2011585144 MEDLINE PMID 21645196 (<http://www.ncbi.nlm.nih.gov/pubmed/21645196>).
424. Vondracek TG, Pham TP, Huycke MM. A hospital-based pharmacy intervention program for pneumococcal vaccination. *Archives of Internal Medicine*. 1998 1998;158(14):1543-7. PMID: 1998247282 MEDLINE PMID 9679795 (<http://www.ncbi.nlm.nih.gov/pubmed/9679795>).
425. Vos BD, Delem A, Hardt K, et al. A short report on clinical evaluation of RIX4414: highlights of world-wide development. *Vaccine*. 2006 1;24(18):3777-8. PMID: 2006202646 MEDLINE PMID 16584814 (<http://www.ncbi.nlm.nih.gov/pubmed/16584814>).
426. Vu DM, De Boer AW, Danzig L, et al. Priming for immunologic memory in adults by meningococcal group C conjugate vaccination. *Clinical and Vaccine Immunology*. 2006 June;13(6):605-10. PMID: 2006329179 MEDLINE PMID 16760316 (<http://www.ncbi.nlm.nih.gov/pubmed/16760316>).
427. Vzquez-Lvarez MDC, Medrano-Lpez C, Camino-Lpez M. H1N1 influenza vaccination and infection in pediatric heart transplants. *Journal of Heart and Lung Transplantation*. 2010 November;29(11):1318. PMID: 2010595915 MEDLINE PMID 20822923 (<http://www.ncbi.nlm.nih.gov/pubmed/20822923>).
428. Waites KB, Canupp KC, Edwards K, et al. Immunogenicity of pneumococcal vaccine in persons with spinal cord injury. *Archives of Physical Medicine and Rehabilitation*. 1998 Dec;79(12):1504-9. PMID: WOS:000077421800003.
429. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. *Pediatrics*. 2010 February;125(2):e208-e13. PMID: 2010090832 MEDLINE PMID 20100757 (<http://www.ncbi.nlm.nih.gov/pubmed/20100757>).
430. Wang TJ, Hu CC, Lin HC. Increased risk of anterior uveitis following herpes zoster: A nationwide population-based study. *Archives of Ophthalmology*. 2012 April;130(4):451-5. PMID: 2012229090 MEDLINE PMID 22491915 (<http://www.ncbi.nlm.nih.gov/pubmed/22491915>).
431. Ward J, Brenneman G, Letson GW, et al. Limited efficacy of *Haemophilus influenzae* type b conjugate vaccine in Alaska native infants. *New England Journal of Medicine*. 1990 1990;323(20):1393-401. PMID: 1991010714 MEDLINE PMID 2233906 (<http://www.ncbi.nlm.nih.gov/pubmed/2233906>).

432. Ward RL, Bernstein DI, Smith VE, et al. Rotaviruses immunoglobulin A responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. *Journal of Infectious Diseases*. 2004;189(12):2290-3. PMID: 2004254623.
433. Warne G. Letter from Australia [2]. *National Medical Journal of India*. 2007 November/December;20(6):313-4. PMID: 2008076759.
434. Wehrle PF. Injury associated with the use of vaccines. *Clinical Therapeutics*. 1985;7(3):282-4. PMID: 1985174497 MEDLINE PMID 3873276 (<http://www.ncbi.nlm.nih.gov/pubmed/3873276>).
435. Weinberg A, Song LY, Walker R, et al. Anti-Influenza Serum and Mucosal Antibody Responses After Administration of Live Attenuated or Inactivated Influenza Vaccines to HIV-Infected Children. *J AIDS-Journal of Acquired Immune Deficiency Syndromes*. 2010 Oct;55(2):189-96. PMID: WOS:000282504100014.
436. Weinberg GA, Murphy TV, Granoff DM. Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in vaccinated children who developed Haemophilus disease. *Pediatrics*. 1990 Oct;86(4):617-20. PMID: 2216629.
437. Weinberg SH, Butchart AT, Davis MM. Size of clinical trials and introductory prices of prophylactic vaccine series. *Human Vaccines and Immunotherapeutics*. 2012 August;8(8):1066-70. PMID: 2012533263.
438. Weir E. Meningococcal disease: Oh no, not another childhood vaccine. *Canadian Medical Association Journal*. 2002;166(8):1064-6. PMID: 2002139317 MEDLINE PMID 12002985 (<http://www.ncbi.nlm.nih.gov/pubmed/12002985>).
439. Wenger JD, Pierce R, Deaver KA, et al. Efficacy of Haemophilus-Influenzae Type-B Polysaccharide-Diphtheria Toxoid Conjugate Vaccine in United-States Children Aged 18-59 Months. *Lancet*. 1991 Aug;338(8764):395-8. PMID: WOS:A1991GB44600001.
440. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. *Lancet*. 2006 Oct;368(9546):1495-502. PMID: WOS:000241582700027.
441. Widdowson MA, Steele D, Vojdani J, et al. Global rotavirus surveillance: Determining the need and measuring the impact of rotavirus vaccines. *Journal of Infectious Diseases*. 2009 November;200(SUPPL. 1):S1-S8. PMID: 2010002010 MEDLINE PMID 19817589 (<http://www.ncbi.nlm.nih.gov/pubmed/19817589>).
442. Wilson K, Hawken S, Kwong JC, et al. Impact of birth weight at term on rates of emergency room visits and hospital admissions following vaccination at 2 months of age. *Vaccine*. 2011 Oct;29(46):8267-74. PMID: WOS:000296988500014.

443. Winston CA, Wortley PM, Lees KA. Factors associated with vaccination of medicare beneficiaries in five US Communities: Results from the racial and ethnic adult disparities in immunization initiative survey, 2003. *Journal of the American Geriatrics Society*. 2006 Feb;54(2):303-10. PMID: WOS:000235098300015.
444. Wiwanitkit V. MR finding in vaccine-associated paralytic poliomyelitis. *Pediatric Radiology*. 2010 Sep;40(9):1583; author reply 4. PMID: 20567967.
445. Wolfe MS. Travel medicine. *Current Opinion in Infectious Diseases*. 1999 1999;12(5):433-8. PMID: 1999431286.
446. Wong CM, Yang L, Chan KP, et al. Influenza-associated hospitalization in a subtropical city. *PLoS Medicine / Public Library of Science*. 2006 Apr;3(4):e121. PMID: 16515368.
447. Wood N, McIntyre P, Marshall H, et al. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. *Pediatric Infectious Disease Journal*. 2010 Mar;29(3):209-15. PMID: 20009964.
448. Wortley PM, Farizo KM, Sorillo F, et al. Pneumococcal and Influenza Vaccination Levels among Hiv-Infected Adolescents and Adults Receiving Medical-Care in the United-States. *AIDS*. 1994 Jul;8(7):941-4. PMID: WOS:A1994NU94700010.
449. Wyman MN, Richard J-L, Vidondo B, et al. Prospective pertussis surveillance in Switzerland, 1991-2006. *Vaccine*. 2011 Mar 3;29(11):2058-65. PMID: 21251904.
450. Yalcin SS, Kondolot M, Albayrak N, et al. Serological response to influenza vaccine after hematopoietic stem cell transplantation. *Annals of Hematology*. 2010 Sep;89(9):913-8. PMID: 20119669.
451. Yao X, Hamilton RG, Weng NP, et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. *Vaccine*. 2011 12;29(31):5015-21. PMID: 2011358003 MEDLINE PMID 21565245 (<http://www.ncbi.nlm.nih.gov/pubmed/21565245>).
452. Yawn BP, Wollan P, St Sauver J. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? *American Journal of Epidemiology*. 2011 Nov 1;174(9):1054-61. PMID: 21920944.
453. Ye Y, Wang W, Wang X, et al. The clinical epidemiology of pediatric patients with measles from 2000 to 2009 in shanghai, china. *Clinical Pediatrics*. 2011 Oct;50(10):916-22. PMID: 21561935.
454. Yen C, Figueroa JR, Uribe ES, et al. Monovalent rotavirus vaccine provides protection against An emerging fully heterotypic G9P[4] rotavirus strain in Mexico. *Journal of Infectious Diseases*. 2011 1;204(5):783-6. PMID: 2011456652 MEDLINE PMID 21810915 (<http://www.ncbi.nlm.nih.gov/pubmed/21810915>).

455. Zerr DM, Blume HK, Berg AT, et al. Nonfebrile illness seizures: A unique seizure category? *Epilepsia*. 2005 Jun;46(6):952-5. PMID: WOS:000229802200018.
456. Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. *Arthritis Research & Therapy*. 2011;13(5):R174. PMID: 22024532.
457. Zhang Q, Pettitt E, Burkinshaw R, et al. Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. *Pediatric Infectious Disease Journal*. 2002;21(3):209-13. PMID: 2002097518 MEDLINE PMID 12005084 (<http://www.ncbi.nlm.nih.gov/pubmed/12005084>).
458. Zwiauer KF, Weinzettel R, Zwiauer VM. Clinical manifestation of intusseption before and after introduction of an oral rotavirus vaccine in austria. *Journal of Pediatric Gastroenterology and Nutrition*. 2011 June;52 SUPPL. 1:E165-E6.

Rejected for Design (Individual Case Report, No Comparison Group, Commentary, Non-Systematic Review, Passive Surveillance) – 1,549

1. Polio vaccine and congenital defects. British Medical Journal. 1967 Feb 25;1(5538):510. PMID: 6017538.
2. Pneumococcal polysaccharide vaccine. Recommendation of the Immunization Practices Advisory Committee. Annals of Internal Medicine. 1982 Feb;96(2):203-5. PMID: 6277218.
3. Pneumococcal vaccine. Health and Public Policy Committee, American College of Physicians. Annals of Internal Medicine. 1986 Jan;104(1):118-20. PMID: 3940479.
4. Immunization during pregnancy. ACOG technical bulletin number 160--October 1991. International Journal of Gynaecology & Obstetrics. 1993 Jan;40(1):69-79. PMID: 8094357.
5. Facts about pertussis and DTP vaccine. EPI Newsletter. 1994 Jun;16(3):5. PMID: 12345538.
6. WHO meeting on maternal and neonatal pneumococcal immunization. Weekly Epidemiological Record. 1998 Jun 19;73(25):187-8. PMID: 9648498.
7. From the Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. JAMA. 1999 Dec 8;282(22):2113-4. PMID: 10591321.
8. Measles immunization in HIV-infected children. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Pediatric AIDS. Pediatrics. 1999 May;103(5 Pt 1):1057-60. PMID: 10224192.
9. Pneumococcal vaccination for elderly subjects: license extension. Still no proof of clinical efficacy. Prescrire International. 2000 Aug;9(48):106-9. PMID: 11067718.
10. 7-valent pneumococcal conjugate vaccine: new preparation. Prevents rare invasive infections in infants. Prescrire International. 2002 Feb;11(57):7-10. PMID: 11985376.
11. Rotavirus vaccine ready for licensing. WHO Drug Information. 2004 2004;18(2):129-30. PMID: 2004362555.
12. CDC's advisory committee recommends new vaccine to prevent rotavirus. Indian Journal of Medical Sciences. 2006 Feb;60(2):89-90. PMID: 16538799.
13. Global Advisory Committee on Vaccine Safety, 1-2 December 2005. Weekly Epidemiological Record. 2006 Jan 13;81(2):15-9. PMID: 16671243.
14. New rotavirus vaccine is likely on its way. Child Health Alert. 2006 Feb;24:1. PMID: 16526105.

15. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants. *Prescrire International*. 2006 Dec;15(86):227-33. PMID: 17167934.
16. RotaTeq: A new oral rotavirus vaccine. *Medical Letter on Drugs and Therapeutics*. 2006 31;48(1240):61-3. PMID: 2008221795 MEDLINE PMID 16874281 (<http://www.ncbi.nlm.nih.gov/pubmed/16874281>).
17. New rotavirus vaccines safe and effective in large clinical trials. *Gastroenterology*. 2006 Mar;130(3):627-8. PMID: WOS:000236210100001.
18. Rotavirus vaccine and intussusception. *WHO Drug Information*. 2007 2007;21(1):8. PMID: 2008001204.
19. Safety updates on rotavirus vaccine. *Expert Review of Vaccines*. 2007 Apr;6(2):130-. PMID: WOS:000245821400005.
20. Adjuvanted hepatitis B vaccine: new drug. Patients with renal failure: similar response rate but fewer boosters needed. *Prescrire International*. 2008 Dec;17(98):234-6. PMID: 19422145.
21. Risk levels for febrile seizures with combined measles-mumps-rubella-varicella vaccine. *Expert Review of Vaccines*. 2010 Aug;9(8):810-. PMID: WOS:000281104800004.
22. Herpes zoster vaccine (Zostavax) revisited. *Medical Letter on Drugs and Therapeutics*. 2010 31;52(1339):41. PMID: 2010390996 MEDLINE PMID 20508580 (<http://www.ncbi.nlm.nih.gov/pubmed/20508580>).
23. Adverse effects of papillomavirus vaccination: 2009 data. *Prescrire International*. 2010 Jun;19(107):124. PMID: 20738043.
24. Safety of rotavirus vaccines: postmarketing surveillance in the WHO Region of the Americas. *Weekly Epidemiological Record*. 2011 Feb 18;86(8):66-72. PMID: 21337810.
25. Aaby P, Benn C, Nielsen J, et al. Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries. *BMJ Open*. 2012;2(3)PMID: 2012335376.
26. Aaby P, Jensen H, Samb B, et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. *Lancet*. 2003 Jun 28;361(9376):2183-8. PMID: 12842371.
27. Aaby P, Knudsen K, Whittle H, et al. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate. *Journal of Pediatrics*. 1993 Jun;122(6):904-8. PMID: 8501567.

28. Aaby P, Martins C, Bale C, et al. Sex Differences in the Effect of Vaccines on the Risk of Hospitalization Due to Measles in Guinea-Bissau. *Pediatric Infectious Disease Journal*. 2010 Apr;29(4):324-8. PMID: WOS:000276565600008.
29. Aagaard L, Hansen EW, Hansen EH. Adverse events following immunization in children: Retrospective analysis of spontaneous reports over a decade. *European Journal of Clinical Pharmacology*. 2011 March;67(3):283-8. PMID: 2011203245 MEDLINE PMID 21079934 (<http://www.ncbi.nlm.nih.gov/pubmed/21079934>).
30. Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in denmark: A retrospective analysis of reports made to the danish medicines agency from 1998 to 2007. *Drug Safety*. 2010 2010;33(4):327-39. PMID: 2010179689 MEDLINE PMID 20297864 (<http://www.ncbi.nlm.nih.gov/pubmed/20297864>).
31. Abarca K, Ibanez I, de la Fuente P, et al. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years. *Vaccine*. 2011 08;29(48):8855-62. PMID: 2011659714 MEDLINE PMID 21983354 (<http://www.ncbi.nlm.nih.gov/pubmed/21983354>).
32. Abedi GR, Mutuc JD, Lawler J, et al. Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak. *Vaccine*. 2012 Nov 19;30(49):7052-8. PMID: 23041123.
33. Abramson JS, Baker CJ, Fisher MC, et al. Possible association of intussusception with rotavirus vaccination. *Pediatrics*. 1999 1999;104(3 I):575. PMID: 1999316531 MEDLINE PMID 10469790 (<http://www.ncbi.nlm.nih.gov/pubmed/10469790>).
34. Abzug MJ, Nachman SA, Muresan P, et al. Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. *Clinical Infectious Diseases*. 2013 May;56(10):1488-97. PMID: 23378284.
35. Abzug MJ, Pelton SI, Song L-Y, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. *Pediatric Infectious Disease Journal*. 2006 Oct;25(10):920-9. PMID: 17006288.
36. Abzug MJ, Qin M, Levin MJ, et al. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. *Journal of Infectious Diseases*. 2012 Aug 15;206(4):512-22. PMID: 22693229.
37. Acharya D, Desai A, Nanavaty N, et al. Evaluation of immunogenicity and tolerance of single dose haemophilus influenzae type B (PRP-T) vaccine. *Indian Pediatrics*. 1995 Oct;32(10):1077-82. PMID: 8984044.

38. Adam D, Fehnle K. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations. *Vaccine*. 2008 Nov;26(47):5944-51. PMID: 18801402.
39. Adunsky A, Bernheim J. Pneumococcal vaccine in systemic lupus erythematosus. *Arthritis & Rheumatism*. 1980 Nov;23(11):1330. PMID: 7447971.
40. Agergaard J, Nante E, Poustrup G, et al. Diphtheria-tetanus-pertussis vaccine administered simultaneously with measles vaccine is associated with increased morbidity and poor growth in girls. A randomised trial from Guinea-Bissau. *Vaccine*. 2011 Jan 10;29(3):487-500. PMID: 21093496.
41. Aguilar-Betancourt A, Gonzalez-Delgado CA, Cinza-Estevez Z, et al. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults. *Human Vaccines*. 2008 Jan-Feb;4(1):54-9. PMID: 18441530.
42. Aguilar-Betancourt A, Gonzalez-Delgado CA, Cinza-Estevez Z, et al. Safety and immunogenicity of a combined hepatitis B virus Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults. *Human Vaccines*. 2008 Jan-Feb;4(1):54-9. PMID: WOS:000257001000008.
43. Ahman H, Kayhty H, Tamminen P, et al. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well- tolerated and able to induce an antibody response in infants. *Pediatric Infectious Disease Journal*. 1996 1996;15(2):134-9. PMID: 1996059433 MEDLINE PMID 8822286 (<http://www.ncbi.nlm.nih.gov/pubmed/8822286>).
44. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, et al. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial. *Journal of Infectious Diseases*. 1996 1996;173(1):83-90. PMID: 1996005021 MEDLINE PMID 8537687 (<http://www.ncbi.nlm.nih.gov/pubmed/8537687>).
45. Ahonkhai VI, Lukacs LJ, Jonas LC, et al. Clinical experience with PedvaxHIB, a conjugate vaccine of *Haemophilus influenzae* type b polysaccharide--*Neisseria meningitidis* outer membrane protein. *Vaccine*. 1991 Jun;9 Suppl:S38-41; discussion S2-3. PMID: 1891956.
46. Ahonkhai VI, Lukacs LJ, Jonas LC, et al. *Haemophilus influenzae* type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB(registered trademark)): Clinical evaluation. *Pediatrics*. 1990 1990;85(4 SUPPL.):676-81. PMID: 1990099879 MEDLINE PMID 2107518 (<http://www.ncbi.nlm.nih.gov/pubmed/2107518>).
47. Aikawa NE, Campos LM, Goldenstein-Schaineberg C, et al. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. *Scandinavian Journal of Rheumatology*. 2013;42(1):34-40. PMID: 22992045.

48. Aikawa NE, Campos LMA, Silva CA, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. *Journal of Rheumatology*. 2012 Jan;39(1):167-73. PMID: 22089462.
49. Aikawa NE, Campos LMA, Silva CA, et al. Glucocorticoid: Major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in juvenile autoimmune rheumatic diseases patients. *Arthritis and Rheumatism*. 2011;63(10):2011-11.
50. Alavian SM, Tabatabaei SV. Effects of Oral Levamisole as an Adjuvant to Hepatitis B Vaccine in Adults With End-Stage Renal Disease: A Meta-Analysis of Controlled Clinical Trials. *Clinical Therapeutics*. 2010 Jan;32(1):1-10. PMID: WOS:000275078600001.
51. al-Eissa YA. Reactogenicity and safety of meningococcal A and C vaccine in Saudi children. *Annals of Tropical Paediatrics*. 1994;14(4):275-9. PMID: 7880088.
52. Allwinn R, Gauer S, Hofeld H, et al. Efficacy and side effects of H1N1 vaccination in renal transplant and dialysis patients. *Transplant International*. 2011 October;24 SUPPL. 3:34.
53. Al-Mazrou Y, Khalil M, Findlow H, et al. Immunogenicity and Safety of a Meningococcal Quadrivalent Conjugate Vaccine in Saudi Arabian Adolescents Previously Vaccinated with One Dose of Bivalent and Quadrivalent Meningococcal Polysaccharide Vaccines: a Phase III, Controlled, Randomized, and Modified Blind-Observer Study. *Clinical & Vaccine Immunology: CVI*. 2012 Jul;19(7):999-1004. PMID: 22552602.
54. Almeida VDC, Mussi-Pinhata MM, De Souza CBS, et al. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants. *Vaccine*. 2009 Jun 12;27(29):3856-61. PMID: 19443091.
55. Al-Mendalawi MD. Post varicella zoster virus myelitis in immunocompetent patients. *Neurosciences*. 2011 October;16(4):388. PMID: 2011575327 MEDLINE PMID 21983391 (<http://www.ncbi.nlm.nih.gov/pubmed/21983391>).
56. Al-Sukaiti N, Reid B, Lavi S, et al. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome. *Journal of Allergy & Clinical Immunology*. 2010 Oct;126(4):868-9. PMID: 20810153.
57. Amanna IJ. Balancing the efficacy and safety of vaccines in the elderly. *Open Longevity Science*. 2012 2012;6:64-72. PMID: 2012422054.
58. Ambrosch F, Wiedermann G, Crooy P, et al. Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. *Bulletin of the World Health Organization*. 1983;61(2):317-23. PMID: 6407768.
59. Amendola A, Tanzi E, Zappa A, et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. *Vaccine*. 2002 Nov 1;20(31-32):3720-4. PMID: 12399200.

60. Amir J, Melamed R, Bader J, et al. Immunogenicity and safety of a liquid combination of DTP-PRP-T [corrected] vs lyophilized PRP-T reconstituted with DTP.[Erratum appears in Vaccine 1997 Nov;15(16):1813]. *Vaccine*. 1997 Feb;15(2):149-54. PMID: 9066031.
61. Andersen DV, Jorgensen IM. MMR vaccination of children with egg allergy is safe. *Danish Medical Journal*. 2013 Feb;60(2):A4573. PMID: 23461988.
62. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. *The Lancet Infectious Diseases*. 2008 October;8(10):642-9. PMID: 2008443646 MEDLINE PMID 18922486 (<http://www.ncbi.nlm.nih.gov/pubmed/18922486>).
63. Anderson EL, Decker MD, Englund JA, et al. Interchangeability of conjugated *Haemophilus influenzae* type b vaccines in infants. *JAMA*. 1995 Mar 15;273(11):849-53. PMID: 7869554.
64. Anderson P, Pichichero M, Edwards K, et al. Priming and induction of *Haemophilus influenzae* type b capsular antibodies in early infancy by Dpo20, an oligosaccharide-protein conjugate vaccine. *Journal of Pediatrics*. 1987 Nov;111(5):644-50. PMID: 3499499.
65. Anderson P, Pichichero ME. *Haemophilus influenzae* type b vaccine. *Pediatrics*. 1989 Jan;83(1):145-6. PMID: 2909967.
66. Andrade D, Seguro L, Ribeiro A, et al. Is H1N1 influenza vaccine safe and effective in patients with SSc? *Rheumatology*. 2012 February;51 SUPPL. 2:ii23.
67. Andre FE, D'Hondt E, Delem A, et al. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: Rationale and summary of findings. *Vaccine*. 1992 1992;10(SUPPL. 1):S160-S8. PMID: 1992360501 MEDLINE PMID 1335652 (<http://www.ncbi.nlm.nih.gov/pubmed/1335652>).
68. Andrews NJ, Walker WT, Finn A, et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. *Vaccine*. 2011 Oct 19;29(45):7913-9. PMID: 21875635.
69. Andrisani G, Frasca D, Armuzzi A, et al. Response to the 2009 vaccine for influenza A/H1N1 in patients with inflammatory bowel disease on anti TNF(alpha) therapy. *Journal of Crohn's and Colitis*. 2011 February;5(1):S78-S9.
70. Andrisani G, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-(alpha) agents: Effects of combined therapy with immunosuppressants. *Journal of Crohn's and Colitis*. 2012.
71. Anh DD, Carlos CC, Thiem DV, et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix (TM)) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. *Vaccine*. 2011 Mar;29(11):2029-36. PMID: WOS:000288731000008.

72. Ankrah DN, Mantel-Teeuwisse AK, De Bruin ML, et al. Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study. *Drug Safety*. 2013 Apr;36(4):259-66. PMID: 23508545.
73. Annunziata P, Carnicelli N, Galluzzi P, et al. Erratum: Miller-Fisher syndrome following vaccination against influenza virus A/H1N1 in an AIDS patient. *Infection*. 2012 April;40(2):233. PMID: 2012378205.
74. Ansari F, Baker RD, Patel R, et al. Varicella immunity in inflammatory bowel disease. *Journal of Pediatric Gastroenterology & Nutrition*. 2011 Oct;53(4):386-8. PMID: 21505365.
75. Aplasca-De Los Reyes MR, Dimaano E, Macalalad N, et al. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. *Human Vaccines and Immunotherapeutics*. 2012 July;8(7):881-7. PMID: 2012427210.
76. Arguedas A, Soley C, Abdelnour A, et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. *Human Vaccines*. 2011 Jan 1;7(1):58-66. PMID: 21285531.
77. Arguedas A, Soley C, Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. *N Engl J Med*. 2010 Jan 28;362(4):370-2. PMID: 20042746.
78. Aristegui J, Dal-Re R, Diez-Delgado J, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. *Vaccine*. 2003 Sep 8;21(25-26):3593-600. PMID: 12922087.
79. Aristegui J, Dal-Re R, Garrote E, et al. Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at 2, 4 and 6 months of age. *Vaccine*. 1998 Dec;16(20):1976-81. PMID: 9796053.
80. Arnold WC, Steele RW, Rastogi SP, et al. Response to pneumococcal vaccine in renal allograft recipients. *American Journal of Nephrology*. 1985;5(1):30-4. PMID: 3881958.
81. Arnou R, Eavis P, Pardo J-RDJ, et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. *Human Vaccines*. 2010 Apr;6(4):346-54. PMID: 20372053.

82. Arnou R, Fiquet A, Thomas S, et al. Immunogenicity and safety of ZOSTAVAX([REGISTERED]) approaching expiry potency in individuals aged >=50 years. *Human Vaccines*. 2011 Oct;7(10):1060-5. PMID: 21941091.
83. Arya LS, Ghai OP, Saraya AK. Thrombocytopenic purpura following DPT vaccination. *Pediatr Hematol Oncol*. 1993 Oct-Dec;10(4):381-3. PMID: 8292527.
84. Asahina N, Matsunami Y, Sueda K, et al. Vaccine-associated paralytic poliomyelitis in a non-immunocompromised infant. *Pediatrics International*. 2010 Oct;52(5):838-41. PMID: 20880307.
85. Asante KP, Abdulla S, Agnandji S, et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.[Erratum appears in Lancet Infect Dis. 2011 Oct;11(10):727]. *The Lancet Infectious Diseases*. 2011 Oct;11(10):741-9. PMID: 21782519.
86. Ashok G, Rajendran P, Jayam S, et al. Assessment of immune response and safety of two recombinant hepatitis B vaccines in healthy infants in India. *African Journal of Biotechnology*. 2011 Oct;10(59) PMID: WOS:000299737800027.
87. Ashok G, Rajendran P, Jayam S, et al. Assessment of immune response and safety of two recombinant hepatitis B vaccines in healthy infants in India. *African Journal of Biotechnology*. 2011 3;10(59):12707-10. PMID: 2011562015.
88. Asindi AA, Bell EJ, Browning MJ, et al. Vaccine-induced polioencephalomyelitis in Scotland. *Scottish Medical Journal*. 1988 1988;33(4):306-7. PMID: 1988227422 MEDLINE PMID 2847313 (<http://www.ncbi.nlm.nih.gov/pubmed/2847313>).
89. Aspinall S, Traynor D, Bedford P, et al. Lot-to-lot consistency study of the fully liquid pentavalent DTwP-HepB-Hib vaccine Quinvaxem(registered trademark) demonstrating clinical equivalence, suitability of the vaccine as a booster and concomitant administration with measles vaccine. *Human Vaccines and Immunotherapeutics*. 2012 August;8(8):1109-18. PMID: 2012533269.
90. Atanasovski M, Dele-Michael A, Dasgeb B, et al. A case report of Gianotti-Crosti post vaccination with MMR and dTaP. *International Journal of Dermatology*. 2011 May;50(5):609-10. PMID: 2011221443 MEDLINE PMID 21506982 (<http://www.ncbi.nlm.nih.gov/pubmed/21506982>).
91. Auriel E, Regev K, Dori A, et al. Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance. *Muscle & Nerve*. 2011 Jun;43(6):893-4. PMID: 21607970.
92. Austrian R. Prevention of pneumococcal infection by immunization with capsular polysaccharides of *Streptococcus pneumoniae*: current status of polyvalent vaccines. *Journal of Infectious Diseases*. 1977 Aug;136 Suppl:S38-42. PMID: 19543.

93. Autret-Leca E, Grimaldi-Bensouda L, Daubin C, et al. Heptavalent pneumococcal conjugate vaccine (PCV7): French survey of serious adverse reactions. Therapie. 2011 January-February;66(1):81-6. PMID: 2011203530.
94. Avdicova M, Prikazsky V, Hudeckova H, et al. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. European Journal of Pediatrics. 2002 Nov;161(11):581-7. PMID: 12424582.
95. Avery RK. Influenza vaccines in the setting of solid-organ transplantation: Are they safe? Current Opinion in Infectious Diseases. 2012;15.
96. Awaidy SA, Bawikar S, Prakash KP, et al. Surveillance of adverse events following immunization: 10 years' experience in Oman ORIGINAL (NON-ENGLISH) TITLE Surveillance des manifestations postvaccinales indesirables: Dix ans d'experience a Oman. Eastern Mediterranean Health Journal. 2010 May;16(5):474-80. PMID: 2010348624 MEDLINE PMID 20799545 (<http://www.ncbi.nlm.nih.gov/pubmed/20799545>).
97. Bader MS. Immunization for the elderly. American Journal of the Medical Sciences. 2007 Dec;334(6):481-6. PMID: 18091370.
98. Badsha H, Daher M, Edwards CJ. Live polio vaccine exposure while receiving anti-TNF therapy for reactive arthritis. International Journal of Rheumatic Diseases. 2010 May;13(2):184-6. PMID: 2010348985 MEDLINE PMID 20536606 (<http://www.ncbi.nlm.nih.gov/pubmed/20536606>).
99. Bagatin D, Augustin G, Bagatin T. Post-vaccination dermatolipomyonecrosis. Wiener Klinische Wochenschrift. 2009 September;121(17 18):551. PMID: 2009604746 MEDLINE PMID 19890743 (<http://www.ncbi.nlm.nih.gov/pubmed/19890743>).
100. Bakare N, Menschik D, Tiernan R, et al. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine. 2010 Sep 14;28(40):6609-12. PMID: 20674876.
101. Baker CJ, Kasper DL. Group B streptococcal vaccines. Reviews of Infectious Diseases. 1985 Jul-Aug;7(4):458-67. PMID: 3898306.
102. Baker CJ, Rench MA, Edwards MS, et al. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. New England Journal of Medicine. 1988 Nov 3;319(18):1180-5. PMID: 3050524.
103. Ball R, Ball LK, Wise RP, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: Reports to the Vaccine Adverse Event Reporting System. Pediatric Infectious

Disease Journal. 2001;20(2):219-23. PMID: 2001066762 MEDLINE PMID 11224848 (<http://www.ncbi.nlm.nih.gov/pubmed/11224848>).

104. Banda R, Yambayamba V, Lalusha BD, et al. Safety of live, attenuated oral vaccines in HIV-infected Zambian adults: Oral vaccines in HIV. Vaccine. 2012 Aug;30(38):5656-60. PMID: 22789509.

105. Banzhoff A, Haertel S, Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Human Vaccines. 2011 May;7(5):539-48. PMID: 21422814.

106. Banzhoff A, Stoddard JJ. Effective influenza vaccines for children: A critical unmet medical need and a public health priority. Human Vaccines and Immunotherapeutics. 2012 March;8(3):389-93. PMID: 2012244556.

107. Barbaud A, Deschildre A, Waton J, et al. Hypersensitivity and vaccines: an update. European Journal of Dermatology. 2013 Apr;23(2):135-41. PMID: 23238161.

108. Barnes G. Intussusception and rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition. 1999;29(4):375. PMID: 2000199297 MEDLINE PMID 10512393 (<http://www.ncbi.nlm.nih.gov/pubmed/10512393>).

109. Barnes G, Srivastava A, Carlin J, et al. Delta-F508 cystic fibrosis mutation is not linked to intussusception: implications for rotavirus vaccine. Journal of Paediatrics & Child Health. 2003 Sep-Oct;39(7):516-7. PMID: 12969205.

110. Barnett ED, Pelton SI, Cabral HJ, et al. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clinical Infectious Diseases. 1999;29(1):191-2. PMID: 1999252965 MEDLINE PMID 10433584 (<http://www.ncbi.nlm.nih.gov/pubmed/10433584>).

111. Bartlett BL, Tyring SK. Safety and efficacy of vaccines. Dermatologic Therapy. 2009 March-April;22(2):97-103. PMID: 2009149338 MEDLINE PMID 19335721 (<http://www.ncbi.nlm.nih.gov/pubmed/19335721>).

112. Barton M, Wasfy S, Dipchand AI, et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity. Pediatric Infectious Disease Journal. 2009 Aug;28(8):688-92. PMID: 19633514.

113. Basilico FC, Bernat JL. Vaccine-associated poliomyelitis in a contact. Journal of the American Medical Association. 1978;239(21):2275. PMID: 1978344721 MEDLINE PMID 650811 (<http://www.ncbi.nlm.nih.gov/pubmed/650811>).

114. Bassily S, Kotkat A, Gray G, et al. Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. American Journal of Tropical Medicine & Hygiene. 1995 Oct;53(4):419-22. PMID: 7485697.

115. Bassis AV, Fairley JA, Ameln RT, et al. Cutaneous Rosai-Dorfman disease following pneumococcal vaccination. *Journal of the American Academy of Dermatology*. 2011 October;65(4):890-2. PMID: 2011516782 MEDLINE PMID 21920257 (<http://www.ncbi.nlm.nih.gov/pubmed/21920257>).
116. Batista-Duharte A, Lindblad EB, Oviedo-Orta E. Progress in understanding adjuvant immunotoxicity mechanisms. *Toxicology Letters*. 2011 Oct;203(2):97-105. PMID: 2011235888 MEDLINE PMID 21392560 (<http://www.ncbi.nlm.nih.gov/pubmed/21392560>).
117. Bavdekar SB, Maiya PP, Subba Rao SD, et al. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants. *Indian Pediatrics*. 2007 Jul;44(7):505-10. PMID: 17684303.
118. Baxter D. Impaired functioning of immune defences to infection in premature and term infants and their implications for vaccination. *Human Vaccines*. 2010 June;6(6):494-505. PMID: 2010504455 MEDLINE PMID 20519937 (<http://www.ncbi.nlm.nih.gov/pubmed/20519937>).
119. Baxter R, Baine Y, Ensor K, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. *Pediatric Infectious Disease Journal*. 2011 Mar;30(3):e41-8. PMID: 21200360.
120. Baxter R, Jeanfreau R, Block SL, et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. *Pediatric Infectious Disease Journal*. 2010 Oct;29(10):924-30. PMID: 20431425.
121. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok[REGISTERED] trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. *Vaccine*. 2011 Mar 9;29(12):2272-8. PMID: 21277410.
122. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. *Journal of Infectious Diseases*. 2012 Oct;206(8):1250-9. PMID: 22904335.
123. Begg NT, Miller E, Fairley CK, et al. Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type B conjugate vaccines given for primary immunisation by separate or mixed injection. *Vaccine*. 1995 Nov;13(16):1547-50. PMID: 8578840.
124. Begg NT, Miller E, Fairley CK, et al. Antibody-Responses and Symptoms after Dtp and Either Tetanus or Diphtheria Haemophilus-Influenzae Type-B Conjugate Vaccines Given for Primary Immunization by Separate or Mixed Injection. *Vaccine*. 1995 Nov;13(16):1547-50. PMID: WOS:A1995TF20500011.

125. Begue P, Stagnara J, Vie-Le-Sage F, et al. Immunogenicity and reactogenicity of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccines given concurrently with Haemophilus type b conjugate vaccine or as pentavalent vaccine. *Pediatric Infectious Disease Journal*. 1997 Aug;16(8):787-94. PMID: 9271042.
126. Belec L, Authier F-J, Gherardi RK. Safety and immunogenicity of hepatitis B vaccine regimens in adults with HIV-1. *JAMA*. 2011 Jul 13;306(2):156; author reply -7. PMID: 21750288.
127. Bell F, Heath P, MacLennan J, et al. Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule. *European Journal of Pediatrics*. 1999 Apr;158(4):329-36. PMID: 10206134.
128. Bell F, Heath P, Shackley F, et al. Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T). *Vaccine*. 1998 Apr;16(6):637-42. PMID: 9569476.
129. Bell F, Martin A, Blondeau C, et al. Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation. *Archives of Disease in Childhood*. 1996 Oct;75(4):298-303. PMID: 8984914.
130. Belliveau MJ, Kratky V, Evans GA, et al. Acute orbital inflammatory syndrome following H1N1 immunization. *Canadian Journal of Ophthalmology*. 2011 December;46(6):552-3. PMID: 2011710782 MEDLINE PMID 22153648 (<http://www.ncbi.nlm.nih.gov/pubmed/22153648>).
131. Belongia EA, Irving SA, Shui IM, et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. *Pediatric Infectious Disease Journal*. 2010 Jan;29(1):1-5. PMID: 19907356.
132. Belshe RB, Frey SE, Graham I, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. *Journal of Infectious Diseases*. 2011 Mar 1;203(5):666-73. PMID: 21282194.
133. Benn CS. Combining vitamin A and vaccines: convenience or conflict? *Danish Medical Journal*. 2012 Jan;59(1):B4378. PMID: 22239846.
134. Benn CS, Aaby P. Diphtheria-tetanus-pertussis vaccination administered after measles vaccine: Increased female mortality? SOURCE *Pediatric Infectious Disease Journal* (2012). Date of Publication: 7 Jun 2012. 2012.
135. Benn CS, Lund S, Fisker A, et al. Should infant girls receive micronutrient supplements? *International Journal of Epidemiology*. 2009 2009;38(2):586-90. PMID: 2009174576 MEDLINE PMID 19147706 (<http://www.ncbi.nlm.nih.gov/pubmed/19147706>).

136. Bennett JV, Fernandez de Castro J, Poblete RM, et al. A new, rapid, and promising approach to aerosol immunization: inflatable bags and valved masks. *Vaccine*. 2009 Jul 23;27(34):4571-5. PMID: 19539584.
137. Bentsi-Enchill AD, Zongo I, Khamassi S, et al. Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso. *Vaccine*. 2007 Sep 3;25 Suppl 1:A72-8. PMID: 17544552.
138. Beran J, Beutels M, Levie K, et al. A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. *Journal of Travel Medicine*. 2000 Sep-Oct;7(5):246-52. PMID: 11231208.
139. Beran J, Hobzova L, Wertzova V, et al. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02(V)) in healthy adults. *Human Vaccines*. 2010 July;6(7):578-84. PMID: 2010520518 MEDLINE PMID 20523113 (<http://www.ncbi.nlm.nih.gov/pubmed/20523113>).
140. Beran J, Kervyn D, Wertzova V, et al. Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. *Vaccine*. 2010 Aug 23;28(37):5993-7. PMID: 20637766.
141. Bergfors E, Trollfors B, Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. *Vaccine*. 2003 Aug;22(1):64-9. PMID: 2003446835 MEDLINE PMID 14604572 (<http://www.ncbi.nlm.nih.gov/pubmed/14604572>).
142. Berkowitz CD, Ward JI, Meier K, et al. Safety and immunogenicity of *Haemophilus influenzae* type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of age. *Journal of Pediatrics*. 1987 Apr;110(4):509-14. PMID: 3550021.
143. Bernal N, Huang L-M, Dubey AP, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. *Human Vaccines*. 2011 Feb;7(2):239-47. PMID: 21343698.
144. Bernal N, Szenborn L, Edison A, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable *Haemophilus influenzae* protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines. *Pediatric Infectious Disease Journal*. 2011 Jan;30(1):69-72. PMID: 20980933.
145. Berner R, Boisnard F, Thomas S, et al. Safety and immunogenicity of fully liquid DTaP(5)-IPV-Hib pediatric combination vaccine (Pediacel((registered trademark))) compared to DTaP(3)-HBV-IPV/Hib (Infanrix((registered trademark)) Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11-18 months of age: A phase III, modified double-blind, randomized, controlled, multicenter study. *Vaccine*. 2012.

146. Berner R, Boisnard F, Thomas S, et al. Safety and immunogenicity of fully liquid DTaP(5)-IPV-Hib pediatric combination vaccine (Pediacel([REGISTERED])) compared to DTaP(3)-HBV-IPV/Hib (Infanrix([REGISTERED]) Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11-18 months of age: A phase III, modified double-blind, randomized, controlled, multicenter study. *Vaccine*. 2012 Jul 27;30(35):5270-7. PMID: 22691430.
147. Bernier RH, Frank Jr JA, Dondero Jr TJ, et al. Diphtheria-tetanus toxoids-pertussis vaccination and sudden infant deaths in Tennessee. *Journal of Pediatrics*. 1982 1982;101(3):419-21. PMID: 1982209354 MEDLINE PMID 7108666 (<http://www.ncbi.nlm.nih.gov/pubmed/7108666>).
148. Bernsen RM, van der Wouden JC. Is childhood immunisation associated with atopic disease from age 7 to 32 years? *Thorax*. 2007 Oct;62(10):925; author reply 6. PMID: 17909195.
149. Bernsen RMD, Van Der Wouden JC. Re: No epidemiological evidence for infant vaccinations to cause allergic disease. *Vaccine*. 2005 10;23(12):1427. PMID: 2005053523 MEDLINE PMID 15670875 (<http://www.ncbi.nlm.nih.gov/pubmed/15670875>).
150. Bernstein D. Efficacy of the pentavalent rotavirus vaccine in subjects after 1 or 2 doses in the rotavirus efficacy and safety trial. *Pediatrics*. 2008 Jan;121(1):223; author reply -4. PMID: 18166579.
151. Bernstein DI, Glass RI, Rodgers G, et al. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. *JAMA*. 1995 Apr 19;273(15):1191-6. PMID: 7707626.
152. Bernstein DI, Ward RL. Rotarix: development of a live attenuated monovalent human rotavirus vaccine. *Pediatric Annals*. 2006 Jan;35(1):38-43. PMID: 16466074.
153. Bernstein HH, Noriega F. Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: A randomized, open-label, phase 3 study. *Vaccine*. 2011 2011;29(11):2212-21. PMID: 2011104692 MEDLINE PMID 20609398 (<http://www.ncbi.nlm.nih.gov/pubmed/20609398>).
154. Bewley KM, Schwab JG, Ballanco GA, et al. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen. *Pediatrics*. 1996 Nov;98(5):898-904. PMID: 8909483.
155. Bhandari N, Sharma P, Taneja S, et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. *Journal of Infectious Diseases*. 2009 Aug 1;200(3):421-9. PMID: 19545211.

156. Biai S, Rodrigues A, Nielsen J, et al. Vaccination status and sequence of vaccinations as risk factors for hospitalisation among outpatients in a high mortality country. *Vaccine*. 2011 May;29(20):3662-9. PMID: WOS:000290977700007.
157. Billal DS, Hotomi M, Yamanaka N. Rotavirus vaccine for developing countries. *The Lancet*. 2008 20080809/15;372(9637):444. PMID: 2008373042.
158. Bines J. Intussusception and rotavirus vaccines. *Vaccine*. 2006 May 1;24(18):3772-6. PMID: 16099078.
159. Bines JE. Rotavirus vaccines and intussusception risk. *Current Opinion in Gastroenterology*. 2005 Jan;21(1):20-5. PMID: 15687880.
160. Bingham CO, 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. *Arthritis & Rheumatism*. 2010 Jan;62(1):64-74. PMID: 20039397.
161. Bird SM. Febrile convulsions after seasonal influenza immunisation in UK. *Lancet*. 2011 Jul 30;378(9789):399-400; author reply PMID: 21803201.
162. Bissantz N, Jenke AC, Trampisch M, et al. Hospital-based, prospective, multicentre surveillance to determine the incidence of intussusception in children aged below 15 years in Germany. *Bmc Gastroenterology*. 2011;11:26. PMID: 21435207.
163. Bjune G, Closs O, Froholm LO, et al. Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. *NIPH Annals*. 1991 Dec;14(2):81-91; discussion -3. PMID: 1812439.
164. Black S. The clinical impact of pneumococcal conjugate vaccines. *American Journal of Managed Care*. 1999 Nov;5(SUPPL. 17):S1010-S7. PMID: 2000000365.
165. Black S, Friedland LR, Ensor K, et al. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. *Pediatric Infectious Disease Journal*. 2008 Apr;27(4):341-6. PMID: 18316985.
166. Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. *European Journal of Pediatrics*. 2002 Dec;161 Suppl 2:S127-31. PMID: 12494258.
167. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. *Pediatric Infectious Disease Journal*. 2000 Mar;19(3):187-95. PMID: 10749457.
168. Black S, Shinefield H, Ray P, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. *Pediatric Infectious Disease Journal*. 1999

December;18(12):1041-6. PMID: 1999436773 MEDLINE PMID 10608621
(<http://www.ncbi.nlm.nih.gov/pubmed/10608621>).

169. Black SB, Cimino CO, Hansen J, et al. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. *Pediatric Infectious Disease Journal*. 2006 Apr;25(4):306-11. PMID: 16567981.
170. Black SB, Shinefield HR. b-CAPSA I Haemophilus influenzae, type b, capsular polysaccharide vaccine safety. *Pediatrics*. 1987 Mar;79(3):321-5. PMID: 3822630.
171. Black SB, Shinefield HR, Fireman B, et al. Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use. *Journal of Infectious Diseases*. 1992 Jun;165 Suppl 1:S139-43. PMID: 1588149.
172. Black SB, Shinefield HR, Ray P, et al. Safety of combined oligosaccharide conjugate Haemophilus influenzae type b (HbOC) and whole cell diphtheria-tetanus toxoids-pertussis vaccine in infancy. The Kaiser Permanente Pediatric Vaccine Study Group. *Pediatric Infectious Disease Journal*. 1993 Dec;12(12):981-5. PMID: 8108224.
173. Blatter M, Friedland LR, Weston WM, et al. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. *Vaccine*. 2009 Jan 29;27(5):765-72. PMID: 19041352.
174. Blatter MM, Klein NP, Shepard JS, et al. Immunogenicity and Safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age. *Pediatric Infectious Disease Journal*. 2012 August;31(8):e133-e40. PMID: 2012419784.
175. Blitshteyn S. Postural tachycardia syndrome after vaccination with Gardasil. *European Journal of Neurology*. 2010 July;17(7):e52. PMID: 2010352058 MEDLINE PMID 20402758 (<http://www.ncbi.nlm.nih.gov/pubmed/20402758>).
176. Block SL, Falloon J, Hirschfield JA, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. *Pediatric Infectious Disease Journal*. 2012 Jul;31(7):745-51. PMID: 22466322.
177. Block SL, Ruiz-Palacios GM, Guerrero ML, et al. Dose-range Study of MF59-adjuvanted Versus Nonadjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in Six- to Less Than Thirty-Six-month-old Children. *Pediatric Infectious Disease Journal*. 2012 Jul;31(7):e92-8. PMID: 22481427.

178. Block SL, Yi T, Sheldon E, et al. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. *Vaccine*. 2011 Nov 21;29(50):9391-7. PMID: 21983154.
179. Boccaro F, Benhaim-Sigaux N, Cohen A. Acute myopericarditis after diphtheria, tetanus, and polio vaccination. *Chest*. 2001 2001;120(2):671-2. PMID: 2001332118 MEDLINE PMID 11502677 (<http://www.ncbi.nlm.nih.gov/pubmed/11502677>).
180. Bocchini Jr JA. Efficacy of the pentavalent rotavirus vaccine in subjects after 1 or 2 doses in the rotavirus efficacy and safety trial: In reply [6]. *Pediatrics*. 2008 January;121(1):223-4. PMID: 2008022043.
181. Boghani DC, Ali QK. Patient with probable side effect of hepatitis vaccination. CME Journal Ophthalmology. 2000 2000;4(3):86-7. PMID: 2001103434.
182. Booy R, Richmond P, Nolan T, et al. Immediate and longer term immunogenicity of a single dose of the combined *Haemophilus influenzae* type b-*Neisseria meningitidis* serogroup c-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age. *Pediatric Infectious Disease Journal*. 2011 April;30(4):340-2. PMID: 2011214242 MEDLINE PMID 21068692 (<http://www.ncbi.nlm.nih.gov/pubmed/21068692>).
183. Booy R, Taylor SA, Dobson SRM, et al. Immunogenicity and Safety of Prp-T Conjugate Vaccine Given According to the British Accelerated Immunization Schedule. *Archives of Disease in Childhood*. 1992 Apr;67(4):475-8. PMID: WOS:A1992HR68500002.
184. Borba EF, Saad CGS, Pasoto SG, et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? *Rheumatology*. 2012 Jun;51(6):1061-9. PMID: 22298793.
185. Borner N, Muhlberger N, Jelinek T. Tolerability of multiple vaccinations in travel medicine. *Journal of Travel Medicine*. 2003 March/April;10(2):112-6. PMID: 2003138738 MEDLINE PMID 12650655 (<http://www.ncbi.nlm.nih.gov/pubmed/12650655>).
186. Botet Asensi FI, Veronese A, Del Carmen Otero M, et al. Immunogenicity and safety in infants of a DTwPHib full liquid vaccine. *Acta Paediatrica*. 2003 May;92(5):541-5. PMID: 12839281.
187. Botham SJ, Isaacs D. Incidence of apnoea and bradycardia in preterm infants following triple antigen immunization. *J Paediatr Child Health*. 1994 Dec;30(6):533-5. PMID: 7865269.
188. Botham SJ, Isaacs D, Henderson-Smart DJ. Incidence of apnoea and bradycardia in preterm infants following DTP(w) and Hib immunization: A prospective study. *Journal of Paediatrics and Child Health*. 1997 1997;33(5):418-21. PMID: 1997331261 MEDLINE PMID 9401886 (<http://www.ncbi.nlm.nih.gov/pubmed/9401886>).

189. Boudville IC, Phua KB, Quak SH, et al. The epidemiology of paediatric intussusception in Singapore: 1997 to 2004. Annals of the Academy of Medicine, Singapore. 2006 Oct;35(10):674-9. PMID: 17102889.
190. Bouree P. Immunity and immunization in elderly. Pathologie Biologie. 2003 Dec;51(10):581-5. PMID: 14622949.
191. Bradley SF. Influenza in the elderly: Prevention is the best strategy in high-risk populations. Postgraduate Medicine. 1996 1996;99(2):138-44+46-49. PMID: 1996056403 MEDLINE PMID 8632963 (<http://www.ncbi.nlm.nih.gov/pubmed/8632963>).
192. Brakemeier S, Schweiger B, Lachmann N, et al. Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(registered trademark)) in renal transplant recipients. Nephrology Dialysis Transplantation. 2012 January;27(1):423-8. PMID: 2012075978 MEDLINE PMID 21613386 (<http://www.ncbi.nlm.nih.gov/pubmed/21613386>).
193. Breiman RF, Brooks WA, Goswami D, et al. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine. 2009 Sep 4;27(40):5472-9. PMID: 19616493.
194. Bridy-Pappas AE, Margolis MB, Center KJ, et al. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention. Pharmacotherapy: The Journal of Human Pharmacology & Drug Therapy. 2005 Sep;25(9):1193-212. PMID: 16164394.
195. Broeders NE, Hombrouck A, Lemy A, et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clinical Journal of The American Society of Nephrology: CJASN. 2011 Nov;6(11):2573-8. PMID: 21921153.
196. Brookhart MA, Walker AM, Lu Y, et al. Characterizing vaccine-associated risks using cubic smoothing splines. American Journal of Epidemiology. 2012 Nov 15;176(10):949-57. PMID: 23100246.
197. Brophy JC, Ward BJ, Samson L, et al. Immunogenicity of AS03-adjuvanted H1N1 pandemic influenza vaccine in HIV-infected children. Canadian Journal of Infectious Diseases and Medical Microbiology. 2011 Spring;22 SUPPL. SB:36B.
198. Bryan P, Seabroke S. No increased risk of febrile convulsions after seasonal influenza immunisation in UK. Lancet. 2011 Mar 12;377(9769):904. PMID: 21397766.
199. Bryant KA, Block SL, Baker SA, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010 May;125(5):866-75. PMID: 20435707.
200. Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics. 2011 June;127(6):e1375-e85.

PMID: 2011303443 MEDLINE PMID 21624883
(<http://www.ncbi.nlm.nih.gov/pubmed/21624883>).

201. Buettcher M, Heininger U, Braun M, et al. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: Case definition and guidelines for data collection, analysis, and presentation. *Vaccine*. 2007 Jul;25(31):5875-81. PMID: 2007335610.
202. Bulkow LR, McMahon BJ, Wainwright RB, et al. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine formulation in healthy adults. *Arctic Medical Research*. 1993 Jul;52(3):118-26. PMID: 8397580.
203. Bults M, Kemmeren JM, van der Maas NAT. Adverse events following booster doses of diphtheria-tetanus-inactivated poliovirus and acellular pertussis vaccines for 4-year-old children in The Netherlands. *Vaccine*. 2007 Jul 20;25(29):5272-7. PMID: 17573165.
204. Bunupuradah T, Ananworanich J, Pancharoen C, et al. Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression. *Vaccine*. 2011 Apr;29(16):2962-7. PMID: WOS:000290062700021.
205. Burwen DR, Sandhu SK, MacCurdy TE, et al. Surveillance for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2009-2010. *American Journal of Public Health*. 2012 Oct;102(10):1921-7. PMID: 22970693.
206. Busse WW, Peters SP, Fenton MJ, et al. Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. *Journal of Allergy & Clinical Immunology*. 2011 Jan;127(1):130-7, 7.e1-3. PMID: 21145578.
207. Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. *International Journal of Infectious Diseases*. 2012 February;16(2):e110-e6. PMID: 2012044276.
208. Cadoz M, Armand J, Arminjon F, et al. A new 23 valent pneumococcal vaccine: immunogenicity and reactogenicity in adults. *Journal of Biological Standardization*. 1985 Jul;13(3):261-5. PMID: 4030796.
209. Caillet C, Durrieu G, Jacquet A, et al. Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. *European Journal of Clinical Pharmacology*. 2011 Jun;67(6):649-51. PMID: 21153631.
210. Cakir FB, Timur C, Yoruk A, et al. Seroconversion status after single dose and double doses of varicella vaccination in children with leukemia. *Pediatric Hematology & Oncology*. 2012 Mar;29(2):191-4. PMID: 21787125.
211. Calbo F, Dal-Re R, Diez-Delgado J, et al. Comparative trial to assess the reactogenicity of the diphtheria-tetanusacellular pertussis (DTPa) vaccine plus Haemophilus influenza type b (Hib) conjugate vaccine and that of the diphtheria-tetanus-whole cell pertussis (DTPw) vaccine

plus Hib conjugate vaccine, administered in single injection as a booster dose to 14-20 months-old children. *Medicina Clinica*. 2002;19;118(1):1-4. PMID: 2002064432 MEDLINE PMID 11803003 (<http://www.ncbi.nlm.nih.gov/pubmed/11803003>).

212. Cale CM, Klein NJ. The link between rotavirus vaccination and intussusception: implications for vaccine strategies. *Gut*. 2002 Jan;50(1):11-2. PMID: 11772959.
213. Calmy A, Bel M, Nguyen A, et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. *HIV Medicine*. 2012 April;13(4):207-18. PMID: 2012139702 MEDLINE PMID 22093373 (<http://www.ncbi.nlm.nih.gov/pubmed/22093373>).
214. Campagne G, Garba A, Fabre P, et al. Safety and immunogenicity of three doses of a *Neisseria meningitidis* A + C diphtheria conjugate vaccine in infants from Niger. *Pediatric Infectious Disease Journal*. 2000 Feb;19(2):144-50. PMID: 10694002.
215. Campbell AL, Bryant KA. Routine childhood immunizations. *Primary Care; Clinics in Office Practice*. 2001 Dec;28(4):713-38, vi. PMID: 11739027.
216. Campbell H, Byass P, Ahonkhai VI, et al. Serologic responses to an *Haemophilus influenzae* type b polysaccharide-*Neisseria meningitidis* outer membrane protein conjugate vaccine in very young Gambian infants. *Pediatrics*. 1990 Jul;86(1):102-7. PMID: 2113671.
217. Campbell JD, Chambers CV, Brady RC, et al. Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adults. *Human Vaccines*. 2011 Jan 1;7(1):81-8. PMID: 21285532.
218. Campbell WN, Hendrix E, Cryz S, Jr., et al. Immunogenicity of a 24-valent *Klebsiella* capsular polysaccharide vaccine and an eight-valent *Pseudomonas* O-polysaccharide conjugate vaccine administered to victims of acute trauma. *Clinical Infectious Diseases*. 1996 Jul;23(1):179-81. PMID: 8816151.
219. Caniza MA, Hunger SP, Schrauder A, et al. The controversy of varicella vaccination in children with acute lymphoblastic leukemia. *Pediatric Blood and Cancer*. 2012 January;58(1):12-6. PMID: 2011629669 MEDLINE PMID 20848637 (<http://www.ncbi.nlm.nih.gov/pubmed/20848637>).
220. Caniza MA, Hunger SP, Schrauder A, et al. The controversy of varicella vaccination in children with acute lymphoblastic leukemia. *Pediatric Blood & Cancer*. 2012 Jan;58(1):12-6. PMID: 20848637.
221. Cao H, Lavange LM, Heyse JF, et al. Medical records-based postmarketing safety evaluation of rare events with uncertain status. *Journal of Biopharmaceutical Statistics*. 2013 Jul 4;23(4):744-55. PMID: 23786578.

222. Capeding MR, Cadorna-Carlos J, Book-Montellano M, et al. Immunogenicity and safety of a DTaP-IPV//PRP approximately T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. *Bulletin of the World Health Organization*. 2008 Jun;86(6):443-51. PMID: 18568273.
223. Capeding MZR, Puumalainen T, Gepanayao CP, et al. Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein-conjugated pneumococcal vaccine in Filipino infants. *BMC Infectious Diseases*. 2003 Aug 10;3:17. PMID: 12908876.
224. Cappelletti M, Taddeo A, Colombo E, et al. Immunogenicity and Safety of Seasonal Influenza Vaccination in Patients with Classic Kaposi's Sarcoma. *Journal of Investigative Dermatology*. 2012;24.
225. Carcione D, Blyth CC, Richmond PC, et al. Safety surveillance of influenza vaccine in pregnant women. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 2013 Feb;53(1):98-9. PMID: 23406000.
226. Carlsson RM, Claesson BA, Selstam U, et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. *Pediatric Infectious Disease Journal*. 1998 Nov;17(11):1026-33. PMID: 9849987.
227. Carmona A, Miranda M, Barrio F, et al. Reactogenicity and immunogenicity of combined haemophilus influenzae type B-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccine-hib-menc-TT booster with routine MMR vaccine. *Pediatric Infectious Disease Journal*. 2010 March;29(3):269-71. PMID: 2010145503 MEDLINE PMID 19952860 (<http://www.ncbi.nlm.nih.gov/pubmed/19952860>).
228. Carmona A, Omenaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. *Vaccine*. 2010 Aug 16;28(36):5837-44. PMID: 20600478.
229. Carniel EF, Antonio MARGM, Zanolli ML, et al. Clinical trials field strategies with novel vaccines produced in Brazil ORIGINAL (NON-ENGLISH) TITLE Estrategias de campo em ensaios clinicos com novas vacinas produzidas no Brasil. *Revista Paulista de Pediatria*. 2012 June;30(2):202-9. PMID: 2012438939.
230. Carr S, Allison KJ, Van De Velde L-A, et al. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. *Journal of Infectious Diseases*. 2011 Nov 15;204(10):1475-82. PMID: 21949042.
231. Carraro G, Naso A, Montomoli E, et al. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvanted pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. *Vaccine*. 2012 Feb 1;30(6):1170-80. PMID: 22178096.

232. Cartwright K, Morris R, Rumke H, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. *Vaccine*. 1999;4;17(20-21):2612-9. PMID: 1999235600 MEDLINE PMID 10418910 (<http://www.ncbi.nlm.nih.gov/pubmed/10418910>).
233. Carvajal A, Ortega PG, Sainz M, et al. Adverse events associated with pandemic influenza vaccines: comparison of the results of a follow-up study with those coming from spontaneous reporting. *Vaccine*. 2011 Jan 10;29(3):519-22. PMID: 21112311.
234. Castro JF, Bennett JV, Rincon HG, et al. Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol). *Vaccine*. 2005 Jan 11;23(8):1079-84. PMID: 15620482.
235. Center KJ, Hansen JR, Lewis E, et al. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine. *Pediatric Infectious Disease Journal*. 2009 May;28(5):438-40. PMID: 19319016.
236. Center KJ, Strauss A. Safety experience with heptavalent pneumococcal CRM197-conjugate vaccine (Prevenar) since vaccine introduction. *Vaccine*. 2009 May 26;27(25-26):3281-4. PMID: 19200818.
237. Centers for Disease C, Prevention. Suspension of rotavirus vaccine after reports of intussusception--United States, 1999.[Erratum appears in MMWR Morb Mortal Wkly Rep. 2004 Sep 24;53(37):879]. *MMWR - Morbidity & Mortality Weekly Report*. 2004 Sep 3;53(34):786-9. PMID: 15343145.
238. Centers for Disease C, Prevention. Postmarketing monitoring of intussusception after RotaTeq vaccination--United States, February 1, 2006-February 15, 2007. *MMWR - Morbidity & Mortality Weekly Report*. 2007 Mar 16;56(10):218-22. PMID: 17363890.
239. Centers for Disease C, Prevention. Addition of history of intussusception as a contraindication for rotavirus vaccination. *MMWR - Morbidity & Mortality Weekly Report*. 2011 Oct 21;60(41):1427. PMID: 22012117.
240. Centers for Disease C, Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. *MMWR - Morbidity & Mortality Weekly Report*. 2012 Jun;61(21):394-5. PMID: 22647745.
241. Centers for Disease C, Prevention, Advisory Committee on Immunization P. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. *MMWR Morb Mortal Wkly Rep*. 2008 Mar 14;57(10):258-60. PMID: 18340332.

242. Cerbino-Neto J, Santos AT, Gouvea MI, et al. Comparison of adverse events following immunization with pandemic influenza A (H1N1)pdm09 vaccine with or without adjuvant among health professionals in Rio de Janeiro, Brazil. *Memorias do Instituto Oswaldo Cruz*. 2012 Nov;107(7):923-7. PMID: 23147150.
243. Chaibou MS, Bako H, Salisou L, et al. Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010. *Vaccine*. 2012 Jul 27;30(35):5229-34. PMID: 22709955.
244. Chandramohan D, Hodgson A, Coleman P, et al. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine. *Vaccine*. 2007 Sep 3;25 Suppl 1:A83-91. PMID: 17521782.
245. Chandran A, Santosham M. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine. *Expert Review of Vaccines*. 2008 Dec;7(10):1475-80. PMID: 19053204.
246. Chandwani S, Beeler J, Li H, et al. Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225. *Journal of Infectious Diseases*. 2011 Jul;204 Suppl 1:S179-89. PMID: 21666159.
247. Chang HG, Smith PF, Ackelsberg J, et al. Intussusception, rotavirus diarrhea, and rotavirus vaccine use among children in New York state. *Pediatrics*. 2001 Jul;108(1):54-60. PMID: 11433054.
248. Chang S, Ball R, Braun MM. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006. *Vaccine*. 2008 2;26(19):2428-32. PMID: 2008210701 MEDLINE PMID 18406499 (<http://www.ncbi.nlm.nih.gov/pubmed/18406499>).
249. Chang S, O'Connor PM, Slade BA, et al. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007. *Vaccine*. 2013 Feb 27;31(10):1447-52. PMID: 23142308.
250. Chang Y-T, Guo C-Y, Tsai M-S, et al. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients. *Vaccine*. 2012 Jul 13;30(33):5009-18. PMID: 22658967.
251. Charkoudian LD, Kaiser GM, Steinmetz RL, et al. Acute retinal necrosis after herpes zoster vaccination. *Archives of Ophthalmology*. 2011 Nov;129(11):1495-7. PMID: 22084222.
252. Charman T. The highs and lows of counting autism. *American Journal of Psychiatry*. 2011 September;168(9):873-5. PMID: 2011496939 MEDLINE PMID 21890797 (<http://www.ncbi.nlm.nih.gov/pubmed/21890797>).

253. Chatterjee A, O'Keefe C, Varman M, et al. Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers: A randomized, controlled, open-label, multicenter study. *Vaccine*. 2012;14;30(23):3360-8. PMID: 2012222630.
254. Chatterjee S, Rego SJ, D'Souza F, et al. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule. *BMC Infectious Diseases*. 2010;10:298. PMID: 20950457.
255. Chavant F, Favreliere S, Lafay-Chebassier C, et al. Memory disorders associated with consumption of drugs: Updating through a case/noncase study in the French PharmacoVigilance Database. *British Journal of Clinical Pharmacology*. 2011 December;72(6):898-904. PMID: 2011622723 MEDLINE PMID 21557759 (<http://www.ncbi.nlm.nih.gov/pubmed/21557759>).
256. Chavant F, Ingrand I, Jonville-Bera AP, et al. The PREGVAXGRIP Study: a Cohort Study to Assess Foetal and Neonatal Consequences of In Utero Exposure to Vaccination Against A(H1N1)v2009 Influenza. *Drug Safety*. 2013 Jun;36(6):455-65. PMID: 23516007.
257. Chazono M, Hirota T, Yoshida I, et al. Safety follow-up in a cohort of Biken acellular DPT vaccine recipients in Japan. *Developments in Biological Standardization*. 1991;73:323-7. PMID: 1778326.
258. Chen J, Heyse JF, Heaton P, et al. Age dependence of the risk of intussusception following [corrected] rhesus-human reassortant rotavirus tetravalent vaccine: is it beyond doubt?. [Erratum appears in Am J Epidemiol. 2010 Jul 1;172(1):125]. *American Journal of Epidemiology*. 2010 May 1;171(9):1046-54. PMID: 20400464.
259. Chen J, Heyse JF, Heaton P, et al. Re: "Age Dependence of the Risk of Intussusception Following Tetravalent Rhesus-Human Reassortant Rotavirus Tetravalent Vaccine: Is It Beyond Doubt?" Reply. *American Journal of Epidemiology*. 2010 Oct;172(7) PMID: WOS:000282166900019.
260. Chen RT. Evaluation of vaccine safety after the events of 11 September 2001: Role of cohort and case-control studies. *Vaccine*. 2004;7;22(15 16):2047-53. PMID: 2004198046 MEDLINE PMID 15121321 (<http://www.ncbi.nlm.nih.gov/pubmed/15121321>).
261. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. *The Vaccine Safety Datalink Team. Pediatrics*. 1997 Jun;99(6):765-73. PMID: 9164767.
262. Chen RT, Pool V, Takahashi H, et al. Combination vaccines: Postlicensure safety evaluation. *Clinical Infectious Diseases*. 2001;15;33(SUPPL. 4):S327-S33. PMID: 2001441953 MEDLINE PMID 11709768 (<http://www.ncbi.nlm.nih.gov/pubmed/11709768>).
263. Chen WH, Winokur PL, Edwards KM, et al. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a

component of the U.S. pandemic preparedness plan in 2009. *Vaccine*. 2012 Jun;30(28):4240-8. PMID: 2012314753.

264. Chen WH, Winokur PL, Edwards KM, et al. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. *Vaccine*. 2012 Jun;30(28):4240-8. PMID: 22537984.
265. Cheng HK, Rajadurai VS, Amin Z, et al. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine. *Southeast Asian Journal of Tropical Medicine & Public Health*. 2004 Sep;35(3):685-92. PMID: 15689088.
266. Cheong HJ, Song JY, Heo JY, et al. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. *Vaccine*. 2011 Jan 10;29(3):523-7. PMID: 21055502.
267. Cheong HJ, Song JY, Heo JY, et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. *Clinical & Vaccine Immunology: CVI*. 2011 Aug;18(8):1358-64. PMID: 21715575.
268. Cherian T, Thomas N, Raghupathy P, et al. Safety and immunogenicity of Haemophilus influenzae type B vaccine given in combination with DTwP at 6, 10 and 14 weeks of age. *Indian Pediatrics*. 2002 May;39(5):427-36. PMID: 12037271.
269. Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. *Pediatric Infectious Disease Journal*. 2009 Apr;28(4 Suppl):S109-18. PMID: 19325447.
270. Chi R-C, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. *Clinical Infectious Diseases*. 2010 May 15;50(10):1331-8. PMID: 20377407.
271. Chioato A, Noseda E, Felix SD, et al. Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study. *Clinical & Vaccine Immunology: CVI*. 2010 Dec;17(12):1952-7. PMID: 20962212.
272. Chippaux JP, Garba A, Ethevenaux C, et al. Immunogenicity, safety, and memory of different schedules of *Neisseria meningitidis* A/C-diphtheria toxoid conjugate vaccine in infants in Niger. *Vaccine*. 2004 Mar;22(25-26):3303-11. PMID: 15308353 (<http://www.ncbi.nlm.nih.gov/pubmed/15308353>).

273. Chiu HH, Huang LM, Lee PI, et al. Diphtheria, tetanus and whole cell pertussis vaccine combined with hepatitis B vaccines: A comparison of two doses (10 (μ g) and 5 (μ g)). *Pediatric Infectious Disease Journal*. 1998 March;17(3):206-11. PMID: 1998106916 MEDLINE PMID 9535247 (<http://www.ncbi.nlm.nih.gov/pubmed/9535247>).
274. Choe YJ, Cho H, Bae G-R, et al. Guillain-Barre syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition. *Vaccine*. 2011 Mar 3;29(11):2066-70. PMID: 21255684.
275. Choe YJ, Cho H, Kim SN, et al. Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010. *Vaccine*. 2011 Oct 13;29(44):7727-32. PMID: 21827815.
276. Choe YJ, Cho H, Song KM, et al. Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea. *Japanese Journal of Infectious Diseases*. 2011;64(4):297-303. PMID: 21788704.
277. Choi J-H, Choo EJ, Huh A, et al. Immunogenicity and safety of diphtheria-tetanus vaccine in adults. *Journal of Korean Medical Science*. 2010 Dec;25(12):1727-32. PMID: 21165286.
278. Choi U, Lee SY, Kwak GY, et al. Immunogenicity and safety of primary and secondary DTaP booster vaccination. *Journal of the Korean Medical Association*. 2011 September;54(9):979-87. PMID: 2011560263.
279. Choo S, Zuckerman J, Goilav C, et al. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. *Vaccine*. 2000 Jun 1;18(24):2686-92. PMID: 10781855.
280. Chou JF, Kernan NA, Prockop S, et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). *Biology of Blood & Marrow Transplantation*. 2011 Nov;17(11):1708-13. PMID: 21664979.
281. Chouraqui JP, Van Egroo LD, Fichot MC. Acidified milk formula supplemented with *bifidobacterium lactis*: Impact on infant diarrhea in residential care settings. *Journal of Pediatric Gastroenterology and Nutrition*. 2004 Mar;38(3):288-92. PMID: WOS:000220589600010.
282. Christenson B, Lundbergh P, Hedlund J, et al. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. *Lancet*. 2001 Mar 31;357(9261):1008-11. PMID: 11293594.
283. Christie CDC, Duncan ND. Rotavirus vaccine trial in Jamaica. *West Indian Medical Journal*. 2012;61(4) PMID: 2012529420.

284. Christou EM, Wargon O. Stevens-Johnson syndrome after varicella vaccination. *Medical Journal of Australia*. 2012;5;196(4):240-1. PMID: 2012132562 MEDLINE PMID 22409681 (<http://www.ncbi.nlm.nih.gov/pubmed/22409681>).
285. Chu DWS, Kwong ASK, Tsui WWS, et al. Cross-clade immunogenicity and safety of an AS03A-adjuvanted prepandemic H5N1 influenza vaccine in Hong Kong. *Hong Kong Medical Journal*. 2011 Feb;17(1):39-46. PMID: 21282825.
286. Ciarlet M, He S, Lai S, et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. *Pediatric Infectious Disease Journal*. 2009 Mar;28(3):177-81. PMID: 19209092.
287. Ciarlet M, Sani-Grosso R, Yuan G, et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. *Pediatric Infectious Disease Journal*. 2008 Oct;27(10):874-80. PMID: 18756184.
288. Ciarlet M, Schodel F. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq. *Vaccine*. 2009 Dec 30;27 Suppl 6:G72-81. PMID: 20006144.
289. Citron ML, Moss BM. Pneumococcal-vaccine-induced thrombocytopenia. *JAMA*. 1982 Sep 10;248(10):1178. PMID: 7109129.
290. Claesson BA, Trollfors B, Lagergard T, et al. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. *Journal of Pediatrics*. 1988 May;112(5):695-702. PMID: 3361379.
291. Clarke M, Marshall H. Rotavirus vaccination for prevention of serious acute gastroenteritis and the importance of postlicensure safety monitoring. *Journal of Infectious Diseases*. 2012;1;206(1):3-5. PMID: 2012308449 MEDLINE PMID 22539816 (<http://www.ncbi.nlm.nih.gov/pubmed/22539816>).
292. Clarke SC. Control of pneumococcal disease in the United Kingdom - The start of a new era. *Journal of Medical Microbiology*. 2006 August;55(8):975-80. PMID: 2006387505 MEDLINE PMID 16849715 (<http://www.ncbi.nlm.nih.gov/pubmed/16849715>).
293. Clarkson A, Conroy S, Burroughs K, et al. Surveillance for adverse drug reactions in children: A paediatric regional monitoring centre. *Paediatric and Perinatal Drug Therapy*. 2004;2004;6(1):20-3. PMID: 2004358628.
294. Classen JB, Classen DC. Association between type 1 diabetes and hib vaccine. Causal relation is likely. *BMJ*. 1999 Oct 23;319(7217):1133. PMID: 10531116.

295. Clements KM, Chancellor J, Nichol K, et al. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. *Value in Health*. 2011 September-October;14(6):800-11. PMID: 2011512561 MEDLINE PMID 21914499 (<http://www.ncbi.nlm.nih.gov/pubmed/21914499>).
296. Clements-Mann ML, Wright PF, Hoshino Y, et al. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. *Vaccine*. 1999 4;17(20 21):2715-25. PMID: 1999235613 MEDLINE PMID 10418923 (<http://www.ncbi.nlm.nih.gov/pubmed/10418923>).
297. Clerici M, Rizzardini G, Cossu MV, et al. Probiotic strains BB-12(registered trademark) and L. casei 431(registered trademark) increase the immune response to an influenza vaccine: A randomized, double-blind, placebo-controlled study. *European Journal of Pharmacology*. 2011 September;668 SUPPL. 1:e3-e4.
298. Clifford V, Crawford NW, Royle J, et al. Recurrent apnoea post immunisation: Informing re-immunisation policy. *Vaccine*. 2011 05;29(34):5681-7. PMID: 2011399970 MEDLINE PMID 21693156 (<http://www.ncbi.nlm.nih.gov/pubmed/21693156>).
299. Clothier HJ, Lee KJ, Sundararajan V, et al. Human papillomavirus vaccine in boys: background rates of potential adverse events. *Medical Journal of Australia*. 2013;198(10):554-8. PMID: 23725271.
300. Cohen J. Medicine. Rethinking a vaccine's risk.[Erratum appears in *Science* 2001 Sep 14;293(5537):1997]. *Science*. 2001 Aug 31;293(5535):1576-7. PMID: 11533457.
301. Coleman BL, McGeer AJ, Halperin SA, et al. A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine. *Vaccine*. 2012 Sep 28;30(44):6287-93. PMID: 22902784.
302. Collignon P, Doshi P, Jefferson T. Ramifications of adverse events in children in Australia. *BMJ*. 2010;(2010) 340(7759):1262. PMID: 2010343617.
303. Collins CL, Salt P, McCarthy N, et al. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. *Vaccine*. 2004 Oct 22;22(31-32):4262-9. PMID: 15474717.
304. Committee on Obstetric P. ACOG Committee Opinion No. 521: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. *Obstetrics & Gynecology*. 2012 Mar;119(3):690-1. PMID: 22353979.
305. Conlin AM, Bukowinski AT, Sevick CJ, et al. Safety of the pandemic H1N1 influenza vaccine among pregnant U.S. military women and their newborns. *Obstetrics & Gynecology*. 2013 Mar;121(3):511-8. PMID: 23635612.

306. Cook IF, Pond D, Hartel G. Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. *Vaccine*. 2007 Jun 15;25(25):4767-74. PMID: 17512098.
307. Cook J. Australian experience with non-adjuvant H1N1 vaccine (Panvax and Panvax Junior). *Australian Prescriber*. 2010 August;33(4):121-3. PMID: 2010533658.
308. Cook KM, Evans G. The national vaccine injury compensation program. *Pediatrics*. 2011 May;127(SUPPL. 1):S74-S7. PMID: 2011239120 MEDLINE PMID 21502255 (<http://www.ncbi.nlm.nih.gov/pubmed/21502255>).
309. Cooper C, Klein M, Walmsley S, et al. High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. *HIV Clinical Trials*. 2012 1;13(1):23-32. PMID: 2012150842 MEDLINE PMID 22306585 (<http://www.ncbi.nlm.nih.gov/pubmed/22306585>).
310. Cooper C, Mackie D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV (TM) safety and efficacy. *Expert Review of Vaccines*. 2011 Apr;10(4):417-27. PMID: WOS:000290834400009.
311. Cooper C, Thorne A, Canadian Institutes of Health Research-Canadian HIVTNIVRG. Influenza vaccine oculorespiratory syndrome incidence is reduced in HIV. *Vaccine*. 2011 Oct 19;29(45):7876-7. PMID: 21872629.
312. Cooper C, Thorne A, Klein M, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. *PLoS ONE [Electronic Resource]*. 2011;6(3):e17758. PMID: 21512577.
313. Cooper PA, Madhi SA, Huebner RE, et al. Apnea and its possible relationship to immunization in ex-premature infants. *Vaccine*. 2008 25;26(27 28):3410-3. PMID: 2008273451 MEDLINE PMID 18490084 (<http://www.ncbi.nlm.nih.gov/pubmed/18490084>).
314. Cordero E, Perez-Ordonez A, Aydillo TA, et al. Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients. *American Journal of Transplantation*. 2011 Oct;11(10):2205-13. PMID: 21831151.
315. Cordonnier C, Labopin M, Chesnel V, et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: Results from the EBMT IDWP01 trial. *Vaccine*. 2010 24;28(15):2730-4. PMID: 2010153577 MEDLINE PMID 20117269 (<http://www.ncbi.nlm.nih.gov/pubmed/20117269>).
316. Correia O, Nunes JP, Vaz-da-Silva MJ, et al. Acute exanthematous pustular dermatitis after pneumococcal vaccine [3]. *Dermatology*. 1993 1993;187(3):217. PMID: 1993267320 MEDLINE PMID 8219429 (<http://www.ncbi.nlm.nih.gov/pubmed/8219429>).

317. Coursaget P, Bringer L, Sarr G, et al. Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine. *Vaccine*. 1992;10(6):379-82. PMID: 1534640.
318. Couzin-Frankel J. New network to track drugs and vaccines in pregnancy. *Science*. 2010 26;327(5969):1066-7. PMID: 2010145181.
319. Crawford N. Immunizations in children with cancer. *Paediatrics and Child Health*. 2012 March;22(3):121-2. PMID: 2012139859.
320. Crespo M, Collado S, Mir M, et al. Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. *Clinical Journal of The American Society of Nephrology: CJASN*. 2011 Sep;6(9):2208-14. PMID: 21852661.
321. Cristiani C, Tuccori M, Pepe P, et al. Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. *Vaccine*. 2011 Apr 18;29(18):3443-8. PMID: 21396903.
322. Cronin J, Scorr A, Russell S, et al. A review of a paediatric emergency department vaccination programme for patients at risk of allergy/anaphylaxis. *Acta Paediatrica*. 2012 Sep;101(9):941-5. PMID: 22612789.
323. Croxtall JD, Dhillon S. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (NimenrixTM). *Drugs*. 2012 Dec 24;72(18):2407-30. PMID: 23231026.
324. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza a (H1N1) vaccine in an immunocompromised population: A prospective study comparing HIV-infected adults with HIV-uninfected adults. *Clinical Infectious Diseases*. 2011 1;52(1):138-46. PMID: 2011093231 MEDLINE PMID 21148532 (<http://www.ncbi.nlm.nih.gov/pubmed/21148532>).
325. Crum-Cianflone NF, Hullsiek KH, Roediger M, et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. *Journal of Infectious Diseases*. 2010 1;202(7):1114-25. PMID: 2010562671 MEDLINE PMID 20795819 (<http://www.ncbi.nlm.nih.gov/pubmed/20795819>).
326. Cserti-Gazdewich CM, Pendergrast JM, Reis M. Postvaccination hyperhemolysis coinciding with remission of Epstein Barr virus (EBV)-associated immune thrombocytopenic purpura (ITP). *American Journal of Hematology*. 2009 September;84(9):612-3. PMID: 2009465276 MEDLINE PMID 19610018 (<http://www.ncbi.nlm.nih.gov/pubmed/19610018>).
327. Cuba IPVSCG. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. *New England Journal of Medicine*. 2007 Apr 12;356(15):1536-44. PMID: 17429085.

328. Cullen G, Baden RP, Cheifetz AS. Vaccination in inflammatory bowel disease. *American Journal of Gastroenterology*. 2011 Jan;106(1):168. PMID: 21212760.
329. Cunningham CK, Rudy BJ, Xu J, et al. Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States. *Pediatric Infectious Disease Journal*. 2010 Jun;29(6):530-4. PMID: 20173677.
330. Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: A review. *Bulletin of the World Health Organization*. 2007 September;85(9):719-26. PMID: 2007453401 MEDLINE PMID 18026629 (<http://www.ncbi.nlm.nih.gov/pubmed/18026629>).
331. Czajka H, Volker S, Fred Z, et al. Erratum to "A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra(trademark)): Immunogenicity and safety profile" by Czajka et al. [Vaccine 27 (47) (2009) 6504-6511] (DOI:10.1016/j.vaccine.2009.07.076). *Vaccine*. 2012.
332. D'Acremont V, Tremblay S, Genton B. Impact of vaccines given during pregnancy on the offspring of women consulting a travel clinic: a longitudinal study. *Journal of Travel Medicine*. 2008 Mar-Apr;15(2):77-81. PMID: 18346239.
333. Dagan R. Immunisation with a pneumococcal 7-valent conjugate vaccine. *International Journal of Clinical Practice*. 2002 May;56(4):287-91. PMID: 12074212.
334. Dagan R, Amir J, Livni G, et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.[Erratum appears in *Pediatr Infect Dis J*. 2007 Nov;26(11):1071 Note: Froesner, Gert [corrected to Foresner, Gert]; Schaetzl, Hermann M [corrected to Schatzl, Hermann M]]. *Pediatric Infectious Disease Journal*. 2007 Sep;26(9):787-93. PMID: 17721372.
335. Dagan R, Igbaria K, Piglansky L, et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and *Haemophilus influenzae* type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. *Pediatric Infectious Disease Journal*. 1997 Dec;16(12):1113-21. PMID: 9427455.
336. Dagan R, Kayhty H, Wuorimaa T, et al. Tolerability and immunogenicity of an eleven valent mixed carrier *Streptococcus pneumoniae* capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. *Pediatric Infectious Disease Journal*. 2004 Feb;23(2):91-8. PMID: 14872172.
337. D'Alessandro D, Ciriminna S, Rossini A, et al. Requests of medical examinations after pneumococcal & influenza vaccination in the elderly. *Indian Journal of Medical Research*. 2004 May;119 Suppl:108-14. PMID: 15232174.
338. Dallar Y, Bostancı I, Bozdayı G, et al. Rotavirus-associated intussusception followed by spontaneous resolution. *Turkish Journal of Gastroenterology*. 2009 September;20(3):209-13.

PMID: 2009551548 MEDLINE PMID 19821204
(<http://www.ncbi.nlm.nih.gov/pubmed/19821204>).

339. Damm O, Rose MA, Greiner W, et al. Cost-effectiveness of vaccinating children aged 2-17 years with intranasal live attenuated influenza vaccine (LAIV) in germany. *Value in Health.* 2011 November;14(7):A280.

340. Daum RS, Hogerman D, Rennels MB, et al. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. *Journal of Infectious Diseases.* 1997 Aug;176(2):445-55. PMID: 9237711.

341. David S, Vermeer-de Bondt PE, van der Maas NAT. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands. *Vaccine.* 2008 Oct 29;26(46):5883-7. PMID: 18775463.

342. Davidson G, Elliott EJ, Kirkwood C, et al. Preventing rotavirus gastroenteritis: do you have the facts? *Journal of Paediatrics & Child Health.* 2007 Jul-Aug;43(7-8):564-7. PMID: 17635688.

343. Davidson LE, Fiorino AM, Snydman DR, et al. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. *European Journal of Clinical Nutrition.* 2011 Apr;65(4):501-7. PMID: 21285968.

344. Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. *Pediatrics.* 1997 Nov;100(5):767-71. PMID: 9346975.

345. Dayan GH, Thorley M, Yamamura Y, et al. Serologic response to inactivated poliovirus vaccine: A randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. *Journal of Infectious Diseases.* 2007 1;195(1):12-20. PMID: 2006625373 MEDLINE PMID 17152004 (<http://www.ncbi.nlm.nih.gov/pubmed/17152004>).

346. Dbaibo G, Van der Wielen M, Reda M, et al. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. *International Journal of Infectious Diseases.* 2012 Aug;16(8):e608-15. PMID: 22704725.

347. D'Cruz OF, Shapiro ED, Spiegelman KN, et al. Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barre syndrome) after immunization with Haemophilus influenzae type b conjugate vaccine. *Journal of Pediatrics.* 1989 Nov;115(5 Pt 1):743-6. PMID: 2809907.

348. De Aristegui Fernandez J, Cos Arregui B, Zurimendi Carril A, et al. Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine

(Prevenar(registered trademark)) administered in previously unvaccinated Spanish children aged 24 to 36 months. Vaccine. 2005 Mar;23(16):1917-22. PMID: 2005095973 MEDLINE PMID 15793941 (<http://www.ncbi.nlm.nih.gov/pubmed/15793941>).

349. de Aristegui Fernandez J, Cos Arregui B, Zurimendi Carril A, et al. Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar) administered in previously unvaccinated Spanish children aged 24 to 36 months. Vaccine. 2005 Mar 14;23(16):1917-22. PMID: 15793941.

350. de Carvalho JF, Shoenfeld Y. Status epilepticus and lymphocytic pneumonitis following hepatitis B vaccination. European Journal of Internal Medicine. 2008 Jul;19(5):383-5. PMID: 18549949.

351. De Roux A, Schmoele-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: Conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clinical Infectious Diseases. 2008 1;46(7):1015-23. PMID: 2008201282 MEDLINE PMID 18444818 (<http://www.ncbi.nlm.nih.gov/pubmed/18444818>).

352. de Roux A, Schmole-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.[Erratum appears in Clin Infect Dis. 2008 May 1;46(9):1488 Note: Schmoele-Thoma, B [corrected to Schmole-Thoma, B]]. Clinical Infectious Diseases. 2008 Apr 1;46(7):1015-23. PMID: 18444818.

353. De Schryver A, Verstrepen K, Vandersmissen L, et al. Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers. Journal of Viral Hepatitis. 2011 Apr;18(4):e5-10. PMID: 20735800.

354. de Serres G, Gariepy MC, Coleman B, et al. Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine. PLoS ONE [Electronic Resource]. 2012;7(7) PMID: 2012395916.

355. De Sousa A, Rabariaona LP, Tenkorang O, et al. Pharmacovigilance of malaria intermittent preventive treatment in infants coupled with routine immunizations in 6 African countries. Journal of Infectious Diseases. 2012 1;205(SUPPL. 1):S82-S90. PMID: 2012094779 MEDLINE PMID 22315391 (<http://www.ncbi.nlm.nih.gov/pubmed/22315391>).

356. De Wals P, Black S, Borrow R, et al. Modeling the impact of a new vaccine on pneumococcal and nontypable *Haemophilus influenzae* diseases: A new simulation model. Clinical Therapeutics. 2009 October;31(10):2152-69. PMID: 2009630031 MEDLINE PMID 19922887 (<http://www.ncbi.nlm.nih.gov/pubmed/19922887>).

357. de Whalley P, Walker W, Snape MD, et al. A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children. Health Technology Assessment (Winchester, England). 2011 Dec;15(45):v-vi, xi-xiii, 1-128. PMID: 22257497.

358. deBruyn JC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. *Inflammatory Bowel Diseases*. 2012 Jan;18(1):25-33. PMID: 21472826.
359. deBruyn JCC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. *Inflammatory Bowel Diseases*. 2012 Jan;18(1):25-33. PMID: 21472826.
360. Decker MD, Edwards KM, Bradley R, et al. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. *Journal of Pediatrics*. 1992 Feb;120(2 Pt 1):184-9. PMID: 1735812.
361. Deeks SL, Lim GH, Simpson MA, et al. Estimating background rates of Guillain-Barre Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign. *BMC Public Health*. 2011;11:329. PMID: 21586163.
362. Deforest A, Long SS, Lischner HW, et al. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. *Pediatrics*. 1988 Feb;81(2):237-46. PMID: 3340474.
363. Deivanayagam N, Nedunchezian K, Ahamed SS, et al. Intramuscular injection as a provoking factor for paralysis in acute poliomyelitis. A case control study. *Indian Pediatrics*. 1993 Mar;30(3):335-40. PMID: 8365783.
364. Della Cioppa G, Nicolay U, Lindert K, et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 ([REGISTERED]) adjuvant: results from a dose-finding clinical trial in older adults. *Human vaccines & Immunotherapeutics*. 2012 Feb;8(2):216-27. PMID: 22426371.
365. Della Cioppa G, Nicolay U, Lindert K, et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 () adjuvant: results from a dose-finding clinical trial in older adults. *Human vaccines & Immunotherapeutics*. 2012 Feb;8(2):216-27. PMID: 22426371.
366. Della Cioppa G, Vesikari T, Sokal E, et al. Trivalent and quadrivalent MF59((registered trademark))-adjuvanted influenza vaccine in young children: A dose- and schedule-finding study. *Vaccine*. 2011 03;29(47):8696-704. PMID: 2011659678 MEDLINE PMID 21906647 (<http://www.ncbi.nlm.nih.gov/pubmed/21906647>).
367. Dell'Era L, Corona F, Daleno C, et al. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. *Vaccine*. 2012 Jan 20;30(5):936-40. PMID: 22138210.
368. Delong G. A positive association found between autism prevalence and childhood vaccination uptake across the U.S. population. *Journal of Toxicology and Environmental Health*

- Part A: Current Issues. 2011 January;74(14):903-16. PMID: 2011330687 MEDLINE PMID 21623535 (<http://www.ncbi.nlm.nih.gov/pubmed/21623535>).
369. Deng M-P, Hu Z-H, Wang H-L, et al. Developments of subunit and VLP vaccines against influenza a virus. *Virologica Sinica*. 2012 Jun;27(3):145-53. PMID: 22684468.
370. Denholm JT, Neal A, Yan B, et al. Acute encephalomyelitis syndromes associated with H1N1 09 influenza vaccination. *Neurology*. 2010 Dec 14;75(24):2246-8. PMID: 21172848.
371. Dennehy PH, North American Human Rotavirus Vaccine Study G. A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. *Vaccine*. 2006 May 1;24(18):3780-1. PMID: 16111790.
372. Desai R, Cortese MM, Meltzer MI, et al. Potential intussusception risk versus benefits of rotavirus vaccination in the United States. *Pediatric Infectious Disease Journal*. 2012;27.
373. Desai R, Parashar UD, Lopman B, et al. Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America. *Clinical Infectious Diseases*. 2012 May;54(10):1397-405. PMID: 22431803.
374. DeStefano F, Vaccine Safety Datalink Research G. The Vaccine Safety Datalink project. *Pharmacoepidemiology & Drug Safety*. 2001 Aug-Sep;10(5):403-6. PMID: 11802585.
375. DeStefano F, Weintraub ES, Chen RT. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. *Neurology*. 2005 Apr 12;64(7):1317; author reply PMID: 15832457.
376. DeWilde S, Carey IM, Richards N, et al. Do children who become autistic consult more often after MMR vaccination? *Br J Gen Pract*. 2001 Mar;51(464):226-7. PMID: 11255906.
377. DeWolfe Miller F. Intussusception and an oral rotavirus vaccine. *New England Journal of Medicine*. 2001 Jun 14;344(24):1866; author reply -7. PMID: 11407352.
378. Dhingra MS, Rao R, Bhat S, et al. Evaluation of the immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Shan 4) with EasyFour™ in Indian infants administered per EPI schedule: a phase III trial. *Human Vaccines*. 2010 Jul;6(7):572-7. PMID: 20421723.
379. Di Lernia V, Ricci C. Skin manifestations with Rotavirus infections. *International Journal of Dermatology*. 2006 June;45(6):759-61. PMID: 2006337742 MEDLINE PMID 16796645 (<http://www.ncbi.nlm.nih.gov/pubmed/16796645>).

380. DiazGranados CA, Dunning AJ, Jordanov E, et al. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. *Vaccine*. 2013 Jan 30;31(6):861-6. PMID: 23261045.
381. Diaz-Mitoma F, Halperin SA, Tapiero B, et al. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age. *Vaccine*. 2011 Feb 1;29(6):1324-31. PMID: 21134456.
382. Diaz-Ortega JL, Bennett JV, Castaneda D, et al. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: Comparisons with injected MMR. *Vaccine*. 2010 Aug;28(3):692-8. PMID: 2009626889 MEDLINE PMID 19861187 (<http://www.ncbi.nlm.nih.gov/pubmed/19861187>).
383. Diaz-Ortega J-L, Bennett JV, Castaneda D, et al. Aerosolized MMR vaccine: Evaluating potential transmission of components to vaccine administrators and contacts of vaccinees. *Biologicals*. 2012 Jul;40(4):278-81. PMID: 22494953.
384. Dicko A, Odusanya OO, Diallo AI, et al. Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial. *BMC Public Health*. 2011;11:882. PMID: 22112189.
385. Diez-Domingo J, Cantarino MVP, Torrenti JMB, et al. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. *Pediatric Infectious Disease Journal*. 2010 Feb;29(2):148-52. PMID: 19927040.
386. Diez-Domingo J, Delgado JD, Ballester A, et al. Immunogenicity and reactogenicity of a combined adsorbed tetanus toxoid, low dose diphtheria toxoid, five component acellular pertussis and inactivated polio vaccine in six-year-old children. *Pediatric Infectious Disease Journal*. 2005 Mar;24(3):219-24. PMID: 15750457.
387. Diez-Domingo J, Flores SA, Martin JC, et al. A Randomized, Multicenter, Open-Label Clinical Trial to Assess the Anamnestic Immune Response 4 to 8 Years after a Primary Hepatitis B Vaccination Series. *Pediatric Infectious Disease Journal*. 2010 Oct;29(10):972-4. PMID: WOS:000282069700017.
388. Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccine: PHiD-CV. *Expert Review of Antiinfective Therapy*. 2009 Nov;7(9):1063-74. PMID: 19883326.
389. Dip RM, Cabrera MAS. Influenza vaccination in non-institutionalized elderly: a population-based study in a medium-sized city in Southern Brazil. *Cadernos de Saude Publica*. 2010 May;26(5):1035-44. PMID: 20563403.

390. Domachowske JB, Blatter M, Chandrasekaran V, et al. A Randomized, Controlled Trial in Children to Assess the Immunogenicity and Safety of a Thimerosal-free Trivalent Seasonal Influenza Vaccine. *Pediatric Infectious Disease Journal*. 2012 Jun;31(6):605-15. PMID: 22333695.
391. Domachowske JB, Pankow-Culot H, Bautista M, et al. A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3-17 Years. *Journal of Infectious Diseases*. 2013 Jun;207(12):1878-87. PMID: 23470848.
392. Donalisio MR, Rodrigues SMCP, Mendes ET, et al. Adverse events after pneumococcal vaccination. *Jornal Brasileiro De Pneumologia: Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisiologia*. 2007 Feb;33(1):51-6. PMID: 17568868.
393. Donato CM, Ch'Ng LS, Boniface KF, et al. Identification of strains of rotatetq rotavirus vaccine in infants with gastroenteritis following routine vaccination. *Journal of Infectious Diseases*. 2012 1;206(3):377-83. PMID: 2012417551.
394. Donnini I, Scappini B, Guidi S, et al. Acquired severe aplastic anemia after H1N1 influenza virus vaccination successfully treated with allogeneic bone marrow transplantation. *Annals of Hematology*. 2012 March;91(3):475-6. PMID: 2012108872 MEDLINE PMID 21681390 (<http://www.ncbi.nlm.nih.gov/pubmed/21681390>).
395. Dransfield MT, Harnden S, Burton RL, et al. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. *Clinical Infectious Diseases*. 2012 1;55(5):e35-e44. PMID: 2012475151.
396. Dransfield MT, Nahm MH, Han MK, et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*. 2009 15;180(6):499-505. PMID: 2009474484 MEDLINE PMID 19556517 (<http://www.ncbi.nlm.nih.gov/pubmed/19556517>).
397. Drees M, Tambourelli B, Denstman A, et al. Sustained high influenza vaccination rates and decreased safety concerns among pregnant women during the 2010-2011 influenza season. *Vaccine*. 2013 Jan 2;31(2):362-6. PMID: 23146674.
398. Drucker J. Poliomyelitis in France: epidemiology and vaccination status. *Pediatric Infectious Disease Journal*. 1991 Dec;10(12):967-9. PMID: 1766723.
399. Duff P. Influenza vaccine: a safe bet for mother and baby. *Obstetrics & Gynecology*. 2013 Mar;121(3):503-4. PMID: 23635609.
400. Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [Prevenar 13([REGISTERED])]: profile report. *Paediatric Drugs*. 2012 Feb 1;14(1):67-9. PMID: 22149553.

401. Duggan ST, Plosker GL. Intanza(registered trademark) 15(mu)g intradermal seasonal influenza vaccine: In older adults (aged (greater-than or equal to)60 Years). *Drugs and Aging*. 2010;27(7):597-605. PMID: 2010365583.
402. Durando P, Alicino C, De Florentiis D, et al. Improving the protection against *Streptococcus pneumoniae* with the new generation 13-valent pneumococcal conjugate vaccine. *Journal of Preventive Medicine and Hygiene*. 2012 June;53(2):68-77. PMID: 2012467780.
403. Dutta AK, Verghese VP, Pemde HK, et al. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, *Haemophilus influenzae* type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine. *Indian Pediatrics*. 2009 Nov;46(11):975-82. PMID: 19955579.
404. Edelman R. Perspective on the development and deployment of rotavirus vaccines. *Pediatric Infectious Disease Journal*. 1987 1987;6(8):704-10. PMID: 1987218510 MEDLINE PMID 2823210 (<http://www.ncbi.nlm.nih.gov/pubmed/2823210>).
405. Ehrlich HJ, Muller M, Kollaritsch H, et al. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. *Vaccine*. 2012 Jun 22;30(30):4543-51. PMID: 22475864.
406. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. *Human Vaccines*. 2011 Dec;7(12):1343-58. PMID: 22048173.
407. El Bashir H, Heath PT, Papa T, et al. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine. *Vaccine*. 2006 Mar 24;24(14):2544-9. PMID: 16417952.
408. El Sahly H. MF59(trademark) as a vaccine adjuvant: A review of safety and immunogenicity. *Expert Review of Vaccines*. 2010 October;9(10):1135-41. PMID: 2010571720.
409. El Sahly HM, Davis C, Kotloff K, et al. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: A randomized clinical trial. *Journal of Infectious Diseases*. 2012 1;205(5):703-12. PMID: 2012093406 MEDLINE PMID 22275399 (<http://www.ncbi.nlm.nih.gov/pubmed/22275399>).
410. El-Darouti MA, Hegazy RA, Abdel Hay RM, et al. Live attenuated varicella vaccine: A new effective adjuvant weapon in the battlefield against severe resistant psoriasis, a pilot randomized controlled trial. *Journal of the American Academy of Dermatology*. 2012 March;66(3):511-3. PMID: 2012113496 MEDLINE PMID 22342019 (<http://www.ncbi.nlm.nih.gov/pubmed/22342019>).

411. Elkayam O, Ablin J, Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. *Autoimmunity Reviews*. 2007 Apr;6(5):312-4. PMID: 17412304.
412. Elkayam O, Amir S, Mendelson E, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. *Arthritis care & research*. 2011 Jul;63(7):1062-7. PMID: 21425247.
413. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. *Clinical Infectious Diseases*. 2002 Jan 15;34(2):147-53. PMID: 11740700.
414. Ellenberg SS, Foulkes MA, Midthun K, et al. Evaluating the safety of new vaccines: Summary of a workshop. *American Journal of Public Health*. 2005 May;95(5):800-7. PMID: 2005198869 MEDLINE PMID 15855455 (<http://www.ncbi.nlm.nih.gov/pubmed/15855455>).
415. Ellison VJ, Davis PG, Doyle LW. Adverse reactions to immunization with newer vaccines in the very preterm infant. *Journal of Paediatrics & Child Health*. 2005 Aug;41(8):441-3. PMID: 16101980.
416. Engels EA, Chen J, Viscidi RP, et al. Poliovirus vaccination during pregnancy, maternal seroconversion to simian virus 40, and risk of childhood cancer. *American Journal of Epidemiology*. 2004 15;160(4):306-16. PMID: 2004340755 MEDLINE PMID 15286015 (<http://www.ncbi.nlm.nih.gov/pubmed/15286015>).
417. Englund JA, Glezen WP. Passive immunization for the prevention of otitis media. *Vaccine*. 2000 Dec 8;19 Suppl 1:S116-21. PMID: 11163474.
418. Englund JA, Walter EB, Gbadebo A, et al. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. *Pediatrics*. 2006 September;118(3):e579-e85. PMID: 2007030586 MEDLINE PMID 16950949 (<http://www.ncbi.nlm.nih.gov/pubmed/16950949>).
419. Eriksson KA, Jan. Recent advances in mucosal vaccines and adjuvants. *Current Opinion in Immunology*. 2002 1;14(5):666-72. PMID: 2002383933 MEDLINE PMID 12183170 (<http://www.ncbi.nlm.nih.gov/pubmed/12183170>).
420. Escolano S, Farrington CP, Hill C, et al. Intussusception after rotavirus vaccination--spontaneous reports. *New England Journal of Medicine*. 2011 Dec 1;365(22):2139. PMID: 22129263.
421. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. *New England Journal of Medicine*. 2001 Feb 8;344(6):403-9. PMID: 11172176.

422. Eskola J, Olander RM, Hovi T, et al. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet. 1996 Dec 21-28;348(9043):1688-92. PMID: 8973430.
423. Espinosa-Padilla SE, Murata C, Estrada-Parra S, et al. Immunogenicity of A 23-Valent Pneumococcal Polysaccharide Vaccine Among Mexican Children. Archives of Medical Research. 2012 July;43(5):402-5. PMID: 2012540268.
424. Esposito S, Daleno C, Piccioli I, et al. Immunogenicity and safety of intradermal influenza vaccine in children. Vaccine. 2011 Oct 13;29(44):7606-10. PMID: 21855592.
425. Esposito S, D'Angelo E, Daleno C, et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with beta-thalassemia major. Vaccine. 2010 Nov 23;28(50):7825-8. PMID: 20888873.
426. Esposito S, Marchisio P, Ansaldi F, et al. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. Vaccine. 2010 Aug 31;28(38):6137-44. PMID: 20670909.
427. Esposito S, Meregalli E, Daleno C, et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrology Dialysis Transplantation. 2011 Jun;26(6):2018-24. PMID: 20974645.
428. Esposito S, Pugni L, Bosis S, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine. 2005 Feb 25;23(14):1703-8. PMID: 15705475.
429. Esposito S, Pugni L, Daleno C, et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics. 2011 May;127(5):e1161-8. PMID: 21464195.
430. Esposito S, Selicorni A, Daleno C, et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. Human Vaccines. 2011 Jun;7(6):613-7. PMID: 21508673.
431. Esposito S, Tagliaferri L, Daleno C, et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine. 2011 Feb 11;29(8):1677-82. PMID: 21199699.
432. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate

vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clinical & Vaccine Immunology: CVI. 2010 Jun;17(6):1017-26. PMID: 20427630.

433. Esteghamati A, Keshtkar A, Heshmat R, et al. Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran. Archives of Iranian Medicine. 2011 Mar;14(2):91-5. PMID: 21361714.

434. Estivariz CF, Molnar Z, Venczel L, et al. Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary. American Journal of Epidemiology. 2011 Aug 1;174(3):316-25. PMID: 21685412.

435. Fabrizi F, Dixit V, Messa P, et al. Intradermal vs intramuscular vaccine against hepatitis B infection in dialysis patients: a meta-analysis of randomized trials. Journal of Viral Hepatitis. 2011 Oct;18(10):730-7. PMID: WOS:000295091500034.

436. Fabrizi F, Dixit V, Messa P, et al. Hepatitis B virus vaccine in chronic kidney disease: Improved immunogenicity by adjuvants? A meta-analysis of randomized trials. Vaccine. 2012 Mar;30(13):2295-300. PMID: WOS:000302050500007.

437. Faingezicht I, Avila-Aguerro ML, Cervantes Y, et al. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine. Pan American Journal of Public Health. 2002 Oct;12(4):247-57. PMID: 12431356.

438. Fairley CK, Begg N, Borrow R, et al. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. Journal of Infectious Diseases. 1996 Dec;174(6):1360-3. PMID: 8940235.

439. Faldella G, Galletti S, Corvaglia L, et al. Safety of DTaP-IPV-Hib-HBV hexavalent vaccine in very premature infants. Vaccine. 2007 Jan 22;25(6):1036-42. PMID: 17088013.

440. Falvo C, Horowitz H. Adverse reactions associated with simultaneous administration of multiple vaccines to travelers. Journal of General Internal Medicine. 1994 1994;9(5):255-60. PMID: 1994158851 MEDLINE PMID 8046527
(<http://www.ncbi.nlm.nih.gov/pubmed/8046527>).

441. Farr C. Intussusception alert. Nursing. 2007 Apr;37(4):10. PMID: 17413328.

442. Farrell RA. Comment: Human papillomavirus vaccination, induced autoimmunity, and neuromyelitis optica. Neurology. 2012 Jul 17;79(3):287. PMID: 22722623.

443. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine. 2001 Nov 12;20(3-4):545-53. PMID: 11672921.

444. Felldin M, Studahl M, Svennerholm B, et al. The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients. *Transplant International*. 2012 Feb;25(2):166-71. PMID: 22117586.
445. Ferguson M, Risi G, Davis M, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. *Journal of Infectious Diseases*. 2012 Mar;205(5):733-44. PMID: 22315336.
446. Fernandes P, Jorge S, Lopes JA. Relapse of Nephrotic Syndrome Following the Use of 2009 Pandemic Influenza A(H1N1) Vaccine. *American Journal of Kidney Diseases*. 2010 July;56(1):185-6. PMID: 2010341744 MEDLINE PMID 20620684 (<http://www.ncbi.nlm.nih.gov/pubmed/20620684>).
447. Fernandez JD, Arregui BC, Carril AZ, et al. Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevnar (R)) administered in previously unvaccinated Spanish children aged 24 to 36 months. *Vaccine*. 2005 Mar;23(16):1917-22. PMID: WOS:000227769800004.
448. Ferraz-Filho JRL, dos Santos Torres U, de Oliveira EP, et al. MRI findings in an infant with vaccine-associated paralytic poliomyelitis. *Pediatric Radiology*. 2010 Dec;40 Suppl 1:S138-40. PMID: 20440488.
449. Ferrera G, Cuccia M, Mereu G, et al. Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: A randomized, controlled trial in children primed according to a 2+1 schedule in infancy. *Human Vaccines and Immunotherapeutics*. 2012 March;8(3):345-52. PMID: 2012244551.
450. Findlow H, Borrow R, Andrews N, et al. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom. *Pediatric Infectious Disease Journal*. 2012 June;31(6):616-22. PMID: 2012304671.
451. Fine HF, Kim E, Flynn TE, et al. Acute posterior multifocal placoid pigment epitheliopathy following varicella vaccination. *British Journal of Ophthalmology*. 2010 March;94(3):282-3+363. PMID: 2010174467 MEDLINE PMID 18728052 (<http://www.ncbi.nlm.nih.gov/pubmed/18728052>).
452. Fisher JPH, Bate J, Hambleton S. Preventing varicella in children with malignancies: what is the evidence? *Current Opinion in Infectious Diseases*. 2011 Jun;24(3):203-11. PMID: 21455062.
453. Fisker AB, Bale C, Jorgensen MJ, et al. High-dose vitamin A supplementation administered with vaccinations after 6 months of age: Sex-differential adverse reactions and morbidity. *Vaccine*. 2013 Jun 28;31(31):3191-8. PMID: 23680441.

454. Fleming JD, Fogo AJ, Creamer DJ. Stevens-Johnson syndrome triggered by seasonal influenza vaccination and flucloxacillin: A pathogenetic hypothesis. *European Journal of Dermatology*. 2011 May-June;21(3):434-5. PMID: 2011413504 MEDLINE PMID 21680282 (<http://www.ncbi.nlm.nih.gov/pubmed/21680282>).
455. Fletcher MA, Fabre P, Debois H, et al. Vaccines administered simultaneously: directions for new combination vaccines based on an historical review of the literature. *International Journal of Infectious Diseases*. 2004 Nov;8(6):328-38. PMID: 15494254.
456. Flynn PM, Cunningham CK, Rudy B, et al. Hepatitis B vaccination in HIV-infected youth: A randomized trial of three regimens. *Journal of Acquired Immune Deficiency Syndromes*. 2011 1;56(4):325-32. PMID: 2011137338 MEDLINE PMID 21350366 (<http://www.ncbi.nlm.nih.gov/pubmed/21350366>).
457. Flynn PM, Nachman S, Muresan P, et al. Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. *Journal of Infectious Diseases*. 2012 Aug 1;206(3):421-30. PMID: 22615311.
458. Folkenberg M, Callreus T, Svanstrom H, et al. Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009-March 2010. *Vaccine*. 2011 Feb 1;29(6):1180-4. PMID: 21172382.
459. Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. *Pediatrics*. 2001 Oct;108(4):E58. PMID: 11581466.
460. Forrest BD, Steele AD, Hiemstra L, et al. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. *Vaccine*. 2011 May 9;29(20):3633-9. PMID: 21440036.
461. Fortner KB, Kuller JA, Rhee EJ, et al. Influenza and tetanus, diphtheria, and acellular pertussis vaccinations during pregnancy. *Obstetrical and Gynecological Survey*. 2012 April;67(4):251-7. PMID: 2012224216.
462. Fox BC, Peterson A. Leukocytoclastic vasculitis after pneumococcal vaccination. *American Journal of Infection Control*. 1998 Jun;26(3):365-6. PMID: 9638297.
463. Fox RI, Fox CM. Sjogren's syndrome: Infections that may play a role in pathogenesis, mimic the disease, or complicate the patient's course. *Indian Journal of Rheumatology*. 2011 March;6(1):13-25. PMID: 2011259578.
464. Frampton JE. DTaP(5)-IPV-Hib vaccine (Pediacel[REGISTERED]). *Paediatric Drugs*. 2011 Dec 1;13(6):401-15. PMID: 21999652.
465. Frank AL, Labotka RJ, Rao S, et al. Haemophilus influenzae type b immunization of children with sickle cell diseases. *Pediatrics*. 1988 Oct;82(4):571-5. PMID: 3262857.

466. Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac (TM). *Human Vaccines & Immunotherapeutics*. 2012 Jun;8(6):715-24. PMID: WOS:000307105200013.
467. Fraunfelder FW, Suhler EB, Fraunfelder FT. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. *Cutaneous and Ocular Toxicology*. 2010 Mar;29(1):26-9. PMID: WOS:000274856100005.
468. Frayha HH, Dent P, Shannon HS, et al. Safety and immunogenicity of subcutaneous H. influenzae vaccines in 15-17 month-old children. *Clinical & Investigative Medicine - Medecine Clinique et Experimentale*. 1991 Oct;14(5):379-87. PMID: 1742915.
469. Frayha HH, Shaheen H, Ganelin RS, et al. Clinical and Serologic Responses of Saudi Children to Haemophilus-Influenzae Type-B Capsular Polysaccharide Diphtheria Toxoid Conjugate Vaccine. *Annals of Saudi Medicine*. 1993 May;13(3):215-21. PMID: WOS:A1993LU63500002.
470. Freedman SB, Reed J, Burwen DR, et al. Transient bulging fontanelle after vaccination: case report and review of the vaccine adverse event reporting system. *Journal of Pediatrics*. 2005 Nov;147(5):640-4. PMID: 16291356.
471. Fregnani JH, Carvalho AL, Eluf-Neto J, et al. A school-based human papillomavirus vaccination program in barretos, Brazil: final results of a demonstrative study. *PLoS ONE [Electronic Resource]*. 2013;8(4):e62647. PMID: 23638130.
472. French Jr RW, Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. *Clinical and Vaccine Immunology*. 2012 August;19(8):1296-303. PMID: 2012459613.
473. French R, Jr., Thompson A, Yeh SH, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine. *Pediatric Infectious Disease Journal*. 2011 Dec;30(12):1086-91. PMID: 21983216.
474. French RW, Jr., Belshe R, Brady RC, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone[REGISTERED]) administered by intradermal and intramuscular route in healthy adults. *Vaccine*. 2011 Aug 5;29(34):5666-74. PMID: 21699951.
475. French RW, Jr., Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. *Clinical & Vaccine Immunology: CVI*. 2012 Aug;19(8):1296-303. PMID: 22739693.

476. Frey SE, Bernstein DI, Gerber MA, et al. Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. *Journal of Infectious Diseases*. 2012 Sep 15;206(6):828-37. PMID: 22802432.
477. Fridman D, Monti A, Bonnet M-C, et al. Safety of a second dose of varicella vaccine administered at 4 to 6 years of age in healthy children in Argentina. *Human Vaccines*. 2011 Oct;7(10):1066-71. PMID: 21989288.
478. Fu C, Xu J, Tan H, et al. Serious adverse reactions should be further monitored after influenza A (H1N1) vaccination among children: postmarketing experience with 570,000 vaccinations between October 2009 and August 2010 in Guangzhou, China. *Pediatric Infectious Disease Journal*. 2011 Jul;30(7):631-2. PMID: 21673552.
479. Fuchshuber A, Kuhnemund O, Keuth B, et al. Pneumococcal vaccine in children and young adults with chronic renal disease. *Nephrology Dialysis Transplantation*. 1996 Mar;11(3):468-73. PMID: 8671817.
480. Fujii T, Naganuma M, Kunisaki R, et al. Prevalence of influenza infection and safety of human infection with influenza a (H1N1) vaccine in patients with IBD patients treated with immunomodulators and biologics. *Gastroenterology*. 2011 May;140(5 SUPPL. 1):S771.
481. Fukase H, Furue H, Yasuda Y, et al. Assessment of the immunogenicity and safety of varying doses of an MF59([REGISTERED])-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. *Vaccine*. 2012 Jul 13;30(33):5030-7. PMID: 22472791.
482. Fukuda K, Thompson WW, Cox N. Vaccinating Japanese schoolchildren against influenza. *New England Journal of Medicine*. 2001 Jun 21;344(25):1946-7; author reply 7-8. PMID: 11419435.
483. Funkhouser AW, Wassilak SG, Orenstein WA, et al. Estimated effects of a delay in the recommended vaccination schedule for diphtheria and tetanus toxoids and pertussis vaccine. *JAMA*. 1987 Mar 13;257(10):1341-6. PMID: 3493356.
484. Furck AK, Richter JW, Kattner E. Very low birth weight infants have only few adverse events after timely immunization. *Journal of Perinatology*. 2010 February;30(2):118-21. PMID: 2010102377 MEDLINE PMID 19710678 (<http://www.ncbi.nlm.nih.gov/pubmed/19710678>).
485. Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. *Arthritis & Rheumatism*. 2011 Jun;63(6):1486-96. PMID: 21384334.
486. Gabutti G, Zepp F, Schuerman L, et al. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine co-administered with a hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3,

5 and 11 months of age. Scandinavian Journal of Infectious Diseases. 2004;36(8):585-92. PMID: 2004403850 MEDLINE PMID 15370670 (<http://www.ncbi.nlm.nih.gov/pubmed/15370670>).

487. Gadzinowski J, Albrecht P, Hasiec B, et al. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine. Vaccine. 2011 Apr 5;29(16):2947-55. PMID: 21335032.

488. Gadzinowski J, Tansey S, Mellelieu T, et al. A phase 3 trial evaluating the safety, tolerability and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate vaccine. Vaccine. 2008; PMID: WOS:000268750600111.

489. Gaebler JW, Kleiman MB, French MLV. Neurologic complications in oral polio vaccine recipients. Journal of Pediatrics. 1986;108(6):878-81. PMID: 1986175866 MEDLINE PMID 3012055 (<http://www.ncbi.nlm.nih.gov/pubmed/3012055>).

490. Gaglani MJ, Piedra PA, Riggs M, et al. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008 May;27(5):444-52. PMID: 18401289.

491. Gagneur A, Nowak E, Lemaitre T, et al. Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: The IVANHOE study. Vaccine. 2011 Dec;29(21):3753-9. PMID: 2011226126 MEDLINE PMID 21443962 (<http://www.ncbi.nlm.nih.gov/pubmed/21443962>).

492. Gajdos V, Soubeyrand B, Vidor E, et al. Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (R)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (R)) given as a booster dose at 6 years of age. Human Vaccines. 2011 May;7(5):549-56. PMID: WOS:000291095300016.

493. Gajdos V, Soubeyrand B, Vidor E, et al. Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS ([REGISTERED])) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio ([REGISTERED])) given as a booster dose at 6 years of age. Human Vaccines. 2011 May;7(5):549-56. PMID: 21441781.

494. Galindo BM, Concepcion D, Galindo MA, et al. Vaccine-related adverse events in Cuban children, 1999-2008. MEDICC review. 2012 Jan;14(1):38-43. PMID: 22334111.

495. Galindo Santana BM, Concepcion D, Galindo MA, et al. Vaccine-related adverse events in Cuban children, 1999-2008. MEDICC Review. 2012 January;14(1):38-43. PMID: 2012066223.

496. Galiza EP, Heath PT. Pneumococcal conjugate vaccines. A review. Minerva Medica. 2007 Apr;98(2):131-43. PMID: 17519855.

497. Gall SA. Prevention of Pertussis, Tetanus, and Diphtheria Among Pregnant, Postpartum Women, and Infants. *Clinical Obstetrics and Gynecology*. 2012 Jun;55(2):498-588. PMID: WOS:000303042500017.
498. Garcia-Sicilia J, Gillard P, Carmona A, et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. *Vaccine*. 2011 Jun 10;29(26):4353-61. PMID: 21504774.
499. Gargiullo PM, Murphy TV, Davis RL. Is there a safe age for vaccinating infants with tetravalent rhesus-human reassortant rotavirus vaccine? *Journal of Infectious Diseases*. 2006 Dec 15;194(12):1793-4; author reply 4-5. PMID: 17109356.
500. Gasparini R, Amicizia D, Lai PL, et al. Aflunov(registered trademark): A prepandemic influenza vaccine. *Expert Review of Vaccines*. 2012 February;11(2):145-57. PMID: 2012089452 MEDLINE PMID 22309663 (<http://www.ncbi.nlm.nih.gov/pubmed/22309663>).
501. Gasparini R, Conversano M, Bona G, et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. *Clinical & Vaccine Immunology: CVI*. 2010 Apr;17(4):537-44. PMID: 20164251.
502. Gasparini R, Lai P. Utility of virosomal adjuvated influenza vaccines: A review of the literature. *Journal of Preventive Medicine and Hygiene*. 2010 March;51(1):1-6. PMID: 2010374744 MEDLINE PMID 20853669 (<http://www.ncbi.nlm.nih.gov/pubmed/20853669>).
503. Gasparini R, Schioppa F, Lattanzi M, et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. *International Journal of Clinical Practice*. 2010 Mar;64(4):432-8. PMID: 20039974.
504. Gatchalian S, Reyes M, Bernal N, et al. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. *Human Vaccines*. 2005 Sep-Oct;1(5):198-203. PMID: 17012860.
505. Gatchalian S, Yao Y, Zhou B, et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. *Vaccine*. 2008 24;26(18):2234-41. PMID: 2008192614 MEDLINE PMID 18394765 (<http://www.ncbi.nlm.nih.gov/pubmed/18394765>).
506. Gatchalian SR, Ramakrishnan G, Bock HL, et al. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content *Haemophilus influenzae* type b vaccine in Filipino children. *Human Vaccines*. 2010 Aug;6(8):664-72. PMID: 20657177.

507. Gatchatian S, Patestroque E, De Vleeschauwer I, et al. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. International Journal of Infectious Diseases. 2008 May;12(3):278-88. PMID: WOS:000255834000010.
508. Gaughran F, Walwyn R, Lambkin-Williams R, et al. Flu: effect of vaccine in elderly care home residents: a randomized trial. J Am Geriatr Soc. 2007 Dec;55(12):1912-20. PMID: 18081669.
509. Gay N, Ramsay M, Waight P. Rotavirus vaccination and intussusception [12]. Lancet. 1999 Nov;354(9182):956. PMID: 1999315893 MEDLINE PMID 10489989 (<http://www.ncbi.nlm.nih.gov/pubmed/10489989>).
510. Geier DA, Geier MR. An evaluation of the effects of thimerosal on neurodevelopmental disorders reported following DTP and Hib vaccines in comparison to DTPH vaccine in the United States. Journal of Toxicology & Environmental Health Part A. 2006 Aug;69(15):1481-95. PMID: 16766480.
511. Geier DA, King PG, Sykes LK, et al. RotaTeq vaccine adverse events and policy considerations. Medical Science Monitor. 2008 Mar;14(3):PH9-16. PMID: 18301365.
512. Geier DA, King PG, Sykes LK, et al. The temporal relationship between RotaTeq immunization and intussusception adverse events in the Vaccine Adverse Event Reporting System (VAERS). Medical Science Monitor. 2012 Feb;18(2):PH12-7. PMID: 22293889.
513. Gensicke H, Datta AN, Dill P, et al. Increased incidence of Guillain-Barre Syndrome after surgery. European Journal of Neurology. 2012.
514. Gentile A, Umido V, Czerniuk P, et al. Immunogenicity and reactogenicity of a combined fully liquid DTPw-HepB-Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine. International Journal of Infectious Diseases. 2011 Jan;15(1):e24-9. PMID: 21093342.
515. Gershon AA, Levin MJ, Weinberg A, et al. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J. 2009 Jul;28(7):653-5. PMID: 19561431.
516. Gervaix A, Caflisch M, Suter S, et al. Guillain-Barre-Syndrome Following Immunization with Haemophilus-Influenzae Type-B Conjugate Vaccine. European Journal of Pediatrics. 1993 Jul;152(7):613-4. PMID: WOS:A1993LJ08700017.
517. Gidudu J, Sack DA, Pina M, et al. Diarrhea: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011 29;29(5):1053-71. PMID: 2011043493 MEDLINE PMID 21130754 (<http://www.ncbi.nlm.nih.gov/pubmed/21130754>).

518. Gilbert CL, Klopfer SO, Martin JC, et al. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults \geq 50 years. *Human Vaccines*. 2011 Dec;7(12):1336-42. PMID: WOS:000299784500021.
519. Gil-Bistes D, Kluger N, Bessis D, et al. Pityriasis lichenoides chronic after measles-mumps-rubella vaccination. *Journal of Dermatology*. 2012 May;39(5):492-3. PMID: 2012218636.
520. Gilca R, Deceuninck G, De Serres G, et al. Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children. *Pediatrics*. 2011 November;128(5):e1084-e91. PMID: 2011606732 MEDLINE PMID 21987710 (<http://www.ncbi.nlm.nih.gov/pubmed/21987710>).
521. Gilderman LI, Lawless JF, Nolen TM, et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. *Clin Vaccine Immunol*. 2008 Feb;15(2):314-9. PMID: 18077611.
522. Gillberg C., Heijbel H. MMR and autism. *Autism*. 1998;2:423-24.
523. Gimenez-Sanchez F, Kieninger DM, Kueper K, et al. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. *Vaccine*. 2011 Aug;29(35):6042-8. PMID: WOS:000294145900028.
524. Girgis CM, Russo RR, Benson K. Subacute thyroiditis following the H1N1 vaccine. *Journal of Endocrinological Investigation*. 2010 July-August;33(7):506. PMID: 2010541712 MEDLINE PMID 20671410 (<http://www.ncbi.nlm.nih.gov/pubmed/20671410>).
525. Gisbert JP, Menchen L, Garcia-Sanchez V, et al. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*. 2012 June;35(12):1379-85. PMID: 2012283976.
526. Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: A randomized controlled trial. *Pediatric Infectious Disease Journal*. 2010 August;29(8):756-62. PMID: 2010417404 MEDLINE PMID 20661103 (<http://www.ncbi.nlm.nih.gov/pubmed/20661103>).
527. Glass RI. New hope for defeating rotavirus. *Scientific American*. 2006 Apr;294(4):46-51, 4-5. PMID: 16596879.
528. Glass RI, Bressee J, Jiang B, et al. Rotavirus and rotavirus vaccines. *Advances in Experimental Medicine & Biology*. 2006;582:45-54. PMID: 16802618.

529. Glass RI, Bressee JS, Parashar UD, et al. The future of rotavirus vaccines: a major setback leads to new opportunities. *Lancet*. 2004 May 8;363(9420):1547-50. PMID: 15135605.
530. Glass RI, Parashar UD. Rotavirus vaccines - Reply. *New England Journal of Medicine*. 2006 Apr;354(16):1750-1. PMID: WOS:000236893900021.
531. Glass RI, Parashar UD, Bressee JS, et al. Rotavirus vaccines: current prospects and future challenges. *Lancet*. 2006 Jul 22;368(9532):323-32. PMID: 16860702.
532. Glezen WP, Simonsen L. Commentary: benefits of influenza vaccine in US elderly--new studies raise questions. *Int J Epidemiol*. 2006 Apr;35(2):352-3. PMID: 16368723.
533. Gloriani NG, Srinivasa K, Bock HL, et al. Immunogenicity of Hbv Vaccine during Stated Shelf-Life. *Southeast Asian Journal of Tropical Medicine and Public Health*. 2010 Jul;41(4):876-82. PMID: WOS:000280521900013.
534. Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. *Bulletin of the World Health Organization*. 1971;45(3):279-82. PMID: 5316907.
535. Gold R, Barreto L, Ferro S, et al. Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age. *The Canadian Journal of Infectious Diseases & Medical Microbiology*. 2007 Jul;18(4):241-8. PMID: 18923741.
536. Gold R, Scheifele D, Barreto L, et al. Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. *Pediatric Infectious Disease Journal*. 1994 May;13(5):348-55. PMID: 8072815.
537. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. *Clinical Infectious Diseases*. 2009 November;49(9):1318-25. PMID: 2010000660 MEDLINE PMID 19814624 (<http://www.ncbi.nlm.nih.gov/pubmed/19814624>).
538. Goldblatt D, Southern J, Ashton L, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. *Pediatric Infectious Disease Journal*. 2006 April;25(4):312-9. PMID: 2006163612 MEDLINE PMID 16567982 (<http://www.ncbi.nlm.nih.gov/pubmed/16567982>).
539. Goldman G. Comparison of VAERS fetal-loss reports during three consecutive influenza seasons: Was there a synergistic fetal toxicity associated with the two-vaccine 2009/2010 season? *Human & Experimental Toxicology*. 2013 May;32(5):464-75. PMID: 23023030.

540. Goldstein GL. Pneumococcal vaccine in asthmatics. *New England Journal of Medicine*. 1982 Jun 24;306(25):1554. PMID: 7078621.
541. Gomber S, Sharma R, Ramachandran VG. Immunogenicity of low dose intradermal hepatitis B vaccine and its comparison with standard dose intramuscular vaccination. *Indian Pediatrics*. 2004 Sep;41(9):922-6. PMID: 15475635.
542. Goodman MJ, Nordin JD, Belongia EA, et al. Henoch-Schonlein Purpura and Polysaccharide Meningococcal Vaccine. *Pediatrics*. 2010 Aug;126(2):E325-E9. PMID: WOS:000280565700034.
543. Goodman MJ, Nordin JD, Belongia EA, et al. Henoch-Schonlein purpura and polysaccharide meningococcal vaccine. *Pediatrics*. 2010 Aug;126(2):e325-9. PMID: 20624811.
544. Gordon DL, Sajkov D, Woodman RJ, et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing AdvaxTM polysaccharide adjuvant. *Vaccine*. 2012 Aug 3;30(36):5407-16. PMID: 22717330.
545. Gordon DL, Sajkov D, Woodman RJ, et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax(trademark) polysaccharide adjuvant. *Vaccine*. 2012.
546. Gordon SB, Malamba R, Mthunthama N, et al. Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses. *Vaccine*. 2008 Mar;26(42):5400-6. PMID: 2008429083 MEDLINE PMID 18708114 (<http://www.ncbi.nlm.nih.gov/pubmed/18708114>).
547. Gorse GJ, Falsey AR, Fling JA, et al. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age. *Vaccine*. 2013 May 1;31(19):2358-65. PMID: 23499604.
548. Gottfredsson M, Reynisson IK, Ingvarsson RF, et al. Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. *Clinical Infectious Diseases*. 2011 Nov;53(9):e117-24. PMID: 21946191.
549. Goulleret N, Mauvisseau E, Essevaz-Roulet M, et al. Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). *Vaccine*. 2010 Aug 16;28(36):5878-82. PMID: 20600487.
550. Grabenstein JD, Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. *Vaccine*. 2012 Jun 22;30(30):4435-44. PMID: 22542818.
551. Granoff DM, Osterholm MT. Safety and efficacy of *Haemophilus influenzae* type b polysaccharide vaccine. *Pediatrics*. 1987 Oct;80(4):590-2. PMID: 3498928.

552. Greenberg DP, Vadheim CM, Marcy SM, et al. Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4 and 6 months of age. The Kaiser-UCLA Vaccine Study Group. *Vaccine*. 1996 Jun;14(8):811-6. PMID: 8817829.
553. Greenberg DP, Vadheim CM, Wong VK, et al. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. *Pediatric Infectious Disease Journal*. 1996 July;15(7):590-6. PMID: 1996218974 MEDLINE PMID 8823852 (<http://www.ncbi.nlm.nih.gov/pubmed/8823852>).
554. Greenberg DP, Ward JI, Burkart K, et al. Factors influencing immunogenicity and safety of two *Haemophilus influenzae* type b polysaccharide vaccines in children 18 and 24 months of age. *Pediatric Infectious Disease Journal*. 1987 Jul;6(7):660-5. PMID: 3497380.
555. Greenberg DP, Wong VK, Partridge S, et al. Immunogenicity of a *Haemophilus influenzae* type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. *Pediatric Infectious Disease Journal*. 2000 Dec;19(12):1135-40. PMID: 11144372.
556. Greenberg DP, Wong VK, Partridge S, et al. Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of age. *Pediatric Infectious Disease Journal*. 2002 Aug;21(8):769-77. PMID: 12192167.
557. Greenhawt MJ, Chernin AS, Howe L, et al. The safety of the H1N1 influenza A vaccine in egg allergic individuals. *Annals of Allergy, Asthma, & Immunology*. 2010 Nov;105(5):387-93. PMID: 21055666.
558. Griffiss JM, Brandt BL, Altieri PL, et al. Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults. *Infection & Immunity*. 1981 Dec;34(3):725-32. PMID: 6800954.
559. Griffiss JM, Brandt BL, Altieri PL, et al. Safety and immunogenicity of a group 29E meningococcal capsular polysaccharide vaccine in adults. *Infection & Immunity*. 1983 Jan;39(1):247-52. PMID: 6401693.
560. Grilli G, Fuiano L, Biasio LR, et al. Simultaneous influenza and pneumococcal vaccination in elderly individuals. *European Journal of Epidemiology*. 1997 Apr;13(3):287-91. PMID: 9258527.
561. Grimpel E, Laudat F, Patterson S, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. *Vaccine*. 2011 Dec 6;29(52):9675-83. PMID: 22008822.
562. Grimpel E, Wysocki J, Boisnard F, et al. Immunogenicity and safety of fully liquid DTaP5-IPV-Hib compared with DTaP3-IPV/Hib when both coadministered with a heptavalent

pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: a phase III, single-blind, randomised, controlled, multicentre study. *Vaccine*. 2011 Oct 6;29(43):7370-8. PMID: 21807056.

563. Grimwood K. Unraveling rotaviruses, oral vaccines and intussusception. *Journal of Paediatrics & Child Health*. 2005 Sep-Oct;41(9-10):471-2. PMID: 16150060.

564. Gross TP, Hayes SW. Haemophilus conjugate vaccine and Guillain-Barre syndrome. *Journal of Pediatrics*. 1991 Jan;118(1):161. PMID: 1986087.

565. Groth N, Montomoli E, Gentile C, et al. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. *Vaccine*. 2009 Jan 29;27(5):786-91. PMID: 19027046.

566. Guerra FA, Blatter MM, Greenberg DP, et al. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. *Pediatrics*. 2009 Jan;123(1):301-12. PMID: 19117896.

567. Guerra FA, Gress J, Werzberger A, et al. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. *Pediatric Infectious Disease Journal*. 2006 Oct;25(10):912-9. PMID: 17006287.

568. Gumede N, Muthambi V, Schoub BD. Immunodeficiency-associated vaccine-derived poliovirus type 3 in infant, South Africa, 2011. *Emerging Infectious Diseases*. 2012 Jun;18(6):992-4. PMID: 22607733.

569. Guo B, Page A, Wang H, et al. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China. *Vaccine*. 2013 Jan 11;31(4):603-17. PMID: 23200940.

570. Gupta A, Agarwal SK. Immunization in Renal Transplant Recipients: Where Do We Stand? *Hong Kong Journal of Nephrology*. 2010 April;12(1):6-11. PMID: 2010239625.

571. Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. *N Engl J Med*. 1996 Feb 8;334(6):349-55. PMID: 8538705.

572. Gyhrs A, Lyngholm E, Larsen SO, et al. Immunogenicity and safety of a tetravalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine. *Scandinavian Journal of Infectious Diseases*. 1999;31(6):579-85. PMID: 10680989.

573. Haber P, Iskander J, Walton K, et al. Internet-based reporting to the vaccine adverse event reporting system: A more timely and complete way for providers to support vaccine safety.

Pediatrics. 2011 May;127(SUPPL. 1):S39-S44. PMID: 2011239116 MEDLINE PMID 21502243 (<http://www.ncbi.nlm.nih.gov/pubmed/21502243>).

574. Haber P, Patel M, Iskander J, et al. Importance of On-time RotaTeq Vaccination and Long-term Active Surveillance In Reply. Pediatrics. 2008 Nov;122(5):1154-. PMID: WOS:000260542500032.

575. Haber P, Patel M, Izurieta HS, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics. 2008 Jun;121(6):1206-12. PMID: 18519491.

576. Haber P, Patel M, Pan Y, et al. Intussusception After Rotavirus Vaccines Reported to US VAERS, 2006-2012. Pediatrics. 2013 Jun;131(6):1042-9. PMID: 23669521.

577. Hajiabdolbaghi M, Jam S, SeyedAlinaghi S, et al. Adverse reactions of trivalent influenza vaccine in HIV-infected individuals. Acta Medica Iranica. 2010 Mar-Apr;48(2):95-100. PMID: 21133001.

578. Hak E, van Loon S, Buskens E, et al. Design of the Dutch prevention of influenza, surveillance and management (PRISMA) study. Vaccine. 2003 Apr 2;21(15):1719-24. PMID: 12639495.

579. Hakim H, Allison KJ, Van De Velde L-A, et al. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine. 2012 Jan 20;30(5):879-85. PMID: 22155630.

580. Halasa NB, Gerber MA, Chen Q, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J Infect Dis. 2008 May 15;197(10):1448-54. PMID: 18444800.

581. Hales K, Barriere SL. Polyvalent pneumococcal vaccines: a review. American Journal of Hospital Pharmacy. 1979 Jun;36(6):773-7. PMID: 380332.

582. Hall AJ. Ecological studies and debate on rotavirus vaccine and intussusception. Lancet. 2001 Oct 13;358(9289):1197-8. PMID: 11675051.

583. Halperin BA, Halperin SA, McGrath P, et al. Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age. Pediatric Infectious Disease Journal. 2002 May;21(5):399-405. PMID: 12150176.

584. Halperin SA, Barreto L, Eastwood BJ, et al. Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine. 1997 Feb;15(3):295-300. PMID: 9139489.

585. Halperin SA, Davies HD, Barreto L, et al. Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. *Journal of Pediatrics*. 1997 Apr;130(4):525-31. PMID: 9108847.
586. Halperin SA, Diaz-Mitoma F, Dull P, et al. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. *European Journal of Clinical Microbiology & Infectious Diseases*. 2010 Mar;29(3):259-67. PMID: 20033465.
587. Halperin SA, Gupta A, Jeanfreau R, et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. *Vaccine*. 2010 Nov 23;28(50):7865-72. PMID: 20943209.
588. Halperin SA, King J, Law B, et al. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. *Clinical Infectious Diseases*. 1999 May;28(5):995-1001. PMID: 10452624.
589. Halperin SA, Langley JM, Hesley TM, et al. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children. *Human Vaccines*. 2005 Nov-Dec;1(6):245-50. PMID: 17012871.
590. Halperin SA, McDonald J, Samson L, et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. *Clinical & Investigative Medicine - Medecine Clinique et Experimentale*. 2002 Dec;25(6):243-51. PMID: 12516995.
591. Halperin SA, McNeil S, Langley J, et al. Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. *Vaccine*. 2011 Oct 26;29(46):8459-65. PMID: 21803091.
592. Halperin SA, Scheifele D, Barreto L, et al. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. *Pediatric Infectious Disease Journal*. 1999 Sep;18(9):772-9. PMID: 10493336.
593. Halperin SA, Scheifele D, Mills E, et al. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. *Vaccine*. 2003 Jun 2;21(19-20):2298-306. PMID: 12744860.

594. Halperin SA, Smith B, Mabrouk T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. *Vaccine*. 2002 Jan 15;20(7-8):1240-7. PMID: 11803087.
595. Halperin SA, Smith B, Russell M, et al. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. *Pediatric Infectious Disease Journal*. 2000 Apr;19(4):276-83. PMID: 10783014.
596. Halperin SA, Tapiero B, Diaz-Mitoma F, et al. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. *Vaccine*. 2009 Apr 28;27(19):2540-7. PMID: 19124057.
597. Halperin SA, Tapiero B, Law B, et al. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers. *Vaccine*. 2006 May 1;24(18):4017-23. PMID: 16516357.
598. Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. *Vaccine*. 2012 Mar;30(15):2556-63. PMID: WOS:000302822600008.
599. Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. *Vaccine*. 2012 Mar 28;30(15):2556-63. PMID: 22326642.
600. Halsey NA. A causal association between Haemophilus influenzae type b (Hib) vaccine and diabetes. *Autoimmunity*. 2003 May;36(3):123. PMID: 12911277.
601. Halsey NA, Blatter M, Bader G, et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b hepatitis B vaccine. *Pediatric Infectious Disease Journal*. 1997 Jul;16(7):675-9. PMID: WOS:A1997XK75600009.
602. Halsey NA, Spika JS, Lum GM, et al. Adverse reactions to pneumococcal polysaccharide vaccine in children. *Pediatric Infectious Disease*. 1982 Jan-Feb;1(1):34-6. PMID: 7177893.
603. Halvorsen S. The meningococcal serogroup B vaccine protection trial in Norway 1988-1991: trial surveillance by an independent group. *NIPH Annals*. 1991 Dec;14(2):135-6; discussion 6-7. PMID: 1812427.

604. Hammitt LL, Bulkow LR, Singleton RJ, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: No evidence of hyporesponsiveness. *Vaccine*. 2011;29(12):2287-95. PMID: 2011104705 MEDLINE PMID 21255685 (<http://www.ncbi.nlm.nih.gov/pubmed/21255685>).
605. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. *Annals of Neurology*. 2011 Sep;70(3):410-7. PMID: 21866560.
606. Hao L, Toyokawa S, Kobayashi Y. Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000. *Japanese Journal of Infectious Diseases*. 2008 Mar;61(2):100-3. PMID: 18362395.
607. Harmark L, van Hunsel F, Hak E, et al. Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring. *Vaccine*. 2011 Feb 24;29(10):1941-7. PMID: 21236235.
608. Harris G, Nolan T, Hartman L. Clinical signs associated with triple antigen (DTP) vaccination in infants. *Journal of Paediatrics and Child Health*. 1995;31(3):228-32. PMID: 1995173209 MEDLINE PMID 7669385 (<http://www.ncbi.nlm.nih.gov/pubmed/7669385>).
609. Harrison BJ, Thomson W, Pepper L, et al. Patients who develop inflammatory polyarthritis (IP) after immunization are clinically indistinguishable from other patients with IP. *Br J Rheumatol*. 1997 Mar;36(3):366-9. PMID: 9133970.
610. Hasan S, Yousef M, Shridharani S. Severe febrile systemic reaction to pneumococcal vaccine. *Journal of the National Medical Association*. 2005 Feb;97(2):284-5. PMID: 15712794.
611. Hatz C, Cramer JP, Vertruyen A, et al. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. *Vaccine*. 2012 Jul 6;30(32):4820-7. PMID: 22626675.
612. Hatz C, von Sonnenburg F, Casula D, et al. A randomized clinical trial to identify the optimal antigen and MF59([REGISTERED]) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. *Vaccine*. 2012 May 14;30(23):3470-7. PMID: 22446638.
613. Hatz C, von Sonnenburg F, Casula D, et al. A randomized clinical trial to identify the optimal antigen and MF59() adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. *Vaccine*. 2012 May 14;30(23):3470-7. PMID: 22446638.
614. Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine Gardasil. *Journal of Adolescent Health*. 2011 November;49(5):467-75. PMID: 2011593965.

615. Hawcutt DB, Mainie P, Riordan A, et al. Reported paediatric adverse drug reactions in the UK 2000-2009. *British Journal of Clinical Pharmacology*. 2012 March;73(3):437-46. PMID: 2012087844 MEDLINE PMID 21988288 (<http://www.ncbi.nlm.nih.gov/pubmed/21988288>).
616. Heath PT, McVernon J. The UK hib vaccine experience. *Archives of Disease in Childhood*. 2002 2002;86(6):396-9. PMID: 2002199926 MEDLINE PMID 12023165 (<http://www.ncbi.nlm.nih.gov/pubmed/12023165>).
617. Heaton PM, Goveia MG, Miller JM, et al. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. *Journal of Infectious Diseases*. 2005 Sep 1;192 Suppl 1:S17-21. PMID: 16088800.
618. Heijbel H, Jefferson T. Vaccine safety - Improving monitoring. *Vaccine*. 2001 21;19(17-19):2457-60. PMID: 2001113300 MEDLINE PMID 11257377 (<http://www.ncbi.nlm.nih.gov/pubmed/11257377>).
619. Heininger U, Group D-H-I-S, Sanger R, et al. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and *Haemophilus influenzae* type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. *Vaccine*. 2007 Jan 22;25(6):1055-63. PMID: 17049692.
620. Helle EPJ, Koskenvuo K, Heikkila J. Myocardial complications of immunisations. *Annals of Clinical Research*. 1978 1978;10(5):280-7. PMID: 1979078262 MEDLINE PMID 736507 (<http://www.ncbi.nlm.nih.gov/pubmed/736507>).
621. Hengge UR, Scharf RE, Kroon FP, et al. Severe serum sickness following pneumococcal vaccination in an AIDS patient. *International Journal of Std & Aids*. 2006 Mar;17(3):210-1. PMID: 16510015.
622. Herbergs C, Melgert B, Van Der Laan JW, et al. New adjuvanted vaccines in pregnancy: What is known about their safety? *Expert Review of Vaccines*. 2010 December;9(12):1411-22. PMID: 2010654059 MEDLINE PMID 21105777 (<http://www.ncbi.nlm.nih.gov/pubmed/21105777>).
623. Herceg A. *Haemophilus influenzae* type b vaccination [13]. *Medical Journal of Australia*. 1993 1993;159(1):70. PMID: 1993247750 MEDLINE PMID 8316135 (<http://www.ncbi.nlm.nih.gov/pubmed/8316135>).
624. Hernandez-Bernal F, Aguilar-Betancourt A, Aljovin V, et al. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults. *Human Vaccines*. 2011 Oct;7(10):1026-36. PMID: WOS:000296564800015.
625. Hernandez-Bernal F, Aguilar-Betancourt A, Aljovin V, et al. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults. *Human Vaccines*. 2011;7(10)PMID: 2011578241.

626. Hesley TM, Reisinger KS, Sullivan BJ, et al. Concomitant administration of a bivalent *Haemophilus influenzae* type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity. *Pediatric Infectious Disease Journal*. 2004 Mar;23(3):240-5. PMID: 15014300.
627. Hessel L, Guenaneche F, Biasio LR, et al. Reply to "Panico MG, Caporale V, Attena F. Adverse events following hexavalent vaccine (Hexavac): knowledge and information sources". *Vaccine*. 2007 Mar 30;25(14):2539-40. PMID: 17465039.
628. Higashigawa M, Maegawa K, Honma H, et al. Vaccine-associated paralytic poliomyelitis in an infant with perianal abscesses. *Journal of Infection & Chemotherapy*. 2010 Oct;16(5):356-9. PMID: 20449625.
629. Hilleman MR, Carlson AJ, Jr., McLean AA, et al. *Streptococcus pneumoniae* polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. *Reviews of Infectious Diseases*. 1981 Mar-Apr;3 Suppl:S31-42. PMID: 7025159.
630. Hirtz DG, Nelson KB, Ellenberg JH. Seizures following childhood immunizations. *Journal of Pediatrics*. 1983 1983;102(1):14-8. PMID: 1983061690 MEDLINE PMID 6848712 (<http://www.ncbi.nlm.nih.gov/pubmed/6848712>).
631. Hirve S, Bavdekar A, Juvekar S, et al. A comparative study to evaluate the safety and immunogenicity of two lots of *Haemophilus influenzae* type-B conjugate vaccine manufactured at different scales. *Vaccine*. 2011 Jul 26;29(33):5363-7. PMID: 21651947.
632. Hirve S, Bavdekar A, Pandit A, et al. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: A Phase II/III double-blind randomized controlled trial. *Vaccine*. 2012.
633. Ho C-F, Lin T-Y. Pneumococcal vaccines. *Chang Gung Medical Journal*. 2005 Nov;28(11):765-72. PMID: 16422182.
634. Hodgson A, Forgor AA, Chandramohan D, et al. A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana. *PLoS ONE [Electronic Resource]*. 2008;3(5):e2159. PMID: 18478093.
635. Hofmann C, Baur M-O, Schroten H. Anti-NMDA receptor encephalitis after TdaP-IPV booster vaccination: cause or coincidence? *Journal of Neurology*. 2011 Mar;258(3):500-1. PMID: 20878418.
636. Hojsak I, Avitzur Y, Mor E, et al. Antibody response to influenza vaccine in pediatric liver transplant recipients. *Pediatric Infectious Disease Journal*. 2011 June;30(6):491-4. PMID: 2011306239 MEDLINE PMID 21248658 (<http://www.ncbi.nlm.nih.gov/pubmed/21248658>).

637. Holdiness MR. Rare systemic dermatologic reaction after pneumococcal vaccine administration. *Southern Medical Journal*. 2003 Jan;96(1):64-5. PMID: 12602719.
638. Holmes SJ, Fritzell B, Guito KP, et al. Immunogenicity of *Haemophilus influenzae* type b polysaccharide-tetanus toxoid conjugate vaccine in infants. *American Journal of Diseases of Children*. 1993 Aug;147(8):832-6. PMID: 8352217.
639. Holmlund E, Nohynek H, Quiambao B, et al. Mother-infant vaccination with pneumococcal polysaccharide vaccine: Persistence of maternal antibodies and responses of infants to vaccination. *Vaccine*. 2011 20;29(28):4565-75. PMID: 2011316318 MEDLINE PMID 21550374 (<http://www.ncbi.nlm.nih.gov/pubmed/21550374>).
640. Honkanen PO, Keistinen T, Kivela SL. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. *Archives of Internal Medicine*. 1996 Jan 22;156(2):205-8. PMID: 8546555.
641. Honkanen PO, Makela PH. Pneumococcal vaccination in the elderly: an underused option? *BioDrugs*. 1999 Jul;12(1):19-25. PMID: 18031159.
642. Hoppenbrouwers K, Kanra G, Roelants M, et al. Priming effect, immunogenicity and safety of an *Haemophilus influenzae* type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. *Vaccine*. 1999 Feb 26;17(7-8):875-86. PMID: 10067694.
643. Hoppenbrouwers K, Lagos R, Swennen B, et al. Safety and immunogenicity of an *Haemophilus influenzae* type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. *Vaccine*. 1998 May-Jun;16(9-10):921-7. PMID: 9682338.
644. Hoppenbrouwers K, Roelants M, Ethevenaux C, et al. The effect of reconstitution of an *Haemophilus influenzae* type b-tetanus toxoid conjugate (PRP-T) vaccine on the immune responses to a diphtheria-tetanus-whole cell pertussis (DTwP) vaccine: a five-year follow-up. *Vaccine*. 1999 Jun 4;17(20-21):2588-98. PMID: 10418907.
645. Hosoda M, Inoue H, Miyazawa Y, et al. Vaccine-associated paralytic poliomyelitis in Japan. *Lancet*. 2012 Feb 11;379(9815):520. PMID: 22325660.
646. Hottinger AF, George A-CC, Bel M, et al. A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. *Oncologist*. 2012;17(3):436-45. PMID: 22357731.
647. Houston TP. Small-vessel vasculitis following simultaneous influenza and pneumococcal vaccination. *New York State Journal of Medicine*. 1983 Oct-Nov;83(11-12):1182-3. PMID: 6580565.

648. Hua L, Hongtao H, Shunqin W, et al. Simultaneous vaccination of Chinese applicants for a United States immigrant visa. *Travel Medicine & Infectious Disease*. 2008 May;6(3):130-6. PMID: 18486068.
649. Hua W, Izurieta HS, Slade B, et al. Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. *Pediatric Infectious Disease Journal*. 2009 Nov;28(11):943-7. PMID: 19755926.
650. Huang DT-N, Chiu N-C, Chi H, et al. Protracted fever with cellulitis-like reaction in pneumococcal polysaccharide-vaccinated children. *Pediatric Infectious Disease Journal*. 2008 Oct;27(10):937-9. PMID: 18776824.
651. Huang HH, Huang CC, Hsueh PY, et al. Bilateral sudden deafness following H1N1 vaccination. *Otolaryngology - Head and Neck Surgery*. 2010 December;143(6):849-50. PMID: 2010653645 MEDLINE PMID 21109091 (<http://www.ncbi.nlm.nih.gov/pubmed/21109091>).
652. Huang L-M, Lin T-Y, Juergens C. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan. *Vaccine*. 2012 Mar 9;30(12):2054-9. PMID: 22198517.
653. Huang W-T, Chen W-C, Teng H-J, et al. Adverse events following pandemic A (H1N1) 2009 monovalent vaccines in pregnant women--Taiwan, November 2009-August 2010. *PLoS ONE* [Electronic Resource]. 2011;6(8):e23049. PMID: 21850250.
654. Huber BM, Goetschel P. Extensive limb swelling after vaccination. *Journal of Pediatrics*. 2011 June;158(6):1033. PMID: 2011270657 MEDLINE PMID 21315373 (<http://www.ncbi.nlm.nih.gov/pubmed/21315373>).
655. Hulbert-Powell E, Perez-Gaxiola G. Review: Flu vaccines provide a moderate risk reduction in healthy children. *Archives of Disease in Childhood: Education and Practice Edition*. 2012;11.
656. Huppertz H-I, Soriano-Gabarro M, Grimpel E, et al. Intussusception among young children in Europe. *Pediatric Infectious Disease Journal*. 2006 Jan;25(1 Suppl):S22-9. PMID: 16397426.
657. Hviid A. Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. *Journal of Pediatrics*. 2011 Jan;158(1):170. PMID: 21146049.
658. Hwang S-M, Choe K-W, Cho S-H, et al. The adverse events of influenza A (H1N1) vaccination and its risk factors in healthcare personnel in 18 military healthcare units in Korea. *Japanese Journal of Infectious Diseases*. 2011;64(3):183-9. PMID: 21617300.
659. Hwang S-M, Kim H-L, Min K-W, et al. Comparison of the Adverse Events Associated with MF59-Adjuvanted and Non-Adjuvanted H1N1 Vaccines in Healthy Young Male Korean Soldiers. *Japanese Journal of Infectious Diseases*. 2012 May;65(3):193-7. PMID: 22627298.

660. Ichikawa T, Tsuji A, Fujino M, et al. Effect of early measles vaccination (AIK-C strain) for preterm infants. *Pediatrics International*. 2013 Apr;55(2):163-8. PMID: 23379893.
661. Igari H, Segawa S, Watanabe A, et al. Immunogenicity of a monovalent pandemic influenza A H1N1 vaccine in health-care workers of a university hospital in Japan. *Microbiology & Immunology*. 2010 Oct;54(10):618-24. PMID: 21118299.
662. Igari H, Watanabe A, Chiba H, et al. Effectiveness and safety of pandemic influenza A (H1N1) 2009 vaccine in healthcare workers at a university hospital in Japan. *Japanese Journal of Infectious Diseases*. 2011;64(3):177-82. PMID: 21617299.
663. Ikematsu H, Nagai H, Kawashima M, et al. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. *Human vaccines & Immunotherapeutics*. 2012 Feb;8(2):260-6. PMID: 22426369.
664. Ikematsu H, Nagai H, Kawashima M, et al. Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. *Human Vaccines*. 2010 Nov;6(11):888-93. PMID: 20980795.
665. Inamadar AC, Palit A. Blue cellulitis: A rare entity in the era of Hib conjugate vaccine [3]. *Pediatric Dermatology*. 2004 January/February;21(1):90-1. PMID: 2004091860 MEDLINE PMID 14871339 (<http://www.ncbi.nlm.nih.gov/pubmed/14871339>).
666. Ipp MM, Gold R, Goldbach M, et al. Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. *Pediatrics*. 1989 May;83(5):679-82. PMID: 2717284.
667. Irving GJ, Holden J, Yang R, et al. Hepatitis A immunisation in persons not previously exposed to hepatitis A. *Cochrane Database of Systematic Reviews*. 2012;7:CD009051. PMID: 22786522.
668. Ishigami M, Kamei H, Nakamura T, et al. Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts. *Journal of Gastroenterology*. 2011 Mar;46(3):367-77. PMID: WOS:000289003700011.
669. Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. *Biology of Blood & Marrow Transplantation*. 2011 Mar;17(3):434-8. PMID: 20950701.
670. Izurieta HS, Sutter RW, Baughman AL, et al. Vaccine-associated paralytic poliomyelitis in the United States: no evidence of elevated risk after simultaneous intramuscular injections of vaccine. *Pediatric Infectious Disease Journal*. 1995 Oct;14(10):840-6. PMID: 8584308.

671. Jackson LA, Baxter R, Reisinger K, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. *Clin Infect Dis*. 2009 Jul 1;49(1):e1-10. PMID: 19476428.
672. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. *JAMA*. 1999 Jan 20;281(3):243-8. PMID: 9918479.
673. Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. *Pediatr Infect Dis J*. 2009 Feb;28(2):86-91. PMID: 19116603.
674. Jackson LA, Nelson JC, Whitney CG, et al. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population. *Vaccine*. 2006 Jan 12;24(2):151-6. PMID: 16122845.
675. Jackson LA, Neuzil KM, Nahm MH, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. *Vaccine*. 2007 16;25(20):4029-37. PMID: 2007192289 MEDLINE PMID 17391816 (<http://www.ncbi.nlm.nih.gov/pubmed/17391816>).
676. Jackson LA, Neuzil KM, Whitney CG, et al. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. *Vaccine*. 2005 May 25;23(28):3697-703. PMID: 15882530.
677. Jackson LA, Patel SM, Swamy GK, et al. Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. *Journal of Infectious Diseases*. 2011 15;204(6):854-63. PMID: 2011480316 MEDLINE PMID 21849282 (<http://www.ncbi.nlm.nih.gov/pubmed/21849282>).
678. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. *Vaccine*. 2009 23;27(34):4656-61. PMID: 2009321466 MEDLINE PMID 19520201 (<http://www.ncbi.nlm.nih.gov/pubmed/19520201>).
679. Jacobson RM, Adegbienro A, Pankratz VS, et al. Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. *Vaccine*. 2001 Mar 21;19(17-19):2428-33. PMID: 11257373.
680. Jacquest D, Stout I. Reactions to Haemophilus influenzae type B vaccine. *Canadian Journal of Public Health*. 1989 1989;80(4):304-5. PMID: 1990148125 MEDLINE PMID 2790640 (<http://www.ncbi.nlm.nih.gov/pubmed/2790640>).
681. Jacquet JM, Begue P, Grimpel E, et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. *Vaccine*. 2006 Mar 20;24(13):2440-8. PMID: 16406224.

682. Janow G, Ilowite NT. Pediatric rheumatic disease: Vaccination in pediatric rheumatic disease - Risks and benefits. *Nature Reviews Rheumatology*. 2012 April;8(4):188-90. PMID: 2012198498.
683. Jansen AGSC, Sanders EAM, Smulders S, et al. Adverse reactions to simultaneous influenza and pneumococcal conjugate vaccinations in children: randomized double-blind controlled trial. *Pediatric Allergy & Immunology*. 2008 Sep;19(6):552-8. PMID: 18221474.
684. Jariwala S, Vernon N, Shlizberg J. Henoch-Schonlein Purpura after Hepatitis a Vaccination. *Annals of Allergy Asthma & Immunology*. 2011 Aug;107(2):180-1. PMID: WOS:000294242500015.
685. Javelle E, Soulier B, Brosset C, et al. Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. *Vaccine*. 2011 Feb 1;29(6):1123-5. PMID: 21172376.
686. Jefferson T, Demicheli V. No evidence that vaccines cause insulin dependent diabetes mellitus. *J Epidemiol Community Health*. 1998 Oct;52(10):674-5. PMID: 10023469.
687. Jenkins DR, Rees JC, Hale JP, et al. Childhood neoplasia and Haemophilus influenzae type b vaccine failure [11]. *Lancet*. 1996 1996;348(9020):131. PMID: 1996212549 MEDLINE PMID 8676697 (<http://www.ncbi.nlm.nih.gov/pubmed/8676697>).
688. Jilich D, Havlickova M, Vesely D, et al. Immunogenicity and safety of pandemic H1N1 2009 influenza vaccine for HIV-1 patients. *Acta Virologica*. 2012;56(4):349-51. PMID: 23237093.
689. Jin LJ, Wang GY, Zhao XL, et al. Characterization and immune effect of the hepatitis B-BCG combined vaccine for using a needle inoculation. *Vaccine*. 2010 Aug;28(37):6041-51. PMID: WOS:000281627100018.
690. Johann-Liang R, Josephs S, Dreskin SC. Analysis of anaphylaxis cases after vaccination: 10-year review from the national vaccine injury compensation program. *Annals of Allergy, Asthma and Immunology*. 2011 May;106(5):440-3. PMID: 2011243366 MEDLINE PMID 21530879 (<http://www.ncbi.nlm.nih.gov/pubmed/21530879>).
691. Johns TL, Hutter GE. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel). *Annals of Pharmacotherapy*. 2010 Mar;44(3):515-23. PMID: 20197476.
692. Jones CE, Naidoo S, De Beer C, et al. Maternal HIV Infection and Antibody Responses Against Vaccine-Preventable Diseases in Uninfected Infants. *Jama-Journal of the American Medical Association*. 2011 Feb;305(6):576-84. PMID: WOS:000287080500022.
693. Jones IG, Tyrrell H, Hill A, et al. Randomised controlled trial of combined diphtheria, tetanus, whole-cell pertussis vaccine administered in the same syringe and separately with

Haemophilus influenzae type b vaccine at two, three and four months of age. *Vaccine*. 1998 Jan;16(1):109-13. PMID: 9607017.

694. Jonville-Bera AP, Autret E, Galy-Eyraud C, et al. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-merieux serums et vaccins. *Pediatr Infect Dis J*. 1996 Jan;15(1):44-8. PMID: 8684875.

695. Josefsberg JO, Buckland B. Vaccine process technology. *Biotechnology and Bioengineering*. 2012 June;109(6):1443-60. PMID: 2012225878.

696. Junqueira ALN, Tavares VR, Martins RMB, et al. Safety and immunogenicity of hepatitis B vaccine administered into ventrogluteal vs. anterolateral thigh sites in infants: A randomised controlled trial. *International Journal of Nursing Studies*. 2010 Sep;47(9):1074-9. PMID: WOS:000281383500003.

697. Juntunen-Backman K, Peltola H, Backman A, et al. Safe immunization of allergic children against measles, mumps, and rubella. *American Journal of Diseases of Children*. 1987 Oct;141(10):1103-5. PMID: 3630996.

698. Kallweit U, Hidalgo H, Engel A, et al. Post H1N1 vaccination narcolepsy-cataplexy with decreased CSF beta-amyloid. *Sleep Medicine*. 2012 March;13(3):323. PMID: 2012106250.

699. Kamboj KK, King CL, Greenspan NS, et al. Immunization with Haemophilus influenzae type b-CRM(197) conjugate vaccine elicits a mixed Th1 and Th2 CD(4+) T cell cytokine response that correlates with the isotype of antipolysaccharide antibody. *Journal of Infectious Diseases*. 2001 Oct 1;184(7):931-5. PMID: 11528593.

700. Kang J-H, Oh C-E, Lee J, et al. Safety and immunogenicity of a new trivalent inactivated split-virus influenza vaccine in healthy Korean children: a randomized, double-blinded, active-controlled, phase III study. *Journal of Korean Medical Science*. 2011 Nov;26(11):1421-7. PMID: 22065897.

701. Kankawinpong O, Sangsajja C, Cholapand A, et al. Immunogenicity and safety of an inactivate pandemic H1N1 vaccine provided by the Thai ministry of public health as a routine public health service. *Southeast Asian Journal of Tropical Medicine & Public Health*. 2012 May;43(3):680-6. PMID: 23077848.

702. Kanra G, Kara A, Demiralp O, et al. Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants. *Human Vaccines*. 2006 Jul-Aug;2(4):155-60. PMID: 17012890.

703. Kanra G, Viviani S, Yurdakok K, et al. Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine. *Pediatrics International*. 2003 Jun;45(3):314-8. PMID: 12828588.

704. Kanra G, Viviani S, Yurdakok K, et al. Safety, tolerability and immunogenicity of a Haemophilus influenzae type b vaccine containing aluminum phosphate adjuvant administered at 2, 3 and 4 months of age. *Turkish Journal of Pediatrics*. 1999 Oct-Dec;41(4):421-7. PMID: 10770109.
705. Kanra G, Yurdakok K, Ceyhan M, et al. Immunogenicity and safety of Haemophilus influenzae type b capsular polysaccharide tetanus conjugate vaccine (PRP-T) presented in a dual-chamber syringe with DTP. *Acta Paediatrica Japonica*. 1997 Dec;39(6):676-80. PMID: 9447756.
706. Kapikian AZ. Ecological studies, rotavirus vaccination, and intussusception.[Erratum appears in Lancet 2002 Aug 10;360(9331):494]. *Lancet*. 2002 Mar 23;359(9311):1065-6; author reply 6. PMID: 11937208.
707. Kapikian AZ, Simonsen L, Vesikari T, et al. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. *Journal of Infectious Diseases*. 2005 Sep 1;192 Suppl 1:S22-9. PMID: 16088801.
708. Kapusinszky B, Molnar Z, Szomor KN, et al. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. *FEMS Immunology & Medical Microbiology*. 2010 Mar;58(2):211-7. PMID: 19863665.
709. Karam AG, Cherry JD. Hypotonic and hyporesponsive episodes after diphtheria-tetanus-acellular pertussis vaccination. *Pediatric Infectious Disease Journal*. 2007 October;26(10):966-7. PMID: 2007477250 MEDLINE PMID 17901810
(<http://www.ncbi.nlm.nih.gov/pubmed/17901810>).
710. Karayiannis P, Main J, Thomas HC. Hepatitis vaccines. *British Medical Bulletin*. 2004 2004;70:29-49. PMID: 2005021038 MEDLINE PMID 15339856
(<http://www.ncbi.nlm.nih.gov/pubmed/15339856>).
711. Kattan JD, Konstantinou GN, Cox AL, et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy. *Journal of Allergy and Clinical Immunology*. 2011 July;128(1):215-8. PMID: 2011361511 MEDLINE PMID 21624648
(<http://www.ncbi.nlm.nih.gov/pubmed/21624648>).
712. Katzenstein TL. Pneumococcal vaccination of HIV-infected individuals: safety and efficacy. *AIDS Patient Care & Stds*. 1997 Aug;11(4):269-75. PMID: 11361841.
713. Kau L, Sadowski CA, Hughes C. Vaccinations in older adults: Focus on pneumococcal, influenza and herpes zoster infections. *Canadian Pharmacists Journal*. 2011 May;144(3):132-41. PMID: 2011310209.

714. Kaur S, Handa S. Erythema multiforme following vaccination in an infant. Indian Journal of Dermatology, Venereology and Leprology. 2008;174(3):251-3. PMID: 2008317547 MEDLINE PMID 18583795 (<http://www.ncbi.nlm.nih.gov/pubmed/18583795>).
715. Kayhty H, Ahman H, Eriksson K, et al. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatric Infectious Disease Journal. 2005 Feb;24(2):108-14. PMID: 15702037.
716. Kayhty H, Peltola H, Eskola J, et al. Immunogenicity of Haemophilus influenzae oligosaccharide-protein and polysaccharide-protein conjugate vaccination of children at 4, 6, and 14 months of age. Pediatrics. 1989 Dec;84(6):995-9. PMID: 2587155.
717. Keating GM. Rotavirus vaccine (RotaTeq). Paediatric Drugs. 2006;8(3):197-202; discussion 3-4. PMID: 16774301.
718. Keating GM. Rotavirus vaccine RIX4414 (Rotarix). Paediatric Drugs. 2006;8(6):389-95; discussion 96-7. PMID: 17154645.
719. Keipp Talbot H, Rock MT, Johnson C, et al. Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin. PLoS ONE [Electronic Resource]. 2010;5(12) PMID: 211011111.
720. Kelen K, Ferenczi D, Jankovics I, et al. H1N1 vaccination in pediatric renal transplant patients. Transplantation Proceedings. 2011 May;43(4):1244-6. PMID: 21620100.
721. Kelley NS, Osterholm MT, Belongia EA. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. New England Journal of Medicine. 2011 Mar 24;364(12):1181; author reply -2. PMID: 21428786.
722. Kelly H. Evidence for a causal association between oral polio vaccine and transverse myelitis: A case history and review of the Literature. Journal of Paediatrics & Child Health. 2006 Apr;42(4):155-9. PMID: 16630313.
723. Kelly H, Mercer G, Cowling BJ. The association of seasonal influenza vaccination with pandemic influenza H1N1 2009 infection. Vaccine. 2012 Sep;30(12):2037-8. PMID: 2012111125 MEDLINE PMID 22119923 (<http://www.ncbi.nlm.nih.gov/pubmed/22119923>).
724. Kelly H, Valenciano M. Estimating the effect of influenza vaccines. The Lancet Infectious Diseases. 2012 January;12(1):5-6. PMID: 2011703315 MEDLINE PMID 22032845 (<http://www.ncbi.nlm.nih.gov/pubmed/22032845>).
725. Kelly HA, Skowronski DM, De Serres G, et al. Adverse events associated with 2010 CSL and other inactivated influenza vaccines. Medical Journal of Australia. 2011 Sep 19;195(6):318-20. PMID: 21929484.

726. Kelly WN. Potential risks and prevention, part 4: Reports of significant adverse drug events. *American Journal of Health-System Pharmacy*. 2001;58(15):1406-12. PMID: 2001269949 MEDLINE PMID 11494785 (<http://www.ncbi.nlm.nih.gov/pubmed/11494785>).
727. Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. *Journal of Allergy and Clinical Immunology*. 2012 July;130(1):25-43. PMID: 2012369097.
728. Kelton JG. Vaccination-Associated relapse of immune thrombocytopenia. *JAMA*. 1981 Jan 23-30;245(4):369-70. PMID: 6969806.
729. Kemmeren JM, Timmer SS, van der Maas NAT, et al. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children. *Vaccine*. 2011 Jun 10;29(26):4373-7. PMID: 21514347.
730. Kemmeren JM, van der Maas NAT, de Melker HE. Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children. *European Journal of Pediatrics*. 2011 Mar;170(3):339-45. PMID: 20857144.
731. Kemmeren JM, Vermeer-de Bondt PE, van der Maas NAT. Discolored leg syndrome after vaccination--descriptive epidemiology. *European Journal of Pediatrics*. 2009 Jan;168(1):43-50. PMID: 18546020.
732. Kemp ML, Hart MB. MMR vaccine and autism: is there a link? *JAAPA*. 2010 2010 Jun;23(6):48. PMID: 20653261.
733. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N Engl J Med*. 2009 Nov 5;361(19):1838-47. PMID: 19890126.
734. Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. *J Am Geriatr Soc*. 2007 Oct;55(10):1499-507. PMID: 17908055.
735. Khalifa YM, Monahan PM, Acharya NR. Ampiginous choroiditis following quadrivalent human papilloma virus vaccine. *British Journal of Ophthalmology*. 2010 January;94(1):137-9. PMID: 2010049782 MEDLINE PMID 20385534 (<http://www.ncbi.nlm.nih.gov/pubmed/20385534>).
736. Khan FS, Virant FS, Furukawa CT, et al. Influenza vaccine administration in egg allergic children. *Journal of Allergy and Clinical Immunology*. 2012 February;129(2 SUPPL. 1):AB70.
737. Khare S, Kumari S, Nagpal IS, et al. Oral polio vaccination in infants: beneficial effect of additional dose at birth. *Indian Journal of Pediatrics*. 1993 Mar-Apr;60(2):275-81. PMID: 8244504.

738. Khetsuriani N, Imnadze P, Baidoshvili L, et al. Impact of unfounded vaccine safety concerns on the nationwide measles-rubella immunization campaign, Georgia, 2008. *Vaccine*. 2010 Sep 7;28(39):6455-62. PMID: 20674880.
739. Kiefaber RW. Thrombocytopenic purpura after measles vaccination. *N Engl J Med*. 1981 Jul 23;305(4):225. PMID: 7195464.
740. Kienast AK, Mentze D, Hoeger PH. Nicolau's syndrome induced by intramuscular vaccinations in children: Report of seven patients and review of the literature. *Clinical and Experimental Dermatology*. 2008 September;33(5):555-8. PMID: 2008392734 MEDLINE PMID 18627396 (<http://www.ncbi.nlm.nih.gov/pubmed/18627396>).
741. Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. *Vaccine*. 2010 Jul 28(25):4192-203. PMID: 2010290087 MEDLINE PMID 20417262 (<http://www.ncbi.nlm.nih.gov/pubmed/20417262>).
742. Kilpi T, Ahman H, Jokinen J, et al. Protective Efficacy of a Second Pneumococcal Conjugate Vaccine against Pneumococcal Acute Otitis Media in Infants and Children: Randomized, Controlled Trial of a 7-Valent Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine in 1666 Children. *Clinical Infectious Diseases*. 2003 Jan;37(9):1155-64. PMID: 2003453178 MEDLINE PMID 14557958 (<http://www.ncbi.nlm.nih.gov/pubmed/14557958>).
743. Kilpi TM, Silfverdal SA, Nilsson L, et al. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. *Human Vaccines*. 2009 May;5(1):18-25. PMID: 2009301611 MEDLINE PMID 18690013 (<http://www.ncbi.nlm.nih.gov/pubmed/18690013>).
744. Kim C-H, Kim JS, Cha S-H, et al. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants. *Pediatric Infectious Disease Journal*. 2011 Dec;30(12):e235-43. PMID: 21817957.
745. Kim DS, Shin SH, Lee HJ, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to Korean children receiving routine pediatric vaccines. *Pediatric Infectious Disease Journal*. 2012;24.
746. Kim DS, Shin SH, Lee HJ, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines. *Pediatric Infectious Disease Journal*. 2013 Mar;32(3):266-73. PMID: 23011012.
747. Kim J-H, Cho H-Y, Hennessey KA, et al. Adverse events following immunization (AEFI) with the novel influenza a (H1N1) 2009 vaccine: findings from the national registry of all

vaccine recipients and AEFI and the passive surveillance system in South Korea. Japanese Journal of Infectious Diseases. 2012 Mar;65(2):99-104. PMID: 22446114.

748. Kim KH, Kim YK, Kim NH, et al. Immunogenicity and safety of LBVH0101, a new Haemophilus influenzae type b tetanus toxoid conjugate vaccine, compared with Hiberix(trademark) in Korean infants and children: A randomized trial. Vaccine. 2012 27;30(10):1886-94. PMID: 201211553 MEDLINE PMID 22245607 (<http://www.ncbi.nlm.nih.gov/pubmed/22245607>).

749. Kim KH, Lee H, Chung EH, et al. Immunogenicity and safety of two different Haemophilus influenzae type b conjugate vaccines in Korean infants. Journal of Korean Medical Science. 2008 Dec;23(6):929-36. PMID: 19119431.

750. Kim SJ, Kim SH, Jee YM, et al. Vaccine-associated paralytic poliomyelitis: a case report of flaccid monoparesis after oral polio vaccine. Journal of Korean Medical Science. 2007 Apr;22(2):362-4. PMID: 17449951.

751. Kim Y-J, Kim K-T, Kim J-H, et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years.[Erratum appears in J Korean Med Sci. 2010 Dec;25(12):1831 Note: Ng, Timothy [added]; Bi, Dan [added]; OK, Jin-Ju [added]; Descamps, Dominique [added]; Bock, Hans L [added]]. Journal of Korean Medical Science. 2010 Aug;25(8):1197-204. PMID: 20676333.

752. Kim YK, Eun BW, Kim NH, et al. Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in Korean children aged 6-35 months. Scandinavian Journal of Infectious Diseases. 2013 Jun;45(6):460-8. PMID: 23294036.

753. Kimura A, Toneatto D, Kleinschmidt A, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clinical & Vaccine Immunology: CVI. 2011 Mar;18(3):483-6. PMID: 21177912.

754. King SD, Ramlal A, Wynter H, et al. Safety and immunogenicity of a new Haemophilus influenzae type b vaccine in infants under one year of age. Lancet. 1981 Oct 3;2(8249):705-9. PMID: 6116855.

755. Kitchin N, Southern J, Morris R, et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine. 2006 1;24(18):3964-70. PMID: 2006223038 MEDLINE PMID 16517034 (<http://www.ncbi.nlm.nih.gov/pubmed/16517034>).

756. Kitchin NRE, Southern J, Morris R, et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with

meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood. 2007 January;92(1):11-6. PMID: 2007044809 MEDLINE PMID 16670121 (<http://www.ncbi.nlm.nih.gov/pubmed/16670121>).

757. Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010 Jul;126(1):e1-8. PMID: 20587679.

758. Klein NP, Gans HA, Sung P, et al. Preterm Infants' T Cell Responses to Inactivated Poliovirus Vaccine. Journal of Infectious Diseases. 2010 Jan;201(2):214-22. PMID: WOS:000273051200008.

759. Klein NP, Lewis E, Baxter R, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012 May;129(5):809-14. PMID: 22473362.

760. Klein NP, Reisinger KS, Johnston W, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatric Infectious Disease Journal. 2012 Jan;31(1):64-71. PMID: 22094635.

761. Klein NP, Shepard J, Bedell L, et al. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine. 2012 Jun 6;30(26):3929-36. PMID: 22504039.

762. Klein NP, Weston WM, Kuriyakose S, et al. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Vaccine. 2012 Jan 11;30(3):668-74. PMID: 22064267.

763. Klepper MJ, Edwards B. Individual case safety reports--how to determine the onset date of an adverse reaction: a survey. Drug Safety. 2011 Apr 1;34(4):299-305. PMID: 21417502.

764. Klooster TMV, Kemmeren JM, Van Der Maas NAT, et al. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine. 2011 20;29(28):4601-7. PMID: 2011316322 MEDLINE PMID 21549785 (<http://www.ncbi.nlm.nih.gov/pubmed/21549785>).

765. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. New England Journal of Medicine. 2003 Oct 2;349(14):1341-8. PMID: 14523142.

766. Knuf M, Faber J, Barth I, et al. A combination vaccine against measles, mumps, rubella and varicella. Drugs of Today. 2008 April;44(4):279-92. PMID: 2008310823 MEDLINE PMID 18536786 (<http://www.ncbi.nlm.nih.gov/pubmed/18536786>).

767. Knuf M, Habermehl P, Cimino C, et al. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-

IPV/Hib combination vaccine in healthy infants. *Vaccine*. 2006 May 29;24(22):4727-36. PMID: 16616973.

768. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. *Vaccine*. 2010 Jan 8;28(3):744-53. PMID: 19887137.

769. Knuf M, Pankow-Culot H, Grunert D, et al. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable *haemophilus influenzae* protein D conjugate vaccine in infants. *Pediatric Infectious Disease Journal*. 2012 January;31(1):e31-e6. PMID: 2012016970 MEDLINE PMID 21909049 (<http://www.ncbi.nlm.nih.gov/pubmed/21909049>).

770. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix(trademark) hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. *Vaccine*. 2011 06;29(25):4264-73. PMID: 2011280673 MEDLINE PMID 21420417 (<http://www.ncbi.nlm.nih.gov/pubmed/21420417>).

771. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with InfanrixTM hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. *Vaccine*. 2011 Jun 6;29(25):4264-73. PMID: 21420417.

772. Knuf M, Schmitt H-J, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. *Journal of Pediatrics*. 2008 May;152(5):655-60, 60.e1. PMID: 18410769.

773. Knuf M, Vetter V, Celzo F, et al. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; BoostrixTM IPV). *Human Vaccines*. 2010 Jul;6(7):554-61. PMID: 20448468.

774. Knuf M, Vetter V, Celzo F, et al. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix(trademark) IPV). *Human Vaccines*. 2010 July;6(7):554-61. PMID: 2010520515.

775. Knuf M, Zepp F, Helm K, et al. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. *European Journal of Pediatrics*. 2012 Mar;171(3):463-70. PMID: WOS:000300668400009.

776. Knuf M, Zepp F, Meyer CU, et al. Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. *European Journal of Pediatrics*. 2010 Aug;169(8):925-33. PMID: 20148263.

777. Knutsson N, Trollfors B, Taranger J, et al. Immunogenicity and reactogenicity of diphtheria, tetanus and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine. *Vaccine*. 2001 Aug 14;19(31):4396-403. PMID: 11483264.
778. Kobayashi M, Ohfuji S, Fukushima W, et al. Immunogenicity and reactogenicity of a monovalent inactivated 2009 influenza A vaccine in adolescents: with special reference to pre-existing antibody. *Journal of Pediatrics*. 2012 Apr;160(4):632-7.e1. PMID: 22094234.
779. Koh KJ, Warren L, Moore L, et al. Wells' syndrome following thiomersal-containing vaccinations. *Australasian Journal of Dermatology*. 2003 August;44(3):199-202. PMID: 2003323613 MEDLINE PMID 12869046 (<http://www.ncbi.nlm.nih.gov/pubmed/12869046>).
780. Kolivras A, Andre J. Gianotti-Crosti syndrome following hepatitis A vaccination. *Pediatric Dermatology*. 2008 November-December;25(6):650. PMID: 2008572364 MEDLINE PMID 19067881 (<http://www.ncbi.nlm.nih.gov/pubmed/19067881>).
781. Kondo S, Abe K. The effects of influenza virus infection on FEV1 in asthmatic children. The time-course study. *Chest*. 1991 Nov;100(5):1235-8. PMID: 1935277.
782. Kong BP, Seng HQ, Fong SL, et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus Influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. *Annals of the Academy of Medicine Singapore*. 2008 July;37(7):546-53. PMID: 2008387647 MEDLINE PMID 18695765 (<http://www.ncbi.nlm.nih.gov/pubmed/18695765>).
783. Konno R, Tamura S, Dobbelaere K, et al. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial. *International Journal of Gynecological Cancer*. 2010 Apr;20(3):404-10. PMID: 20375805.
784. Konno R, Tamura S, Dobbelaere K, et al. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial. *International Journal of Gynecological Cancer*. 2010 Jul;20(5):847-55. PMID: 20606533.
785. Kosalaraksa P, Thisyakorn U, Benjaponpitak S, et al. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B/PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. *International Journal of Infectious Diseases*. 2011 Apr;15(4):e249-56. PMID: 21334243.
786. Koskineni M, Vaheri A. Effect of measles, mumps, rubella vaccination on pattern of encephalitis in children. *Lancet*. 1989 Jan 7;1(8628):31-4. PMID: 2563011.

787. Kostianovsky A, Charles P, Alves JF, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. *Clinical and Experimental Rheumatology*. 2012 Jan-Feb;30(1):S83-S9. PMID: WOS:000304499000018.
788. Kovel A, Wald ER, Guerra N, et al. Safety and immunogenicity of acellular diphtheria-tetanus-pertussis and Haemophilus conjugate vaccines given in combination or at separate injection sites. *Journal of Pediatrics*. 1992 Jan;120(1):84-7. PMID: 1731030.
789. Krairittichai U, Chittaganpitch M. Efficacy of the trivalent influenza vaccination in Thai patients with hemodialysis or kidney transplant compared with healthy volunteers. *Journal of the Medical Association of Thailand*. 2013 Mar;96 Suppl 3:S1-7. PMID: 23682516.
790. Kubavat AH, Mittal R, Patel PM, et al. A clinical trial to assess the immunogenicity and safety of Inactivated Influenza Vaccine (Whole Virion) IP (Pandemic Influenza (H1N1) 2009 Monovalent Vaccine; VaxiFlu-STM) in healthy Indian adult population. *Journal of Postgraduate Medicine*. 2011 Apr-Jun;57(2):102-8. PMID: 21654130.
791. Kuehn BM. IOM review finds vaccine adverse events are rare and usually reversible. *JAMA - Journal of the American Medical Association*. 2011 5;306(13):1427. PMID: 2011551799 MEDLINE PMID 21972299 (<http://www.ncbi.nlm.nih.gov/pubmed/21972299>).
792. Kulkarni PS, Manjunath K, Agarkhedkar S, et al. Safety and immunogenicity of an adjuvanted whole virion, inactivated A (H1N1) 2009 influenza vaccine in young and elderly adults, and children. *Vaccine*. 2012 Dec 17;31(1):20-2. PMID: 23131207.
793. Kumar A, Dutta AK, Saili A, et al. Immunogenicity and tolerance of H. influenzae type b, tetanus toxoid conjugate vaccine given concurrently or in combination. *Indian Journal of Pediatrics*. 1997 Nov-Dec;64(6):839-47. PMID: 10771928.
794. Kumar D, Chen MH, Wong G, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. *Clinical Infectious Diseases*. 2008 1;47(7):885-92. PMID: 2008450787 MEDLINE PMID 18715160 (<http://www.ncbi.nlm.nih.gov/pubmed/18715160>).
795. Kumar D, Rotstein C, Miyata G, et al. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. *Journal of Infectious Diseases*. 2003 15;187(10):1639-45. PMID: 2003201164 MEDLINE PMID 12721944 (<http://www.ncbi.nlm.nih.gov/pubmed/12721944>).
796. Kung H-C, Huang K-C, Kao T-M, et al. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza. *Vaccine*. 2010 Oct 21;28(45):7337-43. PMID: 20817013.

797. Kurikka S, Kayhty H, Peltola H, et al. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. *Pediatrics*. 1995 Jun;95(6):815-22. PMID: 7761204.
798. Kurikka S, Olander RM, Eskola J, et al. Passively acquired anti-tetanus and anti-Haemophilus antibodies and the response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infancy. *Pediatric Infectious Disease Journal*. 1996 Jun;15(6):530-5. PMID: 8783351.
799. Kuronen T, Peltola H, Nors T, et al. Adverse reactions and endotoxin content of polysaccharide vaccines. *Developments in Biological Standardization*. 1977;34:117-25. PMID: 402298.
800. Kuruma KAM, Borba EF, Lopes MH, et al. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. *Lupus*. 2007;16(5):350-4. PMID: WOS:000248089800007.
801. Kussmaul SC, Horn BN, Dvorak CC, et al. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. *Bone Marrow Transplantation*. 2010 Jul;45(11):1602-6. PMID: 2010618609 MEDLINE PMID 20190839 (<http://www.ncbi.nlm.nih.gov/pubmed/20190839>).
802. Kuter BJ, Brown MLH, Hartzel J, et al. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad(registered trademark)). *Human Vaccines*. 2006 September/October;2(5):205-14. PMID: 2006573463 MEDLINE PMID 17035730 (<http://www.ncbi.nlm.nih.gov/pubmed/17035730>).
803. Kwak GY, Kwon HJ, Kim JH, et al. The immunogenicity and safety of DTaP interchangeable immunization among Korean children. *Vaccine*. 2012 Jun 29;30(31):4644-7. PMID: 22579862.
804. Labriola L, Hombrouck A, Marechal C, et al. Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. *Nephrology Dialysis Transplantation*. 2011 April;26(4):1424-8. PMID: 2011198098 MEDLINE PMID 21273236 (<http://www.ncbi.nlm.nih.gov/pubmed/21273236>).
805. Lackmann GM. Comparative investigation of the safety of hexavalent vaccines for primary scheduled infant immunizations in Germany over a time period of 2 years. *Medical Science Monitor*. 2004 September;10(9):PI96-PI8. PMID: 2004410721 MEDLINE PMID 15328494 (<http://www.ncbi.nlm.nih.gov/pubmed/15328494>).
806. Lackner TE, G Hamilton R, J Hill J, et al. Pneumococcal polysaccharide revaccination: immunoglobulin g seroconversion, persistence, and safety in frail, chronically ill older subjects. *Journal of the American Geriatrics Society*. 2003 Feb;51(2):240-5. PMID: 12558722.
807. Lagler H, Wenisch JM, Tobudic S, et al. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived,

non-adjuvanted, whole-virion vaccination. *Vaccine*. 2011 Sep 16;29(40):6888-93. PMID: 21803100.

808. Lagos R, Munoz A, Levine MM, et al. Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants. *Vaccine*. 2009 Apr 14;27(17):2299-305. PMID: 19428843.

809. Lagos RE, Munoz AE, Levine MM, et al. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. *Human Vaccines*. 2011 May;7(5):511-22. PMID: 21441782.

810. Lai YC, Yang KC, Hsieh SM, et al. Persistence of Immunogenicity of a Monovalent Influenza Virus A/H1N1 2009 Vaccine in Healthy Volunteers. *Clinical and Vaccine Immunology*. 2012 Mar;19(3):429-35. PMID: WOS:000300841200021.

811. Lalwani S, Chatterjee S, Chhatwal J, et al. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: A single-blind, randomized, controlled study. *Human Vaccines and Immunotherapeutics*. 2012 May;8(5):612-22. PMID: 2012397558.

812. Lang L. Rotavirus Vaccines Prove Powerful Against Diarrhea. *Gastroenterology*. 2010 April;138(4):1221-2. PMID: 2010188120.

813. Langley JM, Halperin SA, Rubin E, et al. Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial. *Pediatric Infectious Disease Journal*. 2012 Feb;31(2):189-92. PMID: 22173143.

814. Langley JM, Predy G, Guasparini R, et al. An adolescent-adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. *Vaccine*. 2007 Jan 22;25(6):1121-5. PMID: 17045366.

815. Langley JM, Scheifele DW, Quach C, et al. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. *Vaccine*. 2012 May 14;30(23):3389-94. PMID: 22469860.

816. Langue J, Ethevenaux C, Champsaur A, et al. Safety and immunogenicity of Haemophilus influenzae type b-tetanus toxoid conjugate, presented in a dual-chamber syringe with diphtheria-tetanus-pertussis and inactivated poliomyelitis combination vaccine. *European Journal of Pediatrics*. 1999 Sep;158(9):717-22. PMID: 10485302.

817. Lapatsanis P, Lapatsanis D. Pertussis vaccine and infantile spasms. *Vaccine*. 2007;25(3):404-5. PMID: 2006593391 MEDLINE PMID 16962689 (<http://www.ncbi.nlm.nih.gov/pubmed/16962689>).
818. Laroche P, Barrand M, Wood SC, et al. The immunogenicity and safety of a new combined diphtheria, tetanus and poliomyelitis booster vaccine (Td-eIPV). *Infection*. 1999 Jan-Feb;27(1):49-56. PMID: 10206791.
819. Latipov R, Khudoyorov R, Flem E. Childhood intussusception in Uzbekistan: analysis of retrospective surveillance data. *Bmc Pediatrics*. 2011;11:22. PMID: 21435218.
820. Launay O, Desaint C, Durier C, et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. *Journal of Infectious Diseases*. 2011 Jul 1;204(1):124-34. PMID: 21628666.
821. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and Immunogenicity of 4 Intramuscular Double Doses and 4 Intradermal Low Doses vs Standard Hepatitis B Vaccine Regimen in Adults With HIV-1 A Randomized Controlled Trial. *Jama-Journal of the American Medical Association*. 2011 Apr;305(14):1432-40. PMID: WOS:000289424100020.
822. Lawrence G, Boyd I, McIntyre P, et al. Annual report: Surveillance of adverse events following immunisation in Australia, 2005. *Communicable Diseases Intelligence*. 2006;30(3):319-33. PMID: 17120485.
823. Lawrence G, Gold MS, Hill R, et al. Annual report: surveillance of adverse events following immunisation in Australia, 2007. *Communicable Diseases Intelligence*. 2008 Dec;32(4):371-87. PMID: 19374268.
824. Lawrence GL, Aratchige PE, Boyd I, et al. Annual report on surveillance of adverse events following immunisation in Australia, 2006. *Communicable Diseases Intelligence*. 2007 Sep;31(3):269-82. PMID: 17974219.
825. Lazarov A, Attias O, Avinoach I, et al. Infantile acute hemorrhagic edema following vaccine application [2]. *Journal of the European Academy of Dermatology and Venereology*. 1995;1995;5(2):203-4. PMID: 1995283921.
826. Lazarus R, Clutterbuck E, Yu LM, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. *Clinical Infectious Diseases*. 2011;15;52(6):736-42. PMID: 2011190872 MEDLINE PMID 21367726 (<http://www.ncbi.nlm.nih.gov/pubmed/21367726>).
827. Le Corre N, Thibault F, Pouteil Noble C, et al. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial. *Vaccine*. 2012 Dec 14;30(52):7522-8. PMID: 23103195.

828. LeBaron CW, Bi D, Sullivan BJ, et al. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. *Pediatrics*. 2006 Oct;118(4):1422-30. PMID: 17015532.
829. Lederman MM, Schiffman G, Rodman HM. Pneumococcal immunization in adult diabetics. *Diabetes*. 1981 Feb;30(2):119-21. PMID: 7202857.
830. Lee A, Goyal R, Shan HY. Severe protracted fever following pneumococcal vaccine. *American Journal of the Medical Sciences*. 2006 Dec;332(6):351-3. PMID: 17170626.
831. Lee AW, Vesikari T, Gilbert CL, et al. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants. *Vaccine*. 2011 Oct 19;29(45):7942-8. PMID: 21875633.
832. Lee BY, Stalter RM, Bacon KM, et al. Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients. *American Journal of Kidney Diseases*. 2011 May;57(5):724-32. PMID: 2011205904 MEDLINE PMID 21396760 (<http://www.ncbi.nlm.nih.gov/pubmed/21396760>).
833. Lee CY, Lee PI, Huang LM, et al. A simplified schedule to integrate the hepatitis B vaccine into an expanded program of immunization in endemic countries. *Journal of Pediatrics*. 1997 1997;130(6):981-6. PMID: 1997357698 MEDLINE PMID 9202623 (<http://www.ncbi.nlm.nih.gov/pubmed/9202623>).
834. Lee CY, Thippawong J, Huang LM, et al. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. *Pediatrics*. 1999 Jan;103(1):25-30. PMID: 9917435.
835. Lee H, Kim HW, Cho HK, et al. Reappraisal of MMR vaccines currently used in Korea. *Pediatrics International*. 2011 Jun;53(3):374-80. PMID: 20831649.
836. Lee HJ, Kang JH, Henrichsen J, et al. Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy children and in children at increased risk of pneumococcal infection. *Vaccine*. 1995 Nov;13(16):1533-8. PMID: 8578838.
837. Lee SJ, Kim YO, Woo YJ, et al. Neurologic adverse events following influenza A (H1N1) vaccinations in children. *Pediatrics International*. 2012 Jun;54(3):325-30. PMID: 22299607.
838. Lee SJ, Kim YO, Woo YJ, et al. Neurologic adverse events following influenza A (H1N1) vaccinations in children. *Pediatrics International*. 2012 Jun;54(3):325-30. PMID: 22299607.
839. Lee SY, Hwang HS, Kim JH, et al. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate

administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea. *Vaccine*. 2011 Feb 11;29(8):1551-7. PMID: 21215828.

840. Lee SY, Hwang HS, Kim JH, et al. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: A randomized, controlled study in infants in the Republic of Korea. *Vaccine*. 2011 11;29(8):1551-7. PMID: 2011150742 MEDLINE PMID 21215828 (<http://www.ncbi.nlm.nih.gov/pubmed/21215828>).

841. Lee YY, Lee R, Yamamoto LG. Intussusception incidence relative to rotavirus vaccine use in Honolulu. *Clinical Pediatrics*. 2005 Nov-Dec;44(9):791-5. PMID: 16327966.

842. Leeb A, Carcione D, Richmond PC, et al. Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults. *Vaccine*. 2011 Oct 19;29(45):7920-4. PMID: 21864621.

843. Lehmann D, Kakazo M, Yarsley S, et al. Safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine (PedvaxHIB) in Papua New Guinean children. *Papua New Guinea Medical Journal*. 1998 Sep-Dec;41(3-4):102-11. PMID: 10934551.

844. Lehmann D, Pomat WS, Riley ID, et al. Studies of maternal immunisation with pneumococcal polysaccharide vaccine in Papua New Guinea. *Vaccine*. 2003 Jul 28;21(24):3446-50. PMID: 12850357.

845. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.[Erratum appears in Lancet Oncol. 2012 Jan;13(1):e1]. *Lancet Oncology*. 2012 Jan;13(1):89-99. PMID: 22075171.

846. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.[Erratum appears in Lancet Oncol. 2012 Jan;13(1):e1]. *Lancet Oncology*. 2012 Jan;13(1):89-99. PMID: 22075171.

847. Lennon D. Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. *Vaccine* 2007;25(16):3075-9. *Vaccine*. 2007 Sep 28;25(39-40):6835; author reply -6. PMID: 17875437.

848. Leonardi M, Bromberg K, Baxter R, et al. Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children. *Pediatrics*. 2011 Dec;128(6):e1387-94. PMID: 22123890.

849. Lepow M. Clinical trials of the Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine. *Pediatric Infectious Disease Journal*. 1987 Aug;6(8):804-7. PMID: 3313246.

850. Lepow ML, Samuelson JS, Gordon LK. Safety and immunogenicity of Haemophilus influenzae type B polysaccharide-diphtheria toxoid conjugate vaccine in adults. *Journal of Infectious Diseases*. 1984 Sep;150(3):402-6. PMID: 6332863.
851. Lepow ML, Samuelson JS, Gordon LK. Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age. *Journal of Pediatrics*. 1985 Feb;106(2):185-9. PMID: 3871477.
852. Leroux-Roels G, Haelterman E, Maes C, et al. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine. *Clinical & Vaccine Immunology: CVI*. 2011 Sep;18(9):1510-8. PMID: 21734063.
853. Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. *Journal of Infectious Diseases*. 2012 Oct;206(8):1280-90. PMID: 22872734.
854. Leroux-Roels I, Vets E, Freese R, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults (vol 26, pg 6614, 2008). *Vaccine*. 2010 Nov;28(50):8033-. PMID: WOS:000285667400027.
855. Leroy Z, Broder K, Menschik D, et al. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. *Vaccine*. 2012 Mar 2;30(11):2020-3. PMID: 22361303.
856. Lertdumrongluk P, Changsirikulchai S, Limkunakul C, et al. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients. *Vaccine*. 2012 Feb 1;30(6):1108-14. PMID: 22178515.
857. Leung AK, Chiu AS, Siu TO. Subcutaneous versus intramuscular administration of Haemophilus influenzae type b vaccine. *Journal of the Royal Society of Health*. 1989 Apr;109(2):71-3. PMID: 2500525.
858. Leung JSM. Adverse events after flu vaccination in patients with immune disorders. *Hong Kong Medical Journal*. 2010 Apr;16(2):159. PMID: 20354258.
859. Leventhal JS, Berger EM, Brauer JA, et al. Hypersensitivity Reactions to Vaccine Constituents: A Case Series and Review of the Literature. *Dermatitis*. 2012 May-Jun;23(3):102-9. PMID: WOS:000304846700001.
860. Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. *J Infect Dis*. 2006 Jul 15;194(2):247-55. PMID: 16779732.

861. Levine OS, Lagos R, Losonsky GA, et al. No adverse impact on protection against pertussis from combined administration of Haemophilus influenza type b conjugate and diphtheria-tetanus toxoid-pertussis vaccines in the same syringe. *Journal of Infectious Diseases*. 1996 Dec;174(6):1341-4. PMID: 8940230.
862. Lexchin J, Arya N, Singh S. Gardasil(registered trademark) - The new HPV vaccine: The right product, the right time? A commentary. *Healthcare Policy*. 2010 May;5(4):26-36. PMID: 2011083948.
863. Li G, Zhang H, Zhou W, et al. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization. *Vaccine*. 2010 Jun 7;28(25):4215-23. PMID: 20399240.
864. Li RC, Li FX, Li YP, et al. Safety and immunogenicity of a 7-valent pneumococcal conjugate vaccine (Prevenar): primary dosing series in healthy Chinese infants. *Vaccine*. 2008 Apr 24;26(18):2260-9. PMID: 18375021.
865. Li RC, Li FX, Li YP, et al. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP~T vaccine compared to separate vaccines (DTaP, PRP~T and IPV) following primary vaccination of healthy infants in the People's Republic of China. *Vaccine*. 2011 Nov 21;29(50):9337-44. PMID: 22001281.
866. Li RC, Li FX, Li YP, et al. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China. *Vaccine*. 2011 Feb 24;29(10):1913-20. PMID: 21219984.
867. Li RC, Li FX, Li YP, et al. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP approximately T vaccine compared to separate vaccines (DTaP, PRP approximately T and IPV) following primary vaccination of healthy infants in the People's Republic of China. *Vaccine*. 2011 Nov 21;29(50):9337-44. PMID: 22001281.
868. Li X, Wang WWB, Liu GF, et al. Handling missing data in vaccine clinical trials for immunogenicity and safety evaluation. *Journal of Biopharmaceutical Statistics*. 2011 March;21(2):294-310. PMID: 2011145455 MEDLINE PMID 21391003 (<http://www.ncbi.nlm.nih.gov/pubmed/21391003>).
869. Liakou CD, Askiti V, Mitsioni A, et al. Safety, immunogenicity and kinetics of immune response to 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome. *Vaccine*. 2011 Sep 16;29(40):6834-7. PMID: 21803106.
870. Liang X-F, Li L, Liu D-W, et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.[Erratum appears in *N Engl J Med*. 2011 Apr 14;364(15):1481]. *New England Journal of Medicine*. 2011 Feb 17;364(7):638-47. PMID: 21288090.

871. Liao G, Li R, Li C, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. *Journal of Infectious Diseases*. 2012 Jan 15;205(2):237-43. PMID: 22158682.
872. Liese JG, Rieber N, Malzer T, et al. Reactogenicity of tetanus, diphtheria, 5-component acellular pertussis vaccine administered as a sixth consecutive acellular pertussis vaccine dose to adolescents. *Pediatric Infectious Disease Journal*. 2010 Dec;29(12):1067-71. PMID: 20616762.
873. Liese JG, Stojanov S, Berut F, et al. Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP--T-HBs) administered at 2, 4, 6 and 12-14 months of age. *Vaccine*. 2001 Nov 12;20(3-4):448-54. PMID: 11672908.
874. Lievano F, Galea SA, Thornton M, et al. Measles, mumps, and rubella virus vaccine (M-M-RTMII): a review of 32 years of clinical and postmarketing experience. *Vaccine*. 2012 Nov 6;30(48):6918-26. PMID: 22959986.
875. Lim BH, Mahmood TA. Pandemic H1N1 2009 (swine flu) and pregnancy. *Obstetrics, Gynaecology and Reproductive Medicine*. 2010 April;20(4):101-6. PMID: 2010164273.
876. Lim FS, Phua KB, Lee BW, et al. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting. *Southeast Asian Journal of Tropical Medicine & Public Health*. 2011 Jan;42(1):138-47. PMID: 21323176.
877. Lim S-H, Lee J-H, Kim B-C, et al. Adverse reaction of influenza A (H1N1) 2009 virus vaccination in pregnant women and its effect on newborns. *Vaccine*. 2010 Nov 3;28(47):7455-6. PMID: 20832495.
878. Lin CS, Zhu JY, Zheng YB, et al. Effect of GM-CSF in combination with hepatitis B vaccine on revaccination of healthy adult. *Journal of Infection*. 2010 Apr;60(4):264-70. PMID: WOS:000275789100002.
879. Lin CY, Peng CC, Liu HC, et al. Psychogenic movement disorder after H1N1 influenza vaccination. *Journal of Neuropsychiatry and Clinical Neurosciences*. 2011 2011;23(3):E37-E8. PMID: 2011595788 MEDLINE PMID 21948923
(<http://www.ncbi.nlm.nih.gov/pubmed/21948923>).
880. Lin PL, Michaels MG, Green M, et al. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. *Pediatrics*. 2005 Jul;116(1):160-7. PMID: 15995047.
881. Lin SY, Wu ET, Lin CH, et al. The safety and immunogenicity of trivalent inactivated influenza vaccination: a study of maternal-cord blood pairs in taiwan. *PLoS ONE [Electronic Resource]*. 2013;8(6):e62983. PMID: 23762229.

882. Lin TY, Lu CY, Chang LY, et al. Immunogenicity and safety of 10-valent pneumococcal non-typeable *Haemophilus influenzae* protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan. *Journal of the Formosan Medical Association*. 2012.
883. Lin TY, Wang Y-H, Chang L-Y, et al. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--*Haemophilus influenzae* type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants. *International Journal of Infectious Diseases*. 2007 Mar;11(2):129-36. PMID: 16762579.
884. Lin T-Y, Wang Y-H, Chang L-Y, et al. Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/*Haemophilus influenzae* type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age. *Chang Gung Medical Journal*. 2003 May;26(5):315-22. PMID: 12934847.
885. Lin T-Y, Wang Y-H, Huang Y-C, et al. Booster vaccination at 6-8 years of age with a reduced antigen content dTpa-IPV vaccine is immunogenic and safe after priming with whole-cell pertussis vaccine. *Human Vaccines*. 2008 Jan-Feb;4(1):50-3. PMID: 18376147.
886. Lin T-Y, Wang Y-H, Huang Y-C, et al. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, *Haemophilus influenzae* type b conjugate vaccine. *International Journal of Infectious Diseases*. 2007 Nov;11(6):488-95. PMID: 17349809.
887. Linchevski I, Klement E, Nir-Paz R. *Mycoplasma pneumoniae* vaccine protective efficacy and adverse reactions--Systematic review and meta-analysis. *Vaccine*. 2009 Apr 21;27(18):2437-46. PMID: 19368785.
888. Linhares AC, Velazquez FR. Rotavirus P[4]G2 in a vaccinated population, Brazil. *Emerging Infectious Diseases*. 2008;14(5) PMID: 2008291627.
889. Lisotti A, Roda G, Brillanti S, et al. Reactivation of Crohn's disease after pandemic aH1N1 and seasonal flu vaccinations. *Digestive and Liver Disease*. 2010 December;42(12):909-10. PMID: 2010648189 MEDLINE PMID 20417161
(<http://www.ncbi.nlm.nih.gov/pubmed/20417161>).
890. Lloyd-Johnsen C, Justice F, Donath S, et al. Retrospective hospital based surveillance of intussusception in children in a sentinel paediatric hospital: benefits and pitfalls for use in post-marketing surveillance of rotavirus vaccines. *Vaccine*. 2012 Apr 27;30 Suppl 1:A190-5. PMID: 22520131.
891. Lloyd-Puryear MA, Ball LK, Benor D. Should the vaccine injury compensation program be expanded to cover adults? *Public Health Reports*. 1998 May-Jun;113(3):236-42. PMID: 9633868.

892. Lode H, Schmoele-Thoma B, Gruber W, et al. Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 x, 2 x, or 4 x) in healthy subjects aged 70 years or older. *Vaccine*. 2011 Jul 12;29(31):4940-6. PMID: 21596077.
893. Lodolce AE. Shortened interval between tetanus vaccines. *Annals of Pharmacotherapy*. 2012 Jun;46(6):884-8. PMID: 22669800.
894. Loebermann M, Anders G, Brestrich G, et al. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study. *Vaccine*. 2011 Feb 1;29(6):1228-34. PMID: 21167116.
895. Lolekha S, Hiranchote A, Simasathien S. Safety and immunogenicity of combined or associated administration of PRP-T vaccine with diphtheria, tetanus and pertussis vaccine in Thai children. *Journal of Tropical Pediatrics*. 2001 Feb;47(1):24-9. PMID: 11245347.
896. Loomba RS, Aggarwal S, Shah PH, et al. Influenza vaccination and cardiovascular morbidity and mortality: analysis of 292,383 patients. *Journal of Cardiovascular Pharmacology & Therapeutics*. 2012 Sep;17(3):277-83. PMID: 22172681.
897. Lopert R, Nolan T. Panvax febrile reactions not a predictor. *BMJ*. 2010;(2010) 341(7765):163. PMID: 2010415137.
898. Lopman BA, Payne DC, Tate JE, et al. Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011. *Current Opinion in Virology*. 2012 August;2(4):434-42. PMID: 2012485382.
899. Lottenbach KR, Granoff DM, Barenkamp SJ, et al. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population. *Journal of the American Geriatrics Society*. 2004 Nov;52(11):1883-7. PMID: 15507066.
900. Loughlin J, Mast TC, Doherty MC, et al. Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. *Pediatric Infectious Disease Journal*. 2012 Mar;31(3):292-6. PMID: 22173146.
901. Lu C-C, Wang Y-C, Lai J-H, et al. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. *Vaccine*. 2011 Jan 10;29(3):444-50. PMID: 21078406.
902. Lu C-L, Hung C-C, Chuang Y-C, et al. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients. *Vaccine*. 2012 May 21;30(24):3526-33. PMID: 22484349.
903. Lum LCS, Borja-Tabora CF, Breiman RF, et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.

Vaccine. 2010 10;28(6):1566-74. PMID: 2010073090 MEDLINE PMID 20003918
(<http://www.ncbi.nlm.nih.gov/pubmed/20003918>).

904. Macias M, Lanata CF, Zambrano B, et al. Safety and Immunogenicity of an Investigational Fully Liquid Hexavalent DTaP-IPV-Hep B-PRP-T Vaccine at Two, Four and Six Months of Age Compared With Licensed Vaccines in Latin America. *Pediatric Infectious Disease Journal*. 2012 Aug;31(8):e126-32. PMID: 22531237.

905. MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults \geq 60 years old. *Human Vaccines*. 2010 Nov;6(11):894-902. PMID: 20980796.

906. Mackay HJ, McGee J, Villa D, et al. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. *Journal of Clinical Virology*. 2011 Mar;50(3):212-6. PMID: 21168361.

907. Mad'ar R, Benesova D, Brandejska D, et al. Vaccination of Patients with Diabetes Mellitus - a Retrospective Study. *Central European Journal of Public Health*. 2011 Jun;19(2):98-101. PMID: WOS:000291919600009.

908. Mad'ar R, Benesova D, Brandejska D, et al. Vaccination of patients with diabetes mellitus-- a retrospective study. *Central European Journal of Public Health*. 2011 Jun;19(2):98-101. PMID: 21739900.

909. Madhi SA, Cutland C, Jones S, et al. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age in infants in South Africa. *South African Medical Journal*. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2011 Feb;101(2):126-31. PMID: 21678741.

910. Madhi SA, Cutland C, Jones S, et al. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine. *South African Medical Journal*. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2011 Dec;101(12):879-83. PMID: 22273029.

911. Madhun AS, Akselsen PE, Sjursen H, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. *Vaccine*. 2010 16;29(2):266-73. PMID: 2010663992 MEDLINE PMID 21034828
(<http://www.ncbi.nlm.nih.gov/pubmed/21034828>).

912. Madore DV, Johnson CL, Phipps DC, et al. Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months. *Pediatrics*. 1990 Oct;86(4):527-34. PMID: 2216616.

913. Madore DV, Johnson CL, Phipps DC, et al. Safety and Immunological Response to Haemophilus-Influenzae Type-B Oligosaccharide-Crm197 Conjugate Vaccine in 1-Month-Old to 6-Month-Old Infants. *Pediatrics*. 1990 Mar;85(3):331-7. PMID: WOS:A1990CX32100015.
914. Mahadevan U, Cucchiara S, Hyams JS, et al. The London position statement of the World Congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: Pregnancy and pediatrics. *American Journal of Gastroenterology*. 2011 February;106(2):214-23. PMID: 2011082151 MEDLINE PMID 21157441 (<http://www.ncbi.nlm.nih.gov/pubmed/21157441>).
915. Mahajan D, Cook J, Dey A, et al. Annual report: Surveillance of adverse events following immunisation in Australia, 2011. *Communicable Diseases Intelligence Quarterly Report*. 2012 Dec;36(4):E315-32. PMID: 23330706.
916. Mahajan D, Reid S, Cook J, et al. NSW annual report describing adverse events following immunisation, 2011. *New South Wales Public Health Bulletin*. 2012 Dec;23(9-10):187-200. PMID: 23442996.
917. Mair S, Fiquet A, Meghlaoui G, et al. Immunogenicity and safety of PNEUMOVAX II manufactured by a new process in older adults. *Human Vaccines*. 2009 Sep;5(9):608-13. PMID: 19617717.
918. Mallet E, Brachet E, Fernsten P, et al. Immunogenicity and safety of CRM197 conjugated 9-valent pneumococcal and meningococcal C combination vaccine in healthy infants. *Vaccine*. 2011 Aug 5;29(34):5812-9. PMID: 21296118.
919. Mallory RM, Yi T, Ambrose CS. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age. *Vaccine*. 2011 Jun 10;29(26):4322-7. PMID: 21513761.
920. Maltezou HC. Novel (pandemic) influenza A H1N1 in healthcare facilities: implications for prevention and control. *Scandinavian Journal of Infectious Diseases*. 2010 Jul;42(6-7):412-20. PMID: 20331404.
921. Mangay-Angara A, Fulgencio L, Casabal G, et al. A two-dose schedule for immunization of infants using a more concentrated DPT-vaccine. *Developments in Biological Standardization*. 1978;41:15-22. PMID: 753647.
922. Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. *Journal of Pediatrics*. 2010 Apr;156(4):623-8. PMID: 20097358.
923. Manuel O, Humar A, Berutto C, et al. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. *Journal of Heart & Lung Transplantation*. 2011 Jun;30(6):679-84. PMID: 21377898.

924. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. *Clinical Infectious Diseases*. 2011 Jan;52(2):248-56. PMID: 21288852.
925. Manzoli L, Ioannidis JP, Flacco ME, et al. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. *Human vaccines & Immunotherapeutics*. 2012 Jul;8(7):851-62. PMID: 22777099.
926. Marchant CD, Miller JM, Marshall GS, et al. Randomized trial to assess immunogenicity and safety of *Haemophilus influenzae* type b and *Neisseria meningitidis* serogroups C and Y-tetanus toxoid conjugate vaccine in infants. *Pediatric Infectious Disease Journal*. 2010 Jan;29(1):48-52. PMID: 20035207.
927. Marcinak JF, Frank AL, Labotka RL, et al. Immunogenicity of *Haemophilus-Influenzae* Type-B Polysaccharide-Diphtheria Toxoid Conjugate Vaccine in 3-Month-Old to 17-Month-Old Infants with Sickle-Cell Diseases. *Journal of Pediatrics*. 1991 Jan;118(1):69-71. PMID: WOS:A1991EU22200012.
928. Marin LF, Abrahao A, Carvalho FA, et al. Guillain-Barre syndrome associated with H1N1 vaccination.[Erratum appears in Arq Neuropsiquiatr. 2011 Feb;69(1):147 Note: Abrahao, Ayessandro [corrected to Abrahao, Agessandro]]. *Arquivos de Neuro-Psiquiatria*. 2010 Dec;68(6):974-5. PMID: 21243265.
929. Marra F, Young F, Richardson K, et al. A Meta-analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events. *Influenza & Other Respiratory Viruses*. 2013 Jul;7(4):584-603. PMID: 22974174.
930. Marshall GS, Marchant CD, Blatter M, et al. Immune response and one-year antibody persistence after a fourth dose of a novel *Haemophilus influenzae* type b and *Neisseria meningitidis* serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age. *Pediatric Infectious Disease Journal*. 2010 May;29(5):469-71. PMID: 20072077.
931. Marshall GS, Marchant CD, Blatter M, et al. Co-administration of a novel *Haemophilus influenzae* type b and *Neisseria meningitidis* serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States. *Human Vaccines*. 2011 February;7(2):258-64. PMID: 201140107 MEDLINE PMID 21307655 (<http://www.ncbi.nlm.nih.gov/pubmed/21307655>).
932. Marshall H, McIntyre P, Roberton D, et al. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and *Haemophilus influenzae* type b (Hib) vaccine administered separately or together is safe and immunogenic. *International Journal of Infectious Diseases*. 2010 Jan;14(1):e41-9. PMID: 19467896.

933. Marshall H, Nolan T, Roberton D, et al. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years. *Vaccine*. 2006 Aug 28;24(35-36):6120-8. PMID: 16822597.
934. Martinez-Mir I, Garcia LM, Palop V, et al. A prospective study of adverse drug reactions as a cause of admission to a paediatric hospital. *British Journal of Clinical Pharmacology*. 1996 1996;42(3):319-24. PMID: 1996262774 MEDLINE PMID 8877022 (<http://www.ncbi.nlm.nih.gov/pubmed/8877022>).
935. Martinon-Torres F, Gimenez-Sanchez F, Gurtman A, et al. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety. *Pediatric Infectious Disease Journal*. 2012 Apr;31(4):392-9. PMID: 22301472.
936. Martins RdM, Camacho LAB, Marcovitz R, et al. Immunogenicity, reactogenicity and consistency of production of a Brazilian combined vaccine against diphtheria, tetanus, pertussis and Haemophilus influenzae type b. *Memorias do Instituto Oswaldo Cruz*. 2008 Nov;103(7):711-8. PMID: 19057823.
937. Mathian A, Devilliers H, Krivine A, et al. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. *Arthritis & Rheumatism*. 2011 Nov;63(11):3502-11. PMID: 21811996.
938. Matjila MJ, Phohu TC, Banzhoff A, et al. Safety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines. *South African Medical Journal*. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2004 Jan;94(1):43-6. PMID: 14971232.
939. Matson DO. Letter to the editor. *Vaccine*. 2001 6;19(20 22):2763. PMID: 2001120350.
940. Mayet A, Ligier C, Gache K, et al. Adverse events following pandemic influenza vaccine Pandemrix[REGISTERED] reported in the French military forces--2009-2010. *Vaccine*. 2011 Mar 21;29(14):2576-81. PMID: 21296693.
941. Mayet A, Nivoix P, Haus-Cheymol R, et al. Increase in reported adverse events following seasonal influenza vaccination among the French armed forces, 2008-2009: possible role of stimulated reporting and background cases of influenza-like infection. *Public Health*. 2012 Jan;126(1):70-6. PMID: 22137096.
942. Mazurat N. Vaccines and acute myocardial infarction. *Journal (Canadian Dental Association)*. 2010;76:a174. PMID: 21167089.
943. McColgan BP, Borschke FA. Pseudoseptic arthritis after accidental intra-articular deposition of the pneumococcal polyvalent vaccine: a case report. *American Journal of Emergency Medicine*. 2007 Sep;25(7):864.e1-3. PMID: 17870515.

944. McCormack PL, Joura EA. Spotlight on quadrivalent human papillomavirus(Types 6, 11, 16, 18) recombinant vaccine(Gardasil(registered trademark)) in the prevention of premalignant-genital lesions, genital cancer, and genital warts in women. *Biodrugs*. 2011;25(5):339-43. PMID: 2011535901 MEDLINE PMID 21942919 (<http://www.ncbi.nlm.nih.gov/pubmed/21942919>).
945. McCue JD. Adverse reactions to simultaneous influenza and pneumococcal vaccination. *Journal of Family Practice*. 1981 Aug;13(2):175-7. PMID: 7252446.
946. McEvoy SP. A retrospective survey of the safety of trivalent influenza vaccine among adults working in healthcare settings in south metropolitan Perth, Western Australia, in 2010. *Vaccine*. 2012 Apr 5;30(17):2801-4. PMID: 21920401.
947. McGann M, O'Rourke DJ, Peake D, et al. Narcolepsy in close temporal relationship to H1N1 vaccination in Irish children. *Developmental Medicine and Child Neurology*. 2012 January;54 SUPPL.1:29.
948. McIntosh AM, McMahon J, Dibbens LM, et al. Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study. *Lancet Neurology*. 2010 Jun;9(6):592-8. PMID: 20447868.
949. McKenzie K. Italians ban Hib vaccine in BSE scare. *BMJ*. 1997 Feb 8;314(7078):397. PMID: 9040380.
950. McKittrick N, Frank I, Jacobson JM, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. *Annals of Internal Medicine*. 2013 Jan 1;158(1):19-26. PMID: 23277897.
951. McMahon AW, Iskander J, Haber P, et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: Analysis of reports from the Vaccine Adverse Event Reporting System, 1990-2003. *Pediatrics*. 2005 Feb;115(2):453-60. PMID: WOS:000226725000045.
952. McNeil MM, Arana J, Stewart B, et al. A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination—possible stimulated reporting? *Vaccine*. 2012 Mar 23;30(14):2421-6. PMID: 22310205.
953. McNicholas N, Chataway J. Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. *Journal of Neurology*. 2011 Aug;258(8):1545-7. PMID: 21336784.
954. McVernon J, Nolan T, Richmond P, et al. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers. *Pediatric Infectious Disease Journal*. 2012 Jan;31(1):e15-23. PMID: 22094636.

955. Medeiros RH, Figueiredo AEP, Poli-de-Figueiredo CE, et al. Low response to intradermal hepatitis B vaccination in incident hemodialysis patients. *Jornal Brasileiro de Nefrologia*. 2011 Mar;33(1):45-9. PMID: 21541462.
956. Medina DMR, Valencia A, de Velasquez A, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. *Journal of Adolescent Health*. 2010 May;46(5):414-21. PMID: 20413076.
957. Meier S, Bel M, L'Huillier A, et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. *Vaccine*. 2011 Apr 27;29(19):3548-57. PMID: 21419775.
958. Meisel R, Kuypers L, Dirksen U, et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. *Blood*. 2007 Mar 15;109(6):2322-6. PMID: 17090650.
959. Meloni A, Locci D, Frau G, et al. Epidemiology and prevention of rotavirus infection: An underestimated issue? *Journal of Maternal-Fetal and Neonatal Medicine*. 2011 October;24(SUPPL. 2):49-52. PMID: 2011550735.
960. Melton L. Lifesaving vaccine caught in an ethical minefield. *Lancet*. 2000 Jul 22;356(9226):318. PMID: 11071196.
961. Memish ZA, Dbaibo G, Montellano M, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. *Pediatric Infectious Disease Journal*. 2011 Apr;30(4):e56-62. PMID: 21278617.
962. Mendelman PM, Feeley L, Bird S, et al. Immunogenicity and safety of *Haemophilus influenzae* type b polysaccharide-*Neisseria meningitidis* conjugate vaccine in 7.5 micrograms liquid formulation: a comparison of three lots with the 15.0 micrograms lyophilized formulation. Study Group for 7.5 micrograms Liquid PedvaxHIB. *Vaccine*. 1997 Apr-May;15(6-7):775-81. PMID: 9178481.
963. Menge T, Cree B, Saleh A, et al. Neuromyelitis optica following human papillomavirus vaccination. *Neurology*. 2012 Jul 17;79(3):285-7. PMID: 22722628.
964. Menge T, Cree B, Saleh A, et al. Neuromyelitis optica following human papillomavirus vaccination. *Neurology*. 2012 Jul 17;79(3):285-7. PMID: 22722628.
965. Menzies R, Mahajan D, Gold MS, et al. Annual report: surveillance of adverse events following immunisation in Australia, 2008. *Communicable Diseases Intelligence*. 2009 Dec;33(4):365-81. PMID: 20301966.
966. Meriste S, Jacquet J-M, Willems P, et al. Immunologic response to Hib tetanus toxoid conjugated vaccine coadministered with DTPa either mixed or in two separate injections in

toddlers not primed with Hib vaccine. *Human Vaccines*. 2008 Jan-Feb;4(1):31-5. PMID: 18438103.

967. Meriste S, Lutsar I, Tamm E, et al. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine. *Scandinavian Journal of Infectious Diseases*. 2006;38(5):350-6. PMID: 16709537.

968. Meriste S, Tamm E, Willems P, et al. Safety and immunogenicity of combined Dtpa-IPV vaccine for primary and booster vaccination. *Scandinavian Journal of Infectious Diseases*. 1999;31(6):587-91. PMID: 10680990.

969. Mertsola J, Van Der Meeren O, He Q, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. *Clinical Infectious Diseases*. 2010 Sep 15;51(6):656-62. PMID: 20704493.

970. Metanat M, Salehi M, Sharifi-Mood B, et al. Serum antibody responses after intradermal injection of influenza vaccine. *International Journal of Virology*. 2010 2010;6(1):41-4. PMID: 2012053021.

971. Micheletti F, Moretti U, Tridente G, et al. Consultancy and surveillance of post-immunisation adverse events in the Veneto region of Italy for 1992-2008. *Human Vaccines*. 2011 January-February;7(SUPPL.):234-9. PMID: 2012028306.

972. Miernyk KM, Butler JC, Bulkow LR, et al. Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Alaska Native Adults 55-70 Years of Age. *Clinical Infectious Diseases*. 2009 Jul;49(2):241-8. PMID: WOS:000267226900013.

973. Miles Braun M, Patriarca PA, Ellenberg SS. Syncope after immunization. *Archives of Pediatrics and Adolescent Medicine*. 1997 1997;151(3):255-9. PMID: 1997093276 MEDLINE PMID 9080932 (<http://www.ncbi.nlm.nih.gov/pubmed/9080932>).

974. Miller E. Overview of recent clinical trials of acellular pertussis vaccines. *Biologics*. 1999 Jun;27(2):79-86. PMID: 10600188.

975. Miller E, Andrews N, Waight P, et al. Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age. *Clinical & Vaccine Immunology: CVI*. 2011 Mar;18(3):367-72. PMID: 21191076.

976. Miller E, Batten B, Hampton L, et al. Tracking vaccine-safety inquiries to detect signals and monitor public concerns. *Pediatrics*. 2011 May;127(SUPPL. 1):S87-S91. PMID: 2011239122 MEDLINE PMID 21502241 (<http://www.ncbi.nlm.nih.gov/pubmed/21502241>).

977. Miller E, Waight P, Laurichesse H, et al. Immunogenicity and reactogenicity of acellular diphtheria/tetanus/pertussis vaccines given as a pre-school booster: effect of simultaneous administration of MMR. *Vaccine*. 2001 Jul 16;19(28-29):3904-11. PMID: 11427264.
978. Miller FD, Nakagom T, Murphy TV, et al. Intussusception and an oral rotavirus vaccine [1]. *New England Journal of Medicine*. 2001 14;344(24):1866-7. PMID: 2001213494.
979. Miller MA, Meschievitz CK, Ballanco GA, et al. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period. *Pediatrics*. 1995 Apr;95(4):522-7. PMID: 7700752.
980. Mills E, Gold R, Thipphawong J, et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus B conjugate vaccine administered to infants at two, four and six months of age. *Vaccine*. 1998 Apr;16(6):576-85. PMID: 9569468.
981. Milstien JB, Gross TP, Kuritsky JN. Adverse reactions reported following receipt of Haemophilus influenzae type b vaccine: an analysis after 1 year of marketing. *Pediatrics*. 1987 Aug;80(2):270-4. PMID: 3497381.
982. Minervini G, McC Carson BJ, Reisinger KS, et al. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates. *Vaccine*. 2012 Feb;30(8):1476-80. PMID: WOS:000301401000009.
983. Miraglia JL, Abdala E, Hoff PM, et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. *PLoS ONE [Electronic Resource]*. 2011;6(11):e27214. PMID: 22087267.
984. Miranzi SDC, de Moraes SA, de Freitas ICM. Impact of the Haemophilus influenzae type b vaccination program on HIB meningitis in Brazil. *Cadernos de Saude Publica*. 2007 Jul;23(7):1689-95. PMID: WOS:000253805900021.
985. Miriam Pina L, Bassily E, Machmer A, et al. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria-toxoid-conjugate vaccine in infants and toddlers: Three multicenter Phase III studies. *Pediatric Infectious Disease Journal*. 2012;18.
986. Mizuno Y, Kano S, Urashima M, et al. Simultaneous vaccination in Japanese travelers. *Travel Medicine & Infectious Disease*. 2007 Mar;5(2):85-9. PMID: 17298913.
987. Mofleh JA, Akbarian Z, Muserat N, et al. Study of adverse events of A/H1N1 vaccine among health care staff in selected provinces of Afghanistan, 2010. *Eastern Mediterranean Health Journal*. 2012 Sep;18(9):946-50. PMID: 23057387.

988. Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. *New England Journal of Medicine*. 2010;24;362(25):2351-9. PMID: 2010355698 MEDLINE PMID 20573923 (<http://www.ncbi.nlm.nih.gov/pubmed/20573923>).
989. Mohty B, Bel M, Vukicevic M, et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. *Haematologica*. 2011 June;96(6):896-904. PMID: 2011310637 MEDLINE PMID 21422117 (<http://www.ncbi.nlm.nih.gov/pubmed/21422117>).
990. Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: A case-control study. *Annals of the Rheumatic Diseases*. 2012;15.
991. Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. *Annals of the Rheumatic Diseases*. 2013 May;72(5):659-64. PMID: 22589375.
992. Mollah AH, Naher N, Rahman S, et al. Antibody titre against 3 doses of hepatitis B vaccine among preterm and term babies. *Mymensingh Medical Journal: MMJ*. 2012 Jan;21(1):109-13. PMID: 22314464.
993. Moore D, Nelson M, Henderson D. Pneumococcal vaccination and HIV infection. *International Journal of Std & Aids*. 1998 Jan;9(1):1-7. PMID: 9518008.
994. Moore DL, Le Saux N, Scheifele D, et al. Lack of evidence of encephalopathy related to pertussis vaccine: Active surveillance by IMPACT, Canada, 1993-2002. *Pediatric Infectious Disease Journal*. 2004 June;23(6):568-71. PMID: 2004266443 MEDLINE PMID 15194842 (<http://www.ncbi.nlm.nih.gov/pubmed/15194842>).
995. Moraes JCd, Luna EJdA, Grimaldi RA. Immunogenicity of the Brazilian hepatitis B vaccine in adults. *Revista de Saude Publica*. 2010 Apr;44(2):353-9. PMID: 20339636.
996. Morales-Olivas FJ, Martinez-Mir I, Ferrer JM, et al. Adverse drug reactions in children reported by means of the yellow card in Spain. *Journal of Clinical Epidemiology*. 2000 October;53(10):1076-80. PMID: 2000355228 MEDLINE PMID 11027942 (<http://www.ncbi.nlm.nih.gov/pubmed/11027942>).
997. Morelon E, Pouteil Noble C, Daoud S, et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. *Vaccine*. 2010 Oct 4;28(42):6885-90. PMID: 20709000.
998. Morgan R, King D. Influenza vaccination in the elderly. *Postgraduate Medical Journal*. 1996 Jun;72(848):339-42. PMID: 8758010.
999. Morley SL, Pollard AJ. Vaccine prevention of meningococcal disease, coming soon? *Vaccine*. 2001 Dec 12;20(5-6):666-87. PMID: 11738731.

1000. Moro PL, Arana J, Cano M, et al. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010. *Clinical Infectious Diseases*. 2012 Jun;54(11):1608-14. PMID: 22441652.
1001. Moro PL, Broder K, Zheteyeva Y, et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. *American Journal of Obstetrics & Gynecology*. 2011 Nov;205(5):473.e1-9. PMID: 21861964.
1002. Moro PL, Broder K, Zheteyeva Y, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. *American Journal of Obstetrics & Gynecology*. 2011 Feb;204(2):146.e1-7. PMID: 20965490.
1003. Moro PL, Yue X, Lewis P, et al. Adverse events after Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010. *Vaccine*. 2011 21;29(50):9404-8. PMID: 2011622893 MEDLINE PMID 21920404 (<http://www.ncbi.nlm.nih.gov/pubmed/21920404>).
1004. Morris AMS, Elliott EJ, D'Souza RM, et al. Acute flaccid paralysis in Australian children. *Journal of Paediatrics & Child Health*. 2003 Jan-Feb;39(1):22-6. PMID: 12542807.
1005. Moulis G, Pugnet G, Bagheri H, et al. Acquired factor VIII haemophilia following influenza vaccination. *European Journal of Clinical Pharmacology*. 2010 October;66(10):1069-70. PMID: 2010556771 MEDLINE PMID 20582585 (<http://www.ncbi.nlm.nih.gov/pubmed/20582585>).
1006. Mulholland EK, Ahonkhai VI, Greenwood AM, et al. Safety and immunogenicity of Haemophilus influenzae type B-Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants. *Pediatric Infectious Disease Journal*. 1993 Aug;12(8):632-7. PMID: 8414774.
1007. Munch JS, Johnsen BH, Birkeland I, et al. A study of side-effects of Pandemrix[REGISTERED] influenza (H1N1) vaccine on board a Norwegian naval vessel. *International Maritime Health*. 2010;62(4):246-50. PMID: 21348019.
1008. Munoz FM, Englund JA. A step ahead. Infant protection through maternal immunization. *Pediatric Clinics of North America*. 2000 Apr;47(2):449-63. PMID: 10761514.
1009. Munoz FM, Englund JA, Cheesman CC, et al. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. *Vaccine*. 2001 Dec 12;20(5-6):826-37. PMID: 11738746.

1010. Murphy TV, Gargiullo PM, Livengood JR. Intussusception and an oral rotavirus vaccine - Reply. *New England Journal of Medicine*. 2001 Jun;344(24):1866-7. PMID: WOS:000169231000014.
1011. Murphy TV, Gargiullo PM, Wharton M. More on rotavirus vaccination and intussusception. *New England Journal of Medicine*. 2002 Jan 17;346(3):211-2. PMID: 11796862.
1012. Murray DK. Men who have sex with men ... And hepatitis B immunisation. *Bmj*. (2010) 340(7751):825. PMID: 2010231396.
1013. Mushner DM, Manoff SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. *Journal of Infectious Diseases*. 2010 Feb 15;201(4):516-24. PMID: 20092407.
1014. Mushner DM, Manoff SB, McFetridge RD, et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. *Human Vaccines*. 2011 Sep;7(9):919-28. PMID: WOS:000295837200014.
1015. Nahar K, Jahan M, Nessa A, et al. Antibody responses after hepatitis B vaccination among maintenance haemodialysis patients. *Bangladesh Medical Research Council Bulletin*. 2011 2011;37(3):88-91. PMID: 2011681273 MEDLINE PMID 22352227 (<http://www.ncbi.nlm.nih.gov/pubmed/22352227>).
1016. Nailescu C, Xu X, Zhou H, et al. Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study. *Pediatric Nephrology*. 2011 Mar;26(3):459-67. PMID: 21181206.
1017. Nakada H, Narimatsu H, Tsubokura M, et al. Risk of fatal adverse events after H1N1 influenza vaccination. *Clinical Infectious Diseases*. 2010 Jun 1;50(11):1548-9. PMID: 20433361.
1018. Nakagomi O, Cunliffe NA. Rotavirus vaccines: entering a new stage of deployment. *Current Opinion in Infectious Diseases*. 2007 Oct;20(5):501-7. PMID: 17762784.
1019. Nakagomi T. Intussusception and an oral rotavirus vaccine. *New England Journal of Medicine*. 2001 Jun 14;344(24):1866; author reply -7. PMID: 11407353.
1020. Nakano T. Japanese vaccinations and practices, with particular attention to polio and pertussis. *Travel Medicine & Infectious Disease*. 2011 Jul;9(4):169-75. PMID: 21995861.
1021. Narayan A, Ganesan S, Shenoy UV, et al. Provocative poliomyelitis causing postpolio residual paralysis among select communities of two remote villages of North Karnataka in India: a community survey. *Indian Journal of Public Health*. 2011 Oct-Dec;55(4):309-12. PMID: 22298141.

1022. Nascimento Silva JR, Camacho LAB, Siqueira MM, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. *Vaccine*. 2011 Aug 26;29(37):6327-34. PMID: 21640779.
1023. Neuzil KM, Dupont WD, Wright PF, et al. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. *Pediatr Infect Dis J*. 2001 Aug;20(8):733-40. PMID: 11734733.
1024. Nicholson KG, Abrams KR, Batham S, et al. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart. *Health Technology Assessment* (Winchester, England). 2010 Dec;14(55):193-334. PMID: 21208550.
1025. Nicholson KG, Abrams KR, Batham S, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. *The Lancet Infectious Diseases*. 2011 Feb;11(2):91-101. PMID: 21168369.
1026. Nicol M, Huebner R, Mothupi R, et al. Haemophilus influenzae type b conjugate vaccine diluted tenfold in diphtheria-tetanus-whole cell pertussis vaccine: a randomized trial. *Pediatric Infectious Disease Journal*. 2002 Feb;21(2):138-41. PMID: 11840081.
1027. Niederman LG, Marcinak JF. Haemophilus influenzae type b abscess after diphtheria-tetanus toxoids-pertussis immunization. *Pediatric Infectious Disease Journal*. 1990 1990;9(8):597-8. PMID: 1990266376 MEDLINE PMID 2235180 (<http://www.ncbi.nlm.nih.gov/pubmed/2235180>).
1028. Nilsson L, Faldella G, Jacquet JM, et al. A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age. *Scandinavian Journal of Infectious Diseases*. 2005 2005;37(3):221-9. PMID: 2005126138 MEDLINE PMID 15849057 (<http://www.ncbi.nlm.nih.gov/pubmed/15849057>).
1029. Nilsson L, Kjellman NI, Bjorksten B. Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. *Arch Pediatr Adolesc Med*. 2003 Dec;157(12):1184-9. PMID: 14662571.
1030. Nishi J, Tokuda K, Imuta N, et al. Prospective Safety Monitoring of Haemophilus influenzae Type b and Heptavalent Pneumococcal Conjugate Vaccines in Kagoshima, Japan. *Japanese Journal of Infectious Diseases*. 2013;66(3):235-7. PMID: 23698486.
1031. Nolan T, Hogg G, Darcy MA, et al. A combined liquid Hib (PRP-OMP), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: uncontrolled preliminary clinical trial of immunogenicity and reactogenicity. *Vaccine*. 1998 Dec;16(20):2085-9. PMID: 9796068.

1032. Nolan T, Hogg G, Darcy MA, et al. A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: Controlled studies of immunogenicity and reactogenicity. *Vaccine*. 2001;28(15-16):2127-37. PMID: 2001081956 MEDLINE PMID 11228385 (<http://www.ncbi.nlm.nih.gov/pubmed/11228385>).
1033. Nolan T, Hogg G, Darcy MA, et al. Primary course immunogenicity and reactogenicity of a new diphtheria-tetanus whole cell pertussis vaccine (DTPw). *Journal of Paediatrics and Child Health*. 1997 Oct;33(5):413-7. PMID: WOS:A1997YE21800011.
1034. Nolan T, Lambert S, Roberton D, et al. DTPa-HBV-IPV vaccine for primary vaccination of infants. *Journal of Paediatrics & Child Health*. 2007 Sep;43(9):587-92. PMID: 17688642.
1035. Nolan T, Lambert S, Roberton D, et al. A novel combined *Haemophilus influenzae* type b-*Neisseria meningitidis* serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. *Vaccine*. 2007 Dec;25(51):8487-99. PMID: 17996996.
1036. Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. *JAMA*. 2010 Jan 6;303(1):37-46. PMID: 20026597.
1037. Nolan T, Richmond P, Marshall H, et al. Immunogenicity and safety of an investigational combined *haemophilus influenzae* type B-*Neisseria meningitidis* serogroups C and Y-tetanus toxoid conjugate vaccine. *Pediatric Infectious Disease Journal*. 2011 Mar;30(3):190-6. PMID: 20948453.
1038. Nolan T, Richmond PC, McVernon J, et al. Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. *Influenza Other Respi Viruses*. 2009 Nov;3(6):315-25. PMID: 19903213.
1039. Nurkka A, Joensuu J, Henckaerts I, et al. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. *Pediatric Infectious Disease Journal*. 2004 Nov;23(11):1008-14. PMID: 15545855.
1040. Obaro SK, Adegbola RA, Chang I, et al. Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. *Pediatric Infectious Disease Journal*. 2000 May;19(5):463-9. PMID: 10819345.
1041. Obert J, Burgel PR. Pneumococcal infections: association with asthma and COPD. *Medecine et Maladies Infectieuses*. 2012 May;42(5):188-92. PMID: 22444165.
1042. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. *Lancet*. 2003 Aug 2;362(9381):355-61. PMID: 12907008.

1043. O'Brien KL, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. *Pediatrics*. 2000 Nov;106(5):965-72. PMID: 11061761.

1044. Occhionero M, Usai G, Di Martino M, et al. Serum antibodies to capsular polysaccharide vaccine of group A and C Neisseria meningitidis in military recruits in Italy. *Allergologia et Immunopathologia*. 1991 Jan-Feb;19(1):39-41. PMID: 1950941.

1045. Offit PA. The future of rotavirus vaccines. *Seminars in Pediatric Infectious Diseases*. 2002 Jul;13(3):190-5. PMID: 12199615.

1046. Offit PA. Rotavirus vaccines: round two. *Human Vaccines*. 2006 Mar-Apr;2(2):84-5. PMID: 17012884.

1047. Offit PA. Thimerosal and vaccines - A cautionary tale. *New England Journal of Medicine*. 2007 27;357(13):1278-9. PMID: 2007472994 MEDLINE PMID 17898096 (<http://www.ncbi.nlm.nih.gov/pubmed/17898096>).

1048. Offit PA, Clark HF. RotaTeq: a pentavalent bovine--human reassortant rotavirus vaccine. *Pediatric Annals*. 2006 Jan;35(1):29-34. PMID: 16466073.

1049. Ogimi C, Tanaka R, Saitoh A, et al. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. *Pediatric Infectious Disease Journal*. 2011 Mar;30(3):208-11. PMID: 20861757.

1050. Oh C-E, Lee J, Kang J-H, et al. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. *Vaccine*. 2010 Aug 16;28(36):5857-63. PMID: 20600483.

1051. Okada K, Komiya T, Yamamoto A, et al. Safe and effective booster immunization using DTaP in teenagers. *Vaccine*. 2010 Nov 10;28(48):7626-33. PMID: 20883738.

1052. Okada K, Miyazaki C, Kino Y, et al. Phase II and III Clinical Studies of Diphtheria-Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-sIPV). *Journal of Infectious Diseases*. 2013 Jul;208(2):275-83. PMID: 23568174.

1053. Okais C, Gay C, Seon F, et al. Disease-specific adverse events following nonlive vaccines: a paradoxical placebo effect or a nocebo phenomenon? *Vaccine*. 2011 Aug 26;29(37):6321-6. PMID: 21627976.

1054. Okike IO, Yung C, Ladhani S, et al. The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. *Vaccine*. 2011 Sep 2;29(38):6636-40. PMID: 21742005.

1055. Okuda B, Uetani E, Okamoto K. Vaccine-associated paralytic poliomyelitis caused by contact infection. *Internal Medicine*. 2006;45(6):373-5. PMID: 16617188.

1056. Olin P, Rasmussen F, Gottfarb P. Schedules and protection, simultaneous vaccination and safety: Experiences from recent controlled trials. *International Journal of Infectious Diseases.* 1997 Jan;1(3):143-7. PMID: 1997112644.
1057. Olivier C, Belohradsky BH, Stojanov S, et al. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. *Vaccine.* 2008 Jun 13;26(25):3142-52. PMID: 18502545.
1058. Omenaca F, Aristegui J, Tejedor JC, et al. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines. *Pediatric Infectious Disease Journal.* 2011 Nov;30(11):e216-24. PMID: 21747321.
1059. Omenaca F, Dal-Re R, D'Apuzzo V, et al. Reactogenicity of DTPa-HBV/Hib vaccine administered as a single injection vs DTPa-HBV and Hib vaccines administered simultaneously at separate sites, to infants at 2, 4 and 6 months of age. *Vaccine.* 2001 Jul 20;19(30):4260-6. PMID: 11457553.
1060. Omenaca F, Garcia-Sicilia J, Boceta R, et al. Hepatitis B response of premature infants after primary and booster immunisation with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/haemophilus influenzae type B vaccine. *Infectious Diseases in Obstetrics & Gynecology.* 2010;2010:802503. PMID: 20396673.
1061. Omenaca F, Merino JM, Tejedor J-C, et al. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. *Pediatrics.* 2011 Aug;128(2):e290-8. PMID: 21727108.
1062. Omon E, Damase-Michel C, Hurault-Delarue C, et al. Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: the results of a French prospective descriptive study. *Vaccine.* 2011 Dec 6;29(52):9649-54. PMID: 22036887.
1063. Ortalda V, Tomei P, Yabarek T, et al. Immunogenicity and seroconversion after hepatitis B vaccination in haemodialysis patients: Results of two different vaccination schedules. *Nephrology Dialysis Transplantation.* 2012 May;27 SUPPL. 2:ii513-ii4.
1064. Ortiz Arjona MA, Abd Elaziz KM, Caballero Lanzas JM, et al. Coverage and side effects of influenza A(H1N1) 2009 monovalent vaccine among primary health care workers. *Vaccine.* 2011 Aug 26;29(37):6366-8. PMID: 21840463.
1065. O'Ryan M. Reply. *Gastroenterology.* 2006 Oct;131(4):1354-5. PMID: 2006486492.
1066. O'Ryan M. Reply. *Journal of Pediatrics.* 2007 May;150(5):e87. PMID: 2007188626.
1067. O'Ryan M, Lucero Y, Linhares AC. Rotarix[REGISTERED]: vaccine performance 6 years postlicensure. *Expert Review of Vaccines.* 2011 Dec;10(12):1645-59. PMID: 22085167.

1068. O'Ryan ML, Matson DO. A quadrivalent rotavirus vaccine. *New England Journal of Medicine*. 1998 Feb;338(9):620-1. PMID: WOS:000072175700015.
1069. Ostergaard L, Silfverdal S-A, Berglund J, et al. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix([REGISTERED]) in subjects aged 11-17 years: an open, randomised, controlled trial. *Vaccine*. 2012 Jan 17;30(4):774-83. PMID: 22107850.
1070. Ota MO, Akinsola A, Townend J, et al. The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. *Vaccine*. 2011 05;29(16):2999-3007. PMID: 2011178040 MEDLINE PMID 21320549 (<http://www.ncbi.nlm.nih.gov/pubmed/21320549>).
1071. Ottaviani G, Lavezzi AM, Matturri L. Sudden infant death syndrome (SIDS) shortly after hexavalent vaccination: another pathology in suspected SIDS? *Virchows Archiv*. 2006 Jan;448(1):100-4. PMID: 16231176.
1072. Overton ET, Kang M, Peters MG, et al. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. *Vaccine*. 2010 Aug;28(34):5597-604. PMID: WOS:000280952300011.
1073. Ozdemir O, Yazgan H, Demirdoven M, et al. Rotavirus infection rate after two types of rotavirus vaccination observed in a private research/training hospital in anatolian part of Istanbul, Turkey. *Journal of Allergy and Clinical Immunology*. 2010 February;125(2 SUPPL. 1):AB78.
1074. Pace D, Snape M, Westcar S, et al. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. *Pediatric Infectious Disease Journal*. 2007 Nov;26(11):1057-9. PMID: 17984816.
1075. Pace D, Snape M, Westcar S, et al. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: A phase 3 open randomised controlled trial. *Archives of Disease in Childhood*. 2008 November;93(11):963-70. PMID: 2008518496 MEDLINE PMID 18463125 (<http://www.ncbi.nlm.nih.gov/pubmed/18463125>).
1076. Pahud BA, Williams SE, Dekker CL, et al. Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination. *Pediatric Infectious Disease Journal*. 2013 Feb;32(2):163-8. PMID: 23334340.
1077. Palache AM, Scheepers HS, de Regt V, et al. Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. *Dev Biol Stand*. 1999;98:115-25; discussion 33-4. PMID: 10494964.

1078. Palma P, Romiti ML, Bernardi S, et al. Safety and immunogenicity of a monovalent MF59[REGISTERED]-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. *Biologics*. 2012 Mar;40(2):134-9. PMID: 22261282.
1079. Palma P, Romiti ML, Bernardi S, et al. Safety and immunogenicity of a monovalent MF59-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. *Biologics*. 2012 Mar;40(2):134-9. PMID: 22261282.
1080. Palumbo A, Davies F, Kropff M, et al. Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. *Annals of Hematology*. 2010 August;89(8):803-11. PMID: 2010519458 MEDLINE PMID 20232066 (<http://www.ncbi.nlm.nih.gov/pubmed/20232066>).
1081. Paradiso PR. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. *Clinical Infectious Diseases*. 2011 May;52(10):1241-7. PMID: 21507921.
1082. Park SJ, Shin JI. Henoch-Schonlein purpura after hepatitis a vaccination: The role of interleukin 10? *Annals of Allergy, Asthma and Immunology*. 2011 December;107(6):550. PMID: 211673242 MEDLINE PMID 22123392 (<http://www.ncbi.nlm.nih.gov/pubmed/22123392>).
1083. Park S-W, Lee J-H, Kim ES, et al. Adverse events associated with the 2009 H1N1 influenza vaccination and the vaccination coverage rate in health care workers. *American Journal of Infection Control*. 2011 Feb;39(1):69-71. PMID: 21122948.
1084. Parke JC, Jr., Schneerson R, Reimer C, et al. Clinical and immunologic responses to *Haemophilus influenzae* type b-tetanus toxoid conjugate vaccine in infants injected at 3, 5, 7, and 18 months of age. *Journal of Pediatrics*. 1991 Feb;118(2):184-90. PMID: 1993943.
1085. Parretta E, Ianniello B, Ferrazin F, et al. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. *Vaccine*. 2011 May 9;29(20):3708-13. PMID: 21406267.
1086. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. *PLoS ONE [Electronic Resource]*. 2012;7(3) PMID: 2012183679.
1087. Partridge S, Alvey J, Bernstein H, et al. Safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated polio vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a *Haemophilus influenzae* type b conjugate vaccine. *Vaccine*. 2007 Feb 26;25(10):1806-13. PMID: 17240493.
1088. Partridge S, Yeh SH. Clinical evaluation of a DTaP-HepB-IPV combined vaccine. *American Journal of Managed Care*. 2003 Jan;9(1 Suppl):S13-22. PMID: 12564785.

1089. Parvaneh N, Shahmohoudi S, Tabatabai H, et al. Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency. *Journal of Clinical Virology*. 2007 Jun;39(2):145-8. PMID: 17509935.
1090. Patel MK, Patel TK, Tripathi CB. Diphtheria, pertussis (whooping cough), and tetanus vaccine induced recurrent seizures and acute encephalopathy in a pediatric patient: Possibly due to pertussis fraction. *Journal of Pharmacology & Pharmacotherapeutics*. 2012 Jan;3(1):71-3. PMID: 22368426.
1091. Patel MM. Intussusception Risk of Rotavirus Vaccination REPLY. *New England Journal of Medicine*. 2011 Dec;365(22):2138-. PMID: WOS:000297499000019.
1092. Patel MM, Clark AD, Glass RI, et al. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception. *Vaccine*. 2009 May 14;27(22):2916-22. PMID: 19428901.
1093. Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. *New England Journal of Medicine*. 2010 Jan 28;362(4):314-9. PMID: 20107217.
1094. Patel NC, Palmer WC, Krishna M, et al. Lack of an association between autoimmune pancreatitis and Varicella Zoster Virus. *Jop: Journal of the Pancreas [Electronic Resource]*. 2011 Nov;12(6):614-5. PMID: 22072254.
1095. Patel SR, Ortin M. Varicella-zoster reactivation in a patient receiving routine revaccinations after an allogeneic hemopoietic progenitors transplant. *Journal of Pediatric Hematology/Oncology*. 2005 February;27(2):106-8. PMID: 2005089603 MEDLINE PMID 15701988 (<http://www.ncbi.nlm.nih.gov/pubmed/15701988>).
1096. Patja A, Davidkin I, Kurki T, et al. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. *Pediatr Infect Dis J*. 2000 Dec;19(12):1127-34. PMID: 11144371.
1097. Payne DC, Edwards KM, Bowen MD, et al. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. *Pediatrics*. 2010 February;125(2):e438-e41. PMID: 2010090890 MEDLINE PMID 20100758 (<http://www.ncbi.nlm.nih.gov/pubmed/20100758>).
1098. Pedersen C, Breindahl M, Aggarwal N, et al. Randomized trial: Immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. *Journal of Adolescent Health*. 2012 January;50(1):38-46. PMID: 2011700983 MEDLINE PMID 22188832 (<http://www.ncbi.nlm.nih.gov/pubmed/22188832>).

1099. Pedersen C, Breindahl M, Aggarwal N, et al. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. *Journal of Adolescent Health*. 2012 Jan;50(1):38-46. PMID: 22188832.
1100. Pedersen C, Breindahl M, Aggarwal N, et al. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. *Journal of Adolescent Health*. 2012 Jan;50(1):38-46. PMID: 22188832.
1101. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. *J Adolesc Health*. 2007 Jun;40(6):564-71. PMID: 17531764.
1102. Peltola H, Kayhty H, Kuronen T, et al. Meningococcus group A vaccine in children three months to five years of age. Adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide. *Journal of Pediatrics*. 1978 May;92(5):818-22. PMID: 417160.
1103. Peltola H, Makela PH, Elo O, et al. Vaccination against meningococcal group A disease in Finland 1974-75. *Scandinavian Journal of Infectious Diseases*. 1976;8(3):169-74. PMID: 788143.
1104. Peng LA, Liu J, Gao ZL, et al. Inoculation effects of recombinant yeast hepatitis B vaccine used in neonates. *Scientific Research and Essays*. 2011 Feb;6(3):658-62. PMID: WOS:000287940700020.
1105. Perez Schael I, O'Ryan M, Saez-Llorens X, et al. Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience. *Trials in Vaccinology*. 2012;2012:1:10-20.
1106. Perrett KP, Snape MD, Ford KJ, et al. Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants. *Pediatric Infectious Disease Journal*. 2009 Mar;28(3):186-93. PMID: WOS:000264007500005.
1107. Perucchini E, Consonni S, Sandrini MC, et al. Adverse reactions to influenza vaccine alone or with pneumococcal vaccine in the elderly. *Journal of the American Geriatrics Society*. 2004 Jul;52(7):1219-20. PMID: 15209671.
1108. Petousis-Harris H, Poole T, Turner N, et al. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: The importance of routine active safety surveillance. *Vaccine*. 2012 Jul 13;30(33):4945-52. PMID: 22664224.
1109. Petridou E, Kouri N, Vadala H, et al. Frequency and nature of recorded childhood immunization-related errors in Greece. *Journal of Toxicology - Clinical Toxicology*. 2004

2004;42(3):273-6. PMID: 2004377531 MEDLINE PMID 15362594
(<http://www.ncbi.nlm.nih.gov/pubmed/15362594>).

1110. Phongsamart W, Sirisanthana V, Wittawatmongkol O, et al. Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children. *Vaccine*. 2011 Nov 3;29(47):8705-11. PMID: 21893147.

1111. Phua KB, Emmanuel SC, Goh P, et al. A rotavirus vaccine for infants: The Asian experience. *Annals of the Academy of Medicine Singapore*. 2006 January;35(1):38-44. PMID: 2006178228 MEDLINE PMID 16470273 (<http://www.ncbi.nlm.nih.gov/pubmed/16470273>).

1112. Phua KB, Quak SH, Lim FS, et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and *Haemophilus influenzae* type b vaccine in a placebo-controlled rotavirus vaccine study. *Annals of the Academy of Medicine, Singapore*. 2008 Jul;37(7):546-53. PMID: 18695765.

1113. Pichichero M, Papa T, Blatter M, et al. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine. *Pediatric Infectious Disease Journal*. 2006 Nov;25(11):995-1000. PMID: 17072120.

1114. Pichichero ME. Meningococcal conjugate vaccines. *Expert Opinion on Biological Therapy*. 2005 November;5(11):1475-89. PMID: 2005503770 MEDLINE PMID 16255651 (<http://www.ncbi.nlm.nih.gov/pubmed/16255651>).

1115. Pichichero ME, Bernstein H, Blatter MM, et al. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a *Haemophilus influenzae* type b conjugate vaccine. *Journal of Pediatrics*. 2007 Jul;151(1):43-9, 9.e1-2. PMID: 17586189.

1116. Pichichero ME, Blatter MM, Reisinger KS, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-*Haemophilus influenzae* type b combination vaccination. *Pediatric Infectious Disease Journal*. 2002 Sep;21(9):854-9. PMID: 12352809.

1117. Pichichero ME, Green JL, Francis AB, et al. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine. *Scandinavian Journal of Infectious Diseases*. 1996 1996;28(2):159-63. PMID: 1996175519 MEDLINE PMID 8792483 (<http://www.ncbi.nlm.nih.gov/pubmed/8792483>).

1118. Pichichero ME, Latiolais T, Bernstein DI, et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of *Haemophilus influenzae* type b-tetanus toxoid vaccine in two-, four- and six-month-old infants. *Pediatric Infectious Disease Journal*. 1997 Sep;16(9):863-70. PMID: 9306481.

1119. Pier GB. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 *Pseudomonas aeruginosa*. *Journal of Clinical Investigation*. 1982 Feb;69(2):303-8. PMID: 6799548.
1120. Pietrzyk JJ, Wysocki J, Pejcz J, et al. Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with *Haemophilus influenzae* type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age. *Vaccine*. 2008 Sep 26;26(41):5296-303. PMID: 18675870.
1121. Pileggi GS, de Souza CBS, Ferriani VPL. Safety and Immunogenicity of Varicella Vaccine in Patients With Juvenile Rheumatic Diseases Receiving Methotrexate and Corticosteroids. *Arthritis Care & Research*. 2010 Jul;62(7):1034-9. PMID: WOS:000280980000020.
1122. Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. *Clinical Microbiology Reviews*. 1998 January;11(1):1-26. PMID: 1998031623 MEDLINE PMID 9457426 (<http://www.ncbi.nlm.nih.gov/pubmed/9457426>).
1123. Plennevaux E, Blatter M, Cornish MJ, et al. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial. *Vaccine*. 2011 Feb 11;29(8):1569-75. PMID: 21219979.
1124. Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. *Lancet*. 2010 Jan 2;375(9708):41-8. PMID: 20018365.
1125. Pliaka V, Kyriakopoulou Z, Markoulatos P. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. *Expert Review of Vaccines*. 2012 May;11(5):609-28. PMID: 22827246.
1126. Plichta AM. Immunization: protecting older patients from infectious disease. *Geriatrics*. 1996 Sep;51(9):47-52; quiz 3. PMID: 8814114.
1127. Plosker GL. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe. *Drugs*. 2010 Jun 18;70(9):1165-88. PMID: 20518582.
1128. Pomat WS, van den Biggelaar AH, Phuanukoonnon S, et al. Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial. *PLoS ONE [Electronic Resource]*. 2013;8(2):e56698. PMID: 23451070.
1129. Ponka A, Leinonen M. Adverse reactions to polyvalent pneumococcal vaccine. *Scandinavian Journal of Infectious Diseases*. 1982;14(1):67-71. PMID: 7071529.
1130. Popejoy LA, Rivera AI, Gonzales-Torres I. Side-effects and immunogenicity of *Haemophilus influenzae* type B polysaccharide vaccine in a multi-ethnic pediatric population.

Military Medicine. 1989;154(1):25-9. PMID: 1989039243 MEDLINE PMID 2493601 (<http://www.ncbi.nlm.nih.gov/pubmed/2493601>).

1131. Potter RC, Gonik B. Prevention of influenza in mothers and infants. Expert Review of Vaccines. 2009 February;8(2):149-52. PMID: 2009075879.

1132. Poullin P, Gabriel B. Thrombocytopenic purpura after recombinant hepatitis B vaccine. Lancet. 1994 Nov 5;344(8932):1293. PMID: 7967998.

1133. Precioso AR, Miraglia JL, Campos LMA, et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. Vaccine. 2011 Nov 8;29(48):8974-81. PMID: 21945258.

1134. Prosser LA, Lavelle TA, Fiore AE, et al. Cost-effectiveness of 2009 Pandemic influenza A(H1N1) vaccination in the United States. PLoS ONE [Electronic Resource]. 2011;6(7) PMID: 2011417631.

1135. Prymula R, Chlibek R, Splino M, et al. Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable *Haemophilus influenzae*-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, *Haemophilus influenzae* type b and control hepatitis A vaccines. Vaccine. 2008 Aug 18;26(35):4563-70. PMID: 18602724.

1136. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both *Streptococcus pneumoniae* and non-typable *Haemophilus influenzae*: A randomised double-blind efficacy study. Lancet. 2006;367(9512):740-8. PMID: 2006106626 MEDLINE PMID 16517274 (<http://www.ncbi.nlm.nih.gov/pubmed/16517274>).

1137. Prymula R, Plisek S. Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines. Expert Opinion on Biological Therapy. 2008 April;8(4):503-13. PMID: 2008195122 MEDLINE PMID 18352853 (<http://www.ncbi.nlm.nih.gov/pubmed/18352853>).

1138. Prymula R, Schuerman L. 10-valent pneumococcal nontypeable *Haemophilus influenzae* PD conjugate vaccine: Synflorix. Expert Review of Vaccines. 2009 Nov;8(11):1479-500. PMID: 19863240.

1139. Prymula R, Siegrist C-A, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009 Oct 17;374(9698):1339-50. PMID: 19837254.

1140. Punjabi NH, Richie EL, Simanjuntak CH, et al. Immunogenicity and safety of four different doses of *Haemophilus influenzae* type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants. Vaccine. 2006 Mar 10;24(11):1776-85. PMID: 16303216.

1141. Qian L, Tseng HF, Sy LS, et al. Confounder adjustment in vaccine safety studies: comparing three offset terms for case-centered approach. *Vaccine*. 2013 Jan 2;31(2):431-5. PMID: 22871350.
1142. Quiambao B, Van der Meeren O, Kolhe D, et al. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers. *Human Vaccines & Immunotherapeutics*. 2012 Mar;8(3) PMID: WOS:000303057200018.
1143. Radzikowski A, Banaszkiewicz A, Lazowska-Przeorek I, et al. Immunogenecity of Hepatitis A Vaccine in Pediatric Patients with Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*. 2011 May;17(5):1117-24. PMID: WOS:000289367100008.
1144. Rahier JF, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. *Gut*. 2011 Apr;60(4):456-62. PMID: WOS:000288010600010.
1145. Rajantie J, Zeller B, Treutiger I, et al. Vaccination associated thrombocytopenic purpura in children. *Vaccine*. 2007 Feb 26;25(10):1838-40. PMID: 17126957.
1146. Ramkissoon A, Coovadia HM, Jugnundan P, et al. A new combined DTP-HBV-HIB vaccine - Strategy for incorporation of Hib vaccination into childhood immunisation programmes. *South African Medical Journal*. 2001 2001;91(10 I):864-9. PMID: 2001404160 MEDLINE PMID 11732460 (<http://www.ncbi.nlm.nih.gov/pubmed/11732460>).
1147. Rasigade J-P, Sicot N, Laurent F, et al. A history of Panton-Valentine leukocidin (PVL)-associated infection protects against death in PVL-associated pneumonia. *Vaccine*. 2011 Jun 6;29(25):4185-6. PMID: 21527300.
1148. Ravanfar P, Satyaprakash A, Creed R, et al. Existing antiviral vaccines. *Dermatologic Therapy*. 2009 March-April;22(2):110-28. PMID: 2009153643 MEDLINE PMID 19335723 (<http://www.ncbi.nlm.nih.gov/pubmed/19335723>).
1149. Rayani A, Bode U, Habas E, et al. Rotavirus infections in paediatric oncology patients: A matched-pairs analysis. *Scandinavian Journal of Gastroenterology*. 2007 Jan;42(1):81-7. PMID: WOS:000243724800014.
1150. Reinert P, Benkerrou M, de Montalembert M, et al. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease. *Pediatric Infectious Disease Journal*. 2007 Dec;26(12):1105-9. PMID: 18043446.
1151. Reinert P, Cinquetti S, Soubeyrand B, et al. Challenge with hepatitis B vaccine in children previously vaccinated with a hepatitis B-containing combination vaccine. *Advances in Therapy*.

2010 January;27(1):28-38. PMID: 2010215729 MEDLINE PMID 20182924
(<http://www.ncbi.nlm.nih.gov/pubmed/20182924>).

1152. Reinert P, Fiquet A, Thomas S, et al. Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. *Human Vaccines.* 2006 Sep-Oct;2(5):215-21. PMID: 17035735.
1153. Reisinger KS, Baxter R, Block SL, et al. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. *Clin Vaccine Immunol.* 2009 Dec;16(12):1810-5. PMID: 19812260.
1154. Reisinger KS, Block SL. Characteristics of an ideal rotavirus vaccine. *Clinical Pediatrics.* 2008 Jul;47(6):555-63. PMID: 18467670.
1155. Rennels M, King J, Jr., Ryall R, et al. Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers. *Pediatric Infectious Disease Journal.* 2002 Oct;21(10):978-9. PMID: 12400528.
1156. Rennels M, King J, Jr., Ryall R, et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. *Pediatric Infectious Disease Journal.* 2004 May;23(5):429-35. PMID: 15131466.
1157. Rennels MB. Pediatric gastrointestinal infections. *Current Opinion in Infectious Diseases.* 1991 1991;4(1):63-6. PMID: 1991117279.
1158. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of four doses of *Neisseria meningitidis* group C vaccine conjugated to CRM197 in United States infants. *Pediatric Infectious Disease Journal.* 2001 Feb;20(2):153-9. PMID: 11224833.
1159. Rennels MB, Hohenboken MJ, Reisinger KS, et al. Comparison of acellular pertussis-diphtheria-tetanus toxoids and *Haemophilus influenzae* type b vaccines administered separately vs. combined in younger vs. older toddlers. *Pediatric Infectious Disease Journal.* 1998 February;17(2):164-6. PMID: 1998067161 MEDLINE PMID 9493818
(<http://www.ncbi.nlm.nih.gov/pubmed/9493818>).
1160. Rennels MB, Parashar UD, Holman RC, et al. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. *Pediatric Infectious Disease Journal.* 1998 1998;17(10):924-5. PMID: 1998374460 MEDLINE PMID 9802640
(<http://www.ncbi.nlm.nih.gov/pubmed/9802640>).
1161. Rennels MB, Reed GF, Decker MD, et al. Simultaneous administration of *Haemophilus influenzae* type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. *Pediatrics.* 1995 Sep;96(3 Pt 2):576-9. PMID: 7659479.

1162. Resik S, Tejeda A, Lago PM, et al. Randomized Controlled Clinical Trial of Fractional Doses of Inactivated Poliovirus Vaccine Administered Intradermally by Needle-Free Device in Cuba. *Journal of Infectious Diseases*. 2010 May;201(9):1344-52. PMID: WOS:000276248400011.
1163. Reuman PD, Sawyer MH, Kuter BJ, et al. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group. *Pediatric Infectious Disease Journal*. 1997 Jul;16(7):662-7. PMID: 9239770.
1164. Reuman PD, Sawyer MH, Kuter BJ, et al. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB(R) vaccines in healthy children twelve to eighteen months old. *Pediatric Infectious Disease Journal*. 1997 Jul;16(7):662-7. PMID: WOS:A1997XK75600007.
1165. Reygobellet C, Viala-Danten M, Meunier J, et al. Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials. *Human Vaccines*. 2010 April;6(4):336-45. PMID: 2010340982 MEDLINE PMID 20372083 (<http://www.ncbi.nlm.nih.gov/pubmed/20372083>).
1166. Reynales H, Astudillo P, de Valliere S, et al. A prospective observational safety study on MF59() adjuvanted cell culture-derived vaccine, Celtura() during the A/H1N1 (2009) influenza pandemic. *Vaccine*. 2012 Oct 5;30(45):6436-43. PMID: 22902681.
1167. Ribeiro ACM, Guedes LKN, Moraes JCB, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. *Annals of the Rheumatic Diseases*. 2011 Dec;70(12):2144-7. PMID: 21859696.
1168. Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. *New England Journal of Medicine*. 2011 25;365(8):772-3. PMID: 2011477769 MEDLINE PMID 21864191 (<http://www.ncbi.nlm.nih.gov/pubmed/21864191>).
1169. Richie E, Punjabi NH, Harjanto SJ, et al. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children. *Vaccine*. 1999 Mar 17;17(11-12):1384-93. PMID: 10195774.
1170. Richmond P, Goldblatt D, Fusco PC, et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. *Vaccine*. 1999 Nov 12;18(7-8):641-6. PMID: 10547423.
1171. Ridda I, Seale H, Katelaris AL, et al. Pneumococcal colonisation following influenza infection. *Vaccine*. 2011 02;29(38):6444-5. PMID: 2011448853 MEDLINE PMID 21549796 (<http://www.ncbi.nlm.nih.gov/pubmed/21549796>).

1172. Riddell A, Buttery JP, McVernon J, et al. A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide--CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase. *Vaccine*. 2007 May 10;25(19):3906-12. PMID: 17368663.
1173. Riddell A, Buttery JP, McVernon J, et al. A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide-CRM(197) with a meningococcal group C conjugate vaccine in healthy infants: Challenge phase. *Vaccine*. 2007 10;25(19):3906-12. PMID: 2007191727 MEDLINE PMID 17368663 (<http://www.ncbi.nlm.nih.gov/pubmed/17368663>).
1174. Riedemann S, Reinhardt G, Jara J, et al. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months. *International Journal of Infectious Diseases*. 2002 September;6(3):215-22. PMID: 2002338776.
1175. Ries K, Shemonsky NK. Acute lupus erythematosus (SLE) following polyvalent pneumococcal vaccine. *South Dakota Journal of Medicine*. 1981 Mar;34(3):27-8. PMID: 6944793.
1176. Rinderknecht S, Bryant K, Nolan T, et al. The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY). *Human Vaccines and Immunotherapeutics*. 2012 March;8(3):294-301. PMID: 2012244546.
1177. Rinderknecht S, Michaels MG, Blatter M, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age. *Pediatric Infectious Disease Journal*. 2011 Oct;30(10):e179-85. PMID: 21617573.
1178. Rivera L, Mazara S, Vargas M, et al. Phase III, randomized controlled trial to evaluate lot consistency of a trivalent subunit egg-based influenza vaccine in adults. *Vaccine*. 2012.
1179. Robbins JB, Schneerson R. Evaluating the Haemophilus influenzae type b conjugate vaccine PRP-D. *N Engl J Med*. 1990 Nov 15;323(20):1415-6. PMID: 2233910.
1180. Rodrigues LC, Smith PG. Use of the case-control approach in vaccine evaluation: Efficacy and adverse effects. *Epidemiologic Reviews*. 1999;21(1):56-72. PMID: WOS:000082555000005.
1181. Rodriguez R, Dyer PD. Safety of pneumococcal revaccination. *Journal of General Internal Medicine*. 1995 Sep;10(9):511-2. PMID: 8523154.
1182. Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary

report of an observer-blind, randomised trial. *Vaccine*. 2010 Feb 17;28(7):1740-5. PMID: 20034605.

1183. Roman F, Vaman T, Kafeja F, et al. AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. *Clinical Infectious Diseases*. 2010 15;51(6):668-77. PMID: 2010462473 MEDLINE PMID 20687838 (<http://www.ncbi.nlm.nih.gov/pubmed/20687838>).

1184. Romano L, Zanetti AR. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy infants. *Expert Review of Vaccines*. 2011 Sep;10(9):1261-4. PMID: WOS:000296034400008.

1185. Romano L, Zanetti AR. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy infants. *Expert Review of Vaccines*. 2011 September;10(9):1261-4. PMID: 2011525074.

1186. Roscelli JD, Bass JW, Pang L. Guillain-Barre syndrome and influenza vaccination in the US Army, 1980-1988. *Am J Epidemiol*. 1991 May 1;133(9):952-5. PMID: 2028981.

1187. Rose MA, Gruendler M, Schubert R, et al. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics. *Vaccine*. 2009 Aug 20;27(38):5259-64. PMID: 19576944.

1188. Rose MA, Schubert R, Strnad N, et al. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. *Clinical and Diagnostic Laboratory Immunology*. 2005 October;12(10):1216-22. PMID: 2005469446 MEDLINE PMID 16210486 (<http://www.ncbi.nlm.nih.gov/pubmed/16210486>).

1189. Rose NR. Conjugate vaccines and autism. *Medical Hypotheses*. 2011 December;77(6):937-9. PMID: 2011619425 MEDLINE PMID 21907498 (<http://www.ncbi.nlm.nih.gov/pubmed/21907498>).

1190. Rosenblum H, Shoenfeld Y, Amital H. The Common Immunogenic Etiology of Chronic Fatigue Syndrome: From Infections to Vaccines via Adjuvants to the ASIA Syndrome. *Infectious Disease Clinics of North America*. 2011 December;25(4):851-63. PMID: 2011610448 MEDLINE PMID 22054760 (<http://www.ncbi.nlm.nih.gov/pubmed/22054760>).

1191. Rosenfeld RM, Bluestone CD, Casselbrant ML, et al. Treatment. *Annals of Otology, Rhinology and Laryngology*. 2005 Jan;114(1 II):114-39. PMID: 2005036933.

1192. Rothstein EP, Bernstein HH, Glode MP, et al. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines. *American Journal of Diseases of Children*. 1993 Aug;147(8):854-7. PMID: 8394646.

1193. Rottem M, Shoenfeld Y. Vaccination and allergy. *Current Opinion in Otolaryngology & Head & Neck Surgery*. 2004 Jun;12(3):223-31. PMID: 15167034.
1194. Rowhani-Rahbar A, Klein NP, Baxter R. Assessing the safety of influenza vaccination in specific populations: children and the elderly. *Expert Review of Vaccines*. 2012 Aug;11(8):973-84. PMID: 23002978.
1195. Ruiz LP. Re: "Age dependence of the risk of intussusception following tetravalent rhesus-human reassortant rotavirus tetravalent vaccine: is it beyond doubt?". *American Journal of Epidemiology*. 2010 Oct 1;172(7):864. PMID: 20682522.
1196. Ruiz LP, Jr. Intussusception risk of rotavirus vaccination. *New England Journal of Medicine*. 2011 Dec 1;365(22):2137; author reply 8. PMID: 22129261.
1197. Rumke HC, Loch HP, Hoppenbrouwers K, et al. Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. *Vaccine*. 2011 May 17;29(22):3842-9. PMID: 21382484.
1198. Rupp ME, Holley HP, Jr., Lutz J, et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. *Antimicrobial Agents & Chemotherapy*. 2007 Dec;51(12):4249-54. PMID: 17893153.
1199. Russell FM, Licciardi PV, Balloch A, et al. Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. *Vaccine*. 2010 19;28(18):3086-94. PMID: 2010180096 MEDLINE PMID 20199764 (<http://www.ncbi.nlm.nih.gov/pubmed/20199764>).
1200. Russell M, Pool V, Kelso JM, et al. Vaccination of persons allergic to latex: A review of safety data in the Vaccine Adverse Event Reporting System (VAERS). *Vaccine*. 2004 16;23(5):664-7. PMID: 2004482529 MEDLINE PMID 15542187 (<http://www.ncbi.nlm.nih.gov/pubmed/15542187>).
1201. Rutherford EJ, Livengood J, Higginbotham M, et al. Efficacy and safety of pneumococcal revaccination after splenectomy for trauma. *Journal of Trauma-Injury Infection & Critical Care*. 1995 Sep;39(3):448-52. PMID: 7473907.
1202. Ruuskanen O, Salmi TT, Stenvik M, et al. Inactivated poliovaccine: adverse reactions and antibody responses. *Acta Paediatrica Scandinavica*. 1980 May;69(3):397-401. PMID: 6246709.
1203. Ruuskanen O, Viljanen MK, Salmi TT, et al. DTP and DTP-inactivated polio vaccines: comparison of adverse reactions and IGG, IGM and IGA antibody responses to DTP. *Acta Paediatrica Scandinavica*. 1980 Mar;69(2):177-82. PMID: 6989154.

1204. Ryan MAK, McKeehan JA, Gray GC. Pneumococcal vaccine to counter emerging infectious disease threat in the military. *Military Medicine*. 2001 Dec;166(12):1087-90. PMID: WOS:000181419700016.
1205. Saad CGS, Borba EF, Aikawa NE, et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. *Annals of the Rheumatic Diseases*. 2011 Jun;70(6):1068-73. PMID: 21540203.
1206. Sabitha P, Prabha Adhikari MR, Chowdary A, et al. Comparison of the immunogenicity and safety of two different brands of *Salmonella typhi* Vi capsular polysaccharide vaccine. *Indian Journal of Medical Sciences*. 2004 Apr;58(4):141-9. PMID: 15122049.
1207. Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. *Vaccine*. 2012 Jan 30;30(16):2689-96. PMID: 2012154623.
1208. Sacarlal J, Aponte JJ, Aide P, et al. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. *Vaccine*. 2008 Jan 10;26(2):174-84. PMID: 18069097.
1209. Saenger R, Maechler G, Potreck M, et al. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately. *Vaccine*. 2005 Jan 19;23(9):1135-43. PMID: 15629356.
1210. Saez-Llorens X, Guevara JN. Intussusception and rotavirus vaccines: what is the background risk? *Pediatric Infectious Disease Journal*. 2004 Apr;23(4):363-5. PMID: 15071297.
1211. Sakano T, Kittaka E, Tanaka Y. Vaccine-associated poliomyelitis in an infant with agammaglobulinemia. *Acta Paediatrica Scandinavica*. 1980 Jan 1980;69(4):549-51. PMID: 1980204895 MEDLINE PMID 6255734 (<http://www.ncbi.nlm.nih.gov/pubmed/6255734>).
1212. Saksawad R, Likitnukul S, Warachit B, et al. Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children. *Vaccine*. 2011 Jun 24;29(29-30):4735-8. PMID: 21570433.
1213. Salemi S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. *Clinical Immunology*. 2010 Feb;134(2):113-20. PMID: 19846344.
1214. Sandbu S, Feiring B, Oster P, et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. *Clinical & Vaccine Immunology: CVI*. 2007 Sep;14(9):1062-9. PMID: 17634513.
1215. Sanders R, Dabbagh A, Featherstone D. Risk Analysis for Measles Reintroduction After Global Certification of Eradication. *Journal of Infectious Diseases*. 2011 Jul;204:S71-S7. PMID: WOS:000293547600011.

1216. Sanger R, Behre U, Krause K-H, et al. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. European Journal of Pediatrics. 2007 Dec;166(12):1229-36. PMID: 17235521.
1217. Sankilampi U, Honkanen PO, Pyhala R, et al. Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly. Vaccine. 1997 Jul;15(10):1133-7. PMID: 9269058.
1218. Santini-Oliveira M, Camacho LA, Souza TM, et al. H1N1pdm09 adjuvanted vaccination in HIV-infected adults: a randomized trial of two single versus two double doses. PLoS ONE [Electronic Resource]. 2012;7(6):e39310. PMID: 22761759.
1219. Santini-Oliveira M, Camacho LAB, Souza TML, et al. H1N1pdm09 adjuvanted vaccination in HIV-infected adults: A randomized trial of two single versus two double doses. PLoS ONE [Electronic Resource]. 2012;7(6)PMID: 2012358803.
1220. Santosham M, Englund JA, McInnes P, et al. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants. Pediatric Infectious Disease Journal. 2001 Oct;20(10):931-40. PMID: 11642626.
1221. Santosham M, Hill J, Wolff M, et al. Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population.[Erratum appears in Pediatr Infect Dis J 1991 May;10(5):369]. Pediatric Infectious Disease Journal. 1991 Feb;10(2):113-7. PMID: 2062601.
1222. Sarntivijai S, Xiang Z, Shedden KA, et al. Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines. PLoS ONE [Electronic Resource]. 2012;7(11):e49941. PMID: 23209624.
1223. Sato HK, Sanajotta AT, Moraes JC, et al. Rubella vaccination of unknowingly pregnant women: the Sao Paulo experience, 2001. Journal of Infectious Diseases. 2011 Sep 1;204 Suppl 2:S737-44. PMID: 21954275.
1224. Sauve LJ, Bettinger J, Scheifele D, et al. Postvaccination thrombocytopenia in Canada. Pediatric Infectious Disease Journal. 2010 June;29(6):559-61. PMID: 2010315569 MEDLINE PMID 20160658 (<http://www.ncbi.nlm.nih.gov/pubmed/20160658>).
1225. Savy M, Edmond K, Fine PEM, et al. Landscape analysis of interactions between nutrition and vaccine responses in children. Journal of Nutrition. 2009 November;139(11):2154S-218S. PMID: 2009557228 MEDLINE PMID 19793845 (<http://www.ncbi.nlm.nih.gov/pubmed/19793845>).
1226. Schatz M, Chambers CD, Jones KL, et al. Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System.

American Journal of Obstetrics & Gynecology. 2011 Jun;204(6 Suppl 1):S64-8. PMID: 21333964.

1227. Scheifele D, Barreto L, Meekison W, et al. Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? CMAJ Canadian Medical Association Journal. 1993 Oct 15;149(8):1105-12. PMID: 8221449.

1228. Scheifele D, Bjornson G, Barreto L, et al. Controlled trial of Haemophilus influenzae type B diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month-old children, including comparison of arm versus thigh injection. Vaccine. 1992;10(7):455-60. PMID: 1609548.

1229. Scheifele DW, Bjornson GL, Meekison WG, et al. Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants. Canadian Journal of Infectious Diseases. 1994 Mar;5(2):75-81. PMID: 22451769.

1230. Scheifele DW, Guasparini R, Lavigne P. A comparative study of PENTA vaccine booster doses given at 12, 15, or 18 months of age. Vaccine. 1999 Feb 12;17(6):543-50. PMID: 10075160.

1231. Scheifele DW, Halperin SA, Ochnio JJ, et al. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: Results of a randomized, controlled trial. Pediatric Infectious Disease Journal. 2005 December;24(12):1059-66. PMID: 2006003381 MEDLINE PMID 16371866 (<http://www.ncbi.nlm.nih.gov/pubmed/16371866>).

1232. Scheifele DW, Halperin SA, Ochnio JJ, et al. Immunologic considerations for the timing of the booster dose of 7-valent pneumococcal conjugate vaccine in young children. Pediatric Infectious Disease Journal. 2007 May;26(5):387-92. PMID: 17468647.

1233. Scheifele DW, Halperin SA, Rubin E, et al. Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and haemophilus influenzae type B conjugate) when administered as a fourth dose at 15 to 18 months of age. Human Vaccines. 2005 Sep-Oct;1(5):180-6. PMID: 17012882.

1234. Scheifele DW, Meekison W, Guasparini R, et al. Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children. Vaccine. 1995 Jan;13(1):104-8. PMID: 7762265.

1235. Scheifele DW, Ward BJ, Dionne M, et al. Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: Results of a randomized, controlled trial. Vaccine. 2012 Jul 6;30(32):4728-32. PMID: 22652402.

1236. Schessl J, Luther B, Kirschner J, et al. Infections and vaccinations preceding childhood Guillain-Barre syndrome: A prospective study. European Journal of Pediatrics. 2006

September;165(9):605-12. PMID: 2006361574 MEDLINE PMID 16691408 (<http://www.ncbi.nlm.nih.gov/pubmed/16691408>).

1237. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. *Vaccine*. 2012 Nov 20;30 Suppl 5:F123-38. PMID: 23199956.

1238. Schmeink CE, Bekkers RLM, Josefsson A, et al. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls. *Vaccine*. 2011 Nov;29(49):9276-83. PMID: WOS:000297525500022.

1239. Schmitt HJ, Knuf M, Ortiz E, et al. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and *Haemophilus influenzae* type b vaccines given as either separate or mixed injections. *Journal of Pediatrics*. 2000 2000;137(3):304-12. PMID: 2000329506 MEDLINE PMID 10969252 (<http://www.ncbi.nlm.nih.gov/pubmed/10969252>).

1240. Schmitt HJ, Maechler G, Habermehl P, et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel *Haemophilus influenzae*-*Neisseria meningitidis* serogroup C conjugate vaccine. *Clinical and Vaccine Immunology*. 2007 Apr;14(4):426-34. PMID: WOS:000245863500014.

1241. Schmitt HJ, Wirsing von Konig CH, Zepp F, et al. Immunogenicity and reactogenicity of HbOC vaccine administered simultaneously with acellular pertussis vaccine (DTaP) into either arms or thighs of infants. *Infection*. 1997 Sep-Oct;25(5):298-302. PMID: 9334865.

1242. Schmitt HJ, Zepp F, Muschenborn S, et al. Immunogenicity and reactogenicity of a *Haemophilus influenzae* type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. *European Journal of Pediatrics*. 1998 Mar;157(3):208-14. PMID: 9537487.

1243. Schmitt H-J, Maechler G, Habermehl P, et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel *Haemophilus influenzae*-*Neisseria meningitidis* serogroup C conjugate vaccine. *Clinical & Vaccine Immunology: CVI*. 2007 Apr;14(4):426-34. PMID: 17287313.

1244. Schmitt H-J, Siegrist C-A, Salmaso S, et al. B. Zinka et al., Unexplained cases of sudden infant death shortly after hexavalent vaccination. *Vaccine*. 2006 Jul 26;24(31-32):5781-2; author reply 5-6. PMID: 16084630.

1245. Schmitt H-J, Steul KS, Borkowski A, et al. Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants. *Vaccine*. 2008 Apr 24;26(18):2242-52. PMID: 18407386.

1246. Schonbeck Y, Sanders EAM, Hoes AW, et al. Rationale and design of the prevention of respiratory infections and management in children (PRIMAKid) study: a randomized controlled trial on the effectiveness and costs of combined influenza and pneumococcal vaccination in pre-school children with recurrent respiratory tract infections. *Vaccine*. 2005 Sep 30;23(41):4906-14. PMID: 16005552.
1247. Schonberger LB, McGowan Jr JE, Gregg MB. Vaccine associated poliomyelitis in the United States, 1961-1972. *American Journal of Epidemiology*. 1976 1976;104(2):202-11. PMID: 1977167319 MEDLINE PMID 181984 (<http://www.ncbi.nlm.nih.gov/pubmed/181984>).
1248. Schooling CM, McGhee SM, Cowling BJ, et al. Influenza vaccination and hospitalisation in Elderly Health Centres. *Hong Kong Medical Journal*. 2012 Feb;18 Suppl 2:4-7. PMID: 22311352.
1249. Schuerman L, Borys D, Hoet B, et al. Prevention of otitis media: Now a reality? *Vaccine*. 2009 25;27(42):5748-54. PMID: 2009471080 MEDLINE PMID 19666154 (<http://www.ncbi.nlm.nih.gov/pubmed/19666154>).
1250. Schulzke S, Heininger U, Lucking-Famira M, et al. Apnoea and bradycardia in preterm infants following immunisation with pentavalent or hexavalent vaccines. *European Journal of Pediatrics*. 2005 July;164(7):432-5. PMID: 2005301172 MEDLINE PMID 15843978 (<http://www.ncbi.nlm.nih.gov/pubmed/15843978>).
1251. Schumacher Z, Bourquin C, Heininger U. Surveillance for adverse events following immunization (AEFI) in Switzerland-1991-2001. *Vaccine*. 2010 28;28(24):4059-64. PMID: 2010290078 MEDLINE PMID 20406662 (<http://www.ncbi.nlm.nih.gov/pubmed/20406662>).
1252. Schuurmans MM, Tini GM, Dalar L, et al. Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort (vol 30, pg 685, 2011). *Journal of Heart and Lung Transplantation*. 2011 Oct;30(10):1206-. PMID: WOS:000295859400019.
1253. Schwartz HJ, Terr AI. The immune response of allergic and normal subjects to pneumococcal polysaccharide. *International Archives of Allergy & Applied Immunology*. 1971;40(4-5):520-5. PMID: 4397063.
1254. Schwarz TF, Flamaing J, Rumke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥ 65 years. *Vaccine*. 2011 Jul 18;29(32):5195-202. PMID: 21619909.
1255. Scott DA, Komjathy SF, Hu BT, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. *Vaccine*. 2007 14;25(33):6164-6. PMID: 2007355054 MEDLINE PMID 17629361 (<http://www.ncbi.nlm.nih.gov/pubmed/17629361>).

1256. Scudellari M. Vaccine contamination prompts safety review. *Nature Medicine*. 2010 May;16(5):493. PMID: 2010272285 MEDLINE PMID 20448549 (<http://www.ncbi.nlm.nih.gov/pubmed/20448549>).
1257. Selman S, Hayes D, Perin LA, et al. Pneumococcal conjugate vaccine for young children. *Managed Care*. 2000 Sep;9(9):49-52, 4, 6-7 passim. PMID: 11116663.
1258. Seltsam A, Shukry-Schulz S, Salama A. Vaccination-associated immune hemolytic anemia in two children. *Transfusion*. 2000 2000;40(8):907-9. PMID: 2000311459 MEDLINE PMID 10960515 (<http://www.ncbi.nlm.nih.gov/pubmed/10960515>).
1259. Shafrir Y. Vaccination and Dravet syndrome. *Lancet Neurology*. 2010 Dec;9(12):1147-8; author reply 8-9. PMID: 21087737.
1260. Shahgholi E, Ehsani MA, Salamatı P, et al. Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. *Pediatric Blood and Cancer*. 2010 May;54(5):716-20. PMID: 2010217213 MEDLINE PMID 20205258 (<http://www.ncbi.nlm.nih.gov/pubmed/20205258>).
1261. Shahmahmoodi S, Mamishi S, Aghamohammadi A, et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995-2008. *Emerging Infectious Diseases*. 2010 Jul;16(7):1133-6. PMID: 20587188.
1262. Shann F. The nonspecific effects of vaccines and the expanded program on immunization. *Journal of Infectious Diseases*. 2011 15;204(2):182-4. PMID: 2011324487 MEDLINE PMID 21673027 (<http://www.ncbi.nlm.nih.gov/pubmed/21673027>).
1263. Shao PL, Lu CY, Hsieh YC, et al. Immunogenicity and Reactogenicity of Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Inactivated Poliovirus and Haemophilus influenzae Type B Vaccines Administered Concomitantly to Infants as a Three-dose Primary Course. *Journal of the Formosan Medical Association*. 2011 May;110(5):336-41. PMID: WOS:000291081200009.
1264. Shao P-L, Lu C-Y, Chang L-Y, et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine booster in Taiwanese toddlers. *Journal of the Formosan Medical Association*. 2006 Jul;105(7):542-9. PMID: 16877233.
1265. Shao P-L, Lu C-Y, Chang L-Y, et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in Taiwanese infants. *Journal of the Formosan Medical Association*. 2004 Aug;103(8):613-7. PMID: 15340660.
1266. Shao P-L, Lu C-Y, Hsieh Y-C, et al. Immunogenicity and reactogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type B. *Journal of the Formosan Medical Association*. 2011 May;110(5):336-41. PMID: 21621155.

1267. Shapiro ED, Capobianco LA, Berg AT, et al. The immunogenicity of *Hemophilus influenzae* type B polysaccharide-*Neisseria meningitidis* group B outer membrane protein complex vaccine in infants and young children. *Journal of Infectious Diseases*. 1989 Dec;160(6):1064-7. PMID: 2511254.
1268. Sharma A, Agarwal D, Kapoor S, et al. Vaccination as a triggering agent for the development of rheumatoid arthritis. *International Journal of Rheumatic Diseases*. 2011 Feb;14(1):e8-9. PMID: 21303474.
1269. Sharma H, Yadav S, Lalwani S, et al. A phase III randomized, controlled study to assess the immunogenicity and tolerability of DTPw-HBV-Hib, a liquid pentavalent vaccine in Indian infants. *Vaccine*. 2011 Mar 16;29(13):2359-64. PMID: 21288803.
1270. Sharma H, Yadav S, Patil V, et al. A phase III randomized, controlled study to assess and compare the immunogenicity and tolerability of single and multi-dose vials of DTwP-Hib, a fully liquid quadrivalent vaccine and their comparison with TETRAAct-Hib vaccine in Indian infants aged 6-14 weeks. *Vaccine*. 2011 Nov 8;29(48):8773-9. PMID: 21968445.
1271. Sharma HJ, Multani AS, Dutta AK, et al. Safety and immunogenicity of an indigenously developed *Haemophilus influenzae* type b conjugate vaccine through various phases of clinical trials. *Human Vaccines*. 2009 Jul;5(7):483-7. PMID: 19395868.
1272. Sharma HJ, Patil VD, Lalwani SK, et al. Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and *Haemophilus influenzae* type b vaccine manufactured using small and large scale manufacturing process. *Vaccine*. 2012 Jan 11;30(3):510-6. PMID: 22119927.
1273. Sharma HJ, Yadav S, Lalwani SK, et al. Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children. *Human Vaccines*. 2011 Apr;7(4):451-7. PMID: 21403463.
1274. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. *Vaccine*. 2000 Nov 22;19(7-8):916-23. PMID: 11115716.
1275. Shatsky M. Rotavirus vaccine, live, oral, pentavalent (RotaTeq) for prevention of rotavirus gastroenteritis. *American Family Physician*. 2006 15;74(6):1014-6. PMID: 2006460119.
1276. Sheffield JS, Hickman A, Tang J, et al. Efficacy of an Accelerated Hepatitis B Vaccination Program During Pregnancy. *Obstetrics and Gynecology*. 2011 May;117(5):1130-5. PMID: WOS:000289771000014.
1277. Sheikh A, Alves B, Dhami S. Pneumococcal vaccine for asthma. *Cochrane Database of Systematic Reviews*. 2002(1):CD002165. PMID: 11869626.

1278. Sheldon EA, Schwartz H, Jiang Q, et al. A Phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. *Human Vaccines and Immunotherapeutics*. 2012 July;8(7):888-95. PMID: 2012427211.
1279. Shibasaki K, Murakami T, Kushida R, et al. Acute disseminated encephalomyelitis associated with oral polio vaccine. *Internal Medicine*. 2006;45(20):1143-6. PMID: 17106158.
1280. Shields WD, Nielsen C, Buch D, et al. Relationship of pertussis immunization to the onset of neurologic disorders: A retrospective epidemiologic study. *Journal of Pediatrics*. 1988;113(5):801-5. PMID: 1988272572 MEDLINE PMID 3263484 (<http://www.ncbi.nlm.nih.gov/pubmed/3263484>).
1281. Shin SY, Lee SW, Cho YH, et al. Blood-borne transmission of the measles, mumps, and rubella vaccine virus. *Transfusion*. 2011 March;51(3):663-4. PMID: 2011140203 MEDLINE PMID 21388395 (<http://www.ncbi.nlm.nih.gov/pubmed/21388395>).
1282. Shinefield H, Black S, Ray P, et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. *Pediatric Infectious Disease Journal*. 2002 Mar;21(3):182-6. PMID: 12005078.
1283. Shinefield H, Black S, Thear M, et al. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined *Haemophilus influenzae* type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. *Pediatric Infectious Disease Journal*. 2006 Apr;25(4):287-92. PMID: 16567978.
1284. Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. *Pediatric Infectious Disease Journal*. 1999 Sep;18(9):757-63. PMID: 10493334.
1285. Shinoki T, Hara R, Kaneko U, et al. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. *Modern Rheumatology*. 2012.
1286. Shneyer E, Strulov A, Rosenfeld Y. Reduced rate of side effects associated with separate administration of MMR and DTaP-Hib-IPV vaccinations. *Israel Medical Association Journal: Imaj*. 2009 Dec;11(12):735-8. PMID: 20166340.
1287. Shoda A, Hayashi M, Takayama N, et al. Maternal screening and postpartum vaccination for measles infection in Japan: a cohort study. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2011 Jan;118(1):88-92. PMID: 21197682.
1288. Shu M, Liu Q, Wang J, et al. Measles vaccine adverse events reported in the mass vaccination campaign of Sichuan province, China from 2007 to 2008. *Vaccine*. 2011 Apr 18;29(18):3507-10. PMID: 19909830.

1289. Shuster J. Ciprofloxacin-induced immunoglobulin a disease; Palonosetron-induced anaphylaxis; Guillain-Barre Syndrome following H1N1 immunization; Acute profound thrombocytopenia following eptifibatide administration; Clozapine-associated cerebral venous thrombosis; Three excellent reviews: Drug-induced black hairy tongue, Increased *C. difficile* infections with PPI prophylaxis. Hospital Pharmacy. 2010 1;45(9):680-4. PMID: 2010484611.
1290. Siberry GK, Warshaw MG, Williams PL, et al. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal. 2012 Jan;31(1):47-52. PMID: 21987006.
1291. Siddiqui AH, Chitlur MB. Immune thrombocytopenic purpura in a 5-month-old female with rotavirus infection. Pediatric Blood & Cancer. 2010 Apr;54(4):633. PMID: 20054872.
1292. Siebert JN, Posfay-Barbe KM, Habre W, et al. Influence of anesthesia on immune responses and its effect on vaccination in children: Review of evidence. Paediatric Anaesthesia. 2007 May;17(5):410-20. PMID: 2007199579 MEDLINE PMID 17474946 (<http://www.ncbi.nlm.nih.gov/pubmed/17474946>).
1293. Sigurdardottir ST, Davidsdottir K, Arason VA, et al. Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. Vaccine. 2008 Aug 5;26(33):4178-86. PMID: 18606481.
1294. Sigurdardottir ST, Ingolfsdottir G, Davidsdottir K, et al. Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine. Pediatric Infectious Disease Journal. 2002 Jun;21(6):548-54. PMID: 12182380.
1295. Silfverdal SA, Flodmark CE, Rombo L, et al. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial. Vaccine. 2013 Feb 18;31(9):1284-92. PMID: 23306363.
1296. Simoes EA, Balraj V, Selvakumar R, et al. Antibody response of children to measles vaccine mixed with diphtheria-pertussis-tetanus or diphtheria-pertussis-tetanus-polioimmunotherapy vaccine. American Journal of Diseases of Children. 1988 Mar;142(3):309-11. PMID: 3257842.
1297. Simon JK, Carter M, Pasetti MF, et al. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector. Vaccine. 2011 Nov 28;29(51):9544-50. PMID: 21986218.
1298. Simonsen L, Morens D, Elixhauser A, et al. Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception. Lancet. 2001 Oct 13;358(9289):1224-9. PMID: 11675060.

1299. Simonsen L, Morens DM, Blackwelder WC. Ecological studies, rotavirus vaccination, and intussusception. *Lancet*. 2002 Mar 23;359(9311):1066-7; author reply PMID: 11937210.
1300. Simonsen L, Taylor RJ, Kapikian AZ. Rotavirus vaccines. *New England Journal of Medicine*. 2006 Apr 20;354(16):1747-51; author reply -51. PMID: 16625742.
1301. Singleton R, Wenger J, Klejka JA, et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in alaska native children: Results of a clinical trial. *Pediatric Infectious Disease Journal*. 2012;20.
1302. Singleton R, Wenger J, Klejka JA, et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. *Pediatric Infectious Disease Journal*. 2013 Mar;32(3):257-63. PMID: 23001026.
1303. Siwek J. Hemophilus b conjugate vaccines: good news, bad news. *American Family Physician*. 1991 Apr;43(4):1218, 20. PMID: 2008809.
1304. Skowronski DM, Hottes TS, Chong M, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. *Pediatrics*. 2011 Aug;128(2):e276-89. PMID: 21768314.
1305. Skowronski DM, Janjua NZ, Hottes TS, et al. Pneumococcal vaccination and myocardial infarction. *CMAJ Canadian Medical Association Journal*. 2009 Feb 3;180(3):319; author reply 20. PMID: 19188633.
1306. Skowronski DM, Strauss B, De Serres G, et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? *Clin Infect Dis*. 2003 Mar 15;36(6):705-13. PMID: 12627354.
1307. Slack MH, Schapira C, Thwaites RJ, et al. Acellular pertussis and meningococcal C vaccines: Cardio-respiratory events in preterm infants. *European Journal of Pediatrics*. 2003 1;162(6):436-7. PMID: 2003233006 MEDLINE PMID 12756562 (<http://www.ncbi.nlm.nih.gov/pubmed/12756562>).
1308. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. *JAMA*. 2009 Aug 19;302(7):750-7. PMID: 19690307.
1309. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: A randomized comparative trial. *Pediatric Infectious Disease Journal*. 2010 November;29(11):e71-e9. PMID: 2010608871 MEDLINE PMID 20844462 (<http://www.ncbi.nlm.nih.gov/pubmed/20844462>).
1310. Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: A double-blind randomized active-controlled trial. *Pediatric Infectious Disease Journal*. 2010

December;29(12):e80-e90. PMID: 2010699823 MEDLINE PMID 21155091 (<http://www.ncbi.nlm.nih.gov/pubmed/21155091>).

1311. Soares RC, Siqueira MM, Toscano CM, et al. Follow-up study of unknowingly pregnant women vaccinated against rubella in Brazil, 2001-2002. *Obstetrical and Gynecological Survey*. 2012 January;67(1):20-2. PMID: 2012078383.

1312. Soares-Weiser K, Goldberg E, Tamimi G, et al. Rotavirus vaccine for preventing diarrhoea. *Cochrane Database of Systematic Reviews*. 2004(1):CD002848. PMID: 14973994.

1313. Socan M, Frelih T, Janet E, et al. Reactions after pneumococcal vaccine alone or in combination with influenza vaccine. *Vaccine*. 2004 Aug 13;22(23-24):3087-91. PMID: 15297059.

1314. Sonder G, Van den Hoek A. Hepatitis B immunization coverage and risk behaviour among Danish travellers: Are immunization strategies based on single journey itineraries rational? *Journal of Infection*. 2010 April;60(4):309-10. PMID: 2012069875 MEDLINE PMID 20100513 (<http://www.ncbi.nlm.nih.gov/pubmed/20100513>).

1315. Song JY, Cheong HJ, Woo HJ, et al. Immunogenicity and safety of trivalent inactivated influenza vaccine: a randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country. *Journal of Korean Medical Science*. 2011 Feb;26(2):191-5. PMID: 21286008.

1316. Sou T, Meeusen EN, de Veer M, et al. New developments in dry powder pulmonary vaccine delivery. *Trends in Biotechnology*. 2011 April;29(4):191-8. PMID: 2011151587 MEDLINE PMID 21255854 (<http://www.ncbi.nlm.nih.gov/pubmed/21255854>).

1317. Souayah N, Michas-Martin PA, Nasar A, et al. Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009. *Vaccine*. 2011 Jan 29;29(5):886-9. PMID: 20869467.

1318. Souayah N, Nasar A, Suri MFK, et al. Guillain-barre syndrome after vaccination in United States: Data from the centers for disease control and prevention/food and drug administration vaccine adverse event reporting system (1990-2005). *Journal of Clinical Neuromuscular Disease*. 2009 September;11(1):1-6. PMID: 2009490545 MEDLINE PMID 19730016 (<http://www.ncbi.nlm.nih.gov/pubmed/19730016>).

1319. Souayah N, Yacoub HA, Khan HM, et al. Analysis of data from the CDC/FDA vaccine adverse event reporting system (1990-2009) on Guillain-Barre syndrome after hepatitis vaccination in the USA. *Journal of Clinical Neuroscience*. 2012 Aug;19(8):1089-92. PMID: 22705140.

1320. Souayah N, Yacoub HA, Khan HM, et al. Guillain-Barre syndrome after influenza vaccination in the United States, a report from the CDC/FDA vaccine adverse event reporting system (1990-2009). *Journal of Clinical Neuromuscular Disease*. 2012 Dec;14(2):66-71. PMID: 23172385.

1321. Souayah N, Yacoub HA, Khan HM, et al. Guillain-Barre syndrome after H1N1 vaccination in the United States: a report using the CDC/FDA Vaccine Adverse Event Reporting System (2009). *Neuroepidemiology*. 2012;38(4):227-32. PMID: 22555646.
1322. Souayah N, Yacoub HA, Khan HMR, et al. Guillain-Barre Syndrome after H1N1 Vaccination in the United States: A Report Using the CDC/FDA Vaccine Adverse Event Reporting System (2009). *Neuroepidemiology*. 2012;38(4):227-32. PMID: 22555646.
1323. Southern J, Deane S, Ashton L, et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. *Clinical & Diagnostic Laboratory Immunology*. 2004 Nov;11(6):1100-4. PMID: 15539513.
1324. Souza AR, Braga JAP, de Paiva TM, et al. Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia. *Vaccine*. 2010 Jan 22;28(4):1117-20. PMID: 20116631.
1325. Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. *New England Journal of Medicine*. 2011 Jun 16;364(24):2293-304. PMID: 21675889.
1326. Sox C. Acute otitis media: antibiotics are moderately effective and mildly increase the risk of adverse effects; prevalence of different causative bacteria changed after introduction of the heptavalent pneumococcal conjugate vaccine. *Evidence Based Medicine*. 2011 Dec;16(6):181-2. PMID: 21561925.
1327. Spinola SM, Sheaffer CI, Gilligan PH. Antigenuria after Haemophilus influenzae type b polysaccharide vaccination. *Journal of Pediatrics*. 1986 1986;108(2):247-9. PMID: 1986113874 MEDLINE PMID 3484781 (<http://www.ncbi.nlm.nih.gov/pubmed/3484781>).
1328. Spinola SM, Sheaffer CI, Philbrick KB, et al. Antigenuria after Haemophilus influenzae type b polysaccharide immunization: A prospective study. *Journal of Pediatrics*. 1986 1986;109(5):835-8. PMID: 1987012442 MEDLINE PMID 3490560 (<http://www.ncbi.nlm.nih.gov/pubmed/3490560>).
1329. Spitaleri G, Delmonte A, Toffalorio F, et al. Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*. 2010 May;5(5):752-4. PMID: 20421772.
1330. Stangenberg S, John G, Healy H, et al. Response of renal transplant recipients to the monovalent pandemic H1N1 vaccine. *Nephrology*. 2011 September;16 SUPPL. 1:78.

1331. Stanley PJ, Ellis CJ. New vaccines. *British Journal of Hospital Medicine*. 1989;41(4):364-7. PMID: 1989114717 MEDLINE PMID 2655801 (<http://www.ncbi.nlm.nih.gov/pubmed/2655801>).
1332. Stavrikj K, Peova S, Petlickovski A, et al. Safe measles, mumps and rubella vaccine administration in atopic children with high levels of egg white-specific IgE antibody. *Macedonian Journal of Medical Sciences*. 2011 September;4(3):271-4. PMID: 2011559148.
1333. Stavroulopoulos A, Stamogiannos G, Aresti V. Pandemic 2009 influenza H1N1 virus vaccination: compliance and safety in a single hemodialysis center. *Renal Failure*. 2010;32(9):1044-8. PMID: 20863207.
1334. Steele AD, De Vos B, Tumbo J, et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. *Vaccine*. 2010 September;28(39):6542-8. PMID: 2010488890 MEDLINE PMID 18786585 (<http://www.ncbi.nlm.nih.gov/pubmed/18786585>).
1335. Steele AD, Madhi SA, Louw CE, et al. Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa. *Pediatric Infectious Disease Journal*. 2011 Feb;30(2):125-30. PMID: 20842070.
1336. Steele RW. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. *Clinical Pediatrics*. 1998 Dec;37(12):760-1. PMID: 9864656.
1337. Steentoft J, Konradsen HB, Hilskov J, et al. Response to pneumococcal vaccine in chronic obstructive lung disease - The effect of ongoing, systemic steroid treatment. *Vaccine*. 2006 27;24(9):1408-12. PMID: 2006076659 MEDLINE PMID 16297507 (<http://www.ncbi.nlm.nih.gov/pubmed/16297507>).
1338. Stojanov S, Liese JG, Belohradsky BH, et al. Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP~T-HBs) combination vaccine. *Vaccine*. 2007 23;25(43):7549-58. PMID: 2007480826 MEDLINE PMID 17905486 (<http://www.ncbi.nlm.nih.gov/pubmed/17905486>).
1339. Stojanov S, Liese JG, Bendjenana H, et al. Immunogenicity and safety of a trivalent tetanus, low dose diphtheria, inactivated poliomyelitis booster compared with a standard tetanus, low dose diphtheria booster at six to nine years of age. *Munich Vaccine Study Group*. *Pediatric Infectious Disease Journal*. 2000 Jun;19(6):516-21. PMID: 10877165.
1340. Stratton KR, Howe CJ, Johnston RB, Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. *JAMA*. 1994 May 25;271(20):1602-5. PMID: 8182813.
1341. Su EL, Snape MD. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. *Expert Review of Vaccines*. 2011

May;10(5):575-88. PMID: 2011292659 MEDLINE PMID 21604979
(<http://www.ncbi.nlm.nih.gov/pubmed/21604979>).

1342. Suarez E, Asturias EJ, Hilbert AK, et al. A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador. Pan American Journal of Public Health. 2010 Feb;27(2):117-24. PMID: 20339615.

1343. Surquin M, Tielemans C, Nortier J, et al. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency. Human Vaccines. 2011 Sep;7(9):913-8. PMID: WOS:000295837200013.

1344. Surquin M, Tielemans CL, Kulcsar I, et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine. Kidney International. 2010 Feb;77(3):247-55. PMID: WOS:000273573000013.

1345. Sutradhar SC, Wang WW, Schlienger K, et al. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. Clin Vaccine Immunol. 2009 May;16(5):646-52. PMID: 19261769.

1346. Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010 Nov 13;376(9753):1682-8. PMID: 20980048.

1347. Szarewski A, Poppe WAJ, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. International Journal of Cancer. 2012 1;131(1):106-16. PMID: 2012234980 MEDLINE PMID 21858807
(<http://www.ncbi.nlm.nih.gov/pubmed/21858807>).

1348. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis. 2009 Sep 15;200(6):841-8. PMID: 19673651.

1349. Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, et al. Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons. Human vaccines & Immunotherapeutics. 2012 May;8(5):645-52. PMID: 22418809.

1350. Szynczewska E, Chlebna-Sokol D. Immunogenicity and safety of heptavalent conjugate vaccine against *Streptococcus pneumoniae* in pre-term Polish infants. Vaccine. 2011 Sep 16;29(40):7107-13. PMID: 21803093.

1351. Tager A. Preliminary report on the treatment of recurrent herpes simplex with poliomyelitis vaccine (Sabin's). Dermatologica. 1974 1974;149(4):253-5. PMID: 1975208668 MEDLINE PMID 4459181 (<http://www.ncbi.nlm.nih.gov/pubmed/4459181>).

1352. Talbot EA, Brown KH, Kirkland KB, et al. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. *Vaccine*. 2010 Nov 23;28(50):8001-7. PMID: 20875487.
1353. Tamm E, Veronese A, Contorni M, et al. Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. *Vaccine*. 2005 Feb 25;23(14):1715-9. PMID: 15705477.
1354. Tandale BV, Pawar SD, Mishra AC. Immunogenicity and safety of pandemic H1N1 2009 vaccine among adults in field use, India. *Vaccine*. 2012 9;30(12):2043-4. PMID: 2012111130 MEDLINE PMID 22001279 (<http://www.ncbi.nlm.nih.gov/pubmed/22001279>).
1355. Tantawy AAG, Algohary EAM, El-Ghany SMA, et al. Haemophilia A patients are not at increased risk of hepatitis A virus infection: An Egyptian experience. *Egyptian Journal of Medical Human Genetics*. 2012 February;13(1):93-7. PMID: 2012188878.
1356. Tate JE, Simonsen L, Viboud C, et al. Trends in intussusception hospitalizations among US infants, 1993-2004: implications for monitoring the safety of the new rotavirus vaccination program. *Pediatrics*. 2008 May;121(5):e1125-32. PMID: 18450856.
1357. Tate JE, Steele AD, Bines JE, et al. Research priorities regarding rotavirus vaccine and intussusception: a meeting summary. *Vaccine*. 2012 Apr 27;30 Suppl 1:A179-84. PMID: 22520129.
1358. Tauber T, Lahat E, Dolinsky G, et al. Haemophilus influenza type b vaccine in Israel: Experience in a paediatric ambulatory clinic. *Annals of Tropical Paediatrics*. 2001 2001;21(3):231-4. PMID: 2001336384 MEDLINE PMID 11579861 (<http://www.ncbi.nlm.nih.gov/pubmed/11579861>).
1359. Tavana S, Argani H, Gholamin S, et al. Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety. *Influenza & Other Respiratory Viruses*. 2012 Mar;6(2):136-41. PMID: 21955954.
1360. Tavares F, Delaigle A, Slavin D, et al. Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective. *Vaccine*. 2011 Aug 26;29(37):6402-7. PMID: 21527305.
1361. Taweesith W, Puthanakit T, Kowitdamrong E, et al. The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children. *Pediatric Infectious Disease Journal*. 2011 Apr;30(4):320-4. PMID: 20975615.
1362. Taylor B, Lingam R, Simmons A, et al. Autism and MMR vaccination in North London; no causal relationship. *Mol Psychiatry*. 2002;7 Suppl 2:S7-8. PMID: 12142932.

1363. Tejedor JC, Moro M, Merino JM, et al. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. *Pediatric Infectious Disease Journal*. 2008 Jul;27(7):579-88. PMID: 18536619.
1364. Tejedor JC, Moro M, Ruiz-Contreras J, et al. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae Type b and Neisseria meningitidis Serogroup C-tetanus toxoid conjugate vaccine coadministered with a Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months. *Pediatric Infectious Disease Journal*. 2007 Jan;26(1):1-7. PMID: 17195697.
1365. Tejedor JC, Moro M, Ruiz-Contreras J, et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. *Pediatric Infectious Disease Journal*. 2006 Aug;25(8):713-20. PMID: 16874171.
1366. Tejedor J-C, Omenaca F, Garcia-Sicilia J, et al. Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV/Hib vaccine coadministered with a meningococcal C-CRM197 vaccine and response to a DTPa-IPV/Hib booster at 18 months of age. *Pediatric Infectious Disease Journal*. 2006 Oct;25(10):943-5. PMID: 17006294.
1367. Tennis P, Toback SL, Andrews E, et al. A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. *Vaccine*. 2011 Jul 12;29(31):4947-52. PMID: 21596087.
1368. Tennis P, Toback SL, Andrews EB, et al. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season. *Vaccine*. 2012 Sep 14;30(42):6099-102. PMID: 22841479.
1369. Tennis P, Toback SL, Andrews EB, et al. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season. *Vaccine*. 2012;30(42):6099-102.
1370. Tesng HF, Smith N, Sy LS, et al. Evaluation of the incidence of herpes zoster after concomitant vaccination of a polysaccharide pneumococcal vaccine and a zoster vaccine. *American Journal of Epidemiology*. 2011 1;173 SUPPL. 11:S23.
1371. Thakur V, Pati NT, Gupta RC, et al. Efficacy of Shanvac-B recombinant DNA hepatitis B vaccine in health care workers of Northern India. *Hepatobiliary & Pancreatic Diseases International*. 2010 Aug;9(4):393-7. PMID: WOS:000280723700008.
1372. Thaler A. Miller Fisher syndrome in a 66-year-old female after flu and pneumovax vaccinations. *Journal of the American Medical Directors Association*. 2008 May;9(4):283-4. PMID: 18457810.

1373. Thanee C, Pancharoen C, Likitnukul S, et al. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children. *Vaccine*. 2011 Aug 11;29(35):5886-91. PMID: 21729732.
1374. Theeten H, Rumke H, Hoppener FJP, et al. Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. *Current Medical Research and Opinion*. 2007 November;23(11):2729-39. PMID: 2007567879 MEDLINE PMID 17897485 (<http://www.ncbi.nlm.nih.gov/pubmed/17897485>).
1375. Thiem VD, Danovaro-Holliday MC, Canh DG, et al. The feasibility of a school-based VI polysaccharide vaccine mass immunization campaign in Hue City, central Vietnam: streamlining a typhoid fever preventive strategy. *Southeast Asian Journal of Tropical Medicine & Public Health*. 2006 May;37(3):515-22. PMID: 17120972.
1376. Thierry-Carstensen B, Jordan K, Uhlving HH, et al. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults. *Vaccine*. 2012 Aug 10;30(37):5464-71. PMID: 22776216.
1377. Thisyakorn U, Chotpitayasunondh T, Pancharoen C, et al. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand. *Southeast Asian Journal of Tropical Medicine & Public Health*. 2010 Mar;41(2):450-62. PMID: 20578530.
1378. Thisyakorn U, Pancharoen C, Chuenkitmongkol S, et al. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine. *Southeast Asian Journal of Tropical Medicine & Public Health*. 2009 Mar;40(2):282-94. PMID: 19323013.
1379. Thomas C, Moridani M. Interindividual variations in the efficacy and toxicity of vaccines. *Toxicology*. 2010 5;278(2):204-10. PMID: 2010619280 MEDLINE PMID 19837123 (<http://www.ncbi.nlm.nih.gov/pubmed/19837123>).
1380. Thompson DF, Montarella KE. Drug-induced Sweet's syndrome. *Annals of Pharmacotherapy*. 2007 May;41(5):802-11. PMID: 2007238387 MEDLINE PMID 17426076 (<http://www.ncbi.nlm.nih.gov/pubmed/17426076>).
1381. Tichmann I, Preidel H, Grunert D, et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. *Vaccine*. 2005 May 9;23(25):3272-9. PMID: 15837232.

1382. Tichmann-Schumann I, Soemantri P, Behre U, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine. *Pediatric Infectious Disease Journal*. 2005 Jan;24(1):70-7. PMID: 15665713.
1383. Tielemans CL, Vlasak J, Kosa D, et al. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: Results of two open, randomized, comparative trials. *Vaccine*. 2011 Feb;29(6):1159-66. PMID: WOS:000287339800009.
1384. Toback SL, Ambrose CS, Eaton A, et al. A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age. *Vaccine*. 2013 Apr 3;31(14):1812-8. PMID: 23395734.
1385. Tomljenovic L, Shaw CA. Aluminum Vaccine Adjuvants: Are they Safe? *Current Medicinal Chemistry*. 2011 Jun;18(17):2630-7. PMID: WOS:000291645700011.
1386. Tomljenovic L, Spinoza JP, Shaw CA. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe? *Current Pharmaceutical Design*. 2013;19(8):1466-87. PMID: 23016780.
1387. Toneatto D, Ismaili S, Ypma E, et al. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. *Human Vaccines*. 2011 Jun;7(6):646-53. PMID: 21904120.
1388. Toneatto D, Oster P, deBoer ACW, et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. *Human Vaccines*. 2011 Jul;7(7):781-91. PMID: WOS:000294453300018.
1389. Toniolo-Neto J, Weckx LW, Halker E, et al. Safety of simultaneous pneumococcal and influenza vaccination in elderly patients in Brazil. *Drugs & Aging*. 1999;15 Suppl 1:43-5. PMID: 10690795.
1390. Torano G, Toledo ME, Baly A, et al. Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b in human adult volunteers. *Clinical & Vaccine Immunology: CVI*. 2006 Sep;13(9):1052-6. PMID: 16960118.
1391. Torling J, Hedlund J, Konradsen HB, et al. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. *Vaccine*. 2003 Dec 8;22(1):96-103. PMID: 14604576.
1392. Touma Z, Gladman DD, Urowitz MB. Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. *Current Opinion in Rheumatology*. 2013 Mar;25(2):164-70. PMID: 23370371.

1393. Traversa G, Spila-Alegiani S, Bianchi C, et al. Sudden unexpected deaths and vaccinations during the first two years of life in Italy: A case series study. PLoS ONE [Electronic Resource]. 2011;6(1) PMID: 2011071441.
1394. Treanor J, Nolan C, O'Brien D, et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine. 2006 Jan 16;24(3):254-62. PMID: 16129526.
1395. Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatric Infectious Disease Journal. 2012 Jan;31(1):e24-30. PMID: 22157567.
1396. Tregnaghi MW, Stamboulian D, Vanadia PC, et al. Immunogenicity, Safety, and Tolerability of Two Trivalent Subunit Inactivated Influenza Vaccines: A Phase III, Observer-Blind, Randomized, Controlled Multicenter Study. Viral Immunology. 2012 Jun;25(3):216-25. PMID: 22691101.
1397. Tregnaghi MW, Voelker R, Santos-Lima E, et al. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine. 2010 Apr;28(20):3595-601. PMID: WOS:000277882600014.
1398. Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old argentinean infants. Pediatric Infectious Disease Journal. 2011 June;30(6):e88-e96. PMID: 2011308075 MEDLINE PMID 21372751 (<http://www.ncbi.nlm.nih.gov/pubmed/21372751>).
1399. Tro-Baumann B, von Spiczak S, Lotte J, et al. A retrospective study of the relation between vaccination and occurrence of seizures in Dravet syndrome. Epilepsia. 2011 Jan;52(1):175-8. PMID: WOS:000286052800020.
1400. Trofa AF, Klein NP, Paul IM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age. Pediatric Infectious Disease Journal. 2011 Sep;30(9):e164-9. PMID: 21494175.
1401. Trofa AF, Levin M, Marchant CD, et al. Immunogenicity and safety of an inactivated hepatitis a vaccine administered concomitantly with a pneumococcal conjugate vaccine in healthy children 15 months of age. Pediatric Infectious Disease Journal. 2008 Jul;27(7):658-60. PMID: 18536623.
1402. Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med. 1995 Oct 19;333(16):1045-50. PMID: 7675047.

1403. Tsai T, Kyaw MH, Novicki D, et al. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. *Vaccine*. 2010 Feb 17;28(7):1877-80. PMID: 19969117.
1404. Tseng HF, Smith N, Sy LS, et al. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. *Vaccine*. 2011 Oct;29(20):3628-32. PMID: 2011226106 MEDLINE PMID 21435407 (<http://www.ncbi.nlm.nih.gov/pubmed/21435407>).
1405. Tseng HF, Sy LS, Liu IL, et al. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. *Vaccine*. 2013 May 24;31(22):2578-83. PMID: 23579258.
1406. Tudor-Williams G, Frankland J, Isaacs D, et al. Haemophilus influenzae type b conjugate vaccine trial in Oxford: implications for the United Kingdom. *Archives of Disease in Childhood*. 1989 Apr;64(4):520-4. PMID: 2665657.
1407. Tung J, Carlisle E, Smieja M, et al. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. *American Journal of Kidney Diseases*. 2010 October;56(4):713-9. PMID: 2010514452 MEDLINE PMID 20630640 (<http://www.ncbi.nlm.nih.gov/pubmed/20630640>).
1408. Tuttle J, Chen RT, Rantala H, et al. The risk of Guillain-Barre syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. *Am J Public Health*. 1997 Dec;87(12):2045-8. PMID: 9431302.
1409. Tyring SK, Diaz-Mitoma F, Padgett LG, et al. Safety and tolerability of a high-potency zoster vaccine in adults \geq 50 years of age. *Vaccine*. 2007 Feb 26;25(10):1877-83. PMID: 17227688.
1410. Upton JE, Hummel DB, Kasprzak A, et al. No systemic reactions to influenza vaccination in egg-sensitized tertiary-care pediatric patients. *Allergy, Asthma, & Clinical Immunology : Official Journal of the Canadian Society of Allergy & Clinical Immunology*. 2012;8:2. PMID: 22385977.
1411. Urschel S, Rieck BD, Birnbaum J, et al. Impaired cellular immune response to diphtheria and tetanus vaccines in children after thoracic transplantation. *Pediatric Transplantation*. 2011 May;15(3):272-80. PMID: WOS:000289628100014.
1412. Usonis V, Bakasenas V. Does concomitant injection of a combined diphtheria-tetanus-acellular pertussis - Hepatitis B virus - Inactivated polio virus vaccine influence the reactogenicity and immunogenicity of commercial Haemophilus influenzae type b conjugate vaccines? *European Journal of Pediatrics*. 1999 1999;158(5):398-402. PMID: 1999151332 MEDLINE PMID 10333123 (<http://www.ncbi.nlm.nih.gov/pubmed/10333123>).

1413. Uygunil B, Bleesing JJ, Risma KA, et al. Persistent rotavirus vaccine shedding in a new case of severe combined immunodeficiency: A reason to screen. *Journal of Allergy and Clinical Immunology*. 2010 January;125(1 3):270-1. PMID: 2010008834 MEDLINE PMID 20109754 (<http://www.ncbi.nlm.nih.gov/pubmed/20109754>).
1414. Vadheim CM, Greenberg DP, Marcy SM, et al. Safety evaluation of PRP-D Haemophilus influenzae type b conjugate vaccine in children immunized at 18 months of age and older: follow-up study of 30,000 children. *Pediatric Infectious Disease Journal*. 1990 Aug;9(8):555-61. PMID: 2235171.
1415. Vadheim CM, Greenberg DP, Partridge S, et al. Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Kaiser-UCLA Vaccine Study Group. *Pediatrics*. 1993 Aug;92(2):272-9. PMID: 8337029.
1416. Vajo Z, Tamas F, Jankovics I. A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial. *Clinical & Vaccine Immunology: CVI*. 2012 Mar;19(3):313-8. PMID: 22219315.
1417. Vajo Z, Tamas F, Sinka L, et al. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. *Lancet*. 2010 Jan 2;375(9708):49-55. PMID: 20018367.
1418. Valenzuela MTB, Altuzarra RH, Trucco OA, et al. Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-term care facility. *Brazilian Journal of Infectious Diseases*. 2007 June;11(3):322-6. PMID: 2007514334 MEDLINE PMID 17684633 (<http://www.ncbi.nlm.nih.gov/pubmed/17684633>).
1419. Van Buynder PG, Frosst G, Van Buynder JL, et al. Increased reactions to pediatric influenza vaccination following concomitant pneumococcal vaccination. *Influenza & Other Respiratory Viruses*. 2013 Mar;7(2):184-90. PMID: 22498052.
1420. Van Damme P, Leroux-Roels G, Crasta P, et al. Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine. *Journal of Medical Virology*. 2012 Jan;84(1):11-7. PMID: 22052690.
1421. Van Damme P, Moiseeva A, Marichev I, et al. Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study. *BMC Infectious Diseases*. 2010 Dec;10 PMID: WOS:000285919800001.
1422. Van De Geijn EJ, Tukkie R, Van Philips LAM, et al. Bilateral optic neuritis with branch retinal artery occlusion associated with vaccination. *Documenta Ophthalmologica*. 1994;86(4):403-8. PMID: 1994320637 MEDLINE PMID 7835178 (<http://www.ncbi.nlm.nih.gov/pubmed/7835178>).

1423. Van Der Velden AMT, Van Velzen-Blad H, Claessen AME, et al. The effect of ranitidine on antibody responses to polysaccharide vaccines in patients with B-cell chronic lymphocytic leukaemia. *European Journal of Haematology*. 2007 July;79(1):47-52. PMID: 2007315665 MEDLINE PMID 17532765 (<http://www.ncbi.nlm.nih.gov/pubmed/17532765>).
1424. Van Der Vliet D, Pepin S, Lambert M, et al. Similar immunogenicity and safety of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine. *Human Vaccines*. 2010 October;6(10):823-8. PMID: 2010646055.
1425. Van der Wielen M, Van Damme P. Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial. *European Journal of Clinical Microbiology & Infectious Diseases*. 2008 Jul;27(7):495-501. PMID: 18351405.
1426. Van Heerbeek N, Straetemans M, Wiertsema SP, et al. Effect of combined pneumococcal conjugate and polysaccharide vaccination on recurrent otitis media with effusion. *Pediatrics*. 2006 March;117(3):603-8. PMID: 2007022278.
1427. Vanderkooi OG, Scheifele DW, Girgenti D, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. *Pediatric Infectious Disease Journal*. 2012 January;31(1):72-7. PMID: 2012016969 MEDLINE PMID 21960186 (<http://www.ncbi.nlm.nih.gov/pubmed/21960186>).
1428. Vanderkooi OG, Scheifele DW, Girgenti D, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. *Pediatric Infectious Disease Journal*. 2012 Jan;31(1):72-7. PMID: 21960186.
1429. Velickovic Z, Jankovic D, Perovic M, et al. Problems in surveillance on safe immunization conducting in everyday practice. *Medicinski Arhiv*. 2010;64(4):235-9. PMID: 21246924.
1430. Venuta A. Acute arthritis associated with rotavirus gastroenteritis: An unusual extraintestinal manifestation of a common enteric pathogen. *Journal of Clinical Rheumatology*. 2012 January;18(1):49. PMID: 2012004694 MEDLINE PMID 22157276 (<http://www.ncbi.nlm.nih.gov/pubmed/22157276>).
1431. Verbeek NE, van der Maas NA, Jansen FE, et al. Prevalence of SCN1A-Related Dravet Syndrome among Children Reported with Seizures following Vaccination: A Population-Based Ten-Year Cohort Study. *PLoS ONE [Electronic Resource]*. 2013;8(6):e65758. PMID: 23762420.
1432. Verdijk P, Rots NY, Bakker WAM. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. *Expert Review of Vaccines*. 2011 May;10(5):635-44. PMID: 21604984.

1433. Verity CM, Stellitano LS, Winstone AM. The PIND study found no association between vaccination and autism in mitochondrial disease - correction. *Developmental Medicine and Child Neurology*. 2011 May;53(5):477-. PMID: 2011208743 MEDLINE PMID 21480875 (<http://www.ncbi.nlm.nih.gov/pubmed/21480875>).
1434. Vermeer-De Bondt PE, Van Der Maas NAT. The effect of age and dose number on the risk of collapse (hypotonic-hyporesponsive episode) after pertussis vaccination. *Pediatric Infectious Disease Journal*. 2008 April;27(4):355-7. PMID: 2008165788 MEDLINE PMID 18379375 (<http://www.ncbi.nlm.nih.gov/pubmed/18379375>).
1435. Vernacchio L, Bernstein H, Pelton S, et al. Effect of monophosphoryl lipid A (MPL(registered trademark)) on T-helper cells when administered as an adjuvant with pneumococcal-CRM(197) conjugate vaccine in healthy toddlers. *Vaccine*. 2002 1;20(31 32):3658-67. PMID: 2002381781 MEDLINE PMID 12399193 (<http://www.ncbi.nlm.nih.gov/pubmed/12399193>).
1436. Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. *Journal of Pediatrics*. 1998 Aug;133(2):275-8. PMID: 9709721.
1437. Verstraeten T, Davis RL, DeStefano F, et al. Safety of Thimerosal-Containing Vaccines: A Two-Phased Study of Computerized Health Maintenance Organization Databases. *Pediatrics*. 2003 November;112(5):1039-48. PMID: 2003441819 MEDLINE PMID 14595043 (<http://www.ncbi.nlm.nih.gov/pubmed/14595043>).
1438. Vesikari T. Rotavirus vaccines. *Scandinavian Journal of Infectious Diseases*. 2008;40(9):691-5. PMID: 19086243.
1439. Vesikari T, Becker T, Gajdos V, et al. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad((registered trademark))) in infants from 9 months of age. *Vaccine*. 2012 26;30(20):3082-9. PMID: 2012198189.
1440. Vesikari T, Block SL, Guerra F, et al. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. *Pediatric Infectious Disease Journal*. 2012 May;31(5):494-500. PMID: 22301476.
1441. Vesikari T, Forsten A, Herbinger K-H, et al. Safety and immunogenicity of an MF59([REGISTERED])-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. *Vaccine*. 2012 Feb 8;30(7):1388-96. PMID: 22192847.
1442. Vesikari T, Joensuu J, Baer M, et al. Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae b-inactivated polio and hepatitis B vaccines. *Acta Paediatrica, International Journal of*

Paediatrics. 1999;88(5):513-20. PMID: 1999218140 MEDLINE PMID 10426173 (<http://www.ncbi.nlm.nih.gov/pubmed/10426173>).

1443. Vesikari T, Karvonen A, Bianco V, et al. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. *Vaccine.* 2011 Jun;29(25):4274-84. PMID: 21443965.

1444. Vesikari T, Karvonen A, Borrow R, et al. Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccine. *Clinical & Vaccine Immunology: CVI.* 2011 May;18(5):878-84. PMID: 21389149.

1445. Vesikari T, Karvonen A, Korhonen T, et al. Immunogenicity of 10-Valent Pneumococcal Nontypeable *Haemophilus Influenzae* Protein D Conjugate Vaccine When Administered as Catch-up Vaccination to Children 7 Months to 5 Years of Age. *Pediatric Infectious Disease Journal.* 2011 Aug;30(8):E130-E41. PMID: WOS:000293064200001.

1446. Vesikari T, Karvonen A, Lindblad N, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable *Haemophilus influenzae* protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. *Pediatric Infectious Disease Journal.* 2010 Jun;29(6):e47-56. PMID: 20508478.

1447. Vesikari T, Karvonen A, Prymula R, et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. *Vaccine.* 2010 Jul 19;28(32):5272-9. PMID: 20538094.

1448. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. *New England Journal of Medicine.* 2011 Oct 13;365(15):1406-16. PMID: 21995388.

1449. Vesikari T, Martin JC, Liss CL, et al. Safety and Immunogenicity of a Modified Process Hepatitis B Vaccine in Healthy Infants. *Pediatric Infectious Disease Journal.* 2011 Jul;30(7):E109-E13. PMID: WOS:000291675100001.

1450. Vidal P, Reyna J, Saldana P, et al. Events temporarily associated with anti-influenza A (H1N1) vaccination in Mexico. *Archives of Medical Research.* 2011 Oct;42(7):627-32. PMID: 22036935.

1451. Vigano A, Giacomet V, Pariani E, et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. *Clinical & Vaccine Immunology: CVI.* 2011 Sep;18(9):1503-9. PMID: 21795458.

1452. Vilella A, Dal-Re R, Simo D, et al. Reactogenicity profile of a combined hepatitis A and B vaccine in clinical practice: A naturalistic study in adult travellers. *Vaccine*. 2005;31;23(19):2463-7. PMID: 2005112501.
1453. Voelker R. Study finds Tdap vaccine is safe for older adults. *JAMA*. 2012 Dec 26;308(24):2555. PMID: 23268497.
1454. von Kries R. Comment on B. Zinka et al., Unexplained cases of sudden infant death shortly after hexavalent vaccination. *Vaccine*. 2006 Jul 26;24(31-32):5783-4; author reply 5-6. PMID: 16081190.
1455. Von Spiczak S, Helbig I, Drechsel-Baeuerle U, et al. A retrospective population-based study on seizures related to childhood vaccination. *Epilepsia*. 2011 August;52(8):1506-12. PMID: 2011416874 MEDLINE PMID 21692791 (<http://www.ncbi.nlm.nih.gov/pubmed/21692791>).
1456. Waddington CS, Andrews N, Hoschler K, et al. Open-label, randomised, parallelgroup, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-inwater emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. *Health Technology Assessment*. 2010;2010;14(46):1-496. PMID: 2010587743 MEDLINE PMID 20923610 (<http://www.ncbi.nlm.nih.gov/pubmed/20923610>).
1457. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. *BMJ*. 2010;340:c2649. PMID: 20508026.
1458. Wade AG, Crawford GM, Pumford N, et al. Patient reported outcome data following influenza A (H1N1p) vaccination in the 2009-2010 season: web-based and telephone evaluation. *Therapeutics & Clinical Risk Management*. 2011;7:409-20. PMID: 22076117.
1459. Waggie Z, Geldenhuys H, Sutter RW, et al. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa. *Journal of Infectious Diseases*. 2012 Jan 15;205(2):228-36. PMID: 22158680.
1460. Waggie Z, Geldenhuys H, Sutter RW, et al. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa. *Journal of Infectious Diseases*. 2012 Jan 15;205(2):228-36. PMID: 22158680.
1461. Waites KB, Canupp KC, Chen Y-Y, et al. Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine. *Journal of Spinal Cord Medicine*. 2008;31(1):53-9. PMID: 18533412.

1462. Walker FJ, Singleton RJ, Bulkow LR, et al. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. *Clinical Infectious Diseases*. 2005 Jun 15;40(12):1730-5. PMID: 15909258.
1463. Walker RI. New vaccines against enteric bacteria for children in less developed countries. *Expert Review of Vaccines*. 2005 December;4(6):807-12. PMID: 2006012938 MEDLINE PMID 16372876 (<http://www.ncbi.nlm.nih.gov/pubmed/16372876>).
1464. Walker WT, de Whalley P, Andrews N, et al. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. *Clinical Infectious Diseases*. 2012 Mar 1;54(5):661-9. PMID: 22267719.
1465. Walter EB, Moggio MV, Drucker RP, et al. Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease. *Pediatric Infectious Disease Journal*. 1990 1990;9(9):632-5. PMID: 1990298120 MEDLINE PMID 2235187 (<http://www.ncbi.nlm.nih.gov/pubmed/2235187>).
1466. Walters JAE, Smith S, Poole P, et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*. 2010(11) PMID: WOS:000284076200001.
1467. Wang IJ, Huang LM, Guo YL, et al. Haemophilus influenzae type b combination vaccines and atopic disorders: A prospective cohort study. *Journal of the Formosan Medical Association*. 2012.
1468. Ward RL, Bernstein DI. Rotarix: a rotavirus vaccine for the world. *Clinical Infectious Diseases*. 2009 Jan 15;48(2):222-8. PMID: 19072246.
1469. Watemberg N, Dagan R, Arbelli Y, et al. Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. *Pediatric Infectious Disease Journal*. 1991 Oct;10(10):758-63. PMID: 1945578.
1470. Waters O, Ahmad T. Opportunistic infections and vaccinations in IBD patients. *Journal of Crohn's and Colitis*. 2011 June;5(3):263. PMID: 2011269125 MEDLINE PMID 21575894 (<http://www.ncbi.nlm.nih.gov/pubmed/21575894>).
1471. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. *Vaccine*. 2002 May;20(17-18):2166-73. PMID: WOS:000176092600003.
1472. Weckx LY, Thompson A, Berezin EN, et al. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. *Vaccine*. 2012 Dec 14;30(52):7566-72. PMID: 23099331.

1473. Wei S-H, Chao Y-N, Huang S-E, et al. Adverse effects of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in 6- to 7-year-old children. *Pediatrics & Neonatology*. 2011 Feb;52(1):38-41. PMID: 21385656.
1474. Weinberg A, Allshouse AA, MaWhinney S, et al. Responses to Hepatitis A Virus Vaccine in HIV-Infected Women: Effect of Hormonal Contraceptives and HIV Disease Characteristics. *Jaids-Journal of Acquired Immune Deficiency Syndromes*. 2012 May;60(1):E15-E8. PMID: WOS:000303112200003.
1475. Werther RL, Crawford NW, Boniface K, et al. Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency. *Journal of Allergy and Clinical Immunology*. 2009 September;124(3):600. PMID: 2009459042 MEDLINE PMID 19660805 (<http://www.ncbi.nlm.nih.gov/pubmed/19660805>).
1476. West DJ, Hesley TM, Jonas LC, et al. Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants. *Hib-HB Vaccine Study Group. Pediatric Infectious Disease Journal*. 1997 Jun;16(6):593-9. PMID: 9194110.
1477. West DJ, Hesley TM, Jonas LC, et al. Safety and immunogenicity of a bivalent haemophilus influenzae type b/hepatitis B vaccine in healthy infants. *Pediatric Infectious Disease Journal*. 1997 June;16(6):593-9. PMID: 1997182079 MEDLINE PMID 9194110 (<http://www.ncbi.nlm.nih.gov/pubmed/9194110>).
1478. Weston WM, Friedland LR, Wu X, et al. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. *Vaccine*. 2011 29;29(5):1017-22. PMID: 2011043488 MEDLINE PMID 21134450 (<http://www.ncbi.nlm.nih.gov/pubmed/21134450>).
1479. Weston WM, Friedland LR, Wu X, et al. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix()): results of two randomized trials. *Vaccine*. 2012 Feb 21;30(9):1721-8. PMID: 22212127.
1480. Weston WM, Friedland LR, Wu XF, et al. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix (R)): Results of two randomized trials. *Vaccine*. 2012 Feb;30(9):1721-8. PMID: WOS:000301558200022.
1481. Weston WM, Klein NP. Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years. *Expert Review of Vaccines*. 2008 Nov;7(9):1309-20. PMID: 18980534.
1482. Whelan J, Hahne S, Berbers G, et al. Immunogenicity of a hexavalent vaccine co-administered with 7-valent pneumococcal conjugate vaccine: Findings from the national immunization program in the Netherlands. *Human Vaccines and Immunotherapeutics*. 2012 June;8(6):743-8. PMID: 2012397533.

1483. White CJ, Stinson D, Stachle B, et al. Measles, mumps, rubella, and varicella combination vaccine: Safety and immunogenicity alone and in combination with other vaccines given to children. *Clinical Infectious Diseases*. 1997;1997;24(5):925-31. PMID: 1997136850 MEDLINE PMID 9142794 (<http://www.ncbi.nlm.nih.gov/pubmed/9142794>).
1484. White CJ, Stinson D, Staehle B, et al. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group. *Clinical Infectious Diseases*. 1997 May;24(5):925-31. PMID: 9142794.
1485. White SJ, Boldt KL, Holditch SJ, et al. Measles, mumps, and rubella. *Clinical Obstetrics and Gynecology*. 2012 June;55(2):550-9. PMID: 2012239410.
1486. Whitney CG. The potential of pneumococcal conjugate vaccines for children. *Pediatric Infectious Disease Journal*. 2002 Oct;21(10):961-70. PMID: WOS:000178654300016.
1487. Whitney CG. New safety information for an old vaccine. *Clinical Infectious Diseases*. 2005 Jun 15;40(12):1736-7. PMID: 15909259.
1488. Wilhelm DJ, Paegle RD. Thrombocytopenic purpura and pneumonia following measles vaccination. *American Journal of Diseases of Children*. 1967 May;113(5):534-7. PMID: 6067240.
1489. Wilkin T, Lee JY, Lensing SY, et al. Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men. *Journal of Infectious Diseases*. 2010 Oct;202(8):1246-53. PMID: WOS:000288250900014.
1490. Williams DJ, Hall M, Brogan TV, et al. Influenza Coinfection and Outcomes in Children With Complicated Pneumonia. *Archives of Pediatrics & Adolescent Medicine*. 2011 Jun;165(6):506-12. PMID: WOS:000291321000005.
1491. Williams SE, Klein NP, Halsey N, et al. Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009. *Vaccine*. 2011 Oct 26;29(40):6920-7. PMID: 2011489211 MEDLINE PMID 21801776 (<http://www.ncbi.nlm.nih.gov/pubmed/21801776>).
1492. Williams SE, Pahud BA, Vellozzi C, et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. *Vaccine*. 2011 Oct 26;29(46):8302-8. PMID: 21893148.
1493. Williamson R. The balance between privacy, safety and community health. *Journal of Paediatrics & Child Health*. 2003 Sep-Oct;39(7):507-8. PMID: 12969202.

1494. Wilson K, Hawken S. Incidence of adverse events in premature children following 2-mo vaccination. *Human Vaccines and Immunotherapeutics*. 2012 May;8(5):592-5. PMID: 2012397555.
1495. Wilson K, Hawken S, Potter BK, et al. Patterns of emergency room visits, admissions and death following recommended pediatric vaccinations-A population based study of 969,519 vaccination events. *Vaccine*. 2011 May;29(21):3746-52. PMID: WOS:000291072500009.
1496. Win KM, Aye M, Htay-Htay H, et al. Comparison of separate and mixed administration of DTPw-HBV and Hib vaccines: Immunogenicity and reactogenicity profiles. *International Journal of Infectious Diseases*. 1997 1997;2(2):79-84. PMID: 1998084416.
1497. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine.[Erratum appears in JAMA 2000 Dec 27;284(24):3129]. *JAMA*. 2000 Sep 13;284(10):1271-9. PMID: 10979114.
1498. Wiwanitkit V. Adverse effect in diabetic patients who get swine flu vaccination: Implication for vaccine safety. *Diabetologia Croatica*. 2010 2010;39(2):79. PMID: 2010579127.
1499. Wong SH, Lennon DR, Jackson CM, et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. *Pediatric Infectious Disease Journal*. 2009 May;28(5):385-90. PMID: 2009320834 MEDLINE PMID 19384263 (<http://www.ncbi.nlm.nih.gov/pubmed/19384263>).
1500. Wong-Chew RM, Garcia-Leon ML, Espinosa-Torres Torrija B, et al. Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously. *Journal of Infectious Diseases*. 2011 Aug 1;204(3):426-32. PMID: 21742842.
1501. Woo EJ, Ball R, Bostrom A, et al. Vaccine risk perception among reporters of autism after vaccination: Vaccine adverse event reporting system 1990-2001. *American Journal of Public Health*. 2004 June;94(6):990-5. PMID: 2004235158 MEDLINE PMID 15249304 (<http://www.ncbi.nlm.nih.gov/pubmed/15249304>).
1502. Woo EJ, Miller NB, Ball R. Adverse events after hepatitis A B combination vaccine. *Vaccine*. 2006 24;24(14):2685-91. PMID: 2006095770 MEDLINE PMID 16310295 (<http://www.ncbi.nlm.nih.gov/pubmed/16310295>).
1503. Woo EJ, Wise RP, Menschik D, et al. Thrombocytopenia after vaccination: Case reports to the US Vaccine Adverse Event Reporting System, 1990-2008. *Vaccine*. 2011 1;29(6):1319-23. PMID: 2011043528 MEDLINE PMID 21126606 (<http://www.ncbi.nlm.nih.gov/pubmed/21126606>).
1504. Wood N, McIntyre P, Wong M. Vaccination for the paediatrician. *Journal of Paediatrics & Child Health*. 2006 Nov;42(11):665-73. PMID: 17044892.

1505. Wood RA, Berger M, Dreskin SC, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. *Pediatrics*. 2008 September;122(3):e771-e7. PMID: 2009162190 MEDLINE PMID 18762513 (<http://www.ncbi.nlm.nih.gov/pubmed/18762513>).
1506. Wu J, Xu F, Lu L, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. *New England Journal of Medicine*. 2010 16;363(25):2416-23. PMID: 2010690653 MEDLINE PMID 21158658 (<http://www.ncbi.nlm.nih.gov/pubmed/21158658>).
1507. Wu J, Zhong X, Li CKF, et al. Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans. *Vaccine*. 2011 29;29(5):1009-16. PMID: 2011043487 MEDLINE PMID 21130194 (<http://www.ncbi.nlm.nih.gov/pubmed/21130194>).
1508. Wuorimaa T, Dagan R, Eskola J, et al. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. *Pediatric Infectious Disease Journal*. 2001 Mar;20(3):272-7. PMID: 11303829.
1509. Wuorimaa T, Kayhty H, Leroy O, et al. Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults. *Vaccine*. 2001 Feb 28;19(15-16):1863-9. PMID: 11228355.
1510. Wysocki J, Tansey S, Brachet E, et al. Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines. *Vaccine*. 2010 16;28(49):7779-86. PMID: 2010629451 MEDLINE PMID 20883736 (<http://www.ncbi.nlm.nih.gov/pubmed/20883736>).
1511. Xu S, Zhang L, Nelson JC, et al. Identifying optimal risk windows for self-controlled case series studies of vaccine safety. *Statistics in Medicine*. 2011 Mar 30;30(7):742-52. PMID: 21394750.
1512. Yacoub H, Khan H, Islam S, et al. Guillain-Barre Syndrome after Influenza Vaccination in the United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. (1990-2009). *Neurology*. 2010 Mar;74(9):A524-A. PMID: WOS:000275274002508.
1513. Yanagisawa N, Maeda K, Ajisawa A, et al. Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects. *Vaccine*. 2011 Aug 5;29(34):5694-8. PMID: 21689709.
1514. Yeager DP, Toy EC, Baker B, 3rd. Influenza vaccination in pregnancy. *Am J Perinatol*. 1999;16(6):283-6. PMID: 10586981.
1515. Yee SS, Dutta PR, Solin LJ, et al. RE: Efficacy and safety of influenza vaccination during chemotherapy treatment. *Journal of Supportive Oncology*. 2010 November-December;8(6):272. PMID: 2011042975.
1516. Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-Valent pneumococcal conjugate vaccine in infants and toddlers. *Pediatrics*. 2010

September;126(3):e493-e505. PMID: 2010480679 MEDLINE PMID 20732948 (<http://www.ncbi.nlm.nih.gov/pubmed/20732948>).

1517. Yeh SH, Ward JI, Partridge S, et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. *Pediatric Infectious Disease Journal*. 2001 Oct;20(10):973-80. PMID: 11642632.

1518. Yeh SJ, Huang LM, Chen JM, et al. Safety and immunogenicity of a conjugated *Haemophilus influenzae* type B polysaccharide-*Neisseria meningitidis* outer membrane protein vaccine. *Journal of the Formosan Medical Association*. 1997 Feb;96(2):110-5. PMID: 9071836.

1519. Yen C, Tate JE, Steiner CA, et al. Trends in intussusception hospitalizations among US infants before and after implementation of the rotavirus vaccination program, 2000-2009. *Journal of Infectious Diseases*. 2012 1;206(1):41-8. PMID: 2012308445 MEDLINE PMID 22539812 (<http://www.ncbi.nlm.nih.gov/pubmed/22539812>).

1520. Yoge R, Ardit M, Chadwick EG, et al. *Haemophilus influenzae* type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses. *Pediatrics*. 1990 Apr;85(4 Pt 2):690-3. PMID: 2107520.

1521. Yong M, Schoonen WM, Li L, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. *British Journal of Haematology*. 2010 June;149(6):855-64. PMID: 2010294294 MEDLINE PMID 20377590 (<http://www.ncbi.nlm.nih.gov/pubmed/20377590>).

1522. Young HA, Geier DA, Geier MR. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. *Journal of the Neurological Sciences*. 2008 Aug 15;271(1-2):110-8. PMID: 18482737.

1523. Youngster I, Kozer E, Lazarovitch Z, et al. Probiotics and the immunological response to infant vaccinations: a prospective, placebo controlled pilot study. *Archives of Disease in Childhood*. 2011 Apr;96(4):345-9. PMID: 21266337.

1524. Yousef E, Mannan S. Systemic reaction to pneumococcal vaccine: how common in pediatrics? *Allergy & Asthma Proceedings*. 2008 Jul-Aug;29(4):397-9. PMID: 18702888.

1525. Yuen SK, Wong ML, Chan YK, et al. SIADH After Influenza Vaccination. *Hong Kong Journal of Nephrology*. 2010 April;12(1):39-40. PMID: 2010239032.

1526. Yuksel N, Beyazova U, Balci IF, et al. Immunogenicity of a *Haemophilus influenzae* type b-tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey. *International Journal of Infectious Diseases*. 2012 May;16(5):E354-E7. PMID: WOS:000302784000007.

1527. Zafrir Y, Agmon-Levin N, Paz Z, et al. Autoimmunity following Hepatitis B vaccine as part of the spectrum of 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' (ASIA): Analysis of 93 cases. *Lupus*. 2012 February;21(2):146-52. PMID: 2012029364.
1528. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. *New England Journal of Medicine*. 2008 9;359(15):1555-64. PMID: 2008479892 MEDLINE PMID 18799552 (<http://www.ncbi.nlm.nih.gov/pubmed/18799552>).
1529. Zanardi LR, Haber P, Mootrey GT, et al. Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. *Pediatrics*. 2001 Jun;107(6):E97. PMID: 11389295.
1530. Zanetti A, Parlato A, Romano L, et al. Challenge with a hepatitis B vaccine in two cohorts of 4-7-year-old children primed with hexavalent vaccines: An open-label, randomised trial in Italy. *Vaccine*. 2012 24;30(39):5770-5. PMID: 2012477027.
1531. Zangwill KM, Eriksen E, Lee M, et al. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization. *Pediatrics*. 2008 Dec;122(6):e1179-85. PMID: 19047220.
1532. Zangwill KM, Greenberg DP, Chiu C-Y, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants. *Vaccine*. 2003 May 16;21(17-18):1894-900. PMID: 12706674.
1533. Zangwill KM, Yeh SH, Wong EJ, et al. Paralytic Syndromes in Children: Epidemiology and Relationship to Vaccination. *Pediatric Neurology*. 2010 March;42(3):206-12. PMID: 2010099397 MEDLINE PMID 20159431 (<http://www.ncbi.nlm.nih.gov/pubmed/20159431>).
1534. Zastrow A, Schnitzler P, Eckerle I, et al. Immunogenicity and Safety of H1N1 Vaccination in Anorexia Nervosa-Results from a Pilot Study. *International Journal of Eating Disorders*. 2012 January;45(1):146-9. PMID: 2011697169 MEDLINE PMID 22170028 (<http://www.ncbi.nlm.nih.gov/pubmed/22170028>).
1535. Zent O, Arras-Reiter C, Broeker M, et al. Immediate allergic reactions after vaccinations - A post-marketing surveillance review. *European Journal of Pediatrics*. 2002 2002;161(1):21-5. PMID: 2002013131 MEDLINE PMID 11808876 (<http://www.ncbi.nlm.nih.gov/pubmed/11808876>).
1536. Zepp F, Behre U, Kindler K, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. *European Journal of Pediatrics*. 2007 Aug;166(8):857-64. PMID: 17541639.

1537. Zepp F, Knuf M, Heininger U, et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. *Vaccine*. 2004 Jun 2;22(17-18):2226-33. PMID: 15149781.
1538. Zepp F, Schuind A, Meyer C, et al. Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants. *Pediatrics*. 2002 Apr;109(4):e58. PMID: 11927731.
1539. Zhang Z-L, Zhu X-J, Wang X, et al. Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children. *Vaccine*. 2012 Jun 8;30(27):4028-33. PMID: 22537990.
1540. Zheng H, Chen Y, Wang F, et al. Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose. *Vaccine*. 2011 Nov 8;29(48):9098-103. PMID: 21875638.
1541. Zheteyeva Y, Moro PL, Yue X, et al. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System. *American Journal of Obstetrics & Gynecology*. 2013 Jun;208(6):478.e1-6. PMID: 23453881.
1542. Zheteyeva YA, Moro PL, Tepper NK, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. *American Journal of Obstetrics and Gynecology*. 2012 July;207(1):59.e1-e7. PMID: 2012357312.
1543. Zhou W, Pool V, DeStefano F, et al. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. *Pharmacoepidemiol Drug Saf*. 2004 Aug;13(8):505-10. PMID: 15317028.
1544. Zickafoose JS, Benneyworth BD, Riebschleger MP, et al. Hospitalizations for intussusception before and after the reintroduction of rotavirus vaccine in the United States. *Archives of Pediatrics & Adolescent Medicine*. 2012 Apr;166(4):350-5. PMID: 22213609.
1545. Zielen S, Buhring I, Strnad N, et al. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. *Infection & Immunity*. 2000 Mar;68(3):1435-40. PMID: 10678957.
1546. Zimmerman RK, Middleton DB, Burns IT, et al. Routine vaccines across the life span, 2007. *Journal of Family Practice*. 2007 Feb;56(2 Suppl Vaccines):S18-37, C1-3. PMID: 17270108.
1547. Zinka B, Rauch E, Buettner A, et al. Unexplained cases of sudden infant death shortly after hexavalent vaccination. *Vaccine*. 2006 Jul 26;24(31-32):5779-80. PMID: 15908063.

1548. Zollinger WD, Boslego JE, Frasch CE, et al. Safety of vaccines containing meningococcal group B polysaccharide. Lancet. 1984 Jul 21;2(8395):166. PMID: 6146064.
1549. Zuccotti GV, Pariani E, Scaramuzza A, et al. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. Diabetic Medicine. 2011 Dec;28(12):1530-6. PMID: 21916971.

Rejected as Included in 2011 IOM Report – 64

1. Infections and vaccinations as risk factors for childhood type I (insulin-dependent) diabetes mellitus: a multicentre case-control investigation. EURODIAB Substudy 2 Study Group. *Diabetologia*. 2000 Jan;43(1):47-53. PMID: 10663215.
2. The safety of inactivated influenza vaccine in adults and children with asthma. *N Engl J Med*. 2001 Nov 22;345(21):1529-36. PMID: 11794219.
3. Abu-Shakra M, Zalmanson S, Neumann L, et al. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. *J Rheumatol*. 2000 Jul;27(7):1681-5. PMID: 10914851.
4. Ahlgren C, Toren K, Oden A, et al. A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. *Eur J Epidemiol*. 2009;24(9):541-52. PMID: 19633994.
5. Altobelli E, Petrocelli R, Verrotti A, et al. Infections and risk of type I diabetes in childhood: a population-based case-control study. *Eur J Epidemiol*. 2003;18(5):425-30. PMID: 12889689.
6. Andrews N, Stowe J, Miller E, et al. Post-licensure safety of the meningococcal group C conjugate vaccine. *Hum Vaccin*. 2007 Mar-Apr;3(2):59-63. PMID: 17312400.
7. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. *Pediatr Infect Dis J*. 2006 Oct;25(10):870-9. PMID: 17006279.
8. Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. *N Engl J Med*. 2001 Aug 30;345(9):656-61. PMID: 11547719.
9. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. *N Engl J Med*. 2007 Feb 15;356(7):685-96. PMID: 17301299.
10. Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. *Clin Infect Dis*. 2004 Oct 1;39(7):920-7. PMID: 15472840.
11. Bengtsson C, Kapetanovic MC, Kallberg H, et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. *Ann Rheum Dis*. 2010 Oct;69(10):1831-3. PMID: 20603497.
12. Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. *BMJ*. 1992 Apr 25;304(6834):1075-8. PMID: 1586818.

13. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. *Pediatr Infect Dis J.* 2004 Feb;23(2):138-44. PMID: 14872180.
14. Black S, Shinefield H, Ray P, et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. *Pediatr Infect Dis J.* 1997 May;16(5):500-3. PMID: 9154545.
15. Blom L, Nystrom L, Dahlquist G. The Swedish childhood diabetes study. Vaccinations and infections as risk determinants for diabetes in childhood. *Diabetologia.* 1991 Mar;34(3):176-81. PMID: 1884889.
16. Bueving HJ, Bernsen RM, de Jongste JC, et al. Does influenza vaccination exacerbate asthma in children? *Vaccine.* 2004 Nov 15;23(1):91-6. PMID: 15519712.
17. Burwen DR, Ball R, Bryan WW, et al. Evaluation of Guillain-Barre Syndrome among recipients of influenza vaccine in 2000 and 2001. *Am J Prev Med.* 2010 Oct;39(4):296-304. PMID: 20837279.
18. Chen RT, Moses JM, Markowitz LE, et al. Adverse events following measles-mumps-rubella and measles vaccinations in college students. *Vaccine.* 1991 May;9(5):297-9. PMID: 1872012.
19. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. *N Engl J Med.* 2001 Feb 1;344(5):319-26. PMID: 11172162.
20. De Serres G, Skowronski DM, Guay M, et al. Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons. *Arch Intern Med.* 2004 Nov 8;164(20):2266-72. PMID: 15534165.
21. Del Porto F, Lagana B, Biselli R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. *Vaccine.* 2006 Apr 12;24(16):3217-23. PMID: 16466833.
22. DeStefano F, Mullooly JP, Okoro CA, et al. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. *Pediatrics.* 2001 Dec;108(6):E112. PMID: 11731639.
23. DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. *Arch Neurol.* 2003 Apr;60(4):504-9. PMID: 12707063.
24. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. *Lancet.* 1995 Mar 4;345(8949):567-9. PMID: 7619183.

25. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. *Pediatr Infect Dis J.* 2006 Oct;25(10):860-9. PMID: 17006278.
26. France EK, Glanz JM, Xu S, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. *Arch Pediatr Adolesc Med.* 2004 Nov;158(11):1031-6. PMID: 15520339.
27. Goodman MJ, Nordin JD, Harper P, et al. The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age. *Pediatrics.* 2006 May;117(5):e821-6. PMID: 16651286.
28. Greene SK, Kulldorff M, Lewis EM, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. *Am J Epidemiol.* 2010 Jan 15;171(2):177-88. PMID: 19965887.
29. Griffin MR, Ray WA, Mortimer EA, et al. Risk of seizures after measles-mumps-rubella immunization. *Pediatrics.* 1991 Nov;88(5):881-5. PMID: 1945626.
30. Hambidge SJ, Glanz JM, France EK, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. *JAMA.* 2006 Oct 25;296(16):1990-7. PMID: 17062862.
31. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. *Ann Rheum Dis.* 2007 Oct;66(10):1384-7. PMID: 17284544.
32. Hernan MA, Jick SS, Olek MJ, et al. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. *Neurology.* 2004 Sep 14;63(5):838-42. PMID: 15365133.
33. Hocine MN, Farrington CP, Touze E, et al. Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. *Vaccine.* 2007 Aug 1;25(31):5938-43. PMID: 17597263.
34. Holvast A, Stegeman CA, Benne CA, et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. *Ann Rheum Dis.* 2009 Jun;68(6):873-8. PMID: 18625625.
35. Huang WT, Gargiullo PM, Broder KR, et al. Lack of association between acellular pertussis vaccine and seizures in early childhood. *Pediatrics.* 2010 Aug;126(2):263-9. PMID: 20643726.
36. Hughes RA, Charlton J, Latinovic R, et al. No association between immunization and Guillain-Barre syndrome in the United Kingdom, 1992 to 2000. *Arch Intern Med.* 2006 Jun 26;166(12):1301-4. PMID: 16801513.

37. Hurwitz ES, Schonberger LB, Nelson DB, et al. Guillain-Barre syndrome and the 1978-1979 influenza vaccine. *N Engl J Med.* 1981 Jun 25;304(26):1557-61. PMID: 7231501.
38. Hviid A, Stellfeld M, Wohlfahrt J, et al. Childhood vaccination and type 1 diabetes. *N Engl J Med.* 2004 Apr 1;350(14):1398-404. PMID: 15070789.
39. Juurlink DN, Stukel TA, Kwong J, et al. Guillain-Barre syndrome after influenza vaccination in adults: a population-based study. *Arch Intern Med.* 2006 Nov 13;166(20):2217-21. PMID: 17101939.
40. Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. *Pediatr Infect Dis J.* 2010 Jul;29(7):613-7. PMID: 20190673.
41. Kmiecik T, Arnoux S, Kobrynski A, et al. Influenza vaccination in adults with asthma: safety of an inactivated trivalent influenza vaccine. *J Asthma.* 2007 Dec;44(10):817-22. PMID: 18097856.
42. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. *N Engl J Med.* 2002 Nov 7;347(19):1477-82. PMID: 12421889.
43. Makela A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. *Pediatrics.* 2002 Nov;110(5):957-63. PMID: 12415036.
44. Miller AE, Morgante LA, Buchwald LY, et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. *Neurology.* 1997 Feb;48(2):312-4. PMID: 9040712.
45. Miller E, Andrews N, Stowe J, et al. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. *Am J Epidemiol.* 2007 Mar 15;165(6):704-9. PMID: 17204517.
46. Nicholson KG, Nguyen-Van-Tam JS, Ahmed AH, et al. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. *Lancet.* 1998 Jan 31;351(9099):326-31. PMID: 9652613.
47. Pattison E, Harrison BJ, Griffiths CE, et al. Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. *Ann Rheum Dis.* 2008 May;67(5):672-6. PMID: 17823200.
48. Payne DC, Rose CE, Jr., Kerrison J, et al. Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003. *Arch Neurol.* 2006 Jun;63(6):871-5. PMID: 16769869.

49. Pedroza A, Huerta JG, Garcia Mde L, et al. The safety and immunogenicity of influenza vaccine in children with asthma in Mexico. *Int J Infect Dis.* 2009 Jul;13(4):469-75. PMID: 19084453.
50. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. *Lancet.* 1986 Apr 26;1(8487):939-42. PMID: 2871241.
51. Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. *Pediatrics.* 2005 Sep;116(3):e397-407. PMID: 16140685.
52. Ray P, Hayward J, Michelson D, et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. *Pediatr Infect Dis J.* 2006 Sep;25(9):768-73. PMID: 16940831.
53. Scheifele DW, Duval B, Russell ML, et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. *Clin Infect Dis.* 2003 Apr 1;36(7):850-7. PMID: 12652385.
54. Skowronski DM, De Serres G, Scheifele D, et al. Randomized, double-blind, placebo-controlled trial to assess the rate of recurrence of oculorespiratory syndrome following influenza vaccination among persons previously affected. *Clin Infect Dis.* 2003 Oct 15;37(8):1059-66. PMID: 14523770.
55. Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. *Lancet.* 2004 Sep 11-17;364(9438):963-9. PMID: 15364187.
56. Stowe J, Andrews N, Wise L, et al. Bell's palsy and parenteral inactivated influenza vaccine. *Hum Vaccin.* 2006 May-Jun;2(3):110-2. PMID: 17012908.
57. Stowe J, Andrews N, Wise L, et al. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database. *Am J Epidemiol.* 2009 Feb 1;169(3):382-8. PMID: 19033158.
58. Tam CC, O'Brien SJ, Petersen I, et al. Guillain-Barre syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. *PLoS One.* 2007;2(4):e344. PMID: 17406668.
59. Tata LJ, West J, Harrison T, et al. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? *Thorax.* 2003 Oct;58(10):835-9. PMID: 14514932.

60. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. *Lancet*. 1999 Jun 12;353(9169):2026-9. PMID: 10376617.
61. Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. *JAMA*. 2004 Jul 21;292(3):351-7. PMID: 15265850.
62. Ward KN, Bryant NJ, Andrews NJ, et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. *Pediatrics*. 2007 Aug;120(2):314-21. PMID: 17671057.
63. Williams GW, Steinberg AD, Reinertsen JL, et al. Influenza immunization in systemic lupus erythematosus. A double-blind trial. *Ann Intern Med*. 1978 Jun;88(6):729-34. PMID: 352210.
64. Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. *Vaccine*. 2009 Jul 9;27(32):4257-62. PMID: 19486957.

Rejected for IOM Search Identified, Excluded – 85

1. Allsup S, Gosney M, Haycox A, et al. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age. *Health Technology Assessment* (Winchester, England). 2003;7(24):iii-x, 1-65. PMID: 14499051.
2. Allsup S, Haycox A, Regan M, et al. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. *Vaccine*. 2004 Dec 16;23(5):639-45. PMID: 15542184.
3. Allsup SJ, Gosney M, Regan M, et al. Side effects of influenza vaccination in healthy older people: A randomised single-blind placebo-controlled trial. *Gerontology*. 2001 2001;47(6):311-4. PMID: 2001434764 MEDLINE PMID 11721144
(<http://www.ncbi.nlm.nih.gov/pubmed/11721144>).
4. Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. *Vaccine*. 2009 Dec 9;27(52):7304-12. PMID: 19849996.
5. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. *N Engl J Med*. 2001 Feb 1;344(5):327-32. PMID: 11172163.
6. Asturias EJ, Dueger EL, Omer SB, et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. *Journal of Infectious Diseases*. 2007 Sep 1;196(5):692-8. PMID: 17674310.
7. Avendano A, Ferreccio C, Lagos R, et al. Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. *Pediatric Infectious Disease Journal*. 1993 Aug;12(8):638-43. PMID: 8414775.
8. Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. *Vaccine*. 2008 Sep 12;26 Suppl 4:D10-6. PMID: 18611422.
9. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. *J Pediatr*. 2000 Feb;136(2):168-75. PMID: 10657821.
10. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. *N Engl J Med*. 1998 May 14;338(20):1405-12. PMID: 9580647.

11. Belshe RB, Newman FK, Wilkins K, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. *Vaccine*. 2007 Sep 17;25(37-38):6755-63. PMID: 17692438.
12. Benke G, Abramson M, Raven J, et al. Asthma and vaccination history in a young adult cohort. *Australian & New Zealand Journal of Public Health*. 2004 Aug;28(4):336-8. PMID: 15704697.
13. Bernsen RMD, van der Wouden JC. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children. *Pediatric Allergy & Immunology*. 2008 Sep;19(6):544-51. PMID: 18266826.
14. Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopenic purpura. *Br J Clin Pharmacol*. 2003 Jan;55(1):107-11. PMID: 12534647.
15. Black SB, Shinefield HR, France EK, et al. Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. *American Journal of Perinatology*. 2004 Aug;21(6):333-9. PMID: 15311370.
16. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. *Pediatrics*. 2006 Nov;118(5):2135-45. PMID: 17079588.
17. Borcic B, Dobrovsak-Sourek V, Kaic B, et al. A comparative study of reactogenicity and immunogenicity of an oral and an inactivated polio vaccine. *Acta Medica Croatica*. 1998;52(3):155-8. PMID: 9818437.
18. Carbone T, McEntire B, Kissin D, et al. Absence of an increase in cardiorespiratory events after diphtheria-tetanus-acellular pertussis immunization in preterm infants: a randomized, multicenter study. *Pediatrics*. 2008 May;121(5):e1085-90. PMID: 18450851.
19. Chiu SS, Peiris JS, Chan KH, et al. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. *Pediatrics*. 2007 Jun;119(6):1076-82. PMID: 17545373.
20. Chuaychoo B, Wongsurakiat P, Nana A, et al. The immunogenicity of intradermal influenza vaccination in COPD patients. *Vaccine*. 2010 28;28(24):4045-51. PMID: 2010290747 MEDLINE PMID 20412877 (<http://www.ncbi.nlm.nih.gov/pubmed/20412877>).
21. Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. *Eur Heart J*. 2008 Jun;29(11):1350-8. PMID: 18187561.

22. Clements-Mann ML, Dudas R, Hoshino Y, et al. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. *Vaccine*. 2001 Sep 14;19(32):4676-84. PMID: 11535316.
23. De Villiers PJ, Steele AD, Hiemstra LA, et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. *Vaccine*. 2009 Dec 10;28(1):228-34. PMID: 19796721.
24. Deinard AS, Ogburn P, Jr. A/NJ/8/76 influenza vaccination program: effects on maternal health and pregnancy outcome. *Am J Obstet Gynecol*. 1981 Jun 1;140(3):240-5. PMID: 7246624.
25. DeStefano F, Bhasin TK, Thompson WW, et al. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan atlanta. *Pediatrics*. 2004 Feb;113(2):259-66. PMID: 14754936.
26. Dockerty JD, Skegg DC, Elwood JM, et al. Infections, vaccinations, and the risk of childhood leukaemia. *Br J Cancer*. 1999 Jul;80(9):1483-9. PMID: 10424755.
27. Faden H, Duffy L. Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines. *American Journal of Diseases of Children*. 1992 Nov;146(11):1320-3. PMID: 1415071.
28. Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. *J Infect Dis*. 2009 Jul 15;200(2):172-80. PMID: 19508159.
29. Ferreccio C, Clemens J, Avendano A, et al. The clinical and immunologic response of Chilean infants to *Haemophilus influenzae* type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age. *Pediatric Infectious Disease Journal*. 1991 Oct;10(10):764-71. PMID: 1945579.
30. France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. *Pediatrics*. 2008 Mar;121(3):e687-92. PMID: 18310189.
31. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *N Engl J Med*. 2007 May 10;356(19):1928-43. PMID: 17494926.
32. Gatchalian S, Palestroque E, De Vleeschauwer I, et al. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-*Neisseria meningitidis* serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. *International Journal of Infectious Diseases*. 2008

May;12(3):278-88. PMID: 2008187926 MEDLINE PMID 17981067
(<http://www.ncbi.nlm.nih.gov/pubmed/17981067>).

33. Giammanco G, Li Volti S, Mauro L, et al. Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy. *Vaccine*. 1991 1991;9(10):747-50. PMID: 1991287091 MEDLINE PMID 1836919 (<http://www.ncbi.nlm.nih.gov/pubmed/1836919>).
34. Gorse GJ, O'Connor TZ, Young SL, et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: A VA cooperative study. *Vaccine*. 2003 16;21(17 18):2133-44. PMID: 2003156566.
35. Govaert TM, Dinant GJ, Aretz K, et al. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. *BMJ*. 1993 Oct 16;307(6910):988-90. PMID: 8241913.
36. Govaert TM, Dinant GJ, Aretz K, et al. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. *BMJ*. 1993;307(6910):988-90.
37. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. *N Engl J Med*. 1996 Feb 8;334(6):341-8. PMID: 8538704.
38. Grimpel E, Scott D, Laudat F, et al. Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given with Routine Pediatric Vaccination to Healthy Infants in France. *Vaccine*. 2008PMID: WOS:000268750600089.
39. Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N Engl J Med*. 2007 May 10;356(19):1915-27. PMID: 17494925.
40. Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions - Supplemental Table. *N Engl J Med*. 2007 May 10;356(19):1915-27.
41. Haberg SE, Trogstad L, Gunnes N, et al. Risk of Fetal Death after Pandemic Influenza Virus Infection or Vaccination. *N Engl J Med*. 2013 Jan 16PMID: 23323868.
42. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. *Lancet*. 2004 Nov 13-19;364(9447):1757-65. PMID: 15541448.
43. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet*. 2006 Apr 15;367(9518):1247-55. PMID: 16631880.

44. Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. *J Infect Dis.* 2008 Sep 1;198(5):650-8. PMID: 18652550.
45. Hurwitz EL, Morgenstern H. Effects of diphtheria-tetanus-pertussis or tetanus vaccination on allergies and allergy-related respiratory symptoms among children and adolescents in the United States. *J Manipulative Physiol Ther.* 2000 Feb;23(2):81-90. PMID: 10714532.
46. Khanlou H, Sanchez S, Babaie M, et al. The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients. *Arch Intern Med.* 2006 Jul 10;166(13):1417. PMID: 16832008.
47. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. *N Engl J Med.* 1998 Dec 17;339(25):1797-802. PMID: 9854114.
48. Leroux-Roels I, Vets E, Freese R, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. *Vaccine.* 2008 Dec 2;26(51):6614-9. PMID: 18930093.
49. Mallol-Mesnard N, Menegaux F, Auvrignon A, et al. Vaccination and the risk of childhood acute leukaemia: The ESCALE study (SFCE). *International Journal of Epidemiology.* 2007 February;36(1):110-6. PMID: 2007341402 MEDLINE PMID 17227780 (<http://www.ncbi.nlm.nih.gov/pubmed/17227780>).
50. Margolis KL, Nichol KL, Poland GA, et al. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. *JAMA.* 1990 Sep 5;264(9):1139-41. PMID: 2200894.
51. McKeever TM, Lewis SA, Smith C, et al. Vaccination and allergic disease: a birth cohort study. *Am J Public Health.* 2004 Jun;94(6):985-9. PMID: 15249303.
52. Miller C, Miller E, Rowe K, et al. Surveillance of symptoms following MMR vaccine in children. *Practitioner.* 1989 Jan;233(1461):69-73. PMID: 2798288.
53. Miller E, Andrews N, Grant A, et al. No evidence of an association between MMR vaccine and gait disturbance. *Arch Dis Child.* 2005 Mar;90(3):292-6. PMID: 15723921.
54. Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. *Arch Dis Child.* 2001 Mar;84(3):227-9. PMID: 11207170.
55. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. *N Engl J Med.* 2009 Sep 24;361(13):1260-7. PMID: 19776407.

56. Moriniere BJ, van Loon FP, Rhodes PH, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet. 1993 Jun 19;341(8860):1545-50. PMID: 8099637.
57. Munoz FM, Greisinger AJ, Wehmanen OA, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol. 2005 Apr;192(4):1098-106. PMID: 15846187.
58. Munoz N, Manalastas R, Jr., Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009 Jun 6;373(9679):1949-57. PMID: 19493565.
59. Murray DL, Imagawa DT, Okada DM, et al. Antibody response to monovalent A/New Jersey/8/76 influenza vaccine in pregnant women. J Clin Microbiol. 1979 Aug;10(2):184-7. PMID: 583151.
60. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults - A randomized, placebo-controlled trial. Archives of Internal Medicine. 1996 Jul;156(14):1546-50. PMID: WOS:A1996UY33200007.
61. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999 Jul 14;282(2):137-44. PMID: 10411194.
62. Ohmit SE, Gross J, Victor JC, et al. Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination. Vaccine. 2009 Feb 11;27(7):1050-4. PMID: 19095028.
63. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006 Dec 14;355(24):2513-22. PMID: 17167134.
64. Ohmit SE, Victor JC, Teich ER, et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis. 2008 Aug 1;198(3):312-7. PMID: 18522501.
65. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007 Jun 30;369(9580):2161-70. PMID: 17602732.
66. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009 Jul 25;374(9686):301-14. PMID: 19586656.

67. Patja A, Paunio M, Kinnunen E, et al. Risk of Guillain-Barre syndrome after measles-mumps-rubella vaccination. *J Pediatr.* 2001 Feb;138(2):250-4. PMID: 11174624.
68. Perez G, Lazcano-Ponce E, Hernandez-Avila M, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. *Int J Cancer.* 2008 Mar 15;122(6):1311-8. PMID: 18000825.
69. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. *Pediatric Infectious Disease Journal.* 2005 Jan;24(1):57-62. PMID: 15665711.
70. Pichichero ME, Blatter MM, Kennedy WA, et al. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. *Pediatrics.* 2006 Apr;117(4):1084-93. PMID: 16585302.
71. Pichichero ME, DeTora LM, Johnson DR. An adolescent and adult formulation combined tetanus, diphtheria and five-component pertussis vaccine. *Expert Review of Vaccines.* 2006 2006;5(2):175-87. PMID: 2006375786 MEDLINE PMID 16608418 (<http://www.ncbi.nlm.nih.gov/pubmed/16608418>).
72. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. *Pediatr Infect Dis J.* 2007 Mar;26(3):201-9. PMID: 17484215.
73. Roost HP, Gassner M, Grize L, et al. Influence of MMR-vaccinations and diseases on atopic sensitization and allergic symptoms in Swiss schoolchildren. *Pediatr Allergy Immunol.* 2004 Oct;15(5):401-7. PMID: 15482514.
74. Rue-Cover A, Iskander J, Lyn SN, et al. Death and serious illness following influenza vaccination: a multidisciplinary investigation. *Pharmacoepidemiology and Drug Safety.* 2009 Jun;18(6):504-11. PMID: WOS:000267349300010.
75. Shinefield HR, Black SB, Staehle BO, et al. Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX. *Pediatric Infectious Disease Journal.* 1998 Nov;17(11):980-5. PMID: 9849978.
76. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. *New England Journal of Medicine.* 2004 Dec 16;351(25):2611-8. PMID: 15602021.
77. Spitzer WO. Measles, mumps, and rubella vaccination and autism. *N Engl J Med.* 2003 Mar 6;348(10):951-4; author reply -4. PMID: 12622119.

78. Takahashi H, Suzumura S, Shirakizawa F, et al. An epidemiological study on Japanese autism concerning routine childhood immunization history. *Japanese Journal of Infectious Diseases*. 2003 Jun;56(3):114-7. PMID: 12944678.
79. Tam JS, Capeding MR, Lum LC, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. *Pediatr Infect Dis J*. 2007 Jul;26(7):619-28. PMID: 17596805.
80. Taylor B, Miller E, Lingam R, et al. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. *BMJ*. 2002 Feb 16;324(7334):393-6. PMID: 11850369.
81. Touze E, Fourrier A, Rue-Fenouche C, et al. Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. *Neuroepidemiology*. 2002 Jul-Aug;21(4):180-6. PMID: 12065880.
82. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. *Vaccine*. 2008 Dec 2;26(51):6630-8. PMID: 18845199.
83. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. *Lancet Oncol*. 2005 May;6(5):271-8. PMID: 15863374.
84. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals - A randomized trial. *Jama-Journal of the American Medical Association*. 1999 Mar;281(10):908-13. PMID: WOS:000078950600035.
85. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. *N Engl J Med*. 2009 Dec 17;361(25):2414-23. PMID: 19846844.

Rejected for No Relevant Groups (Vaccine and Population) – 33

1. Anderson EL, Belshe RB, Bartram J. Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children. *Journal of Infectious Diseases*. 1986;153(5):823-31. PMID: 1986148918 MEDLINE PMID 3009633 (<http://www.ncbi.nlm.nih.gov/pubmed/3009633>).
2. Andrews N, Miller E, Grant A, et al. Thimerosal exposure in infants and developmental disorders: A retrospective cohort study in the United Kingdom does not support a causal association. *Pediatrics*. 2004 September;114(3):584-91. PMID: 2005485136 MEDLINE PMID 15342825 (<http://www.ncbi.nlm.nih.gov/pubmed/15342825>).
3. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. *Vaccine*. 1998 Feb;16(4):381-7. PMID: 1998005804.
4. Black S, Klein NP, Shah J, et al. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. *Vaccine*. 2010 Jan 8;28(3):657-63. PMID: 19895922.
5. Chotpitayasunondh T, Panpitpat C, Thisyakorn U, et al. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants. *Southeast Asian Journal of Tropical Medicine & Public Health*. 1997 Mar;28(1):91-8. PMID: 9322290.
6. Christy C, Madore HP, Treanor JJ. Safety and immunogenicity of live attenuated rhesus monkey rotavirus vaccine. *Journal of Infectious Diseases*. 1986;154(6):1045-7. PMID: 1987030898 MEDLINE PMID 3023497 (<http://www.ncbi.nlm.nih.gov/pubmed/3023497>).
7. Dagan R, Kassis I, Sarov B, et al. Safety and immunogenicity of oral tetravalent human-rhesus reassortant rotavirus vaccine in neonates. *Pediatric Infectious Disease Journal*. 1992;11(12):991-6. PMID: 1992368170 MEDLINE PMID 1334255 (<http://www.ncbi.nlm.nih.gov/pubmed/1334255>).
8. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. *New England Journal of Medicine*. 2010 Mar 4;362(9):812-22. PMID: 20200385.
9. Goto N, Kawaguchi T, Watarai Y, et al. A vaccine to prevent herpes zoster in kidney transplantation. *American Journal of Transplantation*. 2011 April;11 SUPPL. 2:43.
10. Hansen TS, Jess T, Vind I, et al. Environmental factors in inflammatory bowel disease: A case-control study based on a Danish inception cohort. *Journal of Crohn's and Colitis*. 2011 December;5(6):577-84. PMID: 2011652838 MEDLINE PMID 22115378 (<http://www.ncbi.nlm.nih.gov/pubmed/22115378>).

11. Harjulehto-Mervaala T, Hovi T, Aro T, et al. Oral poliovirus vaccination and pregnancy complications. *Acta Obstetricia et Gynecologica Scandinavica*. 1995 Apr;74(4):262-5. PMID: 7732798.
12. Joensuu J, Koskenniemi E, Pang XL, et al. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. *Lancet*. 1997 Oct 25;350(9086):1205-9. PMID: 9652561.
13. Joensuu J, Koskenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. *Pediatric Infectious Disease Journal*. 1998 April;17(4):334-40. PMID: 998151478 MEDLINE PMID 9576390 (<http://www.ncbi.nlm.nih.gov/pubmed/9576390>).
14. Khan AA, Zahidie A, Rabbani F. Interventions to reduce neonatal mortality from neonatal tetanus in low and middle income countries--a systematic review. *BMC Public Health*. 2013;13:322. PMID: 23570611.
15. Lanata CF, Midthun K, Black RE, et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. *Journal of Infectious Diseases*. 1996 1996;174(2):268-75. PMID: 1996229392 MEDLINE PMID 8699054 (<http://www.ncbi.nlm.nih.gov/pubmed/8699054>).
16. Lehmann D, Pomat WS, Combs B, et al. Maternal immunization with pneumococcal polysaccharide vaccine in the highlands of Papua New Guinea. *Vaccine*. 2002 Mar 15;20(13-14):1837-45. PMID: 11906773.
17. Losonsky GA, Rennels MB, Kapikian AZ. Safety, infectivity, transmissibility and immunogenicity of rhesus rotavirus vaccine (MMU 18006) in infants. *Pediatric Infectious Disease*. 1986 1986;5(1):25-9. PMID: 1986099315 MEDLINE PMID 3003715 (<http://www.ncbi.nlm.nih.gov/pubmed/3003715>).
18. Mrukowicz JZ, Thompson J, Reed GW, et al. Epidemiology of rotavirus in infants and protection against symptomatic illness afforded by primary infection and vaccination. *Vaccine*. 1999 26;17(7-8):745-53. PMID: 1999058249 MEDLINE PMID 10067679 (<http://www.ncbi.nlm.nih.gov/pubmed/10067679>).
19. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine.[Erratum appears in N Engl J Med 2001 May 17;344(20):1564 Note: Livingood, JR [corrected to Livingood, JR]]. *New England Journal of Medicine*. 2001 Feb 22;344(8):564-72. PMID: 11207352.
20. Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal *Haemophilus influenzae* protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.[Erratum appears in Lancet. 2013 May 18;381(9879):1720]. *Lancet*. 2013 Jan 19;381(9862):214-22. PMID: 23158882.

21. Perez-Schael I, Blanco M, Garcia D, et al. Evaluation of the antigenicity and reactogenicity of varying formulations of the rhesus rotavirus-based quadrivalent and the M37 rotavirus vaccine candidates. *Journal of Medical Virology*. 1994;1994;42(4):330-7. PMID: 1994124733 MEDLINE PMID 8046423 (<http://www.ncbi.nlm.nih.gov/pubmed/8046423>).
22. Perez-Schael I, Guntinas MJ, Perez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela.[Erratum appears in N Engl J Med 1998 Apr 2;338(14):1002]. *New England Journal of Medicine*. 1997 Oct 23;337(17):1181-7. PMID: 9337376.
23. Pichichero ME, Losonsky GA. Asymptomatic Infections Due to Wild-Type Rotavirus May Prime for a Heterotypic Response to Vaccination with Rhesus Rotavirus. *Clinical Infectious Diseases*. 1993 Jan;16(1):86-92. PMID: WOS:A1993KG11700014.
24. Pichichero ME, Losonsky GA, Rennels MB, et al. Effect of dose and a comparison of measures of vaccine take for oral rhesus rotavirus vaccine. *Pediatric Infectious Disease Journal*. 1990;1990;9(5):339-44. PMID: 1990157488 MEDLINE PMID 2162027 (<http://www.ncbi.nlm.nih.gov/pubmed/2162027>).
25. Quiambao BP, Nohynek HM, Kayhty H, et al. Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. *Vaccine*. 2007 Jun;30(25):4470-7. PMID: 2007224745 MEDLINE PMID 17442467 (<http://www.ncbi.nlm.nih.gov/pubmed/17442467>).
26. Scott D, Ruckle J, Dar M, et al. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. *Pediatrics International*. 2008 Jun;50(3):295-9. PMID: 18533940.
27. Stermole BM, Grandits GA, Roediger MP, et al. Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults. *Vaccine*. 2011 Apr;5;29(16):2874-80. PMID: 21352938.
28. Tseng HF, Sy LS, Qian L, et al. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. *Clinical Infectious Diseases*. 2013 Feb;56(3):315-21. PMID: 23196953.
29. Verstraeten T, Baughman AL, Cadwell B, et al. Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination. *American Journal of Epidemiology*. 2001 Dec 1;154(11):1006-12. PMID: 11724716.
30. Vesikari T, Rautanen T, Varis T, et al. Rhesus Rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age. *American Journal of Diseases of Children*. 1990;1990;144(3):285-9. PMID: 1990067394 MEDLINE PMID 2154925 (<http://www.ncbi.nlm.nih.gov/pubmed/2154925>).
31. Vesikari T, Varis T, Green K, et al. Immunogenicity and safety of rhesus-human rotavirus reassortant vaccines with serotype 1 or 2 VP7 specificity. *Vaccine*. 1991;1991;9(5):334-9.

PMID: 1991145801 MEDLINE PMID 1651610
(<http://www.ncbi.nlm.nih.gov/pubmed/1651610>).

32. Vodopija I, Baklaic Z, Vlatkovic R. Combined vaccination with live oral polio vaccine and the bovine rotavirus RIT 4237 strain. *Vaccine*. 1986;1986;4(4):233-6. PMID: 1987063773
MEDLINE PMID 3026106 (<http://www.ncbi.nlm.nih.gov/pubmed/3026106>).

33. Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: Pooled analysis of two randomised controlled trials. *Bmj*. 2010;(2010) 340(7748):696. PMID: 2010199167.

Rejected for Correction to Rejected Study – 8

1. Erratum: Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - Report of the National Multicenter Trial (Pediatrics (1996) 97 (7-13)). Pediatrics. 1996 1996;98(1):A38. PMID: 1996204872.
2. Erratum: Intussusception among infants given an oral rotavirus vaccine (New England Journal of Medicine (Feb. 22, 2001) 344 (564-72)). New England Journal of Medicine. 2001 17;344(20):1564. PMID: 2001174517.
3. Chen J, Heyse JF, Heaton P. Erratum: Age dependence of the risk of intussusception following tetrivalent rhesus-human reassortant rotavirus tetravalent vaccine: Is it beyond doubt? (American Journal of Epidemiology (2010) 171: 9 (1046-1054)). American Journal of Epidemiology. 2010 1-jul-2012;172(1):125. PMID: 2012350024.
4. Clark HF. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants (vol 144, pg 184, 2004). Journal of Pediatrics. 2004 Apr;144(4):558-. PMID: WOS:000220760600058.
5. Liang XF. Safety of Influenza A (H1N1) Vaccine in Postmarketing Surveillance in China (vol 364, pg 638, 2011). New England Journal of Medicine. 2011 Apr;364(15):1481-. PMID: WOS:000289467200040.
6. Liang XF, Wang HQ, Wang JZ. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. (vol 375, pg 56, 2010). Lancet. 2010 May;375(9727):1694-. PMID: WOS:000277890200029.
7. Livengood JR. Intussusception among infants given an oral rotavirus vaccine (vol 344, pg 564, 2001). New England Journal of Medicine. 2001 May;344(20):1564-. PMID: WOS:000168677200027.
8. Rennels, Fries S, Froehlich H. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - Report of the National Multicenter Trial (vol 97, pg 7, 1996). Pediatrics. 1996 Jul;98(1):A38-A. PMID: WOS:A1996UU13700017.

Rejected for Duplicate Publication – 22

1. Ambrose CS, Dubovsky F, Yi T, et al. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. European Journal of Clinical Microbiology and Infectious Diseases. 2012.
2. Bernsen RMD, Koes BW, de Jongste JC, et al. Haemophilus influenzae type b vaccination and reported atopic disorders in 8-12-year-old children. Pediatric Pulmonology. 2006 May;41(5):463-9. PMID: 16547964.
3. Buttery J. A rotavirus vaccine for infants prevented rotavirus gastroenteritis with no increase in risk of intussusception. Evidence-Based Medicine. 2006 Aug;11(4):113. PMID: 2006385636.
4. Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. British Journal of Cancer. 2011 Jun 28;105(1):28-37. PMID: 21629249.
5. Christie CD, Duncan ND. Rotavirus vaccine trial in Jamaica. West Indian Medical Journal. 2012 Jul;61(4):405-7. PMID: 23240476.
6. Dennehy PH, Goveia MG, Dallas MJ, et al. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases. 2007 Nov;11 Suppl 2:S36-42. PMID: 18162245.
7. Ebell M. Oral rotavirus vaccines are safe and effective in children. American Family Physician. 2006 May;73(10):1814-. PMID: WOS:000237676800016.
8. Ehrlich HJ, Berezuk G, Fritsch S, et al. Clinical development of a Vero cell culture-derived seasonal influenza vaccine. Vaccine. 2012 Jun 19;30(29):4377-86. PMID: 22172502.
9. Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine. 2001 Jun 14;19(27):3632-5. PMID: 11395196.
10. Fell DB, Sprague AE, Liu N, et al. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. American Journal of Public Health. 2012 Jun;102(6):e33-40. PMID: 22515877.
11. Lin TH, Lin SY, Lin CH, et al. AdimFlu-S() influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine. 2012 Mar 30;30(16):2671-5. PMID: 22342546.
12. Linhares AC, Velazquez FR, Perez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet. 2008 Apr 5;371(9619):1181-9. PMID: 18395579.

13. Miller EK, Dumitrescu L, Cupp C, et al. Atopy history and the genomics of wheezing after influenza vaccination in children 6-59 months of age. *Vaccine*. 2011 Apr;29(18):3431-7. PMID: WOS:000290889700009.
14. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. *N Engl J Med*. 2005 Jun 2;352(22):2271-84. PMID: 15930418.
15. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *New England Journal of Medicine*. 2011 Oct 27;365(17):1576-85. PMID: 22029979.
16. Patel J. Study finds H1N1 vaccine safe for pregnant women. *Expert Review of Vaccines*. 2012 Oct;11(10):1169. PMID: 23320264.
17. Silfverdal SA, Nilsson L, Blennow M, et al. Vaccination of children-summary and conclusions from a systematic review. *Acta Paediatrica, International Journal of Paediatrics*. 2010 September;99(9):1287-9. PMID: 2010457259 MEDLINE PMID 20937069 (<http://www.ncbi.nlm.nih.gov/pubmed/20937069>).
18. Vermeulen JN, Lange JM, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults >=60 years of age. *Vaccine*. 2012 Jan 20;30(5):904-10. PMID: 22154769.
19. Vermeulen JN, Lange JMA, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults (greater-than or equal to)60 years of age. *Vaccine*. 2012 20;30(5):904-10. PMID: 2012018677 MEDLINE PMID 22154769 (<http://www.ncbi.nlm.nih.gov/pubmed/22154769>).
20. Vesikari T, Itzler R, Karvonen A, et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. *Vaccine*. 2009 Dec 11;28(2):345-51. PMID: 19879226.
21. Vesikari T, Karvonen A, Puustinen L, et al. A short report on highlights of world-wide development of RIX4414: An European experience. *Vaccine*. 2006 1;24(18):3779. PMID: 2006202655 MEDLINE PMID 16581159 (<http://www.ncbi.nlm.nih.gov/pubmed/16581159>).
22. Virtanen M, Peltola H, Paunio M, et al. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. *Pediatrics*. 2000 Nov;106(5):E62. PMID: 11061799.

Rejected, Not About Vaccine – 15

1. Almuneef M, Memish Z, Khan Y, et al. Childhood bacterial meningitis in Saudi Arabia. *Journal of Infection*. 1998 Mar;36(2):157-60. PMID: 9570646.
2. Bahl R, Saxena M, Bhandari N, et al. Population-based incidence of intussusception and a case-control study to examine the association of intussusception with natural rotavirus infection among Indian children. *Journal of Infectious Diseases*. 2009 November;200(SUPPL. 1):S277-S81. PMID: 2010002047 MEDLINE PMID 19817609 (<http://www.ncbi.nlm.nih.gov/pubmed/19817609>).
3. Boulagnon C, Leveque N, Renois F, et al. Influenza A/H1N1 (2009) infection as a cause of unexpected out-of-hospital death in the young. *Journal of Forensic Sciences*. 2012 Nov;57(6):1650-5. PMID: 22583168.
4. Chen E, Grimwood K, Beasley S. Operative rates for acute intussusception in New Zealand [2]. *New Zealand Medical Journal*. 2004;117(1202) PMID: 2005483071.
5. Dennehy PH. Transmission of rotavirus and other enteric pathogens in the home. *Pediatric Infectious Disease Journal*. 2000 2000;19(10 SUPPL.):S103-S5. PMID: 2000382180 MEDLINE PMID 11052397 (<http://www.ncbi.nlm.nih.gov/pubmed/11052397>).
6. Gutierrez J, Issacson RS, Koppel BS. Subacute sclerosing panencephalitis: an update. *Developmental Medicine & Child Neurology*. 2010 Oct;52(10):901-7. PMID: 20561004.
7. Janjua NZ, Skowronski DM, Hottes TS, et al. Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: First detection of the association in British Columbia, Canada. *Clinical Infectious Diseases*. 2010 1;51(9):1017-27. PMID: 2010591676 MEDLINE PMID 20887210 (<http://www.ncbi.nlm.nih.gov/pubmed/20887210>).
8. Kale PL, Andreozzi VL, Nobre FF. Time series analysis of deaths due to Diarrhoea in children in Rio de Janeiro, Brazil, 1980-1998. *Journal of Health, Population and Nutrition*. 2004 March;22(1):27-33. PMID: 2004257452 MEDLINE PMID 15190809 (<http://www.ncbi.nlm.nih.gov/pubmed/15190809>).
9. Mori M, Kuwabara S, Miyake M, et al. Haemophilus influenzae infection and Guillain-Barre syndrome. *Brain*. 2000 Oct;123:2171-8. PMID: WOS:000089907400018.
10. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood*. 2011 21;117(16):4190-207. PMID: 2011270705 MEDLINE PMID 21325604 (<http://www.ncbi.nlm.nih.gov/pubmed/21325604>).
11. Nguyen AM, Noymer A. Influenza mortality in the United States, 2009 pandemic: burden, timing and age distribution. *PLoS ONE [Electronic Resource]*. 2013;8(5):e64198. PMID: 23717567.

12. Parashar UD, Kilgore PE, Holman RC, et al. Diarrheal mortality in US infants - Influence of birth weight on risk factors for death. *Archives of Pediatrics & Adolescent Medicine*. 1998 Jan;152(1):47-51. PMID: WOS:000071486300007.
13. Reyes MP, Fisher MW, Lerner AM. Pseudomonas endocarditis: hemagglutinating antibodies to Fisher-Devlin-Gnabasik immunotypes in sera. *Journal of Laboratory & Clinical Medicine*. 1974 Jun;83(6):845-52. PMID: 4213766.
14. Takeuchi M, Osamura T, Yasunaga H, et al. Intussusception among Japanese children: an epidemiologic study using an administrative database. *Bmc Pediatrics*. 2012 Mar;12 PMID: WOS:000304006700001.
15. van der Werf N, Kroese FGM, Rozing J, et al. Viral infections as potential triggers of type 1 diabetes. *Diabetes-Metabolism Research and Reviews*. 2007 Mar;23(3):169-83. PMID: WOS:000245146800001.

Rejected for Vaccine or Formulation Not Currently Recommended in US – 193

1. Aaby P, Ravn H, Roth A, et al. Early diphtheria-tetanus-pertussis vaccination associated with higher female mortality and no difference in male mortality in a cohort of low birthweight children: an observational study within a randomised trial. *Archives of Disease in Childhood*. 2012 Aug;97(8):685-91. PMID: 22331681.
2. Aaby P, Roth A, Ravn H, et al. Randomized Trial of BCG Vaccination at Birth to Low-Birth-Weight Children: Beneficial Nonspecific Effects in the Neonatal Period? *Journal of Infectious Diseases*. 2011 Jul;204(2):245-52. PMID: WOS:000292562200013.
3. Aavitsland P, Bjune G, Aasen S, et al. Adverse events following vaccine or placebo injection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988-1991. *NIPH Annals*. 1991 Dec;14(2):133-4; discussion 6-7. PMID: 1812426.
4. Alami Chentoufi A, Kritzer E, Yu DM, et al. Towards a rational design of an asymptomatic clinical herpes vaccine: The old, the new, and the unknown. *Clinical and Developmental Immunology*. 2012;187585PMID: 2012212220.
5. Ali SS, Chandrashekhar SR, Singh M, et al. A multicenter, prospective, open-label, non-comparative study to evaluate the immunogenicity and tolerance of a new, fully liquid pentavalent vaccine (DTwP-HepB-Hib vaccine). *Human Vaccines*. 2007 Jul-Aug;3(4):116-20. PMID: 17617743.
6. Aljadhey H, Alyabsi M, Alrwisan A, et al. The Safety of H1N1 Vaccine in Children in Saudi Arabia: A Cohort Study Using Modern Technology in a Developing Country. *Drug Safety*. 2012 Jul 1;35(7):555-61. PMID: 22671865.
7. Anderson EL, Bowers T, Mink CM, et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. *Infection & Immunity*. 1994 Aug;62(8):3391-5. PMID: 8039909.
8. Anderson P, Insel RA, Smith DH, et al. A polysaccharide-protein complex from *Haemophilus influenzae* type b. III. Vaccine trial in human adults. *Journal of Infectious Diseases*. 1981 Dec;144(6):530-8. PMID: 7035578.
9. Andrews N, Stowe J, Al-Shahi Salman R, et al. Guillain-Barre syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series. *Vaccine*. 2011 Oct 19;29(45):7878-82. PMID: 21875631.
10. Araujo EC, Clemens SAC, Oliveira CS, et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. *Jornal de Pediatria*. 2007 May-Jun;83(3):217-24. PMID: 17380232.

11. Armstrong PK, Dowse GK, Effler PV, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. *BMJ Open*. 2011 Jan 1;1(1):e000016. PMID: 22021725.
12. Atmar RL, Keitel WA, Quarles JM, et al. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. *Vaccine*. 2011 19;29(45):8066-72. PMID: 2011559946 MEDLINE PMID 21864622 (<http://www.ncbi.nlm.nih.gov/pubmed/21864622>).
13. Atsmon J, Kate-Ilovitz E, Shaikevich D, et al. Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. *Journal of Clinical Immunology*. 2012 Jun;32(3):595-603. PMID: 22318394.
14. Baker CJ, Paoletti LC, RENCH MA, et al. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. *Journal of Infectious Diseases*. 2004 Mar;189(6):1103-12. PMID: WOS:000220001100019.
15. Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. *Journal of Infectious Diseases*. 1999 Jan;179(1):142-50. PMID: 9841833.
16. Bardage C, Persson I, Ortqvist A, et al. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. *BMJ*. 2011;343:d5956. PMID: 21994316.
17. Barnes GL, Lund JS, Adams L, et al. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. *Journal of Paediatrics & Child Health*. 1997 Aug;33(4):300-4. PMID: 9323616.
18. Beam TR, Jr., Crigler ED, Goldman JK, et al. Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. *JAMA*. 1980 Dec 12;244(23):2621-4. PMID: 7431608.
19. Behjati M, Ayatollahi J. Post BCG lymphadenitis in vaccinated infants in Yazd, Iran. *Iranian Journal of Pediatrics*. 2008 2008;18(4):351-6. PMID: 2009150463.
20. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. *New England Journal of Medicine*. 2012 Jan 5;366(1):34-43. PMID: 22216840.
21. Beran J, Abdel-Messih IA, Raupachova J, et al. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. *Clinical Therapeutics*. 2010 Dec;32(13):2186-97. PMID: 21316535.

22. Beran J, Peeters M, Dewe W, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. *BMC Infectious Diseases*. 2013;13:224. PMID: 23688546.
23. Berkowitz CD, Ward JI, Chiu CE, et al. Persistence of antibody and booster responses to reimmunization with *Haemophilus influenzae* type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children initially immunized at 15 to 24 months of age. *Pediatrics*. 1990 Mar;85(3):288-93. PMID: 2304781.
24. Bernsen RMD, Nagelkerke NJD, Thijs C, et al. Reported pertussis infection and risk of atopy in 8- to 12-yr-old vaccinated and non-vaccinated children. *Pediatric Allergy & Immunology*. 2008 Feb;19(1):46-52. PMID: 18086216.
25. Bernstein DI, Sack DA, Rothstein E, et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. *Lancet*. 1999 Jul 24;354(9175):287-90. PMID: 10440305.
26. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. *Vaccine*. 1998 Feb;16(4):381-7. PMID: 9607059.
27. Beytout J, Launay O, Guiso N, et al. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. *Human Vaccines*. 2009 May;5(5):315-21. PMID: 19011374.
28. Bhandari N, Sharma P, Glass RI, et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. *Vaccine*. 2006 Jul 26;24(31-32):5817-23. PMID: 16735085.
29. Bischoff AL, Folsgaard NV, Carson CG, et al. Altered response to A(H1N1)pnd09 vaccination in pregnant women: a single blinded randomized controlled trial. *PLoS ONE [Electronic Resource]*. 2013;8(4):e56700. PMID: 23637733.
30. Black SB, Shinefield HR, Lampert D, et al. Safety and immunogenicity of oligosaccharide conjugate *Haemophilus influenzae* type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. *Pediatric Infectious Disease Journal*. 1991 Feb;10(2):92-6. PMID: 2062620.
31. Bonvehi P, Boutriau D, Casellas J, et al. Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults. *Clinical & Vaccine Immunology: CVI*. 2010 Sep;17(9):1460-6. PMID: 20660140.
32. Borja-Tabora C, Montalban C, Memish ZA, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. *BMC Infectious Diseases*. 2013;13:116. PMID: 23510357.

33. Bresee JS, El Arifeen S, Azim T, et al. Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh. *Pediatric Infectious Disease Journal*. 2001 Dec;20(12):1136-43. PMID: 11740320.
34. Cadranel S, Zeglache S, Jonckheer T, et al. Factors affecting antibody response of newborns to repeated administrations of the rotavirus vaccine RIT 4237. *Journal of Pediatric Gastroenterology & Nutrition*. 1987 Jul-Aug;6(4):525-8. PMID: 3430259.
35. Candela S, Pergolizzi S, Ragni P, et al. An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one. *Vaccine*. 2013 Feb 27;31(10):1431-7. PMID: 22766247.
36. Cassisi G, Sarzi-Puttini P, Cazzola M. Chronic widespread pain and fibromyalgia: Could there be some relationship with infections and vaccinations? *Clinical and Experimental Rheumatology*. 2011 2011;29(6 SUPPL. 69):S118-S26. PMID: 2012228348.
37. Castellanos M, Cinza Z, Dorta Z, et al. Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. *Journal of Gene Medicine*. 2010 January;12(1):107-16. PMID: 2010075090 MEDLINE PMID 19866482 (<http://www.ncbi.nlm.nih.gov/pubmed/19866482>).
38. Castillo-Solorzano C, Reef SE, Morice A, et al. Rubella vaccination of unknowingly pregnant women during mass campaigns for rubella and congenital rubella syndrome elimination, the Americas 2001-2008. *Journal of Infectious Diseases*. 2011 Sep 1;204 Suppl 2:S713-7. PMID: 21954271.
39. Chang EJ, Zangwill KM, Lee H, et al. Lack of association between rotavirus infection and intussusception: implications for use of attenuated rotavirus vaccines. *Pediatric Infectious Disease Journal*. 2002 Feb;21(2):97-102. PMID: 11840074.
40. Cherif H, Hoglund M, Pauksens K. Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients. *European Journal of Haematology*. 2013 May;90(5):413-9. PMID: 23444982.
41. Choo S, Seymour L, Morris R, et al. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants. *Pediatric Infectious Disease Journal*. 2000 Sep;19(9):854-62. PMID: 11001109.
42. Claesson MH. Immunological Links to Nonspecific Effects of DTwP and BCG Vaccines on Infant Mortality. *Journal of Tropical Medicine*. 2011;2011:706304. PMID: 21760811.
43. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.[Erratum appears in J Pediatr. 2004 Apr;144(4):558]. *Journal of Pediatrics*. 2004 Feb;144(2):184-90. PMID: 14760258.

44. Clark HF, Borian FE, Plotkin SA. Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3. *Journal of Infectious Diseases*. 1990 Jun;161(6):1099-104. PMID: 2161038.
45. Clark HF, Burke CJ, Volkin DB, et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. *Pediatric Infectious Disease Journal*. 2003 Oct;22(10):914-20. PMID: 14551493.
46. Classen JB, Classen DC. Clustering of cases of insulin dependent diabetes (IDDM) occurring three years after hemophilus influenza B (HiB) immunization support causal relationship between immunization and IDDM. *Autoimmunity*. 2002 Jul;35(4):247-53. PMID: 12482192.
47. Cox RJ, Pedersen G, Madhun AS, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix MTM adjuvant in a phase I clinical trial. *Vaccine*. 2011 Oct 19;29(45):8049-59. PMID: 21864624.
48. Cutts FT, Zaman SMA, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.[Erratum appears in Lancet. 2005 Jul 2-8;366(9479):28]. *Lancet*. 2005 Mar 26-Apr 1;365(9465):1139-46. PMID: 15794968.
49. Da Silva ESGR, Camacho LAB, Stavola MS, et al. Pregnancy outcomes following rubella vaccination: A prospective study in the State of Rio de Janeiro, Brazil, 2001-2002. *Journal of Infectious Diseases*. 2011 1;204(SUPPL. 2):S722-S8. PMID: 2011546533 MEDLINE PMID 21954273 (<http://www.ncbi.nlm.nih.gov/pubmed/21954273>).
50. Dagan R, Melamed R, Zamir O, et al. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. *Pediatric Infectious Disease Journal*. 1997 Nov;16(11):1053-9. PMID: 9384339.
51. Dang DA, Nguyen VT, Vu DT, et al. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. *Vaccine*. 2012 Apr 27;30 Suppl 1:A114-21. PMID: 22520120.
52. Davis RL, Kolczak M, Lewis E, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. *Epidemiology*. 2005 May;16(3):336-41. PMID: 15824549.
53. de Oliveira LH, Struchiner CJ. Vaccine-associated paralytic poliomyelitis: a retrospective cohort study of acute flaccid paralyses in Brazil. *International Journal of Epidemiology*. 2000 Aug;29(4):757-63. PMID: 10922356.

54. de Vos van Steenwijk PJ, Ramwadhoebe TH, Lowik MJ, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. *Cancer Immunology, Immunotherapy*. 2012 Sep;61(9):1485-92. PMID: 22684521.
55. De Wals P, Deceuninck G, Toth E, et al. Risk of Guillain-Barre syndrome following H1N1 influenza vaccination in Quebec. *JAMA*. 2012 Jul 11;308(2):175-81. PMID: 22782419.
56. Dennehy PH. A short report on the highlights of world-wide development of RIX4414: a North American experience. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. *Vaccine*. 2006 1;24(18):3780-1. PMID: 2006202629 MEDLINE PMID 16111790 (<http://www.ncbi.nlm.nih.gov/pubmed/16111790>).
57. Dennehy PH, Rodgers GC, Jr., Ward RL, et al. Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetrivalent rhesus rotavirus vaccine. US Rhesus Rotavirus Vaccine Study Group. *Pediatric Infectious Disease Journal*. 1996 Nov;15(11):1012-8. PMID: 8933551.
58. Diaz-Ortega JL, Bennett JV, Castaneda D, et al. Aerosolized MMR vaccine: Evaluating potential transmission of components to vaccine administrators and contacts of vaccines. *SOURCE Biologicals* (2012). 2012.
59. Dieleman J, Romio S, Johansen K, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. *BMJ*. 2011;343:d3908. PMID: 21750072.
60. Diez-Domingo J, Garces-Sanchez M, Baldo J-M, et al. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. *Pediatric Infectious Disease Journal*. 2010 Jun;29(6):e35-46. PMID: 20375709.
61. Dikow R, Eckerle I, Ksoll-Rudek D, et al. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. *American Journal of Kidney Diseases*. 2011 May;57(5):716-23. PMID: 21349617.
62. Dos Santos BA, Ranieri TS, Bercini M, et al. An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. *Rev Panam Salud Publica*. 2002 Oct;12(4):240-6. PMID: 12431355.
63. Durrieu G, Palmaro A, Pourcel L, et al. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals. *Drug Safety*. 2012 Oct 1;35(10):845-54. PMID: 22967189.

64. Eick A, Croll J, Weatherholtz R, et al. Safety and immunogenicity of two octavalent pneumococcal conjugate vaccines in American Indian infants. *Vaccine*. 2004 Mar 12;22(9-10):1260-4. PMID: 15003655.
65. el-Sayed N, el-Gamal Y, Abbassy A-A, et al. Monovalent type 1 oral poliovirus vaccine in newborns. *New England Journal of Medicine*. 2008 Oct 16;359(16):1655-65. PMID: 18923170.
66. Eskola J, Kayhty H, Gordon LK, et al. Simultaneous administration of Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine with routine diphtheria-tetanus-pertussis and inactivated poliovirus vaccinations of childhood. *Pediatric Infectious Disease Journal*. 1988 Jul;7(7):480-4. PMID: 3261414.
67. Eskola J, Kayhty H, Takala AK, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. *New England Journal of Medicine*. 1990 Nov 15;323(20):1381-7. PMID: 2233904.
68. Espinoza F, Tregnaghi M, Gentile A, et al. Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: A randomized controlled trial. *BMC Infectious Diseases*. 2010;10(297) PMID: 2010614014.
69. Esposito S, Principi N. Influenza vaccination in young children. *The Lancet Infectious Diseases*. 2011 September;11(9):656-7. PMID: 2011460533.
70. Esteves K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry. *Bulletin of the World Health Organization*. 1988;66(6):739-46. PMID: 3266113.
71. Faridi MMA, Krishnamurthy S. Abortive reaction and time of scar formation after BCG vaccination. *Vaccine*. 2008 17;26(3):289-90. PMID: 2008005505 MEDLINE PMID 18093699 (<http://www.ncbi.nlm.nih.gov/pubmed/18093699>).
72. Farooqi IS, Hopkin JM. Early childhood infection and atopic disorder. *Thorax*. 1998 Nov;53(11):927-32. PMID: 10193389.
73. Fattom A, Fuller S, Propst M, et al. Safety and immunogenicity of a booster dose of *Staphylococcus aureus* types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. *Vaccine*. 2004 Dec 16;23(5):656-63. PMID: 15542186.
74. Fragapane E, Gasparini R, Schioppa F, et al. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. *Clinical & Vaccine Immunology: CVI*. 2010 Nov;17(11):1817-9. PMID: 20810680.
75. Galbraith NS, Crosby G, Barnes JM, et al. Simultaneous immunization with B.C.G., diphtheria-tetanus, and oral poliomyelitis vaccines in children aged 13-14. *British Medical Journal*. 1971 Apr 24;2(5755):193-7. PMID: 5575951.

76. Gillard P, Caplanus A, Knuf M, et al. An assessment of prime-boost vaccination schedules with AS03(A)-adjuvanted prepandemic H5N1 vaccines: A randomized study in European adults. *Influenza and other Respiratory Viruses*. 2012.
77. Gisselsson-Solen M, Melhus A, Hermansson A. Pneumococcal vaccination in children at risk of developing recurrent acute otitis media - A randomized study. *Acta Paediatrica, International Journal of Paediatrics*. 2011 October;100(10):1354-8. PMID: 2011518781 MEDLINE PMID 21517964 (<http://www.ncbi.nlm.nih.gov/pubmed/21517964>).
78. Haber P, Chen RT, Zanardi LR, et al. An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone? *Pediatrics*. 2004 Apr;113(4):e353-9. PMID: 15060267.
79. Heijmans S, De Meulemeester M, Reynders P, et al. Immunogenicity profile of a 3.75-(μg) hemagglutinin pandemic rH5N1 split virion AS03(A)-adjuvanted vaccine in elderly persons: A randomized trial. *Journal of Infectious Diseases*. 2011 15;203(8):1054-62. PMID: 2011183323 MEDLINE PMID 21450995 (<http://www.ncbi.nlm.nih.gov/pubmed/21450995>).
80. Heikkinen T, Young J, van Beek E, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. *American Journal of Obstetrics & Gynecology*. 2012 Sep;207(3):177.e1-8. PMID: 22939717.
81. Henderson J, North K, Griffiths M, et al. Pertussis vaccination and wheezing illnesses in young children: prospective cohort study. The Longitudinal Study of Pregnancy and Childhood Team. *BMJ*. 1999 May 1;318(7192):1173-6. PMID: 10221941.
82. Hien ND, Luan LT, Huong NT, et al. High immunogenicity of measles AIK-C vaccine produced in Vietnam. *Eastern Journal of Medicine*. 2011 2011;16(3):199-207. PMID: 2011572623.
83. Hung IFN, Leung AYM, Chu DWS, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. *Clinical Infectious Diseases*. 2010 Nov 1;51(9):1007-16. PMID: 20887208.
84. Hwang S-J, Chang S-C, Yu C-J, et al. Immunogenicity and safety of an AS03(A)-adjuvanted H5N1 influenza vaccine in a Taiwanese population. *Journal of the Formosan Medical Association*. 2011 Dec;110(12):780-6. PMID: 22248833.
85. Ikeno D, Kimachi K, Kino Y, et al. Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection.[Erratum appears in Microbiol Immunol. 2011 Nov;55(11):822 Note: Dosage error in article text]. *Microbiology & Immunology*. 2010 Feb;54(2):81-8. PMID: 20377741.

86. Jick H, Vasilakis-Scaramozza C, Jick SS. Live attenuated polio vaccine and the risk of intussusception. *British Journal of Clinical Pharmacology*. 2001 Oct;52(4):451-3. PMID: 11678790.
87. Johnson B, Gargiullo P, Murphy TV, et al. Sociodemographic and dietary risk factors for natural infant intussusception in the United States. *Journal of Pediatric Gastroenterology & Nutrition*. 2010 Oct;51(4):458-63. PMID: 20562726.
88. Karsh J, Pavlidis N, Schiffman G, et al. Immunization of patients with Sjogren's syndrome with pneumococcal polysaccharide vaccine: a randomized trial. *Arthritis & Rheumatism*. 1980 Nov;23(11):1294-8. PMID: 7004446.
89. Katial RK, Brandt BL, Moran EE, et al. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. *Infection & Immunity*. 2002 Feb;70(2):702-7. PMID: 11796602.
90. Kaur S, Faridi MMA, Agarwal KN. BCG vaccination reaction in low birth weight infants. *Indian Journal of Medical Research*. 2002 1;116(AUG.):64-9. PMID: 2003047252 MEDLINE PMID 12592992 (<http://www.ncbi.nlm.nih.gov/pubmed/12592992>).
91. Keitel W, Groth N, Lattanzi M, et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. *Vaccine*. 2010 Jan 8;28(3):840-8. PMID: 19835829.
92. Kerdpanich A, Warachit B, Kosuwon P, et al. Primary vaccination with a new heptavalent DTPw-HBV/Hib-Neisseria meningitidis serogroups A and C combined vaccine is well tolerated. *International Journal of Infectious Diseases*. 2008 Jan;12(1):88-97. PMID: 17716936.
93. Khemiri M, Bagais A, Becher SB, et al. Tuberculous meningitis in Bacille Calmette-Guerin-vaccinated children: clinical spectrum and outcome. *Journal of Child Neurology*. 2012 Jun;27(6):741-6. PMID: 22190501.
94. Ki M, Park T, Yi SG, et al. Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. *Am J Epidemiol*. 2003 Jan 15;157(2):158-65. PMID: 12522023.
95. King JC, Jr., Vink PE, Farley JJ, et al. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. *Pediatrics*. 1997 Apr;99(4):575-80. PMID: 9093301.
96. Kotloff KL, Fattom A, Basham L, et al. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults. *Vaccine*. 1996 Apr;14(5):446-50. PMID: 8735558.

97. Kramarz P, France EK, Destefano F, et al. Population-based study of rotavirus vaccination and intussusception. *Pediatric Infectious Disease Journal*. 2001 Apr;20(4):410-6. PMID: 11332666.
98. Lanata CF, Black RE, Flores J, et al. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. *Vaccine*. 1996 Feb;14(3):237-43. PMID: 8920706.
99. Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. *Journal of Infectious Diseases*. 2010 Jun 1;201(11):1644-53. PMID: 20423222.
100. Langley JM, Halperin SA, McNeil S, et al. Safety and immunogenicity of a Proteosome - trivalent inactivated influenza vaccine, given nasally to healthy adults. *Vaccine*. 2006 Mar 6;24(10):1601-8. PMID: 16303215.
101. Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. *Journal of Infectious Diseases*. 2011 Jun 15;203(12):1729-38. PMID: 21606531.
102. Leach A, Ceesay SJ, Banya WA, et al. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. *Pediatric Infectious Disease Journal*. 1996 Apr;15(4):333-9. PMID: 8866803.
103. Ledgerwood JE, Wei C-J, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. *The Lancet Infectious Diseases*. 2011 Dec;11(12):916-24. PMID: 21975270.
104. Lee J, Robinson JL, Spady DW. Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants. *Bmc Pediatrics*. 2006;6:20. PMID: 16784533.
105. Lepow ML, Barkin RM, Berkowitz CD, et al. Safety and immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) in infants. *Journal of Infectious Diseases*. 1987 Oct;156(4):591-6. PMID: 3497990.
106. Lewis SA, Britton JR. Measles infection, measles vaccination and the effect of birth order in the aetiology of hay fever. *Clin Exp Allergy*. 1998 Dec;28(12):1493-500. PMID: 10024220.
107. Li RC, Li Y, Yi N, et al. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis a pediatric vaccines in toddlers, children and adolescents in china. *Pediatric Infectious Disease Journal*. 2013 Feb;32(2):e77-81. PMID: 23334341.

108. Li S-TT, Davis RL, Weiss NS. Intussusception and oral poliovirus vaccination: is there an association? *American Journal of Epidemiology*. 2004 Sep 15;160(6):576-81. PMID: 15353418.
109. Liang X-F, Wang H-Q, Wang J-Z, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.[Erratum appears in Lancet. 2010 May 15;375(9727):1694]. *Lancet*. 2010 Jan 2;375(9708):56-66. PMID: 20018364.
110. Loew-Baselli A, Pavlova BG, Fritsch S, et al. A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory. *Vaccine*. 2012 Sep 7;30(41):5956-66. PMID: 22846396.
111. Lopez P, Caicedo Y, Sierra A, et al. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. *Journal of Infectious Diseases*. 2011 Jun 15;203(12):1719-28. PMID: 21606530.
112. Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. *Vaccine*. 2011 Oct 13;29(44):7826-34. PMID: 21816199.
113. Mackenzie IS, MacDonald TM, Shakir S, et al. Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes. *British Journal of Clinical Pharmacology*. 2012 May;73(5):801-11. PMID: 22082196.
114. Maldonado Y, Hestvik L, Wilson M, et al. Safety and immunogenicity of bovine rotavirus vaccine RIT 4237 in 3-month-old infants. *Journal of Pediatrics*. 1986 Dec;109(6):931-5. PMID: 3537248.
115. Markwick AJ, Rennels MB, Zito ET, et al. Oral tetrivalent rotavirus vaccine can be successfully coadministered with oral poliovirus vaccine and a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine. US Rhesus Rotavirus Vaccine Study Group. *Pediatric Infectious Disease Journal*. 1998 Oct;17(10):913-8. PMID: 9802635.
116. Marshall HS, Richmond PC, Nissen MD, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18 to 36 months: A phase 1 randomized controlled clinical trial. *Pediatric Infectious Disease Journal*. 2012;20.
117. Matson DO. RotaShield: the ill-fated rhesus-human reassortant rotavirus vaccine. *Pediatric Annals*. 2006 Jan;35(1):44-50. PMID: 16466075.
118. McElhaney JE, Simor AE, McNeil S, et al. Efficacy and safety of CVT-E002, a proprietary extract of Panax quinquefolius in the prevention of respiratory infections in influenza-vaccinated

community-dwelling adults: A multicenter, randomized, double-blind, and placebo-controlled trial. *Influenza Research and Treatment*. 2011;759051 PMID: 2012187058.

119. Medical Products Agency. A registry based comparative cohort study in four Swedish counties of the risk for narcolepsy after vaccination with Pandemrix—a first and preliminary report. 2011. www.mpa.se. 2011.

120. Menzel M, Muellinger B, Weber N, et al. Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. *Vaccine*. 2005 Oct 17;23(43):5113-9. PMID: 16029914.

121. Mitchell LA, Tingle AJ, MacWilliam L, et al. HLA-DR class II associations with rubella vaccine-induced joint manifestations. *J Infect Dis*. 1998 Jan;177(1):5-12. PMID: 9419163.

122. Mohrenschlager M, Haberl VM, Kramer U, et al. Early BCG and pertussis vaccination and atopic diseases in 5- to 7-year-old preschool children from Augsburg, Germany: results from the MIRIAM study. *Pediatr Allergy Immunol*. 2007 Feb;18(1):5-9. PMID: 17295793.

123. Moro ML, Nobilio L, Voci C, et al. A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two. *Vaccine*. 2013 Feb 27;31(10):1438-46. PMID: 22885015.

124. Mulholland EK, Byass P, Campbell H, et al. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants. *Annals of Tropical Paediatrics*. 1994;14(3):183-8. PMID: 7825990.

125. Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. *Pediatrics*. 2003 Jul;112(1 Pt 1):66-73. PMID: 12837869.

126. Nagai H, Ikematsu H, Tenjinbaru K, et al. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults. *BMC Infectious Diseases*. 2010;10:338. PMID: 21108818.

127. Nelson JC, Yu O, Dominguez-Islas CP, et al. Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study. *American Journal of Epidemiology*. 2013 Jan 15;177(2):131-41. PMID: 23292957.

128. Nilsson L, Kjellman NI, Bjorksten B. A randomized controlled trial of the effect of pertussis vaccines on atopic disease. *Arch Pediatr Adolesc Med*. 1998 Aug;152(8):734-8. PMID: 9701130.

129. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. *PLoS ONE [Electronic Resource]*. 2012;7(3) PMID: 2012183686.

130. Nokleby H, Feiring B. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials. *NIPH Annals*. 1991 Dec;14(2):95-101; discussion -2. PMID: 1812440.
131. Obaro SK, Enwere GC, Deloria M, et al. Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and *Haemophilus influenzae* type b conjugate vaccine. *Pediatric Infectious Disease Journal*. 2002 Oct;21(10):940-7. PMID: 12394817.
132. Oppermann M, Fritzsche J, Weber-Schoendorfer C, et al. A(H1N1)v2009: A controlled observational prospective cohort study on vaccine safety in pregnancy. *Vaccine*. 2012 Jun 22;30(30):4445-52. PMID: 22564554.
133. Ornoy A, Arnon J, Feingold M, et al. Spontaneous abortions following oral poliovirus vaccination in first trimester. *Lancet*. 1990 Mar 31;335(8692):800. PMID: 1969549.
134. Ortega-Barria E, Kanra G, Leroux G, et al. The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: results from four phase III multicenter trials across three continents. *Vaccine*. 2007 Dec 5;25(50):8432-40. PMID: 17961876.
135. Ouandaogo C-R, Yameogo TM, Diomande FVK, et al. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. *Vaccine*. 2012 May 30;30 Suppl 2:B46-51. PMID: 22230584.
136. Pardon F, Vilarino M, Barbero P, et al. Rubella vaccination of unknowingly pregnant women during 2006 mass campaign in Argentina. *Journal of Infectious Diseases*. 2011 1;204(SUPPL. 2):S745-S7. PMID: 2011546540 MEDLINE PMID 21954276 (<http://www.ncbi.nlm.nih.gov/pubmed/21954276>).
137. Pasternak B, Svanstrom H, Molgaard-Nielsen D, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. *JAMA*. 2012 Jul 11;308(2):165-74. PMID: 22782418.
138. Pasternak B, Svanstrom H, Molgaard-Nielsen D, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. *BMJ*. 2012;344:e2794. PMID: 22551713.
139. Paterson DL, Patel A. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment. *Australian & New Zealand Journal of Surgery*. 1998 May;68(5):340-4. PMID: 9631906.
140. Peltola H, Kayhty H, Sivonen A, et al. *Haemophilus influenzae* type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. *Pediatrics*. 1977 Nov;60(5):730-7. PMID: 335348.

141. Phonrat B, Pitisuttithum P, Chamnanchanunt S, et al. Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais. *Vaccine*. 2013 Mar 1;31(11):1503-9. PMID: 23318149.
142. Pichichero ME. Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion: a metaanalysis. *Journal of Infectious Diseases*. 1990 Sep;162(3):753-5. PMID: 2167344.
143. Pichichero ME, Marsocci SM, Francis AB, et al. A comparative evaluation of the safety and immunogenicity of a single dose of unbuffered oral rhesus rotavirus serotype 3, rhesus/human reassortant serotypes 1, 2 and 4 and combined (tetravalent) vaccines in healthy infants. *Vaccine*. 1993;11(7):747-53. PMID: 8393606.
144. Price CS, Thompson WW, Goodson B, et al. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. *Pediatrics*. 2010 October;126(4):656-64. PMID: 2010559872 MEDLINE PMID 20837594
(<http://www.ncbi.nlm.nih.gov/pubmed/20837594>).
145. Quiambao B, Van Der Meeren O, Kolhe D, et al. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis/hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers. *Human Vaccines and Immunotherapeutics*. 2012 March;8(3):337-44. PMID: 2012244550.
146. Raman T, Mukhopadhyaya A, Eapen CE, et al. Intussusception in southern Indian children: lack of association with diarrheal disease and oral polio vaccine immunization. *Indian Journal of Gastroenterology*. 2003 May-Jun;22(3):82-4. PMID: 12839377.
147. Ray P, Black S, Shinefield H, et al. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. *JAMA*. 1997 Aug 20;278(7):551-6. PMID: 9268275.
148. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. *Pediatrics*. 1996 Jan;97(1):7-13. PMID: 8545227.
149. Rhim JW, Lee KY, Kim SY, et al. Evaluation of immunogenicity and safety of the new tetanus-reduced diphtheria (Td) vaccines (GC1107) in healthy Korean adolescents: a phase II, double-blind, randomized, multicenter clinical trial. *Journal of Korean Medical Science*. 2013 Apr;28(4):586-92. PMID: 23579367.
150. Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial. *The Lancet Infectious Diseases*. 2012 August;12(8):597-607. PMID: 2012432636.

151. Rigau-Perez JG, Overturf GD, Chan LS, et al. Reactions to booster pneumococcal vaccination in patients with sickle cell disease. *Pediatric Infectious Disease*. 1983 May-Jun;2(3):199-202. PMID: 6346278.
152. Riley ID, Lehmann D, Alpers MP, et al. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. *Lancet*. 1986 Oct 18;2(8512):877-81. PMID: 2876325.
153. Roth AE, Benn CS, Ravn H, et al. Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau. *British Medical Journal*. 2010 Mar;340 PMID: WOS:000275931100010.
154. Rubinstein F, Micone P, Bonotti A, et al. Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. *BMJ*. 2013;346:f393. PMID: 23381200.
155. Ruiz-Palacios GM, Guerrero ML, Bautista-Marquez A, et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. *Pediatrics*. 2007 Aug;120(2):e253-61. PMID: 17606534.
156. Saitoh A, Nagai A, Tenjinbaru K, et al. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: An open-label, randomized trial in Japanese children aged 6 months to 17 years. *Human Vaccines and Immunotherapeutics*. 2012 June;8(6):749-58. PMID: 2012397534.
157. Salinas B, Perez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. *Pediatric Infectious Disease Journal*. 2005 Sep;24(9):807-16. PMID: 16148848.
158. Salmon-Ceron D, Durier C, Desaint C, et al. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. *Aids*. 2010 Sep;24(14):2211-23. PMID: WOS:000281249200009.
159. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. *Lancet*. 2012 Feb 18;379(9816):617-24. PMID: 22260988.
160. Santosham M, Letson GW, Wolff M, et al. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. *Journal of Infectious Diseases*. 1991 Mar;163(3):483-7. PMID: 1995721.
161. Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. *Journal of Pediatrics*. 1997 Oct;131(4):632-8. PMID: 9386673.

162. Schmader KE, Levin MJ, Gnann JW, Jr., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. *Clinical Infectious Diseases*. 2012 Apr;54(7):922-8. PMID: 22291101.
163. Schmitt HJ, Faber J, Lorenz I, et al. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. *Vaccine*. 2003 Sep 8;21(25-26):3653-62. PMID: 12922095.
164. Segard OS, Lohse N, Harboe ZB, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: A randomized, controlled trial. *Clinical Infectious Diseases*. 2010 1;51(1):42-50. PMID: 2010346742 MEDLINE PMID 20504165 (<http://www.ncbi.nlm.nih.gov/pubmed/20504165>).
165. Sharma H, Chowdhari S, Raina TR, et al. Sero-Surveillance to Assess Immunity to Rubella and Assessment of Immunogenicity and Safety of a Single dose of Rubella Vaccine in School Girls. *Indian Journal of Community Medicine*. 2010 Jan;35(1):134-7. PMID: 20606938.
166. Sharma H, Patil V, Sharma D, et al. A phase III, randomized controlled study to assess the safety and immunogenicity of a semi-synthetic diphtheria, tetanus and whole-cell pertussis vaccine in Indian infants. *Vaccine*. 2012.
167. Sharma HJ, Oun SA, Bakr SSA, et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. *Clinical Microbiology & Infection*. 2010 Apr;16(4):347-52. PMID: 20222892.
168. Simasathien S, Migasena S, Samakoses R, et al. Vaccination of Thai infants with rhesus-human reassortant tetravalent oral rotavirus vaccine. *Pediatric Infectious Disease Journal*. 1994 Jul;13(7):590-6. PMID: 7970945.
169. Simonsen L, Viboud C, Elixhauser A, et al. More on RotaShield and intussusception: the role of age at the time of vaccination. *Journal of Infectious Diseases*. 2005 Sep 1;192 Suppl 1:S36-43. PMID: 16088803.
170. Slater PE, Ben-Zvi T, Fogel A, et al. Absence of an association between rubella vaccination and arthritis in underimmune postpartum women. *Vaccine*. 1995 Nov;13(16):1529-32. PMID: 8578837.
171. Soares RC, Siqueira MM, Toscano CM, et al. Follow-up study of unknowingly pregnant women vaccinated against rubella in Brazil, 2001-2002. *Journal of Infectious Diseases*. 2011 Sep 1;204 Suppl 2:S729-36. PMID: 21954274.
172. Strobel PM, Ion-Nedelcu N, Baughman AL, et al. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine--a risk factor for vaccine-associated paralytic poliomyelitis. *New England Journal of Medicine*. 1995 Feb 23;332(8):500-6. PMID: 7830731.

173. Sugawara T, Ohsuka Y, Taya K, et al. Diarrhea as a minor adverse effect due to oral polio vaccine. *Japanese Journal of Infectious Diseases*. 2009 Jan;62(1):51-3. PMID: 19168959.
174. Sur D, Ochiai RL, Bhattacharya SK, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. *New England Journal of Medicine*. 2009 Jul 23;361(4):335-44. PMID: 19625715.
175. Tavares F, Nazareth I, Monegal JS, et al. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. *Vaccine*. 2011 Aug 26;29(37):6358-65. PMID: 21596080.
176. Tingle AJ, Mitchell LA, Grace M, et al. Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women. *Lancet*. 1997 May 3;349(9061):1277-81. PMID: 9142061.
177. Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. *Lupus*. 2012 February;21(2):223-30. PMID: 2012029357.
178. Treanor JJ, Clark HF, Pichichero M, et al. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. *Pediatric Infectious Disease Journal*. 1995 Apr;14(4):301-7. PMID: 7603812.
179. Turley CB, Rupp RE, Johnson C, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. *Vaccine*. 2011 Jul 18;29(32):5145-52. PMID: 21624416.
180. Ugpo J, Lucero M, Williams G, et al. Reactogenicity and tolerability of a non-adjuvanted 11-valent diphtheria-tetanus toxoid pneumococcal conjugate vaccine in Filipino children. *Vaccine*. 2009 May;27(20):2723-9. PMID: 2009183639 MEDLINE PMID 18977267 (<http://www.ncbi.nlm.nih.gov/pubmed/18977267>).
181. Verge CF, Howard NJ, Irwig L, et al. Environmental factors in childhood IDDM. A population-based, case-control study. *Diabetes Care*. 1994 Dec;17(12):1381-9. PMID: 7882806.
182. Verity C, Stellitano L, Winstone AM, et al. Guillain-Barre syndrome and H1N1 influenza vaccine in UK children. *Lancet*. 2011 Oct 29;378(9802):1545-6. PMID: 22035553.
183. Vesikari T, Isolauri E, D'Hondt E, et al. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. *Lancet*. 1984 May 5;1(8384):977-81. PMID: 6143964.
184. Vesikari T, Joensuu J. Review of rotavirus vaccine trials in Finland. *Journal of Infectious Diseases*. 1996 1996;174(SUPPL. 1):S81-S7. PMID: 1996270932 MEDLINE PMID 8752295 (<http://www.ncbi.nlm.nih.gov/pubmed/8752295>).

185. Vesikari T, Karvonen A, Forrest BD, et al. Neonatal administration of rhesus rotavirus tetravalent vaccine. *Pediatric Infectious Disease Journal*. 2006 Feb;25(2):118-22. PMID: 16462287.
186. Vesikari T, Karvonen AV, Majuri J, et al. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. *Journal of Infectious Diseases*. 2006 Aug 1;194(3):370-6. PMID: 16826486.
187. Vesikari T, Pepin S, Kusters I, et al. Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. *Human vaccines & Immunotherapeutics*. 2012 Sep;8(9):1283-92. PMID: 22906943.
188. Wiedermann G, Jovanovic D, Georges AM. Immunogenicity and reactogenicity of new multivalent pneumococcal vaccines. *Zentralblatt fur Bakteriologie Mikrobiologie und Hygiene - Abt. 1 Orig. A*. 1982 1982;251(4):494-504. PMID: 1983017408 MEDLINE PMID 7201725 (<http://www.ncbi.nlm.nih.gov/pubmed/7201725>).
189. Wringe A, Fine PEM, Sutter RW, et al. Estimating the extent of vaccine-derived poliovirus infection. *PLoS ONE [Electronic Resource]*. 2008;3(10):e3433. PMID: 18958288.
190. Yang PC, Yu CJ, Chang SC, et al. Safety and immunogenicity of a split-virion AS03(A)-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults. *Journal of the Formosan Medical Association*. 2012 June;111(6):333-9. PMID: 2012372175.
191. Zhou W-Z, Koo H-W, Wang X-Y, et al. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings. *Pediatric Infectious Disease Journal*. 2007 Nov;26(11):1001-5. PMID: 17984806.
192. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. *Lancet*. 2010 Sep;376(9744):895-902. PMID: WOS:000282069100030.
193. Zimmermann U, Gavazzi G, Richard P, et al. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥ 60 years: an open-label, randomised trial. *Vaccine*. 2013 Mar 1;31(11):1496-502. PMID: 23313654.

Rejected for Other – 3

1. de Vos van Steenwijk PJ, Ramwadhoebe TH, Lowik MJG, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. *Cancer Immunology, Immunotherapy*. 2012.
2. Svanstrom H, Callreus T, Hviid A. Temporal data mining for adverse events following immunization in nationwide Danish healthcare databases. *Drug Safety*. 2010 Nov 1;33(11):1015-25. PMID: 20925439.
3. Swingler G, Fransman D, Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type B infections. *Cochrane Database of Systematic Reviews*. 2007(2):CD001729. PMID: 17443509.

Background - 353

1. From the NIH: Pneumococcal vaccination for patients with Sjogren's syndrome. *JAMA*. 1981 Jun 12;245(22):2288. PMID: 7230448.
2. Haemophilus influenzae B immunisation. *Drug and Therapeutics Bulletin*. 1993 1993;31(1):1-2. PMID: 1993037203 MEDLINE PMID 8440158 (<http://www.ncbi.nlm.nih.gov/pubmed/8440158>).
3. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). [Erratum appears in MMWR Morb Mortal Wkly Rep 1997 Mar 14;46(10):227]. *Morbidity & Mortality Weekly Report. Recommendations & Reports*. 1996 Sep 6;45(RR-12):1-35. PMID: 8801442.
4. Poliomyelitis prevention: recommendations for use of inactivated poliovirus vaccine and live oral poliovirus vaccine. American Academy of Pediatrics Committee on Infectious Diseases. *Pediatrics*. 1997 Feb;99(2):300-5. PMID: 9024465.
5. From the Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine--United States, 1998-1999. *JAMA*. 1999 Aug 11;282(6):520-1. PMID: 10450702.
6. . Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morbidity & Mortality Weekly Report. Recommendations & Reports*. 1999 Mar 19;48(RR-2):1-20. PMID: 10219046.

7. Intussusception among recipients of rotavirus vaccine - US, 1998-1999. *Annals of Pharmacotherapy*. 1999 Sep;33(9):1020-1. PMID: WOS:000082401100028.
8. Acellular pertussis vaccines. *Prescrire International*. 2000 2000;9(45):220-3. PMID: 2000044279 MEDLINE PMID 11503804 (<http://www.ncbi.nlm.nih.gov/pubmed/11503804>).
9. Acellular pertussis vaccines. New preparation. Better tolerated but less active? *Prescrire International*. 2000 2000;9(45):204-7. PMID: 2000044272.
10. Haemophilus influenzae type B vaccine safe and effective in early infancy. *South African Medical Journal*. 2002 2002;92(1):3. PMID: 2002055415.
11. Pneumococcal 7-valent conjugate vaccine protects young children. *Drugs and Therapy Perspectives*. 2003 2003;19(7):1-4. PMID: 2003282249.
12. Contraindications to vaccination in children. Mainly immunosuppression and a history of severe reactions. *Prescrire International*. 2003 Jun;12(65):103-7. PMID: 2003226922.
13. Immunization during pregnancy. *International Journal of Gynecology and Obstetrics*. 2003 1;81(1):123-8. PMID: 2003137411 MEDLINE PMID 12737148 (<http://www.ncbi.nlm.nih.gov/pubmed/12737148>).
14. Immunization during pregnancy. *Obstetrics and Gynecology*. 2003 1;101(1):207-12. PMID: 2003021729.
15. MMR vaccine--how effective and how safe? *Drug Ther Bull*. 2003 Apr;41(4):25-9. PMID: 12724845.
16. Rotavirus vaccine - AVANT Immunotherapeutics/GlaxoSmithKline: 89-12, RIX4414. *Drugs in R and D*. 2004 2004;5(2):113-5. PMID: 2004205222 MEDLINE PMID 15293874 (<http://www.ncbi.nlm.nih.gov/pubmed/15293874>).
17. Hepatitis A vaccine recommendations committee on infectious diseases. *Pediatrics*. 2007 July;120(1):189-99. PMID: 2007328906 MEDLINE PMID 17606579 (<http://www.ncbi.nlm.nih.gov/pubmed/17606579>).
18. Little evidence that supports a causal link between most vaccines and Guillain-Barre syndrome. *Drugs and Therapy Perspectives*. 2009 2009;25(11):21-3. PMID: 2009546429.
19. PCV13: Proven efficacy and safety. *International Journal of Infectious Diseases*. 2010 November;14(SUPPL. 5):e8. PMID: 2010597230.
20. Committee opinion No. 467: Human papillomavirus vaccination. *Obstetrics and Gynecology*. 2010 September;116(3):800-3. PMID: 2011075974 MEDLINE PMID 20733476 (<http://www.ncbi.nlm.nih.gov/pubmed/20733476>).

21. Meeting of the Global Advisory Committee on Vaccine Safety, June 2011. Weekly Epidemiological Record. 2011 Jul 22;86(30):321-4. PMID: 21800467.
22. 13-valent pneumococcal conjugate vaccine. Prescrire International. 2011 Jan;20(112):5-7, 9. PMID: 21462782.
23. HPV vaccines and pregnancy: the situation in early 2012. Prescrire International. 2012 Jun;21(128):154-7. PMID: 22822594.
24. Abramson JS, Baker CJ, Fisher MC, et al. Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000 2000;106(2 I):362-6. PMID: 2000289879.
25. Adler UC. The influence of childhood infections and vaccination on the development of atopy: A systematic review of the direct epidemiological evidence. Homeopathy. 2005 July;94(3):182-95. PMID: 2005298301 MEDLINE PMID 16060204 (<http://www.ncbi.nlm.nih.gov/pubmed/16060204>).
26. Al-Safi ZA, Shavell VI, Gonik B. Vaccination in pregnancy. Women's Health. 2011 January;7(1):109-19. PMID: 2011000392 MEDLINE PMID 21175395 (<http://www.ncbi.nlm.nih.gov/pubmed/21175395>).
27. Ambrose CS. Use of intranasal live attenuated influenza vaccine in individuals with asthma or a history of wheezing. Human vaccines & Immunotherapeutics. 2012 Feb;8(2):279; author reply 80. PMID: 22426366.
28. Ambrose CS, Wu XH, Knuf M, et al. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies. Vaccine. 2012 Jan;30(5):886-92. PMID: WOS:000301558000011.
29. Ambrose CS, Yi T, Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza & Other Respiratory Viruses. 2011 Nov;5(6):389-97. PMID: 21668683.
30. Anderson EJ. Intussusception risk of rotavirus vaccination. New England Journal of Medicine. 2011 Dec 1;365(22):2137-8; author reply 8. PMID: 22129262.
31. Anderson EL. Prevention of pertussis. Seminars in Respiratory Infections. 1989 Dec;4(4):284-92. PMID: 2560581.
32. Anonymous. Study: shingles vaccine safe for patients on immune-suppressing drugs. Human vaccines & Immunotherapeutics. 2012 Aug;8(8):1015-6. PMID: 23359877.

33. Avery RK. Vaccination of the immunosuppressed adult patient with rheumatologic disease. *Rheumatic Disease Clinics of North America*. 1999;1999;25(3):567-84. PMID: 1999298466 MEDLINE PMID 10467629 (<http://www.ncbi.nlm.nih.gov/pubmed/10467629>).
34. Babl FE, Lewena S, Brown L. Vaccination-related adverse events. *Pediatric Emergency Care*. 2006 July;22(7):514-22. PMID: 2006367931 MEDLINE PMID 16871116 (<http://www.ncbi.nlm.nih.gov/pubmed/16871116>).
35. Baggs J, Gee J, Lewis E, et al. The vaccine safety datalink: A model for monitoring immunization safety. *Pediatrics*. 2011 May;127(SUPPL. 1):S45-S53. PMID: 2011239117 MEDLINE PMID 21502240 (<http://www.ncbi.nlm.nih.gov/pubmed/21502240>).
36. Balofsky A, Agmon-Levin N, Shoenfeld Y. The new H1N1 and HPV vaccines and old fears. *Current Opinion in Rheumatology*. 2010 July;22(4):431-6. PMID: 2010329949 MEDLINE PMID 20485175 (<http://www.ncbi.nlm.nih.gov/pubmed/20485175>).
37. Bar-On ES, Goldberg E, Hellmann S, et al. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). [Update of Cochrane Database Syst Rev. 2009;(3):CD005530; PMID: 19588375]. *Cochrane Database of Systematic Reviews*. 2012;4:CD005530. PMID: 22513932.
38. Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. *Clin Infect Dis*. 2007 Sep 1;45(5):609-7. PMID: 17682997.
39. Bart KJ, Orenstein WA, Hinman AR. The current status of immunization principles: Recommendations for use and adverse reactions. *Journal of Allergy and Clinical Immunology*. 1987;1987;79(2):296-315. PMID: 1987090583 MEDLINE PMID 3819215 (<http://www.ncbi.nlm.nih.gov/pubmed/3819215>).
40. Battista A, Ruggiero A, Coccia P, et al. Vaccination in children with cancer: A debate. *Central European Journal of Medicine*. 2012 April;7(2):137-41. PMID: 2012265240.
41. Baxter P. Pertussis vaccine encephalopathy: 'Oh! Let us never, never doubt'. *Developmental Medicine & Child Neurology*. 2010 Oct;52(10):883-4. PMID: 21175453.
42. Bechini A, Tiscione E, Boccalini S, et al. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): A review of evidences and recommendations. *Vaccine*. 2012 Jul 27;30(35):5179-90. PMID: 22709953.
43. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. *PLoS ONE* [Electronic Resource]. 2011;6(12):e29249. PMID: 22216224.

44. Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). *Pediatr Infect Dis J.* 1996 Jan;15(1):88-90. PMID: 8684885.
45. Bernstein DI. Live attenuated human rotavirus vaccine, Rotarix. *Seminars in Pediatric Infectious Diseases.* 2006 Oct;17(4):188-94. PMID: 17055369.
46. Bernstein DI. A live attenuated human rotavirus vaccine. *Drugs of Today.* 2007 May;43(5):281-91. PMID: 17724495.
47. Beyer WE, Palache AM, Kerstens R, et al. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. *Eur J Clin Microbiol Infect Dis.* 1996 Jan;15(1):65-70. PMID: 8641306.
48. Beyer WEP, Nauta JJP, Palache AM, et al. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. *Vaccine.* 2011 Aug 5;29(34):5785-92. PMID: 21624411.
49. Bigham M, Copes R. Thiomersal in vaccines: Balancing the risk of adverse effects with the risk of vaccine-preventable disease. *Drug Safety.* 2005 2005;28(2):89-101. PMID: 2005109203 MEDLINE PMID 15691220 (<http://www.ncbi.nlm.nih.gov/pubmed/15691220>).
50. Bines JE, Kohl KS, Forster J, et al. Acute intussusception in infants and children as an adverse event following immunization: Case definition and guidelines of data collection, analysis, and presentation. *Vaccine.* 2004 26;22(5 6):569-74. PMID: 2004041838 MEDLINE PMID 14741146 (<http://www.ncbi.nlm.nih.gov/pubmed/14741146>).
51. Black S, Della Cioppa G, Malfroot A, et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. *Vaccine.* 2010 Oct 21;28(45):7331-6. PMID: 20813217.
52. Blank M, Israeli E, Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). *Lupus.* 2012;21(7):711-4. PMID: 22635209.
53. Blencowe H, Lawn J, Vandelaer J, et al. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. *International Journal of Epidemiology.* 2010 Apr;39 Suppl 1:i102-9. PMID: 20348112.
54. Bliss SJ, O'Brien KL, Janoff EN, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. *The Lancet Infectious Diseases.* 2008 Jan;8(1):67-80. PMID: 17974480.
55. Bonanni P, Cohet C, Kjaer SK, et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. *Vaccine.* 2010 Jul 5;28(30):4719-30. PMID: 20451636.

56. Bonhoeffer J, Heininger U. Adverse events following immunization: Perception and evidence. *Current Opinion in Infectious Diseases*. 2007 June;20(3):237-46. PMID: 2007219546 MEDLINE PMID 17471032 (<http://www.ncbi.nlm.nih.gov/pubmed/17471032>).
57. Bonhoeffer J, Siegrist CA, Heath PT. Immunisation of premature infants. *Archives of Disease in Childhood*. 2006 November;91(11):929-35. PMID: 2006541128 MEDLINE PMID 17056868 (<http://www.ncbi.nlm.nih.gov/pubmed/17056868>).
58. Borchers AT, Keen CL, Shoenfeld Y, et al. Vaccines, viruses, and voodoo. *Journal of Investigational Allergology and Clinical Immunology*. 2002 2002;12(3):155-68. PMID: 2002415477 MEDLINE PMID 12530114 (<http://www.ncbi.nlm.nih.gov/pubmed/12530114>).
59. Bovier PA. Recent advances with a virosomal hepatitis A vaccine. *Expert Opinion on Biological Therapy*. 2008 August;8(8):1177-85. PMID: 2008356109 MEDLINE PMID 18613769 (<http://www.ncbi.nlm.nih.gov/pubmed/18613769>).
60. Brady MT, Bernstein HH, Byington CL, et al. Policy statement - Prevention of varicella: Update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. *Pediatrics*. 2011 September;128(3):630-2. PMID: 2011490230 MEDLINE PMID 21873692 (<http://www.ncbi.nlm.nih.gov/pubmed/21873692>).
61. Broder KR, Martin DB, Vellozzi C. Bridging the gap between data and public health needs. In the heat of a signal: Responding to a vaccine safety signal for febrile seizures after 2010-11 influenza vaccine in young children, United States. *Vaccine*. 2012 2;30(11):2032-4. PMID: 2012104395.
62. Broder KR, Martin DB, Vellozzi C. In the heat of a signal: responding to a vaccine safety signal for febrile seizures after 2010-11 influenza vaccine in young children, United States. *Vaccine*. 2012 Mar 2;30(11):2032-4. PMID: 22361305.
63. Brunell PA, Bass JW, Daum RS. Hemophilus type b polysaccharide vaccine. *Pediatrics*. 1985 1985;76(2):322-4. PMID: 1985189925 MEDLINE PMID 3875076 (<http://www.ncbi.nlm.nih.gov/pubmed/3875076>).
64. Bryant KA, McVernon J, Marchant CD, et al. Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: A pooled analysis of randomized trials. *Human Vaccines and Immunotherapeutics*. 2012 August;8(8):1036-41. PMID: 2012533259.
65. Campion JJ, Casto DT. Haemophilus influenzae type b conjugate vaccine. *Journal of Pediatric Health Care*. 1988 Jul-Aug;2(4):215-8. PMID: 3404376.
66. Caple J. Pentavalent human-bovine reassortant rotavirus vaccine: a review of its efficacy and safety in preventing acute rotavirus gastroenteritis in healthy infants. *Drugs of Today*. 2006 May;42(5):313-9. PMID: 16801994.

67. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist(registered trademark); Fluenz(trademark)): A review of its use in the prevention of seasonal influenza in children and adults. *Drugs*. 2011;71(12):1591-622. PMID: 2011471189 MEDLINE PMID 21861544 (<http://www.ncbi.nlm.nih.gov/pubmed/21861544>).
68. Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. *Drugs*. 2005;65(10):1367-89. PMID: 15977969.
69. Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. *Cochrane Database of Systematic Reviews*. 2013;2:CD000364. PMID: 23450529.
70. Cavassini ML, D'Acremont V, Furrer H, et al. Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers. *Expert Opinion on Pharmacotherapy*. 2005 June;6(6):891-913. PMID: 2005306629 MEDLINE PMID 15952919 (<http://www.ncbi.nlm.nih.gov/pubmed/15952919>).
71. Cendes F, Sankar R. Vaccinations and febrile seizures. *Epilepsia*. 2011 May;52(SUPPL. 3):23-5. PMID: 2011251315 MEDLINE PMID 21542842 (<http://www.ncbi.nlm.nih.gov/pubmed/21542842>).
72. Centers for Disease C, Prevention. Intussusception among recipients of rotavirus vaccine--United States, 1998-1999. *MMWR - Morbidity & Mortality Weekly Report*. 1999 Jul 16;48(27):577-81. PMID: 10428095.
73. Centers for Disease C, Prevention. Withdrawal of rotavirus vaccine recommendation. *MMWR - Morbidity & Mortality Weekly Report*. 1999 Nov 5;48(43):1007. PMID: 10577495.
74. Centers for Disease C, Prevention. Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010. *MMWR - Morbidity & Mortality Weekly Report*. 2010 Apr 30;59(16):485-6. PMID: 20431524.
75. Centers for Disease C, Prevention. Preliminary results: surveillance for Guillain-Barre syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010. *MMWR - Morbidity & Mortality Weekly Report*. 2010 Jun 4;59(21):657-61. PMID: 20520590.
76. Centers for Disease C, Prevention. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11. *MMWR - Morbidity & Mortality Weekly Report*. 2010 Aug 13;59(31):989-92. PMID: 20703207.
77. Centers for Disease C, Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR - Morbidity & Mortality Weekly Report*. 2010 Mar 12;59(9):258-61. PMID: 20224542.

78. Centers for Disease C, Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR - Morbidity & Mortality Weekly Report. 2011 Aug 26;60(33):1128-32. PMID: 21866086.
79. Centers for Disease C, Prevention. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR - Morbidity & Mortality Weekly Report. 2011 Dec 23;60(50):1709-11. PMID: 22189894.
80. Centers for Disease C, Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR - Morbidity & Mortality Weekly Report. 2011 Jan 14;60(1):13-5. PMID: 21228763.
81. Centers for Disease C, Prevention. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2012-13 Influenza Season. MMWR - Morbidity & Mortality Weekly Report. 2012 Aug 17;61:613-8. PMID: 22895385.
82. Centers for Disease C, Prevention, American Academy of Pediatrics Committee on Infectious D. Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). Pediatrics. 2011 Oct;128(4):809-12. PMID: 21949151.
83. Chaithongwongwatthana S, Yamasmit W, Limponsanurak S, et al. Pneumococcal vaccination during pregnancy for preventing infant infection. Cochrane Database of Systematic Reviews. 2012(7) PMID: WOS:000306280400019.
84. Chambers S. Drug review - Prevenar(registered trademark). Drugs in Context. 2006 2006;2(11):475-92. PMID: 2006314606.
85. Chan R. Cochrane review summary for cancer nursing: Influenza vaccination in children having chemotherapy for cancer. Cancer Nursing. 2010 July-August;33(4):327-8. PMID: 2010363185 MEDLINE PMID 20571381 (<http://www.ncbi.nlm.nih.gov/pubmed/20571381>).
86. Chen N, Li Q, Zhang Y, et al. Vaccination for preventing postherpetic neuralgia. Cochrane Database of Systematic Reviews. 2011(3):CD007795. PMID: 21412911.
87. Chen RT. Vaccine risks: Real, perceived and unknown. Vaccine. 1999 29;17(SUPPL. 3):S41-S6. PMID: 1999383405 MEDLINE PMID 10559533 (<http://www.ncbi.nlm.nih.gov/pubmed/10559533>).
88. Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations: An epidemiological review. Paediatric Drugs. 2000 2000;2(4):273-90. PMID: 2000286458 MEDLINE PMID 10946416 (<http://www.ncbi.nlm.nih.gov/pubmed/10946416>).

89. Cheuk DK, Chiang AK, Lee TL, et al. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database of Systematic Reviews. 2011(3):CD006505. PMID: 21412895.
90. Cheuvart B, Friedland LR, Abu-Elyazeed R, et al. The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability. Pediatric Infectious Disease Journal. 2009 Mar;28(3):225-32. PMID: 19209095.
91. Choudhuri D, Huda T, Theodoratou E, et al. An evaluation of emerging vaccines for childhood meningococcal disease. Bmc Public Health. 2011 Apr;11 PMID: WOS:000290281000029.
92. Clark HF, Offit PA, Plotkin SA, et al. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants. Pediatric Infectious Disease Journal. 2006 Jul;25(7):577-83. PMID: 16804425.
93. Classen DC., Classen JB. The timing of pediatric immunization and the risk of insulin-dependent diabetes mellitus. Infect Dis Clin Pract. 1997;6(7):449-54.
94. Clements C, Ball LK, Ball R, et al. Thiomersal in vaccines: Is removal warranted? Drug Safety. 2001 2001;24(8):567-74. PMID: 2001252559 MEDLINE PMID 11480489 (<http://www.ncbi.nlm.nih.gov/pubmed/11480489>).
95. Clements CJ. The evidence for the safety of thiomersal in newborn and infant vaccines. Vaccine. 2004 7;22(15 16):1854-61. PMID: 2004198021 MEDLINE PMID 15121295 (<http://www.ncbi.nlm.nih.gov/pubmed/15121295>).
96. Clements CJ, Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine. 2002 31;20(SUPPL. 3):S24-S33. PMID: 2002204913 MEDLINE PMID 12184361 (<http://www.ncbi.nlm.nih.gov/pubmed/12184361>).
97. Clements CJ, McIntyre PB. When science is not enough - A risk/benefit profile of thiomersal-containing vaccines. Expert Opinion on Drug Safety. 2006 January;5(1):17-29. PMID: 2006018777 MEDLINE PMID 16370953 (<http://www.ncbi.nlm.nih.gov/pubmed/16370953>).
98. Cohen J. Adverse events following immunisation. Medicine Today. 2006 Apr;7(4):67-72. PMID: 2006207186.
99. Collinson A. Safety in numbers: Anaphylaxis risk in childhood immunisation. Archives of Disease in Childhood. 2012 June;97(6):485-6. PMID: 2012301994.
100. Committee on Infectious D. Policy statement-Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics. 2011 Sep;128(3):630-2. PMID: 21873692.

101. Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmunity Reviews. 2008 Dec;8(2):124-8. PMID: 18700175.
102. Cook IF. Sex differences in injection site reactions with human vaccines. Human Vaccines. 2009 2009;5(7):441-9. PMID: 2009516224 MEDLINE PMID 19377279 (<http://www.ncbi.nlm.nih.gov/pubmed/19377279>).
103. Cooper B, Detora L, Stoddard J. Mencevo(registered trademark): A novel quadrivalent meningococcal CRM(197) conjugate vaccine against serogroups A, C, W-135 and y. Expert Review of Vaccines. 2011 January;10(1):21-33. PMID: 2010701549 MEDLINE PMID 21162617 (<http://www.ncbi.nlm.nih.gov/pubmed/21162617>).
104. Cunliffe NA, Nakagomi O. A critical time for rotavirus vaccines: a review. Expert Review of Vaccines. 2005 Aug;4(4):521-32. PMID: 16117709.
105. Curlin G, Landry S, Bernstein J, et al. Integrating safety and efficacy evaluation throughout vaccine research and development. Pediatrics. 2011 May;127(SUPPL. 1):S9-S15. PMID: 2011239112 MEDLINE PMID 21502246 (<http://www.ncbi.nlm.nih.gov/pubmed/21502246>).
106. Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA. 2001 Mar 7;285(9):1183-5. PMID: 11231748.
107. D'Andrilli G, Bovicelli A, Giordano A. HPV vaccines: State of the art. Journal of Cellular Physiology. 2010 September;224(3):601-4. PMID: 2010388484 MEDLINE PMID 20432468 (<http://www.ncbi.nlm.nih.gov/pubmed/20432468>).
108. D'Angio CT. Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability. Paediatric Drugs. 2007;9(1):17-32. PMID: 17291134.
109. Darkes MJM, Plosker GL. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of *Streptococcus pneumoniae* infection. Paediatric Drugs. 2002;4(9):609-30. PMID: 12175274.
110. De Vos B, Vesikari T, Linhares AC, et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal. 2004 Oct;23(10 Suppl):S179-82. PMID: 15502699.
111. Dell'Era L, Esposito S, Corona F, et al. Vaccination of children and adolescents with rheumatic diseases. Rheumatology. 2011 Aug;50(8):1358-65. PMID: WOS:000292832100004.
112. Delore V, Salamand C, Marsh G, et al. Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip. Vaccine. 2006 Mar 6;24(10):1586-92. PMID: 16271424.

113. Demicheli V, Barale A, Rivetti A. Vaccines for women to prevent neonatal tetanus.[Update of Cochrane Database Syst Rev. 2005;(4):CD002959; PMID: 16235306]. Cochrane Database of Systematic Reviews. 2013;5:CD002959. PMID: 23728640.
114. Demicheli V, Rivetti A, Debalini MG, et al. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews. 2012;2:CD004407. PMID: 22336803.
115. Demirjian A, Levy O. Safety and efficacy of neonatal vaccination. European Journal of Immunology. 2009 2009;39(1):36-46. PMID: 2009103530 MEDLINE PMID 19089811 (<http://www.ncbi.nlm.nih.gov/pubmed/19089811>).
116. DeStefano F. Vaccines and autism: Evidence does not support a causal association. Clinical Pharmacology and Therapeutics. 2007 December;82(6):756-9. PMID: 2007557883 MEDLINE PMID 17928818 (<http://www.ncbi.nlm.nih.gov/pubmed/17928818>).
117. Destefano F, Pfeifer D, Nohynek H. Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data. Bulletin of the World Health Organization. 2008 May;86(5):373-80. PMID: 18545740.
118. DeStefano F, Thompson WW. MMR vaccine and autism: an update of the scientific evidence. Expert Rev Vaccines. 2004 Feb;3(1):19-22. PMID: 14761240.
119. Dhillon S. Spotlight on DTPa-HBV-IPVHib vaccine (Infanrix hexa((trademark))). BioDrugs. 2010 2010;24(5):299-302. PMID: 2010470987 MEDLINE PMID 20795752 (<http://www.ncbi.nlm.nih.gov/pubmed/20795752>).
120. Dhillon S. DTPa-HBV-IPVHib vaccine (infanrix hexa(trademark)): A review of its use as primary and booster vaccination. Drugs. 2010 2010;70(8):1021-58. PMID: 2010292020.
121. Dhillon S, Curran MP. Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra). Paediatric Drugs. 2008;10(5):337-47. PMID: 18754700.
122. Dhillon S, Keam SJ. DTaP-IPV/Hib vaccine (Pentacel((registered trademark))). Pediatric Drugs. 2008 2008;10(6):405-16. PMID: 2008535695 MEDLINE PMID 18998751 (<http://www.ncbi.nlm.nih.gov/pubmed/18998751>).
123. Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Expert Review of Vaccines. 2009 Aug;8(8):977-86. PMID: 19627181.
124. Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-Valent, Adsorbed) Prevenar 13((registered trademark)). Drugs. 2010 2010;70(15):1973-86. PMID: 2010559199 MEDLINE PMID 20883054 (<http://www.ncbi.nlm.nih.gov/pubmed/20883054>).

125. Dull PM, McIntosh ED. Meningococcal vaccine development - from glycoconjugates against MenACWY to proteins against MenB - potential for broad protection against meningococcal disease. *Vaccine*. 2012;30(SUPPL. 2):B18-B25. PMID: 2012287507.
126. Eichelberger MC, Sperber E, Wagner M, et al. Clinical evaluation of a single oral dose of human-bovine (UK) reassortant rotavirus vaccines Wa x UK (P1A[8],G6) and Wa x (DS-1 x UK) (P1A[8],G2). *Journal of Medical Virology*. 2002 Mar;66(3):407-16. PMID: 11793395.
127. Eldred BE, Dean AJ, McGuire TM, et al. Vaccine components and constituents: Responding to consumer concerns. *Medical Journal of Australia*. 2006;201:184(4):170-5. PMID: 2006104144 MEDLINE PMID 16489901 (<http://www.ncbi.nlm.nih.gov/pubmed/16489901>).
128. Etter DJ, Zimet GD, Rickert VI. Human papillomavirus vaccine in adolescent women: A 2012 update. *Current Opinion in Obstetrics and Gynecology*. 2012;8.
129. Evans G. Vaccine liability and safety: A progress report. *Pediatric Infectious Disease Journal*. 1996;15(6):477-8. PMID: 1996189560 MEDLINE PMID 8783342 (<http://www.ncbi.nlm.nih.gov/pubmed/8783342>).
130. Faix RG. Maternal immunization to prevent fetal and neonatal infection. *Clinical Obstetrics and Gynecology*. 1991;34(2):277-87. PMID: 1991168891 MEDLINE PMID 1907897 (<http://www.ncbi.nlm.nih.gov/pubmed/1907897>).
131. Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. *Journal of Neurology*. 2011 Jul;258(7):1197-206. PMID: 21431896.
132. Fernandes GC, Camacho LAB, Sa Carvalho M. Surveillance system of vaccine adverse events and local data analysis - The experience in a middle-sized city in Brazil, 1999-2001. *Vaccine*. 2005;18:23(17-18):2349-53. PMID: 2005114455 MEDLINE PMID 15755626 (<http://www.ncbi.nlm.nih.gov/pubmed/15755626>).
133. Ferreccio C, Clemens J, Avendano A, et al. The Clinical and Immunological Response of Chilean Infants to *Haemophilus-Influenzae* Type B-Polysaccharide-Tetanus Protein Conjugate Vaccine Coadministered in the Same Syringe with Diphtheria-Tetanus Toxoids-Pertussis Vaccine at 2, 4 and 6 Months of Age. *Pediatric Infectious Disease Journal*. 1991 Oct;10(10):764-71. PMID: WOS:A1991GJ51500010.
134. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: A meta-analysis of randomized controlled trials. *Archives of Internal Medicine*. 1994;154(23):2666-77. PMID: 1994374270 MEDLINE PMID 7993150 (<http://www.ncbi.nlm.nih.gov/pubmed/7993150>).
135. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.[Erratum appears in MMWR Recomm Rep. 2010 Aug 13;59(31):993], [Erratum appears in MMWR

Recomm Rep. 2010 Sep 10;59(35):1147]. Morbidity & Mortality Weekly Report. Recommendations & Reports. 2010 Aug 6;59(RR-8):1-62. PMID: 20689501.

136. Flohr C, Yeo L. Atopic dermatitis and the hygiene hypothesis revisited. SOURCE Current Problems in Dermatology (2011) 41 (1-34). Date of Publication: May 2011 Pathogenesis and Management of Atopic Dermatitis, Book Series Title:.. 2011 PMID: 2011308604 MEDLINE PMID 21576944 (<http://www.ncbi.nlm.nih.gov/pubmed/21576944>).
137. Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: Prevalence and links with immunizations. Pediatrics. 2006 July;118(1):e139-e50. PMID: 2007025041 MEDLINE PMID 16818529 (<http://www.ncbi.nlm.nih.gov/pubmed/16818529>).
138. Forinash AB, Yancey AM, Pitlick JM, et al. Safety of the HPV bivalent and quadrivalent vaccines during pregnancy. Annals of Pharmacotherapy. 2011 February;45(2):258-62. PMID: 2011107897.
139. Fox KA, Theiler R. Vaccination in pregnancy. Current Pharmaceutical Biotechnology. 2011 June;12(5):789-96. PMID: 2011246833 MEDLINE PMID 21480828 (<http://www.ncbi.nlm.nih.gov/pubmed/21480828>).
140. Frampton JE, Keating GM. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (boostrix(trademark)): A review of its use as a single-dose booster immunization. BioDrugs. 2006 2006;20(6):371-89. PMID: 2007030567 MEDLINE PMID 17176125 (<http://www.ncbi.nlm.nih.gov/pubmed/17176125>).
141. French RW, Jr., Seward JF. Varicella vaccine safety and immunogenicity in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis care & research. 2010 Jul;62(7):903-6. PMID: 20506363.
142. Fritzsche PJ, Helbling A, Ballmer-Weber BK. Vaccine hypersensitivity - Update and overview. Swiss Medical Weekly. 2010 30;140(17 18):238-46. PMID: 2010256443 MEDLINE PMID 20349363 (<http://www.ncbi.nlm.nih.gov/pubmed/20349363>).
143. Gagliardi AM, Gomes Silva BN, Torloni MR, et al. Vaccines for preventing herpes zoster in older adults. Cochrane Database of Systematic Reviews. 2012;10:CD008858. PMID: 23076951.
144. Galiza EP, Heath PT. Adverse events following immunisation - fact and fiction. Paediatrics and Child Health. 2008 November;18(11):508-12. PMID: 2008478823.
145. Geier DA, Geier MR. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Medical Science Monitor. 2004 March;10(3):PI33-PI9. PMID: 2004123596 MEDLINE PMID 14976450 (<http://www.ncbi.nlm.nih.gov/pubmed/14976450>).

146. Ghaffar F. The safety of 7-valent pneumococcal conjugate vaccine. *Expert Opinion on Drug Safety*. 2005 Jul;4(4):631-6. PMID: 16011442.
147. Girard M. Autoimmune hazards of hepatitis B vaccine. *Autoimmunity Reviews*. 2005 February;4(2):96-100. PMID: 2005084167 MEDLINE PMID 15722255 (<http://www.ncbi.nlm.nih.gov/pubmed/15722255>).
148. Gladstone RA, Jefferies JM, Faust SN, et al. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. *Expert Review of Vaccines*. 2012 August;11(8):889-902. PMID: 2012567216.
149. Glass RI, Patel M, Parashar U. Lessons from the US rotavirus vaccination program. *JAMA*. 2011 Oct 19;306(15):1701-2. PMID: 22009102.
150. Gleeson TD, Wallace MR, Tasker SA. Vaccination in patients with HIV infection. *Current Infectious Disease Reports*. 2006 Mar;8(2):151-61. PMID: 2006149208.
151. Glezen WP. Maternal vaccines. *Primary Care - Clinics in Office Practice*. 2001 2001;28(4):791-806. PMID: 2001417166 MEDLINE PMID 11739030 (<http://www.ncbi.nlm.nih.gov/pubmed/11739030>).
152. Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. *Clinical Infectious Diseases*. 2008 May 1;46(9):1459-65. PMID: 18419456.
153. Gold M, Goodwin H, Botham S, et al. Re-vaccination of 421 children with a past history of an adverse vaccine reaction in a special immunisation service. *Archives of Disease in Childhood*. 2000 2000;83(2):128-31. PMID: 2000310293 MEDLINE PMID 10906018 (<http://www.ncbi.nlm.nih.gov/pubmed/10906018>).
154. Goldschmidt I, Pfister ED, Becker M, et al. Acceptance and adverse events of the 2009 H1N1 vaccination in immunosuppressed pediatric liver transplant recipients. *Journal of Pediatrics*. 2011 Feb;158(2):329-33. PMID: 21163496.
155. Goldstone SE, Vuocolo S. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. *Expert Review of Vaccines*. 2012 April;11(4):395-406. PMID: 2012256012.
156. Goveia MG, Ciarlet M, Owen KE, et al. Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine. *Annals of the New York Academy of Sciences*. 2011 Mar;1222:14-8. PMID: 21434938.
157. Goveia MG, Suprun L, Itzler RF, et al. Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. *Pediatric Infectious Disease Journal*. 2010 Mar;29(3):263-5. PMID: 19949360.

158. Graves PM. Hemophilus vaccine and diabetes. *Diabetes Care*. 2000;23(6):872-3. PMID: 2000223918.
159. Gray J. Rotavirus vaccines: safety, efficacy and public health impact. *Journal of Internal Medicine*. 2011 Sep;270(3):206-14. PMID: 21668823.
160. Greenberg DP. Considerations for hepatitis B as part of a combination vaccine. *Pediatric Infectious Disease Journal*. 2001;20(11 SUPPL.):S34-S9. PMID: 2001402762 MEDLINE PMID 11704722 (<http://www.ncbi.nlm.nih.gov/pubmed/11704722>).
161. Greenberg HB. Rotavirus vaccination and intussusception--act two. *New England Journal of Medicine*. 2011 Jun 16;364(24):2354-5. PMID: 21675894.
162. Griffiths UK, Clark A, Gessner B, et al. Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: A systematic review and meta- Analysis of controlled clinical trials. *Epidemiology and Infection*. 2012 August;140(8):1343-55. PMID: 2012418453.
163. Gruber C, Nilsson L, Bjorksten B. Do early childhood immunizations influence the development of atopy and do they cause allergic reactions? *Pediatric Allergy and Immunology*. 2001;12(6):296-311. PMID: 2002030175 MEDLINE PMID 11846867 (<http://www.ncbi.nlm.nih.gov/pubmed/11846867>).
164. Gruber WC, Scott DA, Emini EA. Development and clinical evaluation of Prevnar 13, a 13-valent pneumococcal CRM(197) conjugate vaccine. *Annals of the New York Academy of Sciences*. 2012 Aug;1263(1):15-26. PMID: 22830997.
165. Guidozzi F. The HPV vaccine - What the family practitioner needs to know. *South African Family Practice*. 2008 July/August;50(4):22-4. PMID: 2008495601.
166. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barre syndrome following influenza vaccination. *JAMA*. 2004 Nov 24;292(20):2478-81. PMID: 15562126.
167. Halsey NA, Chesney PJ, Gerber MA, et al. Poliomyelitis prevention: Recommendations for use of inactivated poliovirus vaccine and live oral poliovirus vaccine. *Pediatrics*. 1997 February;99(2):300-5. PMID: 1997104368 MEDLINE PMID 9024465 (<http://www.ncbi.nlm.nih.gov/pubmed/9024465>).
168. Heaton PM, Ciarlet M. Vaccines: the pentavalent rotavirus vaccine: discovery to licensure and beyond. *Clinical Infectious Diseases*. 2007 Dec 15;45(12):1618-24. PMID: 18198497.
169. Heijstek MW, Ott De Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. *Annals of the Rheumatic Diseases*. 2011 October;70(10):1704-12. PMID: 2011496983 MEDLINE PMID 21813547 (<http://www.ncbi.nlm.nih.gov/pubmed/21813547>).

170. Heijstek MW, Ott de Bruin LM, Borrow R, et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. *Autoimmunity Reviews*. 2011 Dec;11(2):112-22. PMID: 21896342.
171. Heininger U. Pertussis immunisation in adolescents and adults. *Advances in Experimental Medicine and Biology*. 2008 2008;609:72-97. PMID: 2009179912 MEDLINE PMID 18193659 (<http://www.ncbi.nlm.nih.gov/pubmed/18193659>).
172. Heyse JF, Kuter BJ, Dallas MJ, et al. Evaluating the safety of a rotavirus vaccine: the REST of the story. *Clinical Trials*. 2008;5(2):131-9. PMID: 18375651.
173. Huang DB, Wu JJ, Tyring SK. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. *Journal of Infection*. 2004 October;49(3):179-209. PMID: 2004383074 MEDLINE PMID 15337336 (<http://www.ncbi.nlm.nih.gov/pubmed/15337336>).
174. Huang W-T, Chang S, Miller ER, et al. Safety assessment of recalled *Haemophilus influenzae* type b (Hib) conjugate vaccines--United States, 2007-2008. *Pharmacoepidemiology & Drug Safety*. 2010 Mar;19(3):306-10. PMID: 20084617.
175. Hussain H, Omer SB, Manganello JA, et al. Immunization safety in US print media, 1995-2005. *Pediatrics*. 2011 May;127(SUPPL. 1):S100-S6. PMID: 2011239124 MEDLINE PMID 21502237 (<http://www.ncbi.nlm.nih.gov/pubmed/21502237>).
176. IOM. Immunization safety review: influenza vaccines and neurological complications. Washington DC: National Academies Press. 2001:78 –9, 88 –9.
177. Iskander J, Broder K. Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience. *Expert Review of Vaccines*. 2008 Feb;7(1):75-82. PMID: WOS:000260047900014.
178. Iskander JK, Gidudu J, Arboleda N, et al. Selected major issues in vaccine safety. *Annales Nestle*. 2008 July;66(2):93-102. PMID: 2008345556.
179. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. *JAMA*. 2005 Dec 7;294(21):2720-5. PMID: 16333007.
180. Jacobson RM. Vaccine safety. *Immunology and Allergy Clinics of North America*. 2003 November;23(4):589-603. PMID: 2004010558 MEDLINE PMID 14753382 (<http://www.ncbi.nlm.nih.gov/pubmed/14753382>).
181. Jamieson DJ, Rasmussen SA. The safety of adjuvants in influenza vaccines during pregnancy: what do we know and why do we need them? *American Journal of Obstetrics & Gynecology*. 2012 Sep;207(3):145-6. PMID: 22939714.

182. Jefferies JMC, Macdonald E, Faust SN, et al. 13-valent pneumococcal conjugate vaccine (PCV13). *Human Vaccines*. 2011;7(10) PMID: 2011578238.
183. Jefferson T, Di Pietrantonj C, Al-Ansary LA, et al. Vaccines for preventing influenza in the elderly. *Cochrane Database of Systematic Reviews*. 2010(2):CD004876. PMID: 20166072.
184. Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. *Cochrane Database of Systematic Reviews*. 2010(7):CD001269. PMID: 20614424.
185. Jefferson T, Price D, Demicheli V, et al. Unintended events following immunization with MMR: a systematic review. *Vaccine*. 2003 Sep 8;21(25-26):3954-60. PMID: 12922131.
186. Jefferson T, Rivetti A, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy children. *Cochrane Database of Systematic Reviews*. 2012;8:CD004879. PMID: 22895945.
187. Jeffery DR. The use of vaccinations in patients with multiple sclerosis. *Infections in Medicine*. 2002 2002;19(2):73-9. PMID: 2002089500.
188. Jick H, Kaye JA. Epidemiology and Possible Causes of Autism. *Pharmacotherapy*. 2003 December;23(12 I):1524-30. PMID: 2003493362 MEDLINE PMID 14695031 (<http://www.ncbi.nlm.nih.gov/pubmed/14695031>).
189. Joura EA, Garland SM, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: Retrospective pooled analysis of trial data. *BMJ*. 2012;344(7851) PMID: 2012205289.
190. Kaczorowski J. Pneumococcal vaccination and cardiovascular events in men. *JAMA*. 2010 Aug 18;304(7):742; author reply 3. PMID: 20716734.
191. Kanessa-thasan N, Shaw A, Stoddard JJ, et al. Ensuring the optimal safety of licensed vaccines: A perspective of the vaccine research, development, and manufacturing companies. *Pediatrics*. 2011 May;127(SUPPL. 1):S16-S22. PMID: 2011239113 MEDLINE PMID 21502248 (<http://www.ncbi.nlm.nih.gov/pubmed/21502248>).
192. Kaplan SL. Haemophilus influenzae type B conjugate vaccines. *Pediatr Ann*. 1990 Dec;19(12):712-3, 6-8. PMID: 2280990.
193. Karande S, Gogtay NJ, Kshirsagar NA. Efficacy and safety of vaccines in Indian children: A review. *Paediatric and Perinatal Drug Therapy*. 2003 2003;5(3):124-34. PMID: 2003260572.
194. Kaye JA, del Mar Melero-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. *BMJ*. 2001 Feb 24;322(7284):460-3. PMID: 11222420.
195. Keating GM, Noble S, Averhoff FM, et al. Recombinant hepatitis B vaccine (Engerix-B(registered trademark)): A review of its immunogenicity and protective efficacy against

- hepatitis B. Drugs. 2003;63(10):1021-51. PMID: 2003197841 MEDLINE PMID 12699402 (<http://www.ncbi.nlm.nih.gov/pubmed/12699402>).
196. Kennedy RC, Byers VS, Marchalonis JJ. Measles virus infection and vaccination: Potential role in chronic illness and associated adverse events. Critical Reviews in Immunology. 2004;24(2):129-56. PMID: 2004535433 MEDLINE PMID 15581394 (<http://www.ncbi.nlm.nih.gov/pubmed/15581394>).
197. Khromava A, Cohen CJ, Mazur M, et al. Manufacturers' postmarketing safety surveillance of influenza vaccine exposure in pregnancy. American Journal of Obstetrics and Gynecology. 2012 September;207(3 SUPPL.):S52-S6. PMID: 2012497478.
198. Kohl KS, Marcy SM, Blum M, et al. Fever after immunization: Current concepts and improved future scientific understanding. Clinical Infectious Diseases. 2004;1;39(3):389-94. PMID: 2004342022 MEDLINE PMID 15307007 (<http://www.ncbi.nlm.nih.gov/pubmed/15307007>).
199. Koppen S, de Groot R, Neijens HJ, et al. No epidemiological evidence for infant vaccinations to cause allergic disease. Vaccine. 2004 Sep 3;22(25-26):3375-85. PMID: 15308362.
200. Kuo AM, Brown JN, Clinard V. Effect of influenza vaccination on international normalized ratio during chronic warfarin therapy. Journal of Clinical Pharmacy and Therapeutics. 2012.
201. Kwok R. Vaccines: The real issues in vaccine safety. Nature. 2011;26;473(7348):436-8. PMID: 2011293237 MEDLINE PMID 21614053 (<http://www.ncbi.nlm.nih.gov/pubmed/21614053>).
202. Labrie JE, 3rd, Keiser PB. Whole cell vaccination for meningococcus: Lessons from an idea for which time has gone. Human Vaccines. 2010 Apr;6(4):360-5. PMID: 20372072.
203. Lacroix I, Damase-Michel C, Kreft-Jais C, et al. 2009 H1N1 influenza vaccines in pregnant women: the French Pharmacovigilance survey. Vaccine. 2011 Feb 4;29(7):1357-8. PMID: 21185422.
204. Lapphra K, Scheifele DW. Can children with minor illnesses be safely immunized? Paediatrics and Child Health. 2011 October;16(8):463. PMID: 2011561841.
205. LaRussa PS, Edwards KM, Dekker CL, et al. Understanding the role of human variation in vaccine adverse events: The clinical immunization safety assessment network. Pediatrics. 2011 May;127(SUPPL. 1):S65-S73. PMID: 2011239119 MEDLINE PMID 21502239 (<http://www.ncbi.nlm.nih.gov/pubmed/21502239>).

206. Lavelle EC, O'Hagan DT. Delivery systems and adjuvants for oral vaccines. *Expert Opinion on Drug Delivery*. 2006 November;3(6):747-62. PMID: 2006571316 MEDLINE PMID 17076597 (<http://www.ncbi.nlm.nih.gov/pubmed/17076597>).
207. Lepage P, Vergison A. Prevention of childhood rotavirus disease through the use of Rotarix and RotaTeq vaccines. *Expert Opinion on Biological Therapy*. 2007 Dec;7(12):1881-92. PMID: 18034653.
208. Lepage P, Vergison A. Impact of rotavirus vaccines on rotavirus disease. *Expert Review of Anti-Infective Therapy*. 2012 May;10(5):547-61. PMID: 2012348240.
209. Lepow ML. Pediatric immunizations and adverse events. *Current Opinion in Infectious Diseases*. 1991 1991;4(4):463-8. PMID: 1991262882.
210. Levavi H. Human papillomavirus vaccination - To adolescents. *Pediatric Endocrinology Reviews*. 2010 September;8(1):2-5. PMID: 2010694220.
211. Lieu TA, Nguyen MD, Ball R, et al. Health outcomes of interest for evaluation in the Post-Licensure Rapid Immunization Safety Monitoring Program. *Vaccine*. 2012 Apr 16;30(18):2824-30. PMID: 22394993.
212. Lindblad EB. Aluminium adjuvants - In retrospect and prospect. *Vaccine*. 2004 9;22(27 28):3658-68. PMID: 2004358343 MEDLINE PMID 15315845 (<http://www.ncbi.nlm.nih.gov/pubmed/15315845>).
213. Linhares AC, Villa LL. Vaccines against rotavirus and human papillomavirus (HPV). *Jornal de Pediatria*. 2006 Jul;82(3 Suppl):S25-34. PMID: 16786101.
214. Livengood JR, Mullen JR, White JW, et al. Family history of convulsions and use of pertussis vaccine. *Journal of Pediatrics*. 1989 Oct;115(4):527-31. PMID: 2552066.
215. Lloyd JC, Haber P, Mootrey GT, et al. Adverse event reporting rates following tetanus-diphtheria and tetanus toxoid vaccinations: data from the Vaccine Adverse Event Reporting System (VAERS), 1991-1997. *Vaccine*. 2003 Sep 8;21(25-26):3746-50. PMID: 12922107.
216. Loebermann M, Winkelmann A, Hartung HP, et al. Vaccination against infection in patients with multiple sclerosis. *Nature Reviews Neurology*. 2012 March;8(3):143-51. PMID: 2012147137.
217. Lu B, Kumar A, Castellsague X, et al. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. *BMC Infectious Diseases*. 2011;11:13. PMID: 21226933.
218. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than

two years of age. Cochrane Database of Systematic Reviews. 2009(4) PMID: WOS:000270687300045.

219. MacDonald NE, Riley LE, Steinhoff MC. Influenza immunization in pregnancy. *Obstet Gynecol*. 2009 Aug;114(2 Pt 1):365-8. PMID: 19622998.

220. Madaan A, Maddox DE. Vaccine allergy: Diagnosis and management. *Immunology and Allergy Clinics of North America*. 2003 November;23(4):555-88. PMID: 2004010557 MEDLINE PMID 14753381 (<http://www.ncbi.nlm.nih.gov/pubmed/14753381>).

221. Mak TK, Mangtani P, Leese J, et al. Influenza vaccination in pregnancy: current evidence and selected national policies. *Lancet Infect Dis*. 2008 Jan;8(1):44-52. PMID: 18156088.

222. Makris MC, Polyzos KA, Mavros MN, et al. Safety of Hepatitis B, Pneumococcal Polysaccharide and Meningococcal Polysaccharide Vaccines in Pregnancy A Systematic Review. *Drug Safety*. 2012;35(1):1-14. PMID: WOS:000298866400001.

223. Manzoli L, De Vito C, Salanti G, et al. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. *PLoS ONE* [Electronic Resource]. 2011;6(9):e24384. PMID: 21915319.

224. Manzoli L, Ioannidis JPA, Flacco ME, et al. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: A critical review and re-analysis of 15 meta-analyses. *Human Vaccines and Immunotherapeutics*. 2012 July;8(7):851-62. PMID: 2012427206.

225. Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morbidity & Mortality Weekly Report Recommendations & Reports*. 2010 May 7;59(RR-3):1-12. PMID: 20448530.

226. Marshall GS. Rotavirus disease and prevention through vaccination. *Pediatric Infectious Disease Journal*. 2009 Apr;28(4):355-62, quiz 63-4. PMID: 19333083.

227. Marshall GS, Gellin BG. Challenges to vaccine safety. *Primary Care - Clinics in Office Practice*. 2001 2001;28(4):853-68. PMID: 2001417169 MEDLINE PMID 11739033 (<http://www.ncbi.nlm.nih.gov/pubmed/11739033>).

228. Marshall V, Gruber M. Influenza immunization during pregnancy: US regulatory perspective. *American Journal of Obstetrics & Gynecology*. 2012 Sep;207(3 Suppl):S57-62. PMID: 22920061.

229. Martin BL, Nelson MR, Hershey JN, et al. Adverse reactions to vaccines. *Clinical Reviews in Allergy and Immunology*. 2003 June;24(3):263-75. PMID: 2003203883 MEDLINE PMID 12721397 (<http://www.ncbi.nlm.nih.gov/pubmed/12721397>).

230. Mary Healy C. Vaccines in pregnant women and research initiatives. *Clinical Obstetrics and Gynecology*. 2012 June;55(2):474-86. PMID: 2012239403.
231. Mathew JL, El Dib R, Mathew PJ, et al. Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status. *Cochrane Database of Systematic Reviews*. 2008;3 PMID: 2008510762.
232. Matson DO. The pentavalent rotavirus vaccine, RotaTeq. *Seminars in Pediatric Infectious Diseases*. 2006 Oct;17(4):195-9. PMID: 17055370.
233. McCormack PL, Keam SJ. Rotavirus vaccine RIX4414 (Rotarix): a review of its use in the prevention of rotavirus gastroenteritis. *Paediatric Drugs*. 2009;11(1):75-88. PMID: 19127963.
234. McIntyre P. Vaccines against invasive Haemophilus influenzae type b disease. *Journal of Paediatrics and Child Health*. 1994 1994;30(1):14-8. PMID: 1994048436 MEDLINE PMID 8148181 (<http://www.ncbi.nlm.nih.gov/pubmed/8148181>).
235. McKeage K, Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix((registered trademark))): A review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. *Drugs*. 2011 2011;71(4):465-88. PMID: 2011144419 MEDLINE PMID 21395359 (<http://www.ncbi.nlm.nih.gov/pubmed/21395359>).
236. McMahon AW, Iskander JK, Haber P, et al. Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine. *Vaccine*. 2008 Jan 17;26(3):427-9. PMID: 18093701.
237. McPhillips H, Marcuse EK. Vaccine safety. *Current Problems in Pediatrics*. 2001 Apr;31(4):91-121. PMID: 11330034.
238. McVernon J, Nolan T. Panvax((registered trademark)): A monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009. *Expert Review of Vaccines*. 2011 January;10(1):35-43. PMID: 2010701546 MEDLINE PMID 21162618 (<http://www.ncbi.nlm.nih.gov/pubmed/21162618>).
239. Merchant N, Waldrop J. The safety advantages of pentavalent vaccines. *Nurse Practitioner*. 2012 Apr 15;37(4):48-53. PMID: 22430930.
240. Michiels B, Govaerts F, Remmen R, et al. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. *Vaccine*. 2011 15;29(49):9159-70. PMID: 2011662699 MEDLINE PMID 21840359 (<http://www.ncbi.nlm.nih.gov/pubmed/21840359>).

241. Miravalle A, Biller J, Schnitzler E, et al. Neurological complications following vaccinations. *Neurological Research*. 2010;1;32(3):285-92. PMID: 2010237387 MEDLINE PMID 20406607 (<http://www.ncbi.nlm.nih.gov/pubmed/20406607>).
242. Mirzayeva R, Steele AD, Parashar UD, et al. Evaluation of rotavirus vaccines in Asia-Are there lessons to be learnt? *Vaccine*. 2009;20;27(SUPPL. 5):F120-F9. PMID: 2009631221 MEDLINE PMID 19931711 (<http://www.ncbi.nlm.nih.gov/pubmed/19931711>).
243. Molinaro GA, Lee DA. Rotavirus vaccines [1]. *New England Journal of Medicine*. 2006;20;354(16):1747. PMID: 2006182386.
244. Monsonego J, Cortes J, Greppe C, et al. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine. *Vaccine*. 2010;29;28(51):8065-72. PMID: 2010662131 MEDLINE PMID 20971114 (<http://www.ncbi.nlm.nih.gov/pubmed/20971114>).
245. Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. *Lancet Infectious Diseases*. 2007 September;7(9):614-24. PMID: 2007405927 MEDLINE PMID 17537674 (<http://www.ncbi.nlm.nih.gov/pubmed/17537674>).
246. Moore MR, O'Brien K, Nuorti JP, et al. Pitfalls in case-control studies of vaccine effectiveness. *Clinical Infectious Diseases*. 2007 Nov;45(9):1241-2. PMID: WOS:000249923700020.
247. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. *BMC Family Practice*. 2000;1;1-10. PMID: 2004473722 MEDLINE PMID 11038265 (<http://www.ncbi.nlm.nih.gov/pubmed/11038265>).
248. Moro PL, Tepper NK, Grohskopf LA, et al. Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy. *Expert Review of Vaccines*. 2012 Aug;11(8):911-21. PMID: 23002972.
249. Mu XD. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing [2]. *New England Journal of Medicine*. 2011;24;364(12):1181. PMID: 2011175441.
250. Muehlhans S, Richard G, Ali M, et al. Safety reporting in developing country vaccine clinical trials-A systematic review. *Vaccine*. 2012;9;30(22):3255-65. PMID: 2012222588.
251. Muhammad RD, Haber P, Broder KR, et al. Adverse events following trivalent inactivated influenza vaccination in children: Analysis of the vaccine adverse event reporting system. *Pediatric Infectious Disease Journal*. 2011 January;30(1):e1-e8. PMID: 2011007702.
252. Munoz FM. Vaccination during pregnancy. *Women's Health*. 2007 March;3(2):227-41. PMID: 2007156609.

253. Munoz FM. Safety of influenza vaccines in pregnant women. *American Journal of Obstetrics and Gynecology*. 2012 September;207(3 SUPPL.):S33-S7. PMID: 2012497476.
254. Munoz FM, Englund JA. Vaccines in pregnancy. *Infectious Disease Clinics of North America*. 2001 2001;15(1):253-71. PMID: 2001129004 MEDLINE PMID 11301819 (<http://www.ncbi.nlm.nih.gov/pubmed/11301819>).
255. Murphy TV, Smith PJ, Gargiullo PM, et al. The first rotavirus vaccine and intussusception: epidemiological studies and policy decisions. *Journal of Infectious Diseases*. 2003 Apr 15;187(8):1309-13. PMID: 12696011.
256. Murray D, Jackson C. A conjugate vaccine for the prevention of pediatric pneumococcal disease. *Military Medicine*. 2002 2002;167(8):671-7. PMID: 2002287476 MEDLINE PMID 12188240 (<http://www.ncbi.nlm.nih.gov/pubmed/12188240>).
257. Nokleby H. Neurological adverse events of immunization: Experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine. *Expert Review of Vaccines*. 2007 October;6(5):863-9. PMID: 2007511617 MEDLINE PMID 17931164 (<http://www.ncbi.nlm.nih.gov/pubmed/17931164>).
258. Noorbakhsh F, Johnson RT, Emery D, et al. Acute Disseminated Encephalomyelitis: Clinical and Pathogenesis Features. *Neurologic Clinics*. 2008 August;26(3):759-80. PMID: 2008348848 MEDLINE PMID 18657725 (<http://www.ncbi.nlm.nih.gov/pubmed/18657725>).
259. Nor Aripin KNB, Choonara I, Sammons HM. Systematic review of safety in paediatric drug trials published in 2007. *European Journal of Clinical Pharmacology*. 2012 February;68(2):189-94. PMID: 2012091447 MEDLINE PMID 21858432 (<http://www.ncbi.nlm.nih.gov/pubmed/21858432>).
260. Nunes MC, Madhi SA. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. *Expert Review of Vaccines*. 2011 July;10(7):951-80. PMID: 2011438482 MEDLINE PMID 21806394 (<http://www.ncbi.nlm.nih.gov/pubmed/21806394>).
261. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. *Human Vaccines & Immunotherapeutics*. 2012 Feb;8(2):161-73. PMID: 22426374.
262. Obaro SK. The new pneumococcal vaccine. *Clinical Microbiology and Infection*. 2002 1;8(10):623-33. PMID: 2002397477 MEDLINE PMID 12390280 (<http://www.ncbi.nlm.nih.gov/pubmed/12390280>).
263. Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. *Lancet Infectious Diseases*. 2004 1;4(8):510-8. PMID: 2004348576 MEDLINE PMID 15288824 (<http://www.ncbi.nlm.nih.gov/pubmed/15288824>).

264. Obonyo CO, Lau J. Efficacy of *Haemophilus influenzae* type b vaccination of children: a meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases. 2006 Feb;25(2):90-7. PMID: 16491301.
265. Offit PA, Jew RK. Addressing Parents' Concerns: Do Vaccines Contain Harmful Preservatives, Adjuvants, Additives, or Residuals? Pediatrics. 2003 December;112(6 I):1394-401. PMID: 2003509020 MEDLINE PMID 14654615 (<http://www.ncbi.nlm.nih.gov/pubmed/14654615>).
266. O'Hagan DT, Rappuoli R. The safety of vaccines. Drug Discovery Today. 2004 1;9(19):846-54. PMID: 2004413840 MEDLINE PMID 15381137 (<http://www.ncbi.nlm.nih.gov/pubmed/15381137>).
267. Omer SB. Safety of quadrivalent human papillomavirus vaccine. Journal of Internal Medicine. 2012 Feb;271(2):177-8. PMID: 22077556.
268. Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine. 2007 Mar 8;25(12):2194-212. PMID: 17267077.
269. Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discovery Medicine. 2010 Feb;9(45):90-7. PMID: 20193633.
270. Orbach H, Tanay A. Vaccines as a trigger for myopathies. Lupus. 2009 2009;18(13):1213-6. PMID: 2009583181 MEDLINE PMID 19880571 (<http://www.ncbi.nlm.nih.gov/pubmed/19880571>).
271. Ornoy A, Tenenbaum A. Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio and encephalitis viruses. Reproductive Toxicology. 2006 May;21(4):446-57. PMID: 16480851.
272. Ortqvist A, Blennow M, Carlsson RM, et al. Vaccination of children - A systematic review. Acta Paediatrica, International Journal of Paediatrics. 2010 September;99(SUPPL. 461):1-192. PMID: 2010454253.
273. O'Ryan M. Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Review of Vaccines. 2007 Feb;6(1):11-9. PMID: 17280473.
274. Pai VB, Heyneman CA, Erramouspe J. Conjugated heptavalent pneumococcal vaccine. Annals of Pharmacotherapy. 2002 Sep;36(9):1403-13. PMID: 12196061.
275. Pancharoen C, Ananworanich J, Thisyakorn U. Immunization for persons infected with human immunodeficiency virus. Current HIV Research. 2004 October;2(4):293-9. PMID: 2004400522 MEDLINE PMID 15544450 (<http://www.ncbi.nlm.nih.gov/pubmed/15544450>).

276. Papaevangelou V, Spyridis N. MenACWY-TT vaccine for active immunization against invasive meningococcal disease. *Expert Review of Vaccines*. 2012 May;11(5):523-37. PMID: 2012348233.
277. Patel MM, Haber P, Baggs J, et al. Intussusception and rotavirus vaccination: a review of the available evidence. *Expert Review of Vaccines*. 2009 Nov;8(11):1555-64. PMID: 19863248.
278. Pavia M, Bianco A, Nobile CGA, et al. Efficacy of Pneumococcal Vaccination in Children Younger Than 24 Months: A Meta-Analysis. *Pediatrics*. 2009 Jun;123(6):E1103-E10. PMID: WOS:000266319000050.
279. Peter G, Myers MG, National Vaccine Advisory C, et al. Intussusception, rotavirus, and oral vaccines: summary of a workshop. *Pediatrics*. 2002 Dec;110(6):e67. PMID: 12456934.
280. Phua KB, Quak SH, Emmanuel S, et al. A short report on highlights of worldwide development of RIX4414: A Singaporean experience. *Vaccine*. 2006 1;24(18):3782-3. PMID: 2006202653 MEDLINE PMID 16600443 (<http://www.ncbi.nlm.nih.gov/pubmed/16600443>).
281. Pichichero ME, Casey JR. Acellular pertussis vaccines for adolescents. *Pediatric Infectious Disease Journal*. 2005 June;24(6 SUPPL.):S117-S26. PMID: 2005273564 MEDLINE PMID 15931139 (<http://www.ncbi.nlm.nih.gov/pubmed/15931139>).
282. Plosker GL. Rotavirus vaccine RIX4414 (Rotarix(trademark)): A pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries. *PharmacoEconomics*. 2011 2011;29(11):989-1009. PMID: 2011571106 MEDLINE PMID 21988293 (<http://www.ncbi.nlm.nih.gov/pubmed/21988293>).
283. Plosker GL. Rotavirus vaccine RIX4414 (Rotarix(trademark)): A pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries. *PharmacoEconomics*. 2011 2011;29(5):439-54. PMID: 2011223971 MEDLINE PMID 21504245 (<http://www.ncbi.nlm.nih.gov/pubmed/21504245>).
284. Plotkin SA. Lessons learned concerning vaccine safety. *Vaccine*. 2001 15;20(SUPPL. 1):S16-S9. PMID: 2001350388 MEDLINE PMID 11587803 (<http://www.ncbi.nlm.nih.gov/pubmed/11587803>).
285. Pomfret TC, Gagnon Jr JM, Gilchrist AT. Quadrivalent human papillomavirus (HPV) vaccine: A review of safety, efficacy, and pharmacoeconomics. *Journal of Clinical Pharmacy and Therapeutics*. 2011 February;36(1):1-9. PMID: 2011016789 MEDLINE PMID 21198715 (<http://www.ncbi.nlm.nih.gov/pubmed/21198715>).
286. Poorolajal J, Mahmoodi M, Haghdoost A, et al. Booster dose vaccination for preventing hepatitis B. *Cochrane Database of Systematic Reviews*. 2010(11)PMID: WOS:000284076200027.

287. Principi N, Esposito S. Use of the 13-valent pneumococcal conjugate vaccine in infants and young children. *Expert Opinion on Biological Therapy*. 2012 May;12(5):641-8. PMID: 22397739.
288. Rasmussen SA. Human teratogens update 2011: Can we ensure safety during pregnancy? *Birth Defects Research Part a-Clinical and Molecular Teratology*. 2012 Mar;94(3):123-8. PMID: WOS:000301433600001.
289. Rath B, Linder T, Cornblath D, et al. "All that palsies is not Bell's [1]"-The need to define Bell's palsy as an adverse event following immunization. *Vaccine*. 2007 21;26(1):1-14. PMID: 2007592408 MEDLINE PMID 18037542 (<http://www.ncbi.nlm.nih.gov/pubmed/18037542>).
290. Ridgway D, Wolff LJ. Active immunization of children with leukemia and other malignancies. *Leukemia & Lymphoma*. 1993 Feb;9(3):177-92. PMID: 8471977.
291. Rightmier E, Stevens V, Brown J. Streptococcus pneumoniae vaccination in older adults. *American Journal of Geriatric Pharmacotherapy*. 2011 Dec;9(6):392-404. PMID: 22047941.
292. Rimland B, McGinnis W. Vaccines and autism. *Laboratory Medicine*. 2002 1;33(9):708-17. PMID: 2002393915.
293. Rivas P, Herrero MD, Puente S, et al. Immunizations in HIV-infected adults. *AIDS Reviews*. 2007 July/September;9(3):173-87. PMID: 2007522502 MEDLINE PMID 17982942 (<http://www.ncbi.nlm.nih.gov/pubmed/17982942>).
294. Rivetti D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. *Cochrane Database of Systematic Reviews*. 2006(3):CD004876. PMID: 16856068.
295. Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. *Expert Review of Vaccines*. 2009 October;8(10):1351-64. PMID: 2009537313 MEDLINE PMID 19803758 (<http://www.ncbi.nlm.nih.gov/pubmed/19803758>).
296. Rosenberg M, Sparks R, McMahon A, et al. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. *Vaccine*. 2009 9;27(32):4278-83. PMID: 2009321262 MEDLINE PMID 19450636 (<http://www.ncbi.nlm.nih.gov/pubmed/19450636>).
297. Royle J. Meningococcal vaccines. *Medicine Today*. 2003 1;4(5):99-100. PMID: 2003207635.
298. Rubinstein E. Vaccination and autoimmune diseases: The argument against. *Israel Medical Association Journal*. 2004 July;6(7):433-5. PMID: 2004327052 MEDLINE PMID 15274538 (<http://www.ncbi.nlm.nih.gov/pubmed/15274538>).
299. Ruiz LP, Jr. Rotavirus vaccines. *New England Journal of Medicine*. 2006 Apr 20;354(16):1747-51; author reply -51. PMID: 16625743.

300. Rutschmann OT, McCrory DC, Matchar DB, et al. Immunization and MS: A summary of published evidence and recommendations. *Neurology*. 2002;24;59(12):1837-43. PMID: 2003029192 MEDLINE PMID 12499473 (<http://www.ncbi.nlm.nih.gov/pubmed/12499473>).
301. Salemi S, D'Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity. *International Reviews of Immunology*. 2010 June;29(3):270-314. PMID: 2010318846 MEDLINE PMID 20521926 (<http://www.ncbi.nlm.nih.gov/pubmed/20521926>).
302. Salemi S, D'Amelio R. Vaccinations and autoimmune diseases. *International Reviews of Immunology*. 2010 June;29(3):239-46. PMID: 2010318849 MEDLINE PMID 20521924 (<http://www.ncbi.nlm.nih.gov/pubmed/20521924>).
303. Sangkomkamhang US, Lumbiganon P, Laopaiboon M. Hepatitis B vaccination during pregnancy for preventing infant infection. *Cochrane Database of Systematic Reviews*. 2011(3) PMID: WOS:000288457900028.
304. Satterwhite TK. Use of the pneumococcal vaccine. *American Family Physician*. 1981 Nov;24(5):209-12. PMID: 7293914.
305. Scott LJ. Tdap(5) vaccine (Covaxis(registered trademark)): A review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (Aged (greater-than or equal to)4 Years), adolescents, and adults. *Biodrugs*. 2010;2010;24(6):387-406. PMID: 2010607096.
306. Scott P, Moss WJ, Gilani Z, et al. Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity. *Journal of Infectious Diseases*. 2011 Jul;204 Suppl 1:S164-78. PMID: 21666158.
307. Shobha V. Common anti-infective prophylaxis and vaccinations in autoimmune inflammatory rheumatic diseases. *Indian Journal of Rheumatology*. 2012 March;7(1):21-8. PMID: 2012202945.
308. Shreffler WG. A synthetic conjugate polysaccharide vaccine against *Haemophilus influenzae* type b. *Pediatrics*. 2005;2005;116(2):573. PMID: 2006369389.
309. Simonsen L, Viboud C, Taylor RJ, et al. Influenza vaccination and mortality benefits: new insights, new opportunities. *Vaccine*. 2009 Oct 23;27(45):6300-4. PMID: 19840664.
310. Skowronski DM, De Serres G. Is routine influenza immunization warranted in early pregnancy? *Vaccine*. 2009;30;27(35):4754-70. PMID: 2009345843 MEDLINE PMID 19515466 (<http://www.ncbi.nlm.nih.gov/pubmed/19515466>).
311. Small TN, Cowan MJ. Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases. *Expert Review of Clinical Immunology*. 2011

March;7(2):193-203. PMID: 2011170552 MEDLINE PMID 21426257
(<http://www.ncbi.nlm.nih.gov/pubmed/21426257>).

312. Smith DH, Madore DV, Eby RJ, et al. Haemophilus b oligosaccharide-CRM197 and other Haemophilus b conjugate vaccines: a status report. *Advances in Experimental Medicine & Biology*. 1989;251:65-82. PMID: 2692432.

313. Smith-McCune K. Quadrivalent HPV vaccine administered to women who became pregnant during trials did not appear to adversely affect pregnancy outcome; however, use during pregnancy is not recommended. *Evidence-Based Medicine*. 2010 June;15(3):80-1. PMID: 2010346922.

314. Soares-Weiser K, Maclehose H, Bergman H, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. *Cochrane Database of Systematic Reviews*. 2012;2:CD008521. PMID: 22336845.

315. Sonneville R, Klein I, de Broucker T, et al. Post-infectious encephalitis in adults: Diagnosis and management. *Journal of Infection*. 2009 May;58(5):321-8. PMID: 2009198785 MEDLINE PMID 19368974 (<http://www.ncbi.nlm.nih.gov/pubmed/19368974>).

316. Souayah N, Nasar A, Suri MFK, et al. Guillain-Barre syndrome after vaccination in United States. A report from the CDC/FDA Vaccine Adverse Event Reporting System. *Vaccine*. 2007 20;25(29):5253-5. PMID: 2007307015 MEDLINE PMID 17560693
(<http://www.ncbi.nlm.nih.gov/pubmed/17560693>).

317. Srivastava VK, Laisram N, Srivastava RK. Immunization status in paralytic poliomyelitis--a hospital based study. *Indian Pediatrics*. 1989 May;26(5):430-3. PMID: 2599610.

318. Stephenson J. Vaccines pose no diabetes, bowel disease risk. *Journal of the American Medical Association*. 2000 8;284(18):2307-8. PMID: 2000399302 MEDLINE PMID 11066164
(<http://www.ncbi.nlm.nih.gov/pubmed/11066164>).

319. Sucher AJ, Chahine EB, Nelson M, et al. Prevnar 13, the new 13-valent pneumococcal conjugate vaccine. *Annals of Pharmacotherapy*. 2011 Dec;45(12):1516-24. PMID: 22045904.

320. Tai JH, Curns AT, Parashar UD, et al. Rotavirus vaccination and intussusception: can we decrease temporally associated background cases of intussusception by restricting the vaccination schedule? *Pediatrics*. 2006 Aug;118(2):e258-64. PMID: 16882770.

321. Tamma PD, Ault KA, del Rio C, et al. Safety of influenza vaccination during pregnancy. *Am J Obstet Gynecol*. 2009 Dec;201(6):547-52. PMID: 19850275.

322. Tapiainen T, Heininger U. Fever following immunization. *Expert Review of Vaccines*. 2005 June;4(3):419-27. PMID: 2005315637 MEDLINE PMID 16026253
(<http://www.ncbi.nlm.nih.gov/pubmed/16026253>).

323. Thjodleifsson B, Davidsdottir K, Agnarsson U, et al. Effect of Pentavac and measles-mumps-rubella (MMR) vaccination on the intestine. *Gut*. 2002 Dec;51(6):816-7. PMID: 12427783.
324. Toback SL, Beigi R, Tennis P, et al. Maternal outcomes among pregnant women receiving live attenuated influenza vaccine. *Influenza & Other Respiratory Viruses*. 2012 Jan;6(1):44-51. PMID: 21672166.
325. Tom-Revzon C. Rotavirus live, oral, pentavalent vaccine. *Clinical Therapeutics*. 2007 Dec;29(12):2724-37. PMID: 18201590.
326. Tozzi AE. Field evaluation of vaccine safety. *Vaccine*. 2004 7;22(15 16):2091-5. PMID: 2004198055 MEDLINE PMID 15121330 (<http://www.ncbi.nlm.nih.gov/pubmed/15121330>).
327. Tsai TF. MF59((registered trademark)) adjuvanted seasonal and pandemic influenza vaccines. *Yakugaku Zasshi - Journal of the Pharmaceutical Society of Japan*. 2011 20111201;131(12):1733-41. PMID: 2011666574.
328. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Annals of the Rheumatic Diseases*. 2011 March;70(3):414-22. PMID: 2011089272 MEDLINE PMID 21131643 (<http://www.ncbi.nlm.nih.gov/pubmed/21131643>).
329. Van Assen S, Elkayam O, Agmon-Levin N, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. *Autoimmunity Reviews*. 2011 April;10(6):341-52. PMID: 2011173065 MEDLINE PMID 21182987 (<http://www.ncbi.nlm.nih.gov/pubmed/21182987>).
330. Van Der Meeren O, Kuriyakose S, Kolhe D, et al. Immunogenicity of Infanrix(trademark) hexa administered at 3, 5 and 11 months of age. *Vaccine*. 2012 5;30(17):2710-4. PMID: 2012169488.
331. Vesikari T. Rotavirus vaccination: A concise review. *Clinical Microbiology and Infection*. 2012.
332. Vesikari T, Giaquinto C, Huppertz H-I. Clinical trials of rotavirus vaccines in Europe. *Pediatric Infectious Disease Journal*. 2006 Jan;25(1 Suppl):S42-7. PMID: 16397428.
333. Wandstrat TL, Kaplan-Machlis B, Temple ME, et al. Tetraivalent rotavirus vaccine. *Annals of Pharmacotherapy*. 1999 July/August;33(7 8):833-9. PMID: 1999288602 MEDLINE PMID 10466913 (<http://www.ncbi.nlm.nih.gov/pubmed/10466913>).

334. Watson W. Pneumococcal conjugate vaccines. *Pediatric Infectious Disease Journal*. 2000;20(4):331-2. PMID: 2000142080 MEDLINE PMID 10783025 (<http://www.ncbi.nlm.nih.gov/pubmed/10783025>).
335. Weaver BA. Epidemiology and natural history of genital human papillomavirus infection. *J Am Osteopath Assoc*. 2006 Mar;106(3 Suppl 1):S2-8. PMID: 16729554.
336. Weber DJ, Rutala WA. Immunization of immunocompromised persons. *Immunology and Allergy Clinics of North America*. 2003 November;23(4):605-34. PMID: 2004010559 MEDLINE PMID 14753383 (<http://www.ncbi.nlm.nih.gov/pubmed/14753383>).
337. Weinberg GA, Granoff DM. Polysaccharide-protein conjugate vaccines for the prevention of *Haemophilus influenzae* type b disease. *Journal of Pediatrics*. 1988 Oct;113(4):621-31. PMID: 3050001.
338. Weldelesassie YG, Whitaker HJ, Farrington CP. Use of the self-controlled case-series method in vaccine safety studies: Review and recommendations for best practice. *Epidemiology and Infection*. 2011 December;139(12):1805-17. PMID: 2011602730 MEDLINE PMID 21849099 (<http://www.ncbi.nlm.nih.gov/pubmed/21849099>).
339. Wharton M. Vaccine safety: Current systems and recent findings. *Current Opinion in Pediatrics*. 2010 February;22(1):88-93. PMID: 2010080849 MEDLINE PMID 19952750 (<http://www.ncbi.nlm.nih.gov/pubmed/19952750>).
340. Wiedermann U, Kollaritsch H. Vaccines against traveler's diarrhoea and rotavirus disease - a review. *Wiener Klinische Wochenschrift*. 2006;118(19-20 Suppl 3):2-8. PMID: 17131234.
341. Wilson K, Mills E, Ross C, et al. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. *Arch Pediatr Adolesc Med*. 2003 Jul;157(7):628-34. PMID: 12860782.
342. Wilson ME. Travel-related vaccines. *Infectious Disease Clinics of North America*. 2001;2001;15(1):231-51. PMID: 2001129003 MEDLINE PMID 11301818 (<http://www.ncbi.nlm.nih.gov/pubmed/11301818>).
343. Woo EJ, Burwen DR, Gatumu SNM, et al. Extensive limb swelling after immunization: Reports to the Vaccine Adverse Event Reporting System. *Clinical Infectious Diseases*. 2003;137(3):351-8. PMID: 2003328908 MEDLINE PMID 12884159 (<http://www.ncbi.nlm.nih.gov/pubmed/12884159>).
344. Yancey AM, Pitlick JM, Forinash AB. The prophylactic role for the human papillomavirus quadrivalent vaccine in males. *Annals of Pharmacotherapy*. 2010 Jul-Aug;44(7-8):1314-8. PMID: 20501891.
345. Yates L, Pierce M, Stephens S, et al. Influenza A/HIN1v in pregnancy: An investigation of the characteristics and management of affected women and the relationship to pregnancy

outcomes for mother and infant. *Health Technology Assessment*. 2010;14(34):109-82.
PMID: 2010418378.

346. Yeh SH. PEDIARIX: clinical trials. *Expert Review of Vaccines*. 2005 Apr;4(2):139-45.
PMID: 15889985.

347. Yih WK, Kulldorff M, Fireman BH, et al. Active surveillance for adverse events: The experience of the vaccine safety datalink project. *Pediatrics*. 2011 May;127(SUPPL. 1):S54-S64.
PMID: 2011239118 MEDLINE PMID 21502252
(<http://www.ncbi.nlm.nih.gov/pubmed/21502252>).

348. Yin JK, Khandaker G, Rashid H, et al. Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. *Influenza & Other Respiratory Viruses*. 2011 Sep;5(5):299-305. PMID: 21668694.

349. Young F, Marra F. A systematic review of intradermal influenza vaccines. *Vaccine*. 2011 Nov 8;29(48):8788-801. PMID: 21968444.

350. Zareba G. A new combination vaccine for measles, mumps, rubella and varicella. *Drugs of Today*. 2006 May;42(5):321-9. PMID: 2006313737 MEDLINE PMID 16801995
(<http://www.ncbi.nlm.nih.gov/pubmed/16801995>).

351. Zhang L, Prietsch SOM, Axelsson I, et al. Acellular vaccines for preventing whooping cough in children. *Cochrane Database of Systematic Reviews*. 2012;3:CD001478. PMID: 22419280.

352. Zimmerman RK, Middleton DB, Burns IT, et al. Routine vaccines across the life span, 2003. *Journal of Family Practice*. 2003 Jan;52(1 Suppl):S1-21. PMID: 12556275.

353. Zuccotti GV. Safety of a virosomal adjuvanted influenza vaccine in children suffering from chronic disease. *Open Vaccine Journal*. 2010;2010;3(1):108-13. PMID: 2011281638.

Mechanistic Studies – 39

1. Childhood immunizations and type 1 diabetes: summary of an Institute for Vaccine Safety Workshop. The Institute for Vaccine Safety Diabetes Workshop Panel. *Pediatr Infect Dis J.* 1999 Mar;18(3):217-22. PMID: 10093941.
2. Agmon-Levin N, Paz Z, Israeli E, et al. Vaccines and autoimmunity. *Nature Reviews Rheumatology.* 2009 2009;5(11):648-52. PMID: 2009579139 MEDLINE PMID 19865091 (<http://www.ncbi.nlm.nih.gov/pubmed/19865091>).
3. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. *Vaccine.* 2007 10;25(19):3752-62. PMID: 2007183669 MEDLINE PMID 17336431 (<http://www.ncbi.nlm.nih.gov/pubmed/17336431>).
4. Ahmed SS, Plotkin SA, Black S, et al. Assessing the safety of adjuvanted vaccines. *SOURCE Science Translational Medicine* (2011) 3:93 Article Number: 93rv2. Date of Publication: 27 Jul 2011. 2011 PMID: 2011412590.
5. Anhoury ML, Arickx M, Boon B, et al. Analysis of a bivalent meningococcal vaccine (A + C). Part I. Analytical and safety data. *Annales de la Societe Belge de Medecine Tropicale.* 1979 Sep;59(3):259-66. PMID: 117760.
6. Annunziata P. Reply to: "Miller Fisher syndrome following vaccination". *Infection.* 2012 February;40(1):103-4. PMID: 2012126926.
7. Aron-Maor A, Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. *Lupus.* 2001;10(3):237-40. PMID: 11315360.
8. Bines JE, Patel M, Parashar U. Assessment of postlicensure safety of rotavirus vaccines, with emphasis on intussusception. *Journal of Infectious Diseases.* 2009 Nov 1;200 Suppl 1:S282-90. PMID: 19817611.
9. Blyth CC, Currie AJ, Wiertsema SP, et al. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms. *Vaccine.* 2011 Jul 18;29(32):5107-13. PMID: 21640152.
10. Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. *Journal of Autoimmunity.* 2001 2001;16(3):309-18. PMID: 2001221056 MEDLINE PMID 11334497 (<http://www.ncbi.nlm.nih.gov/pubmed/11334497>).
11. Christian LM, Iams JD, Porter K, et al. Inflammatory responses to trivalent influenza virus vaccine among pregnant women. *Vaccine.* 2011 Nov 8;29(48):8982-7. PMID: 21945263.
12. Clarke JB. Mechanisms of adverse drug reactions to biologics. *SOURCE Handbook of Experimental Pharmacology* (2010) 196 (453-474). Date of Publication: 2010 Adverse Drug Reactions, Book Series Title:.. 2010 PMID: 2010034207.

13. Cojocaru M, Cojocaru IM, Radu-Popescu MA, et al. The relationship between vaccination and the development of autoimmune diseases. *Farmacia*. 2010;2010;58(6):677-85. PMID: 2011004153.
14. Flanagan KL, Klein SL, Skakkebaek NE, et al. Sex differences in the vaccine-specific and non-targeted effects of vaccines. *Vaccine*. 2011 Mar;29(13):2349-54. PMID: WOS:000289140500001.
15. Higashi HG, Luna E, Precioso AR, et al. Acellular and "low" pertussis vaccines: Adverse events and the role of mutations. *Revista Do Instituto De Medicina Tropical De Sao Paulo*. 2009 May-June;51(3):131-4. PMID: 2009339349 MEDLINE PMID 19551286 (<http://www.ncbi.nlm.nih.gov/pubmed/19551286>).
16. Hilleman MR. Critical overview and outlook: Pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. *Vaccine*. 2003;21(32):4626-49. PMID: 2003438300 MEDLINE PMID 14585670 (<http://www.ncbi.nlm.nih.gov/pubmed/14585670>).
17. Huynh W, Cordato DJ, Kehdi E, et al. Post-vaccination encephalomyelitis: literature review and illustrative case. *Journal of Clinical Neuroscience*. 2008 Dec;15(12):1315-22. PMID: 18976924.
18. Israeli E, Agmon-Levin N, Blank M, et al. Guillain-Barre Syndrome-A Classical Autoimmune Disease Triggered by Infection or Vaccination. *Clinical Reviews in Allergy & Immunology*. 2012 Apr;42(2):121-30. PMID: WOS:000301569400002.
19. Kapetanovic MC, Roseman C, Jonsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. *Arthritis and Rheumatism*. 2011 December;63(12):3723-32. PMID: 2011657726 MEDLINE PMID 21834061 (<http://www.ncbi.nlm.nih.gov/pubmed/21834061>).
20. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. *The Lancet Infectious Diseases*. 2010 May;10(5):338-49. PMID: 2010534658 MEDLINE PMID 20417416 (<http://www.ncbi.nlm.nih.gov/pubmed/20417416>).
21. Koenig HC, Sutherland A, Izurieta HS, et al. Application of the immunological disease continuum to study autoimmune and other inflammatory events after vaccination. *Vaccine*. 2011 Jan;29(5):913-9. PMID: WOS:000287295800009.
22. Lynch M, Shieh W-J, Bresee JS, et al. Intussusception after administration of the rhesus tetravalent rotavirus vaccine (Rotashield): the search for a pathogenic mechanism. *Pediatrics*. 2006 May;117(5):e827-32. PMID: 16651287.

23. Midthun K, Halsey NA, Jett-Goheen M, et al. Safety and immunogenicity of human rotavirus vaccine strain M37 in adults, children, and infants. *Journal of Infectious Diseases*. 1991;164(4):792-6. PMID: 1991333507 MEDLINE PMID 1654365 (<http://www.ncbi.nlm.nih.gov/pubmed/1654365>).
24. Mrozek-Budzyn D, Kieltyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. *Pediatr Infect Dis J*. 2010 May;29(5):397-400. PMID: 19952979.
25. Murphy BR, Morens DM, Simonsen L, et al. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. *Journal of Infectious Diseases*. 2003 Apr 15;187(8):1301-8. PMID: 12696010.
26. Neville B. Dravet syndrome and 'immunization encephalopathy'. *Developmental Medicine & Child Neurology*. 2010 Jun;52(6):590-1. PMID: 20187876.
27. Perdan-Pirkmajer K, Thallinger GG, Snoj N, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. *Lupus*. 2012 Feb;21(2):175-83. PMID: 22235050.
28. Richmand BJ. Hypothesis: Conjugate vaccines may predispose children to autism spectrum disorders. *Medical Hypotheses*. 2011 December;77(6):940-7. PMID: 2011619426 MEDLINE PMID 21993250 (<http://www.ncbi.nlm.nih.gov/pubmed/21993250>).
29. Ronaghy A, de Jager W, Zonneveld-Huijssoon E, et al. Vaccination leads to an aberrant FOXP3 T-cell response in non-remitting juvenile idiopathic arthritis. *Annals of the Rheumatic Diseases*. 2011 Nov;70(11):2037-43. PMID: WOS:000295399700027.
30. Rothman KJ, Young-Xu Y, Arellano F. Age dependence of the relation between reassortant rotavirus vaccine (RotaShield) and intussusception. *Journal of Infectious Diseases*. 2006 Mar 15;193(6):898; author reply -9. PMID: 16479526.
31. Salemi S, D'Amelio R. Could autoimmunity be induced by vaccination? *International Reviews of Immunology*. 2010 Jun;29(3):247-69. PMID: 20521925.
32. Sejvar JJ. Vaccines and neurologic disease. *Seminars in Neurology*. 2011 2011;31(3):338-55. PMID: 2011549339 MEDLINE PMID 21964850 (<http://www.ncbi.nlm.nih.gov/pubmed/21964850>).
33. Shoenfeld Y, Agmon-Levin N. 'ASIA' - Autoimmune/inflammatory syndrome induced by adjuvants. *Journal of Autoimmunity*. 2011 February;36(1):4-8. PMID: 2011057734 MEDLINE PMID 20708902 (<http://www.ncbi.nlm.nih.gov/pubmed/20708902>).
34. Siegrist CA. Mechanisms Underlying Adverse Reactions to Vaccines. *Journal of Comparative Pathology*. 2007 July;137(SUPPL. 1):S46-S50. PMID: 2007305033 MEDLINE PMID 17559869 (<http://www.ncbi.nlm.nih.gov/pubmed/17559869>).

35. Skowronski DM, Lu H, Warrington R, et al. Does antigen-specific cytokine response correlate with the experience of oculorespiratory syndrome after influenza vaccine? *J Infect Dis.* 2003 Feb 1;187(3):495-9. PMID: 12552434.
36. Stubgen JP. Neuromuscular disorders associated with Hepatitis B vaccination. *Journal of the Neurological Sciences.* 2010 May;292(1-2):1-4. PMID: WOS:000276784100001.
37. Tang YW, Li H, Wu H, et al. Host single-nucleotide polymorphisms and altered responses to inactivated influenza vaccine. *J Infect Dis.* 2007 Oct 1;196(7):1021-5. PMID: 17763324.
38. Toubi E. ASIA - autoimmune syndromes induced by adjuvants: Rare, but worth considering. *Israel Medical Association Journal.* 2012 February;14(2):121-4. PMID: 2012115110 MEDLINE PMID 22693796 (<http://www.ncbi.nlm.nih.gov/pubmed/22693796>).
39. Vessal S, Kravis LP. Immunologic mechanisms responsible for adverse reactions to routine immunizations in children. *Clinical Pediatrics.* 1976 Aug;15(8):688-96. PMID: 133013.